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AIDS Vaccine 2013 is proud to introduce this year’s New Investigator Awardees.
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Duke University Medical Center, USA
Yoshinori Fukazawa
Oregon Health & Science University, USA
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University of Oxford, UK
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University of Zurich, Switzerland
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MEASURE/NACA, Nigeria
Tina Ahmed
University of Oxford, UK
Bisi Alimi
AVAC, UK
Ashley Appiagyei
Rwanda-Zambia HIV Research Group, Zambia
Abdul Azeem
National AIDS Control Program, Pakistan
Luchuo Engelbert Bain
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Monday, 7 October
08:30 – 15:30 Satellite Sessions
 See pages 11–15 of Program Book for detailed information.
08:00 – 20:00 Registration / Coat Check L0, Entrance Hall
13:00 – 16:00 Speaker Check-in L1, Room 118
16:00 – 18:00 Opening Session L1, Room 113 – 116
 Chairs: Christian Brander, Bonaventura Clotet, and José M. Gatell
16:00 – 16:10 Welcome Remarks 
2013 Conference Chairs
 Christian Brander1, Bonaventura Clotet2, José M. Gatell3
 1IrsiCaixa Inst for AIDS Res, HIVACAT, ICREA, Barcelona, Spain; 2IrsiCaixa Inst for AIDS Res, HIVACAT, Barcelona, Spain;  
3Hospital Clínic, IDIBAPS, HIVACAT, University of Barcelona, Spain 
16:10 – 16:20 Enric Banda1
 1Director of the Area of Science, Research and the Environment, ”la Caixa” Foundation
16:20 – 16:30 Boi Ruiz i Garcia1
 1Minister of Health, Government of Catalonia
16:30 – 16:40 Opening Remarks from the Vaccine Enterprise
 William Snow1
 1Global HIV Vaccine Enterprise, New York, NY, USA
16:40 – 16:50 Partnership Towards a Tough Target: Communities Are an Essential OS.01 
Ingredient, Not a Cherry on Top
 Ntando Yola1
 1NACOSA, Cape Town, South Africa
16:50 – 17:13 HIV Vaccines in the Context of Vaccine Development in General OS.02 
Stanley A. Plotkin1
 1Univ of Pennsylvania, Doylestown, PA, USA
17:13 – 17:36 Insights from HIV Vaccine Efficacy Trials: What We Are Learning from OS.03 
HVTN 505
 Magdalena Sobieszczyk1
 1Columbia Univ, New York, NY, USA
17:36 – 18:00 Toward Ending the HIV/AIDS Pandemic: Synergy Between OS.04 
Vaccine and Non-vaccine Interventions
 Anthony Fauci1
 1NIAID, NIH, Bethesda, MD, USA
18:00 – 20:00 Welcome Reception L2, Banquet Hall
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Tuesday, 8 October
A full complimentary breakfast buffet is available in the conference hotels: The AC Hotel Barcelona Forum by Marriott and the Hotel Barcelona 
Princess. Breakfast will not be available at the CCIB.
07:30 – 18:00 Registration / Coat Check L0, Entrance Hall
07:30 – 16:30 Speaker Check-in L1, Room 118
08:30 – 10:00 HIV Vaccine Strategies L1, Room 113 – 116
 Plenary Session 01
 Chairs: José Esparza and Peggy Johnston
08:30 – 09:00 Manufacturing HIV Envelope Proteins for HIV Vaccines: An NIAID PL01.01 
Perspective of Where We Are and What Is Still Needed
 Michael Pensiero1
 1NIAID, NIH, Bethesda, MD, USA
09:00 – 09:30 Vaccine Induction of T Cell Immunity to HIV-1 PL01.02 
Andrew McMichael1
 1Univ of Oxford, Oxford, UK
09:30 – 10:00 Pathways of Affinity Maturation of HIV-1 Broadly Neutralizing Antibodies PL01.03 
Barton Haynes1
 1Duke Human Vaccine Inst, Durham, NC, USA
10:00 – 10:30 Refreshment Break L1, Room 111 – 112 
 L2, Room 211 – 212
10:30 – 12:00 T Cell Immunology L1, Room 113 – 114 
Oral Abstract Session 01
 Chairs: Zabrina Brumme and Paul Goepfert 
10:30 – 10:45 Effective CD8+ T Cell Responses Restrict SIV Replication to Follicular OA01.01
 Helper T Cells 
 Yoshinori Fukazawa1, R. Lum1, J. Bae1, A. Okoye1, S.I. Hagen1, H. Park1, A.W. Legasse1,  
M.K. Axthelm1, J.D. Estes2, M. Piatak Jr.2, J.D. Lifson2, L.J. Picker1
 1VGTI, Oregon Hlth & Science Univ, Beaverton, OR, USA; 2SAIC-Frederick, Inc., Frederick Nat’l Laboratory,  
Frederick, MD, USA
10:45 – 11:00 The Breadth of Expandable Central Memory CD8 T Cells Inversely OA01.02 
Correlates with Residual Viral Loads in HIV Elite Controllers 
Zaza Ndhlovu1, E. Stampouloglou2, K. Cesa2, D. Alvino2, A. Piechocka-Trocha2,  
F. Pereyra2, B. Walker2
 1Univ of KwaZulu-Natal, Durban, South Africa; 2Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA
11:00 – 11:15 PD-1 Expression on HIV-1 Specific CD8+ T Cells Is Shaped by Epitope OA01.03 
Specificity, TcR Clonotype Usage and Driven by Antigen Load
 Henrik N. Kløverpris1, A. Stryhn2, S. Buus2, D. Price3, P. Goulder4
 1Univ of KwaZulu-Natal, Durban, South Africa; 2Univ of Copenhagen, Copenhagen, Denmark, 
3Cardiff Univ School of Medicine, Cardiff, Wales, UK; 4Univ of Oxford, Oxford, UK
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11:15 – 11:30 Immunotherapeutic Interventions to Restore HIV-1-Specific CD4 T Cell OA01.04 
Help to NK Cells
 Filippos Porichis1, M. Hart1, L. Barblu2, T.E. Brennan1, D. Kavanagh1, D. Kaufmann2
 1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; 2Centre de Recherche du Centre Hospitalier  
de l’Université de Montréal, Montreal, Canada
11:30 – 11:45 Integrative Analysis of Responses to Dendritic-Cell Vaccination Identifies OA01.05 
Signatures Correlated with Control of HIV Replication: The DALIA Trial 
Rodolphe Thiebaut1, B. Hejblum1, J. Skinner2, M. Montes2, G. Chêne1, K. Palucka2,  
J. Banchereau2, Y. Levy3
 1INSERM U897, Bordeaux, France; 2Baylor Inst for Immunology Res, Dallas, TX, USA; 3INSERM U955,  
Creteil, France
11:45 – 12:00 Effective Antiviral CD8+ T Cells Responses Are Rare in HIV-Positive OA01.06 LB 
Step & Phambili Study Participants but Are Targeted to Low Entropy 
Viral Epitopes 
 Gemma Hancock1, H. Yang1, A.J. McMichael1,  
N. Frahm2, J.M. McElrath2, L. Dorrell1
 1Univ of Oxford, Oxford, UK; 2FHCRC, Seattle, WA, USA
10:30 – 12:00 Adjuvants L1, Room 115 – 116 
Oral Abstract Session 02
 Chairs: Gunilla Karlsson Hedestam and Rick King 
10:30 – 10:45 Engineering an HIV Envelope Protein to Activate Germline B Cell OA02.01
 Receptors of Broadly Neutralizing VRC01-Class Antibodies 
 Andrew McGuire1, A.M. Dreyer1, S. Hoot2, A. Lippy1, A. Stuart1, K.W. Cohen1,  
J. Jardine3, S. Menis3, J.F. Scheid4, A.P. West5, W.R. Schief3, L. Stamatatos1
 1Seattle Biomed, Seattle, WA, USA; 2Altravax Inc., Sunnyvale, CA, USA; 3IAVI Neutralizing Antibody  
CTR  at The Scripps Res Inst, La Jolla, CA, USA; 4The Rockefeller Univ, New York, NY, USA;  
5California Inst of Technology, Pasadena, CA, USA
10:45 – 11:00 Focusing Antibody Responses to Specific Protein Surfaces Through OA02.02 
Site-Selective Glycan Addition
 Torben Schiffner1, K. Leonavicius1, H. Schuster1, L. Kong1, R. Saliba1, F. Wegmann1,  
P. Huang2, G.B. Stewart-Jones1, W.R. Schief3, B.G. Davis1, Q.J. Sattentau1
 1Univ of Oxford, Oxford, UK; 2Univ of Washington, Seattle, WA, USA; 3IAVI Neutralizing Antibody  
CTR at The Scripps Res Inst,, La Jolla, CA, USA
11:00 – 11:15 Comparative Antigenicity and Immunogenicity of Indian and South OA02.03 
African HIV-1 Subtype C Native and CD4 Liganded Envelope Glycoproteins 
M.L. Grant1, M.A. Killick1, N. Cerutti1, A. Capovilla1, Maria A. Papathanasopoulos1
 1Univ of the Witwatersrand Med School, Johannesburg, South Africa
11:15 – 11:30 Immunogenicity of a CD207-Targeted Anti-Gag Vaccine and TLR OA02.04 
Ligand-Dependent Enhancement
 O. Epaulard3, L. Adam3, C. Poux3, G. Zurawski1, P. Rosenbaum3, N. Dereuddre-Bosquet3,  
S. Zurawski1, S. Oh1, G. Romain3, J. Banchereau1, Y. Lévy2, R. Le Grand3, Frederic Martinon3
 1Baylor Inst for Immunology Res, Dallas, TX, USA; 2Vaccine Res Inst, Créteil, France;  
3CEA, Fontenay-aux-Roses, France
11:30 – 11:45 Impact of TLR9 Stimulation on HIV-1 Env-Specific Immune Responses OA02.05 
Elicited in Non-human Primates
 Paola Andrea Martinez Murillo1, C. Sundling1, Y. Feng2, S. O’Dell3, K. Reimann4,  
J. Mascola3, R. Wyatt2, G.B. Karlsson Hedestam1
 1Karolinska Inst, Stockholm, Sweden;  IAVI Neutralizing Antibody CTR at The Scripps Res Inst,  
La Jolla, CA, USA; 3VRC, NIAID, NIH, Bethesda, MD, USA; 4MassBiologics, Univ of Massachusetts Med  
School, Boston, MA, USA
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11:45 – 12:00 Lipid Components in MPER-Based Immunization Regimens Are Critical OA02.06 LB 
for Inducing Broadly Neutralizing Antibody Responses in 2F5 and 4E10 
Knockin Mice
 Y. Chen1, J. Zhang1, H. Bouton-Verville1, A. Newman1, S. Xia1, H. Liao1, D.C. Montefiori1,  
M.A. Moody1, L. Armand1, K. Hwang1, B. Lockwood1, S.M. Dennison1, S.M. Alam1,  
B.F. Haynes1, Laurent Verkoczy1
 1Duke Human Vaccine Inst, Durham, NC, USA
10:30 – 12:00 Clinical Trials L1, Room 117
 Oral Abstract Session 03
 Chairs: Lucy Dorrell and Beatriz Mothe  
10:30 – 10:45 The HIV consv Vaccines Induce Polyfunctional and Highly Proliferative OA03.01
 T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I 
Clinical Trial
 Beatrice O. Ondondo1, T. Ahmed1, B. Nicola1, E. Hayton1, E. Vasilyeva2, N. Frahm2,  
S. Colloca3, A. Nicosia3, A. McMichael1, L Dorrell1, T. Hanke1
 1Univ of Oxford, Oxford, UK; 2FHCRC, Seattle, WA, USA; 3Okairòs, Rome, Italy 
10:45 – 11:00 Phase I Clinical Trials of DNA-Protein Vaccine (CombiHIVvac) Containing OA03.02 
Artificial Multi-Clade Immunogens 
 Larisa Karpenko1, N. Ryndyuk2, Z. Gin’ko2, V. Kuzubov2, S. Bazhan1, L. Lebedev1,  
O. Kaplina1, A. Reguzova1, A. Ryzhikov1, M. Bogryantseva1, S. Usova1, V. Masycheva1,  
E. Nechaeva1, and A. Ilyichev1
 1State Res CTR of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk, Russian Federation;  
2Hospital Number 163 of Russian Federal Med and Biological Agency, Koltsovo, Novosibirsk, Russian Federation
11:00 – 11:15 Comparative Analysis of Binding Antibody Responses Elicited by a OA03.03 
Cross-Section of Human HIV-1 Vaccine Clinical Trials
 Shelly J. Krebs1, S. Narpala2, A. Wheatley2, B.M. Slike1, M. Eller1, S. Ratto-Kim1,  
V.R. Polonis1, J.H. Kim1, M.L. Robb1, M.A. Marovich1, R.A. Koup2, B.S. Graham2,  
N.L. Michael1, A. McDermott2
 1U.S. MHRP, Silver Spring, MD, USA; 2VRC, NIAID, NIH, Bethesda, MD, USA
11:15 – 11:30 Antibody Repertoire Induced by the Multiclade (Env A,B,C) HIV-1 DNA OA03.04 
Prime, rAd5 Boost VRC Vaccine
 Wilton B. Williams1, K. Jones1, P. Liu1, A.M. Trama1, K. Seaton1, M.A. Moody1,  
N. Vandergrift1, K. Wiehe1, H. Liao1, D.C. Montefiori1, C. Ochsenbauer2, J. Kappes2,  
S.M. Hammer3, J. Mascola4, R. Koup4, L. Corey5, G. Nabel4, P. Gilbert6, C.A. Morgan6,  
G. Churchyard7, J. Maenza5, L.R. Baden8, M. Keefer9, B.S. Graham4, G.D. Tomaras1,  
B.F. Haynes1
 1Duke Univ Med CTR, Durham, NC, USA; 2Univ of Alabama at Birmingham, Birmingham, AL, USA;  
3Columbia Univ Med CTR, New York, NY, USA; 4VRC, NIAID, NIH, Bethesda, MD, USA; 5Univ of  
Washington, Seattle, WA, USA; 6SCHARP, FHCRC, Seattle, WA, USA; 7The Aurum Inst, Johannesburg,  
South Africa; 8Brigham and Women’s Hospital, Boston, MA, USA; 9Univ of Rochester Med CTR,  
Rochester, NY, USA
11:30 – 11:45 A Phase I Clinical Trial of an HIV-1 (CN54), Clade C, Trimeric Envelope OA03.05 
Vaccine Delivered by Parenteral, Nasal and Vaginal Routes of Immunisation
 Catherine A. Cosgrove1, C. Lacey2, A.V. Cope3, A. Bartolf1, G. Morris2, C. Yan3, S. Baden1,  
T. Cole3, D. Carter4, E. Brodnicki5, W. Stoehr5, S. McCormack6, R.J. Shattock3
 1St George’s, Univ of London, London, UK; 2Hull York Med School, Univ of York, York, UK; 3Imperial College,  
London, UK; 4Infectious Disease Res Inst, Seattle, WA, USA; 5MRC Clinical Trials Unit, London, UK; 6MRC  
Clinical Trials Unit and Imperial College, London, UK
11:45 – 12:00 HIV-1 Fusion Protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef Induce OA03.06 LB 
Potent and Durable T-Cell and Antibody Responses in Healthy African Adults
 Juliet Mpendo1, G. Omosa-Manyonyi2, E. Ruzagirwa3, W. Kilembe4, F. Roman5,  
M. Koutsoukos1, A. Lombardo6, L. Dally7, P. Chetty6, P. Bourguignon5, P. Hayes6,  
J. Gilmour1, J. Cox6, F. Priddy1
 1Uganda Virus Res Inst, Entebbe, Uganda; 2Kenya AIDS Vaccine Initiative, Nairobi, Kenya; 3MRC-Uganda,  
Entebbe, Uganda; 4Zambia Emory HIV Res Program, Lusaka, Zambia; 5GSK Vaccines, Rixensart, Belgium;  
6IAVI, New York, NY, USA; 7Emmes Corp., Rockville, MD, USA
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12:00 – 13:00 Lunch L2, Banquet Hall
12:00 – 13:00 Delegate Networking Lunch L2, Banquet Hall
Lunch tables have been reserved for young and early-career investigators to network with senior researchers. The list of 
participating researchers is available at the conference registration desk along with a sign-up sheet. Space is limited and will 
be reserved on a first-come, first-served basis. 
13:00 – 14:30 Animal Models L1, Room 113 – 114
 Oral Abstract Session 04
 Chairs: Amitinder Kaur and María Ángeles Muñoz Fernández
13:00 – 13:15 PET/CT Imaging of Simian Immunodeficiency Virus Reveals the OA04.01 
Dynamics of Viral Replication In Vivo
 P. Santangelo1, K. Rogers2, C. Zurla1, E. Alonas1, P. Amancha2, J. Hong2,  
P. Sharma2, D.K. Machiah2, K. Strait2, A.A. Ansari2, Francois Villinger2
 1Georgia Inst of Technology and Emory Univ, Atlanta, GA, USA; 2Emory Univ, Atlanta, GA, USA
13:15 – 13:30 Non-human Primate Model to Study the Role of Serum and Vaginal IgA OA04.02 
in Acquisition of Infection
 N. Hutnick6, M. Kutzler1, Z. Moldoveanu2, M. Hunter3, M. Wise6, J. Yan4, A. Sylvester1,  
B. Pahar3, D. Myles6, A. Khan4, D. Montefiori5, N. Sardesai4, J. Mestecky2, P. Marx3,  
David Weiner6
 1Drexel Univ, Philadelphia, PA, USA; 2Univ of Alabama at Birmingham, Birmingham, AL, USA;  
3Tulane Univ, New Orleans, LA, USA; 4Inovio Pharmaceuticals, Blue Bell, PA, USA; 5Duke Univ,  
Durham, NC, USA; 6Univ of Pennsylvania, Philadelphia, PA, USA
13:30 – 13:45 Vaccine Induced Epitope Specific Antibodies to the SIV Envelope Are OA04.03 
Distinct from Those Induced to the HIV-1 Envelope
 Xiaoying Shen1, R. Howington1, H. Park2, S. Sadagopal3, S. Kwa4, A. Cope5, S. Ding6,  
D. Bolton7, M. Roederer8, R. Amara3, L. Picker2, R. Seder8, J. McElrath9, S. Barnett10,  
R. Shattock5, B. Felber11, G. Pavlakis11, G. Pantaleo12, D. Montefiori1, G. Tomaras1
 1Duke Univ, Durham, NC, USA; 2Oregon Hlth & Science Univ, Beaverton, OR, USA; 3Emory Univ,  
Atlanta, GA, USA; 4GeoVax, Inc., Smyrna, GA, USA; 5Imperial College, London, UK; 6EuroVacc Foundation,  
Amsterdam, Netherlands; 7U.S. MHRP, Silver Spring, MD, USA; 8VRC, NIAID, NIH, Bethesda, MD, USA;  
9Univ of Washington, Seattle, WA, USA; 10Novartis Vaccines and Diagnostics, Inc., Cambridge, MA,  
USA; 11Nat’l Cancer Inst, NIH, Frederick, MD, USA; 12Univ of Lausanne, Lausanne, Switzerland
13:45 – 14:00 Co-administration of Rapamycin with a DNA/MVA SIV Vaccine Improves OA04.04 
Memory CD8 T Cell Response and Enhances Control of SIV251 Infection 
Shanmugalakshmi Sadagopal1, S. Kwa1, R. Basu1, S. Gangadhara1, K. Araki1,  
R. Ahmed1, R. Amara1
 1Emory Univ, Atlanta, GA, USA 
14:00 – 14:15 Protection of Cynomolgus Macaques from Pathogenic SIV Following OA04.05 
Vaccination with Varicella-Zoster Virus Based Vaccines
 D.O. Willer5, A.P. Ambagala1, A.K. Marsh2, K. Haq5, C. Perciani5, J.K. Chan5, R. Pilon3,  
J. Fournier4, P. Sandstrom3, Kelly S. MacDonald5
 1Canadian Food Inspection Agency, Lethbridge, Canada; 2Univ of Toronto, Toronto, Canada;  
3Publ Hlth Agency of Canada, Ottawa, Canada; 4Health Canada, Ottawa, Canada; 5Mt. Sinai  
Hospital, Univ of Toronto, Toronto, Canada
14:15 – 14:30 Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal OA04.06 LB 
Antibodies in SHIV-Infected Rhesus Monkeys
 Dan Barouch1, J. Whitney1, B. Moldt2, F. Klein3, K. Shekhar4, A. Chakraborty4,  
M. Nussenzweig3, D. Burton2
 1Beth Israel Deaconess Med CTR, Boston, MA, USA; 2The Scripps Res Inst, USA; 3The Rockefeller  
Univ, USA; 4MIT, Cambridge, MA, USA
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13:00 – 14:30 B Cell Immunology L1, Room 115 – 116
 Oral Abstract Session 05
 Chairs: José Alcamí and Pascal Poignard
13:00 – 13:15 Structural Basis for HIV-1 gp120 Recognition by a Germ-line Version OA05.01 
of a Broadly Neutralizing Antibody
 Louise Scharf1, A.P. West1, J.F. Scheid2, M.C. Nussenzweig2, P.J. Bjorkman1, R. Diskin3
 1California Inst of Technology, Pasadena, CA, USA;  
2The Rockefeller Univ, New York, NY, USA; 3Weizmann Inst, Rehovot, Israel
13:15 – 13:30 Structural Characterization of Potent, Longitudinally-Defined HIV-1  OA05.02 
V1/V2-Directed Antibodies
 Jason Gorman1, N. Doria-Rose1, C.A. Schramm2, P.L. Moore3, M. Pancera1,  
Y. Yang1, R.P. Staupe1, Z. Zhang2, I.S. Georgiev1, J. Bhiman3, N.L. Longo1,  
L. Morris3, L. Shapiro2, J.R. Mascola1, P.D. Kwong1
 1VRC, NIAID, NIH, Bethesda, MD, USA; 2Columbia Univ, New York, NY, USA; 3Nat’l Inst for Communicable  
Diseases of the Nat’l Hlth Labs Service, Johannesburg, South Africa
13:30 – 13:45 Interplay Between Broadly Cross-Neutralizing V2 Monoclonal Antibodies OA05.03 
and Autologous Viral Evolution 
 Jinal N. Bhiman1, N. Doria-Rose2, P.L. Moore1, M. Nonyane3, S.S. Abdool Karim4,  
P.D. Kwong2, J.R. Mascola2, L. Morris1
 1Nat’l Inst for Communicable Diseases of the Nat’l Hlth Laboratory Service and Univ of the Witwatersrand,  
Johannesburg, South Africa; 2VRC, NIAID, NIH, Bethesda, MD, USA; 3Nat’l Inst for Communicable  
Diseases of the Nat’l Hlth Labs Service, Johannesburg, South Africa; 4CAPRISA, Univ of KwaZulu-Natal,  
Durban, South Africa
13:45 – 14:00 A Diverse Antibody Response to the gp120 N332 Glycan Epitope in an OA05.04 
HIV-Infected Donor
 Katie J. Doores1, K. Le2, D. Sok2, U. Laserson3, F. Vigneault3, J. Laserson4, D. Koller4,  
G. Church3, P. Poignard2, D. Burton2
 1King’s College London and The Scripps Res Inst, London, UK; 2The Scripps Res Inst, La Jolla, CA, USA;  
3Harvard Med School, Boston, MA, USA; 4Stanford Univ, Stanford, CA, USA
14:00 – 14:15 MF59 and ALUM, in Combination with an ALVAC-SIV/gp120 Vaccine,  OA05.05 
Induce Plasmablasts that Differ in the Expression of Homing Markers 
Luca Schifanella1, S. Gordon1, M. Vaccari1, N. Binello1, F. Caccuri1, M. Blackburn1,  
C. Fenizia1, M. Doster1, P. Pegu1, N. Liynage1, X. Shen2, G. Tomaras2, M. Rao3,  
G. Ferrari4, D. Venzon1, D. Stablien5, S. Barnett6, J. Tartaglia7, G. Franchini1
 1Nat’l Cancer Inst, NIH, Bethesda, MD, USA; 2Duke Human Vaccine Inst, Durham, NC, USA;  
3U.S. MHRP, Silver Spring, MD, USA; 4Duke Univ Med CTR, Durham, NC, USA; 5The EMMES Corporation,  
Rockville, MD, USA; 6Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA; 7Sanofi Pasteur,  
Swiftwater, PA, USA
14:15 – 14:30 HIV-1 gp120 Vaccination Elicits a Robust and Durable Anti-V1/V2 IgG OA05.06
 Response and Yet No HIV-1 Env-Specific IgA Response in HIV-Exposed  
Infants
 Genevieve G. Fouda1, C.K. Cunningham1, E.J. McFarland2, W. Borkowsky3, P. Muresan4,  
B.E. Liebl1, H. Liao1, B.F. Haynes1, R. Overman1, N.L. Yates1, G.D. Tomaras1, S.R. Permar1
 1Duke Univ Med CTR, Durham, NC, USA; 2Univ of Colorado, Aurora, CO, USA; 3New York Univ, New York,  
NY, USA; 4SDAC-FSTRF/Harvard School of Publ Hlth, Boston, MA, USA
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13:00 – 14:30 Vaccine Concepts L1, Room 117
 Oral Abstract Session 06
 Chairs: Nicole Frahm and Ralf Wagner
13:00 – 13:15 Identifying the Minimal Mutations in VRC01 Required for Neutralization OA06.01 
Potency and Breadth to Inform Vaccine Design
 Joseph G. Jardine1, D. Sok2, O. Kalyuzhniy1, M. Kubitz3, Y. Adachi4, D.R. Burton2,  
W.R. Schief1
 1The Scripps Res Inst, IAVI, CHAVI-ID, Univ of Washington, La Jolla, CA, USA; 2The Scripps Res Inst,  
IAVI, CHAVI-ID, La Jolla, CA, USA; 3The Scripps Res Inst, CHAVI-ID, La Jolla,CA, USA; 4The Scripps Res Inst,  
IAVI, La Jolla,CA, USA
13:15 – 13:30 Structural Organization and CD4-Induced Reorganization in Soluble OA06.02 
HIV-1 Trimers
 M. Guttman2, A. Cupo1, R.W. Sanders1, J.P. Moore1, Kelly K. Lee2
 1Weill Cornell Med College, New York, NY, USA; 2Univ of Washington, Seattle, WA, USA
13:30 – 13:45 Cell-Surface Display and Panning of HIV-1 Derived Envelope Proteins OA06.03 
Veronika Schmid1, T.H. Bruun1,  
A. Kliche1, R. Wagner1
 1Univ of Regensburg, Regensburg, Germany
13:45 – 14:00 DNA-MVA Prime-Boost Vaccine Eliciting T-Cell Specificities Associated OA06.04 
with HIV-1 Control Is Highly Immunogenic in Mice and Breaks  
CTL Immunodominance
 A. Olvera1, A. Llano2, M. Rosati3, S. Pérez-Álvarez2, V. Kulkarni3, B. Chowdhury3,  
C. Alicea3, R.K. Beach3, N.Y. Sardesai4, T. Hanke5, B. Clotet6, G.N. Pavlakis3,  
B.K. Felber3, C. Brander6, Beatriz Mothe2
 1IrsiCaixa Inst for AIDS Res, HIVACAT; ‘Lluita contra la Sida’ Hospital Universitari “Germans Trias i Pujol”,  
Barcelona, Spain; 2IrsiCaixa Inst for AIDS Res, HIVACAT, Barcelona, Spain; 3Nat’l Cancer Inst-Frederick, NIH,  
Frederick, MD, USA; 4Inovio Pharmaceuticals Biomedical Corp., Blue Bell, PA, USA; 5Univ of Oxford, Oxford, UK;  
6IrsiCaixa Inst for AIDS Res, HIVACAT; ‘Lluita contra la Sida’ Hospital Universitari “Germans Trias i Pujol”;  
Universitat Autònoma de Barcelona, Barcelona, Spain
14:00 – 14:15 Detection of Early CTL Escape in Gag and Nef Using Population-Level OA06.05 
Approaches
 Eric Martin1, J. Carlson2, A. Le1, R. McGovern3, C. Ng3, M. Rahman1, D. Chopera1,  
M. Wainberg4, R. Harrigan3, Z. Brumme1
 1Simon Fraser Univ, Burnaby, Canada; 2Microsoft Research, Los Angeles, CA, USA; 3BC Centre for  
Excellence in HIV/AIDS, Vancouver, Canada; 4McGill Univ, Montreal, Canada
14:15 – 14:30 Neutralizing and Non-neutralizing Antibody Binding to Cleaved, SOSIP- OA06.06 LB 
Stabilized and Uncleaved Soluble HIV-1 Env Trimers, Protomers, and gp120 
 A. Yasmeen3, R.W. Sanders3, R. Ringe3, R. Derking1, A. Cupo3, J. Julien2, A.B. Ward2,  
I.A. Wilson2, J.P. Moore3, Per Johan Klasse3
 1Academic Med CTR, Amsterdam, Netherlands; 2The Scripps Res Inst, La Jolla, CA, USA;  
3Cornell Univ, New York, NY, USA
14:30 – 15:00 Refreshment Break L1, Room 111 – 112
  L2, Room 211 – 212
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15:00 – 16:20 Innate Immunity L1, Room 113 – 114
 Symposium 01
 Chairs: Galit Alter and Karin Lore 
15:00 – 15:20 Antiviral Activity of NK Cells in HIV-1 Infection S01.01 
Marcus Altfeld1
 1Heinrich-Pette-Inst, Hamburg, Germany
15:20 – 15:40 Adjuvants Modify Antibody Effect or Function S01.02 
Alison Mahan1
 1Ragon Inst of MGH, MIT and Harvard,  
Cambridge, MA, USA
15:40 – 16:00 Systems Analysis of Innate Immune Responses Triggered by Viral Vector- S01.03 
Based HIV Vaccine Candidates
 Daniel Zak1
 1Seattle Biomed, Seattle, WA, USA
16:00 – 16:20 Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology S01.04 
Bali Pulendran1
 1Emory Univ, Atlanta, GA, USA
15:00 – 16:20 Linking T and B Cell Responses L1, Room 115 – 116
 Symposium 02
 Chairs: Andreas Meyerhans and Hendrik Streeck
15:00 – 15:20 Memory CD8 T Cells: Issues of Quantity, Quality, and Location S02.01 
David Masopust1
 1Univ of Minnesota, Minneapolis, MN, USA
15:20 – 15:40 Impaired B Cell Help During HIV Infection S02.02 
Elias Haddad1
 1Vaccine and Gene Therapy Inst of Florida,  
Port St. Lucie, FL, USA
15:40 – 16:00 Role of Tfh in HIV Infection S02.03
 M. Perreau1*, A.L. Savoye*1, E. De Crignis1, J.M. Corpataux2, R. Cubas3, E. Haddad3,  
L. De Leval4, C. Graziosi1, Giuseppe Pantaleo1,5
 1Divisions of Immunology and Allergy, 2Thoracic Surgery,3Vaccine and Gene Therapy Institute of Florida,  
Port St.Lucie, FL, USA, 4Institute of Pathology and 5Swiss Vaccine Research Institute, Lausanne University  
Hospital, University of Lausanne, Lausanne, Switzerland
 *The first two authors are listed in alphabetic order and have equally contributed to this study.
16:00 – 16:20 SIAE Inhibition and Enhanced Somatic Hypermutation Against gp140 S02.04 
H. Mattoo1, Shiv Pillai1, R. Wyatt2
 1Massachusetts General Hospital, Boston, MA, USA; 2The Scripps Res Inst, La Jolla, CA, USA
15:00 – 16:40 NHP Vaccines and Correlates of Immune Protection L1, Room 117 
Symposium 03
 Chairs: Roger LeGrand and Jeffery Lifson
15:00 – 15:20 Can AIDS Virus-Specific Classical CD8+ T Cells Control Virus Replication? S03.01 
David Watkins1
 1Univ of Miami, Miami, FL, USA
15:20 – 15:40 Strengths and Limitations of Macaque Models as Predictors of S03.02 
HIV Vaccine Efficacy in Humans  
 Genoveffa Franchini1
 1Nat’l Cancer Inst, NIH, Bethesda, MD, USA
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15:40 – 16:00 Pre-clinical Development of Cytomegalovirus Vectors S03.03 
Louis Picker1
 1Oregon Hlth & Science Univ, Beaverton, OR, USA
16:00 – 16:20 Vaccine Responses to Four Different gp140 Trimers S03.04 
Robin Shattock1
 1Imperial College, London, UK
16:20 – 16.40 Impressive Vaccine Protection Against SIVmac239 by Recombinant S03.05 
Gamma-2 Herpesvirus 
Y. Shin3, W. Lauer1, G. Bischof3, M. Piatak1, J. Lifson1, D. Watkins2, Ronald C. Desrosiers3
 1SAIC Frederick, Inc., Frederick Nat’l Labs, Frederick, MD, USA; 2University of Miami, Miami, FL, USA;  
3New England Primate Research Center, Harvard Medical School, Southborough, MA, USA
16:20 – 16:45 Break
16:45 – 17:16 B Cell Immunology L1, Room 113 – 114
 Poster Discussion Session 01
 Chair: Gabriella Scarlatti
16:45 – 16:52 Heterogeneity of Anti-V2 ADCC Ab Responses and Implications for P03.01 D 
Vaccine Development
 Justin Pollara1, M. Bonsignori1, M. Moody1, S. Alam1, K. Hwang1, T.C. Gurley1, D.M. Kozink1,  
D.J. Marshall1, J.F. Whitesides1, C. Tsao1, J. Kaewkungwal2, S. Nitayaphan3, P. Pitisuttithum2,  
S. Rerks-Ngarm4, G.D. Tomaras1, J.H. Kim5, N.L. Michael5, D.C. Montefiori1, H. Liao1,  
B.F. Haynes1, G. Ferrari1, and the CTR for HIV/AIDS Vaccine Immunology1
 1Duke Univ, Durham, NC, USA; 2Mahidol Univ, Bangkok, Thailand; 3Armed Forces Res Inst of Med  
Sciences, Bangkok, Thailand; 4Ministry of Publ Hlth, Thailand; 5U.S. MHRP, Silver Spring, MD, USA
16:53 – 17:00 Modalities of Broad and Potent Antibody Neutralization at the CD4- P03.02 D 
Binding Site on HIV-1 gp120
 Tongqing Zhou1, L. Chen1, R. Lynch1, X. Wu1, S. Srivatsan1, S. Moquin1, Y. Yang1,  
B. Zhang1, J.R. Mascola1, P.D. Kwong1
 1NIAID, NIH, Bethesda, MD, USA
17:01 – 17:08 Vaccine-Elicited CD4 Binding Site-Directed Antibodies Utilizing the Macaque P03.03 D 
Equivalent of the Human VH1-2 Heavy Chain Variable Gene Segment
 Marjon Navis1, K. Tran2, Y. Li2, G. Phad1, C. Sundling1, R. Wilson2, M. Soldemo1, K. McKee3,  
J. Mascola3, R.T. Wyatt2, G.B. Karlsson Hedestam1
 1Karolinska Inst, Stockholm, Sweden; 2IAVI Neutralizing Antibody Center at The Scripps Res Inst,  
La Jolla, CA, USA; 3VRC, NIAID, NIH, Bethesda, MD, USA
17:09 – 17:16 Analysis of Vaccine-Elicited Antibodies to the HIV-1 gp120 CD4 Binding Site P03.62 LB D 
Reveals Distinct Modes of Env Recognition to Guide Immunogen Re-design
 K. Tran1, C. Poulsen1, J. Guenaga1, N. de Val Alda1, C. Sundling2, R. Wilson1, Y. Li1,  
R. Stanfield1, I. Wilson1, A.B. Ward1, G.B. Hedestam Karlsson2, Richard T. Wyatt1
 1The Scripps Res Inst, La Jolla, CA, USA; 2Karolinska Inst, Stockholm, Sweden
16:45 – 17:24 T Cell Immunology L1, Room 115 – 116
 Poster Discussion Session 02
 Chair: Montserrat Plana
16:45 – 16:52 Host Immune Environment Impact the Level of CD4 Central Memory P12.01 D 
Reconstitution in HIV Subjects Receiving ZFN CCR5 Modified CD4  
T-Cells (SB-728-T)
 Joumana Zeidan1, G. Lee2, J. Ahlers1, J. Lalezari3, R. Mitsuyasu4, S. Wang2,  
M. Giedlin2, W. Tang2, G. Nichol2, M. Cameron1, D. Ando2, R. Sekaly1
 1Vaccine and Gene Therapy Inst - Florida, Port St. Lucie, FL, USA; 2Sangamo Biosciences, Richmond,  
CA, USA; 3Quest Clinical Res, San Francisco, CA, USA; 4UCLA, Los Angeles, CA, USA
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16:53 – 17:00 HIV-1 Protease Inhibitor Alter Cellular Protease Activity, Epitope P12.02 D 
Processing and Presentation to CD8 T Cells
 Georgio Kourjian1, Y. Xu1, J. Boucau1, M. Shimada1, P. Gourdain1, S. Le Gall1
 1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA
17:01 – 17:08 Targeting HIV-1 Where It Hurts P12.03 D
 Tina Ahmed1, P. Hayes2, N. Borthwick1, B. Ondondo1, E. Hayton1, S. Colloca3,  
A. Nicosia3, A. McMichael1, J. Gilmour2, L. Dorrell1, T. Hanke1
 1Univ of Oxford, Oxford, UK; 2IAVI Human Immunology Laboratory, Chelsea and Westminster Hospital  
and Imperial College, London, UK; 3Okairòs, Rome, Italy
17:09 – 17:16 Local Cellular Immune Responses Precede Systemic Responses P12.04 D 
Following Intravaginal SIV Infection in Rhesus Monkeys
 Jinyan Liu1, H. Li1, K. Smith1, E. Borducchi1, K. Stanley1, W. Wagner2, M. Lewis2,  
D. Barouch1
 1Beth Israel Deaconess Med CTR, Harvard Med School, Boston, MA, USA; 2Bioqual, Inc., Rockville, MD, USA
17:17 – 17:24 Immune-Correlates Analysis of the Step HIV Vaccine Efficacy Trial–A P12.05 D 
Post-Hoc Analysis of HIV-Specific and Non-specific Cellular Immune  
Responses
 Yunda Huang1, A. Duerr1, Z. Moodie1, N. Frahm1, S. DeRosa1, J. McElrath1, P. Gilbert1
 1FHCRC, Seattle, WA, USA
16:45 – 17:24 Clinical Trials L1, Room 117
 Poster Discussion Session 03
 Chair: Eric Sandström
16:45 – 16:52 Phase I Safety and Immunogenicity of Electroporated HIV DNA with or P04.01 D 
Without Interleukin 12 in Healthy HIV-Seronegative African Volunteers
 Etienne Karita1, J. Mpendo2, O. Anzala3, J. Nyombayire1, A. Namvumbya2,  
G. Mutua3, C. Schmidt4, J. Cox5, J. Gilmour5, B. Rasmussen4, J. Lehrman4, J. Eldrige6,  
M. Egan6, D. Hannaman7, L. Dally8, C. Smith8, S. Allen9, F. Priddy4, P. Fast4
 1Projet San Francisco, Kigali, Rwanda; 2UVRI-IAVI HIV Vaccine Programme, Entebbe, Uganda;  
3KAVI-Kangemi, Univ of Nairobi, Nairobi, Kenya; 4IAVI, New York, NY, USA; 5IAVI Human Immunology  
Laboratory, London, UK; 6Profectus BioSciences, Inc., Tarrytown, NY, USA; 7ICHOR Med Systems, Inc.,  
San Diego, CA, USA; 8The EMMES Corporation, Rockville, MD, USA; 9Emory Univ, School of Medicine,  
Atlanta, GA, USA
16:53 – 17:00 Enhanced HIV-Specific CD8+ T Cell Responses Following Polytopic P04.02 D 
Administration of VRC rAd5 gag-pol/env A/B/C in HIV-Uninfected  
Healthy Adults
 Ian Frank1, N. Grunenberg2, J. Hural2, P. Edlesfsen2, A. DeCamp2, M. Allen3,  
P. Spearman4, K. Bar1, S. Kalams5, L. Baden6, M. Keefer7, J. Fuchs8, R. Novak9,  
B. Graham10, M. Enama10, N. Frahm2
 1Univ of Pennsylvania, Philadelphia, PA, USA; 2Univ of Washington, Seattle, WA, USA; 3NIAID,  
NIH, Bethesda, MD, USA; 4Emory Univ, Atlanta, GA, USA; 5Vanderbilt Univ, Nashville, TN, USA;  
6Brigham and Women’s Hospital, Boston, MA, USA; 7Univ of Rochester, Rochester, NY, USA;  
8San Francisco Dept of Publ Hlth, San Francisco, CA, USA; 9Univ of Illinois, Chicago, IL, USA; 10VRC,  
NIAID, NIH, Bethesda, MD, USA
17:01 – 17:08 Distinct HIV-Specific Antibody Fc-Profiles in RV144 and VAX003 Vaccinees P04.03 D 
Amy Chung1, M. Ghebremichael1, H. Robinson1, E. Brown2, I. Choi2, M. Rolland3,  
A. Dugast1, T.J. Suscovich1, L. Liao4, A.E. Mahan1, H. Streeck3, S. Rerks-Ngarm5,  
S. Nitayaphan6, M.S. de Souza6, P. Pitisuttithum7, D. Francis8, N.L. Michael3, J.H. Kim3,  
C. Bailey-Kellog2, M.E. Ackerman2, G. Alter1
 1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; 2Dartmouth College, Hanover, NH, USA;  
3U.S. MHRP, Silver Spring, MD, USA; 4Duke Univ Human Vaccine Inst and the CTR for HIV/AIDS Vaccine  
Immunology, Durham, NC, USA; 5Ministry of Publ Hlth, Nonthaburi, Thailand; 6Armed Forces  
Res Inst of Med Sciences, Bangkok, Thailand; 7Mahidol Univ, Bangkok, Thailand; 8Global  
Solutions for Infectious Diseases, South San Francisco, CA, USA
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17:09 – 17:16 Feasibility of Enrolling Female Commercial Sex Workers at High P04.04 D 
Risk of HIV Infection for HIV Vaccine Trials in the Caribbean
 M. Deschamps1, Cecilia Morgan2, C. Zorrilla3, B. Metch2, Y. Donastorg4,  
P. Joseph1, E. Swann5, T. Madenwald2, G. Escamilla2, J.W. Pape1, HVTN 907  
Protocol Team2
 1Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO), Port au  
Prince, Haiti; 2FHCRC, Seattle, WA, USA; 3Maternal and Infant Studies CTR (CEMI), Univ of Puerto Rico  
School of Medicine, San Juan, Puerto Rico; 4Unidad de Vacunas IDCP-COIN-DIGECITSS, Santo Domingo,  
Dominican Republic; 5NIAID, NIH, Bethesda, MD, USA
17:17 – 17:24 Phase I Clinical Trial HIV-CORE002 of a Universal T-Cell Vaccine: One Year P04.05 D 
Follow On and Epitope Mapping
 Nicola J. Borthwick1, A. Nicosia2, A. McMichael1, L. Dorrell1
 1Univ of Oxford, Oxford, UK; 2CEINGE, Naples, Italy
17:30 – 19:00 Poster Session 01 and Reception L1, Room 111 – 112 
 L2, Room 211 – 212
 Poster presentations are scheduled by topic and the last two digits of the abstract presentation number. 
For example, 1.01 is an odd-numbered abstract; whereas 1.02 is an even-numbered abstract.
 Posters are available for viewing throughout the conference, however, Poster Session 01 will feature 
odd-numbered posters only.
Poster Topics Presented in L1, Room 111 – 112
•	 P01:	Adjuvants,	Immunogens	and	Inserts
•	 P02:	Animal	Models	and	Preclinical	Trials
•	 P03:	B	Cell	Immunology	and	Antibody	Functions
•	 P04:	Clinical	Vaccine	Trials	and	Trial	Site	Challenges
•	 P05:	HIV	Transmission	and	Viral	Diversity
Poster Topics Presented in L2, Room 211 – 212
•	 P06:	Immunogenetic	Factors
•	 P07:	Innate	Immunity
•	 P08:	Mucosal	Immunity
•	 P09:	Non-Vaccine	Prevention
•	 P10:	Pediatric	and	Adolescent	Infections	and	Trials
•	 P11:	Social/Ethical/Access/Regulatory	Issues
•	 P12:	T	Cell	Immunity
•	 P13:	Vaccine	Concepts	and	Design
12
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A full complimentary breakfast buffet is available in the conference hotels: The AC Hotel Barcelona Forum by Marriott and the Hotel 
Barcelona Princess. Breakfast will not be available at the CCIB.
07:30 – 18:00 Registration / Coat Check L0, Entrance Hall
07:30 – 16:30 Speaker Check-in L1, Room 118
08:30 – 10:00 Protection from Infection and Disease Progression L1, Room 113 – 116 
Plenary Session 02
 Chairs: Nicole Bernard and Christian Brander
08:30 – 09:00 Genital Immunology and HIV Susceptibility PL02.01 
Rupert Kaul1
 1Univ of Toronto, Ontario, Canada
09:00 – 09:30 Immunodeficiency Virus and the MHC: Past, Present and Future PL02.02 
Philip Goulder1
 1Univ of Oxford, Oxford, UK
09:30 – 10:00 The Role of HIV-1 Viral Evolution in Shaping Broadly Neutralizing Antibodies PL02.03 
Penelope Moore1
 1Nat’l Inst for Communicable Diseases, Johannesburg, South Africa
10:00 – 10:30 Refreshment Break L1, Room 111 – 112
  L2, Room 211 – 212
10:30 – 12:00 HIV Transmission L1, Room 113 - 114
 Oral Abstract Session 07
 Chairs: Jacob Estes and Lynn Morris
10:30 – 10:45 A Role for Glycosylation in HIV Transmission OA07.01 
F. Nawaz1, C. Cicala2, C. Schwing2, D. Wei2, J. Hiatt2, K. Jelicic2, D. Van Ryk2,  
A. Fauci2, James Arthos2
 1New York Univ, New York, NY, USA; 2NIAID, NIH, Bethesda, MD, USA
10:45 – 11:00 Role of Integrin α4β7 in HIV Transmission and Pathogenesis OA07.02 
Simone Irene Richardson1, N. Mkhize1, S. Abdool Karim2, E. Gray1, L. Morris1
 1Nat’l Inst for Communicable Diseases, Johannesburg, South Africa; 2CAPRISA, Univ of KwaZulu-Natal,  
Durban, South Africa
11:00 – 11:15 Profound Alterations in Cholesterol Metabolism Restrict HIV-1 Trans OA07.03 
Infection of CD4 T Cells in Viremic Controllers 
 Giovanna Rappocciolo1, M. Jais1, P. Piazza1, P. Gupta1, C.R. Rinaldo1
 1Univ of Pittsburgh, Pittsburgh, PA, USA
11:15 – 11:30 Highly Potent Broadly Neutralizing Antibodies Lack Potential to Inhibit OA07.04
 HIV-1 Cell-to-Cell Transmission
 Lucia Reh1, I.A. Abela1, P. Rusert1, A. Trkola1
 1Univ of Zurich, Zurich, Switzerland
Program
P
R
O
G
R
A
M
 /
 W
ED
N
ES
D
A
Y
13AIDS Vaccine 2013
Wednesday, 9 October
11:30 – 11:45 Highly Pathogenic Adapted HIV-1 Strains Limit Immune Responses and OA07.05 
Dictates Rapid Disease Progression in Early Infection
 J. Dalmau7, M. Rotger1, I. Erkizia7, A. Rauch2, P. Reche3, M. Pino7, Y. Lie4,  
R. Bellido7, A. Esteve5, E. Coackley4, E. Palou6, C. Brander7, R. Paredes7, T. Wrin4,  
B. Clotet7, A. Telenti1, J. Martinez-Picado7, Julia G. Prado7
 1Univ Hospital CTR and Univ of Lausanne, Switzerland; 2Univ Hospital Bern and Univ of Bern, Switzerland;  
3Universidad Complutense de Madrid, Spain; 4Monogram Biosciences, USA; 5Centre d’Estudis Epidemiològics  
sobre les Infeccions de Transmissió Sexual i Sida de Catalunya , Spain; 6Banc de Sang i Teixits de Barcelona, Spain;  
7 IrsiCaixa Inst for AIDS Res, HIVACAT, Barcelona, Spain
11:45 – 12:00 Genetic Selection Bias at the Heterosexual HIV-1 Transmission Bottleneck OA07.06 LB 
Jonathan Carlson1, D. Monaco2, M. Schaefer2, D. Claiborne2, J. Prince2, D. Dilernia2,  
K. Denis2, W. Kilembe3, J. Tang4, P. Farmer2, R. Kaslow4, P. Goulder5, S. Allen2,  
P. Goepfert4, D. Heckerman1, E. Hunter2
 1Microsoft Research, Los Angeles, CA, USA; 2Emory Univ, Atlanta, GA, USA; 3Zambia Emory HIV Res Project,  
Lusaka, Zambia; 4Univ of Alabama-Birmingham, Birmingham, AL, USA; 5Univ of Oxford, Oxford, UK
10:30 – 12:00 Innate and Mucosal Immunity L1, Room 115 – 116
 Oral Abstract Session 08
 Chairs: Morgane Bomsel and José Peña
10:30 – 10:45 Gut-Homing of Plasmacytoid Dendritic Cells Persists in the Absence  OA08.01 
of HIV/SIV Replication and Contributes to Residual Chronic Immune  
Activation
 R. Keith Reeves1, H. Li1, T. Evans1
 1Harvard Med School, Southborough, MA, USA
10:45 – 11:00 HIV-1 Infection Induces Potent Type I IFN Signatures in Conventional OA08.02 
Dendritic Cells from HIV-1- Elite Controllers 
 Enrique Martin-Gayo1, T. Hickman1, Z. Ouyang1, D. Pimenova1, F. Pereyra1,  
B.D. Walker2, M. Lichterfeld3, X.G. Yu1
 1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; 2Howard Hughes Med Inst, Chevy Chase,  
MD, Boston, MA, USA; 3MGH, Boston, MA, USA
11:00 – 11:15 Acute-Phase Response Proteins Are Overexpressed in Vaginal Mucosa OA08.03 
and Plasma of HIV-Resistant Women upon Viral Challenge
 Adam Burgener1, Y. Keynan2, A. Meyers3, K. Birse1, M. Abou1, G. Westmacott4,  
J. Kimani5, F. Plummer4, K. Fowke2, T. Ball3
 1Publ Hlth Agency of Canada, Winnipeg, Canada; 2Univ of Manitoba, Canada; 3Nat’l Laboratory for  
HIV Immunology, Canada; 4Nat’l Microbiology Laboratory, Canada; 5Univ of Nairobi, Nairobi, Kenya
11:15 – 11:30 Immune Complex – Fc Receptor Interactions Reduce Inflammatory OA08.04 
Responses at the Genital Mucosa as a Correlate of SIV Vaccine-Induced 
Protection
 Liang Shang1, A.J. Smith2, S.W. Wietgrefe1, C.S. Reilly1, P.J. Southern1, K.E. Perkey1,  
L. Duan1, J. Robinson3, R. Johnson4, A.T. Haase1
 1Univ of Minnesota, Minneapolis, MN, USA; 2DeVry Med International, The Bahamas; 3The Scripps Res  
Inst, La Jolla, CA, USA; 4Harvard Med School, Southborough, MA, USA
11:30 – 11:45 Optimization of Systemic and Mucosal Immune Responses to SIV OA08.05 
and HIV-1 Antigens Using Different Protocols of DNA and Protein  
Immunization in Macaques
 George N. Pavlakis1, R. Jalah1, J. Li1, A. Valentin1, M. Rosati1, V. Patel1,  
V. Kulkarni1, C. Alicea1, R. Kelly Beach1, Y. Guan2, J.D. Lifson3, V.M. Hirsch4,  
D. Venzon1, K.E. Broderick5, N.Y. Sardesai5, T.R. Fouts6, A. Pinter7, C. LaBranche8,  
D.C. Montefiori8, S. Shen8, G.D. Tomaras8, B.K. Felber1
 1Nat’l Cancer Inst, NIH, Frederick, MD, USA; 2Inst of Human Virology, Baltimore, MD, USA; 3SAIC-Frederick,  
Inc., Frederick, MD, USA; 4NIAID, NIH, Bethesda, MD, USA; 5Inovio Pharmaceuticals, Inc., Blue Bell, PA, USA;  
6Profectus BioSciences, Inc., Baltimore, MD, USA; 7Univ of Medicine and Dentistry of New Jersey, Newark, NJ,  
USA; 8Duke Univ Med CTR, Durham, NC, USA
14
Program
P
R
O
G
R
A
M
 / W
ED
N
ESD
A
Y
AIDS Vaccine 2013
Wednesday, 9 October
11:45 – 12:00 Immune Correlates of a Functional Cure Following Therapeutic Vaccination OA08.06 LB 
of SIV-Infected Rhesus Macaques
 Deborah Fuller1, A. Narandren2, P. Rajakumar3, J.W. Che3, J. Nyaundai3, H. Michael3,  
E.J. Yager2, F. Cook4, J. Tite4
 1Univ of Washington, Seattle, WA, USA; 2Albany Med College, Albany, NY, USA; 3Univ of Pittsburgh,  
Pittsburgh, PA, USA; 4GSK, Stevenage, UK
10:30 – 11:50 Viral Vaccine Vectors L1, Room 117
 Symposium 04
 Chairs: Dan Barouch and Tomas Hanke
10:30 – 10:50 Development of HIV Vaccines— A Vaccine Manufacturer’s Perspective S04.01 
Gerald Voss1
 1GSK Vaccines, Rixensart, Belgium
10:50 – 11:10 Sendai Virus Vector Vaccine S04.02
 Tetsuro Matano1
 1Nat’l Inst of Infectious Diseases, Tokyo, Japan
11:10 – 11:30 Reinventing the Nucleic Acid Vaccine S04.03
 Andrew Geall1
 1Novartis Vaccine and Diagnostics, Cambridge, MA, USA
11:30 – 11:50 Durable Antibody Responses Induced by DNA and Recombinant S04.04 
Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
 Harriet Robinson1, G. Tomaras2, K. Seaton2, A. Sato3, J. Hural3, S. DeRosa3, N. Frahm3,  
B. Moss4, P. Goepfert5
 1GeoVax, Inc., Smyrna, GA, USA; 2Duke University Med CTR, Durham, NC, USA; 3FHCRC, Seattle, WA,  
USA; 4NIAID, NIH, Bethesda, MD, USA; 5Univ of Alabama at Birmingham, Birmingham, AL, USA
12:00 – 13:00 Lunch L2, Banquet Hall
12:00 – 13:00 Delegate Networking Lunch L2, Banquet Hall
Lunch tables have been reserved for young and early-career investigators to network with senior researchers. The list of 
participating researchers is available at the conference registration desk along with a sign-up sheet. Space is limited and will 
be reserved on a first-come, first-served basis. 
13:00 – 14:20 New Targets from Acute Infection L1, Room 113 – 114 
Symposium 05
 Chairs: Bruce Walker and Carolyn Williamson
13:00 – 13:20 Targeting the Female Reproductive Tract Epithelium to Prevent S05.01 
Transmission and Acute Systemic Infection: Lessons Learned in the  
SIV-NHP Model
 Ashley Haase1
 1Univ of Minnesota, Minneapolis, MN, USA
13:20 – 13:40 Host-Virus Interactions in HIV-1 Rapid Disease Progression S05.02 
Javier Martinez-Picado1
 1 IrsiCaixa Inst for AIDS Res, HIVACAT, Autonomous Univ of Barcelona, Barcelona, Spain
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13:40 – 14:00 Phenotypic Properties of Acute HIV-1 Associated with Transmission S05.03 
Fitness and Virulence 
 Eric Arts1
 1Case Western Reserve Univ School of Med, Cleveland, OH, USA
14:00 – 14:20 Modeling the Effects of Vaccination on Acute Phase CD8+ T Cell S05.04 
Immunodominance Patterns to HIV in Humanized Mice
 Todd Allen1
 1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA
13:00 – 14:20 Humoral Immunity L1, Room 115 – 116
 Symposium 06
 Chairs: Dennis Burton and Eloísa Yuste
13:00 – 13:20 A Pure Native Env Trimer Vaccine Elicits Potent Tier 2 Neutralization to a S06.01 
Quaternary, Glycan-Sensitive Epitope
 James Binley1, B. Chakrabarti2, E. Crooks1, S. Du3, J. Muranaka3, K. Narayan3,  
K. Osawa1, T. Tong1, R. Whalen3, R. Wyatt4
 1Torrey Pines Inst for Molecular Studies, San Diego, CA, USA; 2IAVI Neutralizing Antibody CTR at The Scripps  
Research Institute, La Jolla, CA, USA; 3Altravax, Sunnyvale, CA, USA; 4The Scripps Res Inst, La Jolla, CA, USA
13:20 – 13:40 Genetic Development of HIV-1 Neutralizing Antibody Lineages S06.02 
John Mascola1
 1VRC, NIAID, NIH, Bethesda, MD, USA
13:40 – 14:00 HIV Vaccine Design to Induce Broadly Neutralizing Antibodies S06.03 
William Schief1
 1The Scripps Res Inst, La Jolla, CA, USA
14:00 – 14:20 Recombinant Env Interactions with the BCRs of Broadly Neutralizing S06.04 
Anti-HIV Antibodies
 Leonidas Stamatatos1
 1Seattle Biomedical Res Inst, Seattle, WA, USA
13:00 – 14:30 Clinical Trial Follow-up and Retention L1, Room 117 
Roundtable Discussion
 Chairs: Sheena McCormack and Jose Maria Miró  
The efforts of researchers and institutions and the support and participation of communities impacted by HIV has been and 
continues to be essential to advancing efforts to develop an HIV vaccine. This roundtable will discuss the importance of 
and strategies around recruiting, retaining and following clinical trial participants throughout the entirety of the clinical trial 
process; lessons learned from strata analysis and sub-studies; as well as challenges and strategies to encourage adherence to 
additional preventive measures during and after the trial.  The session will include brief presentations followed by an open 
discussion around the issues raised with attendees.
 Susan Buchbinder
 San Francisco Department of Public Health, San Francisco, CA, USA
 Glenda Gray
 Perinatal HIV Research Unit, Johannesburg, South Africa
 Scott Hammer
 Columbia University Medical Center, NY, USA
 Punnee Pitisuttithum
 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
14:30 – 15:00 Refreshment Break L1, Room 111 – 112
  L2, Room 211 – 212
16
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15:00 – 16:20 Therapeutic Vaccines and Viral Latency L1, Room 113 – 114 
Symposium 07
 Chairs: Felipe Garcia and Rafick-Pierre Sekaly
15:00 – 15:20 Dendritic Cell-Based Immunotherapy in HIV-Infection: “A Bridge Over S07.01 
Troubled Water”
 Jean-Pierre Routy1, M. Jenabian1, C. Nicolette2, I. Tcherepanova2, R. Sekaly3
 1McGill Univ, Montreal, Canada; 2Argos Therapeutics, Durham, NC, USA; 3VGTI Florida, Port St. Lucie, FL, USA
15:20 – 15:40 Viral Persistence Under ART and the Challenges of Eradicating S07.02 
Myeloid Reservoirs
 Mario Stevenson1
 1Univ of Miami Miller School of Med, Miami, FL, USA
15:20 – 15:40 Therapeutic Concepts for HIV Eradication S07.03 
Romas Geleziunas1
 1Gilead Sciences, Inc., Foster City, CA, USA
16:00 – 16:20 Immune Mechanisms and HIV Eradication S07.04 
Michael Lederman1
 1Case Western Reserve Univ, Univ Hospitals Case Med CTR, Cleveland, OH, USA
15:00 – 16:20 New Vaccine Concepts       L1, Room 115 – 116
 Symposium 08
 Chairs: Julía Blanco and Yves Levy
15:00 – 15:20 Refocusing CTL and Antibody Responses with p24gag Conserved S08.01 
Elements Vaccines
 James Mullins1
 1Univ of Washington, Seattle, WA, USA
15:20 – 15:40 HIVACAT T- and B-Cell Immunogen Design and Preclinical Testing S08.02 
Christian Brander1
 1 IrsiCaixa Inst for AIDS Res, HIVACAT, Barcelona, Spain
15:40 – 16:00 Protection Against HIV: Vaccination to Block Inflammation S08.03 
D. Hartigan-O’Connor1, A. Tarantal1, Joseph M. McCune2
 1Univ of California-Davis, Davis, CA, USA; 2Univ of California-San Francisco, San Francisco, CA, USA
16:00 – 16:20 Immunological and Virological Mechanisms of Vaccine-Mediated S08.04 
Protection Against SIV
 A. Buzby1, L. Mach1, L. Shen1, M. Alam2, T. Denny2, G. Ferrari2, R. Gottardo3,  
W. Fischer4, B. Korber4, W. Gu5, M. Nason5, Mario Roederer6
 1Beth Israel Deaconess Med CTR, Boston, MA, USA; 2Duke Univ, Durham, NC, USA; 3FHCRC,  
Seattle, WA, USA; 4LANL, Los Alamos, NM, USA; 5NIAID, NIH, Bethesda, MD, USA;  
6VRC, NIAID, NIH, Bethesda, MD, USA
15:00 – 16:20 Mucosal Immunity L1, Room 117
 Symposium 09
 Chairs: Jason Brenchley and Ronald Desrosiers
15:00 – 15:20 Visualizing Cellular Dynamics of HIV Infection In Vivo S09.01 
Thomas Murooka2 , M. Deruaz2, F. Marangoni2, V. Vrbanac2, E. Seung2, U. von Andrian1,  
A. Tager2, A. Luster2, T. Mempel2
 1Harvard Med School, Boston, MA, USA; 2Massachusetts General Hospital, Boston, MA, USA
15:20 – 15:40 Dynamic Interplay Between Virus and Host Occurring at the Female S09.02 
Reproductive Tract During Acute HIV Infection and Treatment
 J. Victor Garcia-Martinez1
 1Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA
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15:40 – 16:00 Identification and Characterization of Specific IgG-mucin Interactions S09.03 
to Enhance Vaccine Function
 Thomas Hope1, G. Alter2, B. Gunn2, M. Shansab2
 1Northwestern Univ, Chicago, IL, USA; 2Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA
16:00 – 16:20 Prime and Pull: A Vaccine Strategy for Viral Sexually Transmitted Infections S09.04 
Haina Shin1, A. Iwasaki1
 1Yale Univ School of Med, New Haven, CT, USA
16:20 – 16:45 Break
16:45 – 17:32 HIV Transmission L1, Room 113 – 114
 Poster Discussion Session 04
 Chairs: Eric Hunter and Alexandra Trkola
16:45 – 16:52 Rapid Detection of Early HIV-1 Infections by Direct Sequencing of P05.01 D 
an Hypervariable Segment of the Viral Env Gene
 Gabriel Damilano1, E. Socias2, C. Magneres2, G. Turk1, O. Sued2, J. Ruiz1,  
M. Gomez-Carrillo1, H. Salomon1, D. Dilernia3
 1Inst for Biomedical Res on Retroviruses and AIDS, Buenos Aires, Argentina; 2HUESPED Fundation,  
Buenos Aires, Argentina; 3Emory Vaccine CTR, Atlanta, GA, USA
16:53 – 17:00 Mechanism of HIV Entry into the Columnar Epithelium of the Female P05.02 D 
Genital Tract
 Ann Carias1, M. Anderson1, T. Hope1
 1Northwestern Univ, Chicago, IL, USA
17:01 – 17:08 Impact of Host Cell-Specific Glycosylation Differences on SIV P05.03 D 
Infectivity and Mucosal Transmission
 Christina Karsten1, F.F. Buettner2, I. Nehlmeier1, U. Sauermann1,  
B. Neumann1, C. Stahl-Hennig1, R. Gerardy-Schahn2, S. Pöhlmann1
 1German Primate CTR, Göttingen, Germany; 2Inst for Cellular Chemistry, Hannover Med  
School, Hannover, Germany 
17:09 – 17:16 The V1V2 Domain Preserves Envelope Functionality During Free P05.04 D 
Virus Transmission but Is Largely Dispensable for Cell-Cell Transmission 
Oliver Brandenberg1, P. Rusert1, C. Magnus1, J. Weber1, R.R. Regoes2, A. Trkola1
 1Univ of Zurich, Zurich, Switzerland; 2ETH Zurich, Zurich, Switzerland
17:17 – 17:24 Relative Contribution of Gag, Nef, and Env to Minority Variant P05.31 LB D 
Transmission Revealed by Deep Sequencing of Transmission Pairs 
 Rebecca Batorsky1, M. Schaefer2, K. Power1, D. Tully1, E. Hunter2, T. Allen1
 1Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA; 2Emory Univ, Atlanta, GA, USA
17:25 – 17:32 The Nervous System Can Restrict ‘At a Distance’ Langerhans  P08.23 LB D 
Cell-Mediated HIV-1 Transmission via the Neuropeptide Calcitonin  
Gene-Related Peptide 
 Morgane Bomsel1, A Drillet1, L Lopalco2, G Tambussi2, D Tudor1, M Zerbib3,  
N Bary de Lonchanps3, Y Ganor1
 1Institut Cochin- CNRS UMR 8104- INSERM U1016- Paris Descartes Univ, Paris, France;  
2San Raffaele Scientific Inst, Italy, 3GH Cochin-St Vincent de Paul, Paris, France
18
Program
P
R
O
G
R
A
M
 / W
ED
N
ESD
A
Y
AIDS Vaccine 2013
Wednesday, 9 October
16:45 – 17:32 Vaccine Concepts L1, Room 115 – 116
 Poster Discussion Session 05
 Chair: Barbara Felber and Julie McElrath
16:45 – 16:52 Cross-Neutralizing Antibodies Are Elicited in Macaques Immunized P13.01 D 
with DNA and Protein Env Vaccines Derived from Subjects During  
Development of Breadth
 Ann Hessell1, D.C. Malherbe1, F. Pissani1, N. Sather2, H. Robins3, W.F. Sutton1,  
S. Pandey1, B. Park1, L. Stamatatos2, N.L. Haigwood1
 1VGTI, Oregon Hlth & Science Univ, Beaverton, OR, USA; 2Seattle Biomed, Seattle, WA, USA;  
3FHCRC, Seattle, WA, USA
16:53 – 17:00 Synthetic Enhanced EP Delivered Ig DNA Vector Drives Biologically P13.02 D 
Relevant Anti-HIV-1 Envelope Responses In Vivo
 Kar Muthumani1, S. Fligai1, M. Wise1, C. Tingey1, J. Yan2, K.E. Ugen3, D.B. Weiner1
 1Univ of Pennsylvania School of Medicine, Philadelphia, PA, USA; 2Inovio Pharmaceuticals,  
Blue Bell, PA, USA; 3Univ of South Florida Morsani College of Medicine, Tampa, FL, USA
17:01 – 17:08 Increased Neutralizing Antibody Responses Elicited by a Bivalent P13.03 D 
HIV-1 Env Protein Vaccine Comprising Stable Mosaic and Clade C HIV-1  
gp140 Trimers
 Joseph Nkolola1, C.A. Bricault1, A. Cheung1, J. Perry1, M. Seaman1, D. Barouch1
 1Beth Israel Deaconess Med CTR, Boston, MA, USA
17:09 – 17:16 Association of CD8+ T Cell R sponses to Conserved HIV Epitopes P13.04 D 
with Viral Control: Implications for HIV Vaccine Design
 Pratima Kunwar1, N. Hawkins2, W.L. Dinges3, Y. Liu4, E.E. Gabriel2,  
D.A. Swan2, C. Stevens4, J. Maenza4, A.C. Collier4, J.I. Mullins4, T. Hertz2,  
X. Yu2, H. Horton4
 1Seattle Biomedical Res Inst, Seattle, WA, USA; 2FHCRC, Seattle, WA, USA; 3Polyclinic Infectious  
Disease, Seattle, WA, USA; 4Univ of Washington, Seattle, WA, USA
17:17 – 17:24 High Affinity Recognition of Synthetic Glycopeptides by HIV-1 P13.67 LB D 
gp120 V1V2 Loop Broadly Neutralizing Antibodies and Their  
Unmutated Common Ancestors
 Munir Alam1, M.S. Dennison1, B. Aussedat2, Y. Vohra2, P.K. Park2, A. Fernández-Tejada2,  
S. Stewart1, F.H. Jaeger1, K. Anasti1, J.H. Blinn1, T.B. Kepler3, H. Liao1, J.G. Sodrosk4,  
S.J. Danishefsky2, B.F. Haynes1
 1Duke University Medical Center, Durham, NC, USA; 2Sloan-Kettering Institute for Cancer Research,  
New York, NY, USA; 3Boston University School of Medicine, Boston, MA, USA; 4Dana-Farber Cancer  
Institute, Boston, MA, USA
17:25 – 17:32 Novel R5 Tropic Founder Env SHIV for Nonhuman Primate P13.68 LB D 
Immunoprophylactic Studies 
 Jeffrey D. Lifson1, G.Q. Del Prete1, B. Moldt2, B.F. Keele1, J.D. Estes1, K. Oswald1,  
R. Fast1, C.M. Trubey1, J. Smedley1, D.R. Burton2, V. KewalRamani3, M. Piatak, Jr.1,  
P. Bieniasz4, T. Hatziioannou4
 1SAIC Frederick, Inc., Frederick Nat’l Labs, Frederick, MD, USA; 2The Scripps Res Inst, La Jolla, CA, USA;  
3Nat’l Cancer Inst, Frederick, MD, USA; 4The Rockefeller Univ, New York, NY, USA
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16:45 – 17:30 Non-vaccine Prevention and Social-ethical Aspects L1, Room 117 
Poster Discussion Session 06
 Chair: Michael Meulbroek
16:45 – 16:52 Anti-HIV Activity of 5-Hydroxytyrosol, a Microbicidal Candidate P09.01 D 
L. Bedoya2, M. Beltrán2, D. Auñón1, E. Gómez-Acebo1, Jose Alcami2
 1Seprox Biotech, Spain; 2Centro Nacional de Microbiología Instituto de Salud Carlos III, Madrid, Spain
16:53 – 17:00 Neutralization of Diverse HIV Strains by V3 Specific DARPins with P09.02 D 
Different Structural Preferences in Epitope Recognition
 Nikolas Friedrich1, A. Mann1, E. Stiegeler1, Y. Wu1, A. Batyuk1, P. Rusert1, J. Weber1,  
B. Dreier1, M. Robbiani2, J.A. Robinson1, A. Plückthun1, A. Trkola1
 1Univ of Zurich, Zurich, Switzerland; 2Population Council, New York, NY, USA
17:01 – 17:08 Getting to Zero with an HIV Vaccine: Modeling the Impact of Introduction P11.01 D 
of the Current HIV Vaccine Pipeline Under the Investment Framework
 J. Aylward2, E.D. Donaldson1, K. Fisher1, T. Harmon2, M. McGlynn2, Arne Naeveke2,  
J. Stover3, M. Warren1
 1AVAC, New York, NY, USA; 2IAVI, New York, NY, USA; 3Futures Inst, Glastonbury, CT, USA
17:09 – 17:16 A Survey of Community Opinions and Preferences on PrEP, Microbicides P11.02 D 
and Vaccines in 5 Regions and with Key Populations in Kenya
 Judie Mbogua1, B.P. Ngongo1, J. Ndegwa2, B. Bender1, F. Manguyu1
 1IAVI, Nairobi, Kenya; 2Kenya AIDS NGO Consortium, Nairobi, Kenya
17:17 – 17:24 The Role of Stakeholders Involvement Towards the Success of Vaccine/Clinical P11.03 D 
Trials—The Partners PrEP Study
 Charles Brown1
 1Infectious Diseases Inst - PrEP Study, Kampala, Uganda
17:30 – 19:00 Poster Session 02 and Reception L1, Room 111 – 112 
 L2, Room 211 – 212
 Poster presentations are scheduled by topic and the last two digits of the abstract presentation number. 
For example, 1.01 is an odd-numbered abstract; whereas 1.02 is an even-numbered abstract.
 Posters are available for viewing throughout the conference, however, Poster Session 02 will feature 
even-numbered posters only.
Poster Topics Presented in L1, Room 111 – 112
•	 P01:	Adjuvants,	Immunogens	and	Inserts
•	 P02:	Animal	Models	and	Preclinical	Trials
•	 P03:	B	Cell	Immunology	and	Antibody	Functions
•	 P04:	Clinical	Vaccine	Trials	and	Trial	Site	Challenges
•	 P05:	HIV	Transmission	and	Viral	Diversity
Poster Topics Presented in L2, Room 211 – 212
•	 P06:	Immunogenetic	Factors
•	 P07:	Innate	Immunity
•	 P08:	Mucosal	Immunity
•	 P09:	Non-Vaccine	Prevention
•	 P10:	Pediatric	and	Adolescent	Infections	and	Trials
•	 P11:	Social/Ethical/Access/Regulatory	Issues
•	 P12:	T	Cell	Immunity
•	 P13:	Vaccine	Concepts	and	Design
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A full complimentary breakfast buffet is available in the conference hotels: The AC Hotel Barcelona Forum by Marriott and the Hotel 
Barcelona Princess. Breakfast will not be available at the CCIB.
07:30 – 14:30 Registration / Coat Check L0, Entrance Hall
08:30 – 10:00 Innovations in HIV Vaccine Discovery L1, Room 113 – 116 
Plenary Session 03
 Chairs: Brigitte Autran and George Pavlakis
08:30 – 09:00 Nanotechnology Approaches for Designing Novel HIV Vaccines PL03.01 
M. Luo1, María José Alonso2
 1Univ of Manitoba, Manitoba, Canada; 2Univ of Santiago de Compostela, Santiago  
de Compostela, Spain
09:00 – 09:30 Cutaneous Routes for HIV Vaccination Strategies PL03.02 
Behazine Combadiere1
 1INSERM, UPMC, Paris, France
09:30 – 10:00 HIV Vaccine Development: A View from the Outside PL03.03 
Adrian Hill1
 1Univ of Oxford, Oxford, UK
10:00 – 10:30 Refreshment Break L1, Foyer
10:30 – 13:00 Emerging Clinical Trial Data L1, Room 113 – 116
 Plenary Session 04
 Chairs: Mariano Esteban and Britta Wahren
10:30 – 10:55 The First Clinical Evaluation of Conserve-Region Vaccines in Humans PL04.01 
P. Hayes1, J. Vasilyeva2, N. Frahm2, J. Cox1, S. Colloca3, A. Nicosia4,  
J. Gilmour1, Tomas Hanke5
 1IAVI, Imperial College, London, UK; 2FHCRC, Seattle, WA, USA; 3Okairos, Rome, Italy; 4Okairos,  
CEINGE, Univ of Naples, Naples, Italy; 5Univ of Oxford, Oxford, UK
10:55 – 11:20 The HIVIS and TaMoVac Studies, a North-South Collaboration PL04.02 
Muhammad Bakari1
 1Muhimbili Univ of Hlth and Allied Sciences, Dar es Salaam, United Republic of Tanzania 
11:20 – 11:45 Looking Back to Move Forward: Understanding ALVAC/AIDSVAX PL04.03 
Immune Responses
 Robert O’Connell1
 1AFRIMS, Bangkok, Thailand
11:45 – 12:10 Vaccine Induced Antibody Responses in HVTN 505, a Phase IIb HIV-1 Efficacy Trial PL04.04
 Georgia D Tomaras1, X. Shen1, K. Seaton1, H. Janes2, D. Grove2, A. deCamp2, Y. Fong2,  
H. Liao1, Z. Yang3,6, T. Xu1, J. H. Kim4, N. L. Michael4, R. T. Bailer3, G. Ferrari1, J. Mascola3,  
R. A. Koup3, G. Nabel3,6, L. Corey2, S. Karuna2, D. C. Montefiori1, M. J. McElrath2, B. F. Haynes1,  
P. Gilbert2, B. S. Graham3, M. Sobieszczyk5, S. M. Hammer5
 1Duke University Medical Center, Durham, NC; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Vaccine  
Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.;  
4Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD; 5Division of Infectious  
Diseases, Columbia University Medical Center, New York, NY; 6Sanofi, USA
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12:10 – 12:35 An Update on the Phambili/HVTN 503 Study, a Phase IIB HIV Vaccine PL04.05 
Efficacy Study Investigating MRK Ad5 HIV-1 Subtype B gag/pol/nef Vaccine 
Glenda Gray1
 1Perinatal HIV Res Unit, Johannesburg, South Africa
12:35 – 13:00 Meta-Analysis of Ad5-vector HIV Vaccine Trials to Assess the Vaccine Effect PL04.06 
on HIV Acquisition  
Y. Huang1, D. Follmann2, M. Nason2, L. Zhang1, Y. Huang1, D. Mehrotra3 , Z. Moodie1,  
B. Metch1, H. Janes1, M. Keefer4, G. Churchyard6, M. Robb10, P. Fast5, A. Duerr1, L. Corey1,  
J. Mascola2, B. Graham2, M. Sobieszczyk7, J. Kublin1, M. Robertson3, S. Hammer7, G. Gray8,  
S. Buchbinder9, Peter Gilbert1
 1FHCRC, Seattle, WA, USA; 2NIAID, Bethesda, MD, USA; 3Merck, USA; 4Univ of Rochester Med Center,  
Rochester, NY, USA; 5International AIDS Vaccine Initiative (IAVI); 6Aurum Institute, Johannesburg, South Africa;  
7Columbia Univ, New York, NY, USA; 8Perinatal HIV Research Unit, South Africa; 9San Francisco Dept of Publ Hlth,  
San Francisco, CA, USA; 10U.S. Military HIV Research Program, Bethesda, MD, USA
13:00 – 13:50 Closing Session L1, Room 113 – 116
 Chairs: Christian Brander, Bonaventura Clotet, and José M. Gatell
13:00 – 13:20 What Has 30 Years of HIV Vaccine Research Taught Us? Lessons from CS.01 
The Past To Inform The Future
 José Esparza1 
 1Bill & Melinda Gates Foundation, Seattle, WA, USA
13:20 – 13:25 AIDS Vaccine 2013 At-A-Glance 
2013 Conference Chairs
 Christian Brander1, Bonaventura Clotet2, José M. Gatell3
 1IrsiCaixa Inst for AIDS Res, HIVACAT, ICREA, Barcelona, Spain; 2IrsiCaixa Inst for AIDS Res, HIVACAT,  
Barcelona, Spain; 3Hospital Clínic, IDIBAPS, HIVACAT, University of Barcelona, Spain
13:25 – 13:35 AIDS Vaccine Research, Where We Are and Where We Are Going
 Nina Russell1,2
 1Bill & Melinda Gates Foundation, Seattle, WA, USA; 2Global HIV Vaccine Enterprise, New York, NY, USA
13:35 – 13:50 HIV Research for Prevention  
2014 Conference Co-Chairs
 Eric Hunter1, Robin Shattock2
 1Emory Univ, Atlanta, GA, USA, 2Imperial College London, UK
15:00 – 17:00 Satellite Session 
 See pages 16 of Program Book for detailed information.
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OS.01
Partnership Towards a Tough Target: 
Communities Are an Essential Ingredient, Not a 
Cherry on Top
N. Yola1
1NACOSA, Cape Town, South Africa
History has taught us that the way to eradicate a global epidemic is 
to design, produce massively and then systematically vaccinate the 
population with an effective prophylactic vaccine. We have also learned 
from the past that this route to a “silver bullet” may be a long and 
complicated one. Today almost 60 million men, women and children 
having been infected and nearly 25 million attributable deaths, twenty 
five years of this epidemic has taken a horrific toll. In the small country 
of South Africa, more people live with HIV than anywhere else in the 
world. Too many are being infected in that country and around the 
world as we speak. The urgency we felt 3 decades ago to find an 
effective vaccine has in no way diminished. We saw in 2009, the first 
hope that a prophylactic HIV vaccine may be possible, but it is likely 
that this endeavor will , in order to realize real Progress require in 
addition meaningful Partnership and diligent Perseverance. It is a time, 
therefore, to take stock of the role stakeholders have played and to 
ensure strategic engagement so they not only continue to support the 
field, but make it better.
The global race against HIV/AIDS presents realities for all concerned. 
The scientific agenda is not only that of discovering antibodies or 
demystifying the immune response, but of addressing the realities of 
affected communities. Scientific research is less likely to achieve what 
it sets to if these realities are overlooked. The social, economic, political 
and personal realities of people from around the world vary and are 
significant. The real conditions of people in developing countries have 
potential to present both challenging and supportive environment for 
the successes of the trials and ultimately in the implementation of an 
effective vaccine. The theme of this meeting highlights the power of 
drawing scientific Progress together with the ideals of Partnership and 
Perseverance. As the vaccine field advances, we can celebrate strong 
partnerships with trial communities and wider stakeholders. There is 
willingness to work towards a supportive enabling environment for 
clinical trials which can only be achieved through expressive and 
practical partnership. To persevere, we must not desert this investment, 
but look at opportunities to sustain it for the long term, until an end 
to AIDS is realized. 
OS.02
HIV Vaccines in the Context of Vaccine 
Development in General
S.A. Plotkin1
1University of Pennsylvania, Doylestown, PA, USA
The HIV vaccine picture continues to be chiaroscuro, with bright spots 
and shadows. However, real progress has been made, with evidence 
for efficacy, identification of possible correlates of protection, definition 
of immune priming in prime-boost regimens, structural analysis of 
gp160, and the possible utility of effector CD8+ cells, just to name a 
few. On the other hand, it appears that non-specific immune activation 
may be undesirable, so the properties of vectors are critical. I will point 
out that other vaccines in development have had similar problems and 
that vaccine development is not always straightforward.
Opening Session
O
P
EN
IN
G
 S
ES
SI
O
N
23AIDS Vaccine 2013
 
OS.03
Insights from HIV Vaccine Efficacy Trials: What 
We Are Learning from HVTN 505?
M. Sobieszczyk1
1Columbia University, New York, NY, USA
Thirty years following the discovery of HIV-1, a safe and effective 
vaccine remains elusive. The modest protective effect seen in RV144 
contrasts with the negative results of VAX 003, VAX 004, Step, and 
Phambili trials. To this latter list must now be added HVTN 505, a phase 
2b trial of a multigene DNA prime/rAd5 boost vaccine regimen. This 
study enrolled 2504 men and transgender women who have sex with 
men. Vaccinations were discontinued following a DSMB review in April 
2013 as efficacy futility was declared for both the HIV acquisition and 
post-acquisition setpoint viral load endpoints. Although disappointing, 
data generated in HVTN 505 about the immunogenicity profile of 
the vaccine will add new knowledge to the vaccine discovery process 
and provide guidance for prioritizing immunogenicity endpoints for 
subsequent Phase I/II vaccine trials. 
OS.04
Toward Ending the HIV/AIDS Pandemic: 
Synergy Between Vaccine and Non-Vaccine 
Interventions
A. Fauci1
1NIAID, NIH, Bethesda, MD, USA
Significant decreases in rates of HIV acquisition likely can be achieved 
with the growing armamentarium of non-vaccine prevention and 
treatment modalities. However, accomplishing this goal without an 
HIV vaccine will take much longer and, importantly, may not be 
sustainable. Recent advances in understanding the complex B-cell 
pathways to potentially protective immune responses, together with 
greater insight into the role of T cells in this process has heightened the 
feasibility of developing next-generation HIV vaccines. A synergistic 
process involving non-vaccine and vaccine modalities could lead to 
effective and sustained prevention of HIV acquisition, and perhaps, for 
some infected individuals, a functional cure.
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PL01.01
Manufacturing HIV Envelope Proteins for HIV 
Vaccines: An NIAID Perspective of Where We 
Are and What Is Still Needed
M. Pensiero1
1NIAID, NIH, Bethesda, MD, USA
The recent success of RV144 has refocused the HIV vaccine field on the 
importance of including an Env immunogen as part of an efficacious 
vaccine regimen. Over the past two years, there has been considerable 
effort focused on attempting to manufacture HIV Env proteins towards 
that purpose. However, despite the best efforts, there still is a dearth 
of HIV Env available for clinical testing, let alone for use in clinical 
research, to answer basic fundamental questions of how best to 
improve neutralizing breadth and durability. This abstract will provide 
a perspective from an extramural NIAID scientist responsible for 
managing a portfolio of large grants and contracts targeted to support 
HIV Env manufacturing. Not only will common manufacturing hurdles 
be discussed, but also a potential path forward to accelerate advancing 
HIV Env protein manufacturing will be presented, such as using 
transient transfection, management of common product development 
pitfalls, preferred CMO/Analytics outsourcing, etc.  
Understanding the manufacturing issues will provide a clearer 
framework to develop possible solutions and a more realistic 
expectation of the timelines necessary to manufacture an HIV Env of 
sufficient quality attributes (e.g., potency, purity, and identity) for use 
in human clinical trials.  
PL01.02
Vaccine Induction of T Cell Immunity to HIV-1
A. McMichael1
1University of Oxford, Oxford, UK
Because a vaccine that stimulates highly protective antibody immunity 
to HIV-1 is still distant, development of a ‘T cell vaccine’ remains an 
option. In macaques, such a vaccine can clear virus early in infection 
or reduce virus load after infection. Combining a T cell vaccine with an 
antibody inducing vaccine could offer significant benefits if the latter 
was not 100% efficient. However, the STEP and HVTN505 trials of T 
cell stimulating vaccines showed no efficacy in humans. Possibly these 
vaccines generated T cell responses that were too weak, too narrow 
and too focused on variable HIV-1 epitopes. In macaques, protective 
CD8 T cell responses were of much greater magnitude and breadth. 
Indeed, very strong broad activated CD8 T cells can clear early SIV 
infection. What T cell response features determine virus control? Elite 
HIV-1 controllers have: polyfunctional Gag specific T cell responses, 
often restricted by HLA allotypes B57, B58, B27 or B81 which present 
conserved epitopes, cross reacting T cell clonotypes and T cells that 
suppress virus replication in vitro. However, while antigen sensitivity 
and virus inhibition correlate strongly they are not specific for clonotype; 
state of T cell activation rather than polyfunctionality may determine 
antigen sensitivity. Focus on conserved and vulnerable epitopes, not 
only those presented by protective HLA types, must be important. 
How these relate the fitness landscape is also critical. Vaccines should 
target these epitopes rather than following normal immunodominance 
patterns. There are at least four immunogen designs aimed at doing 
this. Our phase one trial of the HIVconsv construct shows that such 
constructs are immunogenic in humans and stimulate T cells that can 
recognize HIV infected cells and suppress virus replication. There is 
now a need to agree on how to optimize such vaccines and to progress 
them to efficacy testing.
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PL01.03
Pathways of Affinity Maturation of HIV-1 
Broadly Neutralizing Antibodies
B. Haynes1
1Duke Human Vaccine Institute, Durham, NC, USA
The induction of broad neutralizing antibodies (BnAbs) is hindered by 
a myriad of roadblocks, not the least of which includes host immune 
regulatory controls. In HIV-1 infected individuals who do develop 
plasma BnAb activity, the evolved virus variants are responsible for 
BnAb induction. The Duke CHAVI-ID team has begun to map both 
BnAb and virus evolution pathways in 17 individuals who were 
followed from the time of HIV-1 infection through induction of plasma 
BnAbs. The status of this work will be presented and new immunization 
strategies that derive from this work will be discussed.
Plenary 01: HIV Vaccine Strategies
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PL02.02
Immunodeficiency Virus and the MHC: Past, 
Present and Future
P. Goulder1
1University of Oxford, Oxford, UK
The role of the MHC in control of immunodeficiency virus infection will 
be addressed, focusing on HIV infection in humans and its SIV model 
in macaques. The studies that have brought us to the current state of 
the art will be reviewed and the potential future impact of HLA/HIV 
coevolution discussed.  
PL02.01
Genital Immunology and HIV Susceptibility
R. Kaul1
1University of Toronto, Ontario, Canada
Although HIV transmission is relatively rare after sexual exposure, it 
has resulted in a devastating global pandemic. Susceptibility to HIV is 
heterogeneous, but understanding the mucosal immune determinants 
of sexual transmission is complicated by the low frequency of 
transmission.
We have carried out ex vivo studies of cervical and foreskin mucosal 
immunology in cohorts of low risk, HIV-infected and HIV-exposed, 
persistently seronegative (HEPS) participants from Canada and East 
Africa. Studies use endocervical cytobrush samples and ectocervical 
biopsies from female participants, and foreskin tissues obtained during 
elective male circumcision. Our focus to date has been on mucosal T 
cell parameters and soluble genital immune factors associated with 
HIV susceptibility. Mucosal T cell immune activation and increased 
expression of the HIV co-receptor CCR5 and/or α4β7 characterize HIV-
enhancing conditions such as asymptomatic herpes infection, bacterial 
vaginosis and candidate microbicides that cause genital irritation. 
Studies performed by blinded investigators demonstrate striking 
similarities between the genital immune environment of HEPS women 
and men. However, only some of these HEPS parameters translate 
into reduced HIV acquisition in prospective cohort studies, while 
others are associated with increased HIV susceptibility and may be 
markers for high-risk sexual activity. Soluble immune factors present in 
genital secretions, including pro-inflammatory cytokines/ chemokines 
and alpha defensins, correlate with increased mucosal T cell “targets” 
and with HIV susceptibility, while IgA with virus-neutralizing capacity 
is associated with protection. Mucosal immunology is an important 
determinant of HIV transmission and susceptibility, but is difficult 
to study in human cohorts and even more difficult to manipulate 
therapeutically. Better tools to rapidly define the impact of candidate 
microbicides, vaccines and other agents on mucosal HIV susceptibility 
are urgently needed.
Plenary 02: Protection from Infection and Disease Progression
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PL02.03
The Role of HIV-1 Viral Evolution in Shaping 
Broadly Neutralizing Antibodies
P. Moore1
1National institute for Communicable Diseases, Johannesburg, 
South Africa
Broadly neutralizing antibodies develop in about a fifth of HIV infected 
people, but usually only do so after years of infection, in the presence 
of high levels of antigenic stimulation. Other factors that lead to the 
development of these kinds of antibodies remain unclear. However, 
the association between viral diversity, superinfection, and the 
development of breadth supports a role for viral evolution in driving 
such responses. We have used detailed longitudinal analyses from 
the CAPRISA cohorts to describe the role of HIV envelope evolution 
in shaping broad antibody responses. This ranges from the creation 
and/or exposure of conserved epitopes through viral escape, to 
the formation of multiple co-circulating immunotypes, all of which 
contribute to the development of broadly neutralizing responses. 
Understanding these interactions between the virus and the host may 
inform novel immunization strategies to elicit protective antibodies.
Plenary 02: Protection from Infection and Disease Progression
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PL03.02
Cutaneous Routes for HIV Vaccination Strategies
B. Combadiere1
1INSERM, UPMC, Paris, France
Most of the current vaccines are administered by intramuscular (IM) or 
subcutaneous (SC) routes, however, intradermal and transcutaneous 
techniques are regaining popularity. Several factors strongly justify 
the use of the cutaneous tissues for vaccination. The rationalization 
of targeting of the different cutaneous layers, i.e. the epidermis, 
dermis, or hypodermis as well as our advances in knowledge about 
the plasticity of antigen-presenting cells (Langerhans cells, dermal 
dendritic cells and dermal macrophages) allow today to propose 
rational immunization procedures. One can thus question the impact 
of vaccine compounds and specific skin APC targeting, on the intensity, 
the nature and the quality of immune responses and consequently on 
the control of infectious diseases. We have studied the mechanism 
of epidermal and intradermal immunization using biodegradable 
nanoparticle-based vaccine (HIV-P24 polylactic acid), attenuated 
viruses (MVA-HIV) or conventional inactivated influenza vaccines in the 
induction of effector immune response. Using conventional influenza 
vaccine in human Phase I clinical trials, we have recently demonstrated 
that hair follicular targeting method induced preferentially Influenza-
specific CD8 T cells, whereas classical intramuscular (IM) route did not. 
Hair follicular penetration of vaccine compounds targets epidermal 
Langerhans Cells (LCs) and induced major CD8 effector cells (human 
and mice) with however mucosal IgA localized in the stratified 
epithelium of the vagina in mice models. Furthermore, recruitment of 
inflammatory cells such as neutrophils in the dermis after intradermal 
delivery impacts the generation of alternative source of effector CD8 
cells in the bone marrow with differential gene signature that the one 
generated in the lymph nodes. Recent advances using a conventional 
vaccine and its the impact of routes of administration (HFT, ID, IM) of 
seasonal influenza vaccine on early gene signature will be discussed. 
Thus, re-directing the immune responses by targeting differential skin 
immunization routes might offers enormous potential for innovative 
vaccination strategies.
PL03.01
Nanotechnology Approaches for Designing 
Novel HIV Vaccines
M. Luo1, M. Alonso2
1University of Manitoba, Manitoba, Canada; 2University of 
Santiago de Compostela, Santiago de Compostela, Spain
Our group has designed novel nanostructures intended to transport 
antigens across biological barriers and to target them to the immune 
system. These nanocarriers have been made of safe materials, i.e. 
poly(lactic acid) and polysaccharides. Within this frame, we have 
identified some critical parameters that confer special properties 
to these nanocarriers, i.e. overcoming mucosal barriers and being 
attracted by macrophages and dendritic cells. Using antigen models 
such as tetanus toxoid (TT) and recombinant Hepatitis B surface Antigen 
(rHBsAg) we have shown the ability of the resulting nanovaccines to 
elicit significant and long-lasting responses following either nasal or 
i.m. administration.
More recently, in collaboration with the University of Manitoba, we 
have applied the nanodelivery technology to a novel HIV vaccine 
targeting sequences around the 12 protease cleavage sites (PCS). 
We have packaged the 12 20-amino acid peptides into a polymer 
nanomatrice and tested the resulting nanovaccine as a nasal boost 
in a preclinical study in Cynomolgus macaques. The results showed 
that nanopackaged antigens were able to boost T cell and antibody 
responses to the peptides in Cynomolgus macaques. Moreover, we 
observed that the macaques could withstand higher dose of intrarectal 
SIVmac239 challenge. The vaccinated macaques could also maintain 
higher CD4+ T cell counts than the controls. These promising results led 
us to plan further preclinical studies to test whether nanodelivery of this 
PCS peptide-based vaccine can be used to prime and boost T cell and 
antibody response and protect macaques from multiple SIVmac251 
intravaginal challenge. The conclusion of this preclinical study is 
that polymer nanostructures are able to ensemble peptide antigens 
and help them overcoming the nasal mucosal barrier and reaching 
the underlying immunocompetent cells. Overall, this nanovaccine 
approach may represent a new paradigm in the development of novel 
peptide-based vaccines and, in particular, HIV vaccines.
Plenary 03: Innovations in HIV Vaccine Discovery
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PL03.03
HIV Vaccine Development: A View from the 
Outside
A. Hill1
1University of Oxford, Oxford, UK
HIV vaccine development faces an extremely difficult scientific 
challenge and innovative new technologies are likely required for an 
efficacious product. The fundamental issues in HIV vaccine design and 
development largely overlap with problems being addressed in other 
areas of both human and veterinary vaccinology. But HIV vaccine 
development probably benefits less from this extensive resource of 
experience and know-how than other vaccine fields. Why this rather 
inward-looking approach persists is unclear but may relate to the 
extensive size of the HIV vaccine field and its exceptional level of 
funding support. I will highlight some of the striking parallels between 
HIV and other vaccine development programmes and illustrate how HIV 
vaccine developers might benefit from lessons learned in other areas. 
These areas include adjuvant choice, optimisation of T cell induction 
with vectored vaccine regimes, mucosal immunisation, small scale 
efficacy trial design, and evaluation of clinical trial results of marginal 
statistical significance. A remarkably large number of new vaccine 
technologies have been pioneered in the malaria field, because of the 
availability of established challenge models in both human and mice, 
and some recent exciting developments will be outlined. Some current 
widespread views in the HIV field appear to outsiders to have very 
little scientific and statistical support. These include the belief that true 
efficacy, and even a correlate of vaccine efficacy, was demonstrated 
in the RV144 Thai trial, that there is likely to be a safety issue with the 
use of Ad5 viral vectors, and that antibody-based vaccines are more 
likely to show true efficacy in the short to medium term than T cell-
based HIV vaccines. 
Plenary 03: Innovations in HIV Vaccine Discovery
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PL04.02
The HIVIS and TaMoVac Studies, a North-South 
Collaboration
M. Bakari1
1Muhimbili University of Health and Allied Sciences, Dar es 
Salaam, United Republic of Tanzania 
HIV remains a significant health problem globally, but more so in 
developing countries. Efforts towards a safe, affordable and efficacious 
vaccine have seen the development of partnerships between the North 
and the South in the search for such a vaccine.
The HIVIS and TaMoVac programmes have built and consolidated 
capacity in Tanzania and Mozambique to conduct HIV vaccine trials, 
following initial investments by European partners.
The specific activities conducted have included studies aimed at 
optimizing HIV vaccine delivery; expansion of capacity to perform 
future phase IIB and III trials; extension of current adult target cohorts 
to youths; and developing capacity to investigate preventive HIV 
vaccines in neonates. The presentation will focus on clinical trial data 
so far accrued.
PL04.01
The First Clinical Evaluation of Conserve-Region 
Vaccines in Humans
P. Hayes1, J. Vasilyeva2, N. Frahm2, J. Cox1, S. Colloca3, A. Nicosia4, 
J. Gilmour1, T. Hanke5
1Imperial College, London, UK; 2Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 3Okairos, Rome, Italy; 
4Okairos, CEINGE, University of Naples, Italy; 5University of 
Oxford, Oxford, UK
Vaccines focusing T cells on the conserved regions of the HIV-1 
proteome as a way of addressing HIV-1 diversity and escape were 
tested for the first time in humans. The vaccines were safe and showed 
efficacy against HIV-1 in vitro.
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PL04.04
Vaccine Induced Antibody Responses in HVTN 
505, a Phase IIb HIV-1 Efficacy Trial
G. Tomaras1, X. Shen1, K. Seaton1, H. Janes2, D. Grove2,  
A. deCamp2, Y. Fong2, H. Liao1, Z. Yang3,6, T. Xu1, J. H. Kim4,  
N. L. Michael4, R. T. Bailer3, G. Ferrari1, J. Mascola3, R. A. Koup3,  
G. Nabel3,6, L. Corey2, S. Karuna2, D. C. Montefiori1, M. J. McElrath2,  
B. F. Haynes1, P. Gilbert2, B. S. Graham3, M. Sobieszczyk5,  
S. M. Hammer5
1Duke University Medical Center, Durham, NC; 2Fred Hutchinson 
Cancer Research Center, Seattle, WA; 3Vaccine Research Center, 
National Institute for Allergy and Infectious Diseases, National 
Institutes of Health, Bethesda, MD.; 4Military HIV Research 
Program, Walter Reed Army Institute of Research, Silver Spring, 
MD; 5Division of Infectious Diseases, Columbia University 
Medical Center, New York, NY; 6Sanofi, USA
The phase IIb multiclade (A,B,C) HIV-1 DNA prime, multiclade (A,B,C) 
rAd5 boost vaccine (HVTN 505) given to U.S. Ad5 seronegative 
volunteers was halted due to lack of efficacy. A previous vaccine trial, 
the RV144 ALVAC prime, A/E gp120 protein boost trial, with 31.2% 
efficacy, demonstrated that gp70 V1/V2 IgG antibodies significantly 
correlated with decreased risk of infection and plasma HIV-1 Env IgA 
antibodies correlated with decreased vaccine efficacy. We examined 
humoral responses in HVTN 505 for vaccine immunogenicity and 
then compared these responses to the RV144 vaccine induced 
antibody response. Analyses of humoral responses between the two 
trials with different efficacy outcomes will be presented. Comparative 
immunogenicity analyses can provide insights into assessment of 
potentially protective antibody responses.
PL04.03
Looking Back to Move Forward: Understanding 
ALVAC/AIDSVAX Immune Responses
R. O’Connell1
1USAMC-AFRIMS, Bangkok, Thailand
Improving upon the 31.2% vaccine efficacy seen following ALVAC-
HIV/AIDSVAC B/E prime-boost administration in the RV144 trial is 
one potential avenue for development of a licensed preventive HIV 
vaccine. Building upon earlier identification of correlates of risk 
and sieve analyses suggesting the importance of anti-V2 antibody 
responses, recent analyses have identified cross-clade reactivity 
to scaffolded V1V2 constructs as correlates of risk and suggested 
an important role in IgG3 anti-envelope responses. Work with new 
monoclonal antibodies has provided insight into the evolution of 
antibody sequences and potential structural interactions with the V2 
domain of gp120 protein. Recent animal studies have also provided 
important corroborative information. Host genetic analyses suggest 
an association between HLA and acquisition. Additionally, correlates 
analysis in combination with molecular sieve analysis have highlighted 
the potential importance of anti-V3 responses.
Gene expression analysis has defined potential mechanisms underlying 
cellular responses associated with vaccine protection. Finally, late 
boosting of RV144 vaccine recipients, 6-8 years following their last 
RV144 vaccination, provides preliminary data regarding antibody and 
cellular responses that may assist in assessing schedule adjustment. 
Finally, the availability of potential correlates of risk in RV144 permit 
review of previous studies to look at the impact of immunogens, primes, 
and adjuvants on the development of anti-V1V2 antibody. This talk will 
address these results, as well as plans for the next efficacy trial. 
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PL04.06
Meta-Analysis of Ad5-vector HIV Vaccine Trials 
to Assess the Vaccine Effect on HIV Acquisition
Y. Huang1, D. Follmann2, M. Nason2, L. Zhang1, Y. Huang1,  
D. Mehrotra3, Z. Moodie1, B. Metch1, H. Janes1, M. Keefer4,  
G. Churchyard6, M. Robb10, P. Fast5, A. Duerr1, L. Corey1, J. 
Mascola2, B. Graham2, M. Sobieszczyk7, J. Kublin1, M. Robertson3,  
S. Hammer7, G. Gray8, S. Buchbinder9, P. Gilbert1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2National Institute of Allergy and Infectious Diseases, Bethesda, 
MD, USA; 3Merck, USA; 4University of Rochester Medical 
Center, Rochester, NY, USA; 5IAVI, NY, New York, USA; 6Aurum 
Institute, Johannesburg, South Africa; 7Columbia University, 
New York, NY, USA; 8Perinatal HIV Research Unit (PHRU), 
South Africa; 9San Francisco Department of Public Health, 
San Francisco, CA, USA; 10U.S. Military HIV Research Program, 
Bethesda, MD, USA
Three randomized, double-blinded, placebo-controlled proof-of-
concept Phase 2b efficacy trials, Step, Phambili and HVTN505, failed 
to demonstrate a protective effect on HIV acquisition using regimens 
containing Adenovirus serotype 5 (Ad5) vector HIV vaccines. 
Vaccinations in all three were halted early and studies subsequently 
unblinded. Step and Phambili tested a Merck vaccine regimen of HIV-
Ad5 immunization at Weeks 0, 4 and 26 in the Americas and South 
Africa, respectively.  HVTN505 tested a VRC vaccine regimen of HIV-
DNA immunization at Weeks 0, 4 and 8, and HIV-Ad5 immunization 
at Week 26 in the US. Extended follow-up of Phambili and HVTN505 
are ongoing. 
To better estimate the effect of HIV Ad5 vaccines on the risk of HIV 
infection, both overall and in important subgroups, a meta-analysis 
was conducted using individual-level data available through August 
26, 2013. The mean (range) months of follow-up was 35 (0−51) for 
Step, 35 (0−43) for Phambili, and 15 (0−28) for HVTN505.  Three 
pre-efficacy trials, HVTN204, RV172 and IAVI001 and their extended 
follow-up studies of the VRC vaccine regimen also accrued HIV 
infections and were included. 
Cox proportional hazard models adjusting for potential baseline 
confounding factors including common demographic and risk behavior 
variables were used to estimate hazard ratios (HRs, vaccine vs. placebo) 
of HIV infection, allowing separate placebo group hazards for each 
study. Nonparametric smooth estimates of the HRs over continuous 
follow-up time were used to assess time-varying HRs. Co-primary 
analyses measured follow-up based on time since first vaccination and 
time since first Ad5 vaccination.  Interaction tests were used to assess 
whether HRs differed across studies, time periods, and subgroups 
defined by gender, Ad5 serostatus, and circumcision status.   
This talk will present the results of the meta-analysis and discuss the 
strengths and limitations of such an approach.
PL04.05
An Update on the Phambili/HVTN 503 
Study, a Phase IIB HIV Vaccine Efficacy Study 
Investigating MRK Ad5 HIV-1 Subtype B gag/
pol/nef Vaccine
G. Gray1
1Perinatal HIV Research Unit, Johannesburg, South Africa
The Phambili study, conducted in South Africa, evaluating the efficacy 
of MRK Ad5 HIV-1 subtype B gag/pol/nef vaccine in test of concept HIV 
vaccine trial. Enrolment into Phambili was paused, vaccinations stopped 
and vaccinations unblinded when the Step study evaluating the same 
vaccine in the Americas, Caribbean and Australia was shown to be 
non-efficacious at the first interim DSMB. We present data on the long-
term follow-up of Phambili participants. We present the final analysis 
of the Phambili endpoint data for three time periods: all study follow-
up, the first 18 months of follow-up, and 18 months after enrollment 
to the end of follow-up. Cox proportional hazards model were used to 
estimate the hazard ratios (HR) for HIV-1 infection due to vaccination 
(vaccine:placebo), overall and within subgroups, adjusted for baseline 
HSV-2 status. Of the 801 participants enrolled, 100 acquired HIV-1 
infection. More infections occurred in vaccinees (n=63) as compared 
to placebo (n=37) (adjusted HR (vaccine:placebo) 1.70, 95% CI 1.13-
2.55). In unplanned subgroup analyses, the HR was most pronounced 
after 18 months (adjusted HR 2.32, 95% CI: 1.26-4.25); during this 
period, it was highest in men (HR=4.26, 95% CI 1.43-12.65) and less 
evident in women (HR=1.66, 95% CI:0.78-3.55) (interaction p = 0.16). 
There was no increase in HR with the number of vaccinations received. 
Although there was no overall significant difference in retention 
between vaccine and placebo (p=0.40), amongst men there was a 
trend toward a higher drop-out rate in the placebo group (p=0.18). 
We saw an increased HR two years after vaccination. This was not 
associated with the number of vaccinations received. As most study 
follow up was in the unblinded period, our analyses maybe subject 
to confounding. Nonetheless, our observations of possible vaccine 
induced- enhancement warrant further investigation. To this end, 
Phambili participants are being recalled.
Plenary 04: Emerging Clinical Trial Data
S01.01
Antiviral Activity of NK Cells in HIV-1 Infection
M. Altfeld1
1Heinrich-Pette-Institut, Hamburg, Germany
NK cells play a critical role in the control of viral infections, and 
increasing data also suggest an antiviral activity against HIV. The 
mechanisms by which NK cell recognize HIV-1 infected cells and can 
mediate anti-HIV activity will be discussed.
S01.02
Adjuvants Modify Antibody Effector Function
A. Mahan1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Antibody N-glycosylation is important for both determining the 
inflammatory profile of IgGs and modifying their capacity to induce 
effector functions, such as antibody-dependent cellular cytotoxicity and 
phagocytosis. This talk will present research into the innate and adaptive 
signals that program specific changes in IgG glycosylation in order to 
determine which signals can be used to elicit highly functional HIV-specific 
antibodies in the context of a vaccine. We have shown that activation of 
nucleic acid–sensing TLRs as well as a combination of adaptive signals 
can induce significant changes in the expression of key glycosylation 
enzymes and are currently determining how the expression of these 
enzymes is regulated and programmed. Ultimately, understanding if 
and how antibody glycosylation is recalled will be important for eliciting 
antibodies with enhanced function through vaccination.
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S01.03
Systems Analysis of Innate Immune Responses 
Triggered by Viral Vector-Based HIV Vaccine 
Candidates
D. Zak1
1Seattle Biomed, Seattle, WA, USA
An efficacious HIV vaccine has the greatest potential to halt the HIV 
pandemic. Systems-level analysis of clinical and preclinical trials 
involving HIV vaccine candidates will accelerate the realization of this 
goal in four ways: (1) identification of correlates of protection (when 
possible), immunogenicity, and reactogenicity; (2) identification of 
candidate regulatory networks controlling host immune responses; 
(3) guiding the re-engineering of vaccine regimens to modulate 
responses; and (4) reverse engineering failed candidate vaccines to 
find out what went wrong and to open new avenues of investigation. 
In this presentation, I describe our work applying systems vaccinology 
to clinical and preclinical trials of several viral vector-based HIV 
vaccine candidates. There are two components of the approach. First, 
we employ transcriptional profiling to extensively characterize local 
and/or systemic innate immune responses induced hours or days after 
vaccination. This analysis reveals the extent to which known and novel 
innate inflammatory pathways are triggered specifically or generically 
by the different vectors. Second, we computationally integrate the 
innate immune responses with vaccine induced functional responses 
that are measured months or years after vaccination. Functional 
responses include vaccine efficacy, immunogenicity, and safety. In this 
manner, we define the relationship between the earliest events after 
vaccination, which are the most readily manipulated, and the ultimate 
clinical outcome. I will present results of three collaborative studies: 
(a) investigating the relationship between adenoviral vector innate 
response magnitude and CD8+ T cell immunogenicity in mice, (b) 
investigating the hierarchy of adeno- and pox-viral innate stimulation 
in nonhuman primates, and (c) comparing innate immune responses 
induced by different adenoviral vector vaccines in humans.
S01.04
Systems Vaccinology: Enabling Rational Vaccine 
Design with Systems Biology
B. Pulendran1
1Emory University, Atlanta, GA, USA
Despite their great success, we understand little about how effective 
vaccines stimulate protective immune responses. Two recent 
developments promise to yield such understanding: the appreciation of 
the crucial role of the innate immune system in sensing microorganisms 
and tuning immune responses, and advances in systems biology. In 
this presentation, I will discuss how these developments are yielding 
insights into the mechanism of some of the most successful vaccines 
ever developed. Furthermore, such developments promise to address 
a major challenge\ in vaccinology: that the efficacy of a vaccine can 
only be ascertained retrospectively, upon infection. The identification 
of molecular signatures induced rapidly after vaccination, which 
correlate with and predict the later development of protective immune 
responses, would represent a strategy to prospectively determine 
vaccine efficacy. Such a strategy would be particularly useful when 
evaluating the efficacy or immunogenicity of untested vaccines, or in 
identifying individuals with sub-optimal responses amongst high risk 
populations, such as infants or the elderly. We have recently used 
a systems biology approach to identify early gene signatures that 
correlate with, and predict the later immune responses in humans 
vaccinated with the live attenuated yellow fever vaccine YF-17D, or 
with the influenza vaccines. I will review these studies, and discuss 
their broader implications for vaccinology.
References
1. Systems vaccinology. Pulendran B, Li S, Nakaya HI. Immunity. 2010 
Oct 29;33(4):516-29.
2. Systems biology approach predicts immunogenicity of the yellow 
fever vaccine in humans. Querec TD, Akondy RS, Lee EK, Cao 
W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, 
Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, 
Mulligan M, Aderem A, Ahmed R, Pulendran B. Nat Immunol. 2009 
Jan;10(1):116-25. Epub 2008 Nov 23.
3. Immunological mechanisms of vaccination. Pulendran B, Ahmed R. 
Nat Immunol. 2011 Jun;12(6):509-17.
4. Systems biology of vaccination for seasonal influenza in humans. 
Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining 
WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan 
V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, 
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S02.02
Impaired B Cell Help During HIV Infection
E. Haddad1
1Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, 
FL, USA
Follicular helper T cells (Tfh) constitute a distinct subset of CD4+ T 
cells that are specialized in providing help to B cells and are required 
for the formation and maintenance of GCs. We show that these cells 
are impaired during HIV infection in HIV infected lymph nodes. We 
show that this impairment is dependent on PD-1/IL-21/ICOS axis. We 
further show that memory Tfh (mTfh) cells present in the periphery 
are surrogates for LN resident follicular helper T cells. We provide 
convincing evidence demonstrating a strong relationship between 
mTfh cells and LN resident Tfh cells. We show, at the transcriptional 
level, that mTfh cells express a significant number of Tfh-specific 
genes. We further show that mTfh cells have the ability to provide 
B cell help similar to LN resident Tfh cells. We also show direct 
evidence supporting a physiological association of mTfh cell function 
with humoral immunity. Interestingly, these memory circulating Tfh 
cells have lost their ability to elicit anti-HIV humoral immunity during 
HIV infection. We demonstrate that mTfh cells obtained from long-
term non-progressors are better in providing B cell help than those 
obtained from progressors. Our data indicates that this could be due 
to weak triggering of the TCR on mTfh that would lead to an aberrant 
interaction with memory B cells. Overall, understanding the biology of 
these cells will reveal important information that can be used in the 
development of HIV vaccines and immunotherapies.
S02.01
Memory CD8 T Cells: Issues of Quantity, Quality, 
and Location
D. Masopust1
1University of Minnesota, Minneapolis, MN, USA
Memory CD8 T cell quantity, quality, and location relate to 
protective efficacy. This presentation will summarize three series 
of investigations, 1) the exploitation of heterologous prime boost 
vaccination to discover parameters regulating effector contraction and 
memory differentiation in mice, 2) the consequences of CD8 T cell 
reactivation within the mouse female reproductive tract, and 3) the 
establishment of robust polyfunctional SIV-specific memory CD8 T 
cells in rhesus macaques via heterologous prime-boost vaccination. 
We demonstrate that anamnestic memory CD8 T cell differentiation 
is flexible, and abundant quantity can be achieved while maximizing 
protective efficacy and preserving proliferative potential. Moreover, we 
describe an additional function for nonlymphoid memory CD8 T cells; 
as local sensors of previously encountered antigens that precipitate 
innate-like alarm signals and draw circulating memory CD8 T cells 
into the tissue. These data indicate that robust anamnestic responses 
in nonlymphoid tissues result from an integrated collaboration 
between both nonlymphoid and circulating populations of memory 
CD8 T cells. Ongoing studies will test the hypothesis that establishing 
preternaturally abundant and functional memory CD8 T cells within 
frontline and circulating compartments may maximize rapid responses 
at the portal of pathogen exposure in the rhesus macaque model of 
stringent vaginal SIV challenge.
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S02.04
SIAE Inhibition and Enhanced Somatic 
Hypermutation Against gp140
H. Mattoo1, S. Pillai1, R. Wyatt2
1Massachusetts General Hospital, Boston, MA, USA; 2The 
Scripps Research Institute, La Jolla, CA, USA
One of the goals in HIV vaccination is the enhancement of somatic 
hypermutation in order to increase the likelihood of obtaining 
neutralizing antibodies against conserved epitopes in HIV gp 140. Sialic 
acid acetyl esterase (SIAE) is a negative regulator of B cell signaling 
and defective SIAE variants have been linked to human autoimmunity. 
SIAE functions in concert with CD22, Lyn, and SHP-1 to maintain 
peripheral tolerance. We examined whether SIAE prevents B cells 
that recognize low affinity antigens from promiscuous collaboration 
with T cells, since T-B collaboration and germinal center formation 
in the context of self-antigens could be deleterious. In the absence 
of SIAE, B cells respond to a low affinity antigen by inducing CCR7 
expression, migrate to the T cell zone, and enhance the generation 
of follicular helper phenotype CD4+ T cells. The absence of SIAE 
induces promiscuous B-T collaboration and enhances follicular helper 
T cell differentiation, somatic hypermutation and CD4+ memory T cell 
responses. Immunization with gp 140 in mice lacking SIAE resulted in 
the generation of markedly higher affinity gp140 specific B cells.
S02.03
Role of Tfh in HIV Infection
M. Perreau1*, A.L. Savoye*1, E. De Crignis1, J.M. Corpataux2,  
R. Cubas3, E. Haddad3, L. De Leval4, C. Graziosi1, G. Pantaleo1,5
1Divisions of Immunology and Allergy, 2Thoracic Surgery, 
3Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, 
FL, USA, 4Institute of Pathology and 5Swiss Vaccine Research 
Institute, Lausanne University Hospital, University of Lausanne, 
Lausanne, Switzerland
*The first two authors are listed in alphabetic order and have 
equally contributed to this study.
In the present study, we have investigated the distribution of HIV-
specific and HIV infected CD4 T cells within different populations of 
memory CD4 T cells isolated from lymph nodes of viremic HIV-infected 
subjects. Four memory CD4 T-cell populations were identified on the 
basis of the expression of CXCR5, PD-1 and Bcl-6: CXCR5-PD-1-Bcl-6-, 
CXCR5+PD-1-Bcl-6-, CXCR5-PD-1+Bcl-6- and CXCR5+PD-1+Bcl-6+. 
On the basis of Bcl-6 expression and functional properties (IL-21 
production and B-cell help), the CXCR5+PD-1+Bcl-6+ cell population 
was considered to correspond to the Tfh cell population. We show that 
Tfh and CXCR5-PD-1+ cell populations are enriched in HIV-specific 
CD4 T cells, and these populations are significantly increased in viremic 
HIV infected subjects as compared to healthy subjects. The Tfh cell 
population contained the highest percentage of CD4 T cells harboring 
HIV DNA and was the most efficient in supporting productive infection 
in vitro. Replication competent HIV was also readily isolated from Tfh 
cells in subjects with nonprogressive infection and low viremia (<1000 
HIV RNA copies). However, only the percentage of Tfh cells correlated 
with the levels of plasma viremia. These results demonstrate that Tfh 
cells serve as the major CD4 T-cell compartment for HIV infection, 
replication and production. 
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S03.02
Strengths and Limitations of Macaque Models as 
Predictors of HIV Vaccine Efficacy in Humans 
G. Franchini1
1National Cancer Institute, NIH, Bethesda, MD, USA
To date, the SIVmac251 macaque model has predicted the efficacy of 
five HIV Phase III vaccine trials conducted in humans. Gp120/Alum 
(AIDSVAX), Ad5 Gag-pol-nef (in the STEP and Phambili trials), and 
DNA-Ad5 gag-pol-env (the HTVN 505 trial, VRC) have not been 
protective, whereas ALVAC-HIV or SIV/gp120Alum (in the RV144 Trial) 
have protected, albeit partially, humans against HIV acquisition and 
Rhesus macaques against SIVmac251 acquisition. Indeed, early data 
from animal studies have contributed to the design of the RV144 
trial, the first human HIV vaccine trial that has demonstrated some 
degree of protection from HIV acquisition with a 31% efficacy. The 
potency of this vaccine needs to be improved. However, it remains 
unclear whether changing the antigens, vector, or adjuvants can 
improve efficacy. The decreased risk of acquisition in RV144 correlated 
with antibodies to V2 and perhaps with subclasses of antibodies that 
mediate ADCC. Since this vaccine regimen elicited negligible CD8 
responses, a plausible hypothesis is that antibodies, rather that CD8 
cells, contribute to the decreased risk of HIV acquisition. Assuming 
that these premises are correct, there is a gap in our knowledge of how 
to induce specific subclasses of antibodies and the appropriate CD4 
help to maintain them overtime. Thus, the development of a more 
effective vaccine for HIV remains largely empirical and requires trial 
and error studies. Thus, predictive, animal models are vital as they 
may be instrumental in testing approaches that can improve the level 
of protection of RV144. Recently, we have reproduced the level of 
protection of a vaccine regimen similar to RV144 in macaques and 
attempted to improve it by changing the antigen design, adjuvants or 
by priming with vaccines other than ALVAC-SIV. Overall, the paradigm 
that has emerged is that “more B or T-cell responses do not translate to 
better protection from virus acquisition, as observed for HIV in human 
vaccine trials. Improving protection may instead require alterations in 
the quality of the CD4 helper response, such as TFH and modulating the 
generation, homing and differentiation of antibody responses. While 
macaque studies will facilitate the development of better HIV vaccine 
candidates, there are several limitations of the animal models that 
must be considered.
S03.01
Can AIDS Virus-Specific Classical CD8+ T Cells 
Control Virus Replication?
D. Watkins1
1University of Miami, Miami, FL, USA
The induction of HIV-specific broadly reactive, potent, neutralizing 
antibodies by vaccination is the ultimate goal of the HIV vaccine 
field. There have been encouraging recent reports of the isolation of 
neutralizing antibodies from HIV-infected individuals. However, it is 
now clear that these antibodies require considerable somatic mutation 
to evolve into effective neutralizing antibodies. Induction of these 
neutralizing antibodies by vaccination, therefore, remains one of the 
key challenges of the field.
In contrast to neutralizing antibodies, we already know how to induce 
HIV-specific CD8 T cells by vaccination. Furthermore, the T cell receptors 
expressed by these antigen-specific CD8 T cells do not require somatic 
mutation to be effective. It is generally thought that these vaccine-
induced CD8 T cells might provide some measure of control of acute 
phase viral replication and then reduce viral replication in the chronic 
phase. Indeed, there is considerable evidence that this can be achieved 
in vaccinated rhesus macaques. Accumulating data also suggests that 
vaccine-induced CD8 T cells can prevent chronic phase replication of 
the AIDS virus. 
In this presentation, we will explore the hypothesis that classical CD8 
T cells can prevent chronic phase viral replication after infection with 
the AIDS virus. We have induced CD8 T cells using a vaccine regimen 
consisting of a recombinant DNA prime, followed by recombinant 
Yellow Fever and recombinant Adenovirus 5 boosts. The majority of 
these vaccine-induced high frequency classical CD8 T cells express 
effector memory cell markers and are focused on a single, conserved 
immunodominant Nef epitope restricted by the elite controller MHC 
class I allele Mamu-B*08. We will present data as to whether these TEM 
CD8 T cells can control chronic phase viral replication after repeated 
low dose rectal challenge of Indian rhesus macaques.
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S03.04
Vaccine Responses to Four Different gp140 
Trimers
R. Shattock1
1Imperial College London, London, UK
Immunization with soluble trimeric glycoprotein is considered an 
improvement upon the use of gp120 monomers. However, soluble 
recombinant trimeric gp140, while more physiologically relevant 
than gp120 monomers, differs from native trimers in that the natural 
cleavage site between gp120 and gp41 is usually mutated and only 
the ectodomains of gp41 with the trimerization motif are included. 
Nevertheless, glycosylation patterns are unchanged between the 
native envelope and the recombinant protein, as is the trimeric 
configuration. The exposure of the CD4 binding site and its binding 
behaviour relative to whole virions is preserved in recombinant trimeric 
proteins. We have performed a series of macaque immunogenicity 
and challenge studies using different gp140 constructs based on 
Clade C (1085, TV-1 and CN54) and Clade B (SF-162). Adjuvant choice 
and route of administration had clear impact on humoral responses 
providing differing levels of protection against vaginal challenge by 
homologous and heterologous SHIV strains. Differences in epitope 
specificity induced by the different trimers was observed, and for one 
(CN54), responses were compared to those elicited in a human phase 
I clinical trial.
S03.03
Pre-clinical Development of Cytomegalovirus 
Vectors
L. Picker1
1Oregon Health & Science University, Beaverton, OR, USA
Cytomegalovirus (CMV) vectors elicit and indefinitely maintain 
high frequency, pathogen-specific, CD4+ and CD8+ T cells at both 
lymphoid and extra-lymphoid effector sites. CMV vector-elicited T 
cells have multiple unique properties, including constitutive effector 
differentiation, the ability to immediately intercept pathogens without 
anamnestic expansion, and unconventional epitope recognition, which 
make these responses well-suited to control and clear persistent 
pathogens with sophisticated immune evasion strategies. This talk will 
discuss the latest data on the efficacy of these vectors in non-human 
primate models and an update on the translation of the CMV vector 
concept to the clinic.
Symposium 03: NHP Vaccines and Correlates of Immune Protection
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S03.05
Impressive Vaccine Protection Against 
SIVmac239 by Recombinant Gamma-2 
Herpesvirus
Y. Shin3, W. Lauer1, G. Bischof3, M. Piatak1, J. Lifson1, D. Watkins2, 
and R.C. Desrosiers3
1SAIC Frederick, Inc., Frederick Nat’l Labs, Frederick, MD, USA; 
2University of Miami, Miami, FL, USA; 3New England Primate 
Research Center, Harvard Medical School, Southborough, MA, USA
Herpesviruses persist for the lifetime of the infected individual and 
immune responses to them similarly persist at readily detectable 
levels for life. Distinct advantages may accrue to use of herpesviruses 
as vaccine vectors because of this persistence. Eight distinct human 
herpesviruses have been defined in three sub-groupings: alpha, 
beta, and gamma. The Desrosiers laboratory has been using the 
gamma-2 herpesvirus of rhesus monkeys called rhesus monkey 
rhadinovirus (RRV) as a vaccine vector for monkey studies. RRV 
is a close monkey homolog of human herpesvirus 8 (HHV-8), the 
Kaposi sarcoma herpesvirus (KSHV). In a previously published study 
(J Virol 85: 12708, 2011), six rhesus monkeys received recombinant 
RRV containing SIV gag, env and a  rev-tat-nef fusion gene. Cellular 
responses of high frequency were elicited and these persisted until 
the time of challenge at 18 weeks. Despite the ability of the RRV-
SIVenv recombinant containing a codon-optimized version of the 
gp160 cassette to make gp160 protein in cultured cells infected in 
vitro, detectable anti-gp160 antibody responses were not elicited. 
Vaccinated monkeys exhibited a 1.7 log reduction in viral loads 
both at peak height and at set point following i.v. challenge with 
10 i.v. infectious doses of SIVmac239. We have now succeeded in 
achieving anti-env antibody responses from RRV-SIVenv by altering 
the codon usage in the gp160 cassette. In work not yet published, Y 
Shin and R Desrosiers have shown that natural induction of gp160 
by rev and natural induction of RRV glycoprotein gH by its natural 
transinducer orf57 are dependent upon the nature of the bad codon 
usage. While gH and gp160 both have a bad codon usage, the nature 
of the bad codon usage for these two glycoproteins is very different. 
Furthermore, orf57 inducibility and rev inducibility can be switched 
simply by altering the codon usage. By changing 10% of the codons 
in the gp160 cassette to reflect the bad codon usage of RRV gH, we 
were able to regulate gp160 expression as a late RRV glycoprotein 
gene product; this relatively simple change in codon usage resulted 
in readily-detectable, persistent anti-gp160 antibody responses and 
the induced antibodies neutralized the SIVmac239 derivative SIV316. 
Using this new RRV-SIVenv recombinant, six rhesus monkeys were 
immunized with RRV-SIVgag, RRV-SIVenv, plus RRV-SIVrevtatnef. 
Challenge of the six vaccinated monkeys and six unvaccinated 
controls began at 18 weeks following the single immunization using 
repeated marginal dose SIVmac239 i.v. challenge spaced three 
weeks apart. Three of the 6 vaccinated monkeys showed a transient 
viral blip two weeks after the second exposure (viral loads of 60, 140 
and 340 RNA copies per ml of plasma), one has remained uninfected 
and the other two have become SIV-infected with low viral loads. 
Five of the six controls have become infected so far, with peak viral 
loads between 10,000,000 and 120,000,000. These results, and the 
results of the Picker laboratory, indicate that persisting viral vectors 
should be a point of emphasis for ongoing AIDS vaccine research.
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S04.02
Sendai Virus Vector Vaccine
T. Matano1
1National Institute of Infectious Diseases, Tokyo, Japan
Viral antigen specific T-cell responses are crucial for the control of 
HIV replication. Viral vectors are promising vaccine tools for inducing 
antigen-specific T-cell responses. We have developed an AIDS vaccine 
using a Sendai virus (SeV) vector and showed the potential of this 
vector to efficiently induce antigen-specific T-cell responses in non-
human primates. A vaccine trial using a Gag-expressing SeV vector 
showed control of SIVmac239 challenge in rhesus macaques. A 
clinical trial phase I of SeV vector AIDS vaccine by IAVI started in April, 
2013. SeV, whose natural host is mice, is nonpathogenic in humans 
and replication-competent SeV vectors are available. Although anti-
human para-influenza virus type 1 antibodies can crossreact with SeV, 
most people do not have high anti-SeV neutralizing titers. Our recent 
study in macaques has indicated the potential of intranasal SeV vector 
immunization to induce mucosal immune responses. These suggest 
that SeV vectors can serve as a vaccine tool for inducing effective T-cell 
responses against HIV infection. Combination of this vector with other 
viral vectors and antigen optimization may lead to the development of 
an effective AIDS vaccine. 
http://www.iavi.org/Information-Center/Press-Releases/Pages/IAVI
-AND-PARTNERS-INITIATE-PHASE-I-TRIAL-OF-A-NOVEL-AIDS-VACCINE
-REGIMEN.aspx
S04.01
Development of HIV Vaccines—A Vaccine 
Manufacturer’s Perspective
G. Voss1
1GlaxoSmithkline Vaccines, Rixensart, Belgium
The presentation will provide an industry perspective on the global 
effort to develop an HIV vaccine. First, the principal steps in developing 
novel vaccines against infectious diseases from discovery to launch will 
be covered. Second, the specific challenges related to the development 
and introduction of new vaccines against diseases of the developing 
world will be described. And third, the additional scientific obstacles 
for an HIV vaccine and the rationale and need for public-private 
development partnerships will be explored.
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S04.04
Durable Antibody Responses Induced by DNA 
and Recombinant Modified Vaccinia Ankara 
Vaccines Expressing HIV-1 Virus-like Particles
H. Robinson1, G. Tomaras2, K. Seaton2, A. Sato3, J. Hural3,  
S. DeRosa3, N. Frahm3, B. Moss4, P. Goepfert5
1GeoVax, Inc., Smyrna, GA, USA; 2Duke University Medical 
Center, Durham, NC, USA; 3Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA; 4NIAID, NIH, Bethesda, MD, USA; 
5University of Alabama at Birmingham, Birmingham, AL, USA
A challenge for HIV-1 vaccines is to induce long lasting antibody (Ab) 
responses to the envelope glycoprotein (Env). Here Clade B DNA and 
recombinant modified vaccinia Ankara (MVA) vaccines producing 
virus like particles (VLPs) displaying trimeric membrane-bound Env 
are tested for safety, immunogenicity, and the 6 month durability of 
elicited immune responses. HVTN trial 205 enrolled 299 individuals 
who were randomly assigned to receive two DNA followed by two 
MVA inoculations (DDMM regimen, (n=149)), three MVA inoculations 
(MMM regimen (n=75)) or placebo (saline, n=75). Humoral and cellular 
responses induced by vaccination were measured. Both regimens 
were safe and well tolerated. At 2 weeks post the final vaccination, 
93.2% and 98.4% of the DDMM and MMM groups, respectively had 
binding Ab for gp140 Env. At 6 months post vaccination, binding Ab 
in both groups had contracted by < 3-fold. Binding Abs were both 
more frequent and higher titer for gp41 than consensus gp120. The 
Abs elicited by both regimens had avidity indices similar to those 
observed in 6 month infections. Both regimens elicited low titer Tier 
1 and 2 neutralizing Ab. For both regimens, T cell responses were 
biased towards Gag, and response rates were higher for CD4+ (66.4% 
DDMM, 43.1% MMM) than CD8+ (21.8% DDMM, 14.9% MMM) T 
cells. The DDMM and MMM VLP regimens elicited avid gp41-biased 
binding Ab that was durable and had low titer Tier 1 and Tier 2 
neutralizing activity.
S04.03
Reinventing the Nucleic Acid Vaccine
A. Geall1
1Novartis Vaccine and Diagnostics, Cambridge, MA, USA
•	 Novartis	has	developed	the	SAM®	vaccine	platform
•	 The	 Platform	 takes	 advantage	of	 cell-free	 RNA	production	 from	a	
transcription reaction and delivery with a synthetic delivery system
•	 The	 broad	 utility	 of	 this	 novel	 vaccine	 technology	 has	 been	
demonstrated with genes encoding antigens from several pathogens 
and found to elicit broad and potent protective immune responses
•	 Responses	 are	 comparable	 to	 a	 viral	 delivery	 technology,	 but	
without the inherent limitations of viral vectors
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S05.02
Host-Virus Interactions in HIV-1 Rapid Disease 
Progression
J. Martinez-Picado1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, Spain
Infectious disease have had a significant impact on history. The 
unanticipated AIDS pandemic clearly shows the influence that 
contagious diseases can have in our world. The examination of how 
we controlled and improved health in previous epidemics should 
facilitate how to deal with future encounters with emergent diseases. 
From a clinical perspective, humans show a remarkable variation in 
the clinical outcome following HIV-1 infection. In absence of highly-
active antiretroviral therapy, median time for development of AIDS 
has been estimated to vary from 8 to 11 years depending on age at 
seroconversion. However, there are departures from this estimate and 
meanwhile some individuals are able to control HIV-1 replication for 
longer periods (elite controllers) others progress quickly to AIDS or 
meet criteria for antiretroviral treatment within the first 3 years after 
seroconversion (rapid progressors). Over the last years, many studies 
have focused in these extreme HIV-1 phenotypes searching for the 
clues of viral pathogenesis and accumulative evidences suggest that 
a combination of viral and host factors are involved in the definition 
of HIV-1 disease outcome. This presentation will focus on the 
immunological and virological factors that contributed to the rapid 
development of AIDS-defining pathogenesis.
S05.01
Targeting the Female Reproductive Tract 
Epithelium to Prevent Transmission and Acute 
Systemic Infection: Lessons Learned in the SIV-
NHP Model
A. Haase1
1University of Minnesota, Minneapolis, MN, USA
In the SIV-rhesus macaque model of HIV-1 transmission to women, 
vaginal exposure to high doses of virus infects initially small populations 
of mainly resident CD4 T cells with an ostensibly resting phenotype. 
Local expansion of these founder populations then disseminates 
infection throughout the lymphoid tissues where additional expansion 
results in a robust systemic acute infection. The initially small size 
of the infected founder populations at the portal of entry point to 
the favorable odds for containment by a vaccine-induced immune 
response and I will discuss targeting the early stages of transmission, 
but I will also describe for the live attenuated SIV-delta-nef vaccine an 
important and active role for the mucosal epithelium in concentrating 
antibodies on the path of virus entry, and in moderating the innate 
immune response to virus exposure that facilitates local expansion 
and systemic infection. 
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S05.04
Modeling the Effects of Vaccination on Acute 
Phase CD8+ T Cell Immunodominance Patterns 
to HIV in Humanized Mice
T. Allen1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Vaccination of rhesus macaques with a RhCMV vector demonstrates 
the ability of CD8+ T cell responses to rapidly contain viral replication 
following mucosal SIV challenge, supporting the importance of cellular 
responses in the design of an effective HIV vaccine. Importantly, the 
immunodominant targeting of conserved regions of the virus where 
escape mutations impose a fitness cost is associated with the ability of 
CD8+ T cell responses to control of HIV, although most individuals fail to 
naturally mount such protective responses. However, additional studies 
in the macaque model now demonstrate the ability of vaccination to 
overcome natural immunodominance hierarchies to redirect acute 
phase CD8+ T cell responses towards more critical regions of SIV 
resulting in enhanced immune control. A more precise understanding 
of protective versus easily escaping decoy CD8 epitopes in HIV, and an 
in vivo model to explore strategies that overcome natural acute phase 
CD8+ T cell immunodominance hierarchies to HIV, would greatly 
enhance our ability to translate these findings towards an effective 
HIV vaccine. Here we apply a combination of in vivo deep sequencing 
and in vitro viral fitness assays to compare the relative ability of 
specific CD8+ T cell responses to control HIV and demonstrate the 
ability to modulate the hierarchy of acute-phase responses to HIV 
through vaccination in the humanized mouse model. This approach 
may aid in the design of vaccine antigens that maximize the potential 
of vaccine-induced CD8+ T cell responses to contain or control HIV. 
S05.03
Phenotypic Properties of Acute HIV-1 Associated 
with Transmission Fitness and Virulence
E. Arts1
1Case Western Reserve University School of Medicine, 
Cleveland, OH, USA
Only one or a limited number of HIV-1 clones are transmitted from 
recipient to donor during primary infection. Little is known about the 
phenotypic properties of the transmitted HIV-1 aside from preference 
for CCR5 usage and the reduced glycan shield. We performed a series 
of genotypic and phenotypic assays to determine possible differences 
between acute/early HIV-1 and chronic virus during transmission and 
to determine how the infecting HIV-1 clone(s) can influence subsequent 
disease progression. In contrast to the homogeneity of acute HIV-1 in 
their blood, HIV-1 genetic diversity in the female genital tract (FGT) 
was very heterogeneous at acute/early infection, i.e. similar to the HIV-
1 diversity observed during chronic disease. These diverse FGT HIV-
1 isolates had more N-linked Env glycosylation sites than the acute 
blood HIV-1. Are these distinct genotypic features during acute HIV 
infection related to possible selection processes during transmission? 
Transmitted and chronic HIV-1 have similar entry kinetics, sensitivity 
to entry inhibitors, and replicative fitness in PBMCs, T cells, and 
macrophages. However, by exposing human penile and cervical 
explant tissues to mixtures of chronic and acute HIV-1, we clearly 
observed that acute HIV-1 was transmitted with greater efficiency 
than chronic virus. Chronic HIV was trapped and replicated only in the 
tissue explants; known to contain high levels of extracellular mannose 
binding lectins (MBLs) and lectins (e.g. Dectin-1) on mucosal epithelial 
cells that prevent infection of high mannose-containing pathogens. 
Higher transmission fitness of acute HIV-1 via DC capture in the 
cervical/penile tissue was correlated with fewer N-linked glycosylation 
sites and reduced C-type lectin binding affinity. Thus, the HIV-1 clone(s) 
may be “favored” for transmission based on escape from the lectin 
“trap” as well as DC capture via enhanced CD4 interactions (based on 
Affinofile and binding studies).
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S06.02
Genetic Development of HIV-1 Neutralizing 
Antibody Lineages
J. Mascola1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Recent advances in antibody isolation and structural characterization 
have provided insights into the conserved neutralization epitopes on 
the viral spike and the mode of antibody recognition. Most of the well-
characterized broadly neutralizing bNAbs derive from donors with 
unusually broad and potent serum neutralization. These bNAbs often 
have a high number of somatic mutations and some have unusually 
long CDRH3 loops, however relatively little is known about the 
immunological pathways that produce these antibodies. We are using 
next generation sequencing of antibody gene transcripts to track the 
development of neutralizing antibody lineages. Among donors with 
for whom early time point and longitudinal samples are available, it 
is possible to trace the origin of a specific antibody lineage and infer 
the unmutated ancestor (naïve BCR) of the mature bNAbs. This analysis 
has been done for donors making bNAbs to the CD4 binding site and 
to the V1V2-glycan epitope. These analyses provide insights into 
the naïve BCR that produce broadly neutralizing antibodies, and the 
maturation pathway required for the antibody to acquire high affinity 
neutralization. 
S06.01
A Pure Native Env Trimer Vaccine Elicits Potent 
Tier 2 Neutralization to a Quarternary, Glycan-
Sensitive Epitope
J. Binley1, B. Chakrabarti2, E. Crooks3, S. Du3, J. Muranaka3,  
K. Narayan3, K. Osawa1, T. Tong1, R. Whalen3, R. Wyatt4
1Torrey Pines Institute for Molecular Studies, San Diego, 
CA, USA; 2IAVI, Neutralizing Antibody Center at The Scripps 
Research Institute, La Jolla, CA, USA; 3Altravax, Sunnyvale, CA, 
USA; 4The Scripps Research Institute, La Jolla, CA, USA
As the exclusive target of nAbs, the native Env trimer is a logical basis 
for a nAb vaccine. Given its immunorecessive nature, purity may be 
essential for its success as a nAb immunogen. In other words, it must 
be free of contamination by other, more immunogenic forms of Env. 
4 groups of rabbits were immunized with: 1) “trimer VLPs”, expressing 
pure native JR-FL Env trimer, cleared of non-functional Env by a 
protease digest, 2) undigested control VLPs, 3) a JR-FL gp140F trimer 
DNA prime-protein boost, and 4) JR-FL gp120 prime-boost. Immune 
sera were characterized for binding, neutralization and specificity. All 
4 immunogens were effective, as judged by monomeric gp120 ELISA, 
although “trimer VLP”-immune sera bound only weakly. One serum 
each from groups 1 and 3 exhibited remarkable IC50s >1:1,000 against 
the JR-FL index virus in the TZM-bl assay. Two group 4 sera exhibited 
titers of ~1:100. Mapping revealed that both potent sera targeted sites 
unusually lacking glycans. Specifically, the group 1 serum neutralization 
was regulated by a glycan at residue 197 in the V1V2 loop stem and 
the group 3 serum was regulated by a glycan at residue 230 in the 
C2 of gp120. Interestingly, the N197-regulated activity recognized a 
quaternary epitope. The two neutralizing sera of group 4 mapped to the 
C3-V4 region. It is perhaps no coincidence that the two most potent sera 
targeted sites that unusually lack a glycan. Similar glycan-deprived sites 
have also accounted for autologous neutralization in natural infection. 
We are now working on strategies to elicit this activity more consistently, 
and to broaden its neutralization coverage. 
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S06.04
Recombinant Env Interactions with the BCRs of 
Broadly Neutralizing Anti-HIV Antibodies
L. Stamatatos1
1Seattle Biomedical Research Institute, Seattle, WA, USA
Broadly neutralizing antibodies (bNAbs) against HIV are believed to 
be a critical component of an effective vaccine. Such antibodies are 
generated during HIV-infection, but have not yet been elicited during 
immunization with recombinant forms of Env (the sole target of anti-
HIV neutralizing antibodies). We and others reported that recombinant 
Env proteins are very inefficient in engaging the germline BCR forms 
of a particular type of bnAbs that target the CD4-binding site; one of 
the most conserved regions of the HIV Env. This lack of engagement 
is a major contributing factor in our unsuccessful attempts to elicit this 
type of antibodies by immunization. However, it is currently not well 
understood whether or not recombinant Envs can engage the germline 
BCR forms of bnAbs that bind to other conserved Env regions. We will 
discuss our efforts to design immunogens, based on circulating HIV 
Envs, that are capable of activating B cells expressing germline BCR 
forms of diverse bNAbs. 
S06.03
HIV Vaccine Design to Induce Broadly 
Neutralizing Antibodies
W. Schief1
1The Scripps Research Institute, La Jolla, CA, USA
Developing a vaccine that induces sustained titers of potent, broadly 
neutralizing antibodies against multiple epitopes is probably necessary, 
though possibly not sufficient, for robust protection against HIV 
infection. At least four different epitopes on the HIV spike are targeted 
by potent, broadly neutralizing antibodies: the VRC01-class epitope 
within the CD4 binding site, the 10E8 epitope within the membrane-
proximal external region, the N332 glycan-dependent supersite at the 
base of V3, and the N160-glycan dependent site on V1V2. Recent and 
newly emerging structural information about these epitopes and their 
antibody accessibilities provides critical data to inform vaccine design. 
This talk will review our efforts employing computational design, in 
vitro screening and nanoparticle engineering to devise immunogens 
and immunization regimens that attempt to focus immune responses 
to particular structural epitopes, activate appropriate germline B cells 
and drive appropriate somatic mutation, with the goal of inducing 
broadly neutralizing antibodies.
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S07.02
Viral Persistence Under ART and the Challenges 
of Eradicating Myeloid Reservoirs
M. Stevenson1
1University of Miami Miller School of Medicine, Miami, FL, USA
Antiretroviral therapy (ART) can sustain suppression of plasma viremia 
for years. However, if therapy is interrupted, there is a rapid resumption 
in viremia. Therefore, HIV-1 has the ability to persist in the face of 
potent ART. Identifying the mechanism through which HIV-1 persists 
in infected individuals on suppressive therapy is central to the goal 
of curing infection in these individuals. For this reason, research is 
focused on establishing tools with which to probe the reservoirs that 
persist in aviremic individuals as well as clinical approaches with 
which to perturb those reservoirs. Can therapeutic vaccines offer some 
utility in accelerating the decline of the reservoirs that maintain HIV 
persistence in the face of antiretroviral therapy? Most attention has 
focused on the role of latently infected T-cells in viral persistence 
and clinical strategies are geared towards purging of these reservoirs. 
However, other factors may be contributing to viral persistence 
including residual viral replication and establishment of myeloid cell 
reservoirs. We will discuss the potential role for macrophage in viral 
persistence and the potential for therapeutic vaccines in eliminating 
chronically infected macrophage. In particular, data suggesting an 
inherent resistance of infected macrophage to cell-mediated immune 
clearance will be presented. These findings have implications for the 
use of therapeutic vaccines in the elimination of viral reservoirs.
S07.01
Dendritic Cell-Based Immunotherapy in HIV-
Infection: “A Bridge Over Troubled Water”
J. Routy1, M. Jenabian1, C. Nicolette2, I. Tcherepanova2, R. Sekaly3
1McGill University, Montreal, Canada; 2Argos Therapeutics, 
Durham, NC, USA; 3VGTI Florida, Port St. Lucie, FL, USA
Antiretroviral therapy (ART) has dramatically reduced the morbidity 
and mortality of HIV-infected patients, whereas HIV-specific immune 
responses remain unchanged, even after years of successful viral control. 
Therapeutic immunization strategies have been proposed to enhance 
immune-specific responses that could allow ART discontinuation over 
time. Dendritic cell (DC)–based immunotherapy that bridges innate 
and adaptive immune responses is the only strategy that has shown 
encouraging results in HIV infection. Type of antigen, immunogen 
delivery method, optimal interaction of antigenic peptide with T cells 
and avoidance of tolerogenic responses are key elements for an 
efficient immunotherapy. DC-based therapy electroporated with RNA 
encoding both CD40 ligand and patients’ own HIV antigens have the 
advantage to induce CD8 HIV-specific T cell responses in the absence 
of requiring CD4T cell help. This approach by not inducing antigen 
cross-presentation, thus avoiding CD4T cell activation should prevent 
the potential for increased viral replication.
Several groups have reported different levels of HIV-specific immune 
restoration by promoting the effector functions of T helper (Th)-1 
cells and/or cytotoxic T lymphocytes in ART-treated patients receiving 
autologous monocyte-derived DC. Following ART discontinuation, a 
decrease of plasma viral load setpoint ≥1 log was observed in several 
studies. Recently, DC-based immunotherapy is also being considered 
as effort aimed at decreasing the HIV reservoir, especially when 
combined with reservoir-mobilizing agents. Clinical study design, 
patient selection, ethics consideration and optimal condition to safely 
discontinue ART as a read-out for HIV remission represent unresolved 
challenges. The induction by DC-based therapy of a robust and 
long-lasting cellular response that recognize the broad set of viruses 
that escaped the immune system will be needed to transform this 
experimental approach into an effective and large scale strategy. 
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S07.04
Immune Mechanisms and HIV Eradication
M. Lederman1
1Case Western Reserve University, Cleveland, OH, USA
A general pessimism about the plausibility of HIV eradication is being 
replaced by a cautious optimism. But for persons with established 
infection, how to get there? Eradication strategies will need to deplete 
cells harboring virus or somehow coax virus out of them. As the 
determinants of HIV activation are largely dependent upon signals 
shared with immune activation, immunologic mechanisms may prove 
useful for activating virus from latency but may not be without risk as 
early efforts to activate HIV expression by activating HIV expression 
have not been well tolerated. And while newer approaches have 
generated only modest signals of HIV activation from latency, the 
effects of this approach on host elements- especially as more potent 
strategies are implemented - are not yet fully understood. It is also 
not yet clear whether activation of HIV expression will result in the 
destruction of latently infected cells without the participation of innate 
or adaptive immune mechanisms. To this end, strategies that involve 
administration of cytokines and a renewal of interest in therapeutic 
vaccines may help to enlist innate and adaptive defenses to clear cells 
that have been induced to newly express viral antigens or peptides 
on their surface. And while this approach may not yet be adaptable 
to most infected persons, the exciting results seen in a few persons 
who have undergone myeloablative therapies and allogeneic stem cell 
transplantation may have been mediated at least in part by the immune 
clearance of graft versus host disease. Will more selective targeting of 
latently infected cells be aided by the identification of markers that can 
more selectively target these cells? As chronic exposure to uncontrolled 
HIV infection appears to result in structural damage to immunologic 
organs in secondary and gut associated lymphoid tissue, it is also not 
yet clear whether viral eradication alone will allow full restoration of 
immunity and attenuation of the inflammatory environment that are 
linked to HAART-era morbidity and mortality.
S07.03
Therapeutic Concepts for HIV Eradication
R. Geleziunas1
1Gilead Sciences, Inc., Foster City, CA, USA
Virus reservoirs that persist during suppressive combination antiretro-
viral therapy (cART) represent barriers to eradication of HIV infection. 
One well documented reservoir of latent HIV resides in memory CD4 
T-cells. Therapeutic strategies that could safely eliminate such latent-
ly infected memory CD4 T-cells may contribute to eradication of HIV. 
One approach being pursued to eliminate HIV reservoirs in memory 
CD4 T-cells is to combine agents capable of activating expression of 
viral proteins from latent proviruses with strategies that could facili-
tate clearance of such cells. Using a primary cell-based HIV latency 
assay and memory CD4 T-cells from HIV+ patients on cART, we have 
identified and characterized the HDAC inhibitor romidepsin (RMD) as 
a potent and broad inducer of HIV expression. Clinical and animal 
studies are underway to determine if RMD can induce expression 
from latent viruses in vivo. Combination of RMD with immune modu-
latory agents such as TLR7 agonists is also being investigated. 
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S08.02
HIVACAT T- and B-Cell Immunogen Design and 
Preclinical Testing
C. Brander1
1IrsiCaixa Foundation, HIVACAT, ICREA, Barcelona, Spain
The HIVACAT program is dedicated to the development of effective 
preventive and therapeutic HIV vaccines. Started in 2008, the 
program includes about 60 investigators at two major HIV research 
centers in Barcelona with expertise in retrovirology and cellular, 
humoral and innate immunity, including mucosal immunity.  T-cell 
immunogen development was based on screening more than 1,000 
HIV-1 clade-B and -C infected individuals for total virus-specific T cell 
immune responses and identifying those specificities that dominate 
the response in subjects with relative viral control. The identified 
regions emerge to be highly conserved and to induce responses of 
high functional avidity and superior ability to suppress in vitro viral 
replication. They are highly enriched for regions that contain sites for 
which mutations cause significant loss of viral replicative capacity. 
This approach has led to the design of an immunogen sequence of 
roughly 500 amino acids encompassing more than 50 optimally 
defined CTL epitopes and all described regions rich in CD4 T cell 
targets. Preclinical testing in mice using DNA and MVA-vectors shows 
broad and evenly distributed responses of high magnitudes. HIVACAT’s 
B-cell immunogen development includes a MPER and a full-length Env 
approach with DNA, VLP and recombinant protein delivery strategies. 
Elevated neutralization activity has been obtained in murine studies 
by in-house developed Env variants when compared to the wild-
type sequence. Prime-boost strategies combining DNA/MVA and VLP 
delivery of HIVACAT-T immunogen, a variant-coveting full-length Gag 
and MPER and Env sequences are under way. 
S08.01
Refocusing CTL and Antibody Responses with 
p24gag Conserved Elements Vaccines
J. Mullins1
1University of Washington, Seattle, WA, USA
HIV sequence diversity is a major hurdle for AIDS vaccine development. 
Our Conserved Elements (CE) vaccine design circumvents this problem 
with immunogens composed of conserved segments of the viral 
proteome and excluding potentially immunodominant regions capable 
of mutating without destroying or limiting virus viability (i.e., “decoy” 
epitopes). The prototype HIV-1 p24gag CE DNA vaccine construct 
(p24CE) encodes 7 viral peptides (of 12-24 amino acids) that were 
generally conserved in >98% of all known HIV-1 M Group sequences. 
While we found a surprisingly weak relationship between sequence 
conservation and viral fitness, we have identified residues critical for 
viral infectivity and fitness, primarily at the capsid hexamerization 
interface. The 7 peptides were linked via short spacer sequences and 
DNA constructs allowed expression and appropriate processing of 15 
of 16 known A-list HIV epitopes in human cells. These peptides were 
recognized in HIV infection and high avidity responses against them 
were associated with virologic control. Exposure to CE-expressing 
autologous dendritic cells in humans induced de novo CD4 and CD8 
responses at levels similar to full-length Gag. Immunization of mice 
and macaques with p24CE DNA elicited strong, cross-clade cellular 
and humoral responses. In contrast, vaccination with full-length, 
p55gag DNA primarily elicited responses to epitopes outside of the 
CE. Boosting of p24CE-primed macaques with p55gag DNA greatly 
augmented CE-specific multifunctional cellular responses as well as 
humoral responses. In a therapeutic vaccine experiment in macaques, 
existing T cell responses induced by infection were found to be 
overcome by subsequent CE vaccination. These results provide a novel 
and effective strategy to avoid immunodominant responses against 
decoy epitopes in both prophylactic and therapeutic settings, while 
focusing responses to critical features of the virus for which limited 
viable escape pathways exist.
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S08.04
Immunological and Virological Mechanisms of 
Vaccine-Mediated Protection Against SIV
A. Buzby1, L. Mach1, L. Shen1, M. Alam2, T. Denny2, G. Ferrari2,  
R. Gottardo3, W. Fischer4, B. Korber4, W. Gu5, M. Nason5,  
M. Roederer6
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Duke University, Durham, NC, USA; 3Fred Hutchison Cancer 
Research Center, Seattle, WA, USA; 4LANL, Los Alamos, NM, 
USA; 5NIAID, NIH, Bethesda, MD, USA; 6Vaccine Research 
Center, NIAID, NIH, Bethesda, MD, USA
Vaccination followed by simian immunodeficiency virus challenge is 
often used to model potential HIV-1 vaccine protection of humans. 
We conducted a large (n=80) macaque vaccine-challenge study to 
define mechanisms of protection, comparing control animals to those 
vaccinated only with mosaic Gag, only with mosaic Env, or only with 
native Env. We show that antibodies to the SIV envelope glycoprotein 
are necessary and sufficient to protect against infection. Both mosaic 
Env and native Env immunization elicit the same protective response, 
but the mosaic Env does so inefficiently. These data suggest caution 
for using mosaic Env for the purpose of eliciting functional antibodies. 
Sequencing of viruses from break-through infections revealed a strong 
vaccine-mediated selective pressure against neutralization sensitive 
viruses within the challenge swarm. We identified a two amino acid 
signature in the envelope that confers a near-global resistance to 
antibody neutralization, manifested as resistance against a diverse 
set of monoclonal antibodies as well as to sera from all vaccinated 
animals. Interconversion of these two amino acids is sufficient to 
confer resistance on easy-to-neutralize SIV clones (e.g., CP3C), as well 
as sensitivity on hard-to-neutralize clones (e.g., CR54).Our data are 
consistent with SIV envelope comprising two serologically-distinct and 
functional structures, either of which can be adopted to varying extents 
by any given clone. Analysis of all transmitted/founder (T/F) viruses 
shows that the native Env vaccination has an efficacy (VE) of 90% 
against the sensitive viruses, but a VE of only 30% against the resistant 
viruses. Thus, highly protective antibody responses against lentiviral 
infection can be elicited by vaccination; broad efficacy will require 
elicitation of antibodies specific to structurally-distinct forms of the 
envelope. Our analyses suggest that determining the resistance profile 
of T/F from clinical trials (RV144, HVTN505) may reveal mechanisms 
underlying the differential, partial efficacy of these vaccines.
S08.03
Protection Against HIV: Vaccination to Block 
Inflammation
D. Hartigan-O’Connor1, A. Tarantal1, J.M. McCune2
1University of California-Davis, Davis, CA, USA; 2University of 
California-San Francisco, San Francisco, CA, USA
Though candidate vaccines against HIV have generally been designed to 
induce a robust adaptive immune response against the virus, we wonder 
whether an effective vaccine might induce tolerance instead. Tolerance 
to HIV may result in abortive infection because, absent the effects of 
inflammation that normally drive viral replication and spread, infected 
cells may be cleared at a faster rate than additional cells can be infected. 
Although such tolerance can be attributed to the deletion of reactive T 
cell clones, we have more recently found that there is a surprisingly high 
degree of maternal microchimerism within the human fetus, inducing 
a robust and tolerogenic CD4+CD25highFoxP3+CD127low regulatory 
T cell compartment (Mold et al., Science 322:1562, 2008) emanating 
from a developmentally-distinct fetal hematopoietic stem cell (Mold 
et al., Science 331:534, 2010). This observation, in turn, prompts the 
question: if maternal cells can so readily move into the human fetus and 
induce such tolerance, why then are not all babies born to HIV-infected 
mothers infected as well? Since in utero infection appears to occur 
only infrequently, it the fetus might be “protected” against HIV in utero 
precisely because a tolerogenic response is mounted when HIV spreads 
transplacentally, limiting further viral replication and spread. Given 
previous studies demonstrating that fetal-maternal microchimerism 
also exists in the monkey (Jimenez et al., Transplantation 79:142, 
2005), we are now testing the hypothesis that induction of tolerance 
to SIV in utero and/or at birth results in protection of rhesus macaques 
against subsequent challenge with SIV. Results will be presented from 
experiments in which tolerance induction has been attempted by (a) 
injection of dams with the attenuated strain SIVmac1A11, (b) injection 
of first trimester fetal macaques with SIVmac1A11 or a lentiviral vector 
encoding SIV Env, and/or (c) oral administration of AT2-inactivated SIV 
to newborn macaques.
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S09.02
Dynamic Interplay Between Virus and Host 
Occurring at the Female Reproductive Tract 
During Acute HIV Infection and Treatment
J. Garcia-Martinez1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
We utilized BLT humanized mice to elucidate and study critical events 
occurring in the FRT and CVS during HIV infection. By performing 
comprehensive analyses of the Tcell subsets present in the FRT and 
CVS, we have gained insight into the human immune cell populations 
in this organ. Consistent with observations made in healthy women, 
the majority of the human lymphocytes present in the FRT and CVS 
from BLT mice are memory Tcells. Consistent with the preferential 
vaginal transmission of CCR5-tropic viruses, a high percentage of CD4+ 
Tcells present in the FRT and CVS express CCR5. Also consistent with 
humans a significant number of the memory CD4+ Tcells present in 
the FRT and CVS of BLT mice expressed α4β7. We next investigated the 
effect of ART on HIV levels in CVS of BLT mice. Consistent with results 
obtained in humans, ART treatment of infected BLT mice resulted in a 
significant decrease in the levels of HIV in both PB and CVS. However, 
the finding showing the absence of cell-free HIV in CVS during ART, but 
the continued presence of infected cells producing HIVRNA could have 
potentially important implications for HIV prevention and eradication 
strategies.
Consistent with the lack of transmission observed in heterosexual 
couples where the infected partner is undergoing ART our analysis 
showed that HIV RNA+ cells present in the mice receiving ART couldn’t 
produce replication competent infectious virus. The availability of a 
small animal model that accurately recapitulates key aspects of human 
conditions represents a unique tool for the invivo study of the intricate 
cellular dynamics occurring during HIV infection in the FRT. Also, this 
model could prove helpful in evaluation of novel approaches to prevent 
HIV transmission and potentially in the evaluation of interventions 
aimed at HIV eradication from cellular reservoirs.
S09.01
Visualizing Cellular Dynamics of HIV Infection 
In Vivo
T. Murooka2 , M. Deruaz2, F. Marangoni2, V. Vrbanac2, E. Seung2, 
U. von Andrian1, A. Tager2, A. Luster2, T. Mempel2
1Harvard Medical School, Boston, MA, USA; 2Massachusetts 
General Hospital, Boston, MA, USA
The mechanisms by which HIV spreads among target cells within 
lymphoid organs are not known. While T cells can be infected by cell-
free HIV, cell-to-cell mediated HIV infection has been proposed to play 
a major role in viral spread, given the high cellular density in lymphoid 
tissues. Stable contacts between infected and uninfected T cells permit 
the formation of virological synapses (VS), which facilitate efficient cell-
cell transfer of virus in vitro. However, it is unclear whether T cell – T 
cell contacts are sufficiently stable in vivo to allow for functional VS 
formation under the conditions of perpetual cell motility in lymphoid 
tissues. To address this, we have taken a visualization approach using 
multiphoton intravital microscopy (MP-IVM) to examine the dynamic 
behavior of HIV-infected T cells in lymph nodes of BLT humanized 
mice. We have found that the majority of productively infected T cells 
migrated robustly, resulting in their even distribution throughout the 
lymph node cortex. Unexpectedly, a subset of infected cells formed 
multinucleated syncytia through HIV envelope (Env)-dependent cell-
cell fusion. Blocking the egress of migratory T cells from LNs into 
efferent lymph, and thus interrupting T cell recirculation, limited HIV 
dissemination and strongly reduced plasma viremia. Thus, we found 
that HIV-infected T cells retain their motility, contributing to local viral 
spread, as well as to systemic dissemination of HIV through T cell 
recirculation through distant tissues. We are currently extending these 
studies to the female reproductive tract. Initial observations from our 
ongoing work will be discussed.
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S09.04
Prime and Pull: A Vaccine Strategy for Viral 
Sexually Transmitted Infections
H. Shin1, A. Iwasaki1
1Yale University School of Medicine, New Haven, CT, USA
Viral sexually transmitted infections (STIs) such as herpes simplex 
virus-2 (HSV-2) and HIV account for a significant amount of morbidity 
and mortality around the world. However, efficacious vaccines for 
viral STIs have been elusive. Strong evidence for the role of T cells 
in controlling viral STIs has led to the design of prophylactic vaccines 
that elicit both systemic cellular and humoral immunity, and yet these 
vaccines have not been successful. In peripheral sites, tissue-resident 
memory T cells have been shown to provide superior protection 
compared to circulating memory T cells. However, the female genital 
tract, which is a portal of entry for viral STIs, is an immunologically 
restrictive tissue that does not allow entry of activated T cells in the 
absence of infection or inflammation. To overcome these obstacles, we 
designed a vaccine strategy called ʻprime and pullʼ to establish tissue-
resident memory T cell population at the barrier tissue. Prime and pull 
relies on two steps: 1) systemic parenteral priming and 2) recruitment 
or “pulling” of activated T cells to the restrictive genital tract by topical 
application of chemokines. We show that prime and pull effectively for 
recruits virus-specific effector T cells to the genital tract, where the cells 
then establish a resident memory pool within the tissue. Furthermore, 
we find that this tissue-resident memory T cell population provides 
protective immunity and may prevent the spread of virus from the 
initial infection site. Thus, prime and pull appears to be a promising 
vaccination strategy for HSV-2, and has the potential to be applied to 
other STIs such as HIV.
S09.03
Identification and Characterization of Specific 
IgG-mucin Interactions to Enhance Vaccine 
Function
T. Hope1, G. Alter2, B. Gunn2, M. Shansab2
1Northwestern University, Chicago, IL, USA; 2Ragon Institute of 
MGH, MIT and Harvard, Cambridge, MA, USA
Current HIV vaccines can generate IgG antibodies that bind to, but 
do not broadly neutralize virions. Such antibodies were generated 
by the antigens delivered in the RV-144 vaccine trial. How such 
antibodies could provide the modest protection observed remains to 
be determined. One potential mechanism is the interaction of vaccine-
induced antibodies with mucus. Antibodies tethered to mucus could 
function to trap viral particles in mucus, effectively neutralizing the 
virus by preventing it from reaching potential target cells. We have 
observed the stable interaction of IgG with cervical and cervicovaginal 
mucus utilizing several different approaches. To begin to identify the 
specificity of interactions, we set up a series of ELISA based assays to 
detect IgG interactions with individual mucins. With this approach, we 
were able to detect a specific interaction of IgG with mucin 16 (MUC16). 
MUC16 is a cell associated mucin which is shed into mucus. The IgG-
MUC16 interaction is mediated by the Fc portion of IgG and sensitive 
to deglycosylation, suggesting that IgG glycotype plays a role in the 
specific interaction. Interestingly, serum IgG binding is enhanced in 
individuals chronically infected with HIV, independent of virus control 
of HAART treatment. Likewise, individuals with Rheumatoid Arthritis 
show a similar increase in serum IgG binding to MUC16 indicating 
that chronic inflammation increases the IgG-MUC16 interaction. 
This increase in interaction also reveals that the targeting of IgG to 
interact with MUC16 can be regulated by the immune response. Using 
biochemical and proteomics approaches, we are gaining insights into 
the molecular determinants of IgG interaction with MUC16. We are also 
generating preliminary results revealing that antibodies can interact 
with other mucins, potentially through different specificities. These 
data demonstrate that antibodies can be targeted to interact with 
mucins and possibly enhance vaccine generated antibody function by 
targeting responses to preferentially interact with mucus.
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What Has 30 Years of HIV Vaccine Research 
Taught Us? Lessons From the Past to Inform the 
Future
J. Esparza1
1Bill & Melinda Gates Foundation, Seattle, WA, USA
Soon after HIV was discovered as the cause of AIDS in 1983-4, there was 
an expectation that a preventive vaccine would be rapidly developed. 
The molecular structure of the virus was essentially elucidated by 
1985, and the first phase I clinical trial of any HIV vaccine was initiated 
in 1986. The first two generations of candidate vaccines were based 
on either the neutralizing antibody, or the cytotoxic T-cell paradigms. 
These paradigms produced important scientific information. Vaccines 
based on these concepts, however, failed to demonstrate efficacy when 
tested in large scale human trials.  The modest efficacy demonstrated 
in 2009 by the Thai RV144 trial, finally provided proof-of-concept that 
an HIV vaccine is an achievable goal. In addition to the exciting science 
that has been produced over the last 30 years, there are general lessons 
learned that could be important in accelerating the development of 
an HIV vaccine: (1) its development is an extremely difficult scientific 
challenge that needs to be approached in a more systematic and 
disciplined fashion; (2) the temptation of just following the fashion 
(or the current paradigm) should be avoided, with more willingness to 
explore truly innovative concepts; (3) clinical trials, especially efficacy 
trials, are essential in obtaining critical information to advance the 
field; (4) HIV vaccine research requires long-term commitment and 
funding; and (5) any effective vaccine development effort requires 
sustainable collaborations with multiple partners (for which the Global 
HIV Vaccine Enterprise was established). The window of opportunity to 
develop an HIV vaccine may be narrowing. To maintain its relevance 
within the broader response to the HIV/AIDS pandemic, HIV vaccine 
research should be conducted with the necessary sense of urgency, 
and in close coordination with other HIV prevention activities.
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OA01.01
Effective CD8+ T Cell Responses Restrict SIV 
Replication to Follicular Helper T Cells 
Y. Fukazawa1, R. Lum1, J. Bae1, A. Okoye1, S.I. Hagen1, H. Park1, 
A.W. Legasse1, M.K. Axthelm1, J.D. Estes2, M. Piatak Jr.2,  
J.D. Lifson2, and L.J. Picker1 
1VGTI, Oregon Health & Science University, Beaverton, OR, 
USA; 2SAIC-Frederick, Inc., Frederick National Laboratory, 
Frederick, MD, USA
Background: HIV and SIV infections are thought to be permanent, 
even in individuals with elite immunologic control. Although latent 
infection of long-lived CD4+ T cells contributes to viral persistence, 
the finding of low-level replication in elite controllers suggests a more 
active sanctuary where productively infected cells are shielded from 
immune destruction.
Methods: We used flow cytometric cell sorting to isolate cell populations 
from lymph nodes (LN) obtained from rhesus macaques (RM) with 
chronic SIVmac239/251 infection and varying SIV replication set-
points, ranging from progressive infection to elite control. In selected 
RM, LN biopsies were obtained before and after in vivo CD8+ cell 
depletion with monoclonal antibody M-T807R1. Sorted populations 
were quantified for replication-competent SIV by inductive co-culture 
and for SIV RNA by qRT-PCR.
Results: In all SIV-infected RM, the frequency of SIV+ cells was 
highest in CD4+ memory T cells, but the distribution of SIV within 
CD4+ memory T cell subsets defined by PD1 expression (low, medium 
and high, with the PD1high subset reflecting follicular helper T cells) 
was strikingly different depending on the viral replication set-point. 
In RM with plasma viral load set point >50,000 copies/ml, SIV was 
similarly distributed among all PD1-defined subsets, but in RM with 
lower SIV set-points, SIV was increasingly restricted to the PD1high 
follicular helper T cells such that virus was almost exclusively restricted 
to this subset in elite controllers (plasma viral load <1,000 copies/ml). 
CD8+ cell depletion of elite controllers resulted in a transient increase 
in plasma viremia and an associated transient re-distribution of SIV 
infection to non-follicular helper cells.
Conclusion: This study shows that productive SIV replication is 
increasingly restricted to follicular helper T cells as CD8+ T cell 
immune pressure increases, indicating that the B cell follicle acts as a 
sanctuary where productively SIV-infected cells are relatively protected 
from effective CD8+ T cell responses.
OA01.02
The Breadth of Expandable Central Memory 
CD8 T Cells Inversely Correlates with Residual 
Viral Loads in HIV Elite Controllers 
Z. Ndhlovu1, E. Stampouloglou2, K. Cesa2, D. Alvino2,  
A. Piechocka-Trocha2, F. Pereyra2, and B. Walker2
1University of KwaZulu-Natal, Durban, South Africa; 2Ragon 
Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Background: Previous studies have shown that elite controllers with 
minimal T cell responses harbor a highly functional, broadly directed 
central memory T cell population that is capable of suppressing HIV in 
vitro. However there is no evidence implicating this cell population in 
the durable control of HIV replication in vivo. 
Methods: We investigated whether there is an association between 
the breadth of expandable central memory CD8 T cell pool and the 
level of viremia during chronic HIV infection. Low frequency HIV-
specific memory CD8 T cells were expanded using autologous epitopic 
and variant peptides. Viral load was measured by standard assays and 
as well as the ultrasensitive single-copy PCR assay. 
Results: We show that HIV elite controllers maintain significantly 
greater breadth of expandable HIV-specific central memory CD8 T cells, 
which are manly directed against HIV Gag (Kruskal-Wallis >0.0001). No 
significant differences were observed in the breadth of this expandable 
population in treated (Kruskal-Wallis >0.2) and untreated (Kruskal-
Wallis >0.5) chronic progressors. Elite controller Gag responses had 
superior in vitro virus inhibition capacity compared to Nef (p<0.01) 
and Env (p<0.01) responses, whereas chronic progressors showed 
diminished inhibitory capacities regardless of HIV protein-specificity 
(Kruskal-Wallis >0.9). Furthermore, we show that elite controller 
memory CD8 T cells remain highly functional even after the inducing 
epitope has escaped. More importantly, we show that the breadth of 
Gag-specific central memory responses have an inverse correlation 
with viral load (r=-0.4, p=0.009). This inverse correlation is sustained 
even when only individuals with suppressed viral loads of between 50 
copies to 1 copy are studied (r=-0.5, p=0.02). 
Conclusion: Together these data reveal a direct link between the 
abundance of central memory CD8 T cells and prolonged maintenance 
of low-level viremia. Our studies highlight a feature of HIV-specific CD8 
T cells that would be desirable in vaccine-induced responses. 
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OA01.04
Immunotherapeutic Interventions to Restore 
HIV-1-Specific CD4 T Cell Help to NK Cells
F. Porichis1, M. Hart1, L. Barblu2, T.E. Brennan1, D. Kavanagh1, 
and D. Kaufmann2
1Ragon Institute of MGH, MIT and Harvard, Cambridge, 
MA, USA; 2Centre de Recherche du Centre Hospitalier de 
l’Université de Montréal, Montreal, Canada
Background: PD-1 and IL-10 blockade can restore antigen-specific 
T cell functions in chronic infections and cancer. In contrast to the 
significant progress made in understanding mechanisms of CD8 T cell 
exhaustion, CD4 T cell dysfunction remains much less explored. Here 
we investigate the impact of combined PD-1 and IL-10 blockade on 
restoring HIV-specific CD4 T cell help to improve natural killer (NK) 
cell function.
Methods: We used Luminex arrays to analyze IFN-γ, IL-2, IL-13 
and IL-12 secretion in supernatants of CD3- or CD8-depleted PBMC 
from HIV-infected individuals with progressive infection.  Cells were 
stimulated for 48h with Gag peptide pools in the presence of isotype 
control antibody, anti-PD-L1 and/or anti-IL-10Rα, anti-IL-12 or anti-IL-2. 
We also used intracellular cytokine staining (ICS) to evaluate NK cell 
function as measured by expression of IFN-γ and CD107.
Results: Contrasting with the moderate effect of single blockade, 
concurrent PD-L1/IL-10Rα blockade resulted in dramatic increases in 
IFN-γ production by HIV-specific CD4 T cells (10-fold) and IL-12 secretion 
by antigen-presenting cells (APCs) (19-fold), which was governed by 
IFN-γ derived from Thelper cells.  ICS assay during the first 12 hours 
of stimulation showed that CD4 T cells are the only subset producing 
IFN-γ.  ICS assay at 48 hours demonstrated a secondary IFN-γ+ NK 
cell response that was CD4 T cell dependent.  Depletion of CD3 T cell 
abrogated IFN-γ production from NK cells. Combined PD-L1/IL-10Rα 
resulted in statistically significant enhancement on the percentage of 
NK cells producing IFN-γ.  Neutralization of IL-12 selectively reduced 
IFN-γ but not CD107 production from NK cells while neutralization of 
IL-2 inhibited both functions.
Conclusion: These data provide important evidence on the therapeutic 
potential of manipulating immunoregulatory pathways to restore HIV-
1-specific CD4 T cell help to APCs and NK cell functions, providing 
evidence for synergistic impact of combined interventions and linking 
restoration of adaptive and innate immunity.  
OA01.03
PD-1 Expression on HIV-1 Specific CD8+ T Cells 
Is Shaped by Epitope Specificity, TcR Clonotype 
Usage and Driven by Antigen Load
H.N. Kløverpris1, A. Stryhn2, S. Buus2, D. Price3, and P. Goulder4
1University of KwaZulu-Natal, Durban, South Africa; University 
of Copenhagen, Copenhagen, Denmark; 3Cardiff University 
School of Medicine, Cardiff, Wales, UK; University of Oxford, 
Oxford, UK
Background: Multiple negative and positive regulatory molecules 
expressed on HIV specific CD8+ T cells define their ability to control 
natural HIV-1 infection. A second determining factor central for the 
antiviral activity is the HIV epitope specificity, yet its relationship to 
antigen load and CD8+ T cell exhaustion during chronic HIV infection 
remains unclear. 
Methods: We used an array of different HLA-B*15:03 and B*42:01 
tetramers and studied a total of n=128 HIV CD8+ T cell responses 
specific for 11 different HIV epitopes to characterize the distribution 
of multiple surface markers, such as PD-1, CD244, LAG-3, CD57 and 
CD127 between epitopes and at the TcR clonotype level. 
Results: We find that the level of PD-1 expression varies greatly 
on CD8+ T cells specific for different HIV epitopes (P<0.001), even 
sampled from the same subject and timepoint. We confirm the 
previously described correlation between PD-1 expression and viral 
load setpoint (R=0.21, P=0.02) but find that it is mainly driven by 
epitopes that do not frequently undergo escape mutation (R=0.37, 
P=0.03), and not by epitopes prone to escape (R=0.19, P=0.11), 
suggesting that antigeneamia drives PD-1 expression and not vice 
versa. In addition, we observe an unequal distribution on different TcR 
Vβ clonotypes recruited within each CD8+ T cell response that is not 
related to clonotype frequency. Finally we show that the PD-1high cells 
are limited to the effector memory population (P<0.001).
Conclusion: Taken together these data suggest that PD-1 expression 
on HIV specific CD8+ T cells is tracking antigen load at the level of 
epitope specificity and clonotype usage and may in fact serve as a 
useful proxy for quantitation of the level of epitopes expressed on the 
surface of infected cells.
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OA01.06 LB
Effective Antiviral CD8+ T Cells Responses Are 
Rare in HIV-Positive Step & Phambili Study 
Participants but Are Targeted to Low Entropy 
Viral Epitopes 
G. Hancock1, H. Yang1, A.J. McMichael1, N. Frahm2, J.M. McElrath2, 
L. Dorrell1
1University of Oxford, Oxford, UK; 2Fred Hutchinson Cancer 
Research Centre, Seattle, WA, USA
Background: Reliable correlates of immunological control are critical 
for HIV vaccine development. We and others have shown the capacity 
of CD8+ T cells to inhibit HIV-1 replication in vitro is highly predictive 
of their antiviral efficacy in vivo. The design of immunogens that could 
elicit effective CD8+ T cell responses is a major challenge.
Methods: Ex vivo CD8+ T cell-mediated antiviral inhibitory activity 
was measured in 36 HIV-1-infected Step and Phambili trial participants 
(20 vaccinees, 16 placebos, blinded analysis) using PBMC sampled 
one year post-infection with a panel of ≤ 5 viruses representing clades 
A, B and C. Frequencies of CD8+ T cells to: (i) total proteome using 
PTE peptides (ii) ‘protective’ peptides (overlapping Gag, Pol, Nef, and 
Vif peptides (OLPs) preferentially targeted by patients with controlled 
viraemia) were determined by IFN-γ intracellular staining and Elispot. 
Results: The majority of study participants lacked potent CD8+ T cell 
antiviral activity and this did not differ significantly between vaccine 
and placebo recipients. Despite strong responses to the total proteome 
(median 1.81% CD8+ T cells), frequencies of IFN-γ-producing T cells 
targeting the ‘protective’ OLPs were modest overall (median 0.02% CD8+ 
T cells). CD8+ T cell-mediated virus inhibition was strongly correlated 
with IFN-γ responses to protective OLP (r = 0.69, p = 0.0001) even after 
controlling for protective HLA alleles, but not to total proteome responses 
(r = 0.11, p= 0.64). Viral load setpoint was negatively correlated with 
CD8+ T cell antiviral activity (r = -0.37, p = 0.05).
Conclusion: Sustained potent CD8+ T cell antiviral inhibitory responses 
were rare in HIV-infected Step and Phambili Study participants but 
were strongly associated with targeting of ‘protective’, low entropy 
regions in HIV-1 Gag and Pol. These findings highlight the importance 
of systematically selecting specific regions within the viral proteome 
for inclusion in immunogens to avoid targeting of irrelevant epitopes. 
OA01.05
Integrative Analysis of Responses to Dendritic-
Cell Vaccination Identifies Signatures 
Correlated with Control of HIV Replication: The 
DALIA Trial
R. Thiebaut1, B. Hejblum1, J. Skinner2, M. Montes2, G. Chêne1,  
K. Palucka2, J. Banchereau2, and Y. Levy3
1INSERM U897, Bordeaux, France; 2Baylor Institute for 
Immunology Research, Dallas, TX, USA; 3INSERM U955, 
Creteil, France
Background: We have reported that vaccination with ex vivo generated 
DC loaded with HIV-lipopeptides in patients (n=19) on antiretroviral 
therapy (ART) was well tolerated and immunogenic. Vaccine-elicited 
HIV-specific T cell responses were associated with improved control 
of viral replication following antiretroviral interruption (ATI from w24 
to w48) (CROI 2012 PB440). Here we have performed an integrated 
analysis of post vaccination immune responses and gene expression 
measured at w16 with viral parameters during ATI.
Methods: Gene expression in whole blood was repeatedly measured 
by gene expression microarrays (Illumina HumanHT-12 v4) at 14 time 
points. Post vaccination (w16) immune responses were evaluated using 
ICS, Multiplex cytokine secretion and Interferon-γ ELISPOT. Peak of 
viral load was the maximum observed plasma HIV RNA during ATI. 
Longitudinal analysis of gene expression data was performed using 
hierarchical models allowing heterogeneity in predefined gene 
sets (Chaussabel’s functional modules). Data integration of gene 
expression, immune responses at w16 and peak of viral load during 
ATI was performed with sparse-Partial Least Square.
Results: During vaccination, 69 modules out of 260 varied significantly 
including T cell (M4.1), protein synthesis (M4.5), apoptosis/survival 
(M6.6) and inflammation (M4.6) modules. We show an inverse 
relationship between HIV-specific responses (production of IL-2, 
IL-13, IL-21, IFN-γ, CD4 polyfunctionality, i.e. production of at least 
two cytokines) and the peak of viral load during ATI. Those cellular 
immune responses were positively correlated to genes associated 
with T cell functional modules (M4.1, M4.15) at w16 and negatively 
correlated to genes associated with inflammation (e.g. EGLIN1, H2AFY, 
LTBR). Specifically, IL-21 secretion, that was associated with control of 
viral replication, was negatively correlated to MFAP3 and TFNRSF1A 
inflammatory genes.
Conclusion: Changes in gene expression profile were associated 
with vaccine-elicited cellular responses and viral rebound during 
ATI. Integrated analysis led to identify DC vaccine signatures likely 
correlated with a better control of HIV replication.
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OA02.02
Focusing Antibody Responses to Specific 
Protein Surfaces Through Site-Selective Glycan 
Addition
T. Schiffner1, K. Leonavicius1, H. Schuster1, L. Kong1, R. Saliba1,  
F. Wegmann1, P. Huang2, G.B. Stewart-Jones1,  .W.R. Schief3,  
B.G. Davis1, and Q.J. Sattentau1
1University of Oxford, Oxford, UK; 2University of Washington, 
Seattle, WA, USA; 3IAVI Neutralizing Antibody Center at The 
Scripps Research Institute, La Jolla, CA, USA
Background: Viruses such as human immunodeficiency virus type-
1 (HIV-1) and influenza A virus display rapidly mutating or non-
neutralizing immunodominant epitopes on their viral glycoproteins to 
escape antibody-mediated neutralization. 
Methods: Immunosilent glycoconjugates with terminal sialic acid were 
added site-selectively to the model protein hen egg lysozyme (HEL), 
mutant an HIV-1 gp120 or engineered gp120 outer domain. Epitope 
mapping was subsequently performed on sera from immunized mice.
Results: Glycoconjugate addition of HEL led to site-selective loss of 
antibody binding to epitopes containing modification sites in vitro. 
Immunization with modified protein led to refocusing of antibody 
responses from masked to unmasked epitopes in vivo. Application of 
this sialic acid masking strategy to HIV antigens led to loss of antibody 
recognition in masked regions whilst maintaining antigenicity of the 
CD4 binding site which is a target of broadly neutralizing antibodies.
Conclusion: Our masking strategy attaches relatively small 
glycoconjugates to properly folded proteins under mild conditions 
with near 100% efficiency. This approach circumvents many of the 
problems, such as improper folding and low occupancy, associated 
with masking strategies using mutational redistribution of N-linked 
glycosylation sites. Thus, sialic acid glycoconjugate masking should 
allow focused targeting of specific antigenic regions for increased B 
cell recognition, improving vaccine antigen design.
OA02.01
Engineering an HIV Envelope Protein to 
Activate Germline B Cell Receptors of Broadly 
Neutralizing VRC01-Class Antibodies
A. McGuire1, A.M. Dreyer1, S. Hoot2, A. Lippy1, A. Stuart1,  
K.W. Cohen1, J. Jardine3, S. Menis3, J.F. Scheid4, A.P. West5,  
W.R. Schief3, and L. Stamatatos1
1Seattle Biomed, Seattle, WA, USA; 2Altravax Inc., Sunnyvale, 
CA, USA; 3IAVI Neutralizing Antibody Center at The Scripps 
Research Institute, La Jolla, CA, USA; 4The Rockefeller 
University, New York, NY, USA; 5California Institute of 
Technology, Pasadena, CA, USA
Background: The recent RV144 trial showed ~30% efficacy. Although 
the protection was modest, the trial indicated for the first time that a 
vaccine against HIV is possible.  Immune correlate analysis suggests 
that the observed protection was due to non-neutralizing antibody 
responses. This efficacy might be improved if a vaccine could elicit 
broadly neutralizing antibodies (bNAbs). Of particular interest for 
vaccine design are the potent VRC01-class bNAbs targeting CD4 binding 
site on Env. Unfortunately, a number of studies have demonstrated 
that recombinant Env proteins do not bind germline-reverted VRC01 
class Abs, indicating that current vaccine strategies using recombinant 
Env are unable to activate progenitor B cells that ultimately give rise 
to VRC01 class Abs.
Methods: We developed reagents and experimental protocols to 
express functional versions of the mature and germline VRC01 and 
NIH45-46 BCRs on the surface of B cells, and assays to monitor B cell 
activation following the antigenic-engagement of these BCRs. 
Results: Although several recombinant Env proteins were capable of 
binding to and stimulating B cells expressing the mature BCR forms, no 
such interactions were recorded with B cells expressing the germline 
BCR forms. However, we identified key conserved glycosylation sites in 
the Loop D and V5 regions of a Clade C Env that prevent the binding 
of  the clonally related germline NIH45-46 and germline VRC01 BCRs. 
Disruption of these glycosylation sites resulted in nM binding affinity to 
germline BCRs and activation of the corresponding B cells.
Conclusion: Our study identifies the earliest roadblock in the elicitation 
of anti-CD4-BS bNAbs; the lack of engagement of the germline 
BCR forms of ‘VRC01’ class antibodies by commonly used HIV Env 
immunogens. Importantly, we have developed a way to overcome this 
roadblock through the design of an HIV Env that engages and activates 
B cells expressing the germline BCR forms of ‘VRC01’ class antibodies.
Oral Abstract Session 02: Adjuvants
Oral Abstract Sessions
O
R
A
L 
A
B
ST
R
A
C
T
 S
ES
SI
O
N
S
59AIDS Vaccine 2013
OA02.04
Immunogenicity of a CD207-Targeted Anti-
Gag Vaccine and TLR Ligand-Dependent 
Enhancement
O. Epaulard3, L. Adam3, C. Poux3, G. Zurawski1, P. Rosenbaum3, 
N. Dereuddre-Bosquet3, S. Zurawski1, S. Oh1, G. Romain3,  
J. Banchereau1, Y. Lévy2, R. Le Grand3,and  F. Martinon3
1Baylor Institute for Immunology Research, Dallas, TX, USA; 
2Vaccine Research Institute, Créteil, France; 3CEA, Fontenay-
aux-Roses, France
Background: The targeting of antigens to dendritic cells (DCs) is an 
attractive concept for the development of new, efficient, safer vaccines. 
In this aim, better understanding of early events at site of intradermal 
(ID) vaccine injection is needed for a rational design of future vaccines.
Methods: Non-human primates (NHPs) were immunized with HIV 
Gag protein associated with an anti-CD207 mAb in fusion protein. 
Sera were collected from vaccinated animals for the titration of Gag-
specific Abs.
NHPs underwent ID injection of PBS, R848 or poly(I:C) in presence 
or not of etanercept (anti-TNFα). Punch biopsies were performed for 
histology or cell extraction and flow cytometry analysis.
Results: We show that directing HIV-Gag to Langerhans cells (LCs) 
through langerin (CD207) efficiently primes a specific immune response 
in NHPs (Ab titer 1.7 log higher than control). This immune response 
was significantly strengthened (Ab titer 0.53 log higher) by the co-
injection of TLR-ligands (TLR-Ls). TLR3-L (poly(I:C)) and TLR7/8-L (R848) 
induced the local recruitment of polymorphonuclear neutrophils (4 fold 
increased, p=0.0006) and macrophages (3 fold increased, p=0.0012) 
. This recruitment was directly correlated to LC activation and their 
migration out of the epidermis. LCs were not directly affected by TLR-L 
and their activation and migration depended on TNF-α secretion by 
TLR-L-stimulated inflammatory cells. This was notably demonstrated 
by inhibiting the TNF-α activity in vivo with etanercept (p=0.0242).
Conclusion: This study highlights new elements of cell activation 
mechanisms in the skin and shows that targeting a vaccine to specific 
DC subsets and stimulating specific cells of the innate immune system 
can increase the efficiency of vaccination.
OA02.03
Comparative Antigenicity and Immunogenicity 
of Indian and South African HIV-1 Subtype 
C Native and CD4 Liganded Envelope 
Glycoproteins
M. Grant1, M.A. Killick1, N. Cerutti1, A. Capovilla1, and  
M.A. Papathanasopoulos1
1University of the Witwatersrand Medical School, 
Johannesburg, South Africa
Background: The ability to induce a potent and broadly neutralizing 
antibody (bNAb) response following vaccination is critical in 
developing an effective HIV-1 vaccine. This study describes the design 
and construction of three HIV-1 subtype C South African (derived from 
founder virus sequences) and three Indian (derived from circulating 
virus sequences) Env immunogens, and their antigenicity and 
immunogenicity testing in the presence or absence of liganded CD4, 
in rabbits.
Methods: Monomeric (gp120) and trimeric (gp140GCN4+) 
conformations for IN26191, IN25710, IN25925, ZACAP45, ZACAP210 
and ZA706010164 were expressed in mammalian cells. Unliganded 
or 2dCD4 S60C liganded Env glycoproteins were purified by lectin 
affinity chromatography, followed by conformation and complex 
purification using size exclusion chromatography. Immunogens/
immune complexes were evaluated by ELISA and Surface Plasmon 
Resonance. Immunogenicity of each conformation alone or complexed 
to 2dCD4 S60C was evaluated in rabbits. Breadth and potency of each 
rabbit serum was tested against 12 pseudoviruses (Tiers 1-3) derived 
from HIV-1 subtype B and C Env using the PhenoSense Neutralizing 
antibody assay (Monogram Bioscience Inc.).
Results: The antigenicity of Envs against a panel of antibodies showed 
no significant differences between South African and Indian Envs, 
as determined by SPR. Minimal neutralizing breadth was obtained 
from animals immunized with IN25925 and ZACAP210 Env only 
conformations. However, animals immunized with Env/2dCD4 S60C 
complexes developed potent bNAbs against all 12 pseudoviruses 
tested, including tier 2 and 3 pseudoviruses. End-point ELISA titre 
results revealed that immunizing with Env/2dCD4 S60C produced 
both Env and 2dCD4 specific titres, but the 2dCD4 S60C titres were 
on average 10x lower than the 2dCD4 S60C only control group, 
suggesting an alternative mechanism of neutralization other than a 
CD4 directed response.
Conclusion: The Env/2dCD4 S60C complex is a super-immunogen and 
elicits potent and broad NAbs against Tier 1, 2, and 3 pseudoviruses. 
Such potent and bNAbs have never been reported previously, and non-
human primate studies are underway.
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OA02.06 LB
Lipid Components in MPER-Based 
Immunization Regimens Are Critical for 
Inducing Broadly Neutralizing Antibody 
Responses in 2F5 and 4E10 Knockin Mice
Y. Chen1, J. Zhang1, H. Bouton-Verville1, A. Newman1, S. Xia1,  
H. Liao1, D.C. Montefiori1, M.A. Moody1, L. Armand1, K. Hwang1,  
B. Lockwood1, S.M. Dennison1, S.M. Alam1, B.F. Haynes1,  
L. Verkoczy1
1Duke Human Vaccine Institute, Durham, NC, USA
Background: Developing an HIV-1 vaccine is hindered by the inability 
of immunogens to elicit broadly neutralizing Abs (BnAbs). Using knockin 
(KI) models expressing the membrane proximal external region (MPER)-
specific BnAbs 2F5 or 4E10, we recently identified common hurdles 
for inducing BnAbs: profound B-cell deletion, and anergy of residual 
clones. However, residual 2F5/4E10 KI B-cells accumulate at distinct 
developmental stages, and subsets of each spontaneously escape 
anergy by selectively losing MPER and lipid specificity, respectively. 
Since 2F5/4E10’s initial interactions with viral membranes (prior to 
MPER binding) are required for neutralization, it is key to identify 
regimens that not only overcome tolerance of 4E10/2F5+B-cells, but 
also target subsets retaining dual (MPER+lipid) reactivity. 
Methods: To dissect components needed to activate anergic, MPER/
lipid+ B-cells, serum Ab responses were assessed in KI mice immunized 
with various constituents of a conjugate immunogen comprised 
of an MPER peptide containing 2F5 and 4E10 epitopes, liposomes, 
and TLR4/9 agonists oCpG and Monophosphoryl Lipid A (MPLA) 
respectively, a regimen that elicits high serum BnAb titers in 2F5 KI 
mice. Additionally, to assess the impact of rescuing 2F5/4E10+B-cells 
from deletion, Ab responses in WT KI mice were compared to those 
overexpressing the anti-apoptotic gene bcl2.  
Results: In 2F5 and 4E10 KI mice, MPER peptides alone, multimerized 
on beads, or formulated with oCpG, elicited minimal MPER/lipid+Ab 
titers. In contrast, peptides conjugated to liposomes and formulated 
with MPLA, elicited robust MPER/lipid+ BnAb titers. However, while 
peripheral B-cell survival signals were required for immunization-induced 
BnAb responses in 4E10 KI mice, they were dispensable in 2F5 KI mice, 
consistent with the latter originating from early, T-independent B-cells.   
Conclusion: Our results suggest that immunization regimens capable 
of eliciting BnAbs directed at both 2F5 and 4E10 MPER epitopes require 
lipid components, and will need to be optimized to target distinct B-cell 
subsets in these two BnAb lineages.
OA02.05
Impact of TLR9 Stimulation on HIV-1 Env-
Specific Immune Responses Elicited in Non-
human Primates
P.A. Martinez Murillo1, C. Sundling1, Y. Feng2, S. O’Dell3,  
K. Reimann4, J. Mascola3, R. Wyatt2, and G.B. Karlsson Hedestam1
1Karolinska Institutet, Stockholm, Sweden; 2IAVI Neutralizing 
Antibody Center at The Scripps Research Institute, La Jolla, CA, 
USA; 3Vaccine Research Center, NIAID, NIH, Bethesda, MD, 
USA; 4MassBiologics, University of Massachusetts Medical 
School, Boston, MA, USA
Background: The identification of safe and effective adjuvants is 
important to promote the development of protective immune responses 
induced by protein-based vaccines. TLR9 agonists were previously 
shown to improve responses to existing vaccines, such as the protein-
based Hepatitis B virus vaccine formulated in alum analogues. Here, 
we assessed the capacity of CpG class C, a well-known TLR9 ligand, to 
quantitatively or qualitatively modulate HIV-1 envelope glycoprotein 
(Env)-specific B and T cell responses induced by Abisco-100. Abisco-100 
is an iscomatrix-based adjuvant frequently used in animal vaccines 
and currently under evaluation for use in humans. 
Methods: Rhesus macaques were inoculated three times with soluble 
YU2 gp140-F trimers in Abisco-100 with or without the addition 
of CpG-C. The impact of TLR9 stimulation on the magnitude and 
durability of antigen-specific antibody titers and memory B cells were 
determined and antibody isotypes and neutralizing activity against a 
panel of different HIV-1 strains were assessed. Finally, phenotypic and 
functional characterization of Env-specific CD4+ and CD8+ T cell was 
performed using multi-color flow cytometry. 
Results: Our results show that the specific antibody titers and 
frequencies of memory B cells displayed similar kinetics and 
magnitude in the presence and absence of CpG, and there was no 
apparent difference in HIV-1 neutralizing activity. By using antibodies 
against specific rhesus macaque antibody isotypes, we found that the 
Env-specific IgG1 titers were somewhat higher than the IgG2 titers in 
animals receiving CpG-C, but this difference was not significant. 
Conclusion: Therefore, while several other studies have shown that 
the addition of CpG influences the magnitude or quality of immune 
responses against other antigen-adjuvant combinations, our results 
show that in rhesus macaques, the addition of CpG-C to Abisco-100 
did not markedly affect the magnitude or quality of HIV-1 Env-specific 
B cell and T cell responses.
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OA03.02
Phase I Clinical Trials of DNA-Protein Vaccine 
(CombiHIVvac) Containing Artificial Multi-
Clade Immunogens 
L. Karpenko1, N. Ryndyuk2, Z. Gin’ko2, V. Kuzubov2, S. Bazhan1,
L. Lebedev1, O. Kaplina1, A. Reguzova1, A. Ryzhikov1,  
M. Bogryantseva1, S. Usova1, V. Masycheva1, E. Nechaeva1, and 
A. Ilyichev1
1State Research Center of Virology and Biotechnology 
VECTOR, Koltsovo, Novosibirsk, Russian Federation; 2Hospital 
Number 163 of Russian Federal Medical and Biological 
Agency, Koltsovo, Novosibirsk, Russian Federation
Background: CombiHIVvac is micelle-like particles, which combine 
artificial multi-clade polyepitope immunogens - pcDNA-TCI (DNA 
vaccine) and TBI protein. The TCI contains over 80 optimally selected 
overlapping epitopes (both CD8+ CTL and CD4+ Th) from Env, Gag, 
Pol, and Nef. The chosen epitopes are highly conservative among HIV-
1 subtypes A, B and C. TBI protein contains conserved B- and T-epitopes 
from Env and Gag. 
Methods: The trial was recruiting 30 volunteers who are healthy HIV-
negative men and women at low risk for HIV infection. They were 
randomly divided into two groups. The first group was vaccinated 
intramuscularly with one dose of CombiHIVvac (75µg of DNApcDNA-
TCI and 50µg of TBI protein) at day 0. The second group received 
one dose of vaccine twice (at days 0 and 28).   Combined clinical 
study and laboratory examination were carried out for each volunteer 
during one year. Immunogenicity was assessed by Immunoblot, ELISA, 
IFN-gamma ELISpot, MHC-pentamers and virus neutralization (using 
HIV-1 Env pseudoviruses ). The samples, which were taken before 
immunization, served as negative controls.
Results: No side effects or negative changes in clinical and 
biochemical parameters were registered after vaccination. Vaccine was 
well tolerated, apyrogenic, no inflammatory reactions at the site of 
administration were found. Neither single nor double intramuscular 
administration of vaccine had persistent effects on the integral 
physiological, hematological or biochemical parameters in volunteers. 
Twofold injection is more efficient and provides developing of more 
effective immune response. All volunteers from second group had 
specific humoral immune response (ELISA, HIV-1 New-Lav Blot and 
prevdoviruses) and were IFN-gamma ELISpot reactive.
Conclusion: CombiHIVvac is safe and well tolerated. Vaccination with 
CombiHIVvac elicited specific as CD8+ T cell and humoral responses. 
The request for Phase II clinical trials is submitted for approval to the 
Russian Ministry of Health.
OA03.01
The HIVconsv Vaccines Induce Polyfunctional 
and Highly Proliferative T Cells that Control In 
Vitro HIV Replication: HIV-CORE002 Phase-I 
Clinical Trial
B.O. Ondondo1, T. Ahmed1, B. Nicola1, E. Hayton1, E. Vasilyeva2, 
N. Frahm2, S. Colloca3, A. Nicosia3, A. McMichael1, L. Dorrell1, 
and T. Hanke1
1University of Oxford, Oxford, UK; 2Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 3Okairòs, Rome, Italy
Background: A safe and efficacious vaccine is urgently needed to 
control HIV/AIDS. HIVconsv is a new generation T cell immunogen 
targeting the most conserved regions of the HIV-1 proteome and thus 
has great potential as a universal HIV vaccine to protect against the 
multiple HIV-1 subtypes. 
Methods: Immunogenicity of the HIVconsv candidate vaccines pSG2.
HIVconsv DNA (D), ChAdV63.HIVconsv (C) and MVA.HIVconsv (M) in 
various combination regimens (CM, DDDCM or DDDMC) was tested 
in healthy HIV-1/2-uninfected, low-risk adults in a double-blind, 
randomized phase I clinical trial. The frequency of vaccine-induced 
T cells in PBMC was measured by ex-vivo IFN-γ ELISPOT assay. The 
functional profile of vaccine-induced CD8+ and CD4+ T cells was 
evaluated in a multi-parameter intracellular cytokine staining assay 
(ICS)  for IFN-γ, TNF-α, IL-2, CD107a and Granzyme-A. Further multi-
functional profiling was done by assessing the quantities of secreted 
cytokines in a Luminex assay. Proliferative capacity of CD4+ and 
CD8+ T cells was quantified by a flow-based CFSE assay, while the 
potential of vaccine-induced T cells to control HIV-1 replication was 
assessed in an in-vitro viral inhibition assay using a panel of eight 
HIV-1 virus isolates.
Results: The HIVconsv vaccines induced high magnitude IFN-γ ELISPOT 
responses reaching over 5000 SFU/M cells at peak. ICS and Luminex 
assays revealed that these vaccine-stimulated T cells comprising both 
CD8+ and CD4+ populations were highly polyfunctional, secreting 
several cytokines and signaling molecules  such as IFN-γ, TNF-α, 
CD107a,  IL-2, IL-10, IL-13, MIP-1β and GM-CSF. Additionally, these 
cells displayed greater proliferation capacity even at 28 weeks post-
immunization, and most importantly, they were capable of inhibiting 
replication of several HIV-1 virus isolates in autologous CD4+ T cells. 
Conclusion: HIVconsv vaccines induce polyfunctional and highly 
proliferative CD8+ and CD4+ T cells with antiviral capacity and could 
potentially control in vivo HIV-1 infection. 
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OA03.04
Antibody Repertoire Induced by the Multiclade 
(Env A, B, C) HIV-1 DNA Prime, rAd5 Boost VRC 
Vaccine
W.B. Williams1, K. Jones1, P. Liu1, A.M. Trama1, K. Seaton1,  
M.A. Moody1, N. Vandergrift1, K. Wiehe1, H. Liao1,  
D.C. Montefiori1, C. Ochsenbauer2, J. Kappes2, S.M. Hammer3,  
J. Mascola4, R. Koup4, L. Corey5, G. Nabel4, P. Gilbert6,  
C.A. Morgan6, G. Churchyard7, J. Maenza5, L.R. Baden8,  
M. Keefer9, B.S. Graham4, G.D. Tomaras1, and B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 
2University of Alabama at Birmingham, Birmingham, AL, USA; 
3Columbia University Medical Center, New York, NY, USA; 
4Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
5University of Washington, Seattle, WA, USA; 6SCHARP, Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; 7The 
Aurum Institute, Johannesburg, South Africa; 8Brigham and 
Women’s Hospital, Boston, MA, USA; 9University of Rochester 
Medical Center, Rochester, NY, USA
Background: The phase II DNA prime, rAd5 boost VRC vaccine (HVTN 
204) exhibited sufficient safety and immunogenicity to advance into a 
phase IIb efficacy trial (HVTN 505) in Ad5 seronegative, circumcised, 
male volunteers in the US. Determining the antibody specificities 
induced by the VRC vaccine will provide insights in the memory B cell 
repertoire elicited by this DNA prime rAd5 boost regimen.
Methods: Antibodies were isolated via antigen-specific single memory 
B cell sorts from 8 subjects who received this VRC vaccine regimen 
(HVTN 204 and 082 trials), using group M consensus and vaccine-
matched Env oligomers, and vaccine-matched MuLV gp70 V1/V2-
fusion proteins. Monoclonal antibodies (mAbs) were generated and 
tested for binding, neutralization, and infectious virion capture.
Results: 235 HIV-1 antibodies were isolated from 8 vaccinees. 92% of 
the antibodies were gp41-reactive, and only 8% reacted with gp120. 
Of 217 gp41 antibodies, 64% used VH1-69. Greater than 90% of the 
VH1-69 gp41 antibodies used the HCDR2-bearing 62L allelic variants. 
In contrast, non-HIV-1 antibodies isolated from HIV-1 infected subjects 
predominantly used the HCDR2 62F allelic variants (P value = 1.8 X10 
-25, Fisher Exact Test). Seventeen gp41 mAbs from fifteen different 
clonal lineages were generated from vaccinees. The gp41 mAbs 
bound recombinant gp41 protein, but failed to bind gp41 overlapping 
peptides, suggesting binding to conformational epitopes. Some gp41 
mAbs were cross-reactive with commensal bacteria. A subset of gp41 
mAbs captured infectious HIV-1 transmitted/founder viruses, but failed 
to neutralize tier 1A viruses.  
Conclusion: This DNA prime, rAd5 boost vaccine regimen induced 
a dominant gp41-specific antibody response. These data raise the 
hypothesis that gp41 dominance may be the result of pre-vaccination 
expansion of B cell precursors that are cross-reactive with a gp41 
structure in the Env gp140 vaccine antigen.
OA03.03
Comparative Analysis of Binding Antibody 
Responses Elicited by a Cross-Section of 
Human HIV-1 Vaccine Clinical Trials
S.J. Krebs1, S. Narpala2, A. Wheatley2, B.M. Slike1, M. Eller1,  
S. Ratto-Kim1, V.R. Polonis1, J.H. Kim1, M.L. Robb1,  
M.A. Marovich1, R.A. Koup2, B.S. Graham2, N.L. Michael1, and  
A. McDermott2
1U.S. MHRP, Silver Spring, MD, USA; 2Vaccine Research 
Center, NIAID, NIH, Bethesda, MD, USA
Background: Using a canary pox prime (ALVAC) and protein boost 
(AIDSVAX B/E) regimen, the RV144 vaccine clinical trial demonstrated 
31% efficacy at 42 months.  Follow-up studies revealed binding 
antibodies to the V1/V2 region of HIV-1 as a correlate of infection 
risk, demonstrating the importance of antibody induction by HIV-
1 vaccines.  These observations have motivated evaluation of the 
specificity, breadth, potency, and duration of binding antibodies 
elicited in previous human vaccine clinical trails in comparison with 
responses to those elicited by the ALVAC prime-protein boost regimen.
Methods: Nine vaccine trials were analyzed using the Meso Scale 
Discovery (MSD) system to detect HIV specific binding antibodies to 
a panel of cross-clade and site-specific antigens that included: trimers 
from clades A, B, and C, gp120 monomers, V1V2 (N160-), V3, MPER, 
and the CD4 binding sites.  Comparative analyses were performed 
on the following trials, which represented a range of immunogens, 
immunization regimens, and delivery methods: VAX003 and RV114 
(protein only), RV132 and RV135 (ALVAC prime, protein boost), RV138 
(ALVAC only), RV158 (MVA only), RV262 (DNA prime, MVA boost), 
RV172A (Ad5 only), and RV172B and VRC008 (DNA prime, Ad5 boost). 
Results: Preliminary results demonstrated the inclusion of a protein 
component within the vaccine regimen increased the potency of binding 
antibody responses to cognate antigens by five-fold. Ad5, ALVAC, MVA, 
and DNA alone elicited minimal binding antibody responses, however 
the combination of prime, boost regimens significantly increased the 
magnitude of these responses.  In addition, increasing the diversity of 
vaccine inserts increased the breadth of cross-clade binding antibodies. 
Conclusion: Using one platform, we compared the capability of 
multiple vaccine regimens to elicit binding antibodies to a variety of 
HIV-1 envelope antigens. These results could significantly influence 
decisions surrounding future HIV vaccine efficacy trials.
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OA03.06 LB
HIV-1 Fusion Protein (F4/AS01) and 
Adenovirus-35 Gag-RT-Int-Nef Induce Potent 
and Durable T-Cell and Antibody Responses in 
Healthy African Adults
J. Mpendo1, G. Omosa-Manyonyi2, E. Ruzagirwa3, W. Kilembe4,  
F. Roman5, M. Koutsoukos1, A. Lombardo6, L. Dally7, P. Chetty6,  
P. Bourguignon5, P. Hayes6, J. Gilmour1, J. Cox6, F. Priddy1
1Uganda Virus Research Institute, Entebbe, Uganda; 2Kenya 
AIDS Vaccine Initiative, Nairobi, Kenya; 3MRC-Uganda, Entebbe, 
Uganda; 4Zambia Emory HIV Research Program, Lusaka, 
Zambia; 5GlaxoSmithKline Vaccines, Rixensart, Belgium; 6IAVI, 
New York, NY, USA; 7Emmes Corp., Rockville, MD, USA
Background: Phase I studies show the F4/AS01 (subtype B) HIV 
vaccine has an acceptable safety profile and induces potent CD4+ 
T-cell and antibody responses, while the Ad35-GRIN vaccine (subtype 
A) is safe and induces robust CD8+ T-cell responses. This randomized, 
double-blind, placebo-controlled study evaluated the safety and 
immunogenicity of these vaccines in prime boost or co-administration 
combinations in healthy African adults.
Methods: Healthy adults (n=147) in Uganda, Kenya and Zambia were 
randomized to receive: F4 fusion protein 10µg formulated in AS01B or 
AS01E at weeks 0 and 4 followed by Ad35-GRIN 2x1010 vp at week 
16, or Ad35-GRIN at week 0 followed by F4/AS01B at weeks 12 and 
16, or co-administration of both vaccines (with AS01B) at weeks 0, 4 
and 16, or placebo in a 4:1 vaccine:placebo ratio for each group.
Results: The vaccines were well-tolerated in all groups. Systemic 
reactions were more common with co-administration, but were mostly 
mild and moderate; all were transient. There were no vaccine-related 
SAE. IFN-gamma ELISpot response rates 4 weeks after the last vaccine 
were higher in the co-administration and Ad35-GRIN primed groups 
(92% and 100%, respectively) compared to the F4/AS01 primed 
groups (50% and 54%). Potent polyfunctional HIV-specific CD4+ and 
CD8+ T-cells were observed in all vaccine groups and particularly in 
co-administration group after only 2 vaccinations. Antibodies against 
F4-fusion protein were seen in >96% of individuals after complete 
vaccination. T-cell and antibody responses persisted up to 1 year post 
last administration. Ad35 neutralization antibodies were detected in 
14% and 48% of individuals after 1 versus 3 administrations of Ad35-
GRIN and were low titer.
Conclusion: The F4/AS01 and Ad35-GRIN vaccines show an 
acceptable safety and reactogenicity profile in sequential prime-
boost or concomitant administration. These combinations of vaccines 
elicit complementary potent, polyfunctional CD4+ and CD8+ T-cell 
responses and antibodies which persisted up to one year.
OA03.05
A Phase I Clinical Trial of an HIV-1(CN54), 
Clade C, Trimeric Envelope Vaccine Delivered 
by Parenteral, Nasal and Vaginal Routes of 
Immunisation
C.A. Cosgrove1, C. Lacey2, A.V. Cope3, A. Bartolf1, G. Morris2,  
C. Yan3, S. Baden1, T. Cole3, D. Carter4, E. Brodnicki5, W. Stoehr 5, 
S. McCormack6, and R.J. Shattock3
1St George’s, University of London, London, UK; 2Hull York 
Medical School, University of York, York, UK; 3Imperial 
College, London, UK; 4Infectious Disease Research Institute, 
Seattle, WA, USA; 5MRC Clinical Trials Unit, London, UK; 6MRC 
Clinical Trials Unit and Imperial College, London, UK
Background: We conducted a phase 1, randomized, exploratory trial 
to assess three immunisations of CN54gp140 vaccine formulations, 
administered in four different regimens at weeks 0, 4 and 8. 
Methods: HIV negative female volunteers aged 18-45 years were 
recruited through two centres and randomised to: (1) Intramuscular 
(IM) 100µg CN54gp140 adjuvanted in 5µg GLA in an acqueous 
formulation (GLA-AF) (2) IM 20µg CN54gp140 in 5µg GLA-AF (3) 
IM priming with 100µg CN54gp140 in 5µg GLA-AF followed by two 
intravaginal (IVAG) boosts with 500 µg CN54gp140 in carbopol gel 
or (4) Intranasal (IN) 100µg CN54gp140 in chitosan. Vaccine specific 
humoral responses were assessed in serum and mucosal samples at 
week 12.
Results: Thirty six women completed all three immunisations and 
there were no vaccine related serious adverse events. The parenteral 
groups had significantly more women with serological and mucosal 
responses at week 12 (p<0.001 and p=0.031 respectively). 9/11 
and 9/9 women receiving 20ug and 100ug IM had serum binding 
anti-gp140 IgG; 4/11 and 4/9 had cervico-vaginal IgG responses. In 
contrast, no volunteers had mucosal responses at week 12 following 
a single IM prime and two IVAG boosts, or three IN immunisations, 
and only 1/11 women in the IM-IVAG group had serum IgG. However, 
responses following additional IM boosting in some nasally primed 
subjects indicated amnestic responsiveness. Serum IgA was not 
detected in any volunteers.
Conclusion: The lower dose of CN54gp140 administered IM was as 
good as the standard dose of CN54gp140, eliciting systemic responses 
in the majority of subjects, and mucosal responses in just over a third 
of female volunteers four weeks after the third dose. The mucosal 
routes failed to induce significant systemic or mucosal responses, in 
spite of the high IVAG dose of 500µg preceded by IM priming.
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OA04.02
Non-human Primate Model to Study the Role 
of Serum and Vaginal IgA in Acquisition of 
Infection
N. Hutnick6, M. Kutzler1, Z. Moldoveanu2, M. Hunter3,  
M. Wise6, J. Yan4, A. Sylvester1, B. Pahar3, D. Myles6, A. Khan4,  
D. Montefiori5, N. Sardesai4, J. Mestecky2, P. Marx3, and  
D. Weiner6
1Drexel University, Philadelphia, PA, USA; 2University of 
Alabama at Birmingham, Birmingham, AL, USA; 3Tulane 
University, New Orleans, LA, USA; 4Inovio Pharmaceuticals, 
Blue Bell, PA, USA; 5Duke University, Durham, NC, USA; 
6University of Pennsylvania, Philadelphia, PA, USA
Background: Following the success of the RV144 trial, correlates 
analysis showed a possible correlation between serum IgA titers and 
lack of vaccine effectiveness. This data is in contrast to the concept 
that a protective HIV vaccine will need to induce strong IgA induction 
to prevent mucosal transmission. To address the role of serum and 
vaginal IgA in HIV acquisition we utilized an adjuvanted DNA vaccine 
previously shown to drive IgA induction in a non-human primate 
vaginal challenge model. 
Methods: Groups of 5 Indian rhesus macaques received a pSIVmac239 
gag/pol and pSIVe660 gp120 alone, with pCCL27 or pCCL28, mucosal 
adjuvants, at weeks 0, 6, 12, 18 and 48. Animals were challenged with 
500 TCID SIVsmE660 intravaginaly twice a week for two weeks. 
Results: We observed higher vaginal IgA titers in adjuvanted animals 
compared with DNA alone. Following challenge, we observed 
a significant control of set point viremia and chronic viremia in 
adjuvanted animals (p<0.05). 80% of adjuvanted animals controlled 
infection compared with only 60% in unadjuvanted animals and 17% 
in naïve challenge controls. Irrespective of vaccine group, animals 
that controlled viremia had the highest vaginal IgA and IgG levels 
post-vaccination. Importantly, there was also no correlation between 
vaginal and serum IgA
Conclusion: Together these data suggest that vaginal IgA is indeed 
protective from mucosal HIV transmission. Future clinical studies 
should incorporate mucosal sampling for correlates analysis because 
there is likely no correlation between serum and vaginal IgA levels. As 
is the case for the effective HPV vaccine, the induction of vaginal IgG 
may also play a role in protection. These data are illuminating in light 
of the RV144 study, that induction of serum IgA is not predictive of IgA 
responses at the vaginal site.
OA04.01
PET/CT Imaging of Simian Immunodeficiency 
Virus Reveals the Dynamics of Viral Replication 
In Vivo
P. Santangelo1, K. Rogers2, C. Zurla1, E. Alonas1, P. Amancha2,  
J. Hong2, P. Sharma2, D.K. Machiah2, K. Strait2, A.A. Ansari2, and 
F. Villinger2
1Georgia Institute of Technology and Emory University, 
Atlanta, GA, USA; 2Emory University, Atlanta, GA, USA
Background: The evaluation of HIV replication relies on indirect 
methods such as plasma viral loads, which does not indicate the 
anatomic origin of the virus detected. In addition, the suspected 
residual virus replication seen during HAART or in long-term non-
progressors with undetectable plasma viral loads cannot be confirmed 
or localized. We hypothesized that a method able to capture specific in 
vivo sites of viral replication would provide a valuable tool to monitor 
antiviral therapies, determine the site of viral reservoirs and provide 
clues as to the sites that need to be protected via vaccination to 
prevent viral progression during the acute infection. 
Methods: Using an anti gp120 monoclonal antibody labelled with 
64Cu, we have developed a novel strategy to image SIV and SIV 
infected cells in vivo using positron emission tomography /computer 
tomography (PET/CT).  PET/CT results were corroborated with SIV 
mRNA levels and in situ detection of SIV by IHC and FISH. 
Results: Using SIVgp120 immunoPET/CT, extensive viral replication 
was seen in the descending colon in most chronically infected, viremic 
monkeys, with lymph nodes, spleen and nasal lymphoid tissues 
prominently positive. In contrast, LTNP monkeys showed a more 
variable distribution of virus signal, with modest signal throughout the 
intestine including small bowel and various lymphoid organs. Of note, 
among reproductive organs, a high intensity signal was detected in 
the epididymis, which was confirmed by in situ detection. Monkeys 
acutely infected intravenously with SIV showed abundant initial signal 
in the upper body including lung and NALT, which gradually cleared, 
while the SIV signal markedly amplified in the lower GI tract during 
chronic infection.  
Conclusion: We submit that we have developed a sensitive real time 
imaging method to evaluate and localize virus replication in vivo. 
The method is non-invasive, can be used repeatedly and is readily 
translatable to the clinic. 
Oral Abstract Session 04: Animal Models
Oral Abstract Sessions
O
R
A
L 
A
B
ST
R
A
C
T
 S
ES
SI
O
N
S
65AIDS Vaccine 2013
OA04.04
Co-administration of Rapamycin with a DNA/
MVA SIV Vaccine Improves Memory CD8 T 
Cell Response and Enhances Control of SIV251 
Infection
S. Sadagopal1, S. Kwa1, R. Basu1, S. Gangadhara1, K. Araki1,  
R. Ahmed1, and R. Amara1
1Emory University, Atlanta, GA, USA
Background: Recent studies in mice and macaques demonstrated 
generation of higher frequency and better quality memory CD8 T cells 
by inhibiting the mTOR pathway using rapamycin. In this study, we 
tested the effect of rapamycin on the immunogenicity and efficacy of 
a DNA/MVA SIV vaccine in rhesus macaques.
Methods: Macaques were primed with a DNA/SIV vaccine on weeks 0 
and 8, and boosted with a MVA/SIV vaccine on weeks 16 and 24 in the 
absence (DM) or presence of rapamycin either during MVA boosts or 
during primes and boosts. Rapamycin treatment was given for a period 
of 32 days starting from day -3 of each immunization where used. 
Macaques were challenged with SIV251 intrarectally at about 21-24 
weeks after the final MVA boost.
Results: Rapamycin treatment did not increase the magnitude but 
reduced contraction of effector CD8 T cell response that resulted in 
higher frequencies of SIV-specific memory CD8 T cells with enhanced 
quality as determined by higher expression of CCR7 and BCl-2 ex vivo 
and higher proliferative capacity in vitro. Rapamycin treatment did 
not significantly alter the memory CD4 T cell response. Post SIV251 
infection, rapamycin-treated macaques demonstrated a marked 
expansion of SIV-specific CD8 T cells reaching up to 50% in blood 
and 25% in gut and this enhanced expansion in rapamycin-treated 
groups was associated with a markedly lower (2-logs compared to 
unvaccinated and 1-log compared to DM) set-point viral loads, better 
preservation of central memory T cells in blood and enhanced survival 
compared to unvaccinated and DM-vaccinated macaques.
Conclusion: Inhibiting mTOR pathway during MVA boosts of a DNA/
MVA vaccine regimen enhances the functional quality of vaccine-
elicited memory CD8 T cell response that is capable of markedly 
restricting a highly pathogenic SIV replication.
OA04.03
Vaccine Induced Epitope Specific Antibodies 
to the SIV Envelope Are Distinct from Those 
Induced to the HIV-1 Envelope
X. Shen1, R. Howington1, H. Park2, S. Sadagopal3, S. Kwa4,  
A. Cope5, S. Ding6, D. Bolton7, M. Roederer8, R. Amara3,  
L. Picker2, R. Seder8, J. McElrath9, S. Barnett10, R. Shattock5,  
B. Felber11, G. Pavlakis11, G. Pantaleo12, D. Montefiori1, and  
G. Tomaras1
1Duke University, Durham, NC, USA; 2Oregon Health & 
Science University, Beaverton, OR, USA; 3Emory University, 
Atlanta, GA, USA; 4GeoVax, Inc., Smyrna, GA, USA; 5Imperial 
College, London, UK; 6EuroVacc Foundation, Amsterdam, 
Netherlands; 7Walter Reed Army Institute of Research, Silver 
Spring, MD, USA; 8Vaccine Research Center, NIAID, NIH, 
Bethesda, MD, USA; 9University of Washington, Seattle, WA, 
USA; 10Novartis Vaccines and Diagnostics, Inc., Cambridge, 
MA, USA; 11National Cancer Institute, NIH, Frederick, MD, 
USA; 12University of Lausanne, Lausanne, Switzerland
Background: Understanding binding antibody specificities induced in 
non-human primates (NHPs) following HIV-1 and SIV Env immunization 
is critical for interpretation of data from preclinical vaccine trials. In 
this study, we determined whether antibody responses following HIV-
1 and SIV immunizations in NHPs can predict antibody responses in 
human clinical trials.
Methods: We determined binding epitopes specificities in 4 NHP SIV 
vaccine studies (DNA, MVA, protein, virus particle, and Ad5) and 4 
NHP HIV-1 vaccine studies (NYVAC/ALVAC/AIDSVAX and protein). 
Microarray linear epitope mapping was used to profile Env-specific 
responses against multiple clades/strains of HIV-1 and SIV, with a 
peptide library that covers full-length gp160 of multiple HIV-1 and 
SIV sequences (1942 peptides total). Binding profiles of NHP and 
human sera against HIV-1 Env, and of NHP against SIV and HIV-1 
Envs, were compared.
Results: Antibody specificities developed in NHP following HIV 
immunizations were similar to that observed in human. However, 
we observed major differences in epitope specific antibodies from 
NHP following SIV versus HIV-1 Env immunizations. First, V2-specific 
antibodies were dominant in SIV-immunized NHPs, whereas V3 specific 
antibodies were dominant in HIV-1 Env immunized NHPs. In two 
of the SIV NHP studies, the anti-V2 response accounted for 35-50% 
of the total binding response, compared to less than 8% for anti-V3 
response. Secondly, the anti-V1 antibody response, while not observed 
in HIV-1 Env vaccinations, commonly developed following SIV Env 
immunizations, and contributed to 7-15% of total binding response.
Conclusion: We found that although NHPs can develop antibody 
specificities to the HIV-1 envelope that are similar to those responses 
induced by human HIV-1 vaccination, epitope specific antibodies to the 
SIV Env differ from the antibody responses to the HIV-1 Env. Thus, NHP 
vaccine studies may require inclusion of HIV-1 envelope sequences, 
instead of SIV envelope, to accurately reflect antibody specificities 
induced by HIV-1 vaccination in human clinical trials.
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OA04.06 LB
Therapeutic Efficacy of Potent Neutralizing 
HIV-1-Specific Monoclonal Antibodies in SHIV-
Infected Rhesus Monkeys
D. Barouch1, J. Whitney1, B. Moldt2, F. Klein3, K. Shekhar4,  
A. Chakraborty4, M. Nussenzweig3, D. Burton2
1Beth Israel Deaconess Medical Center, Boston, MA, USA;  
2The Scripps Research Institute, USA; 3The Rockefeller 
University, New York NY, USA; 4MIT, Cambridge, MA, USA
Background: HIV-1-specific monoclonal antibodies (mAbs) with 
extraordinary potency and breadth have recently been described. In 
humanized mice, combinations of mAbs have been shown to suppress 
viremia, but the therapeutic potential of these mAbs has not yet been 
evaluated in primates with an intact immune system. 
Methods: We evaluated the virologic and immunologic impact 
of infusion of a cocktail of mAbs or individual mAbs in 35 rhesus 
monkeys chronically infected with the highly pathogenic virus SHIV-
SF162P3. 10 mg/kg of the broad and potent HIV-1-specific mAbs 
PGT121, 3BNC117, and b12, or the isotype control mAb DEN3, were 
administered.
Results: Administration of the cocktail of HIV-1-specific mAbs, or 
the single glycan-dependent mAb PGT121, resulted in a rapid and 
precipitous decline of plasma viremia to undetectable levels in 
rhesus monkeys chronically infected with SHIV-SF162P3. A single 
mAb infusion afforded up to a 3.1 log decline of plasma viral 
RNA in 7 days and also reduced proviral DNA in peripheral blood, 
gastrointestinal mucosa, and lymph nodes without the development 
of viral resistance. Moreover, following mAb administration, host Gag-
specific T lymphocyte responses exhibited improved functionality. 
Virus rebounded in the majority of animals after a median of 56 days 
when serum mAb titers had declined to undetectable levels, although 
a subset of animals maintained long-term virologic control in the 
absence of further mAb infusions. 
Conclusion: These data demonstrate a profound therapeutic effect 
of potent neutralizing HIV-1-specific mAbs in SHIV-infected rhesus 
monkeys as well as an impact on host antiviral immune responses. Our 
findings strongly encourage the investigation of mAb therapy for HIV-1 
in humans and have important implications for our understanding of 
immune correlates of protection.
OA04.05
Protection of Cynomolgus Macaques from 
Pathogenic SIV Following Vaccination with 
Varicella-Zoster Virus Based Vaccines
D.O. Willer5, A.P. Ambagala1, A.K. Marsh2, K. Haq5, C. Perciani5, 
J.K. Chan5, R. Pilon3, J. Fournier4, P. Sandstrom3, and  
K.S. MacDonald5
1Canadian Food Inspection Agency, Lethbridge, Canada; 
2University of Toronto, Toronto, Canada; 3Public Health 
Agency of Canada, Ottawa, Canada; 4Health Canada, Ottawa, 
Canada; 5Mt. Sinai Hospital and University of Toronto, 
Toronto, Canada
Background: Varicella Zoster virus (VZV) is a persistently replicating 
virus with the potential to deliver life-long immunity in an HIV vaccine 
setting. As a recombinant vaccine vector, the ability to self-boost 
may overcome the limited capacity of pox- and adenoviral vectors to 
generate long-lived immunogenicity. 
Methods: We describe a comprehensive preclinical non-human 
primate challenge trial with recombinant VZV-SIV constructs 
expressing codon-optimized and safety augmented antigenic targets 
from SIV as candidate prophylactic HIV vaccines. As a strict evaluation 
of our approach, a cohort of MHC-typed cynomolgus macaques were 
administered only a single vaccination with VZV-SIV vaccine or vector 
alone, and subsequently challenged intra-rectally using a weekly low-
dose exposure to highly pathogenic SIV. 
Results: Vaccine-induced durable humoral and cellular immune 
responses were observed with evidence to suggest VZV replication and 
subsequent reactivation driving progressive increases in anti-VZV IgG 
titers.   There was no significant difference in SIV acquisition rates or 
challenge doses to infection between vaccine and control groups over 
the course of multiple low-dose mucosal challenges.   Importantly, the 
vaccine group showed lower peak and set point viral loads (VL) with a 
subset of vaccinees (~35%) with persistent undetectable VL over 1.5 
yrs of follow-up.  We saw no evidence of accelerated disease course or 
increased SIV replication in vaccinees. 
Conclusion: A single dose of human VZV-based SIV vaccines was 
sufficient to provide substantial benefit to vaccinees with apparent early 
disease modification and preliminary evidence to suggest a similar 
capacity to induce viral clearance as recently demonstrated by Louis 
Picker’s related RhCMV-based approach.   Future work will be directed 
to determine the extent of this SIV clearance with subsequent NHP 
trials designed to augment the immunogenicity and capacity of this 
approach. The well documented clinical and safety evaluations of VZV 
vaccines in humans, provides a substantial advantage in developing 
this platform for human clinical trials.
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OA05.02
Structural Characterization of Potent, 
Longitudinally-Defined HIV-1 V1/V2-Directed 
Antibodies
J. Gorman1, N. Doria-Rose1, C.A. Schramm2, P.L. Moore3,  
M. Pancera1, Y. Yang1, R.P. Staupe1, Z. Zhang2, I.S. Georgiev1,  
J. Bhiman3, N.L. Longo1, L. Morris3, L. Shapiro2, J.R. Mascola1, 
and P.D. Kwong1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2Columbia University, New York, NY, USA; 3National Institute 
for Communicable Diseases of the National Health Laboratory 
Service, Johannesberg, South Africa
Background: Approximately 20% of individuals infected with HIV-1 
develop neutralizing antibodies that are cross-reactive with a variety 
of HIV-1 strains. These antibodies generally exhibit extensive affinity 
maturation and are slow to appear. Antibodies targeted against the 
V1/V2 region of Env display lower levels of somatic mutation than 
those targeting other sites of vulnerability and are among the most 
frequently elicited. Comprehensive analysis of B cell ontogeny of 
effective V1/V2 antibodies would provide valuable insight into vaccine 
development aimed at eliciting this class of antibody.  
Methods: Broadly-neutralizing V1/V2-directed antibodies isolated 
from donor CAP256 at various time points following infection were 
isolated, and evolution of antibody development was longitudinally 
analyzed through deep sequencing and structural characterization.
Results: Here we present crystal structures of the antigen-binding 
fragments from several V1/V2-directed antibodies isolated from donor 
CAP256. The antibodies contain long heavy chain 3rd     complementary 
determining regions (CDR H3)s, a common feature among V1/V2-
directed antibodies. The structures reveal a disulfide bond at the 
base of an extended CDR H3 loop and show that tyrosine sulfation 
contributes to a negatively charged surface extended away from the 
framework of the Fab. Deep sequencing data reveal that the length of 
the CDR H3 is the result of a recombination event and does not extend 
over time, however specific features of the mature loop such as the 
disulfide bond are not found early in the lineage.     
Conclusion: Combinatorial studies with structural characterization 
and deep sequencing reveal paths to the development of potent and 
broad V1/V2 directed antibodies. While some structural components 
appear immediately such as the long CDR H3, affinity maturation plays 
an important role in stabilizing specific features. The ontogeny of the 
antibodies presented here reveal that breadth can be achieved rapidly 
and extensive affinity maturation is not a necessary feature of broadly 
neutralizing HIV-1 antibodies. 
OA05.01
Structural Basis for HIV-1 gp120 Recognition 
by a Germ-line Version of a Broadly 
Neutralizing Antibody
L. Scharf1, A.P. West1, J.F. Scheid2, M.C. Nussenzweig2,  
P.J. Bjorkman1, and R. Diskin3
1California Institute of Technology, Pasadena, CA, USA; 
2The Rockefeller University, New York, NY, USA; 3Weizmann 
Institute, Rehovot, Israel
Background: Following infection by HIV-1, the host immune response 
is unable to clear the virus due to a variety of factors, including rapid 
viral mutation and the establishment of latent reservoirs. The only 
target of neutralizing antibodies is the trimeric envelope (Env) spike 
complex, but HIV-1 can usually evade anti-spike antibodies due to 
rapid mutation of its two spike glycoproteins, gp120 and gp41, and 
structural features that allow the spike to hide conserved epitopes. 
Efforts to design an effective antibody-based vaccine against HIV-1 
would benefit from understanding how germ-line B cell receptors 
recognize the gp120/gp41 envelope spike. Recently isolated from 
several infected individuals, potent VRC01-like (PVL) HIV-1 antibodies 
derived from the VH1-2*02 germ-line allele target the CD4 binding site 
on gp120. These antibodies have unprecedented potency and breadth 
for HIV-1 neutralization and some protect against HIV-1 infection in 
animal models. Since the VH1-2*02 germ-line allele is present in up to 
95% of the population, it may be possible to elicit by vaccination similar 
CD4 binding site antibodies in other individuals. VH1-2*02 germ-line 
B cell receptor interactions with gp120 were uncharacterized, which 
was a bottleneck for designing immunogens to elicit PVL antibodies.
Methods: We determined the structures of a VH1-2*02 germ-line 
antibody alone and a germ-line heavy chain/mature light chain 
chimeric antibody complexed with gp120 by X-ray crystallography 
and characterized them through surface plasmon resonance and 
neutralization experiments.
Results: VH1-2*02 residues make extensive contacts with the gp120 
outer domain, including all PVL-signature and CD4-mimicry interactions, 
but not critical CDRH3 contacts with the gp120 inner domain and 
bridging sheet that are responsible for the improved potency of NIH45-
46 over closely-related clonal variants, such as VRC01.
Conclusion: Our results provide insight into initial recognition of HIV-1 
by VH1-2*02 germ-line B cell receptors and may facilitate the design 
of immunogens tailored to engage and stimulate broad and potent 
CD4-binding site antibodies.
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OA05.04
A Diverse Antibody Response to the Gp120 
N332 Glycan Epitope in an HIV-Infected Donor
K.J. Doores1, K. Le2, D. Sok2, U. Laserson3, F. Vigneault3,  
J. Laserson4, D. Koller4, G. Church3, P. Poignard2, and D. Burton2
1King’s College London and The Scripps Research Institute, 
London, UK; 2The Scripps Research Institute, La Jolla, CA, 
USA; 3Harvard Medical School, Boston, MA, USA; 4Stanford 
University, Stanford, CA, USA
Background: Insight into the development of broadly neutralizing 
antibodies (bnAbs) in HIV infected individuals is a major goal in HIV 
vaccine research. bnAbs PGT125-131 were recently isolated from an HIV 
infected donor and shown to be amongst the most broad and potent 
anti-HIV antibodies isolated thus far. Biochemical and crystallographic 
studies have shown that these antibodies are dependent on glycans at 
positions N301 and N332 as well as residues in the V3 loop.
Methods: Here, we use 454 deep sequencing and a novel 
phylogenetic method to study the diversity of the antibody response 
to the N332 epitope in this donor and to probe possible pathways of 
antibody maturation.
Results: Sequence analysis and binding characteristics of PGTs125-
131 suggest that they originated from a single ancestor and organize 
into two main branches. These branches differ by the presence of a 
critical heavy chain insertion and a non-functional light chain deletion. 
We show that although these branches evolved in the same patient, 
distinct patterns of viral neutralization, N332 recognition and glycan 
sensitivity are observed. We show that glycan binding is independent of 
HIV reactivity and may have evolved as an initial step in the antibody 
maturation pathway. Further analysis of memory B cells through deep 
sequencing revealed additional branches that display limited breadth 
and potency. 
Conclusion: In summary, in this HIV-infected donor, there appears 
to be a diverse response to the N332 epitope arising from the same 
recombination event and against the same envelope sequence. These 
findings will help immunogen design strategies aimed at re-eliciting 
this family of potent bnAbs.
OA05.03
Interplay Between Broadly Cross-Neutralizing 
V2 Monoclonal Antibodies and Autologous 
Viral Evolution 
J.N. Bhiman1, N. Doria-Rose2, P.L. Moore1, M. Nonyane3,  
S.S. Abdool Karim4, P.D. Kwong2, J.R. Mascola2, and L. Morris1
1National Institute for Communicable Diseases of the 
National Health Laboratory Service and University of the 
Witwatersrand, Johannesburg, South Africa; 2Vaccine Research 
Center, NIAID, NIH, Bethesda, MD, USA; 3National Institute 
for Communicable Diseases of the National Health Laboratory 
Service, Johannesburg, South Africa; 4CAPRISA, University of 
KwaZulu-Natal, Durban, South Africa
Background: CAP256, an HIV-1 subtype C superinfected individual, 
developed potent broadly cross-neutralizing (BCN) V2 plasma 
antibodies that were critically dependent on R166 and K169. Eleven 
related BCN mAbs targeting V2 have recently been isolated from this 
individual after 30 months post-infection (p.i.). Here we investigated 
the relationship between these mAbs, longitudinal CAP256 viruses 
and previously characterized escape variants.
Methods: CAP256 primary transmitted/founder (t/f) (N160 glycan 
-), superinfecting t/f (N160 glycan +) and 6-, 12-, 21- and 39-month 
viruses were tested for neutralization by the 11 mAbs. The role of 
escape mutations at positions 160-171 in V2 and 437 in C4 was 
investigated using 15 autologous mutants and 3 chimeric viruses.
Results: While the primary t/f was only neutralized by 1 mAb, all 11 
mAbs potently neutralized the superinfecting t/f. All mAbs were unable 
to neutralize the 21- and 39-month viruses. mAbs showed differential 
dependence on individual V2 mutations, however the neutralizing 
activity of all mAbs was abrogated by R166S or K169E mutations. 
Deleting the N160 glycan only slightly affected the neutralizing 
capabilities of each mAb. Finally, a sensitive V1V2 chimeric virus was 
made resistant to all the mAbs through a P437A mutation in C4.
Conclusion: The potent neutralization of the superinfecting t/f but 
not the primary t/f by all mAbs suggested that the superinfecting t/f 
was responsible for eliciting these BCN antibodies. The inability of 
these mAbs (isolated after 30 months p.i.) to neutralize autologous 
clones after 21 months p.i. suggests they arose before this time point 
and that this memory B cell family persisted despite viral escape. The 
presence of circulating viruses with and without the N160 glycan 
after superinfection explains the independence of the mAbs on this 
glycan. The drastic effect of the P437A mutation on mAb activity 
indicates that in the context of the envelope trimer, C4 may modulate 
V2 conformation.
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OA05.06
HIV-1 gp120 Vaccination Elicits a Robust and 
Durable Anti-V1/V2 IgG Response and Yet 
No HIV-1 Env-Specific IgA Response in HIV-
Exposed Infants
G.G. Fouda1, C.K. Cunningham1, E.J. McFarland2,  
W. Borkowsky3, P. Muresan4, B.E. Liebl1, H. Liao1, B.F. Haynes1,  
R. Overman1, N.L. Yates1, G.D. Tomaras1, and S.R. Permar1
1Duke University Medical Center, Durham, NC, USA; 
2University of Colorado, Aurora, CO, USA; 3New York 
University, New York, NY, USA; 4SDAC-FSTRF/Harvard School 
of Public Health, Boston, MA, USA
Background: Effective infant HIV-1 vaccination may be impeded by 
the presence of maternal HIV-1-specific antibodies and the immaturity 
of the infant immune system. Since the RV144 HIV vaccine trial in 
adults indicated an association between anti-V1/V2 IgG antibodies and 
reduced HIV-1 acquisition, it is important to evaluate the elicitation of 
this potentially protective immune response in vaccinated infants.
Methods: HIV-1-exposed infants in PACTG 230 received four doses 
of Chiron rgp120 (SF-2 strain) with MF59 (n=47), VaxGen rgp120 (MN 
strain) absorbed with alum (n=49) or placebo (n=19) between birth 
and 20 weeks of age; and those in PACTG 326 received ALVAC-HIV 
+ AIDSVAX B/B (n=9) or placebo (n=11) between birth and 12 weeks 
of age. HIV-1 envelope-binding IgG /IgA responses were measured by 
BAMA (binding antibody multiplex assay). 
Results: Maternally-acquired antibodies measured by anti-gp41 IgG 
declined to less than 3% of the birth levels at week 52, indicating 
loss of most transplacental HIV-1 antibodies. Vaccine antigen-specific 
(MNgp120) IgG responses were higher in all vaccine groups than 
placebo at week 52 (p<0.001 to 0.008) and were still detected in 56% 
of Chiron rgp120-vaccinated infants at week 104. The magnitude and 
responder frequency of anti-gp70 BcaseA2 V1/V2 IgG at week 24 was 
higher in PACTG 230 vaccinees than placebo (median MFI (frequency), 
Chiron: 23,924 (98%); Vaxgen: 530 (72%); placebo: <100 (19%), 
(p<0.001 for all). The frequency of this response also trended higher 
in ALVAC+AIDSVAX vaccinees than in placebo (86% versus 33%, 
p=0.06). This response was induced despite detectable maternally-
acquired anti-V1/V2 IgG at birth in 72% of infants.  Remarkably, at 
week 52 and 104, respectively, 93% and 63% of infants from the 
Chiron group had detectable anti-V1/V2 IgG, as compared to 64% in 
RV144 vaccinees at peak immunogenicity. No vaccine-elicited HIV-1 
Env-specific IgA antibodies were detected. 
Conclusion: Vaccination of HIV-1-exposed infants can elicit robust 
anti-V1/V2 IgG responses.
OA05.05
MF59 and ALUM, in Combination with 
an ALVAC-SIV/gp120 Vaccine, Induce 
Plasmablasts that Differ in the Expression of 
Homing Markers
L. Schifanella1, S. Gordon1, M. Vaccari1, N. Binello1, F. Caccuri1, 
M. Blackburn1, C. Fenizia1, M. Doster1, P. Pegu1, N. Liynage1,  
X. Shen2, G. Tomaras2, M. Rao3, G. Ferrari4, D. Venzon1,  
D. Stablien5, S. Barnett6, J. Tartaglia7, and G. Franchini1
1 National Cancer Institute, NIH, Bethesda, MD, USA; 2Duke 
Human Vaccine Institute, Durham, NC, USA; 3U.S. MHRP, 
Silver Spring, MD, USA; 4Duke University Medical Center, 
Durham, NC, USA; 5The EMMES Corporation, Rockville, MD, 
USA; 6Novartis Vaccines and Diagnostics Inc., Cambridge, MA, 
USA; 7Sanofi Pasteur, Swiftwater, PA, USA
Background: An ALVAC-HIV/gp120 vaccine provided limited but 
significant protection against HIV-1 acquisition (31.2%) in the RV144 
trial. Antibodies against viral envelope were associated with reduced 
risk of HIV acquisition. The frequency of vaccine-induced antibody 
secreting cells precursors (plasmablasts) has been recently reported 
to correlate with protection from SIV acquisition in rhesus macaques. 
Increasing evidence indicates that chemokines and their receptors 
have a central role in regional targeting of antibody-secreting cells to 
hematopoietic, mucosal or inflammatory sites. Thus, the homing of 
vaccine-induced antibody secreting cells could affect vaccine efficacy. 
Methods: Two groups of twenty-seven macaques each were immunized 
four times with ALVAC-SIV and received two boosts of gp120 
formulated either in ALUM of MF59. One month post immunization 
all animals and forty-seven controls were challenged with repeated 
low doses of SIVmac251 by intra-rectal route. We studied the vaccine 
efficacy and the frequency of plasmablasts expressing alpha4beta7, 
CXCR4 and CXCR3.  
Results: Both strategies induced high titer of binding antibodies to 
SIV-gp120 and a similar frequency of env-specific plasmablasts; 
nevertheless only ALUM group showed a significantly reduced rate of 
SIV acquisition when compared to forty-seven unvaccinated controls 
(Log rank p=0.021). Interestingly, we found that the frequency of 
plasmablasts expressing alpha4beta7 (a mucosal homing marker) 
and CXCR4 (a hematopoietic homing marker) was higher in the 
ALUM group compared to the MF59 group (p=0.049 and p=0.026). 
In addition, there was a trend (p=0.06) for a higher frequency of 
plasmablasts expressing CXCR3 (an inflammatory site homing marker) 
in the MF59 group.
Conclusion: Our data indicate that adjuvants alter the expression of 
chemokine and integrin receptors on plasmablasts that, in turn, can 
affect their homing to mucosal, hematopoietic or inflammatory sites. 
We are investigating whether these phenomena affect vaccine efficacy. 
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OA06.02
Structural Organization and CD4-Induced 
Reorganization in Soluble HIV-1 Trimers
M. Guttman2, A. Cupo1, R.W. Sanders1, J.P. Moore1, and K.K. Lee2
1Weill Cornell Medical College, New York, NY, USA; 
2University of Washington, Seattle, WA, USA
Background: The Envelope glycoprotein (Env) mediates HIV entry 
through a series of receptor-triggered conformational changes leading 
to fusion of viral and host membranes. This trimer of gp120/gp41-
subunit heterodimers is the sole target of neutralizing antibodies. The 
architecture of the pre-fusion trimer as well as its intrinsic dynamics, 
hypothesized to modulate antigenicity, remain unresolved. Efforts 
have been made to engineer stabilized, soluble forms of Env (termed 
“gp140”) as potential next-generation immunogens, including through 
the introduction of trimerization motifs or the addition of intersubunit 
disulfide bonds and mutations that favor the pre-fusion state. Here we 
apply hydrogen/deuterium-exchange mass spectrometry (HDX-MS) to 
assess the structural organization of these Env constructs.
Methods: HDX-MS provides a detailed map of order and structural 
dynamics in proteins by measuring the kinetics of local backbone amide 
solvent exchange. Here, HDX-MS is used to examine monomeric and 
trimeric SOSIP gp140 (isolate Clade A KNH1144), CD4-bound SOSIP 
trimer, as well as uncleaved and trimerization motif-stabilized gp140s.
Results: HDX-MS reveals that significant regions of V1/V2, V3 and 
bridging sheet elements are ordered in SOSIPs, suggesting these 
sites participate in stable interactions in the pre-fusion trimer. The 
gp41 subunit exhibits a profile indicative of a trimerization core with 
additional ordering in the gp41 loop region, which has been proposed 
to interact with gp120. CD4 binding releases V1/V2 and V3 association 
reflected by an increase in solvent exchange; changes in gp41 HR1 
and fusion peptide proximal regions are also observed. By contrast, 
uncleaved gp140 constructs exhibit gp41 profiles consistent with a 
post-fusion, helical bundle organization with loosely tethered gp120 
subunits.
Conclusion: Using HDX-MS, we demonstrate that SOSIP trimers 
represent a reasonably authentic, pre-fusion form of Env. This approach 
enables detailed analysis of the trimers including characterization of 
gp41’s organization, identification of regions involved in trimerization, 
and a detailed mapping of the large-scale reorganization induced by 
CD4 binding.
OA06.01
Identifying the Minimal Mutations in VRC01 
Required for Neutralization Potency and 
Breadth to Inform Vaccine Design
J.G. Jardine1, D. Sok2, O. Kalyuzhniy1, M. Kubitz3, Y. Adachi4, 
D.R. Burton2, and W.R. Schief1
1The Scripps Research Institute, IAVI, CHAVI-ID, University of 
Washington, La Jolla, CA, USA; 2The Scripps Research Institute, 
IAVI, CHAVI-ID, La Jolla, CA, USA; 3The Scripps Research 
Institute, CHAVI-ID, La Jolla, CA, USA; 4The Scripps Research 
Institute, IAVI, La Jolla, CA, USA
Background: VRC01-class broadly neutralizing antibodies (bNAbs) 
have been isolated from a number of HIV-infected individuals. 
Despite substantial differences in primary amino acid sequence, 
these antibodies all derive from VH1-2 and utilize a nearly identical 
mode of binding. One of the perceived hurdles to eliciting a VRC01-
class response by vaccination is that these bNAbs are highly mutated 
(~30% from germline). To inform vaccine development, we sought to 
define the minimal set of somatic mutations needed for broad and 
potent neutralization of HIV-1 by VRC01-class antibodies.
Methods: Libraries of variants of VRC01 and PGV04 (another VRC01-
class bNAb), allowing either germline or mutated residues at each 
mutated position, were displayed on yeast and sorted for binding 
to panels of gp120s from different clades. The least mutated library 
variants that retained high affinity for diverse gp120s were produced 
as soluble IgG and evaluated for neutralization against a large panel 
of HIV-1 pseudoviruses.
Results: Using the strategy outlined above, we developed a minimally 
mutated variant of VRC01 (termed MinVRC01) that maintains 
the neutralization potency and breadth of VRC01 but is only 9% 
mutated from germline. MinVRC01 contains several spatial clusters 
of mutations, and reversion of any single cluster to germline caused 
significant reduction in potency and breadth. Two of these clusters 
lie on the surface of MinVRC01 outside the paratope defined by 
the crystallographic interaction with core gp120, indicating that the 
VRC01 epitope is more complex than previously recognized. These 
two clusters suggest specific structural features of HIV Env that may be 
required in immunogens to induce VRC01-class bNAbs.
Conclusion: Our findings suggest that it may be possible to induce a 
broad and potent VRC01-class antibody response with substantially 
fewer mutations than previously thought. Furthermore, we have 
defined additional, critical components of the VRC01 epitope that 
likely will be required in vaccines to induce VRC01-class bNAbs.
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OA06.04
DNA-MVA Prime-Boost Vaccine Eliciting T Cell 
Specificities Associated with HIV-1 Control Is 
Highly Immunogenic in Mice and Breaks CTL 
Immunodominance
A. Olvera1, A. Llano2, M. Rosati3, S. Pérez-Álvarez2, V. Kulkarni3, 
B. Chowdhury3, C. Alicea3, R.K. Beach3, N.Y. Sardesai4, T. Hanke5, 
B. Clotet6, G.N. Pavlakis3, B.K. Felber3, C. Brander6, and  
B. Mothe2
1IrsiCaixa Institute for AIDS Research, HIVACAT, ‘Lluita 
contra la Sida’ Hospital Universitari “Germans Trias i Pujol”, 
Barcelona, Spain; 2IrsiCaixa Institute for AIDS Research, 
HIVACAT, Barcelona, Spain; 3National Cancer Institute, NIH, 
Frederick, MD, USA; 4Inovio Pharmaceuticals Biomedical 
Corp., Blue Bell, PA, USA; 5University of Oxford, UK; 6IrsiCaixa 
Institute for AIDS Research, HIVACAT, Hospital Universitari 
“Germans Trias i Pujol”, Universitat Autònoma de Barcelona, 
Barcelona, Spain
Background: A T cell immunogen guided by human immunogenicity 
data could help avoid inducing ineffective responses to potential decoy 
targets. DNA prime followed by recombinant MVA boost regimens 
have been shown to be an effective schedule for induction of robust 
T cell activities.
Methods: The HIVACAT T cell immunogen (HTI) contains 16 HIV-1 
protein segments of 10-70 amino acids in length, which i) are relatively 
conserved, ii) are targeted by individuals with low viral loads, and iii) 
elicit responses of higher avidity and broader cross-reactivity. The 
HTI gene was cloned into a CMV expression vector (pDNA HTI) and 
then inserted into a modified vaccine virus Ankara (MVA HTI). HTI 
immunogenicity after 2xpDNA HTI was compared in C57BL/6 mice 
immunized with a combination of plasmids expressing entire HIV-1 
proteins (pDNA GagPolVifNef). Prime-boost regimens combining pDNA 
HTI and MVA HTI were assessed. Cellular responses were characterized 
using intracellular cytokine and IFNγ ELISPOT assays.
Results: The HTI covered >50 optimal defined CD4+ and CD8+ T cell 
epitopes with >40 different HLA restrictions, without overrepresentation 
of B27/B57/B58 alleles. In C57BL/6 mice, the HTI induced broad CD4+ 
and CD8+ T cell responses to all segments within Gag, Pol, Vif and Nef 
compared to a more narrow, Gag-dominated response seen in animals 
immunized with pDNA GagPolVifNef. These responses were strongly 
increased both in breadth and magnitude by using heterologous 
regimens consisting of 3xpDNA HTI prime followed by 1xMVA HTI 
boost compared to 3xpDNA HTI only (median magnitude of 2865 
vs 777 SFC/106 splenocytes respectively, p=0.0087). No responses 
to potential junctional neoepitopes between the joint segments were 
observed.
Conclusion: 3xpDNA HTI prime-MVA HTI boost was strongly 
immunogenic in mice, induced broad CD4+ and CD8+ T cell responses 
and was able to break the immunodominance to less beneficial targets 
while ensuring a broad HLA class I and class II coverage for use as a 
global HIV vaccine
OA06.03
Cell-Surface Display and Panning of HIV-1 
Derived Envelope Proteins
V. Schmid1, T.H. Bruun1, A. Kliche1, and R. Wagner1
1University of Regensburg, Regensburg, Germany
Background: Available display systems allow screening of millions of 
candidate proteins and are the method of choice to identify optimized 
antigen-antibody binding. To overcome the limitations of prokaryotic 
expression and presentation in phage display libraries, eukaryotic 
display platforms were developed. We established a mammalian cell-
surface display to present HIV-1 envelope derivatives in a natural, 
trimeric, membrane bound environment. This allows us to generate 
affinity enhanced envelope derivatives against broadly neutralizing 
antibodies (bNAbs) in order to select potent Envelope (Env) based 
vaccine candidates.
Methods: An HIV-1 derived lentiviral vector was developed to infect 
HEK293T cells at a lowmultiplicity of infection (MOI), in order to 
correlate phenotype and genotype. The vector was designed and 
proven to express both GFP and Env in a constant relationship, enabling 
indirect normalization of produced Env by detecting GFP. After staining 
with an appropriate bNAb, Env-displaying cells were selected for high 
affinity binding via FACS sorting.
Results: A small model library of Env variants with distinct binding 
capacities towards the bNAb 447-52D was used for evaluation. In a 
proof-of-concept experiment, the Env variant with the highest affinity 
to the applied bNAb could be enriched up to tenfold after two rounds 
of selection.
Conclusion: Hence, the technique provides the possibility to screen for 
membrane-bound Env variants with high binding capacities towards 
the bNAb applied. By using bNAbs for selection of envelopes out of 
different libraries new candidates for the potential use in HIV vaccine 
trials can be identified. 
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OA06.06 LB
Neutralizing and Non-neutralizing Antibody 
Binding to Cleaved, SOSIP-Stabilized and 
Uncleaved Soluble HIV-1 Env Trimers, 
Protomers, and gp120 
A. Yasmeen3, R.W. Sanders3, R. Ringe3, R. Derking1, A. Cupo3,  
J. Julien2, A.B. Ward2, I.A. Wilson2, J.P. Moore3, P. Klasse3
1Academic Medical Center, Amsterdam, Netherlands;  
2The Scripps Research Institute, La Jolla, CA, USA; 3Cornell 
University, New York, NY, USA
Background: The structure and immunogenicity of soluble HIV-
1 trimers (BG505 SOSIP.664 gp140, subtype A), cleaved between 
gp120 and the gp41 ectodomain, will be described in a Satellite 
Symposium. In other designs of soluble gp140 trimers, cleavage is 
usually eliminated. As immunogens, soluble trimers should mimic 
functional, virion-associated trimers by binding neutralizing but not 
non-neutralizing antibodies. How do cleaved and uncleaved trimers 
compare in this regard? And how do these two trimer forms compare 
antigenically with gp120 monomers and gp140 protomers (gp120 
disulfide-linked to the gp41 ectodomain)? 
Methods: We expressed variants of BG505 Env in 293T cells, and 
purified them by 2G12-affinity and size-exclusion chromatography. 
Env was C-terminally D7324-epitope- or His-tagged, which allowed 
minimally disruptive immobilization to sensor chips for kinetic 
measurement of MAb binding by surface plasmon resonance (SPR). 
MAb binding was compared with neutralization of the sequence-
matched BG505 virus (Tier 2). 
Results: MAbs PGV04, VRC01, PG9, PG16, PGT121, PGT123, PGT135, 
PGT145, and 2G12 neutralized BG505 and bound well to cleaved 
trimers; b6, b12, 14e, and F240 did not neutralize and bound negligibly. 
Conversely, b6 and b12 bound well, PG9, PG16, and PGT145 poorly, 
to uncleaved trimers, gp140 protomers, and gp120. MAbs VRC01 
and 2G12 bound similarly to trimers and gp140 protomers. Kinetics-
based affinity and stoichiometry measurements for sCD4, PG9, PG16, 
PGT121, PGT123, PGT128, and 2G12 agreed, where applicable, with 
calorimetric data and electron micrographs; the latter method also 
showed cleaved and uncleaved trimers to be morphologically distinct. 
Conclusion: We found that trimerization has a stronger antigenic 
influence on gp120 epitopes than hetero-dimerization with the gp41 
ectodomain alone. Uncleaved trimers and the monomeric Env forms 
expose mostly non-neutralization epitopes; the cleaved trimers are 
better antigenic mimics of functional spikes. The antigenicity and 
structural integrity of cleaved BG505 SOSIP.664 trimers support their 
evaluation as immunogens for the induction of bNAbs. 
OA06.05
Detection of Early CTL Escape in Gag and Nef 
Using Population-Level Approaches
E. Martin1, J. Carlson2, A. Le1, R. McGovern3, C. Ng3, M. Rahman1, 
D. Chopera1, M. Wainberg4, R. Harrigan3, and Z. Brumme1
1Simon Fraser University, Burnaby, Canada; 2Microsoft Research, 
Los Angeles, CA, USA; 3BC Centre for Excellence in HIV/AIDS, 
Vancouver, Canada; 4McGill University, Montreal, Canada
Background: Population-level analyses of chronic infection cohorts 
have facilitated the identification of HLA-associated polymorphisms in 
HIV-1, but it is unclear to what extent immune escape can be detected 
using similar methods during early infection. To address this issue, 
we compared immune escape signals in early and chronic cohorts of 
equivalent statistical power.
Methods: A cross-sectional early cohort of subtype-B infected 
individuals sampled a median 88 [IQR 63-120] days following infection 
(N=221, 203, 233 for Gag, Protease/RT and Nef) was compared against 
a chronic dataset of equal size and comparable HLA class I distribution 
for the presence of 400 published HLA-associated polymorphisms 
derived from an independent cohort of N>1800 chronically-infected 
individuals. A threshold of p<0.01 (q<0.25) was defined as positive 
population-level evidence for immune escape.
Results: At p<0.01, 148 (37%) of the 400 HLA-associated 
polymorphisms were detected in early and/or chronic cohorts, 
yielding an appropriate denominator for this dataset size. Of these, 
20 (representing 15%, 3% and 18% of known HLA-associated 
polymorphisms in Gag, Pol, Nef) were detectable in early infection, 
albeit at median 35-fold lower odds ratios than chronic infection. Early 
escape signals mapped to 7 published and 3 predicted CTL epitopes (3 
in Gag, 1 in Pol and 6 in Nef). While certain early escape signals were 
expected (e.g.: B*57:01/T242N exhibited the strongest early escape 
signal, p=4x10-9), others occurred within understudied or novel 
epitopes. A minority of early escape signals were not observed in the 
chronic dataset, suggesting transient CTL escape pathways.
Conclusion: Up to 18% of known HLA-associated polymorphisms, 
notably in Gag and Nef, are detectable at the population level within 
three months of infection. Results underscore the reproducible nature 
of HIV-1 immune escape in terms of mutational pathways and 
timecourse of selection. Population-level approaches can complement 
longitudinal studies to characterize HIV-host adaptation during this 
critical infection stage.
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OA07.02
Role of Integrin α4β7 in HIV Transmission and 
Pathogenesis
S.I. Richardson1, N. Mkhize1, S. Abdool Karim2, E. Gray1, and  
L. Morris1
1National Institute for Communicable Diseases, Johannesburg, 
South Africa; 2CAPRISA, University of KwaZulu-Natal, Durban, 
South Africa
Background: The integrin α4β7, which mediates the trafficking of 
T lymphocytes to the gut associated lymphoid tissue (GALT), a site 
of rapid HIV replication, has been described as an attachment factor 
for the envelope protein gp120. While differences in binding affinity 
of early transmitting and chronic gp120s for α4β7 have been noted, 
this has not translated to any differences in replication. We aimed to 
investigate what role this binding interaction has in HIV pathogenesis 
over time.
Methods: All-trans retinoic acid-activated CD4+ T cells were incubated 
with or without HP2/1 (anti-α4 monoclonal antibody) or Act-1 (anti-
α4β7 monoclonal antibody) prior to adding virus. Infectious virus was 
prepared using matched envelope genes from 8 individuals in the 
CAPRISA Acute Infection cohort representing the transmitted/founder 
virus and variants from 1-39 months post infection (p.i.). Replication 
was monitored by p24 ELISA.
Results: While the transmitted/founder and later viruses from 39 
months p.i. were equivalently dependent on α4β7 for viral replication, 
those from 6 and 12 months p.i were significantly less dependent 
on α4β7.  The strength of this interaction was negatively correlated 
with CD4 count at the time that the virus was isolated. Interestingly 
individuals that developed broadly cross neutralising responses had a 
lower dependence on α4β7compared to those that do not.
Conclusion: These data suggests that interactions with α4β7 are 
preferable for transmission and late chronic infection but are diminished 
following acute viral expansion. This correlates with HIV pathology; the 
virus would have a greater dependence on α4β7 important for wide-
spread dissemination during transmission and acute infection, with the 
need for spread greatly decreased thereafter. The difference between 
α4β7 dependence in acute and chronic infection in the first year 
illustrate the selective advantage that α4β7 may offer to transmission. 
These findings may lead to vaccine and therapeutic opportunities in 
which dependence on α4β7 for replication may be exploited.
OA07.01
A Role for Glycosylation in HIV Transmission
F. Nawaz1, C. Cicala2, C. Schwing2, D. Wei2, J. Hiatt2, K. Jelicic2, 
D. Van Ryk2, A. Fauci2, and J. Arthos2
1New York University, New York, NY, USA; 2NIAID, NIH, 
Bethesda, MD, USA
Background: Heterosexual transmission of HIV-1 across mucosal 
tissues involves a complex series of events that are not fully understood. 
The envelope protein of some transmitted (founder) viruses bear a 
distinct signature described by a reduced number of potential N-linked 
glycosylation sites (PNGs). Interestingly, the leader peptides of env from 
founder viruses have been shown to encode basic residues at specific 
sites, providing a second “transmission signature”. The specific aim of 
this study is to determine the manner in which these two transmission 
signatures influence structural features of HIV-1 envelope (env) and 
their potential role in transmission fitness. 
Methods: Recombinant envelope proteins bearing the two signatures 
of founder viruses were produced and their reactivity with CD4 and a 
panel of antigenic and glycan specific probes was evaluated by flow-
cytometry and surface-plasmon-resonance.
Results: The removal of PNGs that are frequently missing in founder 
viruses exerts a pronounced influence on the interaction of the 
envelope with the CD4 and CCR5 receptors, which functions as 
the principal docking and fusion receptors utilized by HIV to infect 
CD4+ T cells.  The leader peptide signature was found to influence 
qualitative aspects of env glycosylation in a manner that also impacts 
env structure and its interaction with both CD4 and CCR5. In addition 
leader peptides derived from founder viruses were shown to influence 
the affinity of the HIV env for DC-SIGN, a receptor expressed on 
dendritic cells that is believed to facilitate mucosal transmission.   
Conclusion: The two distinguishing features of founder envs both 
impact env glycosylation, which in turn impacts env structure and its 
interaction with cell-surface receptors critical to transmission.  These 
observations underscore the critical role of glycosylation on HIV env 
structure. In this way selective alterations in glycosylation may increase 
the fitness of transmitting viruses. 
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OA07.04
Highly Potent Broadly Neutralizing Antibodies 
Lack Potential to Inhibit HIV-1 Cell-to-Cell 
Transmission
L. Reh1, I.A. Abela1, P. Rusert1, and A. Trkola1
1University of Zurich, Zurich, Switzerland
Background: HIV-1 utilizes two different ways to transmit between 
cells: free-virus and cell-to-cell transmission. While the contribution 
of the two transmission modes in natural infection has not yet been 
defined, there is compelling evidence that cell-to-cell transmission 
allows the virus to evade antiretrovirals and broadly neutralizing 
antibodies (bnAbs). However, only few reagents have been assessed 
for their capacity to inhibit cell-to-cell transmission and we urgently 
need information how bnAbs, promising candidates for vaccine design, 
function in that process.
Methods: Our group has recently developed assay systems that allow 
for unambiguous discrimination between free-virus and cell-to-cell 
transmission using CD4- and CCR5-expressing cell lines or PBMC, 
either infected with replication competent virus or transfected with 
pseudotyped virus. Target cells overexpress rhesusTRIM5α which 
efficiently restricts free-virus but not cell-to-cell transmission. (Abela 
et al., 2012)
Results: Using these assays, we probed the efficacy of the highly potent 
PG and PGT bnAbs in comparison to gp120-directed (b12, VRC01) and 
gp41-directed (T20, 10E8) inhibitors to block cell-to-cell transmission 
of a range of Tier-1 and Tier-2 strains. Strikingly, we found for all 
strains tested that PG9, PG16, PGT121, PGT128, PGT130, PGT135 and 
PGT145 showed a dramatically decreased inhibition capacity during 
cell-to-cell transmission in contrast to MPER-specific bnAbs maintaining 
their activity during cell-to-cell transmission. Time-of-addition studies 
showed that unlike MPER bnAbs, the PGT bnAbs are capable to block 
HIV only before CD4-engagement but not afterwards. This highlights 
that CD4-engagement is the rate limiting step during cell-to-cell 
transmission and difficult for gp120-specific bnAbs to interfere with. 
Conclusion: Our studies confirm that free-virus and cell-to-cell 
transmission of HIV are not equally susceptible to different entry 
inhibitors. In particular gp120-specific antibodies lack activity during 
cell-to-cell transmission. As HIV initially spreads locally in the newly 
infected host, presumably involving cell-to-cell transmission, vaccines 
and inhibitors targeting both free-virus and cell-to-cell transmission 
should be actively sought for.
OA07.03
Profound Alterations in Cholesterol 
Metabolism Restrict HIV-1 Trans Infection of 
CD4 T Cells in Viremic Controllers 
G. Rappocciolo1, M. Jais1, P. Piazza1, P. Gupta1, and  
C.R. Rinaldo1
1University of Pittsburgh, Pittsburgh, PA, USA
Background:  HIV-1 controllers inhibit infection for years without 
antiretroviral therapy. We hypothesized that professional antigen-
presenting cells (APC), i.e., dendritic cells (DC) and B cells, from HIV-1 
infected, viremic controllers (VC), are inefficient in trans infection of T 
cells due to altered cholesterol metabolism, thus reducing spread of 
virus and controlling disease progression. 
Methods: We assessed HIV-1 trans infection of autologous CD4 T cells 
by APC from 8 VC, 8 progressors (PR) and 7 seronegatives (SN) in 
the longitudinal Multicenter AIDS Cohort Study. Total cell cholesterol 
content and efflux was measured. APC from VC were treated with 
siRNA to inhibit ABCA1-mediated cholesterol transport, and from SN 
with nuclear receptor ligands to upregulate cholesterol efflux and 
Levastatin to inhibit cholesterol synthesis. 
Results: Strikingly, APC from none of the VC (0/8) trans infected CD4 
T cells with HIV-1, whereas APC from 8/8 PR and 7/7 SN demonstrated 
efficient trans infection. There was no difference in direct (cis) HIV-
1 infection of T cells from the 3 groups. Importantly, APC from VC 
had impaired trans infection both prior to and after primary HIV-1 
infection (seroconversion), whereas APC from PR had this capacity both 
before and after seroconversion. APC but not T cells from VC showed 
significantly lower cholesterol content and higher efflux compared 
to SN and PR. Alteration of cholesterol metabolism reduced trans 
infection by APC from SN, while interference with the ABCA1 pathways 
in VC restored their ability to transmit virus.
Conclusion: We show that APC from VC completely lack the ability 
to trans infect T cells. This was associated with profoundly enhanced 
cholesterol metabolism that appears to be an inherited trait. Our results 
provide important new clues to control of HIV-1 infection. 
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OA07.06 LB
Genetic Selection Bias at the Heterosexual HIV-1 
Transmission Bottleneck
J. Carlson1, D. Monaco2, M. Schaefer2, D. Claiborne2, J. Prince2,  
D. Dilernia2, K. Denis2, W. Kilembe3, J. Tang4, P. Farmer2,  
R. Kaslow4, P. Goulder5, S. Allen2, P. Goepfert4, D. Heckerman1,  
E. Hunter2
1Microsoft Research, Los Angeles, CA, USA; 2Emory University, 
Atlanta, GA, USA; 3Zambia Emory HIV Research Project, Lusaka, 
Zambia; 4University of Alabama at Birmingham, Birmingham, 
AL, USA; 5University of Oxford, Oxford, UK
Background: HIV infection typically occurs by the transmission of a 
single virion from the transmitting source partner (TSP) quasispecies. 
This process is poorly understood and it is not known if this 
transmission bottleneck is mediated by an active selection process that 
induces a bias for certain genetic variants or is the consequence of a 
stochastically unbiased event.
Methods: We developed a statistical model for transmission bias 
and applied it to sequences from 129 virologically linked Zambian 
transmission pairs (median 45d post transmission). For each position 
in Gag, Pol and Nef, the odds that the dominant TSP variant was 
transmitted were estimated as a function of virologic and clinical 
features.
Results: The odds that a dominant (>75% in the quasispecies) TSP 
amino acid was unequivocally observed in the seroconverter were 
strongly correlated with the frequency of the amino acid at that position 
in the overall cohort (p<1e-100), indicating a strong preference for the 
transmission of consensus residues. Consistent with a fitness-induced 
selection bias, polymorphisms were less likely to be transmitted if 
they had a large impact on in silico protein stability (p<1e-3), had 
no putative compensatory mutations (p<5e-7), were in viruses with 
low in vitro replicative capacity (p<5e-7), or were predicted to be de 
novo HLA escape mutations in the TSP (p<5e-4). As predicted by the 
model, three well-established risk factors—TSP viral load, seroconverter 
gender (female) and genitourinary infections—independently reduced 
the transmission selection bias (p<1e-4). A sequence-derived 
transmissibility index significantly segregated the TSPs in the cohort 
from risk-matched chronically infected individuals (173) who had not 
transmitted to their partners (p=0.01).
Conclusion: The identification of virologic parameters that strongly 
correlate with transmission of TSP polymorphisms argues strongly 
for biased selection of virions, while the ability of these parameters 
to predict whether an individual would transmit suggests the clinical 
importance of this transmission selection bias. 
OA07.05
Highly Pathogenic Adapted HIV-1 Strains Limit 
Immune Responses and Dictates Rapid Disease 
Progression in Early Infection
J. Dalmau7, M. Rotger1, I. Erkizia7, A Rauch2, P. Reche3, M. Pino7, 
Y. Lie4, R. Bellido7, A. Esteve5, E. Coackley4, E. Palou6, C. Brander7, 
R. Paredes7, T. Wrin4, B. Clotet7, A. Telenti1, J. Martinez-Picado7, 
and J.G. Prado7
1University Hospital Center and University of Lausanne, 
Switzerland; 2University Hospital Bern and University of 
Bern, Switzerland; 3Universidad Complutense de Madrid, 
Spain; 4Monogram Biosciences, USA; 5Centre d’Estudis 
Epidemiològics sobre les Infeccions de Transmissió Sexual i 
Sida de Catalunya, Barcelona, Spain; 6Banc de Sang i Teixits 
de Barcelona, Spain; 7IrsiCaixa Institute for AIDS Research, 
HIVACAT, Barcelona, Spain
Background: The study of HIV-1 Rapid Progressors (RP) has been 
limited so far to particular case reports. Nevertheless, a broad 
functional analysis of viral and host factors leading to RP will provide 
crucial information for an accurate description of the correlates of 
disease outcome.
Methods: With this aim, we study a previously unreported large 
group of HIV-1 RP (n=46) and compared to infected individuals with 
average disease progression, or Standard Progressors (SP, n=46) 
early after HIV-1 seroconversion (≤ 1 year). Viral factors were tested 
in terms of virus coreceptor usage, replicative capacity and sequence 
variation. Additionally, HLA immunogenetics markers, host CD8+ T 
cell responses and plasma neutralizing activity were determined.
Results: Our data demonstrate the existence of particularly pathogenic 
HIV-1 strains in RP during recent infection. Viral strains were 
characterized by preferential X4/Dual-Mixed coreceptor usage (26.3% 
RP vs. 2.8% SP; p=0.006), and high in vitro replicative capacity 
(median 81.5% vs. 67.9%; p=0.025). Host immunogenetic markers 
revealed an increased frequency of common Caucasian haplotypes 
including A*02:01, B*07:02 and B*08:01 (RP vs. SP; p=0.003), in 
detriment of protective ones in rapid progression. In addition, viral 
strains demonstrated an increased variation at CD8+ T cell HIV-1 
Gag epitopes (RP vs. SP; p=0.008), as indicator of virus adaptation 
to common alleles and further supported by a weak or even absent 
CD8+ T cell responses measured in vitro. Meanwhile, no differences in 
humoral responses were observed between groups
Conclusion: These data indicate an uncommon convergence of 
viral factors in rapid progression in recent infections. Consequently, 
widespread of particularly aggressive HIV-1 strains leading to rapid 
disease progression should be taken into account to implement future 
immunotherapeutic and vaccine strategies.
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OA08.02
HIV-1 Infection Induces Potent Type I IFN 
Signatures in Conventional Dendritic Cells from 
HIV-1- Elite Controllers 
E. Martin-Gayo1, T. Hickman1, Z. Ouyang1, D. Pimenova1,  
F. Pereyra1, B.D. Walker2, M. Lichterfeld3, and X.G. Yu1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Howard Hughes Medical Institute, Chevy Chase, MD, 
USA; 3Massachusetts General Hospital, Boston, MA, USA
Background: Recent data suggest that in most HIV-1-infected 
individuals, cell-intrinsic immune responses to HIV-1 are blocked by 
host proteins such as Samhd1 and trex1 in conventional dendritic cells 
(cDC). Elite controllers (EC) control HIV-1 replication in the absence of 
treatment, but immune defense mechanisms in these patients are not 
well understood. Here, we investigated cell-intrinsic innate immune 
responses to HIV-1 in cDCs from these specific patients. 
Methods: PBMC from EC, untreated chronic progressors (CP), HAART-
treated and HIV-1 negative subjects were ex vivo infected with HIV-
1. cDCs were isolated and expression of viral replication products, 
Samhd1, Trex1, type I IFNs and 30 IFN stimulated genes (ISGs) were 
subsequently analyzed by qPCR. Type I IFN transcriptional signatures 
were obtained by unsupervised hierarchical clustering and co-
expression analyses.
Results: cDC from HIV-1 negative persons were moderately 
susceptible to HIV-1, while cDC from CP only weakly supported HIV-1 
replication, likely due to high-level Samdh1 expression and impaired 
reverse transcription. cDC from EC also showed low susceptibilities 
to productive HIV-1 infection, but reverse transcription in these cells 
was largely unaltered, while restriction of viral replication seemed 
to preferentially occur at the level of viral integration. Importantly, 
in contrast to CP, HIV-1 infection of cDCs from EC induced a unique 
transcriptional signature of type I IFN-stimulated genes, and a selective 
upregulation of four putative cell-intrinsic sensors of microbial DNA. 
Functionally, these altered patterns of viral restriction and potent IFN 
signatures in cDC from EC were associated with increased cellular 
immune activation, and improved abilities to prime T cell responses 
in vitro.   
Conclusion: cDC from EC can mount cell-intrinsic immune responses 
against HIV-1 thought effective sensing of HIV-1 DNA, which may 
support the generation of highly effective HIV-1-specific T cell 
responses in these patients.    
OA08.01
Gut-Homing of Plasmacytoid Dendritic Cells 
Persists in the Absence of HIV/SIV Replication 
and Contributes to Residual Chronic Immune 
Activation
R. Reeves1, H. Li1, and T. Evans1
1Harvard Medical School, Southborough, MA, USA
Background: Lentivirus infections are characterized by a dramatic 
loss of mucosal CD4+ T cells, breakdown of the gut mucosa, and 
subsequent chronic immune activation.  Residual immune activation 
persists even during ART therapy and is the single greatest cause of 
ongoing disease morbidities.
Methods: Plasmacytoid dendritic cells, primary producers of IFN-α, from 
naive patients and rhesus macaques, chronically HIV-infected persons 
and SIV-infected macaques, ART-treated humans and macaques, and 
elite controllers of HIV were analyzed in blood and tissues using 
polychromatic flow cytometry.  Cells were evaluated functionally by 
intracellular cytokine staining and spatially by immunohistochemistry.
Results: During both HIV and SIV infections blood pDCs were depleted 
compared to naïve subjects.  However, correlating with plasma viremia, 
the remaining pDCs upregulated the gut-homing marker, α4β7.   Even 
during ART and ‘Elite Controllers’ pDCs remained reduced in blood and 
α4β7 expression was still significantly upregulated compared to naïve 
animals.  Absolute numbers and frequencies of pDCs in jejunum and 
colon were 3-fold greater in infected compared to naïve macaques. 
pDCs accumulating in the mucosae during infection secreted high 
levels of IFN-α, MIP1-β, and TNF-α, resulting in net increases in 
cytokines in mucosal tissues. In both humans and macaques, pDC 
trafficking to the gut mucosa was associated with an increase in PAMPS 
— microbial translocated LPS and CpG-DNA — in plasma, regardless 
of ART treatment or elite control status.  Furthermore, pDC trafficking 
to the gut was associated with increased markers of activation on 
circulating T cells.
Conclusion: Here we show a novel mechanism by which pDCs are 
not depleted during lentivirus infections, but rather traffic to and 
accumulate in the gastrointestinal mucosa.  This accumulation 
occurred even in the absence of HIV and SIV replication and was 
associated with chronic immune activation.  These data suggest that 
alternative stimuli contribute to pDC activation and gut-trafficking as a 
prime source of residual chronic immune activation.
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OA08.04
Immune Complex – Fc Receptor Interactions 
Reduce Inflammatory Responses at the Genital 
Mucosa as a Correlate of SIV Vaccine-Induced 
Protection
L. Shang1, A.J. Smith2, S.W. Wietgrefe1, C.S. Reilly1, P.J. Southern1, 
K.E. Perkey1, L. Duan1, J. Robinson3, R. Johnson4, and A.T. Haase1
1University of Minnesota, Minneapolis, MN, USA; 2DeVry 
Medical International, The Bahamas; 3The Scripps Research 
Institute, La Jolla, CA, USA; 4Harvard Medical School, 
Southborough, MA, USA
Background: Previous studies of mucosal transmission have implicated 
that an efficacious prophylactic HIV/SIV vaccine should be able to 
prevent viral replication/expansion at the genital mucosa.  So far, this 
scenario has only been achieved experimentally using live-attenuated 
SIV vaccines.  Thus, great interest lies in identifying correlates and 
mechanisms of such a protection. 
Methods: A global genomics approach, tissues analysis, and explant 
cultures were used to reveal important components of protective 
responses in the female genital mucosa of SIVmac239Δnef-
vaccinated animals.
Results: Genome-wide transcriptional analysis revealed a 
downregulation of inflammation-related genes, but a selective 
enrichment of an anti-inflammatory program in the genital mucosa 
upon virus exposure in Δnef-vaccinated animals.  The inhibitors of NF-
kB and MAPK pathways, COMMD1 and SPRED1, were upregulated 
in the mucosal epithelium.  Additionally, the Δnef vaccine induced a 
progressive accumulation of SIV-specific non-neutralizing antibodies 
(mostly IgGs) at the female genital mucosa. Surprisingly, these 
antibodies were concentrated at the mucosal epithelium, colocalized 
with FcRn.  Moreover, the inhibitory receptor FcγR2b is the only FcγR 
expressed on rhesus genital epithelium.  Therefore, we hypothesized 
that SIV-specific immune complex-FcγR2b interaction induced 
inhibitory signaling in mucosal epithelium, and examined its role 
in suppressing proinflammatory responses to virus exposure.  The 
exposure of cervical epithelium to SIV-specific immune complexes, 
formed by pre-incubating SIV with either vaccinated sera or rhesus 
anti-SIVgp41 mAb 4.9C, increased the expression of COMMD1 and 
SPRED1 in genital epithelial cells, while did not alter proinflammatory 
cytokine expression.  This effect was abrogated by an FcγR2b-blocking 
Ab, antibody deglycosylation, and conditions disrupting immune 
complexes (a mild acid or base treatment).
Conclusion: The SIV-specific immune complexes-FcγR2b interaction 
suppressed proinflammatory responses in the genital epithelium; 
therefore, contributed to the vaccine-induced protection. These 
highlighted an unappreaciated, non-neutralizing role of SIV-specific 
Abs at the mucosal surface and implicated mucosal epithelium as a 
critical, initial immunological sensor that determines the outcome of 
viral transmission.
OA08.03
Acute-Phase Response Proteins Are 
Overexpressed in Vaginal Mucosa and Plasma 
of HIV-Resistant Women upon Viral Challenge
A. Burgener1, Y. Keynan2, A. Meyers3, K. Birse1, M. Abou1,  
G. Westmacott4, J. Kimani5, F. Plummer4, K. Fowke2, and T. Ball3
1Public Health Agency of Canada, Winnipeg, Canada; 
2University of Manitoba, Manitoba, Canada; 3National 
Laboratory for HIV Immunology, Canada; 4National 
Microbiology Laboratory, Canada; 5University of Nairobi, 
Nairobi, Kenya
Background: The primary receptive portals of entry for HIV are 
through mucosal surfaces.  Our previous studies show that HIV-
exposed uninfected individuals (HESN) have unique innate responses 
associated with resistance to HIV infection, including increased 
anti-viral antiprotease expression coupled with a reduced immune 
activation phenotype.  However, we do not know whether this immune 
state is static or induced upon viral exposure. To answer this question 
we challenged HESN women with a live attenuated Flumist vaccine 
and analyzed their mucosal and systemic immune responses using a 
systems biology approach.  
Methods: HESN women (n=10) and HIV-susceptible controls (n=10) 
were challenged with an intranasal Flumist vaccine, and clinical 
samples (cervicovaginal lavage (CVL), plasma) were collected at Day 0, 
1, 7 post-challenge. Mucosal/plasma were analyzed by a combination 
of label-free tandem mass spectrometry, hierarchical clustering, and 
pathway analysis. 
Results: HESN women exhibited significant changes both mucosally 
and systemically upon vaccine challenge 1 and 7 days post-exposure. 
Of the >450 proteins identified in CVL, 62 were overexpressed (p<0.05), 
and 48 overexpressed in plasma (of 220 proteins) (p<0.05), over that of 
controls.  Expression profiles showed significant correlations between 
compartments. Hierarchical clustering identified two major functional 
pathways distinguishing HESN individuals, including the acute 
phase and LXR-RXR response pathways (p<1x10-17).  Many of these 
factors include antiproteases (serpins), apolipoproteins, complement 
components, and SAA proteins which have known inhibitory properties 
against HIV.
Conclusion: As the acute phase response pathway has been implicated 
as important for controlling inflammation and early stage viremia in 
HIV-infected individuals, overexpression of this pathway supports the 
hypothesis that these factors are contributing to reduced susceptibility 
to infection.  Understanding the role of these pathways in mucosal 
susceptibility to HIV may help guide existing microbicide/vaccine 
strategies against HIV.
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Immune Correlates of a Functional Cure 
Following Therapeutic Vaccination of SIV-
Infected Rhesus Macaques
D. Fuller1, A. Narandren2, P. Rajakumar3, J.W. Che3, J. Nyaundai3, 
H. Michael3, E.J. Yager2, F. Cook4, J. Tite4
1University of Washington, Seattle, WA, USA; 2Albany Medical 
College, Albany, NY, USA; 3University of Pittsburgh, Pittsburgh, 
PA, USA; 4GlaxoSmithKline, Stevenage, UK
Background: Therapeutic vaccines that increase T cell responses may 
improve treatment of HIV. We previously showed that therapeutic 
immunization of SIV-infected macaques with a DNA vaccine during 
antiretroviral drug therapy prevented viral rebound in 9/14 animals for 
at least 6 months after withdrawing drugs. 
Methods: To determine if the protection from viral rebound was 
durable or required re-vaccination, 5 of the 9 protected animals were 
re-vaccinated and four were left untreated. To define what immune 
responses contributed to protection from viral rebound, we compared 
mucosal and systemic CD4+ and CD8+ T cell responses in animals 
that maintained viral control for > 18 months after stopping ART to 
responses in a set of animals that exhibited viral rebound within 6 
months post-ART.
Results: Re-vaccination resulted in distinct but transient increases in 
the magnitude, function and breadth in the specificity of the T cell 
response. However, most of the animals, regardless of re-vaccination, 
continued to exhibit durable protection from viral rebound (<100 viral 
RNA copies/ml) and no evidence of disease for the duration of the study 
(2 years after stopping ART). A higher frequency of multifunctional 
CD8+ T cell responses, higher CD4+ T cell proliferation, and broader 
specificity in the mucosal SIV-specific T cell response in the gut 
correlated with long term protection from viral rebound and significant 
reduction of residual virus in the gut. 
Conclusion: These results indicate that a single series of DNA 
vaccinations was sufficient to provide long term viral control and 
furthermore, suggest that vaccines that induce both systemic and 
mucosal T cell responses during HAART may be an effective approach 
to achieve a functional cure.
OA08.05
Optimization of Systemic and Mucosal Immune 
Responses to SIV and HIV-1 Antigens Using 
Different Protocols of DNA and Protein 
Immunization in Macaques
G.N. Pavlakis1, R. Jalah1, J. Li1, A. Valentin1, M. Rosati1, V. Patel1, 
V. Kulkarni1, C. Alicea1, R. Kelly Beach1, Y. Guan2, J.D. Lifson3, 
V.M. Hirsch4, D. Venzon1, K.E. Broderick5, N.Y. Sardesai5,  
T.R. Fouts6, A. Pinter7, C. LaBranche8, D.C. Montefiori8, S. Shen8, 
G.D. Tomaras8, and B.K. Felber1
1National Cancer Institute, NIH, Frederick, MD, USA; 2Institute 
of Human Virology, Baltimore, MD, USA; 3SAIC-Frederick, 
Inc., Frederick, MD, USA; 4NIAID, NIH, Bethesda, MD, USA; 
5Inovio Pharmaceuticals, Inc., Blue Bell, PA, USA; 6Profectus 
BioSciences, Inc., Baltimore, MD, USA; 7University of Medicine 
and Dentistry of New Jersey, Newark, NJ, USA; 8Duke 
University Medical Center, Durham, NC, USA
Background: Understanding the quality of immune responses 
developing after different vaccine regimens is essential for improving 
the prospects of AIDS vaccines. We analyzed different regimens of 
DNA/protein immunization with SIV or HIV-1 antigens to identify 
magnitude, breadth, mucosal dissemination as well as their protective 
ability. We compared DNA vaccination by electroporation in the 
presence of IL-12 DNA, a protocol that showed strong responses in 
DNA vaccinated humans, to DNA and protein vaccine regimens.
Methods: Rhesus macaques were vaccinated using electroporation 
with either DNA, DNA/protein co-immunization, or DNA prime 
followed by protein boost. Humoral (including neutralizing, linear and 
conformational antibodies) and cellular responses were followed over 
time.  Vaccinated macaques were challenged to determine immune 
correlates of protection.
Results: Although DNA vaccination achieved strong humoral 
responses, protein boost after DNA vaccination greatly increased 
Ab levels. Importantly, a co-immunization strategy of DNA/protein 
injected in the same muscle the same time induced highest and broad 
humoral responses.  Similar data were obtained using either purified 
Env proteins or inactivated viral particles. Inclusion of DNA in the 
vaccine promoted persistence of plasma antibody levels for greater 
than 2 years. SIV DNA/protein vaccination induced: higher SIV Env-
specific IgG in saliva; more responders with higher SIV Env-specific 
IgG in rectal fluids; higher and longer-lasting plasma bAb and Nab to 
homologous and heterologous Env; and Ab to V1/V2. Systemic and 
mucosal vaccine-induced Ab responses against SIVsmE660 correlated 
with slower virus acquisition upon challenge. In addition, vaccinated 
macaques showed strong protection against chronic viremia compared 
to controls.  Similar to SIV, HIV DNA/protein (purified Env) vaccination 
also induced higher Ab levels compared to DNA only, including 
significant higher levels of V1/V2 Abs.
Conclusion: DNA/protein co-delivery increases the magnitude and 
longevity of systemic and mucosal humoral immune responses in 
immunized rhesus macaques.
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P01.01
A Novel PD1 Isoform Exhibits Potent 
Intramolecular Adjuvant Activity in Potentiating 
HIV-1 Specific Protective Immunity
Z. Chen1, J. Zhou1, A.K. Cheung1, H. Liu 1, Z. Tan1, and L. Liu1
1University of Hong Kong LKS Faculty of Medicine, Hong Kong
Background: Inducing effective and specific immunity is important 
in the protection and elimination of HIV-1 infection. Programmed 
death-1 (PD1) up-regulation during HIV-1 chronic infections results in 
“exhausted” function of CD8+ T cells, but is restored by blockade of 
the PD1/PD-L pathway with antibodies or a soluble form of (s)PD1. 
Apart from sPD1, the other three spliced variants previously identified 
currently have no known function. 
Methods: In this study, we identified a new isoform of human PD1, 
named Δ42PD1, that contains a 42-nucleotide in-frame deletion 
located at exon 2 near its IgV domain found expressed in PBMCs by 
RT-PCR.  We then characterized the biological function of Δ42PD1 both 
in vitro and in vivo. 
Results: We found that Δ42PD1 is distinct from PD1 because it does 
not engage PD-L1 or PD-L2 expressed on dendritic cells (DCs). It, 
however, is capable of inducing the production of pro-inflammatory 
cytokines (TNF-α, IL-6, IL-1β) especially in DCs. We, then, used 
Δ42PD1 as an intramolecular adjuvant to construct a DNA fusion 
vaccine with HIV-1 Gag p24 antigen. Following immunization in Balb/c 
mice, a significantly enhanced level of anti-p24 antibody titer and 
p24-specific CD8+ T cell responses were elicited that persisted for at 
least 7.5 months. Importantly, vaccinated mice were protected against 
pathogenic vaccinia-Gag virus and lethal tumor challenges, likely due 
to the improved proliferative and cytotoxic functions of the elicited 
CD8+ T cells. 
Conclusion: Our findings not only identified a novel human PD1 
isoform that has immunoregulatory function but also demonstrated a 
novel vaccine strategy in enhancing host protective immunity against 
HIV-1 infection. 
P01.02
Design and Evaluation of Chimeric HIV-1 
Envelope Glycoproteins with Embedded 
Cytokine Domains to Target B Cells
G. Isik1, T. van Montfort1, N.P. Chung1, S. Menis1, W.R. Schief 1, 
J.P. Moore1, and R.W. Sanders1
1University of Amsterdam, Amsterdam, Netherlands
Background: One reason that we do not have an HIV-1 vaccine is 
because several factors limit the quantity and quality of the antibodies 
raised against the viral envelope glycoprotein complex (Env). The 
immunogenicity of Env can be increased by fusion to co-stimulatory 
molecules and we have shown that embedding a cytokine protein 
domain such as GM-CSF within the Env sequence enhanced Env-
specific antibody and T cell responses in mice.
Methods: A stabilized Env trimer was engineered harboring the 
interleukin-21 (IL-21) within the V1/V2 domain of gp120. The 
expression of Env-IL21 was analyzed by SDS-PAGE. We performed 
probing studies with a panel of neutralizing antibodies and receptor 
mimics in a trimer ELISA to investigate the conformation of Env. 
The functionality of the IL-21 was tested on human B cells by 
immunoglobulin ELISA and flow cytometry.  
Results: We hypothesized that targeting Env vaccines directly to B 
cells, by fusing them to molecules that bind and activate these B cells, 
would improve Env-specific antibody responses. We describe soluble 
Env trimers with embedded IL-21 domains, designed to activate B 
cells that recognize Env. Env-IL21 is expressed efficiently and antibody 
probing with neutralizing antibodies revealed that the Env components 
are folded correctly. Furthermore, IL21-conjugated Env trimers potently 
activated human B cells in vitro and induced the secretion of IgA, IgG 
and IgM and enhanced plasmablast formation. In addition to IL21, 
we have been exploring the use of A PRoliferation-Inducing Ligand 
(APRIL). Env-APRIL induced higher anti-Env antibody responses in 
rabbits, and neutralizing antibodies against Tier 1 viruses. 
Conclusion: We have shown that chimeric HIV-1 Env trimers with 
costimulatory domains show improved immunogenicity compared 
to Env alone and we work on further improving the design. These 
studies should guide the further design of chimeric proteins and 
assist the development of an HIV-1 vaccine inducing protective 
humoral immunity.
Posters
P
O
ST
ER
S
81AIDS Vaccine 2013
Topic 01: Adjuvants, Immunogens and Inserts
82
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L1, Room 111 – 112.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L1, Room 111 – 112.
P01.04
Engineered Immunogens that Raise Antibodies 
to a Single Epitope
J. Mata-Fink1, M.C. Hanson1, E. Falkowska2, D. Burton2, D. Irvine1, 
and K. Wittrup1
1Massachusetts Institute of Technology, Cambridge, MA, USA; 
2The Scripps Research Institute, La Jolla, CA, USA 
Background: A broadly effective HIV vaccine will have to elicit broadly 
neutralizing antibodies to conserved epitopes from which the virus 
cannot easily escape. The CD4 binding site (CD4bs) is one such epitope 
against which several antibodies (e.g. b12, VRC01) have been isolated. 
Passive immunization experiments in macaques demonstrate that 
prophylactic administration of CD4bs-directed antibodies is protective, 
whereas therapeutic administration is not.
Methods: Yeast surface display is a powerful method for rapidly 
engineering complex glycoproteins. We begin with a stripped core 
gp120 scaffold and use directed evolution by yeast surface display 
to generate a panel of immunogens that present a functional CD4 
binding site but are otherwise highly diverse. We also develop an 
accompanying suite of tools with which to map conformational 
epitopes of neutralizing antibodies and monitor the specificity of 
serum following immunization.
Results: Mice immunized with these diversified immunogens in series 
elicit CD4bs-directed antibodies to the exclusion of all others. The 
elicited antibodies were isolated from hybridomas, sequenced, and 
tested for neutralization. The antibodies did not neutralize HIV in a 
TZM-bl assay, and they did not bind to intact trimeric envelope.
Conclusion: Though the elicited antibodies were non-neutralizing, we 
have demonstrated a generalized method of generating diversified 
immunogens that share a common, complex epitope. When 
administered in series, these immunogens elicit antibodies to the 
shared epitope. This method should be adaptable to scaffolds based on 
trimeric gp160 that more accurately mimic the native viral envelope.
P01.03
Cyclophilin A as Genetic Adjuvant, Induced 
Broader and Long-Lasting Gag-Specific Cellular 
Immune Response Based on CyPA-Gag Specific 
Interaction
J. Hou1, Y. Liu1, and Y. Shao1
1Chinese Center for Disease Control and Prevention, Beijing, 
China
Background: It is reported that, when dendritic cells succumb to 
HIV-1 infection co-transfected with SIV Vpx protein, HIV-1 induces 
DC maturation, stimulate an antiviral type I interferon response and 
activation of T cells. These processes are dependent on the interaction 
of newly synthesized HIV-1 capsid with cellular cyclophilin A (CyPA). In 
this study, we investigated the suitability of CyPA as a genetic adjuvant 
for an HIV-1 Gag DNA vaccine.
Methods: We designed single expression cassette that including 
Gag and CyPA gene respectively; and also constructed dual 
expression cassette that expressed both Gag and CyPA gene in one 
plasmid. 6-week-old female BALB/C mice were administrated thrice 
intramuscularly with variance DNA vaccine at two weeks interval. 
Gag-specific IFN-γ ELISPOT and ELISA detected cellular and humoral 
response after two weeks following the last immunization.
Results: In CyPA specific adjuvanticity analysis, we found CyPA 
could not enhance Env or irrelevant antigen immunity but augment 
HIV Gag-specific cellular immune responses. In the dual expression 
cassette regimen, the cellular immune responses showed that, 
Gag/CyPA could stimulate high level Gag-specific cellular immune 
responses, compared with Gag alone. Moreover, based on CyPA 
mutations Co-IP analysis, we assume adjuvant effect of CyPA is based 
on Gag-CyPA specific interaction. In assessing the potential effect of 
CyPA on the breadth of T cell responses in mice, CyPA broadened the 
T cells’ response spectrum of Gag peptides, with 8 pools showing 
significant enhancement through CyPA use. In the longitudinal 
analysis of immunogenicity, Gag-specific cellular immune responses 
induced by CyPA were maintained at high level from 210 days after 
the final inoculation, compared with Gag alone.
Conclusion: There is firstly report that Cyclophilin A could augment 
HIV-1 Gag specific cellular immune response as genetic adjuvant 
in multiplex DNA immunization strategies. And this adjuvanticity is 
specific, broad, long-lasting and based on Gag-CyPA interaction.
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P01.06
In Vivo Tracking of an Anti-HIV Vaccine by 
Near-Infrared Fluorescence Imaging in Non-
human Primates 
N. Salabert2, F. Martinon2, G. Zurawski1, T. Kortulewski2,  
S. Zurawski1, A. Cosma2, J. Banchereau1, R. Le Grand2, and  
C. Chapon2
1Baylor Institute for Immunology Research, Dallas, TX, USA; 
2CEA, Fontenay-aux-Roses, France
Background: Non invasive and longitudinal imaging approaches are 
required to study the dynamics of skin antigen presenting cells (APCs) 
migration to the draining lymph nodes (LNs) following immunization 
in order to better understand the mechanisms leading to the induction 
of cellular and humoral immune responses. Here we evaluated the 
dynamic of migration of a fluorescent anti-langerin antibody fused to 
HIV antigen using in vivo near infrared fluorescence (FNIR) imaging 
after intradermal injection with or without resiquimod (R-848), an 
agonist of Toll-like receptor 7 and 8, in non-human primate (NHP). 
Methods: Anti-langerin-HIVgag-FNIR (exc. 682nm; em. 710nm) was 
injected intradermally, with or without R-848 in NHP (n=3). In vivo 
NIR fluorescent imaging was performed prior to and at different times 
post-injection (FluobeamTM, Fluoptics). The fluorescent intensity was 
measured using ImageJ software. Confocal time-lapse microscopy 
was then performed on whole skin biopsies to track fluorescent APCs 
in both dermis and epidermis. Cell tracking and quantification were 
performed by using Volocity software (Perkin elmer).
Results: The NIR fluorescent-labelled anti-langerin-HIVgag vaccine was 
visualized by in vivo imaging for up to 48 hours post-injection in NHP. 
At 2h post-injection, the signal intensity at the injection site of anti-
langerin-HIVgag-FNIR was 46.8 ± 2.3% of the injected fluorescence 
whereas the one measured at the injection site of α-langerin-gag-FNIR 
and R-848 was lower (28.89 ± 11.9%). Confocal videomicroscopy 
confirmed that the anti-langerin-HIVgag-FNIR specifically targeted 
langerhans cells, which were also stained by anti-HLADR and anti-
CD1a monoclonal antibodies. 
Conclusion: In vivo NIR fluorescence imaging can be used to monitor 
the effect of a vaccine and/or an adjuvant on APC from the skin to 
the LNs in NHP. This approach will allow better characterization of 
the early cellular events in different experimental settings such as 
vaccination and immune therapeutic interventions.
P01.05
Increase in HIV-1 Envelope Incorporation into 
Virions Mediated by Genetic Modification of 
the Cytoplasmic Tail of Envelope
M.J. Hogan1, A.P. Jordan1, A. Conde1, D. Weissman1, and  
J.A. Hoxie1
1University of Pennsylvania, Philadelphia, PA, USA
Background: Vaccine-elicited antibody responses against HIV Env are 
characteristically weak and short-lived. One method to induce potent 
antibody responses uses proteins presented as an array on viruses 
or virus-like particles (VLPs). However, this approach has proven 
challenging for HIV, which expresses Env at low levels on virions. 
Although Env incorporation into virions can be increased by removal 
of the cytoplasmic tail, this effect is modest, typically with only a 2-3-
fold increase in Env incorporation relative to wild-type HIV. Based on 
rational manipulation of trafficking signals in the Env cytoplasmic tails 
of HIV and SIV, which can have positive or negative effects on Env 
incorporation, we sought to derive virion-based immunogens with 
greatly enhanced levels of Env trimers.
Methods: The cytoplasmic tail of HIV-1 was modified 1) to remove all 
known endocytosis signals and 2) to incorporate a segment from the 
SIV Env cytoplasmic tail that can positively affect Env incorporation. 
We generated virions from HEK 293T cells and quantified Env 
incorporation via the Env:Gag ratio, as measured by antigen-capture 
ELISA for p24 and gp120.
Results: Envelopes that lacked a cytoplasmic tail and/or contained 
mutations that ablated known endocytosis signals resulted in a ≤2-
fold increase in Env content on virions. However, when HIV Env also 
contained a 13 amino acid segment from the proximal region of the 
SIV Env cytoplasmic tail, HIV Env incorporation could be increased 
3- to 8-fold. In contrast to other reported approaches to increase HIV 
Env incorporation, viruses containing these changes could establish a 
spreading infection in CD4+ T cell lines.
Conclusion: The novel Env modifications we describe here are 
effective across different HIV isolates and clades and can be applied 
in combination with other approaches to increase the surface density 
of Env on inactivated virus or VLP vaccines. The effect of these 
modifications on immunogenicity is currently under investigation.
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P01.08
Improving Cell Surface Expression and 
Immunogenicity of HIV-1 Envelope by 
Modification of Residues Within the 
Cytoplasmic Tail 
A. Conde1, A. Jordan1, M. Hogan1, D. Weissman1, and J. Hoxie1
1University of Pennsylvania School of Medicine, Philadelphia, 
PA, USA
Background: HIV-1 Envelope (Env) protein is an ideal target for an 
HIV-1 vaccine, but has been poorly immunogenic in clinical trials to 
date.  Env contains endocytosis motifs within its cytoplasmic tail (CT) 
that may decrease Env expression on the surface of infected cells and 
reduce immunogenicity. HIV-1 and Simian Immunodeficiency Virus 
(SIV) Env proteins contain a conserved endocytosis signal represented 
by the sequence GYxxΦ (where G=Gly, Y=Tyr, x=any amino acid, 
and Φ=an amino acid with a bulky hydrophobic side chain, such as 
Leu).  Previous studies using SIVmac Env showed that expression was 
increased on the surface of transfected cells when this endocytosis 
motif was disrupted.  This increase was augmented when the CT was 
truncated to remove distal endocytosis signals. However, in the context 
of HIV-1 Env, these mutations do not significantly increase surface 
expression.  Therefore, we hypothesized that the CT of SIVmac Env 
contains positive signals for surface expression. HIV-1 Env constructs 
containing SIVmac sequences may be ideal candidates for optimizing 
cell surface expression of Env, with the end goal of improving 
immunogenicity of Env through increased dendritic cell-mediated 
antigen presentation to B cells.  
Methods: In this series of experiments, we used HIV-1 Env 
derived from multiple virus isolates and clades (89.6, JRFL, R3A, 
and 1086C), and generated a series of constructs containing the 
SIVmac segment with various CT mutations. 293T cells or primary 
human dendritic cells were transfected or infected with vaccinia 
virus encoding Env, and surface expression was measured by 
immunostaining and flow cytometry.  
Results: Incorporation of SIVmac CT sequences into HIV-1 Env resulted 
in up to a 30-fold increase in Env expression on the surface of 293T 
and dendritic cells. 
Conclusion: CT-modified HIV-1 Envs are promising candidates for 
improving immunogenicity in the context of an HIV vaccine; these 
constructs are currently being tested in small animal models. 
P01.07
Local Immunomodulation of TLR3-Triggered 
Immune Activation by Single-Stranded DNA 
Oligonucleotides in Non-human Primates
C. Poux1, A.E. Sköld2, D. Brodin2, F. Martinon1, R. Le Grand1, and 
A. Spetz2
1CEA, Paris, France; 2Karolinska Institutet, Stockholm, Sweden
Background: Among other pathways, HIV initiates immune responses 
through TLR3 engagement. It was recently shown that single-stranded 
DNA oligonucleotides (ssDNA-ODN) can modulate the immune 
response triggered by PolyI:C, a TLR3 ligand (TLR3-L). Therefore, 
its potency as a novel skin adjuvant to prevent TLR3-exacerbated 
inflammation was tested in vivo in non-human primates.
Methods: Cynomolgus macaques (n=12) were injected intradermally 
on the back with PBS on one side and with PolyI:C alone or with ssDNA-
ODN on the other side. After 24h, skin biopsies were performed to study 
local cellular events (flow cytometry), cytokine secretion (luminex) and 
expression arrays (Agilent system). Statistical significance was tested 
by Kruskal-Wallis followed by Dunn’s multiple comparison tests and 
Fisher´s exact test.
Results: As expected, i.d. injection of TLR3-L induced skin inflammation 
with infiltration of polymorphonuclear cells (PMN, p<0.05) and 
maturation of skin DC subsets (CD80/86 expression, p<0.01). HLA-
DR - CD14 + macrophages were also recruited in dermis (fold increase 
(FI) =9) and a group of HLA-DR + CD1a - cells accumulated (FI=31 and 
p<0.01) in epidermis. Addition of ssDNA-ODN appeared to dampen 
maturation of Langerhans cells (p<0.05) and reduced infiltration of 
dermal macrophages and epidermal HLA-DR + CD1a - cells (FI=2 
and 9, respectively). Microarray data revealed that PolyI:C injection 
induced innate immunity with significant induction of many interferon 
regulated genes (p<0.05) (fold change (FC) range 35-2640 at 10% 
FDR). ssDNA-ODN presence reduced pro-inflammatory cytokines 
transcription as compared to PolyI:C injection alone. In parallel, mRNA 
expression of immune-regulatory cytokines, such as IL-10 family 
members and IL-17A, was increased. Luminex analyses performed on 
supernatants from skin biopsies explants confirmed IL-10 induction 
(FI=15) and reduced IL-6 production after addition of ssDNA-ODN. 
However, several interferon regulated innate HIV-1 restriction factors 
(p<0.01, FC>4) were induced even in the presence of ssDNA-ODN.
Conclusion: These results demonstrate local ssDNA-ODN effective 
modulation of TLR3-induced immune response and support future 
clinical investigation in non-human primates.
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P01.10
Characterization of Scaffolded PGT128-
Specific V3-Glycopeptides for Use as HIV-1 
Immunogens
S. Srivatsan1, T. Zhou1, J. Zhu1, Y. Yang1, X. Du1, B. Zhang1, and 
P.D. Kwong1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: The glycan-V3 loop on gp120 is one of the major 
sites of vulnerability on the HIV-1 spike. Several broadly neutralizing 
human antibodies that target this site have been isolated. One of them, 
PGT128, achieves broad and potent neutralization of over 70% of HIV-
1 strains. Structural studies revealed that PGT128 interacts with the 
backbone of V3 in addition to glycans on the V3 loop. The elicitation of 
PGT128-like antibodies with structurally designed V3-peptides and the 
resolution of immunogenic determinants of such designs, as potential 
immuogens in animal models are fascinating questions, which have 
yet to be explored. 
Methods: To create PGT128-specific immunogens, we performed 
structure-based design to transplant the epitope of interest containing 
the three N-linked glycans and a segment of V3, onto various scaffold 
proteins. In addition, various combinations of glycan-knockout 
mutants were created to explore the importance of each glycan. To 
further explore the relationship between antibody recognition and 
conformational flexibility, a non-scaffolded V3 peptide was also 
created and tested as a control. 
Results: We characterized these designed immunogens with 
biochemical, biophysical and structural approaches. Our results 
indicate that these small scaffolded proteins are readily secreted by 
mammalian cells in multiple glycoforms. Surface plasmon resonance 
binding data revealed that these 11 designed immunogens were able 
to bind PGT128 with high affinities, ranging from 2 nM to 35 nM. 
Binding assays preformed with glycan mutants and non-scaffolded V3 
peptide confirmed the importance of glycan binding and conformation 
of the V3 peptide in PGT128 binding, respectively. Structural analysis 
of selected immunogens is currently ongoing. 
Conclusion: Structure-based design of proteins was able to produce 
immunogens, with high affinity and specificity to PGT128. The ability 
to tailor immunogens, with specific antigencity and conformation 
using structural biology, represents a first and important step in the 
activation, expansion and maturation of PGT128-like B cell lineages.
P01.09
Nanoparticle Based Delivery of TLR4 
and TLR7/8 Ligands with SIV Envelope 
Immunogens Induce Systemic and Mucosal 
Humoral Immunity in Rhesus Macaques
S.P. Kasturi1, J. Wrammert1, M. Pham1, P. Xiao1, Y. Kovalenkov1, 
X. Chen1, M.J. Johnson1, E. Hunter1, P.A. Kozlowski2, F. Villinger1, 
P. Spearman1, C.A. Derdeyn1, and B. Pulendran1
1Emory University, Atlanta, GA, USA; 2Louisiana State 
University School of Medicine, New Orleans, LA, USA
Background: A major obstacle to obtaining protective immunity 
against HIV is defining adjuvants that induce high affinity and broadly 
neutralizing antibody responses against envelope (Env) proteins. Our 
data demonstrated that a combination of TLR4 ligand and TLR7 or 7/8 
ligands delivered using synthetic nanoparticles strikingly enhanced 
the magnitude, quality and durability of humoral and cellular immune 
responses against protein immunogens in mice and rhesus macaques 
(Nature,2011Feb24;470(7335):543-7). We hypothesized that such 
a combination of ligands could significantly enhance humoral and 
cellular immunity against SIV immunogens in rhesus macaques with 
implications for HIV-1 vaccine development in humans
Methods: Nanoparticles containing a combination of TLR4 and TLR7/8 
ligands (NP adjuvant) were used to adjuvant virus-like particles (VLPs) 
and recombinant antigens (gp140), both derived from the SIVmac239 
virus.  Immune responses were compared with those elicited by 
antigen delivered in alum, an adjuvant currently used in humans. 
Rhesus macaques were immunized four times at eight-week intervals. 
Innate and adaptive immune responses were monitored at early and 
late time points post vaccinations.
Results: NP adjuvant significantly expanded subsets of monocytes and 
dendritic cells in peripheral blood at early time points post vaccination. 
NP adjuvant induced sustained polyfunctional Env specific CD4+ 
T cell responses in the presence of gp140 but not in the presence 
of VLPs. NP adjuvant in the presence of gp140 induced robust Env 
specific plasmablast responses in peripheral blood after each booster 
immunization and induced long-lived plasma cells in bone marrow 
and draining lymph nodes. NP adjuvant in comparison with alum, 
induced significantly higher Env specific binding antibody responses 
(IgG and IgA) in serum, vaginal secretions and rectal secretions
Conclusion: Our results indicate that synthetic nanoparticles carrying 
select combination of TLR ligands offer a novel approach to engineer 
robust and durable Env specific humoral affinity in rhesus macaques 
with implications for HIV-1 vaccine development in humans.
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P01.12
Enhancement of SIV-Specific Cell Mediated 
Immunity by Co-administration of Soluble 
PD-1 and Tim-3 as Molecular Adjuvants in Mice
L. Feng1, L. Xiao1, C. Sun1, P. Li1, Y. Jin1, and L. Chen1
1Chinese Academy of Sciences, Guangzhou, China
Background: An HIV/SIV vaccine that contains multiple antigens 
may confer better effective protection. The magnitude and breadth 
of immune responses may be limited, especially for the sub-
dominant antigens.
Methods: In this study, we evaluated the immunogenicity of a multiple 
antigenic SIV vaccine (gag, pol, env, nef, vpx, vpr, vif, raf, tat) in 
combination with two molecular adjuvants, soluble PD-1 (sPD-1) and 
soluble Tim-3 (sTim-3), harbored in recombinant adenoviral vectors. 
The use of sPD-1 and sTim-3 is to block the inhibitory receptors PD-1 
and Tim-3, and thus to maximize the activation of CD4 and CD8 + T 
cells by MHC-epitope complex. 
Results: Although the mice immunized with SIV vaccine produced 
antigen specific cell mediated immunity (CMI), mice immunized 
with SIV vaccine co-inoculated with sPD-1 and/or sTim-3 showed 
significantly stronger CMI, reflected by the generation of more IFN-γ+ 
CD4+T and CD8+T cells and the enhanced proliferation of antigen 
specific T lymphocytes. Interestingly, the CMI elicited by non-structural 
proteins vif and tat were significantly enhanced in both magnitude 
and breadth. 
Conclusion: Our study provided a strategy to enhance vaccine induced 
cellular responses, which may be adopted to improve the vaccination 
effects against SIV/HIV or other chronic infections. Future study will be 
carried out using a SIVmac239 model in rhesus macaques.
P01.11
Solution Structural Analysis of the Secondary 
Structure for HIV-1 gp120 Outer Domain by 
NMR Spectroscopy
M. Sastry1, L. Xu1, S. Bhattacharya2, G.J. Nabel1, C.A. Bewley3, 
and P.D. Kwong1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2New York Structural Biology Center, New York, NY, USA; 
3NIH/NIDDK, Bethesda, MD, USA
Background: The heavily glycosylated outer domain (OD) of HIV-1 
gp120 has been proposed as a minimal immunogen to elicit broadly 
neutralizing antibodies.  Immunization with a number of different OD 
variants has thus far failed to elicit neutralizing antibodies. Solution 
structure of the unliganded OD and an understanding of its dynamic 
properties may assist in the use of OD as an immunogen.  
Methods: NMR spectroscopic characterization of proteins requires the 
production of protein samples enriched in 15 N/ 13 C and/or 2 H 
stable isotopes. The heavily glycosylated OD is especially problematic 
to express using conventional prokaryotic expression systems. We 
developed a method to enrich glycoproteins with 15 N/ 13 C isotopes 
using a mammalian expression system that exploits the high level of 
protein expression obtained from an adenoviral vector. We employed 
heteronuclear NMR spectroscopy to obtain structural and dynamic 
information of unliganded OD. Three dimensional NMR experiments 
for sequential and side-chain assignments along with  15 N and  13 
C edited NOESY experiments were recorded on uniformly labeled OD 
as well as on an OD sample selectively enriched in  15 N/ 13 C for Ile, 
Leu and Val.
Results: We successfully produced isotopically enriched OD samples, 
suitable for NMR analysis. Standard triple resonance NMR experiments 
on the uniformly labeled OD were combined with backbone and 
isotope edited experiments recorded on an OD sample that was 
selectively enriched in  15 N/ 13 C for Ile, Leu and Val to assign HN, C’, 
C alpha  , and N backbone resonances in 128 of the 220 residues of OD. 
These preliminary backbone assignments were further validated using 
HC(C)H and (H)CCH TOCSY side-chain experiments.   
Conclusion: We succeeded in assigning ~1/2 of the backbone for 
unliganded OD with triple resonance and side-chain NMR experiments. 
Extension of these assignments with NOESY experiments is now 
proceeding. Our results indicate that solving a solution structure of the 
HIV-1 gp120 OD by NMR spectroscopy is feasible.  
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P01.14
Epitope Competition Could Influence the 
Kinetics of Specific CD8+ T Cell Responses 
During Repeated DNA Vaccination
Y. Ren1, Y. Wan1, J. Wang1, and J. Xu1
1Shanghai Public Health Clinical Center, Shanghai, China
Background: Previous study suggested that specific T cell responses 
against HIV-1 Gag were suppressed when being co-expressed with HIV-
1 Env. Epitope competition was postulated to be one of the underlying 
mechanisms. The objective of this study is to elucidate the influences 
of epitope competition on specific T cell responses during repeated 
DNA vaccination.
Methods: DNA vaccines expressing Gag92, Env203 or Gag92/
Env203 fusion epitope (Gag92 and Env203 were mouse T cell 
epitopes identified in our previous work) were constructed. C57BL/6 
mice were immunized with single epitope DNA vaccines (pSV-gag92 
or pSV-env203), fusion gene DNA vaccine (pSV-gag92/env203) and 
the mixed single epitope DNA vaccines (pSV-gag92+pSV-env203). 
Epitope specific CD8 T cell responses were analyzed by the method of 
intracellular cytokines staining.
Results: We assayed the epitope specific T cell response after 3-time 
intramuscular immunization, and found that the frequency of Env203-
specific IFN-γ+CD8+ T cell [(1.001±0.2676)%] was significantly higher 
than Gag92-specific IFN-γ+CD8+ T cell[(0.1563±0.09369)%] in pSV-
gag92/env203 immunizing group. While, no significant difference 
was observed in the group immunized with mixed DNA vaccines 
(pSV-gag92+pSV-env203). Moreover, the mixed single epitope DNA 
vaccines could induce higher rate of Gag92-specific IFN-γ+CD8+ T cell 
response [(0.4220±0.4497)%] than pSV-gag92/env203.
Furthermore, dynamic observation showed the specific IFN-γ+CD8+ 
T cell responses against non-dominant epitope(Gag92) could not be 
efficiently boosted during repeated vaccination of pSV-gag92/env203 
fusion gene vaccine and only dominant epitope(Env203) specific IFN-
γ+CD8+ T cell responses could be improved. While, the mixed single 
epitope DNA vaccines could induce much more balanced CD8+ T cell 
responses against both epitopes.
Conclusion: Epitope competition could significantly decrease the 
frequency of specific T cell response against non-dominant epitope. This 
is true not only at the end but also during the process of repeated DNA 
vaccination. And separate expression of different epitopes may help to 
balance the magnitudes of T cell responses among different epitopes.
P01.13
Mimetic Peptide Selection from Phage-Display 
Libraries Using Patient Sera Evidence Epitope 
Structural Features for the Apex of V3 Loop in 
gp120
Y. Palacios-Rodriguez1, T. Gazarian1, A. Majluf-Cruz2, L. Huerta1, 
and K. Gazarian1
1Mexican National Autonomous University, Mexico; 2General 
Hospital No. 1 Gabriel Mancera, IMSS, Mexico 
Background: The crown region of the V3 loop in HIV-1 that contains 
the conserved amino acid sequence GPGR/G is known as the principal 
neutralizing determinant due to the extraordinary ability of antibodies 
to this region to neutralize the virus. Apparently it is one of the most 
vulnerable viral target for which synthetic peptide models are explored 
for vaccine candidates. Peptide mimics of the epitope recognized in 
random phage-display libraries by patient anti-V3 antibodies could be 
of high utility but were not so far obtained due to the heterogeneity of 
the antibodies that V3 produces.
Methods: The screening of random phage-display libraries of high 
complexity including linear 12mer and constrained 7mer peptides was 
developed using polyclonal antibodies from HIV-1 subtype B-infected 
Mexican patients.
Results: The short constrained peptides selected presented two 
conserved amino acid sequences: PR-L in N-terminus and GPG in the 
C-terminus representing the two known epitope binding sites. In an 
interesting way the GPG triad has the same function as the V3 crown 
GPGR sequence but without the involvement of the R despite its being 
considered as the signature of the epitope in B-subtype viruses. In the 
case of the PR-L motif, it contains a proline not existing in the epitope, 
this amino acid is postulated to induce a beta-turn in the backbones 
of all peptides and create a spatial element mimicking the N-terminal 
conformational variable binding site. As immunogens, polyclonal 
antibodies to these mimotopes induced in rabbit recognized a panel 
of V3 peptides and moderately decreased the fusion between HIV-1 
Env- and CD4-expressing Jurkat cells.
Conclusion: The identified structural features of V3 mimotopes are 
sources of information on the fine structure-function properties of HIV-
1 principal neutralizing domain and contributing to rational design of 
anti-HIV-1 immunogens.
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P01.16
Stability of an Acute HIV-1 Tanzanian 
Subtype C gp145 Envelope Protein for Clinical 
Development 
G.R. Matyas1, M. Rao1, C. Tucker1, V. Kalyanaraman2,  
S. Whitney2, T. VanCott2, N.L. Michael1, M.L. Robb1, V. Polonis1, 
and C.R. Alving1
1U.S. MHRP, Silver Spring, MD, USA; 2Advanced Bioscience 
Laboratories, Inc., Rockville, MD, USA
Background: There has been renewed interested in a vector prime and 
protein boost strategy since the RV144 clinical trials.  One of the lead 
candidates to be used as a protein boost is a CHO expressed gp145 
trimer envelope protein derived from an acute Tanzanian HIV-1 isolate 
(CO6980v0c22), which is currently being manufactured for clinical 
trials. A number of questions have arisen as to the best formulation 
buffer and the stability to lyophilization and multiple freeze-thaws.
Methods: The gp145 envelope protein was expressed in a stable 
CHO cell line, purified and placed in PBS, pH 7.4. The stability of 
gp145 was tested in PBS or after dialysis with Tris-saline buffer, pH 
7.4.  Samples frozen once and stored at 4ºC were compared with 
samples that were subjected to three -80ºC freeze-thaw cycles. 
Samples were lyophilized from PBS or Tris-saline and reconstituted. 
The gp145 subjected to the various treatments was analyzed by 
ELISA for binding to various monoclonal antibodies, VRC01, PG9, 
PG16 and pooled plasma from patients chronically infected with HIV 
clade C.  The gp145 was also analyzed on blue native gels followed 
by Western blotting with these antibodies. 
Results: No significant difference was observed in binding with each 
of the antibodies to the gp145 formulated in PBS when stored at 4ºC, 
lyophilized or repeatedly frozen and thawed.  However, changing the 
buffer from PBS to Tris-saline caused 30-50% reduction in the binding 
of VRC01, PG9 and PG16.  No changes in binding were observed 
with the clade C plasma.  However, lyophilization of the gp145 from 
Tris-saline further reduced the binding of each of the antibodies an 
additional 10-20%. 
Conclusion: These data demonstrate that use of PBS as a buffer for 
gp145 is preferable to Tris-saline.  The gp145 protein in PBS can be 
lyophilized and reconstituted and can undergo multiple freeze-thaws 
with no loss of antibody binding ability.
P01.15
Multi-envelope Transmitted Founder DNA 
Vaccine Induces Potent Cross Clade Humoral 
Responses in Guinea Pig and Rabbits
M. Wise1, K. Muthumani1, J. Mendoza2, N. Hutnick1, J. Yan2,  
D. Montefiori3, C. Labranche3, K. Broderick2, N. Sardesai2, and  
D. Weiner1
1University of Pennsylvania, Philadelphia, PA, USA; 2Inovio 
Pharmaceuticals, Blue Bell, PA, USA; 3Duke University, 
Durham, NC, USA
Background: It has been reported that guinea pigs vaccinated with 
transmitted founder gp140 envelope proteins are able to induce low 
but broad neutralizing antibodies to both tier 1 and tier 2 viruses. 
This general induction of coverage may be ideal for a priming 
immunization, establishing a response which is able to be boosted 
with the addition of either chronic or consensus envelopes. Since the 
DNA vaccine platform is seen as a priming regiment, we aimed to 
investigate if similar broad response could be induced using primary 
transmitter founder (TF) gp160 immunogens from clades A, B, and C. 
Methods: Initial immunogenicity studies of individual constructs 
were performed in guinea pigs. Additional combination studies were 
performed in rabbits with between 4 to 6 immunizations followed by 
in vivo electroporation. 
Results: All guinea pigs seroconverted with two immunization of 
individual plasmid expressing clade A TF envelope. Rabbits sequentially 
immunized with different clade A TF envs developed limited binding 
titers to primary gp120s. However, if these same plasmids were 
grouped together and immunized, all rabbits showed robust binding 
titers to cross-clade primary gp120s after two immunizations and 
limited tier 1 neutralization. Including TF envelopes from different 
clades increased binding titers and neutralization breadth and potency. 
Antibody epitope mapping revealed vaccination was inducing primarily 
V3 binding. 
Conclusion: We have shown that DNA plasmids expressing TF gp160 
immunogens are both expressed and induce a potent immune 
response. We have observed for the first time that exposure of the 
immune system to multiple envelopes at one time can dramatically 
change the immune phenotype induced. This finding has profound 
implications for development of an HIV vaccine. Further studies into 
how this priming response can be broadened are currently under 
investigation. We are also determining the role of T follicular helper 
cells driving humoral responses to DNA vaccines. 
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P01.18 LB
Increased HIV-1 Immunogenicity of Replication 
Competent NYVAC 
J.L. Heeney1, B. Jacobs2, M. Esteban3, R. Wagner4, K. Foulds5,  
M. Roederer5, S. Self6, S. Barnett7, J. Tartaglia8, D. Montefiori9,  
G. Tomaras10, G. Pantaleo11
1University of Cambridge, Cambridge, UK; 2Arizona State 
University, Tempe, AZ, USA; 3Centro Nacional de Biotecnologia-
Consejo Superior de Investigaciones Cientificas, Madrid, Spain; 
4University of Regensburg, Regensburg, Germany; 5Vaccine 
Research Center, NIAID, NIH, Bethesda, MD, USA; 6SCHARP, 
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
7Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA; 
8Sanofi-Pasteur, Swiftwater, PA, USA; 9University Medical 
Center, Durham, NC, USA; 10Duke University Medical Center, 
Durham, NC, USA; 11Centre Hospitalier Universitaire Vaudois, 
Lausanne, Switzerland
Background: The human RV144 efficacy trial revealed a 31% efficacy 
rate against acquisition of HIV infection using the ALVACvcp1521/ 
AIDSVAX gp120 B/E prime boost regimen. In addition to a modest 
efficacy rate, the duration of protection was relatively short-lived, 
suggesting that both vaccine components must be improved. The 
Copenhagen vaccinia derived replication deficient NYVAC has been 
shown to be highly immunogenic in combination with DNA priming in 
both non-human primates (NHPs) and human clinical trials. 
Methods: Host range genes K1L and C7L were reinserted in NYVAC 
vectors expressing HIV-1 clade C Env, and Gag-Pol-Nef to restore 
replication in human cells. This replication competent NYVAC-KC 
was compared head to head with the parental replication deficient 
NYVAC-C vectors for immunogenicity in rhesus macaques using two 
different prime-boost vaccine schedules; a) 2x NYVAC at week 0 and 
4 followed by 3x NYVAC+gp120/MF59 at week 12 and 24 and 48; b) 
3x DNA at week 0, 4 and 8 followed by 1x NYVAC at week 20 and 3x 
gp120/MF59 at week 28, 32 and 48. T-cell responses were assessed 
by ICS and IFN-γ ELISpot and humoral responses by anti-Env binding 
IgG antibodies, neutralizing antibodies, Env V1V2 IgG and ADCC.
Results: The DNA prime/NYVAC boost regimen induced vigorous 
polyfunctional CD4+ and CD8+ T-cell responses (IFN-g+IL-2+TNF+ 
by ICS and ±5000 SFUs/106 cells at peak response). In the absence 
of DNA priming T-cell responses were significantly higher within the 
NYVAC-C KC (>1 log) as compared to NYVAC-C. T-cell responses were 
significantly lower compared to DNA primed groups. Marked IgG Env 
antibody responses including IgG V1V2 responses were detected in all 
groups although there was a trend to higher responses in the absence 
of DNA priming.
Conclusion: Replication competent NYVAC-KC significantly increased 
immunogenicity as compared to NYVAC thus providing the rationale 
for moving NYVAC-KC to clinical development.
P01.17
Comparable Antigenicity and Immunogenicity 
of Multimeric Forms of a Novel, Acute HIV-
1 Subtype C Gp145 Envelope for Clinical 
Development  
L. Wieczorek1, S. Krebs1, V. Kalyanaraman2, S. Whitney2,  
G.R. Matyas1, M. Rao1, C.R. Alving1, T. Tong1, S. Molnar1,  
M. Wesberry1, A. Laurence Chenine1, S. Tovanabutra1,  
E. Sanders-Buell1, B. Slike1, S. Alam3, H. Liao3, B.F. Haynes3,  
C. Williams4, S. Zolla-Pazner4, C. Moscoso5, H. Cheng5,  
M. Hoelscher6, L. Maboko6, N. Michael1, M.L. Robb1,  
T. VanCott2, M. Marovich7, and V. Polonis1
1U.S. MHRP, Silver Spring, MD, USA; 2Advanced Bioscience 
Laboratories, Inc., Rockville, MD, USA;  3Duke University, 
Durham, NC, USA; 4Veteran’s Affairs New York Harbor 
Healthcare System and New York University School of 
Medicine, New York, NY, USA; 5University of California-
Davis, Davis, CA, USA; 6Mbeya Medical Research Project and 
University of Munich, Munich, Germany; 7U.S. MHRP, Silver 
Spring, and DAIDS, NIH, Bethesda, MD, USA
Background: Broadly reactive neutralizing antibodies (NAbs) that target 
the quaternary structure of the V1/V2, V3 and CD4 binding domains 
of the HIV-1 Env trimer highlight the importance of representing the 
functional Env spike in immunogen design. Considering the novel 
properties and global representation of subtype C, a trimeric C Env 
(CO6980v0c22) derived from an acute Tanzanian HIV-1 isolate was 
developed as a candidate vaccine.
Methods: The CO6980v0c22 gp145 Env was expressed in a stable 
CHO cell line. Purified oligomers were fractionated into dimers, trimers 
and higher order multimers using size exclusion chromatography. The 
trimeric structure of gp145 was evaluated by cryo-electon microscopy. 
Antigenicity was determined by BiaCore and Octet Biosensor analysis. 
Rabbits were vaccinated with individual protein fractions; the rabbit 
sera were assessed for binding antibodies by ELISA, and for NAbs 
using PBMC-based and TZM-bl pseudovirus assays.
Results: Expressed gp145 was found to contain 60% physical trimers. 
Larger multimeric, trimeric and dimeric fractions were purified to 95%, 
92% and 94% homogeneity, respectively. The gp145 trimer bound 
NAbs that target the MPER (4E10), CD4bs (VRC01, b6, b12), V2/V3 
epitopes (PG9, PG16) and the V3 crown (447-52D), as well as the cell-
expressed alpha4beta7 receptor. After three immunizations, rabbits 
developed strong binding antibody titers (up to 10 ^ 6) to several Env 
antigens, including the V1V2gp70 MuLV scaffold protein used in RV 
144 correlates discovery.  Neutralization was observed against Tier 1 
subtype B and C pseudoviruses, and against Tier 1 and Tier 2 IMC from 
three different clades.  No differences in antigenicity or immunogenicity 
were observed between the various oligomeric protein fractions.
Conclusion: These data demonstrate the antigenic and immunogenic 
features of a novel acute subtype C HIV-1 Env that warrants further 
testing for clinical development. GMP production of the gp145 trimer 
is ongoing.
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P01.19 LB
A Trimeric HIV-1 gp140-BAFF Fusion Construct 
Enhances Mucosal Anti-trimeric HIV-1 gp140 
IgA in Mice
J. Liu1, K. Clayton1, Y. Li1, M. Haaland1, J. Schwartz1, H. Sivanesan1, 
A. Saiyed1, A. Bozorgzad1, W. Zhan1, F. Yue1, J. Rini1, M. Ostrowski1
1University of Toronto, Toronto, Canada
Background: Although trimeric HIV-1 gp140 can mimic native HIV-
1 envelope (Env) spikes on viral surface, derived vaccines still can 
not induce potent broadly neutralizing antibodies (bNAbs). HIV-1-Env 
specific IgA at mucosa may block HIV-1 transmission through mucosal 
surface. The tumor necrosis factor superfamily members, APRIL, BAFF, 
and CD40L, were previously shown to promote antibody responses, 
including mucosal IgA. We tested whether APRIL, BAFF or CD40L 
conjugated HIV-1 gp140 constructs could enhance anti-HIV-1-Env 
mucosal IgA responses.
Methods: FLAG-tagged codon-optimized HIV-1 YU2 gp140 sequence 
was linked to an exogenous trimerization domain, foldon, which was 
then fused with mouse APRIL, BAFF, and CD40L sequence. FLAG-
tagged codon-optimized HIV-1 YU2 gp140 with or without foldon 
were constructed as controls. Following expression in HEK-293T 
cells, the constructs were assessed for proper expression, gp140 
folding, and trimerization, via protein gel electrophoresis/western 
blotting, immunoprecipitation, and Native-PAGE, respectively. Protein 
production was scaled up in bioreactors and proteins were isolated 
using FLAG-tag affinity purification. . Balb/c mice were randomly 
divided into 6 groups (4 mice per group): 1. Gp140; 2. Gp140-foldon; 
3. GP140-APRIL; 4. Gp140-BAFF; 5. Gp140-CD40L; 6. Naïve. Mice 
were primed intramuscularly 3 times with DNA plasmids and boosted 
intraperitonealy 2 times with the proteins (Phosphate-buffered saline 
instead of DNA/protein was injected into naïve group mice). Vaginal 
lavage and fecal pellet were collected before and then every 2 weeks 
after vaccinations. Samples from the same group were pooled together 
and anti-HIV-1 trimeric gp140 IgA in the pooled samples were detected 
by kinetic ELISA, using trimeric HIV-1 YU2 gp140 as coating antigen.
Results: The fusion constructs formed stable trimers consistent with 
proper folding of HIV-1 Env. Presently, we tested samples from 4 
weeks after the last boost. Gp140-BAFF enhanced anti-HIV-1 trimeric 
gp140 IgA in fecal pellet and vaginal lavage, which was 4.8 and 10 
fold, respectively, of that induced by gp140-foldon control. Gp140-
APRIL and gp140-CD40L did not show enhancement. Further work is 
in progress to analyze the induced antibodies.
Conclusion: The trimeric HIV-1 gp140-BAFF fusion construct enhanced 
mucosal anti-HIV-1 trimeric gp140 IgA and deserves to be studied 
further as a possible HIV-1 vaccine candidate.
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P02.02
Replicating VSV-SIV Chimeric Viral Vector 
Immunogenicity in Indian Rhesus Macaques
G. Morrow1, C. Jurgens1, A. Domi1, J. Coleman1, P. Sharma1,  
R. Powell1, I. Ouellette1, J. DeStefano1, J. Martinez1, H. Arendt1,  
B. Rasmussen1, C.R. King1, and C. Parks1
1IAVI, New York, NY, USA
Background: Live attenuated vaccines have been developed to prevent 
viral diseases including smallpox and measles; however, for HIV this is 
not practical. Therefore, we developed replication-competent vesicular 
stomatitis virus (VSV) vectors in which VSV glycoprotein (G) was 
replaced with SIVenv and SIVgag producing chimeric viruses (VSV-SIV). 
Methods: Chimeric vaccines were tested in two NHP studies to compare 
systemic and mucosal immunization routes. NHPs were primed with 
VSV-SIV and boosted with Adenovirus-5 containing SIVgag and SIVenv 
(Ad5-SIV). In the first study, VSV-SIV was administered intramuscularly 
(IM) and in the second, VSV-SIV was delivered by combined intranasal 
(IN) and oral (OR) inoculation. Additionally, to improve mucosal 
uptake, some animals in the second study were vaccinated with VSV 
G-pseudotyped chimeric virus.
Results: In the 1st study, NHPs were primed 3 times, IM 8 weeks apart 
with 10 4, 10 6 or 10 8 pfu of VSV-SIV followed by an Ad5-SIV boost. 
Humoral immune responses were dose dependent with the highest 
dose inducing SIVenv antibodies after each prime.  Following the Ad5 
boost, antibody titers increased 3-5 logs and pseudovirus-neutralizing 
activity was detected in the 10 6 and 10 8 groups.  In the 2nd study, 10 
8 pfu VSV-SIV was administered mucosally (IN/OR) and in one group, 
VSV-SIV was pseudotyped with VSV-G. Mucosal immunization induced 
humoral responses of similar magnitude to IM while G-pseudotyped 
virus enhanced Env-specific antibody by 4-logs and pseudovirus 
neturalization 1-2 fold. Gag antibody titers were low after VSV-SIV but 
priming was evident with a 5-log increase in titers following boost. 
T cell responses were low but detectable and increased significantly 
following Ad5-SIV boost indicative of priming by the VSV. NHPs in the 
2nd study are being 
Conclusion: VSV-SIV chimeras are safe and immunogenic at 10 8 pfu 
when administered to macaques systemically and mucosally. VSV-
SIV immunization induced pseudovirus neutralizing antibodies and 
immunogenicity is improved by G-pseudotyping broadening the VSV 
cell tropism.  
P02.01 
Isolation of mAbs from Sorted Single B Cells 
by RT/PCR for Analysis of B Cell Responses 
to HIV-1 MPER Epitope in Vaccinated Rhesus 
Macaques
R. Zhang1, M. Moody1, M. Alam1, J. Yu1, S. Santra2, G. Kelsoe1,  
S. Sekaran1, R. Bhaskarabhatla3, M. Wang1, T. Gurley1, A. Allen1, 
L. Armand1, D. Marshall1, J. Whitesides1, L. Sutherland1,  
R. Scearce1, A. Foulger1, M. Cooper1, J. Pritchett1, A. Hogan1,  
R. De1, C. Stolarchuk1, E. Solomom1, E. Friberg1, Y. Yang1, F. Gao1, 
J. Schmitz2, T. Kepler3, B. Haynes1, and H. Liao1
1Duke University, Durham, NC, USA; 2Beth Israel Deaconess 
Medical Center, Boston, MA, USA; 3Boston University, 
Boston, MA, USA
Background: Rhesus macaques are important models for evaluation 
of HIV-1 vaccines. Analysis of immunoglobulin (Ig) VH and VL genes 
derived from single B cells is a powerful technology for definition of 
Ig repertoires to viral infections and vaccination. We have produced a 
large panel of recombinant mAbs from immunized rhesus macaques 
to ask if a HIV-1 gp41 immunogen could induce an antibody lineage 
with binding characteristics of a broadly neutralizing antibody (BnAb).
Methods: Primers were designed for amplification of rhesus Ig VH 
and VL gene segments from sorted single memory B cells by RT/
PCR. The isolated VH and VL gene segments were analyzed using a 
newly assembled and annotated database of rhesus germline gene 
segments, and used to produce mAbs using linear antibody gene 
expression constructs generated by PCR without cloning. PBMC from 
rhesus macaques that were immunized with HIV-1 JRFL Env followed 
by boosts with MPER 2F5 epitope peptide in liposomes were used for 
sorting HIV-1 antigen-specific single memory B cells.
Results: A total of 195 unique VH and VL gene pairs were isolated 
from sorted single memory B cells and expressed as IgG1, of which, 
106 mAbs reacted with HIV-1 Env antigens. We found 34.4% of these 
antibodies belonged to 23 clonal lineages. Antibodies in the CH167 
clonal lineage (5 members) have VH mutation frequencies ranging 
from 1.4%-4.2% and bound to HIV-1 gp41, MPER epitope with a 
footprint involving the 2F5-nominal epitope, DKW. MAbs bound to 
MPER peptide-liposomes in a 2F5-like 2-step binding mechanism.
Conclusion: A streamlined strategy for amplification and expression of 
rhesus Ig VH and VL genes has been developed for study of the rhesus 
macaque antibody repertoire in response to immunization with HIV-1 
vaccines. Our study showed that immunization with HIV-1 JRFL Env 
and MPER peptide-liposomes induced an antibody clonal lineage with 
characteristics of precursors of an MPER BnAb.
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P02.04
CDV Vectors as Vaccine Candidates
A. Domi1, G. Morrow1, J. Zhang1, O. Wallace1, J. Coleman1,  
P. Sharma1, R. Powell1, I. Ouellette1, B. Rasmussen1, C.R. King1, 
and C. Parks1
1IAVI, New York, NY, USA
Background: The development of a live attenuated HIV vaccine 
is not considered to be an option at this time. Our approach is to 
use unrelated live viruses as vectors to deliver an AIDS vaccine by 
developing a replication-competent, recombinant canine distemper 
virus vectors expressing HIV genes. As a proof of concept we developed 
two rCDV vectors containing simian immunodeficiency virus (SIV) 
genes encoding Gag and Env proteins (CDV-SIV).
Methods: Non-human primates were immunized intranasally (IN) at 
weeks 0 and 6. Two animals received CDV-SIV vectors at 10 7 pfu and 
a control animal received empty CDV vector.  All animals received an 
Ad5-SIVGag and Ad5-SIVEnv boost and were subsequently challenged 
with SIVmac239 by intrarectal route.
Results: CDV/SIV genome copies could be detected in intestinal tissue, 
cells from bronchalveolar lavage and in the oral cavity (4 weeks post 2nd 
immunization). Low level Env specific T cell responses were detected 
after each CDV immunization. Env antibodies were detected following 
the 1st CDV immunization and were further boosted following 2nd 
CDV immunization. After Ad5-SIV boost, a robust increase in Env and 
Gag specific T cell responses was seen in both BAL and PBMCs. Env 
antibody titers increased and Gag antibodies were detected following 
Ad5-SIV. All animals were intrarectally challenged with increasing 
doses of pathogenic SIVmac239. One immunized monkey became 
infected after one challenge. The remaining animals, resistant to two 
subsequent IR challenges, were ultimately infected intravenously. One 
CDV-SIV immunized NHP showed a peak viral load 3 logs lower than 
the control and although being infected both the immunized NHPs 
have maintained low viral loads for several months compared to the 
control animal.
Conclusion: rCDV vectors were shown to be safe and induce immune 
responses in a prime/boost regimen resulting in sustained control of 
SIV replication to low levels. A repeat study is currently underway to 
investigate these results further.
P02.03 
Immunogenicity of HIV Virus-Like Particles 
in Rhesus Macaques by Intra-Nasal 
Administration
L. Buonaguro1, M. Tagliamonte1, M. Visciano1, H. Andersen2,  
M. Lewis2, R. Pal3, M. Tornesello1, U. Schroeder4, J. Hinkula5,  
B. Wahren6, and F.M. Buonaguro1
1Istituto Nazionale Tumori “Fond. Pascale” - Napoli, Italy, 
Naples, Italy; 2Bioqual Inc., Rockville, MD, USA; 3Advanced 
Bioscience Laboratories, Inc., Kensington, MD, USA; 4Eurocine 
Vaccines AB, Karolinska Institutet Science Park, Stockholm, 
Sweden; 5Linköping University, Linköping, Sweden; 
6Karolinska Institutet, Stockholm, Sweden
Background: The development of vaccination strategies able to 
elicit protective systemic and mucosal immune response represent a 
major goal in the HIV vaccine field. To this aim we have evaluated 
the immunogenicity of HIV-VLPs in Rhesus Macaques by a sequential 
combination of mucosal (intra-nasal, i.n.) and systemic (intra-muscular, 
i.m.) routes, according to homologous (VLP + VLP) or heterologous 
(DNA + VLP) prime-boost schedules.
Methods: 24 female Rhesus Macaques were equally divided in four 
experimental arms. Groups 1 and 2 were immunized by the i.n. route, 
using the homologous prime-boost protocol in the absence (Group 1) 
or in the presence (Group 2) of the Eurocine L3 nasal lipid adjuvant. 
Group 3 was immunized using the heterologous prime-boost protocol 
in the presence of Eurocine L3 and N3 adjuvants. Additionally, group 
2 received two further boosting doses of VLPs by the i.m. route, 22 
weeks after the last i.n. administration. Group 4 was the control group.
Results: The data show that i.n. administration of HIV-VLPs, in either 
homologous or heterologous prime-boost protocol, does not elicit 
measurable serum Ab titers. Moreover, it does not efficiently prime 
the systemic immune system, since two subsequent i.m. injections 
were needed to elicit serum Ab titers. Similarly, i.n. administration of 
HIV-VLPs, in both prime-boost protocols, does not elicit measurable 
mucosal Ab titers. However, it seems to prime the mucosal immune 
system which, six months after the last i.n. boost , is able to respond 
after the two i.m. immunizations.
Conclusion: HIV-VLPs are immunogenic in NHPs by homologous 
and heterologous prime-boost schedules. The i.n. administration 
was not fully effective but primed the mucosal immune response for 
subsequent boosting dose by i.m. route. Results are encouraging for 
elicitation of immune response at mucosal port of entry but further 
investigation is required.
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P02.06
Testing Efficacy of DNA/IL-12 Delivered by 
Electroporation with Vector Boost in the 
SIVmac239 System
G. Morrow1, A. Wilson1, R. Powell1, I. Ouellette1, J. Coleman1,  
P. Sharma1, R. Lindsay1, C. Boggiano1, B. Rasmussen1,  
D. Barouch2, C. Parks1, and C.R. King1
1IAVI, New York, NY, USA; 2Beth Israel Deaconess Medical 
Center, Boston, MA, USA
Background: We have previously demonstrated that vaccination with 
SIV ORFs encoding the full SIV genome (9 gene) with plasmid IL-12 
(pIL-12) delivered via electroporation (EP) followed by a Adenovirus-5 
SIV ORFs (Ad5-SIV) boost, can protect non-human primates (NHPs) 
from infection or reduce viral load of NHPs that do become infected. 
We undertook the study below to further investigate the utility of EP 
DNA/IL-12 and Adenovirus prime/boost regimen.
Methods: Five groups of NHPS: 1) SIV-DNA plus Ad5-SIV 9 gene,  2) 
SIV-DNA plus Ad5-SIV 4 gene (Gag, Pol, Env, Nef) 3) SIV-DNA plus 
Ad35-SIV 4 gene,  4) SIV-DNA alone 9 gene and 5) Controls were 
immunized 3 times by EP 8 weeks apart with pIL-12 followed by Ad5-
SIV or Ad35-SIV boost. 
Results: SIV-DNA prime induced low level T cell responses in all SIV-
DNA groups predominantly against Gag, Env and Nef proteins. Gag, 
Env, Pol and Nef antibody titers and SIV pseudovirus neutralizing 
antibodies were of similar magnitude for 9 and 4 gene groups. 
Following Adenovirus-SIV boost there was significant increase in T cell 
responses. While all groups demonstrated similar quality of response 
for CD4 and CD8’s, producing IFNg, TNFa and IL-2, the frequency of 
these responses varied, with both 4 gene groups demonstrating higher 
frequencies of multifunctional CD4 T cells compared to other groups. 
Mucosal surfaces and serum demonstrated increased levels of SIV 
specific mucosal IgG and IgA and serum antibodies in both Ad5-SIV 
and the Ad35-SIV group compared to DNA alone and control groups. 
We also observed significant increases in neutralizing antibody titers in 
both 4 and 9 gene groups to Tier 1A and 2 pseudoviruses.
Conclusion: Results demonstrate induction of effective cellular and 
humoral immune responses can be maintained when the number 
of SIV vaccine immunogens delivered is reduced and alternative 
adenoviruses are capable of inducing immune responses of the same 
or greater magnitude as Ad5.
P02.05
Optimization of HIV-1 Envelope DNA Vaccine 
Candidates Within Three Different Animal 
Models, Guinea Pigs, Rabbits and Cynomolgus 
Macaques
M. Borggren1, L. Vinner1, B.S. Andresen1, B. Grevstad1, J. Repits1, 
M. Melchers2, T.L. Elvang1, R.W. Sanders2, N. Dereuddre-
Bosquet3, G. Stewart-Jones4, E. Bowles4, P. Biswas5, G. Scarlatti5, 
M. Jansson6, L. Heyndrickx7, R. Le Grand3, and A. Fomsgaard1
1Statens Serum Institute, Copenhagen, Denmark; 2Academic 
Medical Center of the University of Amsterdam, Amsterdam, 
Netherlands; 3CEA, Fontenay-aux-Roses, France; 4University 
of Oxford, John Radcliffe Hospital, Oxford, UK; 5San Raffaele 
Scientific Institute, Milan, Italy; 6Lund University, Sweden; 
7Institute of Tropical Medicine, Antwerp, Belgium
Background: HIV-1 DNA vaccines have many desired features. 
Evaluation of HIV-1 vaccine candidates often starts in small animal 
models before macaques and human trials. Here we selected 
and optimized DNA vaccine candidates by systematic testing in 
rabbits for induction of broadly neutralizing antibodies (bNAb) and 
compared three different animal models guinea pigs, rabbits and 
cynomolgus macaques. 
Methods: Env from the prototype Bx08 and two elite neutralizers 
were selected. Codon-optimized genes encoded secreted gp140 or 
membrane bound gp150, or were modified for stabilized soluble 
trimer products (SOSIP-R6-IZ mutations), and delivered individually or 
mixed. Specific IgG after repeated i.d. inoculations with electroporation 
confirmed in vivo expression and immunogenicity. 
Results: Evaluation in rabbits and guinea pigs displayed similar results. 
The optimal DNA construct in rabbits was a trivalent mix of non-
modified codon-optimized gp140 envs (SSImix). Despite potent and 
broad NAb responses in guinea pigs and rabbits, the DNA vaccinated 
macaques displayed less bNAb activity. 
Conclusion: It is concluded that a trivalent mix of non-modified gp140 
genes from rationally selected clinical isolates is optimal to induce 
high and broad NAb in the rabbit model, but this optimization does 
not directly translate into cynomolgus macaques. This suggests species-
specific differences in the quality of immune response to HIV-1 env DNA. 
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P02.08
Development of an Early Stage Investigator 
Scholar Program for Preclinical Researchers
B. Adamson1, J. Fuchs2, P. Johnson3, B. Haynes4, C. Sopher1,  
D. Flood1, J. Kublin1, and the NIAID HIV Vaccine Trials Network1
1HIV Vaccine Trials Network, Seattle, WA, USA; 2San Francisco 
Department of Public Health, San Francisco, CA, USA; 
3Harvard Medical School, Boston, MA, USA; 4Duke University 
Medical Center, Durham, NC, USA
Background: Key themes from the March 2008 NIAID Vaccine 
Summit were 1) to strengthen linkages between preclinical and 
clinical researchers to collaboratively tackle key areas of scientific 
inquiry, and 2) to attract and retain new, talented investigators to the 
HIV vaccine field.
Methods: The HIV Vaccine Trials Network (HVTN) and the Center for 
HIV/AIDS Vaccine Immunology (CHAVI), with funding from NIAID, 
created a novel mentored research program for early stage investigators 
(ESIs) doing HIV vaccine research in non-human primate (NHP) models. 
From 2008–2012, HVTN and CHAVI recruited, reviewed, and selected 
14 scholars during 3 application cycles; scholars proposed 1-2 year 
projects under guidance from senior preclinical and clinician scientists. 
HVTN provided training workshops on host genetics, challenge models, 
starting a lab, seeking funding, and other professional development 
topics.  Post-program surveys were collected from 11 of 14 scholars 
and 15 of 24 mentors; key milestones (e.g., publications, positions, 
grants) were tracked for all scholars.
Results: Scholars presented their final results at 10 HVTN and CHAVI 
conferences. Training programs were well received (mean score 4.6 on 
scale 1-5 with 5 as high score). Combined, the 14 HVTN/CHAVI NHP 
ESI Scholars published 69 peer-reviewed manuscripts and presented 
55 abstracts based on their awarded project results.  Together they 
have received 11 promotions or appointments and 29 grants summing 
more than $28.4 million for future HIV research. Nine of 11 surveyed 
scholars intend to stay in the field of HIV vaccine research.  All mentors 
reported a plan to continue mentoring their scholar beyond the 
program period.
Conclusion: A novel mentored research program that aims to 
strengthen the linkage between preclinical and clinical HIV vaccine 
researchers produced important scientific advances and bolstered the 
careers of young investigators.  Future investment in targeted mentored 
research programs to advance HIV vaccine science is warranted.
P02.07
Adaptation of HIV-1 Envelope to Macaque 
CD4 Affects Antibody Recognition of the V1V2 
Region
D.F. Boyd1 and J. Overbaugh1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Background: Species-specific differences between the human and 
macaque CD4 receptor restrict the ability of HIV-1 envelope variants 
to infect macaque cells. Two independent mutations, in the C2 region 
(A204E) and V3 loop (G312V) of gp120, confer efficient use of the 
macaque CD4 receptor to diverse HIV-1 envelope variants.  Changes 
in the HIV envelope required for infection of macaque cells are 
particularly relevant to understanding the biological and antigenic 
properties of pathogenic SHIVs, which have been selected to replicate 
and persist in macaques. 
Methods: To assess the effect of these changes on the antigenic 
properties, neutralization sensitivity to broadly neutralizing monoclonal 
antibodies (Mabs) was determined for 5 HIV-1 envelopes incorporating 
the A204E and G312V mutations and for a HIV-1 envelope from the 
pathogenic SHIV AD8. The Mabs tested recognize the CD4 binding 
site (VRC01), the V1V2 region (PG9/16) and the V3 loop (PGT 
121/128/145). IC50 values were determined for each envelope variant/
Mab combination using the TZM-bl assay.
Results: Introduction of A204E and G312V had only a modest (<10-
fold) effect on the neutralization sensitivity to the CD4 binding site 
antibody VRC01 and V3-specific Mabs (PGT 121/128/145), except for 
one wild type and mutant pair where there was an increase in IC50 
for all three V3-specifc Mabs. In contrast, for approximately half of 
the envelope pairs, particularly those encoding A204E, there was a 
dramatic effect (>100-fold increase) in the IC50 value for antibodies 
recognizing the V1V2 region (PG9/16). Interestingly, HIV-1 envelope 
from SHIV AD8 exhibited a similar pattern of resistance to V1V2 
antibodies without change in sensitivity to VRC01 and PGT Mabs when 
compared to the parental envelope.
Conclusion: These data suggest that adaptation of HIV-1 envelopes to 
macaque CD4 results in structural changes that affect recognition at 
epitopes distal to the CD4 binding site.
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P02.10 
Ancestral vs. Consensus vs. Polyvalent: 
Envelope Effects on Vaccine Efficacy in an 
Equine Lentiviral Attenuated Vaccine Model
J.K. Craigo1, C. Ezzelarab1, S.J. Cook2, C. Liu2, D. Horohov2,  
C.J. Issel2, and R.C. Montelaro1
1University of Pittsburgh School of Medicine, Pittsburgh, PA, 
USA; 2University of Kentucky, Lexington, KY, USA
Background: Env is a determinant of lentiviral vaccine efficacy.  We 
previously demonstrated a significant, inverse, linear relationship 
between EIAV Env divergence and protection from disease, utilizing 
our EIAVD9   attenuated vaccine and variant challenge strains, EV0, EV6, 
and EV13  (homologous, 6%, and 13% Env divergence, respectively). 
We further explore the relationship between Env evolution, diversity, 
and vaccine efficacy by directly comparing three approaches to Env 
immunogen development in our attenuated vaccine model.
Methods: Ancestral, consensus, and polyvalent vaccines were 
evaluated in the EIAV D9   backbone substituted with defined, controlled 
Envs based on natural isolates from which EV0, EV6, and EV13 are 
derived.  A consensus Env was engineered utilizing approximately 
90 isolates detected throughout all stages of disease. To create the 
consensus Env, amino acid and nucleotide sequences were aligned, 
hand-edited, synthesized, and cloned into the EIAVD9   backbone 
(ConD9). To create a polyvalent EIAV D9   (TriD9), we cloned the EV6 
and EV13 Envs into the EIAVD9   backbone, and administered in a 
1:1:1 mixture with EIAVD9.  Three groups of ponies were vaccinated 
via two inoculations, at one-month intervals, of 3X103 TCID50   of 
ancestral/Env-D9 (D9), ConD9, or TriD9.  We designed a structured 
quasispecies challenge that consisted of three strains, EV0, EV6 and 
EV13.  Six months post-second vaccination, animals were challenged 
with a rigorous three-dose regimen of 103 TCID50   (every-other-day).
Results: Attenuated strains replicated at normal levels without EIAV-
associated illness. Each group experienced different levels of disease 
upon challenge.  TriD9 vaccinates demonstrated the highest levels of 
protection (P<0.0001) while the ConD9 the lowest level of protection 
(P=0.0002).  Further analysis demonstrated a significant trend for the 
complexity of immunogen and protective efficacy (Logrank test for 
trend, P=0.02).
Conclusion: Results directly compare for the first time an 
ancestral, consensus, and polyvalent Env, utilizing an attenuated 
vaccine (which to-date has demonstrated the highest levels of 
vaccine immunogenicity) and validate an Env protection scheme: 
polyvalent>ancestral>consensus.
P02.09 
Altered Immunodominance Hierarchy and 
Increased T Cell Breadth upon HIV-1 Conserved 
Element DNA Vaccination in Macaques
B.K. Felber1, V. Kulkarni1, A. Valentin1, M. Rosati1, C. Alicea1,  
N.Y. Sardesai2, S. Le Gall3, B. Mothe4, C. Brander4, M. Rolland5, 
J.I. Mullins5, and G.N. Pavlakis1
1National Cancer Institute, NIH, Frederick, MD, USA; 2Inovio 
Pharmaceuticals, Inc., Blue Bell, PA, USA; 3Ragon Institute 
of MGH, MIT and Harvard, Cambridge, MA, USA; 4IrsiCaixa 
Institute for AIDS Research, HIVACAT, Autonomous University 
of Barcelona, Barcelona, Spain; 5University of Washington, 
Seattle, WA, USA
Background: We tested the hypothesis that a vaccine candidate 
composed of highly Conserved Elements (CE) of the HIV proteome 
excluding the variable regions would help overcome problems of viral 
sequence diversity and potential negative effects of immunodominance, 
two hurdles in the development of an effective AIDS vaccine. CE were 
selected based on both stringent conservation and association of 
specific elements with immune control. A prototype HIV DNA vaccine 
expresses 7 CE identified in p24 gag as a single protein and was able 
to induce robust cross-clade specific immune responses in mice.
Methods: Macaques were immunized by IM injection followed by 
electroporation with two DNA plasmids providing potential epitopes 
found in >99% of all HIV-1 M group sequences. Cellular immune 
responses were compared to those obtained upon vaccination with 
gag DNA only.
Results: CE DNA vaccination induced robust immunity in all 10 
vaccinated macaques, whereas full-length gag DNA vaccination 
elicited CE responses in only 5 of 11 animals targeting fewer CE per 
animal. CE DNA vaccination elicited highly cytotoxic T cells against CE, 
capable of Granzyme B production and degranulation, desired features 
for an effective vaccine. Importantly, boosting CE-primed macaques 
with DNA expressing full-length p55 gag increased both magnitude 
of CE responses and breadth of Gag immunity, demonstrating altered 
immunodominance hierarchy in the presence of pre-existing CE-
specific responses.  
Conclusion: Combination of conserved elements and full-length 
immunogen provides a novel strategy to increase the magnitude and 
breadth of immune responses to Gag, and allows for the development 
and expansion of subdominant responses. This vaccine allows the 
immune system to target the ‘Achilles heel’ of the virus, for which few 
escape pathways exist. Inclusion of a conserved element immunogen 
provides a novel and effective strategy to broaden responses against 
any highly diverse pathogen by avoiding decoy epitopes, while 
focusing responses to critical and invariable viral elements.
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P02.12 
Protection from SIVmac251 Acquisition by an 
ALVAC/SIV/gp120 Regimen Is Not Improved by 
the Increase of Anti-Envelope Antibodies and T 
Cell Responses
M. Vaccari1, S.N. Gordon1, M. Doster1, N. Liynage1, P. Pegu1,  
L. Schifanella1, B.F. Keele2, X. Shen3, G.D. Tomaras3, M. Rao4, 
D.C. Montefiori5, G. Ferrari5, K. Foulds6, M. Roederer6,  
D. Venzon1, D.M. Stablein7, J.H. Kim4, N.L. Michael4, S. Phogat9, 
S.W. Barnett9, J. Tartaglia8, and G. Franchini1
1National Cancer Institute, NIH, Bethesda, MD, USA; 2SAIC-
Frederick, Inc., National Cancer Institute, NIH, Frederick, MD, 
USA; 3Duke Human Vaccine Institute, Durham, NC, USA; 4U.S. 
MHRP, Silver Spring, MD, USA; 5Duke University Medical 
Center, Durham, NC, USA; 6Vaccine Research Center, NIAID, 
NIH, Bethesda, MD, USA; 7The EMMES Corporation, Rockville, 
MD, USA; 8Sanofi Pasteur, Swiftwater, PA, USA; 9Novartis 
Vaccines and Diagnostics, Cambridge, MA, USA
Background: A prime-boost regimen of recombinant canarypox 
priming (ALVAC-HIV) with HIV (Clade B and E) -gp120 proteins boosting 
formulated in Alum has resulted in significant but limited protection 
from HIV acquisition in the Thai Trial (RV144). We hypothesized that 
the use of the Th1/Th2- adjuvant MF59 as an alternative to the Th2- 
Alum, could improve the protection elicited by the ALVAC-SIV/gp120 
vaccine platform, by increasing antibody response to the envelope as 
well as T cell responses.
Methods: We vaccinated 54 macaques four times (0,4, 12 and 24 
weeks) with the identical ALVAC backbone used in RV144, expressing 
SIV mac251 Gag-pro and gp120TM (instead of the HIV-1 Envs used in 
RV144), and then we boosted 27 macaques twice (12 and 24 weeks) 
with both SIVmac251- and SIVsmE660- gp120 proteins formulated 
either with Alum or with MF59. A total of 24 adjuvanted or naïve 
animals were included as concurrent controls and additional 23 as 
historical controls. All the animals were exposed to 120 TCID50 of 
SIVmac251, by the intra-rectal route, once a week, at 4 weeks after the 
last immunization.
Results: ALVAC-SIV gp120/Alum (RV144-like) resulted in significant 
protection from SIVmac251 acquisition (log rank p=0.021). MF59 
significantly increased binding antibody titer, ADCC, neutralizing 
antibodies, and CD4+ T cell producing cytokines to the SIV-envelope. 
Surprisingly, however, MF59 did not improve the efficacy of the 
ALVAC/gp120 regimen (log rank p=0.56). In addition, ALVAC-SIV 
gp120/MF59 had significantly higher number of transmitted founder 
variants compared to ALVAC-SIV gp120/Alum regimen.
Conclusion: In conclusion, the combination of ALVAC-SIV vaccine 
and gp120/MF59 was more immunogenic than that of gp120/Alum; 
however it did not increase protection against SIVmac251 acquisition.
P02.11 
Analysis of Early Antibody Response in 
Macaques Infected with SHIV-1157 Virus, with 
Introduced V1/V2-Dependent Quaternary 
Neutralizing Epitopes 
C. Krachmarov1, K. Revesz1, U. Ganapathi1, L. Peng1, Z. Lai1,  
R. Prattipati1, L. McMahon1, W. Honnen1, J.F. Theis1, P.S. Firpo2, 
Y. Li2, S. Hu2, and A. Pinter1
1PHRI Center/UMDNJ, Newark, NJ, USA; 2University of 
Washington, Seattle, WA, USA
Background: A number of highly potent neutralizing antibodies 
directed against quaternary epitopes (QNEs) in HIV envelope 
proteins have been recently described. To analyze the development 
of antibodies and antibody-dependent neutralization responses after 
infection in macaques we generated a mutant clade C-derived virus, 
SHIV1157ipd3N4 (Q170K/I192R) that expressed a high affinity QNE. 
Here we describe the Env-specific binding and neutralizing antibody 
activities induced in the early stages of viral infection. 
Methods: Sera samples from macaques during the first 24 weeks 
after infection were screened by ELISA for antibody binding to 
various rgp120, rgp140, V1/V2, V3 and CD4bs protein constructs. 
Neutralization activity was determined in pseudovirus luciferase assay. 
Anti-gp120 and V1/V2-specific antibodies were isolated from infected 
sera by immunoaffinity chromatography on gp120 and gp70-V1/V2 
columns and further characterized for binding and neutralizing activity 
against SHIV and HIV-1 pseudoviruses.
Results: High-titered, anti-gp120/gp140-binding antibody response 
developed shortly (~2-4 weeks) post-infection. Most animals 
developed anti-V1/V2 antibody responses by week 8 and many 
possessed specific anti-V3 antibodies. A robust autologous neutralizing 
activity appeared in several animals during weeks 12-16, which 
plateaued over the following few months. High-titered cross-reactive 
neutralizing antibodies were also present against several Tier 1 viruses. 
Immunoaffinity depletion of infected sera indicated that much of the 
neutralizing activity was directed against targets in the V1/V2 region.
Conclusion: The immune response in early stages of HIV infection 
is of particular interest for vaccine development. The generation of 
a pathogenic SHIV expressing high affinity forms of QNEs provides 
a model system for examining the development of antibody 
response against these epitopes. This virus retains the Tier 2 
phenotype, so the induction of autologous neutralizing activity is of 
particular interest. These animals are being followed to see whether 
the specificity of this response broadens with time, and whether 
this system will provide insight into the development of broadly 
neutralizing antibody specificities.
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P02.14
Delayed Onset of Graft Versus Host Disease in 
Immunodeficent HLA-DQ8 Transgenic Immune 
Deficient Mice Repopulated by Human PBMCs
S.M. Büchner1, K. Sliva1, J. Kirberg1, and B.S. Schnierle1
1Paul-Ehrlich-Institut, Langen, Germany
Background: Hematopoietic humanization of mice is frequently used 
to study the human immune system and its reaction upon experimental 
intervention. Immune compromised NOD-Rag1-/- mice, additionally 
deficient for the common gamma chain of cytokine receptors (yc) 
(NOD-Rag1-/- yc-/- mice), lack B, T and NK cells and allow for efficient 
human peripheral mononuclear cell (PBMC) engraftment. Yet, a major 
experimental drawback for studies using these mice is the rapid onset 
of graft versus host disease (GvHD). 
Methods: In order to elucidate the contribution of the xenogenic 
murine MHC class II in this context, we generated immune deficient 
mice expressing human MHC class II (HLA-DQ8) on a mouse class 
II deficient background (Aß-/-). We studied repopulation and onset of 
GvHD in this mouse strain following transplantation of DQ8 haplotype 
matched human PBMCs. 
Results: Surprisingly, the presence of HLA class II significantly 
promotes the repopulation rates in these mice and virtually all of the 
engrafted cells were CD3+ T cells. Also, the presence of HLA class II did 
not advance B cell engraftment, such that humoral immune responses 
were undetectable. However, the overall survival of DQ8-expressing 
mice was significantly prolonged, compared to mice expressing mouse 
MHC class II molecules, and correlated with an increased time span 
until onset of GvHD. 
Conclusion: Our data thus demonstrate that this new mouse strain 
is useful to study GvHD and the prolonged animal survival makes it 
superior for experimental intervention following PBMC engraftment.
P02.13
Latent SIV Turns Over Surprisingly Quickly Off 
Therapy: Implications for HIV Cure Studies
J.C. Reece1, J. Petravic2, R. De Rose1, A. Grimm2, A. Martyushev2, 
M. Davenport2, and S. Kent1
1University of Melbourne, Melbourne, Australia; 2University of 
New South Wales, Sydney, Australia
Background: Understanding latent HIV is essential to cure the 
infection. However, the dynamics of the turnover of latent HIV in 
subjects not on combination anti-retroviral therapy (cART) is poorly 
understood, as latent HIV is often defined in the presence of cART.
Methods: We further advanced a pigtail macaque model of SIV 
infection to quantify immune escape and compensatory mutations 
in serial samples of plasma SIV RNA and FACS-sorted resting CD4 T 
cell SIV DNA. We studied 3 CTL epitopes (KP9, KVA10, KSA10) and 
a mutation that compensates for KP9 escape (V145A). All epitopes 
examined escape with unique patterns and time-frames in 20 
macaques, using real-time PCR (for KP9) and Roche 454 sequencing.
Results: In the setting of high viral loads (>10e5 copies/ml), there 
was rapid penetration of KP9 (Gag) CTL escape mutation from plasma 
RNA into resting CD4 T cell SIV DNA, suggesting a rapid turnover of 
latent SIV DNA (~1 day). In the setting of low viral loads, similar to 
cART treatment, turnover of latent SIV DNA was much longer (up to 
10e5 days). There was a significant inverse correlation between viral 
load and turnover of latent SIV DNA, by both real time PCR and deep 
sequencing. Escape at the 2 Tat CTL epitopes and the compensatory 
mutation occurred in a less predictable pattern, often evolving over 
time to settle on a fixed mutation, often at time points beyond acute 
infection. This results in a complex and delayed pattern of penetration 
of escape mutations from plasma RNA into resting CD4 T cells.
Conclusion: The rapid turnover of resting CD4 T cell SIV DNA with 
high viral loads in this model suggests the latent reservoir of SIV may 
be more vulnerable to “purging” at the initiation of cART rather than 
after long-term cART. This has implications for clinical trials to cure HIV.
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P02.16 
HIV and SIV Vaccine Antigens Expressed by 
Live Attenuated Rubella Vectors Elicit Durable 
Immunity in Rhesus Macaques
K. Virnik1, M. Hockenbury1, Y. Ni1, J. Beren1, V. Kulkarni2,  
M. Rosati2, C. Alicea2, G.N. Pavlakis2, B.K. Felber2, and  
I. Berkower1
1FDA, Bethesda, MD, USA; 2National Cancer Institute, NIH, 
Frederick, MD, USA 
Background: Live attenuated viral strains are among the most 
successful vaccines.  Unfortunately, for HIV, an attenuated strain could 
present safety concerns due to insertional mutagenesis and reversion 
to wild type.
Methods: We have used live attenuated rubella vaccine strain RA27/3 
as a vector to express HIV MPER and SIV Gag antigens. The vaccine 
strain has demonstrated safety and immunogenicity in millions of 
children, and one dose protects for life against rubella.  Rubella readily 
infects rhesus macaques.  This was the first successful trial of rubella 
vectors in macaques, in combination with DNA vaccines in a prime and 
boost strategy.
Results: Rubella vectors have replicated to high titers in cell 
culture, however, replication in vivo, immunogenicity, and antibody 
durability were unknown. The rubella vectors replicated robustly in 
rhesus macaques, while expressing SIV and HIV antigens, and they 
were highly immunogenic. The anti-Gag antibody titers elicited by 
immunization were greater than or equal to those induced by natural 
SIV infection.  The antibodies have persisted for over 9 months.  Repeat 
immunization with rubella vectors boosted the titer of anti-rubella and 
anti-Gag antibodies, indicating the induction of memory B cells.  In 
addition, rubella vectors elicited a strong antibody response to the HIV 
MPER insert. Priming with DNA vaccine and boosting with the vector 
resulted in increased levels of Gag specific CD8+ T cells.
Conclusion: Rubella vectors combine the growth, immunogenicity, 
and safety of rubella vaccine with the antigenicity of the inserts. 
By presenting these antigens in the context of an acute infection, 
at a high level and for a prolonged duration, these vectors may 
stimulate a stronger and more persistent immune response, 
including production of high affinity antibodies and maturation 
of memory B cells. Rhesus macaques will provide an ideal animal 
model for demonstrating immunogenicity of novel vectors and 
protection against SIV or SHIV challenge.
P02.15 
Persistently SIV-Seronegative Macaques Elicit 
Mucosal Immune Responses Following Serial 
Low-Dose SIV Mucosal Challenge
K. Haq2, D.O. Willer2, J.K. Chan2, R. Pilon1, P. Sandstrom1, and 
K.S. MacDonald2
1Public Health Agency of Canada, Ottawa, Canada; 2Mt. Sinai 
Hospital, University of Toronto, Toronto, Canada
Background: Multi-low dose mucosal SIV challenge of NHPs has 
become widely adopted to improve the physiological relevance of the 
model.  This approach also improves our ability to observe efficacious 
SIV vaccines that may otherwise have been deemed non-protective 
following a single high dose parenteral challenge.
Methods: We immunized a cohort of cynomolgus macaques 
intratracheally with recombinant vectors expressing SIV Gag/Pol/
Env and Nef/Tat/Rev immunogens or empty vector. One year post-
vaccination, animals were challenged weekly with SIVmac239 
intra-rectally following a dose escalation regimen. Peripheral blood 
was collected to determine systemic vaccine- or challenge-specific 
cellular and humoral responses.  Rectal biopsies were collected mid-
way through the challenge phase to evaluate mucosal vaccine- and 
challenge-specific T lymphocyte as measured by expression of IFN-γ, 
IL-2, TNF-α and CD107a.  
Results: Multiple sub-infectious challenges elicited detectable SIV 
specific cellular immune responses in T lymphocytes in rectal mucosa. 
Moreover, modest cellular responses were also detectable in blood. 
Cumulative CD8+ cytokine responses in rectal tissue correlated with 
apparent resistance to infection as measured by # of challenges, 
total dose and infecting dose. Individually, CD8+ TNFα responses 
showed the strongest correlation with this protective effect. Mucosal 
polyfunctional responses were detected in vaccinees and controls 
against SIV determinants not present in the vaccine construct.   An 
increase in polyfunctional CD4+ responses correlated with higher 
doses and number of SIV challenges to infection, and a lack of these 
responses negatively influenced peak and set-point VLs.  SIV-specific 
antibodies were detectable in serum of seronegative animals after 16 
weeks of challenge.
Conclusion: We show that multiple low dose challenges with 
pathogenic SIV can induce cellular and humoral responses in the 
absence of detectable infection by real time PCR and SIV co-culture. 
Further studies may reveal how immune responses generated as a 
consequence of low dose challenges may affect disease course/
pathogenesis following SIV infection.       
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P02.18 
Combination of Therapeutic Vaccination and 
Chemotherapy Conferred Partial Control of 
SIV Infection in SIVmac239-Infected Rhesus 
Macaques
L. Feng1, C. Sun1, L. Xiao1, P. Li1, Y. Jin1, L. Zhang2, and L. Chen1
1Chinese Academy of Sciences, Guangzhou, China; 2Tsinghua 
University, Beijing, China
Background: Antiretroviral chemotherapy could substantially reduce 
viremia in HIV-infected people or SIV-infected macaques. However, 
life-long usage of chemotherapeutic drugs possesses problems of 
economic burden, drug resistance, and other site effects. Therapeutic 
vaccination may provide an alternative approach for a “functional cure”, 
defined as control of viral load without or with less drug administration.
Methods: In this study, we treated six SIVmac239-infected Chinese 
rhesus monkeys with reverse transcriptase inhibitor tenofovir/PMPA 
and emtricitabine/FTC followed by immunization with a previously 
reported AVIP (adenoviral vector infected PBMCs) vaccination 
(JV86:11031, 2012).
Results: The result showed that this strategy could delay viral 
rebound, partially suppress viral load by ~1 log in set-point and 
significantly improve the survival rate and quality of life.  All 
macaques appears to be healthy and without symptoms of AIDS, 
while most untreated animals were dead due to AIDS by 3 years after 
infection. These macaques have the induction of SIV-specific immune 
responses with more IFN-γ+CD4+T cells, polyfunctional CD4+ and 
CD8+ T cells, and higher proliferation capacity of antigen specific 
CD4+ and CD8+ T cells.
Conclusion: Our results indicated that combination of antiretroviral 
chemotherapy with AVIP vaccination warrants further study to explore 
its potential for effective control against HIV/SIV infection.
P02.17 
Creating a Novel Non-human Primate Model 
for Preclinical Vaccine Efficacy Studies Using a 
Synthetic Swarm of SIVmac239
G.Q. Del Prete2, H. Park1, C. Reid2, K. Oswald2, C. Kahl1, J.D. Estes2, 
M. Piatak2, J.D. Lifson2, L.J. Picker1, and B.F. Keele2
1Oregon Health & Science University, Beaverton, OR, USA; 
2SAIC-Frederick, Inc., Frederick, MD, USA
Background: Mucosal HIV-1 transmission typically results in 
establishment of systemic infection with one or a few variants, an 
important feature to recapitulate in developing authentic models of 
mucosal transmission of SIV in NHPs.  However, infection with a single 
variant from a diverse viral isolate may increase variability between 
animals since distinct variants within the stock may differ functionally. 
To decrease variability between animals while retaining the ability to 
conveniently enumerate the number of transmitted/founder variants, 
we modified SIVmac239 to generate 10 unique clones that differ 
by 2-3 synonymous mutations (molecular-tags), thereby providing 
a biologically homogeneous virus population distinguishable by 
sequence analysis.
Methods: A molecularly-tagged virus stock was produced by pooled 
transfection of all 10 clones with or without subsequent short-term 
expansion in RhPBMC.  Indian-origin rhesus macaques were challenged 
intrarectally, intravaginally, or intravenously.  The proportion of each 
variant in each inoculum and in plasma from infected animals was 
determined by single genome amplification (n=5,346).  
Results: All 10 variants were detected in nearly equal proportions for 
transfection and RhPBMC-expanded stocks. Intrarectal challenge with 
transfection-derived virus led to productive infection in 6/6 animals 
with a median of 2 variants.  Following intravaginal challenge, this 
same stock infected 5/9 animals with a median of 4 variants (range 
2-8).  For the PBMC-expanded stock, 12/12 animals became infected 
within 11 repeated low-dose intrarectal challenges with a median of 1 
variant per animal.  Using this same stock intravenously, 5IU and 1IU 
each infected 3/3 animals following a single challenge with 2-5 and 
1-2 variants, respectively, and 0.2IU infected 3/3 (1-2 variants) within 
three challenges.
Conclusion: Both transfection and PBMC-expanded stocks of 
molecularly-tagged SIVmac239 were transmissible and the number 
of variants conveniently discernible by sequence analysis.  This model 
establishes methods to enumerate transmitted/founder variants while 
maintaining the consistency of using an infectious molecular clone, 
which may benefit pre-clinical vaccine development in NHP.
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P02.20 
Rapid-Repeated Low Dose Challenges with 
SIVmac239 Infect Animals in a Condensed 
Challenge Window
J. Greene1, M. Reynolds1, B. Cain1, N. Pham1, and D. O’Connor1
1University of Wisconsin-Madison, Madison, WI, USA
Background: Simian immunodeficiency virus (SIV) infection of non-
human primates is the predominant model for prospective HIV studies. 
Yet, these studies frequently utilize extremely high doses of SIV that 
ensure infection after a single challenge but do not recapitulate 
sexual HIV transmission. Investigators have moved to using low-dose 
challenges in which animals are challenged once every week or every 
two weeks in order to better replicate sexual HIV transmission. Using 
this protocol, some animals require over ten challenges before HIV 
infection is detectable in the blood leading to expensive and time 
consuming studies. 
Methods: Here we challenged 12 Mauritian cynomolgus macaques 
with a low (100TCID50) dose of SIVmac239 intrarectally three times a 
day for three consecutive days for a total of 9 challenges. 
Results: Ten of twelve animals had positive plasma viral loads after this 
challenge regimen. Peak viral loads exceeded 1x10 6 vRNA copies/ml 
of plasma in all animals and 1x10 7 vRNA copies/ml of plasma in 6 
of 10 animals. Additionally, post-peak viral loads were consistent with 
previously observed viral loads in macaques of the same species. 
Conclusion: This challenge model represents a straightforward 
advance in SIV challenges that may allow investigators to proceed 
more rapidly with their studies and perform invasive sampling during 
the very early acute phase after a low-dose challenge.
P02.19 
Amino Acid Mutations Around Protease 
Cleavage Sites of SIVmac239 Correlate with 
Lower Viral Load and Higher CD4+ Counts in 
Cynomolgus Macaques
M. Luo1, R. Capina1, D. Tang1, X.Y. Yuan1, J. Pinto2, C. Prego2,  
M. Alonso2, C. Barry1, R. Pilon1, C. Daniuk1, D. La1, J. Tuff1,  
S. Pillet1, T. Bielawny1, P. Lacap1, C. Czarnecki1, G. Wong1,  
S. Tyler1, B. Liang1, T.B. Ball1, P. Sandstrom1, G. Kobinger1, and  
F.A. Plummer1
1National Microbiology Laboratory, Winnipeg, Canada; 
2University of Santiago de Compostela, Spain
Background: The protease of HIV-1 is a small 99-amino acid aspartic 
enzyme that mediates the cleavage of Gag, Gag-Pol and Nef precursor 
polyproteins. This process is highly specific, temporally regulated and 
essential for the production of infectious viral particles. A total of 
twelve proteolytic reactions are required to generate a viable virion, 
thus, a vaccine targeting the sequences around the 12 protease 
cleavage sites (PCS) of HIV-1 can be used to prevent infection and 
disease progression.
Methods: We have conducted a proof of concept study using 
Cynomolgus macaques and pathogenic SIVmac239 as a model. The 
macaques were immunized with recombinant VSVs (rVSV) expressing 
12 20-amino acid peptides overlapping 12 PCS of SIVmac239 and 
boosted with Nanopackaged peptides. The macaques were intrarectally 
challenged with an increased dose of SIVmac239 (1000, 2000, 4000, 
4000, 4000TCID50). Viral infection, viral load, CD4+ counts were 
conducted to evaluate the effect of the vaccine in protection from 
infection and disease progression. Viral mutations around the PCS 
were evaluated by 454 pyrosequencing and correlated with Viral load.
Results: Antibody and T cell response to the PCS peptides correlated 
with protection against higher dose of SIVmac239 challenge 
(p=0.005,R2=0.42). The vaccinated macaques maintained higher 
CD4+ counts than the controls (p=0.0002). Viral sequence analysis 
detected extensive sequence variations around the PCS and correlation 
analysis showed amino acid mutations around the 12 PCS (-5/+5, 
-10/+10, and regions just outside -10/+10) correlated with lower viral 
load (p<0.0001). 
Conclusion: Targeting sequences around the 12 PCS is an effective 
vaccine approach against HIV-1, a virus attacking a key component 
of immune system, CD4+ T cells. Because a single failed cleavage 
reaction is sufficient to generate noninfectious virions, targeting 
12 PCS attacks HIV protease function from 12 different directions. 
Furthermore, the sequences around the PCS are relatively conserved; 
targeting 12 PCS can deal with viral diversity and take the advantage 
of viral mutation.
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P02.22 
Multiclade E-DNA Prime Enhances the 
Functional Antibody Response Induced by 
a Recombinant gp120 Boost in Non-human 
Primates
M. Wise1, N. Hutnick1, J. Pollara2, D. Myles1, A. Khan3,  
S. Barnette4, G. Ferrari2, D. Montefiori2, N. Sardesai3, and  
D. Weiner1
1University of Pennsylvania, Philadelphia, PA, USA; 2Duke 
University, Durham, NC, USA; 3Inovio Pharmaceuticals, Blue 
Bell, PA, USA; 4Novartis Pharmaceuticals, USA
Background: The partial success of the RV144 trial provided the 
critical benchmark for HIV vaccine design and testing showing for the 
first time a vaccine was capable of inducing antibody responses that 
correlated with risk of infection in humans. The study also suggests 
that a prime-boost strategy may be required for a successful vaccine. 
We have focused on improving the antibody induction with our E-DNA 
vaccine approach and tested potency of a multi-clade prime-boost 
strategy in non-human primates.
Methods: Initial studies were performed in rabbits receiving multi-
clade envelope DNA prime at weeks 0, 3, 6, and 9 followed by a 
boost with multi-valent gp120 at week 45. Groups of 5 Indian Rhesus 
macaques were vaccinated at weeks 0, 6, 12 and 18 with pVax gag/
pol/env A, B, C, D, A/E. Monkeys were boosted at week 32 with SF162 
gp120. An additional 4 monkeys received only the protein boost. 
Results: In rabbits, the DNA prime induced potent cross clade binding 
titers after two immunizations. After protein boosting these levels 
increased over 100 fold. In monkeys, the multi-envelope (ME) DNA 
prime was capable of inducing potent cross clade cellular and humoral 
response. The ME DNA prime also generated tier 1 neutralizing titers 
great than 1:100. The recombinant protein boost enhanced these titers 
50-100 fold while single dose protein alone induced lower binding 
titers and no neutralization activity.  Importantly, antibody dependent 
cellular cytotoxicity (ADCC) was also only detected following the DNA 
prime/ protein boost. 
Conclusion: Improvements in immune potency have been achieved 
using these E-DNA vaccines. These vaccine regimens have binding 
and neutralizing titers in non-human primates and serves as an 
effective prime platform for a recombinant protein boost, which further 
enhances the magnitude and functional profile of responses. 
P02.21 
Characterization of Antibodies Targeting the 
Receptor and Co-receptor Binding Region of 
SIV Envelope
R. Mason1, H. Welles1, S. Schmidt1, B. Chakrabarti2, Z. Yang1,  
K. Saunders1, J. Mascola1, and M. Roederer1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2The Scripps Research Institute, India
Background: Non-human primate models of SIV infection are useful 
for studying vaccine mediated and immune correlates of protection. 
Some studies suggest antibody mediated correlates of protection 
against SIV but little is known about binding or neutrlizing epitopes on 
SIV Env. Thus, we sought to study SIV infection of rhesus macaques 
to identify phenotypic and functional characteristics of protective SIV-
specific antibody responses.
Methods: Trimeric SIVgp140 probes and J08-scaffolded V1V2 probes 
were used to isolate putative CD4-binding site (CD4bs)- and V1V2-
specific B cells, respectively. Individual CD4bs- and V1V2-specific B cells 
were isolated by indexed cell sorting and matched immunoglobulin 
heavy and light chain genes from individual B cells were amplified 
by RT-PCR, cloned and expressed in vitro and purified monoclonal 
antibodies (mAbs) tested for SIV-specific binding and neutralization.
Results: We sorted 160 CD4bs- and 152 V1V2-specific B cells 
(0.02% and 0.09% of total CD20+ B cells) from SIV vaccinated and 
challenged rhesus macaques. Four of six mAbs cloned from putative 
CD4bs-specific B cells bound to monomeric and trimeric SIV gp140, 
were confirmed to be CD4bs-specific by competition ELISA and had 
potent but varying neutralizing activity against SIVmac and SIVsm 
Tier 1 and 2 isolates. We also screened 15 mAbs cloned from V1V2 
probe-sorted B cells. One mAb did not bind monomeric or trimeric 
SIVgp140 while 10 mAbs bound only monomeric SIVgp140, 2 of 
which had detectable neutralizing activity against SIVsm Tier 1. The 
remaining 4 mAbs bound both monomeric and trimeric SIVgp140, had 
potent neutralizing activity against Tier 1 SIVmac251 and detectable 
neutralizing activity against Tier 1 SIVsm.
Conclusion: We have isolated and characterized SIV CD4bs-specific 
and V1V2-specific mAbs. Use of additional probes will facilitate 
identification and characterization of the range of protective SIV 
Env-specific epitopes which can be used to optimize HIV vaccine 
immunogens, adjuvants and/or vaccine regimens.
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P02.24 
Use of NOD/SCID/β2 Humanized Mice to Test a 
Novel Lentiviral-Based HIV-1 Vaccine 
M. Moussa1, G. Arrode-Brusés1, A. Smaoune1, A. Malogolovkin1, 
I. Liagoskin1, and C. Yahia1
1University Joseph Fourier Grenoble, Grenoble, France
Background: Humanized immunodeficient mice have been used as 
small animal model to recapitulate HIV-1 infection and pathogenesis 
and to evaluate vaccine prototypes. We used hu-NOD/SCID/β2 mice 
to evaluate the immunogenicity of a novel CAL-SHIV-IN- lentivector 
HIV vaccine. This vector was derived from the genome of the highly 
pathogenic SHIV-KU2, lacking the integrase gene and driven by the 
constitutive LTRs of the naturally attenuated caprin arthritis encephalitis 
lentivirus (CAEV). 
Methods: Plasmid DNA was transfected into HEK-293-T cells by 
lipofection and viral protein assembly was examined by electron 
microscopy. Virus in culture medium was assayed for infectivity 
in the human CD4+ T cell line M8166. BALB/c and hu-NOD/SCID/
β2 mice were IM-injected by a single dose CAL-SHIV-IN- DNA. Mice 
were euthanized at week 2 and 4 post-immunization and plasma and 
Splenocytes were isolated. INF-γ ELISPOT and multi-parametric FACS 
assays were used to examine Ag-specific T cells producing cytokines 
and proliferating. ELISA was used to detect the presence of vaccine-
induced antibodies. 
Results: CAL-SHIV-IN- induced specific immune responses in both 
BALB/c and hu-NOD/SCID/β2 mice, with increased responses at week 
2 post-immunization. Interestingly Ag-specific T cells and antibodies 
induced by the vector were significantly higher in humanized hu-
NOD/SCID/β2 compared to BALB/c micpe. These results provided the 
demonstration that the additional cycle of replication in human target 
cells has significantly improved the antigenicity of the novel vector.
Conclusion: These prove of concept in the hu-SCID mouse model 
provided the basis to instigate the immunogenicity of this lentivector 
in NHP model (see Arrode et al.). The new NSG and NOG SCID models 
that have been demonstrated to be more efficient should provide 
enhanced data.  
P02.23
Profiling SIV Envelope Variants from 
Breakthrough Infections in a DNA/MVA 
Vaccination Trial
S. Reddy2, S. DeVictor2, G.P. Bell2, L.A. Sheorey2, Y. Alkhalid2,  
E. Hunter2, H.L. Robinson1, R. Amara2, and C.A. Derdeyn 2
1GeoVax, Inc., Smyrna, GA, USA; 2Emory University, Atlanta, 
GA, USA
Background: A SIVmac239 based recombinant DNA prime/MVA 
boost vaccine with and without GM-CSF adjuvant was previously 
tested in rhesus macaques along with an MVA only regimen. After 
heterologous SIVsmE660 challenge, 71% protection was observed 
in the GM-CSF group, which was positively associated with antibody 
avidity. We hypothesized that comparing envelope (Env) glycoproteins 
from SIV variants that established infections in vaccinated macaques 
to those from unvaccinated macaques, and between immunization 
groups, could reveal signatures of vaccine induced immune pressure 
that favoured transmission of select SIV variants.
Methods: Post-challenge plasma samples were collected from 
infected macaques in each vaccine group at weeks 1 or 2 post 
infection. Viral RNA was reverse transcribed and single genome 
PCR was used to amplify the entire Env coding region. Multiple SGA 
Env sequences from 14 macaques were analysed by aligning amino 
acids, generating phylogenetic trees and using the Los Alamos HIV 
Database Highlighter program.
Results: Highlighter analysis of SIV Env sequences revealed that 
a single founder variant established infection in each macaque, 
regardless of the vaccination group. Phylogenetic analysis 
demonstrated that the Env sequences from the SIVsmE660 challenge 
stock and founder viruses from the macaques in the vaccine and 
control groups intermingled and exhibited less than 3% diversity 
overall. Amino acid alignments showed that the changes were 
focused in the gp120 V1V2 domain and gp41 cytoplasmic tail. 
However, no distinct genotypic signatures indicating vaccine-induced 
selective pressure emerged from these analyses.
Conclusion: The results indicate that a single variant established 
infection in each macaque; however, evidence for selective 
transmission of a particular SIVsmE660 Env variant based on 
vaccination induced immune pressure was not apparent from the 
genotypic analyses. Phenotypic characterization of founder Envs 
could elucidate whether the DNA/MVA with GM-CSF regimen resulted 
in selective transmission of neutralization resistant viruses from the 
SIVsmE660 challenge quasispecies.
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P02.26 
Priming with Adenovirus26 Vaccines Affects 
ALVAC-SIV/gp120 Vaccine Efficacy Tested in a 
SIVmac251 Challenge Model Performed One-
Month Post-Vaccination
S.N. Gordon1, M. Vaccari1, M.N. Doster1, N.P. Liyanage1, P. Pegu1, 
L. Schifanella1, F. Caccuri1, B.F. Keele2, K.E. Foulds3, X. Shen4, 
G.D. Tomaras4, D.C. Montefiori5, M. Roederer3, G. Ferrari5,  
D. Venzon1, D. Stablien6, D.H. Barouch7, B.K.  Felber1,  
G.N. Pavlakis1, N.L. Michael8, J. Tartaglia9, and G. Franchini1
1National Cancer Institute, NIH, Bethesda, MD, USA; 2SAIC-
Frederick, Inc., National Cancer Institute, NIH, Frederick, 
MD, USA; 3Vaccine Research Center, NIAID, NIH, Bethesda, 
MD, USA; 4Duke Human Vaccine Institute, Durham, NC, 
USA; 5Duke University Medical Center, Durham, NC, USA; 
6The EMMES Corporation, Rockville, MD, USA; 7Beth Israel 
Deaconess Medical Center, Boston, MD, USA; 8U.S. MHRP, 
Silver Spring, MD, USA; 9Sanofi Pasteur, Swiftwater, PA, USA
Background: The 31.2% efficacy afforded by ALVAC-HIV/gp120 
vaccines (RV144 Thai trial) needs to be improved. ALVAC-SIV/gp120 
vaccines tested in a SIVmac251   macaque model, demonstrated a similar 
immunogenicity and 40% vaccine efficacy at each challenge. We used 
this model to test whether priming with DNA or adenovirus 26 could 
improve the immunogenicity and efficacy of ALVAC/gp120 vaccines.
Methods: Twenty-seven macaques were given four vaccinations with 
ALVAC expressing SIV genes. A second cohort of twenty-four macaques 
had the two initial ALVAC vaccinations replaced with either DNA or 
Adenovirus 26 expressing SIV genes. All vaccinated animals were 
boosted with SIV-gp120 protein in alum. Four weeks post immunization, 
vaccinated macaques and 41 controls were given repeated low-dose 
intra rectal challenges with SIVmac251. The immunogenicity and efficacy 
of each regimen was evaluated.
Results: DNA-ALVAC/gp120, Ad26-ALVAC/gp120 and ALVAC/gp120 
vaccine regimens induced equivalent gp120 binding antibodies that 
recognized the V1/V2 region. The Ad26 primed group demonstrated 
significantly greater neutralization of SIV tier 1 viruses and increased 
SIV specific IFNγ responses. When the rate of SIV acquisition of 
each vaccination regimen was compared to controls, priming with 
DNA or ALVAC resulted in an equivalent significant protection from 
SIV acquisition (51.2 and 40% efficacy respectively). Intriguingly, 
despite increased immunogenicity, the rate of SIV acquisition was not 
significantly different between the Ad26-ALVAC/SIV+gp120 regimen 
and controls. 
Conclusion: Priming with DNA or ALVAC resulted in a significant 
reduction in the rate of SIV acquisition. Surprisingly, we observed a lack 
of protective efficacy when Ad26 was combined with ALVAC-SIV/gp120. 
This finding differs from other studies that demonstrated protective 
efficacy using Ad26-MVA regimens with challenges 3-9 months post 
vaccination. The time between vaccination and challenge may affect 
efficacy. Understanding the evolution of protective responses and the 
resulting virologic consequences in macaque models, could inform the 
design of human trials that use these vaccine modalities.
P02.25 
A Combined Saavi MVA-C and Novartis Gp140 
Env Protein Vaccine Boost Elicits Robust HIV 
Cellular and Humoral Responses in a Non-
human Primate Model
G.K. Chege1, D.C. Montefiori2, S. Barnett3, C.M. Gray1,  
W.A. Burgers1, T.L. Muller1, E.G. Shephard1, C. Williamson1,  
G. Ferrari2, and A. Williamson1
1University of Cape Town, Cape Town, South Africa; 2Duke 
University Medical School, Durham, NC, USA; 3Novartis 
Vaccines & Diagnostics Inc., Cambridge, MA, USA
Background: We previously reported induction of cellular responses 
by SAAVI DNA-C/SAAVI MVA-C (DNA/MVA) prime/boost immunisation. 
These vaccines express matched gag, rt, nef, tat and env genes based 
on HIV-1 clade C. In view of the moderate protection reported in RV144 
efficacy trial in which a combined poxvirus/Env protein regimen was 
used, we included a protein vaccine in the present study.
Methods: Seven rhesus macaques which had received a DNA/MVA 
prime/boost vaccine regimen >3 years previously were re-vaccinated 
with MVA followed by a boost with Novartis TV1 gp140ΔV2 protein 
in MF59 adjuvant (Env protein) and finally with a combined MVA/Env 
protein vaccination. A control group (n=3) was vaccinated with Env 
protein only. HIV responses were quantified in the blood at various 
time points and lymphoid tissues at experimental endpoint using an 
IFN-γ ELISPOT assay. Binding (bAb) and neutralising (nAb) antibodies 
were measured and Env-specific IgG-secreting cells were quantified in 
a B cell ELISPOT assay.
Results: Peak cumulative IFN-γ ELISPOT responses were achieved in 
the blood 1 week after re-vaccination with MVA. Robust IFN-γ ELISPOT 
responses were detected in inguinal, mesenteric, iliac and bronchial 
lymph nodes and spleen following combined MVA/Env protein 
vaccination. A single boost with protein in primed animals induced 
strong nAb responses against multiple tier 1 viruses and sporadic 
weak responses against multiple tier 2 viruses, whereas no nAbs were 
detected post prime. Moderate improvement in the magnitude of 
responses to tier 1 viruses and breadth against tier 2 viruses was seen 
after the combined MVA/Env protein boost in these animals.  Similar 
responses were seen after 2 inoculations with protein only. Env-specific 
bAb and IgG-secreting cells were detected in the blood after MVA, Env 
protein and combined MVA/Env protein vaccinations.
Conclusion: These data demonstrate the potential of poxvirus-
vectored and protein candidate HIV vaccines in generating cellular and 
humoral immune responses when used in combination.
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P02.28 
Rhesus Full Length Single Chain (rhFLSC) 
Protects Rhesus Macaques from Heterologous 
Intrarectal Challenge with Multiple Low Doses 
of SHIV162P3
T.R. Fouts1, I. Prado1, K. Bobb1, R. Xu1, M. Egan1, G. Tomaras2,  
D. Montefiori2, G. Lewis3, A. DeVico3, and J. Eldridge1
1Profectus BioSciences, Inc., Baltimore, MD, USA; 2Duke 
University School of Medicine, Durham, NC, USA; 3University 
of Maryland School of Medicine, Baltimore, MD, USA
Background: We evaluated whether a rhesus variant of Full Length 
Single Chain (rhFLSC) could protect against a multiple low dose, 
heterologous, mucosal, SHIV challenge model and identify potential 
correlates to any protection observed.
Methods: Groups of 6 rhesus macaques were inoculated with either 
gp120(BaL) or rhFLSC formulated in either Iscomatrix, a saponin 
containing iscom, or RC529-SE, a stable emulsion of; squalene, 
glycerol, phosphatidyl choline and a synthetic monophosphoryl lipid 
A, a TLR-4 agonist. Untreated naïve animals were included as controls. 
All animals were challenged rectally at weekly intervals with 50 TCID 
(50) SHIV162P3 and monitored for infection.  Cellular and humoral 
immunity was assessed throughout the experiment.
Results: Analysis of the immune responses vs the rate that the 
immunized animals became infected during the challenge phase 
generated several key observations. (1) Slower acquisition rates were 
observed in animals that presented titers to rhFLSC that were 2x higher 
than gp120 (rhFLSC/gp120 titer >2); competitive epitope titers to a 
CD4i MAb, N12-i2 >1:100; higher titers to transmitted founder clade C 
envelope derived from HIV-1(1086.C) (AUC titers > 10,000).  (2) Similar 
to the pattern observed in RV144 (4), protection in Rh048 was highest 
through the early challenge phase (first 4 challenges) after which all of 
the naïve controls became infected, and waned thereafter. (3)Increased 
acquisition rates and risk were associated with higher T cell responses 
as assessed by IL-2 and IFN-g ELISPOT. Polyfunctional FACS analysis of 
the envelope specific CD4+ and CD8+ responses revealed that the T 
cells responses were primarily single function but little to no evidence 
of T cells with 2 or more functions.
Conclusion: Based on these results, we conclude that immunization 
with rhFLSC can provide sterilizing protection but that an overabundance 
of single function T cells may provide targets for HIV infection that 
negate the efficacy provided by rhFLSC.
P02.27 
Newly Developed gp140 Trimeric Formulations 
Induce Inter-subtype HIV-1 Neutralization 
When Administered After DNA Prime Regimen 
to Cynomolgus Macaques
E. Morandi10, L. Heyndrickx1, I. Mangeot-Méderlé2, E. Bowles3,  
B. Grevstad4, M. Jansson5, L. Buonaguro6, M. Ramaswamy7,  
P. Biswas10, A. Fomsgaard4, G. Vanham1, G. Stewart-Jones3,  
N. Bosquet2, H. Schuitemaker8, A. Spetz9, R. Le Grand2, and  
G. Scarlatti10
1Institute of Tropical Medicine, Antwerp, Belgium; 2CEA, 
Fontenay-aux-Roses, France; 3University of Oxford, Oxford, 
UK; 4Statens Serum Institut, Copenhagen, Denmark; 5Lund 
University, Lund, Sweden; 6Istituto Nazionale Tumori, Napoli, 
Italy; 7National Institute for Biological Standards and Control, 
Hertfordshire, UK; 8Academic Medical Center at the University 
of Amsterdam, Amsterdam, Netherlands; 9Karolinska 
Institutet, Stockholm, Sweden; 10San Raffaele Scientific 
Institute, Milan, Italy
Background: New immunogens capable of inducing broadly 
neutralizing antibodies (NAbs) are a priority in HIV-1 vaccine research.
The NGIN consortium developed a set of new gp140 immunogens of 
HIV-1 subtype A and B derived from the virus of infected individuals, 
who had developed broadly neutralizing antibodies (NAbs) during 
follow-up.The gp140 trimeric proteins inducing the best NAbs in 
immunized rabbits were forwarded for immunization of cynomolgus 
macaques(NHP).
Methods: Immunization was performed with a prime-boost regimen 
including a trivalent gp140 DNA delivered by electroporation followed 
by the gp140 trimeric protein boost given by intramuscular injection 
with the adjuvant CAF01. NGIN pursued three immunization strategies 
with the prime-boost being: 1) intra-subtype (B DNA – B gp140), 2) 
inter-subtype (B DNA – A gp140), and 3) inter-virus group (HIV B 
DNA – SIV gp140). The third approach was introduced to test whether 
boosting with a heterologous virus would favour antibody responses 
to highly conserved regions.
Results: In all immunization strategies HIV-1 gp120 specific IgG but 
not IgA were detected by ELISA in the serum of NHP after the DNA 
immunizations and further enhanced after each protein boost. Low titer 
subtype specific NAbs were detected after DNA immunization. Protein 
boost enhanced intra-subtype Nabs to higher titers, and broadened 
the NAb reactivity to inter-subtype Tier 1 viruses. No vaginal mucosal 
NAbs were detected. Peptide microarray analysis showed inter-subtype 
antibodies to the gp41 immunodominant regions and env V3 loop in 
all vaccination strategies used, whereas antibodies directed to C2 and 
C5 were detected only in the HIV-1 immunization strategies (1 and 2).
Conclusion: In conclusion, the NGIN consortium has developed a new 
set of unique gp140 trimers. Although only neutralizing activity against 
Tier 1 viruses was induced, the elicited humoral immunity showed 
great breath in reactivity across viruses from different subtypes. Work 
supported by EC-FP7-grant NGIN_201433.
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P02.30 LB
Vectored ImmunoProphylaxis with VRC07 
Protects BLT Humanized Mice from Vaginal 
Transmission of Founder HIV
A.B. Balazs1, O. Yong1, C.M. Hong1, J. Chen1, D.S. Rao2, D. An2,  
and D. Baltimore1
1California Institute of Technology, Pasadena, CA, USA; 
2University of California-Los Angeles, Los Angeles, CA, USA
Background: Recently, a number of antibodies capable of broadly 
neutralizing HIV have been isolated from HIV infected patients, stimulating 
efforts to elicit their production in naive individuals. As an alternative to 
vaccination, we recently described vectored immunoprophylaxis (VIP) 
as an approach capable of generating high serum concentrations of a 
desired monoclonal antibody in mice following a single intramuscular 
injection of a specialized adeno associated viral vector (AAV). Mice that 
received VIP encoding b12, VRC01 or VRC07 antibodies demonstrated 
long-term circulating antibody expression in serum, and VIP-treated 
humanized mice exhibited remarkable protection against high dose, 
intravenous challenge with CXCR4-tropic HIV. However, most human 
infections are initiated by transmission of CCR5-tropic strains through 
mucosal tissues.
Methods: To measure the efficacy of VIP against clinically relevant 
strains, we humanized VIP-treated mice by adoptive transfer of 
peripheral blood mononuclear cells (PBMC) and challenged these 
animals with CCR5-tropic HIV strains including JR-CSF, as well as 
REJO.c, a transmitted molecular founder. To determine the ability of 
VIP to prevent mucosal transmission of clinically relevant HIV, we 
developed a repetitive intravaginal challenge model in VIP-treated BLT 
humanized mice that were challenged weekly with JR-CSF or REJO.c 
and monitored for infection.
Results: PBMC humanized mice expressing b12 or VRC01 were 
protected from intravenous challenge with JR-CSF. In contrast, the 
b12-resistant REJO.c strain readily infected PBMC humanized mice 
expressing b12 antibody, while mice expressing VRC01 demonstrated 
nearly complete protection following challenge. Intravaginally 
challenged BLT animals expressing luciferase as a control all became 
infected over the study period while a majority of animals expressing 
VRC01 or VRC07 had no detectable HIV infection despite repeated 
intravaginal challenges with JR-CSF or REJO.c.
Conclusion: VIP is capable of protecting humanized mice from 
challenge by diverse HIV strains and can prevent vaginal transmission. 
These findings warrant continued development of VIP as a novel 
approach for HIV prevention.
P02.29 
DNA Prime/Subunit Boost Using SIV (E660) 
Based rhFLSC Yields 75% Efficacy Against 
Cross Clade SIVmac251 Intrarectal Challenge
T. Fouts1, J. Schwartz1, I. Prado1, R. Xu1, A. Ota-Setlik1, G. Lewis2, 
R. Pal3, and K. Bagley1
1Profectus BioSciences, Inc., Baltimore, MD, USA; 2University 
of Maryland School of Medicine, Baltimore, MD, USA; 
3Advanced Bioscience Laboratories, Rockville, MD, USA
Background: The rhesus version of the FLSC protected macaques 
against repeat rectal challenges with SHIV162P3 but the level of 
efficacy was low.  To improve efficacy, we evaluated a DNA prime with 
different genetic adjuvants including IL-12 followed by a subunit boost 
in the SIVmac251 challenge model.
Methods: Groups of 8 rhesus macaques were immunized 
with multiantigen pDNA expressing gag/pol(SIVsmE543) and 
rhFLSC(SIVsmE660) coadministered with plasmids expressing either 
LTA1, IL-12 or LTA1+IL-12.  Control groups received no adjuvant 
plasmid or were left untreated.  At week 42, vaccinated animals 
received rhFLSC (SIVsmCG7V) formulated in Al(OH)3.  All animals were 
then rectally challenged weekly for 10 weeks starting at week 44 with 
a cross-clade SIVmac251 stock.
Results: DNA prime + IL-12 followed by a subunit boost generated 75% 
efficacy as compared to the same protocol without IL-12.   Althought 
antibody binding titers and neutralizing titers to Teir 1 SIVmac251 were 
>10(4) in all vaccinated groups, efficacy did not correlate with either. 
The regimen using IL-12+LTA1 generated superior CMI responses 
throughout the study; however, this group did not exhibit superior 
protection.  While correlates of protection remain to be defined in this 
study, this level of efficacy is we observed with a DNA prime + IL-12 
followed by a rhFLSC subunit boost is consistent with the best that was 
observed by others that used prime/boost regimens.
Conclusion: Using a protocol of a SIVsmE543 multiantigen DNA prime 
that included rhFLSC(SIVsmE660) adjuvanted with pIL-12, followed 
by a boost with rhFLSC(SIVsmCG7V) subunit formulated in Al(OH)3, 
we were able to generated 75% efficacy as compared to the same 
protocol without IL-12 against a stringent cross-clade multiple low 
dose intrarectal challenge with SIVmac251. 
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P02.32 LB
Viral Evolution Following Infection with a 
Derivative of SHIV1157ipd3N4 Sensitive to V2-
Dependent, QNE-Specific, Broadly Neutralizing 
Antibodies
J.F. Theis1, C. Krachmarov1, K. Revesz1, A. de Parseval1, Y. Li2,  
P.S. Firpo3, P.L. Moore4, L. Morris4, S. Hu2, and A. Pinter1
1Rutgers University, Newark, NJ, USA; 2University of 
Washington, Seattle, WA, USA; 3Washington National Primate 
Research Center, Seattle, WA, USA; 4Institute for Communicable 
Diseases, Johannesburg, South Africa
Background: PG9 and PG16 are founding members of a class of broadly 
neutralizing antibodies (BNAbs) that target V2-dependent quaternary 
neutralization epitopes (QNEs) that includes the conserved N-linked glycan 
at position N160. CAP256 sera contain related highly potent BNAbs that 
target an overlapping epitope not dependent on N160. Commonly used 
SHIVs (SHIV-SF162P3, SHIV-1157ipd3N4, SHIV-AD8, and SHIV-BaL) 
poorly express these epitopes. Two changes in SHIV-1157ipd3N4 Env, 
Q170K and I192R, conferred sensitivity to QNE-specific NAbs. This mutant 
is infectious and pathogenic in pigtail macaques. 
Methods: Tracking the course of infection with SHIV1157+QNE should 
allow the recapitulation of steps leading to the production of QNE-
specific BNAbs. We monitored the development of antibody responses 
and evolution of Env sequences in infected macaques. SGA was used 
to amplify sequences; representative sequences were cloned for 
analysis of neutralization sensitivity. 
Results: Autologous neutralizing antibodies were detected at week 16 
post-infection (PI). At week 16 PI, 12/13 sequences contained mutations 
at position K143 that conferred resistance to sera from weeks 16 - 
32 PI. These viruses were sensitive to week 35 sera, indicating the 
development of a new antibody response. At week 24, only ~half of the 
sequences had K143 mutations, and the remaining had V1 deletions 
and mutations elsewhere in Env, including the K169E mutation that 
in other Env contexts conferred resistance to neutralization by PG9, 
PG16, and CAP256 sera.
Conclusion: In this macaque, the initial antibody response targeted V1 
and/or V2, and escape mutants were readily selected. Neutralization 
of the escape mutants by week 35 sera indicates evolution of a new 
antibody response that broadens neutralizing activity. This suggests 
that this SHIV should be useful for studies of the evolution of V2-
dependent, QNE-specific BNAbs in macaques. This SHIV should also 
prove useful as a challenge stock for vaccine trials attempting to 
induce these antibodies.
P02.31 LB
A Single Immunization with Integrase Defective 
Lentiviral Vector Expressing gp140 Induces 
Persistent and Functional Immune Response in 
Rhesus Monkeys
M. Blasi2, D. Negri2, S. Santra1, R. Parks2, X. Shen2, G. Tomaras2,  
S. Permar2, D. Montefiori2, C. LaBranche2, G. Ferrari2, M. Alam2,  
H. Liao2, A.M. Moody2, B.F. Haynes2, M.E. Klotman2, and A. Cara2
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Duke University, Durham, NC, USA
Background: Integrase defective lentiviral vector (IDLV) expressing 
antigens induces long-lasting and protective immune responses in 
mice after a single immunization. IDLV persists at the site of inoculum 
in the absence of integration, resulting in a prolonged antigen 
expression. The aim of this study was to demonstrate in monkeys that 
immunization with IDLV delivering the prototype clade C transmitted 
founder HIV-1 Env 1086.Cgp140 (IDLV-Env) induces sustained and 
functional anti-Env antibodies (Abs) and T cell responses.
Methods: Six rhesus monkeys were primed with IDLV-Env and boosted 
at 1 year after priming. An analysis of Ab response was assessed over 
time. Binding, epitope mapping, neutralizing activity and ADCC of 
anti-Env Abs were evaluated at sequential time points. IFNg ELISPOT 
was performed to evaluate persistence and presence of functional Env-
specific T cells.
Results: A single immunization with IDLV-Env induced strong and 
prolonged immune responses. Anti-Env Abs peaked between 2 and 6 
weeks and were still present at 1 year after the vaccination. All monkeys 
showed neutralizing Abs in serum samples starting from 6 weeks and 
peaking at 14 weeks after immunization. Three out of 6 monkeys 
showed ADCC in serum samples and 4 out of 6 had detectable anti-
V1V2 Abs. High levels of IFNg producing T cells were elicited in all 
monkeys, decreasing over time, but still detectable up to 1 year after 
immunization. Abs and T cell responses showed a significant increase 
after the boost.
Conclusion: This is the first demonstration that an IDLV-based vaccine 
expressing HIV Envelope is able to induce functional, comprehensive 
and persistent immune responses in non-human primates. These 
results support the further evaluation of IDLV as a delivery system in 
the context of a HIV-1 vaccine.
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P02.34 LB
Optimized Multidrug-Resistant HIV-1 Reverse 
Transcriptase Induces Strong Immune 
Responses in DNA-Immunized Mice
M. Isaguliants1, E. Starodubova2, S. Petkov1, A. Kilpelainen1,  
G. Glowacki1, O. Krotova2, V. Karpov3, and B. Wahren1
1Karolinska Institutet, Stockholm, Sweden; 2Engelhardt 
Institute of Molecular Biology RAS, Moscow, Russian 
Federation; 3Engelhardt Institute of Molecular Biology, 
Moscow, Russian Federation
Background: Development of multigene DNA-vaccines against 
HIV faces a problem of low immunogenic performance of enzymes 
genes, in particularly reverse transcriptase (RT). Under the pressure 
of antiretroviral drugs, RT accumulates mutations. Mutated protein 
escapes the effect of drugs, but at the same time becomes more 
immunogenic. Basing on this, we designed a new DNA-immunogen 
encoding RT with multiple drug-resistance mutations, and tested its 
performance in preclinical trials.
Methods: RT gene cloned earlier from HIV-patient with multiple drug 
resistance mutations (RT1.14) was expression-optimized and mutated 
further to deprive RT of the enzymatic activity generating RT1.14opt-in. 
Genes were expressed in HeLa cells, expression level and proteolytic 
stability was assessed by immunoblotting. BALB/C mice (n=4 per 
group, in two repeats) were injected intradermally or intramuscularly 
with plasmids. Injections were followed by electroporation (DermaVax). 
Immune responses were assessed by IFN-g/IL-2 Fluorospot (Mabtech) 
and indirect ELISA. Gene delivery and dynamics of expression was 
followed by in vivo imaging using a co-delivered gene of the reporter 
protein luciferase.
Results: Gene optimization led to an 2-fold increase in protein expression. 
Half-life of active RT1.14 in HeLa cells was 2-3h, of RT1.14opt, 6-8h and of 
RT1.14opt-in, 2-3h. RT1.14opt-in gene induced significant IFN-g, IL-2 and 
dual IFN-g/IL-2 responses; RT1.14opt gene, a significant IL-2 response; 
and viral RT1.14, a weak IFN-g response. Only optimized genes induced 
anti-RT IgG of G1, G2b subclasses in titter 80000, and RTopt-in gene, 
also IgG2a in titer 30000 indicating a mixed Th1/Th2 type of immune 
response. In vivo imaging demonstrated that the immune response 
induced by RT1.14opt and RT1.14opt-in genes cleared the expressing 
cells from the injection sites.
Conclusion: Thus, the immune responses induced by novel genes 
significantly exceeded cellular responses to any previously tested 
RT gene variant. In conclusion, codon-optimized gene of multidrug-
resistant RT represents a good candidate for inclusion into a therapeutic 
multi-gene HIV vaccine.
P02.33 LB
Acute SIV Infection Induces Hypercytotoxicity 
and Massive Numerical Loss of Innate Lymphoid 
Cells in the Gastrointestinal Tract
H. Li1, T.I. Evans1, M. Connole1, J. Gillis1, F.E. Wong1, Y. Yu1, and 
R. Reeves1
1Harvard Medical School, Southborough, MA, USA
Background: Studies from our lab and others have identified a novel 
NK cell-like population restricted to mucosal tissues and distinguishable 
from classical NK cells by high expression of NKp44 and RORγt. So-
called innate lymphoid cells (ILCs) play a key role in mucosal defense 
and homeostasis, but are depleted from colorectum during chronic SIV 
infection. However, nothing is known about the kinetics of ILC loss, or 
if it occurs systemically. 
Methods: This planned sacrifice study included a total of twenty-one 
rhesus macaques — six naïve; six infected with SIVmac239 sacrificed 
at 14 days post-infection; and 9 infected with SIVmac239 sacrificed 
in chronic stage disease. Tissue from colon, jejunum and mucosae-
draining lymph nodes were collected from all animals. ILCs and classical 
NK cells were enumerated and analyzed phenotypically by surface and 
intracellular flow cytometry, as well as immunohistochemistry, and mono- 
and polyfunctions were quantified by intracellular cytokine staining. 
Results: During acute SIV infection a massive up to 8-fold loss of 
NKp44+ ILCs was observed in all mucosal tissues, but classical NK 
cells were maintained in number. Both ILCs and NK cells exhibited 
significantly increased levels of apoptosis, but while classical NK cells 
also showed increased proliferation, ILCs did not. Interestingly, ILCs, 
which are normally noncytolytic, dramatically upregulated cytotoxic 
functions in acute and chronic infection and acquired a polyfunctional 
phenotype secreting IFN-γ, MIP1-β, and TNF-α, but decreased 
production of the prototypical cytokine, IL-17. Classical NK cells had 
a less dramatic change in function, but exhibited upregulated perforin 
expression and increased cytotoxicity.
Conclusion: Herein we demonstrate the first evidence for acute, 
systemic, and permanent loss of mucosal ILCs during SIV infection. The 
massive reduction appears to involve apoptosis without compensatory 
de novo development/proliferation, but the full mechanism of depletion 
and the impact of functional change so early in infection are unclear.
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P02.36 LB 
Intradermal DNA Immunization with HIV-1 
Protease Followed by Electroporation Improves 
Immunogen Delivery and Potency in Mice
M. Isaguliants1, S. Petkov1, and B. Wahren1
1Karolinska Institutet, Stockholm, Sweden
Background: DNA-vaccines can be effective against many infectious 
diseases due to their safety, stability, and ease of manufacture. However, 
they still lack in immunogenic performance, especially compared to live 
attenuated viruses, recombinant proteins, or viral vectors. A considerable 
improvement in DNA-vaccine immunogenicity was achieved with the 
development of immunization technique, specifically application of 
in vivo electroporation. In this study we evaluated the capacity of a 
plasmid encoding inactivated HIV-1 protease (PRin) (Hallengärd,2011) to 
direct antigen expression and induce immune responses in BALB/c mice.
Methods: PR DNA and a reporter luciferase gene were delivered 
by intradermal (ID) or intramuscular (IM) injections followed by 
electroporation (DermaVax). Expression kinetics was monitored by in 
vivo quantification of reporter luminescence (Caliper). Antigen-specific 
cellular immune responses were assessed as in vitro secretion of 
IFN-g and IL-2 by murine splenocytes stimulated with PR, peptides 
representing immunodominant immunodominant CD4+ and CTL-
epitopes of PR and control antigens (Fluorospot,Mabtech). Antibody 
response to PR (NIBSC) was assessed by ELISA.
Results: Compared to IM, ID delivery resulted in a 2-fold higher initial 
reporter expression which peaked earlier (day 1 compared to 4 for 
IM) and demonstrated significantly lower endpoint levels. PRin gene 
injected ID induced 3 times greater number of IFN-g and IL-2-secreting 
splenocytes recognizing CD4+ and CTL epitopes of PR than PRin gene 
injected IM. Immunization route had no effect on the epitope hierarchy: 
in both groups IFN-g response to CTL was stronger than to CD4, while 
magnitude of IL-2 and IFN-g/IL-2 responses to CD4+ and CTL-epitopes 
were the same (Wilcoxon test). Anti-PR antibody responses triggered 
via both routes were low.
Conclusion: These data show that the correct immunogen delivery 
can strongly improve the magnitude of immune response induced by 
DNA vaccines. With further improvements, the ability of DNA-vaccines 
to induce an immune response would reach the level required for 
human applications.
P02.35 LB 
Rapid Appearance of Vaccine-Induced 
Potentially Protective Anti-Env Antibody 
Responses with Early Co-administration of 
gp120 with NYVAC or DNA
J.L. Heeney1, R. Wagner2, M. Esteban3, B. Jacobs4, K. Foulds5,  
M. Roederer5, S. Self6, S. Barnett7, S. Phogat8, D. Montefiori9,  
G. Tomaris9, and G. Pantaleo10
1University of Cambridge, Cambridge, UK; 2University of 
Regensburg, Regensburg, Germany; 3Centro Nacional de 
Biotecnologia-Consejo Superior de Investigaciones Cientificas, 
Madrid, Spain; 4Arizona State University, Tempe, AZ, USA; 
5Vaccine Research Center, NIAID, NIH, Bethesda, MD, 
USA; 6SCHARP, Fred Hutchinson Cancer Research Center, 
Seattle, WA, USA; 7Novartis Vaccines and Diagnostics Inc., 
Cambridge, MA, USA; 8Sanofi-Pasteur, Swiftwater, PA, USA; 
9Duke University Medical Center, Durham, NC, USA; 10Centre 
Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Background: The RV144 study demonstrated that anti-Env antibody 
responses (including V1V2 IgG) were scarcely detected before gp120/
AIDSVAX administration, e.g. during the first 3 months and waned 
rapidly by month 12, e.g. 6 months after the last ALVAC/AIDSVAX 
boost. These results suggest that early appearance and longer 
persistence of V1V2 IgG antibodies may be associated with a better 
vaccine protection. 
Methods: The newly generated DNA-C and NYVAC-C were used in 
different prime/boost combinations with bivalent clade C gp120 (TV1 
and 1086) proteins formulated in MF59 at week 0, 4, 12, 24 and 48. 
DNA and NYVAC were used either as a prime alone at week 0 and 4 or 
co-administered with the bivalent gp120 at all time points. One arm of 
the study evaluated DNA+bivalent gp120 at all time points. Each study 
group consisted of 8 mature rhesus macaques. Vaccine-induced T-cell 
responses were assessed by ICS and IFNg ELISpot. Humoral responses 
were assessed by binding antibody multiplex assays (including V1/
V2 IgG), peptide microarray, neutralisation assays, and ADCC assays. 
Results: Administration of the bivalent gp120 protein in combination 
with DNA or NYVAC at week 0 and 4 was consistently associated with 
high levels of binding IgG anti-Env including V1V2 antibodies by week 
6 (2 weeks after the 2nd protein administration) as compared to the 
study Groups receiving NYVAC or DNA alone as a prime. In these latter 
Groups, antibody responses were only detected at week 14 (2 weeks 
after the 1st protein administration in combination with NYVAC). The 
influence of early bivalent gp120 administration on the long-term 
persistence of binding IgG anti-Env and neutralizing antibodies is 
currently being assessed and will be presented at the conference.
Conclusion: Early bivalent gp120 protein co-administration with 
NYVAC or DNA was associated with rapid appearance (week 6) of 
vaccine-induced potentially protective antibody responses.
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P02.37 LB 
Immunization of Humanized BLT Mice Against 
Gag Alters Early HIV-Specific CD8+ T Cell 
Responses and Transiently Suppresses Viremia
T.E. Dudek1, C.R. Maldini1, V.D. Vrbanac2, E.F. Mellors1, D. Tully1, 
K.A. Power1, R. Batorsky1, E. Seung2, M. Deruaz2, K.F. Bryant3,  
M. Altfeld1, A.D. Luster2, D.M. Knipe3, A.M. Tager2, and T.M. Allen1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; 
2Massachusetts General Hospital, Boston, MA, USA; 3Harvard 
Medical School, Boston, MA, USA
Background: Humanized BLT mice appear to accurately reflect HIV-
specific CD8+ T cell responses observed during natural infection (Dudek 
et al, Science Translational Medicine 2012). However, little is known 
regarding the potential of this model to elicit vaccine-induced immunity.
Methods: Four sets of BLT mice reconstituted from distinct human 
donors were immunized with a PLGA microparticle prime and a 
replication-defective HSV vector boost. Mice were then challenged 
intravaginally with a moderate dose of HIV (Groups 1 and 2) or 
intraperitoneally with a high dose (Groups 3 and 4) and bled every 
two weeks to measure cellular immune responses, viral loads and 
sequence evolution.
Results: Following intravaginal challenge, 3/6 mice from Group 
1 successfully suppressed viremia for up to 6 weeks with a mean 
difference in viral loads of 1.7 log10 (p ≤ 0.03) during this period. Post-
challenge Gag-vaccinated mice exhibited a more rapid and stronger 
Gag-specific T cell response compared to mock-immunized mice. 
Alternatively, in Group 2, expressing a distinct HLA haplotype, only 
1/9 mice delayed viremia for up to 4 weeks and had an overall 0.4 
log10 mean difference at week 6 post-challenge (p = 0.03). With the 
more demanding high-dose intraperitoneal challenge, a transient 0.5 
log10 difference in the mean viral loads was observed at week 6 post-
challenge (p < 0.04; Groups 3 and 4).
Exploring a mechanism for the immune-mediated control of HIV 
in Group 1, deep sequencing revealed increased rates of immune 
selection pressure in p17 by 6 weeks post-infection in vaccinated 
mice (3/6 Gag-vaccinated vs 1/4 mock-immunized), supportive of 
enhanced Gag-specific immunity. Importantly, Gag-vaccinated mice 
that exhibited control showed delayed viral escape in this epitope, 
suggestive of preservation of this response.
Conclusion: These results suggest that humanized BLT mice support 
vaccination studies aimed at elucidating the importance of altering 
CD8+ T cell immunodominance hierarchies against various HIV targets.
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P03.02 D
Modalities of Broad and Potent Antibody 
Neutralization at the CD4-Binding Site on HIV-
1 gp120
T. Zhou1, L. Chen1, R. Lynch1, X. Wu1, S. Srivatsan1, S. Moquin1, 
Y. Yang1, B. Zhang1, J.R. Mascola1, and P.D. Kwong1
1NIAID, NIH, Bethesda, MD, USA
Background: The functionally conserved site of CD4-attachment on 
HIV-1 gp120 is one of the major sites of vulnerability to neutralizing 
antibodies. Broad and potent human antibodies that target this site, 
represented by antibody VRC01, have been found in half a dozen 
donors. VRC01-class antibodies utilize a common V-gene origin 
VH1-2*02 and achieve broad neutralization by partially mimicking 
CD4. Recently, antibodies with non-IGVH1-2*02 origin and relatively 
long CDRH3, some capable of neutralizing as effectively as VRC01, 
were isolated from 4 donors. Elucidation of the mechanisms used 
by different antibodies to achieve effective neutralization is of great 
importance to vaccine design.
Methods: To define the modalities of antibody recognition of the CD4-
binding site (CD4BS), we crystallized VRC01-class antibodies from 6 
donors and non-VRC01 class antibodies from 4 donors in complex 
with HIV-1 gp120, and analyzed the structures for common and special 
features in HIV-1 recognition.
Results: Structures of VRC01-class antibodies revealed a convergence 
in viral recognition with Vgene-encoded CDRH2 and framework 
H3 mimicking the action of CD4 C’C” ridge, despite variations in 
antibody sequences and donor origins. In contrast, structures of non-
IGVH1-2*02 antibodies showed canonical V(D)J-encoded CDRH3 
recognition at the CD4BS without CD4 mimicry. Comparison of the 
Vgene-encoded and V(D)J-encoded modalities of gp120 recognition, 
however, indicated that these antibodies recognize a common set of 
residues that forms a “super site” of recognition at the CD4BS. Despite 
differences in the Vgene-encoded and V(D)J-encoded modalities, the 
orientations of CD4BS antibodies relative to the viral spike appear to 
be confined within 45 degree of freedom indicating restricted antibody 
accessibility to the CD4BS on viral spike.
Conclusion: Broad and potent neutralization of HIV-1 can be 
achieved through multiple modalities of recognition at the CD4-
binding site. However, the accessibility to this site on viral spike may 
be restricted to certain range of approach for antibodies to achieve 
effective neutralization.
P03.01 D
Heterogeneity of Anti-V2 ADCC Ab Responses 
and Implications for Vaccine Development
J. Pollara1, M. Bonsignori1, M. Moody1, S. Alam1, K. Hwang1, 
T.C. Gurley1, D.M. Kozink1, D.J. Marshall1, J.F. Whitesides1, C. 
Tsao1, J. Kaewkungwal2, S. Nitayaphan3, P. Pitisuttithum2, S. 
Rerks-Ngarm4, G.D. Tomaras1, J.H. Kim5, N.L. Michael5, D.C. 
Montefiori1, H. Liao1, B.F.  Haynes1, G. Ferrari1, and the Center 
for HIV/AIDS Vaccine Immunology1
1Duke University, Durham, NC, USA; 2Mahidol University, 
Bangkok, Thailand; 3Armed Forces Research Institute of 
Medical Sciences, Bangkok, Thailand; 4 Ministry of Public 
Health, Thailand; 5U.S. MHRP, Silver Spring, MD, USA
Background: Anti-V1/V2 HIV-1 envelope (Env) binding antibodies 
(Abs) correlated with decreased risk of HIV-1 infection in the RV144 
clinical trial. We isolated four anti-V2 monoclonal Abs (mAbs) from 
vaccine recipients and characterized their ability to recognize HIV-1 
Env on the surface of infected cells and to mediate ADCC. We also 
determined whether anti-V2 Abs synergize with vaccine-induced 
anti-C1 conformational Abs to bind HIV-1 infected cells and mediate 
ADCC.
Methods: HIV-1 Env-specific mAbs were isolated from memory B cells 
of vaccine recipients enrolled in the RV135 and RV144 trials. CD4 + 
target cells infected with clade AE (CM235), clade B (BaL), and clade C 
(1086.C) infectious molecular clones were used to evaluate the breadth 
of mAb binding. The ability of the anti-V2 mAbs to synergize with 
vaccine-induced anti-C1 antibodies for the recognition of infected cells 
and ADCC was evaluated on clade AE CM235-infected target cells.
Results: All four RV144 vaccine-induced V2 IgG mAbs displayed unique 
profiles for binding HIV-1 infected cells and mediating ADCC. Env 
binding characteristics of CH58 mAb most closely recapitulate those 
of Ab responses correlated with lower risk of infection. Interestingly, 
some combinations of anti-V2 mAbs (i.e. CH58, HG107) and anti-C1 
mAbs displayed functional synergy. Functional synergy is defined as 
enhanced binding of anti-V2 mAbs to infected cells, higher peak ADCC 
activity, and improved ADCC endpoint titers to levels similar to those 
detectable in the plasma of RV144 vaccine recipients.
Conclusion: RV144 vaccine-induced anti-V2 mAbs are of diverse fine 
specificities and recognize different conformational structures of Env 
present on the surface of infected cells. This specificity impacts the 
ability of these mAbs to mediate ADCC, and to act in synergy with 
vaccine-induced anti-C1 mAbs. Understanding how to induce mAbs 
with fine specificities capable of functional synergy will inform future 
vaccine design. (NIH-U19 AI067854-07, NIH AI07392).
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P03.04 
Enhanced DNA Vaccine with Protein Boost 
Delivered by EP Expands B- and T cell 
Responses and Neutralizing Phenotype In Vivo
K. Muthumani1, M. Wise1, B.E. Kate2, J. Yan2, C. Lucke1, B. Bian1, 
J. Mendoza2, N.Y. Sardesai2, and D.B. Weiner1
1University of Pennsylvania School of Medicine, Philadelphia, 
PA, USA; 2Inovio Pharmaceuticals, Blue Bell, PA, USA
Background: An effective HIV vaccine will most likely require the 
induction of strong T cell responses, broadly neutralizing antibodies 
(NAbs), and the elicitation of antibody-dependent cellular cytotoxicity 
(ADCC). Previously, we demonstrated the induction of strong HIV/
SIV cellular immune responses in macaques using consensus DNA 
immunogens delivered via electroporation (EP). While these results 
demonstrated the increased magnitude and breadth of cellular 
responses using DNA immunogens, DNA’s ability to induce high 
antibody titers and neutralization has remained limited.
Methods: Here, we investigate the immunogenicity of consensus 
Envelope DNA constructs encoding gp140 sequences from HIV-1 
subtypes A, B, and C in a DNA prime-protein boost vaccine regimen. 
Guinea pigs were primed with single- and multi-clade DNA via EP and 
boosted with recombinant gp120 protein. Sera were then analyzed for 
gp120 binding and neutralizing antibody activity. 
Results: Immunization with recombinant Env protein alone induced 
low-titer antibodies while a prime-protein boost protocol was able to 
induce significantly higher antibody titers. Sera from prime-protein 
boost groups were also able to neutralize a high percentage of viruses 
against a panel of tier 1 clade B viruses as well as multiple tier 1 clade 
A and clade C viruses. 
Conclusion: This study suggests that optimized DNA constructs 
and improved delivery modalities may be able to induce the B cell 
activation and antibody production that has eluded DNA vaccines 
in the past. Further investigation of the impact of this approach on 
immune breadth is underway.    
P03.03 D
Vaccine-Elicited CD4 Binding Site-Directed 
Antibodies Utilizing the Macaque Equivalent of 
the Human VH1-2 Heavy Chain Variable Gene 
Segment
M. Navis1, K. Tran2, Y. Li2, G. Phad1, C. Sundling1, R. Wilson2,  
M. Soldemo1, K. McKee3, J. Mascola5, R.T. Wyatt2, and G.B. 
Karlsson Hedestam1
1Karolinska Institutet, Stockholm, Sweden; 2IAVI Neutralizing 
Antibody Center at The Scripps Research Institute, La Jolla, 
CA, USA;  3Vaccine Research Center, NIAID, NIH, Bethesda, 
MD, USA
Background: Potent broadly neutralizing antibodies (bNAbs) isolated 
from HIV-1 infected individuals have yielded information about their 
interaction with conserved determinants, such as the CD4 binding site 
(CD4bs), on the envelope glycoproteins. One common feature of many 
CD4bs-directed bNAbs is their use of the same heavy chain variable 
gene segment, VH1-2, suggesting that activation of B cells expressing 
this V-segment is important for the elicitation of CD4bs-directed bNAbs. 
Therefore, we asked if the macaque homologue of VH1-2 is used by 
CD4bs-directed Abs elicited by subunit Env vaccination.
Methods: Using a well-defined Env immunogen, we previously reported 
detailed analyses of HIV-1 Env vaccine-elicited antibody responses 
in rhesus macaques. Here, we identified the macaque equivalent to 
human VH1-2. We then isolated CD4bs-specific antibodies utilizing 
this V-segment by single-cell sorting followed by PCR of matched 
heavy and light chain transcripts. Isolated monoclonal antibodies 
(MAbs) were evaluated for Env binding and neutralization activity. 
Epitope mapping was performed for the most potent MAb, GE356, and 
the Ab paratope was characterized by alanine scanning of the CDRs of 
the heavy and light chains and directly compared to VRC01. 
Results: Of 154 heavy chain sequences initially screened we produced 
4 functional clonally unrelated CD4bs-directed MAbs utilizing the 
macaque equivalent of human VH1-2. All MAbs were capable of 
neutralizing Tier 1 viruses and one MAbs, GE356; displayed improved 
neutralization compared to previously isolated vaccine-elicited CD4bs-
directed Abs of diverse VH usage. Alanine scanning of GE356 showed 
that amino acid residues in the CDR3 and to a lesser extent CDR1 
were critical for neutralization, demonstrating its differential mode of 
interaction with HIV-1 Env compared to VRC01.
Conclusion: Using single-cell sorting of macaque memory B cells, 
we isolated CD4bs-directed MAbs utilizing the macaque equivalent 
of the human VH1-2 representing the first demonstration that B 
cells expressing this V-segment are activated by Env immunization 
in primates.
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P03.06 
Improved Definition of Memory B Cells by the 
CD45RB Marker Allows the Identification of 
New Altered B Cell Subsets in HIV-1 Infected 
Patients
J. Carrillo1, E. Negredo2, J. Puig2, M. Curriu1, J. Navarro3,  
M. Crespo3, B. Clotet4, and J. Blanco1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2Fundació Lluita contra la SIDA, Barcelona, Spain; 
3Hospital Universitari Vall d’Hebron, Barcelona, Spain; 
4IrsiCaixa Institute for AIDS Research, HIVACAT, Fundació 
Lluita contra la SIDA, Barcelona, Spain 
Background: HIV-1 infected individuals show an impaired B cell 
memory compartment. CD27 is widely used as surrogate marker for 
the identification of memory B cells in human. However, a CD27- 
memory B cell population, which is expanded in HIV-1 infected 
individuals, has been identified in humans. Recently, CD45RB has 
been suggested as a new marker for human memory B cells. Thus, we 
have explored whether use of both CD27 and CD45RB may be useful 
to study memory B cells in HIV-1 infection.
Methods: Viremic untreated HIV-1 patients (n=12), aviremic HIV-
1-infected individuals under HAART (n=18) and uninfected healthy 
control (10) were analyzed.  Memory B cell compartment was defined 
using anti-CD19, anti-IgD, anti-CD27 and anti-CD45RB antibodies.
Results: HIV-1 infected patients showed reduced CD27+CD45RB+ B 
cells, in both the IgD+ (marginal zone-like B cells) and IgD- (switched 
B cells) subsets. Interestingly, when the switched B cell subset was 
analyzed, the percentage of CD27+CD45RB- was higher in untreated 
HIV-1 infected individuals than in healthy controls (p< 0.05) and 
its normalization by HAART correlated with the extent of CD4 T cell 
recovery. Despite this, patients that recover CD4 T cells still harbored 
increased frequencies of CD27-CD45RB+IgD- B cells compared with 
uninfected controls (p<0.05)
Conclusion: The combination of CD27 and CD45RB allows a better 
identification of the memory B cell compartment. Whereas the 
CD27+CD45RB+ memory B cell compartment is reduced in HIV-1 
infected patients, the CD27+CD45RB-IgD- is increased in untreated 
infected individuals and remains overrepresented in patient with a poor 
immunological responses to HAART, suggesting that the activation of 
the immune system may play a major role in the expansion of this B 
cell population.
P03.05
Systematic Profiling of Polyclonal HIV 
Antibodies and Prediction of Effector Functions
E.P. Brown1, C. Bailey-Kellogg1, G. Alter2, and M. Ackerman1
1Dartmouth College, Hanover, NH, USA; 2Ragon Institute of 
MGH, MIT and Harvard, Cambridge, MA, USA
Background: Antibody-dependent effector functions (ADEF) with the 
ability to recruit the innate immune response may play an important 
role in combating the spread of HIV infections.  ADEF are mediated 
by the antibody Fc and depend on antibody class and glycosylation 
status.  We describe the systematic profiling of the Fc-regions of HIV-
specific antibodies isolated from different patient sera.     
Methods: Using a LuminexTM-based suspension array, HIV antibody 
fractions binding to various HIV antigens are captured on beads and 
probed for binding to (1) antibody class-specific binding reagents, 
(2) Fc receptors, (3) complement proteins and (4) different lectins. 
The obtained binding profiles are correlated with other measures of 
effector function and may help to understand which ADEF are crucial 
to provide protection.
Results: We demonstrate comparable results to many current gold 
standard measurements including ELISA and Biacore using monoclonal 
Abs and polyclonal sera from patients.  In addition, we have profiled 
a large cohort of HIV+ patients and some vaccinees to learn how the 
overall antibody response differs based on patient class or vaccine.
Conclusion: In the future we wish to further elucidate which ADEF are 
important in driving protective clinical responses.  Such knowledge 
would be important for our understanding of the overall humoral 
response to HIV infection.  On a more practical note, we would also 
be able to screen for such correlates in future vaccine trials using our 
robust and high throughput system.
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P03.08
Microplate-Formatted Mammalian Protein 
Expression for Dissection and Improvement of 
Antibodies and Immunogens
Y. Yang1 and P.D. Kwong1
1NIAID, NIH, Bethesda, MD, USA
Background: Mammalian protein expression is a critical step in 
the functional assessment of antibodies and immunogens.  Recent 
technologies have enhanced the identification of antibody variants (e.g. 
from 454-based sequencing of B cell transcripts) as well as the design 
of immunogens.  When hundreds of antibody variants or thousands 
of immunogen candidates need to be expressed and characterized, a 
bottleneck arises with current conventional expression and purification 
methods, which are often an inefficient, time-consuming and resource-
intensive process.
Methods: Presented here is a 96-well microplate-formatted method 
of transfection, expression, and screening.  The method has been 
optimized for secretion from mammalian cells, to improve the efficiency 
of a high-throughput protein expression, and to facilitate functional 
dissection of broad neutralization antibodies and immunogens. 
Results: Compared to standard protein expression (e.g. from individual 
100-ml expression), the reduction to 0.1-ml expression represents a 
1000-fold reduction in volume.  Despite this reduction, the expression 
of secreted antibodies such as VRC01 is generally higher.  Throughput, 
however, is dramatically enhanced, with a single plate able to 
produce 96 different immunogens, at levels of expression for secreted 
immunogens which are suitable for direct assessment of function by 
ELISA.
Conclusion: The 96-well expression platform presented here offers 
ease of use and efficiencies in time and cost effectiveness, while 
maintaining – and even in many instances improving – relative 
higher quality and yield.  The method provides a potential tool 
for high throughput characterization of antibody variants and 
secreted immunogens, which should help to facilitate discovery and 
development of HIV-1 neutralizing antibodies and immunogens.
P03.07
3D Map of Positional Variability in V1V2
E. Shmelkov1 and T. Cardozo1
1New York University School of Medicine, New York, NY, USA
Background: A molecular correlate of risk for HIV-1 infection is 
associated with the V1V2 domain of gp120, suggesting that an epitope 
targeted by protective antibodies (Abs) is located in this region. In our 
study, we combined the most recent structural and epidemiological 
data to map the potential sites of broadly neutralizing antibody 
epitopes in V1V2.
Methods: First, each position of V1V2 was scored according to its 
amino acid variability as previously described by Almond et al. (V1V2 
sequence information was obtained from the LANL HIV Database). 
Specifically, we calculated the variability score as 1 – p/n (p is the 
number of occurrences of the most common amino acid at a given 
position; n is the total number of V1V2 sequences), and normalized 
it in a way that the most variable position in the loop had the score 
of 100%. Then, the resulting positional variability score was mapped 
onto the 3D structures of V1V2 bound to anti-V1V2 Abs PG9, PG16, 
CH58, and CH59.
Results: Our map of positional variability demonstrates that the most 
variable positions of V1V2 are clustered to three linear regions: one 
of which is located in V1 (positions 133-152) and two in V2 (169-172; 
185-190). For example, the Abs CH58 and CH59 target one of these 
highly variable sites that accounts for their relatively narrow cross-
reactivity. Nevertheless, the majority of the remaining, less variable 
positions in V1V2 are not likely to be accessible by Abs as they are 
masked by the glycans and/or the V1V2 fold, leaving only three 
relatively conserved prospective epitopes exposed: one linear epitope 
located on the tip of the V2 loop (162-168) and two discontinuous 
epitopes located in proximity to the integrin binding site.
Conclusion: Our 3D map suggests three conserved unmasked sites on 
V1V2, which could be utilized as leads for the detection of protective 
anti-V1V2 Abs.
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P03.10 
Characterization of Highly Neutralizing 
Antibody Sensitive HIV-1 gp120 Induced Under 
High Concentrations of Maraviroc (MVC) In Vitro
S. Boonchawalit1, S. Harada2, S. Matsushita1, and K. Yoshimura2
1Graduate School of Medical Sciences, Kumamoto University, 
Kumamoto, Japan; 2National Institute of Infectious Diseases, 
Shinjuku, Japan
Background: The small-molecule CCR5 antagonist maraviroc (MVC) is 
the first CCR5 inhibitor licensed for clinical use. Recently, we selected 
HIV-1 variants resistant to MVC in vitro, and found that the resistant 
variants became highly sensitive to anti-Env neutralizing monoclonal 
antibodies (nMAbs). In this study, to determine the key mutations for 
the accessibility of nMAbs to the epitopes in Env, we constructed the 
MVC-resistant clones and investigated the susceptibility to anti-Env 
nMAbs and autologous plasma IgGs.
Methods: We exposed high CCR5-expressing PM1/CCR5 cells to 
a clinical isolate (HIV-1KP-5) with MVC for induction of MVC-bound 
CCR5-adapted variants at 48 passages. We also passaged HIV-1KP-5 in 
low CCR5-expressing parental PM1 cells for low CCR5-adapted variant. 
We constructed three infectious clones with each 48-passaged Env.
Results: The MVC-bound CCR5-adapted variants acquired four 
mutations, T297I (V3), M434I (C4), V200I (C2), and K305R (V3) in 
the gp120. The MVC-bound CCR5-adapted clones containing the four 
mutations and low CCR5-adapted clones showed higher sensitivity to 
MAbs b12 (anti-CD4bs) and 4E9C (anti-CD4i) than the passage control 
clone. Interestingly, the clone with the MVC-bound CCR5-adapted Env 
was highly sensitive to anti-V3 MAb KD-247, while the low CCR5-
adapted and passage control clones were not. We also examined 
whether the infectious clones were neutralized by autologous plasma 
IgGs. The plasma IgGs were able to completely neutralize the clone 
with the MVC-selected Env (IC50: 2.6–37 µg/ml), but not the low 
CCR5-adapted and the passage control clones.
Conclusion: These findings indicated that such MVC-bound CCR5-
adapted mutations might contribute to the expression of neutralizing 
epitopes for not only CD4bs and CD4i, but also the anti-V3 MAb. The 
data also suggest that the four mutations modulate exposure of V3 
epitope. Further elucidation of this mechanism using a number of 
mutant clones with single mutation is underway.
P03.09
Infection Enhancement in Sieve Analysis of 
AIDSVAX Clinical Trials
E. Shmelkov1 and T. Cardozo1
1New York University School of Medicine, New York, NY, USA
Background: Elicitation of a protective antibody (Ab) immune response 
by vaccination could prevent infection with HIV-1. However, some 
vaccines increase susceptibility to infection by the target pathogen. 
Despite the fact that the antibody-dependent enhancement (ADE) of 
HIV-1 infection in vitro was first described in 1980s, no indication 
of vaccine-induced enhancement was observed in clinical trials until 
recently, when the increased HIV-1 acquisition risk was detected in 
selected subgroups of vaccinees in the STEP study. More recently, a 
case-control analysis of RV144 revealed that binding of IgA to Env was 
directly correlated with infection risk.
Methods: We conducted a sieve analysis for ADE effects in the 
AIDSVAX clinical trials. The distributions of epitopes targeted by 
several anti-V3 monoclonal Abs (mAbs) among the breakthrough HIV-
1 sequences were profiled, and the epitope-specific infection counts in 
vaccinated and placebo cohorts were compared. Distributions of the 
same epitopes in the breakthrough sequences from the STEP study 
were studied as a negative control.
Results: Using two epitope-prediction methods, Signature Motif 
Method and Method of Dynamic Epitopes, we detected a significant 
difference in VAX004 ‘vaccine’ cohort in the occurrence of overlapping 
epitopes targeted by mAbs 447-52D, 537-10D, and 268-D. For all 
three mAbs, the number of vaccinees infected with viruses bearing 
a cognate epitope was significantly greater than the corresponding 
number in placebo recipients, suggesting possible ADE effects. No 
significant difference was detected in STEP study.
Conclusion: From a purely molecular epidemiological point of view, 
certain mAb-defined V3 epitopes may have been associated with ADE 
in the VAX004 trial.  Notably, in vitro enhancement of HIV-1 infection 
by mAb 268-D has previously been reported. The epitopes targeted by 
447-52D and 537-10D are molecular subsets of the 268-D epitope. 
Our results raise the hypothesis that vaccine-elicited Abs similar in 
specificity to 268-D may have enhanced HIV-infection in subjects in 
the VAX004 clinical trial.
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P03.12 
Evidence for a Continuous Drift of the HIV-
1 Species Towards Higher Resistance to 
Neutralizing Antibodies over the Course of the 
Epidemic
M.Bouvin-Pley1, M. Morgand1, A. Moreau1, P. Jestin2,  
C. Simonnet1, L. Tran2, C. Goujard2, L. Meyer2, F. Barin1, and  
M. Braibant1
1Research Unit INSERM 966 Morphogenesis and Antigenicity 
of HIV and Hepatitis Virus, Tours, France; 2Research Unit 
INSERM U1018 Université Paris Sud, Paris, France
Background: Most of the patients develop autologous neutralizing 
antibodies (NAbs) during HIV-1 infection. These NAbs drive the viral 
evolution and lead to the selection of escape variants at the individual 
level. The aim of our study was to check if, subsequently to the selective 
pressure exerted by the individual NAbs responses, the HIV-1 species 
evolved at the population level towards an enhanced resistance to 
antibody neutralization.
Methods: We compared the neutralization sensitivity of early/
transmitted HIV-1 variants from patients infected by subtype B viruses 
at three calendar periods (1987-1991/1996-2000/2006-2010). 
Infectious pseudotyped viruses expressing envelope glycoproteins 
representative of the viral quasi-species infected each patient were 
generated. Their sensitivity to neutralization was compared by pools 
of human neutralizing sera and by an updated panel of 13 human 
monoclonal (HuMo) broadly NAbs. In addition, to verify whether 
the viral evolution coincided with a poorer capability to induce 
NAbs, the neutralizing activity of sera collected at least 3 years after 
seroconversion from 60 (2x30) subtype B infected patients enrolled 
at the two extreme periods of the study (1987-1991/2003-2007) was 
tested towards reference tier 2 heterologous viruses.
Results: A significantly progressive enhanced resistance to 
neutralization was observed over time, both by human sera and by 
most of the HuMoNAbs tested (b12, VRC01, VRC03, NIH45-46G54W, 
PG9, PG16, PGT121, PGT128, PGT145). Despite this evolution, one 
combination of two HuMoNAbs (NIH45-46G54W and PGT128) still was 
able to neutralize the most contemporary HIV-1 variants. Moreover, 
we observed a significant reduction of the heterologous neutralizing 
activity of sera from individuals infected most recently (2003-2007) 
compared to patients infected earlier (1987-1991), suggesting that the 
increasing resistance of the HIV species to neutralization coincided 
with a decreased immunogenicity.
Conclusion: These data provide evidence for an ongoing adaptation 
of the HIV-1 species to the humoral immunity of the human population 
over the course of the epidemic.
P03.11
Elicitation of Broadly Neutralizing HIV-1 
Antibodies by Guiding the Immune Responses 
Using Primary and Secondary Immunogens
Z. Yang1, J. Li1, T. Yuan1, L. Chen2, Q. Lou2, H. Ying2, and  
M. Zhang1
1University of Hong Kong, Hong Kong; 2Zhejiang Academy of 
Medical Sciences, Hangzhou, China
Background: Broadly neutralizing HIV-1 monoclonal antibodies 
(bnmAbs) are potential key components of protective immunity. Such 
antibodies have not been induced by any vaccine immunogens so far. 
HIV-1 envelop proteins lack detectable binding to putative germline 
form of bnmAbs, which may partly explain the poor performance 
of envelop-based vaccine. We hypothesized that B cell-lineage 
immunogens targeting the germline B cell receptors of bnmAbs may 
help prime the immune system and guide the immune response. 
Methods: Using b12 as a model antibody, we screened various cDNA 
libraries against b12 germline and intermediate antibodies. Isolated 
(poly) peptides were either synthesized or expressed as human Fc 
fusion proteins. Rabbit immunization was carried out by priming 
with the (poly) peptides and boosting with SF162 gp140 trimer. 
Immunization with SF162 trimer alone was used as a control. Rabbit 
IgGs were tested by competition ELISA with mature IgG1 b12, and by 
TZM-bl neutralization assay. 
Results: Prime with b12 germline antibody specific peptides or peptide-
Fc fusions followed by boost with envelop trimer induced rabbit 
antibodies that competed with mature IgG1 b12, while immunization 
with SF162 envelop trimer alone did not induce b12-like antibodies. 
The estimated EC50s were 675nM and 133.33nM for peptide and 
peptide-Fc primed rabbit IgGs, respectively. We are currently testing 
purified rabbit IgGs with a large panel of HIV-1 isolates in TZM-bl 
neutralization assay. Preliminary result indicated that immune rabbit 
IgGs did not neutralize four tier 2 HIV-1 isolates. 
Conclusion: Our results indicate that “two immunogens” (primary 
and secondary) strategy can direct the immune response and elicit 
antibodies that mimic the target bnmAb(s) in binding, but eliciting 
antibodies that mimic the target bnmAb(s) in neutralization requires 
further investigation. Boost with HIV-1 envelop trimer may distract the 
targeted immune responses. Our study suggests that non-HIV-derived 
(poly) peptides may be used as primary immunogens to guide HIV-1-
specific immune responses. 
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P03.14 
Isolation and Characterization of an 
Autoreactive CD4bs Broad Neutralizing 
Antibody from a Chronic HIV-1 Controller with 
Systemic Lupus Erythematosus
M. Bonsignori1, K. Wiehe1, R.M. Lynch2, S.K. Grimm3, D.M. Kozink1, 
K. Hwang1, J.A. Eudailey1, G. Yang1, M.E. Ackerman3, G. Kelsoe1, 
H. Liao1, M.A. Moody1, T.B. Kepler4, D.C. Montefiori1, J.R. Mascola2, 
and B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2Vaccine 
Research Center, NIAID, NIH, Bethesda, MD, USA; 3Dartmouth 
College, Hanover, NH, USA; 4Boston University School of 
Medicine, Boston, MA, USA
Background: The HIV-1 broadly neutralizing antibodies’ (bNabs) 
frequent polyreactivity, long HCDR3s and/or high levels of somatic 
mutations suggest that their development might be limited by immune 
tolerance controls.  We hypothesized that concomitant autoimmune 
diseases may facilitate the development of bNabs in HIV-1 infected 
subjects. We have identified a HIV-1 infected patient with Systemic 
Lupus Erythematosus (SLE) who controlled viral load despite the 
absence of protective HLA types and whose plasma broadly neutralized 
HIV-1, mostly via CD4bs antibodies. We sought to identify these 
antibodies and isolated bNAb CH98.
Methods: Memory B cells were cultured at near-clonal dilution. CH98 
autoreactivity was tested by Hep-2 cell indirect IF staining, ANA assay 
and a ProtoArray5 microchip for 9600 human host cellular antigens. 
CH98 epitope was mapped on a panel of 31 YU2 gp120 core mutants. 
CH98 threading onto known gp120-complexed CD4bs bNAb structures 
was modeled using the Rosetta 3.3 software.
Results: CH98 was retrieved from a memory B cell culture with RSC3/
RSC3Δ371I differential binding and neutralized 63% of 43 isolates 
in a multi-clade panel of tier-1 and 2 viruses (median IC50 =4.2ug/ml 
[range :< 0.02-49ug/ml]). CH98 heavy (VH 3-30) and light (VL 2-23) 
chains displayed high levels of somatic mutations (25% and 16%, 
respectively), long CDR3s (21 and 12 aa, respectively), an apparent 
24-nt n-region in LCDR3, and a 15-nt deletion in LCDR1. On HEp-2 
cells, CH98 displayed diffuse cytoplasmic reactivity, strong binding 
to dividing cells and binding to intracellular vesicles. CH98 reacted 
with numerous human proteins and bound strongly to the E3 ubiquitin 
ligase STUB-1.  Remarkably, CH98 bound to dsDNA, an SLE-related 
specificity.  Epitope mapping and structural modeling studies suggest 
that CH98 binds to the CD4bs through the HCDR3 with an orientation 
similar to that of CD4bs bNAb CH103.
Conclusion: These data are consistent with the hypothesis that 
tolerance dysregulation induced by SLE may have played a role in 
CH98 bNAb development and maturation.
P03.13
Improving HIV-1-Neutralizing Antibodies 
Through Use of Somatic Variants Identified by 
Next Generation Sequencing
B. Zhang1, Y. Kwon1, R.S. Rudicell1, K. McKee1, Z. Zhang2,  
X. Wu1, NISC Comparative Sequencing Program1, J.C. Mullikin1, 
L. Shapiro2, J.R. Mascola1, and P.D. Kwong1
1NIH, Bethesda, MD, USA; 2Columbia University, New York, 
NY, USA
Background: The discovery of HIV-1 neutralizing antibodies with 
high potency and breath makes the passive immunization with these 
antibodies increasingly promising. Improvement of these antibodies 
against a diverse of target viruses should facilitate the passive 
immunization development. Efforts have been made to improve 
antibody parameters such as neutralizing potency, breath, solubility, 
autoreactivity, and half-life. In each donor, millions of somatic variant 
of broadly neutralizing antibodies can be found, and some of them 
may have desired properties. We hypothesized somatic variants of 
existing VRC01-like HIV-1 neutralizing antibody identified by next 
generation sequencing can improve neutralizing potency and breath. 
Methods: We determined sequences of somatic variants of HIV-1 
neutralizing antibody heavy and light chain genes by next generation 
sequencing from the same patient where VRC01 was isolated. When 
they were paired with VRC01 heavy and light respectively, selected 
antibodies show high neutralizing activity. We then use the heavy 
chain and light chain genes to pair with optimized versions of VRC01 
heavy and light chains to make antibody variants. Neutralizing activity 
of the antibody variants was assessed on a panel of HIV-1 viruses.
Results: Results showed a few antibodies among these pairs increased 
neutralizing potency for up to three times. Two antibodies had a 
geometric mean IC 50 under 0.1ug/ml. These antibodies are under 
evaluation for autoreactivity and solubility. Mutants derived from the 
antibodies are also under construction and functional analysis.
Conclusion: We conclude that exploring of somatic variants is a useful 
tool to improve breath and potency for such therapeutic antibody 
that targets multiple virus variants. Human immune system provides 
a natural mechanism to optimize antibodies, and identify antibody 
variants through next generation sequencing could facilitate the 
development of the passive therapeutic approach. 
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P03.16 
A Unique Inflammatory Signature Tracks with 
the Development of Bnabs in the Absence of 
High Viremia
A. Dugast1, K. Benedict2, M. Hoffner1, F. Pereyra1, M. Seaman3,  
D. Lauffenburger2, and G. Alter1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2MIT, Cambridge, MA, USA; 3Beth Israel Deaconess 
Medical Center, Boston, MA, USA
Background: Over the past decade, there has been an exponential 
increase in the discovery of a number of new broadly neutralizing 
Abs (bNAbs). However, the mechanism by which bNabs are induced 
is unclear. While previous studies have implicated high viremia and 
associated immune activation as potential drivers for the development 
of bNAbs, it is unclear whether the virus and/or inflammation drive 
this potentiation of the antibody response, or whether particular 
inflammatory profiles may tune B cell immunity effectively. Here we 
sought to dissect the inflammatory signals associated wtih bNAb 
evolution in a large cohort of subjects that spontaneously control 
viral replication (Controllers), and to define whether viremia and 
inflammation can be unlinked as predictors of the induction of bNAbs.
Methods: Neutralizing activity, 19-plex cytokine analyses, and 
antibody subclass titers were performed in 103 Controllers. A decision 
tree was used to define the inflammatory profile associated with the 
evolution of bNAb activity.
Results: Among the 19 cytokines/chemokines tested, we observed 
that high plasma levels of CXCL13, sCD40L, TNFa, IP10, IL8 and 
MIP1b were enriched in Controllers that evolved bNAbs compared to 
those that did not. While none of the cytokines could independently 
predict bNAb evolution, we found that a specific pattern of cytokine 
production was associated with the evolution of bNAbs including high 
levels of TNFa and sCD40L but low levels of IL6. Conversely, subjects 
unable to induce bNAbs elicited a different cytokine profile marked by 
the absence of TNFa and IL8 but high levels of IFNg.
Conclusion: Overall, these data suggest particular inflammatory 
profiles; in the absence of active high level viral replication and 
diversification are associated with the evolution of protective humoral 
immune responses. Therefore vaccine adjuvanting approaches 
potentially able to elicit these profiles may play a key role in driving 
bNAbs that may provide sterilizing protection from infection.
P03.15
Dynamic Profiling of Antibody Responses 
Against HIV-1 Throughout Acute and Chronic 
Infection
S. Jin2, X. Shi2, Y. Ji1, Q. Wang2, H. Wang2, C. Yao2, Y. Zuo2,  
J. Yang2, T. Zuo2, L. Fu2, K. Arledge2, X. Han1, H. Shang1, and  
L. Zhang2
1No. 1 Hospital of China Medical University, Shenyang, China; 
2School of Medicine, Tsinghua University, Beijing, China
Background: Antibody response plays a crucial role in controlling 
HIV-1 infection.  However, our comprehensive understanding of this 
intricate process is far from complete. 
Methods: We report here a novel and robust technique to characterize 
polyclonal antibody responses using a large combinatorial antigen 
library displayed on the surface of the yeast. By positive selection of 
viral antigens recognized by patient plasma, a comprehensive profile 
of immune response can be qualitatively and quantitatively measured. 
Results: We characterized anti-HIV antibody responses in chronic 
and acute patients.  In the former, we found that antibodies primarily 
(~70%) targeted gp41, while a smaller proportion targeted gp120 
(~30%). Within gp41 and gp120, major antigenic regions were 
identified in the V1-V2, the V3-V5 domain, N-terminal gp41 and 
C-terminal gp41 domains.  For acute patients, we profiled the responses 
of an epidemiologically-linked pair for two years post-infection.  In 
both cases, we found that the majority of antibodies were directed 
against N-terminal gp41 during the first three months of infection. 
An anti-V3-V5 response was detected soon afterwards, followed by 
emergence of an anti-V1-V2 response about six months post-infection. 
Over the course of infection, the proportion of antibodies targeting 
N-terminal gp41 decreased, while that against V3-V5 and V1-V2 
increased, indicating that the in vivo polyclonal response is dynamic 
and evolving nature.  We are currently studying the contribution of 
each antigenic domain to overall neutralization activity. 
Conclusion: These results demonstrate that our yeast library system 
can comprehensively assess HIV-specific antibodies generated in vivo, 
and for the first time offers an efficient means of qualitatively and 
quantitatively mapping polyclonal immune responses.  We believe 
that applying this technique to a cohort of HIV-infected individuals 
with distinct virological and immunological features, as well as 
recipients of candidate vaccines, will improve our understanding of 
protective immunity and guide the development of effective vaccines 
and therapeutics. 
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P03.18 
Antibody Glycosylation Can Be Transiently 
Altered After Vaccination Against HIV
A. Mahan1, J. Tedesco1, K. Dionne1, A. Chung1, J. Cox2, W. Koff2, 
D. Barouch3, N. Michael4, J. Kim4, T. Suscovich1, and G. Alter1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, 
MA, USA; 2IAVI, New York, NY, USA; 3Beth Israel Deaconess 
Medical Center, Boston, MA, USA; 4U.S. MHRP, Silver Spring, 
MD, USA
Background: Structural changes in the N-linked glycan of the IgG Fc 
region are known to significantly alter antibody effector functions, 
including antibody dependent cellular cytotoxicity (ADCC), complement 
deposition, and antibody dependent phagocytosis. To date, little is 
known about how these glycans are regulated in vivo and whether 
vaccination can effectively elicit particular glycan structures.
Methods: In this study, we investigated the glycosylation structures 
of bulk and HIV-specific antibodies elicited in multiple HIV vaccine 
trials including RV144 (canarypox-Env/Gag/Pro & rgp120), VAX003 
(rgp120), V001 (DNA-Gag/Pol/Env & Ad5-Gag/Pol/Env), IPCAVD 
(Ad26-Env), and P002 (MVA-Env). We used capillary electrophoresis 
to separate and quantify the glycan structures released from 
IgGs to determine whether the vaccine groups elicited different 
glycosylation patterns.
Results: We found that the trials that utilized multiple doses of 
recombinant gp120, VAX003 and RV144, significantly changed 
the glycosylation patterns on bulk IgGs in vaccinees compared to 
the placebo groups. However, none of the other trials induced any 
significant changes in IgG glycans. Changes in RV144-induced IgG 
glycans were significantly correlated with antibody effector function. 
In particular, ADCC activity was negatively correlated with fucose 
content and sialic acid while galactose content correlated with FcR 
binding. Furthermore, we observed that the antibody glycan structures 
in RV144 vaccinees reverted to those observed in pre-vaccination 
samples between six and twelve months after the final immunization, 
which correlates with the previously reported waning of the vaccine-
induced immune response. 
Conclusion: In this study, we observed that significant changes in 
IgG glycosylation occur only in vaccines that contain multiple doses 
of recombinant protein, and these changes do not correlate with 
vaccine-elicited antibody titer. Additionally, these data support using 
IgG glycosylation as marker of antibody functionality and vaccine-
induced protection in the humoral immune response that should be 
investigated further along with other, better-studied humoral functions 
such as titer, ADCC activity, or FcR binding.
P03.17
Spontaneous-Death Fails to Explain the Lack of 
Recovery of B Cell Subsets in HAART-Treated 
HIV-1 Infected Patients 
J. Carrillo1, E. Negredo2, J. Puig2, B. Clotet3, and J. Blanco4
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2Fundació Lluita contra la SIDA, Barcelona, Spain; 
3IrsiCaixa Institute for AIDS Research, HIVACAT, Fundació 
Lluita contra la SIDA, Barcelona, Spain; 4IrsiCaixa Institute for 
AIDS Research, HIVACAT, Fundació Institut d´Investigació en 
Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain
Background: HIV-1 infection induces a specific loss of CD27+ memory 
B cells, which decrease in parallel with disease progression. Moreover, 
these cells are not properly recovered after HAART. Increased apoptosis 
of memory B cells could explain this phenomenon. Therefore, we have 
evaluated the absolute number and frequency of several B cell subsets 
and their sensitivity to spontaneous-death in HIV-1 infected patients.
Methods: Naïve and memory B cells from 40 HAART-treated 
virologically-supressed HIV-1+ patients and 27 uninfected individuals 
were analyzed by flow cytometry using antibodies against CD19, IgD 
and CD27. Absolute numbers were analyzed in fresh samples, while 
spontaneous cell-death of the different B cell subsets was determined 
using DiOC6 and Sytox Blue after 24-hours of ex-vivo culture. 
Results: Selected HIV infected individuals showed lower CD4 T cells 
than uninfected individuals (648±235 cells/µL vs 812±342 cells/µL, 
p=0.046). However, the number of B cells was equivalent (151±91 
cells/µL vs 129±73 cells/µL,). The analysis of B cells subsets confirmed 
the reduced proportion of CD27+ memory B cells in HAART-treated 
patients, in both, the IgD+ (p=0.0012) and the switched compartment 
(p=0.012). However, the analysis of spontaneous cell-death in B cell 
subsets did not show significant differences between HAART-treated 
HIV-1+ patients and uninfected individuals. In both groups, the CD27+ 
memory B cell subsets were more resistant to cell death than naïve B 
cells or CD27- switched B cells (p<0.0001), strongly suggesting that the 
expression of CD27 is associated with the survival of B cells in both 
HIV1+ patients and uninfected individuals.
Conclusion: Our results indicate that HIV-1+ patients showing a similar 
number of B cells and a lower frequency of CD27+ memory B cells 
exhibit similar levels of spontaneous memory B cell death suggesting 
that mechanisms other than apoptosis may be the major contributors 
to incomplete B cell subsets recovery in these patients.
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P03.20
A Family of Broad and Highly Potent V1V2-
Directed HIV-1 Neutralizing Antibodies 
with Long CDRH3s from a South African 
Seroconverter
N.A. Doria-Rose1, P. Moore2, R. Staupe1, J. Bhiman2, M. Ernandes1, 
I. Georgiev1, R. Bailer1, M. Louder1, S. O’Dell1, K. McKee1,  
E. Crooks3, S. Schmidt1, S. Abdool Karim4, J. Gorman1,  
C. Schramm5, N. Longo1, M. Pancera1, R. Rudicell1, Y. Yang1,  
Z. Zhang5, J. Zhu1, J. Binley3, L. Shapiro5, P. Kwong1, L. Morris2, 
and J. Mascola1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, 
USA; 2National Institute for Communicable Diseases of the 
National Health Laboratory Services, Johannesburg, South 
Africa; 3Torrey Pines Institute, San Diego, CA, USA; 4CAPRISA, 
University of KwaZulu-Natal, Durban, South Africa; 5Columbia 
University, New York, NY, USA
Background: Understanding the natural development of broad and 
potent HIV-1 neutralizing antibodies (NAbs) provides critical clues for 
rational vaccine design. The V1V2 region of HIV gp120 is a major site 
of vulnerability to NAbs. We therefore studied longitudinal samples 
from an HIV-1 seroconverter, CAP256, whose serum breadth and 
specificity had been mapped to V1V2.
Methods: Using PBMC samples collected from donor CAP256 at 1, 
2, and 4 years post-infection, we performed single-B cell cultures, 
followed by screening of culture supernatants by microneutralization 
assay. Positive wells were subjected to RTPCR to recover heavy and 
light chain immunoglobulin genes, which were subcloned, paired, 
and expressed. The resulting monoclonal antibodies (mAbs) were 
characterized by TZM-bl neutralization assay and ELISA.
Results: We isolated twelve V1V2-directed neutralizing mAbs from 
one somatic family from donor CAP256. The mAbs are 8-15% 
mutated in the VH gene, with extremely long CDRH3s of 37-39 amino 
acids. The broadest mAb neutralized 47% of a panel of 200 global 
HIV isolates, and 60% of isolates from Africa, with a highly potent 
geometric mean IC50 of 0.008 ug/ml. The mAbs are dependent on 
the quarternary structure of the viral spike, binding to intact virus-
like particles but not to monomeric Env proteins. Their neutralization 
activity maps to amino acid contacts within strand C of V1V2. Unlike 
the other broad V1V2 mAbs such as PG9, the CAP256 mAbs are only 
partially and variably dependent on the glycan at position N160 for 
heterologous neutralization. Despite this difference, neutralization 
fingerprint analysis shows a strong correlation between these mAbs 
and the PG9 class.
Conclusion: The broad and potent neutralizing activity of donor 
CAP256 can be attributed to a family of V1V2-directed mAbs. The 
discovery of mAbs with properties similar to the PG9 class yet different 
epitope requirements suggest a multiplicity of modes of recognition for 
this site of vulnerability. 
P03.19 
Analysis of Interaction Between Gp120 and 
CD4 Mimic Small Compounds that Enhance the 
Activity of Anti-HIV Neutralizing Antibodies
S. Harada1, S. Boonchawalit1, S. Matsushita2, and K. Yoshimura1
1National Institute of Infectious Diseases, Japan, Shinjuku-Ku, 
Tokyo, Japan; 2Kumamoto University, Kumamoto, Japan
Background: CD4 mimic small compounds (CD4MCs), NBD-556 and 
its analogues bind to the Phe43 cavity of gp120 and inhibit the gp120-
CD4 interaction. NBD-556 can also induce conformational changes in 
the gp120 architecture thereby exposing masked epitopes on the Env 
protein. In this study, we investigated the evolution of HIV-1 under the 
CD4MCs pressure to elucidate the interactions between gp120 and 
CD4MCs.
Methods: To select HIV-1 variants resistant to CD4MCs in vitro, we 
exposed PM1 cells to not only the bulked primary KP-5P virus but 
also the cloned KP-5P virus. The viruses were serially passaged in the 
presence of CD4MCs. 
Results: Initial in vitro selection experiments were carried out with 
the bulked primary KP-5P virus. Resistance against CD4MCs was 
associated with V255M, T375N/I, and M426I substitutions. For 
exclusion of the selection of preexisting variants within the KP-5P 
population, we constructed the molecular clone KP-5P virus. Using the 
cloned virus for induction of resistant variants against the CD4MCs, 
we also observed same mutations, V255M, T375N/I, and M426I. The 
finding indicates that these substitutions were acquired by de novo 
mutation. We observed F217L, V255M, G321D, T375N/I, I424T, 
N425K, M426I and I439V substitutions in vitro passages using the 
bulked and cloned viruses. The resistant profiles of the bulked and 
cloned viruses to CD4MCs were almost same, but not all. However, 
V255M, T375N/I and M426I substitutions might be key positions 
because the mutations appeared in different CD4MC-escaped variants. 
Conclusion: In summary, the three mutated positions (V255, T375, 
and M426) are found in the Phy43-cavity, and are closely interact 
to the surface of NBD-556 molecule on the crystal structure (PDB: 
3TGS). Elucidation of the molecular details governing the interactions 
between another gp120 and CD4MCs will assist in synthesizing novel 
CD4MCs to search for drugs with more potent power to change the 
tertiary structure of Env.
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P03.22
Engineering a Next Generation VRC01-Like 
Antibody with Improved In Vitro and In Vivo 
Function
R.S. Rudicell1, A. Pegu1, S. Ko1, Y. Kwon1, I. Georgiev1, X. Wu2,  
J. Zhu3, X. Chen1, N. Doria-Rose1, T. Zhou1, Y. Yang1, B. Zhang1, 
J. Todd1, S. O’Dell1, M. Louder1, J. Boyington1, W. Shi1, Z. Yang1, 
B.F. Haynes4, M. Roederer1, S. Rao1, P.D. Kwong1, J.R. Mascola1, 
and G.J. Nabel5
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2The Rockefeller University, New York, NY, USA; 3The Scripps 
Research Institute, La Jolla, CA, USA; 4Duke University Medical 
Center, Durham, NC, USA; 5Sanofi, Cambridge, MA, USA
Background: VRC01, which targets the conserved CD4 binding site 
on HIV-1 Env, is able to neutralize diverse strains of HIV-1 in vitro and 
can protect non-human primates (NHP) from SHIV challenge. Phase 
I clinical trials of VRC01 are scheduled to begin this year. Here, we 
present a new, engineered, second-generation VRC01-like monoclonal 
antibody (mAb) with increased potency, breadth, and half-life.
Methods: Using deep sequencing and bioinformatics, we identified 
VRC07, a clonal relative of VRC01 with increased neutralization 
potency and breadth. Structure guided designs were used to further 
optimize the potency and breadth of VRC07 while maintaining minimal 
auto-reactivity. Pharmacokinetics of top candidates were determined in 
Rhesus macaques.
Results: Both in vivo safety and efficacy were primary concerns; 
thus, we screened structure-based, rationally designed variants of this 
antibody for both neutralization potential and auto-reactivity. Through 
this process, we identified four optimized VRC07 candidates that had 
at least a 10-fold increase in potency, increased breadth, and minimal 
auto-reactivity. An FcRn binding site mutation was added to the 
optimized mAbs to increase their half-life. Pharmacokinetic analyses 
in non-human primates confirmed both the increased half-life and 
minimal auto-reactivity.
Conclusion: mAbs represent a promising intervention for the 
prevention and treatment of HIV/AIDS whose efficacy in humans has 
yet to be determined. For optimal activity, mAbs should be optimized 
for potency, breadth, and in vivo stability and safety. Here, we have 
successfully used a rational, structure-based optimization strategy to 
engineer a next generation HIV-1 mAb. Clinical manufacturing of our 
top candidate has begun. Additionally, we are initiating NHP passive 
transfer studies to determine the plasma mAb concentration necessary 
for protection from a high dose SHIV challenge.
P03.21
Characterizing the Functional Autoreactivity 
and Polyspecificity of the MPER-Specific bNAb 
4E10 and an Ensemble of Its Germline-Encoded 
Precursors
K. Finton3, J. Jaffe3, B. Larman1, K. Larimore3, D. Friend3,  
C. Correnti3, A. Stuart2, T. Vanden Bos3, S. Elledge1,  
P. Greenberg3, L. Stamatatos2, and R.K. Strong3
1Harvard University Medical School, Boston, MA, USA; 2Seattle 
BioMed, Seattle, WA, USA; 3Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA
Background: The bNAb 4E10 recognizes an epitope in the HIV 
gp41 MPER. Previous attempts at eliciting 4E10, by vaccination with 
envelope-derived or reverse-engineered immunogens, have failed, but 
have yielded tight-binding, computationally-designed 4E10 ‘epitope-
scaffolds’ that can elicit epitope-specific responses. The ontogeny 
of functional 4E10-equivalent responses has been presumed to be 
blocked by inherent autoreactivity. Previously identified candidate 
4E10 autoantigens include the mitochondrial lipid cardiolipin and a 
nuclear splicing factor, 3B3.
Methods: Heavy-chain knock-in mice were generated to confirm 
functional autoreactivity. A large-scale peptide library was used to 
identify candidate protein autoantigens. Carefully-controlled SPR 
binding assays were performed to characterize 4E10, substructure and 
germline precursor recognition of candidate autoantigens and epitope-
scaffolds. Immunohistochemistry was used to validate autoantigens. 
Crystal structures of a panel of 4E10 germline precursors were 
determined, alone and in complexes. 
Results: 4E10 knock-in mice displayed significant B cell compartment 
dysregulation, consistent with autorecognition. However, 4E10 
bound only weakly and non-specifically to cardiolipin-containing 
liposomes, through interactions dominated by electrostatic rather than 
hydrophobic interactions. Based on peptide library binding patterns, 
4E10 displays limited, focused polyspecificity and recognizes a novel 
epitope shared by three inositol trisphosphate receptors (ITPRs). Tissue 
staining demonstrated reactivity consistent with ITPR1 as the likeliest 
candidate autoantigen and precluded nuclear antigens, such as 3B3. 
Conclusion: These results argue that 4E10 recognition of lipids in 
general, or cardiolipin specifically, is unlikely to affect selection or 
neutralization mechanisms and that 4E10 MPER and ITPR1 recognition 
are distinct enough to permit eliciting 4E10-like responses while 
evading autoimmunity. Functional, structural and binding studies of 
an ensemble of the twelve likeliest 4E10 germline-encoded precursors 
show no neutralizing potency, extremely weak binding to Env, but 
strong affinities for epitope-scaffolds, and remarkable conservation 
of recognition mechanisms. These results, in combination with the 
observed variation in the human 4E10 precursor repertoire, suggest 
pathways to achieve 4E10-equivalent responses by vaccination.
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P03.24
CD4-Induced Epitopes Are Exposed on Cell-
Bound HIV-1: Potential Targets for Fc Receptor 
Mediated Humoral Immunity
M. Mengistu1, K. Ray1, G. Lewis1, and A. DeVico1
1University of Maryland School of Medicine, Baltimore, MD, USA
Background: The partially successful RV144 vaccine trial produced 
non-neutralizing antibodies that mediate antibody-dependent cellular 
cytotoxicity (ADCC) against the Human Immunodeficiency Virus type 1 
(HIV-1). These antibodies recognize the CD4-induced (CD4i) C1 region 
of gp120. However, such findings are enigmatic in view of previous 
arguments that CD4i epitopes are hidden on viral trimers before, and 
during interaction with host cell. It is therefore critical to understand the 
antigenicity of conserved epitopes on the HIV envelope that become 
exposed during productive viral replication. 
Methods: We studied the antigenicity of CD4i epitopes on cell-bound 
virions, by visualizing epitope exposure on single virus particles 
as they interact with target cells using confocal microscopy. CD4i 
antibodies are thought to be sterically occluded from the virus – cell 
interface, but they have been linked with potent ADCC activity. So we 
examined the location of CD4i epitopes recognized by A32, 17b, and 
C11 with ~ 20nm precision using stochastic optical reconstruction 
microscopy (STORM).  
Results: We find that some CD4i epitopes are poorly represented on 
free HIV-1 triggered with soluble CD4, but became exposed upon 
attachment to CD4+ cells. Patterns of exposure varied with antibody; 
however, in general the level of CD4i exposure was similar to 
neutralizing epitopes b12 and 2G12. CD4i epitopes appear distal to 
the virus – cell contact site, where they can be accessed by antibodies 
involved in ADCC.
Conclusion: The patterns of CD4i epitope exposure are consistent 
with the ADCC activities of cognate antibodies against bound virions. 
CD4i antibodies were able to gain access to their targets due to the 
unexpected epitope exposure on gp120, distal to the site of contact 
with cell surface CD4. These findings indicate that HIV-1 exhibits 
a diversity of epitope exposure upon attachment that may provide 
unique insights for understanding how humoral immunity impacts 
HIV infection.
P03.23
Nature of Synergistic ADCC Activity Mediated 
by Human Monoclonal Antibodies (mAbs) 
Against HIV-1 Env
C. Orlandi1, Y. Guan1, M.E. Pazgier1, M.M. Sajadi1,  
R.M. Kamin-Lewis1, A.L. DeVico1, and G.K. Lewis1
1University of Maryland, Baltimore, MD, USA
Background: Antibody-dependent cellular cytotoxicity (ADCC) 
appears to play a key role in the protection against HIV-1 infection. 
It inversely correlates with progression in natural infection and has 
emerged as a correlate of protection in non-human primate vaccine 
protocols and human clinical studies. It is known that mAbs can yield 
synergistic neutralization of HIV-1 but it is not known whether this 
occurs for ADCC. Accordingly, we developed an approach to address 
this question.
Methods: Our studies used an ADCC assay format based on gp120 
sensitized target cells and pairs of human IgG1 mAbs specific for highly 
conserved epitopes of gp120 that are exposed during viral entry and 
are potent ADCC targets. Synergy versus antagonism between pairs of 
these mAbs was quantified by employing the Chou-Talalay method.
Results: Analysis of dose-response curves revealed optimal regions 
of synergy for each mAb pair. Interestingly, regions of additivity and 
antagonism were also observed with patterns unique to each mAb 
pair indicating that they are epitope dependent.  Notably, strong 
synergy was maintained or enhanced when one mAb was paired 
with a variant partner engineered to abrogate Fc receptor binding 
(LALA mutation). These findings indicate that synergistic ADCC 
activity does not demand that all contributing antibodies engage 
Fc receptor. Accordingly, we hypothesize that ADCC synergy arises 
because certain combinations of antibodies 1) yield stabilized antigen 
crosslinking on target cells and/or 2) position FcR binding domains 
in a manner that optimizes Fc receptor engagement. Cases where 
synergy is enhanced with LALA variants could be further explained by 
reduced local competition for Fc receptor binding. These possibilities 
are being explored in ongoing studies.
Conclusion: These results provide the basis for future studies to 
increase the potencies of mAb cocktails for in vitro ADCC assays and 
also for passive immunization in non-human primates.
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P03.26
A Distinct Nef-Specific CTL Escape Selection 
Preceding Chronic Phase Neutralizing Antibody 
Induction Against Highly Resistant SIVmac239
H. Yamamoto1 and T. Matano1
1National Institute of Infectious Diseases, Musashi-Murayama 
City, Japan
Background: Neutralizing antibodies (NAbs) against human 
immunodeficiency virus type 1 (HIV-1) are promising immunological 
effectors but are absent in primary infections. Moreover, how NAbs 
against especially resistant HIV strains eventually develop in vivo 
remains unknown. To address this, we examined mechanisms of 
chronic phase NAb induction against the maximally NAb-resistant 
simian immunodeficiency virus (SIV) strain SIVmac239.
Methods: Through continuous screening, we have newly identified 
a cohort of Burmese rhesus macaques (n = 9) inducing autologous 
SIVmac239-NAbs in the chronic phase of infection. Temporal course of 
plasma viral loads, NAb titers, viral sequence variations, T cell responses 
and in vitro properties of selected mutant SIVs were examined.
Results: The SIVmac239-NAb inducers were all conventional 
progressors. Seven out of nine animals selected for a mutation Nef 
G63E, preceding NAb induction at around 1 year post-challenge. 
The frequency of selection was significantly high (p = 0.0008 by 
Chi-square test) when compared with a previously characterized 
NAb non-inducer cohort (n = 17). This was viral escape from CD8+ T 
cell responses specific for a Nef62-70 QW9 (QGQYMNTPW) epitope 
restricted redundantly by Mamu-B*039:01 and Mamu-B*004:01. 
SIV with the Nef G63E CTL escape mutation exhibited acclelerated 
apoptotis with attenuation of Akt Ser473 phosphorylation in infected 
cells. The difference in Akt was preserved in Nef-invaded bystander B 
cells in coculture, in which Akt signaling negatively regulates cellular 
maturation.
Conclusion: This is the first study to report in vivo events preceding 
NAb induction against highly resistant AIDS virus and implicates that B 
cell signal modulation in vivo may be crucial for antibody-based AIDS 
vaccine design.
P03.25
Antibody-Dependent Cellular Cytotoxicity 
Mediated by Passively Acquired Antibodies Is 
Negatively Correlated with Mortality in HIV-
Infected Infants
C. Milligan1 and J. Overbaugh2
1Fred Hutchinson Cancer Research Center, University of 
Washington School of Medicine, Seattle, WA, USA; 2Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA
Background: Rational design of an effective vaccine against HIV-1 
requires understanding the functional characteristics of antibodies 
capable of preventing disease transmission or providing a therapeutic 
benefit. Antibody-dependent cellular cytotoxicity (ADCC) has been 
described as a potential correlate of protection in both human and 
macaque vaccine studies. Mother-to-child transmission provides 
another setting in which to examine the role of ADCC in infection 
as infants acquire passive antibodies from their mothers while in 
utero. These antibodies are present prior to HIV-1 exposure through 
breastfeeding and may protect from infection or progression.
Methods: We evaluated the ADCC activity of passively acquired 
antibodies from 72 infants of HIV-1 positive mothers. The infants were 
HIV RNA-negative at birth but continually exposed to the virus via 
breastfeeding and followed for up to two years during which time 21 
infants became infected. Inclusion criteria included: breastfed >/= 3 
months, >/= 6 months follow-up of negative infants, and availability 
of a plasma sample from the first week of life.  These plasmas were 
tested against an infant-derived, subtype A envelope variant using a 
rapid and fluorometric ADCC assay.
Results: Infants who remained uninfected had higher ADCC activity 
than those who became infected, however this correlation did not 
achieve statistical significance. The results were similar when the 
analysis was restricted to infants infected in the first six weeks of life, at 
which time passively acquired antibody levels are the highest. In those 
infants who became infected, ADCC activity was negatively correlated 
with risk of mortality after infection. In a cox proportional hazards 
model, a one-unit increase in ADCC activity was associated with a 5% 
decrease in risk of death (p=0.041).
Conclusion: These data suggest that passively acquired antibodies 
that act through ADCC may impact disease progression in infants, with 
higher HIV-specific ADCC activity at the time of exposure providing a 
protective effect.
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P03.28
HIV Antibodies Catch Infectious Particles 
Independently of Their Neutralising Profiles    
M. Lambotin1, G. Laumond1, S. Schmidt1, T. Decoville1,  
M. Peressin1, B. Su1, M.E. Biedma1, A. Proust1, and C. Moog1
1INSERM U1110, Fédération de Médecine Translationnelle de 
Strasbourg, Strasbourg, France
Background: Formation of antibody/virus immune complexes has 
been proposed to decrease the number of virus accessible to target 
cells, limiting virus infectivity. Therefore, anti-HIV specific antibodies 
(Abs) able to bind HIV infectious particles may be particularly relevant 
at the mucosal site, to participate in HIV protection. 
Methods: Following incubation of HIVSF162 with increasing 
concentrations (from 1 to 50 µg/mL) of antibodies, HIV/IgG complexes 
were purified onto protein A columns. Bound and unbound fractions 
were submitted to anti-HIV p24 and anti-IgG ELISA to determine 
quantity of virus and immunoglobulin in each fraction. Infectivity of 
captured and non-captured virus was further assessed by titration on 
TZM-bl cells. 
Results: We observed that neutralizing IgGs 2G12 and 2F5 dose-
dependently bind p24-containing particles, with 2G12 catching more 
HIV particles than 2F5. The capacity of the non-neutralizing inhibitory 
IgG 4B3 to bind the p24-containing particles is not modified by 
incubation with increasing IgG concentrations, suggesting that 4B3 
retention capacity is already maximal at 1 µg/mL. Interestingly, this 
virus capture resulted in decreased infectivity whatever the neutralizing 
or non- neutralizing profiles of IgG, indicating that these antibodies are 
bound to infectious HIV-1 particles, even if such catching capacity was 
weak. This assay is currently adapted to define capture of infectious 
particles by antibodies of IgA subtype. Differential capacities of IgG 
versus IgA isotypes to catch HIV infectious particles will be investigated.
Conclusion: We demonstrated that anti-HIV antibodies were able to 
catch HIV infectious particles, independently of their neutralization 
profile. This capture activity may be particularly relevant at the mucosal 
site, since it may limit the quantity of accessible infectious particles. 
Immunisation strategies inducing HIV specific antibodies with high 
capture potency should therefore be considered as an added-value in 
development of an effective HIV vaccine.
P03.27
Antibody Responses to Recombinant gp120, 
gp70 V1V2 Proteins and Cyclic V2 Peptide in 
Thai Phase I/II Vaccine Trials Using Different 
Vaccine Regimens
N. Karasavvas1, C. Karnasuta1, M.S. de Souza2, S. Madnote1,  
D. Inthawong1, H. Savadsuk1, S. Rittiroongrad1, S. Chantakulkij1, 
S. Nitayaphan3, P.  Pitisuttithum4, P. Thongcharoen5,  
V. Siriyanon6, C.A. Andrews7, R.J. O’Connell7, N.L. Michael7,  
V. Ngauy1, and J.H. Kim7
1U.S. Army Medical Component - Armed Forces Research 
Institute of Medical Sciences (USAMC-AFRIMS), Bangkok, 
Thailand; 2Southeast Asian Research Collaboration with 
University of Hawaii (SEARCH), Thai Red Cross AIDS Research 
Centre (TRCARC), Bangkok, Thailand; 3Royal Thai Army 
- Armed Forces Research Institute of Medical Sciences (RTA-
AFRIMS), Bangkok, Thailand; 4Mahidol University, Bangkok, 
Thailand; 5Siriraj Hospital, Mahidol University, Bangkok, 
Thailand; 6Chiangmai University, Chiangmai, Thailand; 7U.S. 
MHRP, Silver Spring, MD, USA 
Background: RV132 and RV135 were phase I/II Thai clinical vaccine 
trials preceding RV144. Both trials used canarypox vCP1521 as a prime. 
Bivalent HIV-1 gp120 subtypes B/CRF01_AE (SF2/CM235) in MF59 
and bivalent gp120 subtypes B/CRF01_AE (MN/A244) in alum was 
used as boosts in RV132 and RV135 (RV144 equivalence), respectively.
Methods: IgG binding antibody responses induced by RV132 and 
RV135 regimens were compared using ELISA with a panel of antigens: 
recombinant gp120 CRF01_AE (A244 and TH023) and subtype B (MN); 
gp70 V1/V2 (CaseA2 and TH023) scaffolds (in RV144 these inversely 
correlated with infection); and cyclic V2 peptide TH023. Responses 
were further characterized into IgG1 and IgG3 subtypes.
Results: IgG responses were absent in placebo and post second 
immunization with ALVAC in both regimens. Antibody responses to 
gp120 were detected post first boost increasing at post second boost 
with geometric mean titers (GMT) of 606 and 2425 (A244), 419 and 
3676 (TH023), and 174 and 1270 (MN) in RV132, and of 4422 and 
9051 (A244), 230 and 4422 (TH023), and 4222 and 19855 (MN) in 
RV135. IgG responses to gp70TH023 were detected in both RV132 
(GMT, 481) and RV135 (GMT, 1131) but to gp70CaseA2 were only 
detected in RV135 (GMT, 191). GMT to cyclic V2 were similar for both 
regimens (GMT~300). IgG1 and IgG3 responses to gp120A244 and 
gp70TH023 were lower in RV132 (GMT, 209 and 87, and 52 and 22) 
than in RV135 (GMT, 746 and 325, and 102 and 29), respectively. 
IgG1 and IgG3 responses to gp70CaseA2 were only found in RV135 
(GMT=13).
Conclusion: IgG responses against recombinant gp120 induced in 
RV135 were more robust than RV132. However, both vaccine regimens 
induced similar responses to the cyclic V2 peptide. Antibodies to 
gp70CaseA2 were only detected in RV135. These data support the 
need for head-to-head clinical studies for future comparison and 
down-selection of vaccine regimens.
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P03.30
Evidence for Conservation of the V1/V2- but 
Not V3- Glycan-Dependent Neutralizing 
Epitopes Within Divergent Groups of HIV-1
M. Morgand1, M. Braibant1, M. Bouvin-Pley1, E. Gong2,  
J. Plantier3, F. Simon4, and F. Barin1
1Université François-Rabelais, INSERM U966, Tours, France; 
2The Beatson Institute for Cancer Research, Glasgow, UK; 
3Équipe d’Accueil 2656, Université de Rouen and CHU 
Charles Nicolle, Rouen, France; 4Laboratoire de Virologie, 
Hôpital Saint-Louis, Paris, France
Background: HIV-1 has been classified into 4 groups: M, N, O and 
P. Cross-group broadly neutralizing antibodies have been detected in 
some HIV-1 infected individuals. The aim of this study was to analyze 
the sensitivity to neutralization of a panel of non-M primary isolates 
(PI) to a series of highly potent human monoclonal broadly neutralizing 
antibodies (HuMoNabs). 
Methods: The sensitivity to neutralization of 14 non-M HIV-1 PIs (12 
O, 1 N, and 1 P) was analyzed in neutralization assays using TZM-bl 
cells. The panel of HuMoNabs was composed of PG9, PG16, PGT121, 
PGT128, PGT145, VRC01 and VRC03. These HuMoNabs were isolated 
from patients infected by HIV-1 group M variants. PG9, PG16 and 
PGT145 target a glycan-dependent epitope located in the V1-V2 region 
of gp120 whereas PGT121 and PGT128 target a glycan-dependent 
epitope located in the V3 region. VRC01 and VRC03 target the CD4 
binding site (CD4bs) of gp120. 
Results: Three group O PIs were neutralized by PG9 and PG16 (IC50 
range = 0.23-7.62 µg/mL) and a fourth group O PI was neutralized by 
PG9 only (IC50 = 9.39 µg/mL). The group N PI (YBF30) was highly 
sensitive to neutralization by both PG9 (IC50 = 0.28 µg/mL) and PG16 
(IC50 < 0.12 µg/mL), but resistant to other HuMoNabs. The group P PI 
(RBF168) was neutralized by PGT145 only (IC50 = 0.13 µg/mL). None 
of the non-M PIs was neutralized at the highest concentration tested (10 
µg/mL) by the HuMoNabs targeting the V3 glycan-dependent epitopes, 
PGT121 and PGT128. Similarly the HuMoNabs VRC01 and VRC03 that 
target the CD4bs did not neutralize any of the non-M isolates at the 
concentration tested.
Conclusion: Our data suggest that the V1-V2 glycan-dependent 
neutralizing epitopes targeted by the HuMoNabs PG9/PG16 and 
PGT145 are conserved within the divergent groups of HIV-1. It makes 
them potentially interesting targets for vaccine strategies.
P03.29
Improving the Potency of Neutralizing 
Anti-HIV-1 Antibodies with a CD4 Mimetic 
Compound
K.P. Ramirez1, T. Kuwata1, Y. Maruta1, K. Tanaka1, M. Alam1,  
K. Rahman1, Y. Kawanami1, I. Enomoto1, H. Tamamura2,  
K. Yoshimura3, and S. Matsushita1
1Kumamoto University, Kumamoto, Japan; 2Tokyo Medical 
and Dental University, Tokyo, Japan; 3National Institute of 
Infectious Diseases, Tokyo, Japan
Background: The pursuit of a prophylactic vaccine against HIV-1 
and the development of novel therapeutic strategies are primordial. 
Recently, broad and potent neutralizing monoclonal antibodies 
(MAbs) against HIV-1 had been reported; however, these antibodies 
are difficult to elicit during infection and vaccination.  We aim to find 
strategies able to improve the modest and narrow neutralizing activity 
of antibodies commonly elicited by HIV-1 infected patients.
Methods: MAbs were obtained by immortalization of a patient’s B cells 
with EBV and molecular cloning of IgG. Binding to monomeric gp120 
and Env was determined by ELISA and flow cytometry, respectively. 
Neutralization activity was evaluated with the single-round infection 
assay using TZM-bl cells and pseudovirus. 
Results: YYA-021 has anti-viral activity; low cytotoxicity, and enhances 
the neutralization activity of MAbs against JR-FL. We observed that 
YYA-021 also enhances the binding of CD4i MAbs to monomeric 
gp120 of subtype B and to Env of subtype B and C; and when we 
evaluated the neutralization activity of five anti-V3 MAbs, two CD4bs 
MAbs and three CD4i MAbs against 12 viruses of the Standard Panel 
B; we observed significant enhancement in the neutralization activity 
of all the anti-V3 and CD4i antibodies over a range between 2 to 9 of 
the evaluated viruses.  In a series of 12 viruses of the Standard Panel C, 
YYA-021 was able to enhance neutralization of 3 viruses for two CD4i 
MAbs and one virus for an anti-V3 MAb. Moreover, when we evaluated 
the effect of YYA-021 over six transmitted/founder virus, we found that 
three out of six were sensitive to YYA-021 and that the neutralization 
activity of the anti-V3 and CD4i antibodies was also enhanced in the 
presence of YYA-021.
Conclusion: CD4 mimetic compounds, such as YYA-021, could 
improve the performance of classical neutralizing antibodies with 
limited reactivity against viruses of subtype B, C and transmitted/
founder viruses.
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P03.32
Crystal Structure of the 2F5-like Antibody m66 
in Complex with Its HIV-1 gp41 Epitope
G. Ofek1, B. Zirkle1, Y. Yang1, K. McKee1, Z. Zhu2, M.K. Louder1, 
J.R. Mascola1, D.S. Dimitrov2, and P.D. Kwong1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2National Cancer Institute, NIH, Frederick, MD, USA
Background: Neutralizing antibodies that target the membrane-
proximal external region (MPER) of the HIV-1 gp41 transmembrane 
glycoprotein have been shown to target either the N-terminus of the 
MPER, such as 2F5 and m66, or the C-terminus of the MPER, such as 
z13e1, 4E10, and 10E8. Antibody m66, originally isolated by phage 
display from a donor with 2F5-like serum activity, targets an epitope 
within the N-terminus of the gp41 MPER that overlaps the 2F5 epitope.
Methods: We determined the crystal structure of m66, both free 
and in complex with its gp41 epitope. The structure allowed us to 
compare its mode of gp41 recognition with that of other MPER-specific 
antibodies. Elements of m66 critical for recognition of the epitope in 
lipid and soluble contexts, and for virus neutralization, were delineated 
through accompanying biochemical analyses. 
Results: When bound by m66, the gp41 MPER adopts a conformation 
that has both similarities and differences from the conformation 
bound by 2F5, with similarities occurring largely within the core of 
the epitope. The angle at which m66 approaches gp41 is similar to 
the angle of 2F5 approach, but appears distinct from the angles of 
approach of non-neutralizing MPER-specific antibodies. While the 
heavy chain third complementarity determining region (CDR H3) of 
m66 is largely occupied by contacts with the epitope, mutagenesis of 
the CDR H3 delineates residues critical for recognition of the epitope 
in a lipid context and for virus neutralization.    
Conclusion: The structure of m66 reported here reveals a novel 
antibody-bound conformation of the gp41 MPER, with select structural 
and functional elements shared in common with other neutralizing 
antibodies that target this region. The structure of m66 in complex 
with its epitope thus helps define a conserved site of vulnerability 
within the N-terminus of the HIV-1 gp41 MPER.  
P03.31
A V2 Conformational Immunodominant 
Epitope Recognized by Human Monoclonal 
Antibodies
S. Zolla-Pazner1, C. Williams1, F. Klein2, J. Scheid2, M. Seaman3, 
H. Liao4, M. Nussenzweig2, and H. Mouquet5
1New York University School of Medicine, New York, NY, USA; 
2The Rockefeller University, New York, NY, USA; 3Beth Israel 
Deaconess Medical Center, Harvard Medical School, Boston, 
MA, USA; 4Duke University Medical Center, Durham, NC, USA; 
5Institut Pasteur, Paris, France
Background: The level of V1V2-specific plasma antibodies (Abs) was 
shown to be an inverse correlate of risk in the RV144 clinical vaccine 
trial.  V2-specific Abs of two types appear to have been induced by 
the vaccine regimen:  Abs that target a continuous helical region in 
the C-strand of V2 and Abs that target a discontinuous surface on the 
opposite side of V2 which overlaps and surrounds the putative α4β7 
binding site.  Four mAbs from RV144 vaccinees specific for the C-strand 
helix of V2 have been produced (Liao et al., 2013).  Here we describe 
the reactivity of four new conformational V2 mAbs along with seven 
similar mAbs which were previously characterized (Gorny et al., 2012). 
Methods: These 11 conformational V2 mAbs were derived from six 
clade B-infected individuals using molecular methods (n=4) or EBV 
transformation (n=7) and were selected using trimeric or monomeric 
gp140, monomeric gp120, or a V1V2-gp70 fusion protein. Reactivities 
were assessed by ELISA and standardized TZM.bl neutralization. 
Results: Nine of the 11 conformational V2 mAbs neutralize 20-80% of 
Tier 1 pseudoviruses from clades A, B and C with a median IC50 value 
of 8.6 µg/ml; however, none neutralizes Tier 2 pseudoviruses.  Five 
of the 11 conformational V2 mAbs are encoded by VH1-69, a finding 
consistent with the biased usage of the VH1 gene family by HIV 
Abs.  The conformational V2 mAbs display a VH mutation frequency 
of 2.4% to 13.0% (mean 7.0%) compared to germline. These mAbs 
display similar patterns of ELISA reactivity with fusion proteins carrying 
the V1V2 regions of clade A, B, C and AE strains.  
Conclusion: The epitope targeted by these conformational V2 mAbs 
appears to be an immunodominant region of V2 which elicits Abs that 
are highly cross-reactive, mediating neutralization of Tier 1 viruses.  
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P03.34
A Novel Methodology for Isolating Broadly 
Neutralizing HIV-1 Human Monoclonal 
Antibodies
Z. Sun1, J. Li1, Y. Shao2, and M. Zhang1
1University of Hong Kong, Hong Kong; 2National Center for 
AIDS/STD Control and Prevention, China
Background: Identification of broadly neutralizing HIV-1 human 
monoclonal antibodies (bnmAbs) may aid in development of an 
effective HIV-1/AIDS vaccine and antibody drugs for prevention and 
treatment of HIV-1 infection. Many HIV-1 bnmAbs have been identified 
from HIV-1-infected “elite controllers”, especially in the past three 
years. Most of known bnmAbs were isolated based on their binding to 
HIV-1 envelope glycoprotein (Env) or engineered Envs, thus, large-scale 
expression and purification of isolated clones and characterization of 
purified soluble antibodies for neutralization breadth and potency 
were required, which was costly and time-consuming. 
Methods: Here, we developed a novel methodology for isolating HIV-
1 bnmAbs based on antibody neutralization activity by displaying 
immune antibody libraries on target cell surface followed by sorting 
the cells by antibody neutralization ability to specific pseudotype virus. 
Results: After several rounds of sorting, a panel of human mAbs has 
been isolated from two “elite controllers” that can neutralize various 
isolates from clade B and clade C. 
Conclusion: We are currently measuring the neutralizing capability 
of these mAbs against different clades of virus, and expressing these 
mAbs as soluble form and will test them in a standardized TZM-bl 
neutralization assay to confirm the neutralization breadth and potency 
of isolated mAbs. 
P03.33
Decreased HIV-Specific Antibody-Dependent 
Cellular Cytotoxicity in HIV-Infected Subjects 
on cART: Implications for Therapeutic Vaccines
M. Kramski1, V. Madhavi1, S. Jegaskanda1, R.J. Center1, F.E. Ana 
Sosa Batiz1, J. Ananworanich2, D. Cooper3, A. Kelleher3, D. Hsu3, 
and S.J. Kent1
1University of Melbourne, Melbourne, Australia; 2HIV 
Netherlands Australia Thailand Research Collaboration, Thai 
Red Cross AIDS Research Centre, Bangkok, Thailand; 3The 
Kirby Institute for Infection and Immunity in Society, UNSW 
Medicine, Sydney, Australia
Background: cART cannot eliminate HIV and life-long treatment is 
required. HIV-specific CTL responses decline rapidly following cART 
but alterations in other HIV-specific immune functions that may assist 
in clearing latent HIV infection, specifically antibody-dependent 
cellular cytotoxicity (ADCC), are unknown. We studied ADCC immunity 
in subjects on cART to understand the implications for therapeutic 
vaccines to control HIV infection.
Methods: Forty-nine cART-naive HIV-infected subjects from Thailand 
started cART at baseline. Median baseline CD4 count was 186 cells/
µl (range: 10-350 cells/µl) and viral load 4.9 log10 copies/ml (range: 
2.9-6.3 log10 copies/ml). Longitudinal blood samples were collected 
up to 96 weeks (median CD4 count: 338 cells/µl range: 113-990 cells/
µl; median viral load: <40 copies/ml, range: 40-137 copies/ml). Serum 
was analyzed for HIV-specific antibody binding titers against subtype 
AE envelope (Env/AE) by ELISA. ADCC-mediated killing against Env/AE 
targets was determined using the RFADCC assay. ADCC responses to 
Env/AE and Rev/Tat/Vpu peptide pools were measured using the NK 
cell activation assay. 
Results: A significant reduction in Env-specific ADCC-mediated killing 
(p<0.0002) was observed between baseline (median: 11.8%, IQR: 7.7-
14.1%) and week 96 (median: 7.7%, IQR: 3.9-10.3%). A reduction 
in ADCC-mediated NK cell activation to Env was also detected in 
26/49 subjects but this difference was not significant. However, ADCC 
responses to Rev/Tat/Vpu were significantly reduced (baseline: median 
0.8% NK cell activation; IQR: 0-1.7%; week 96: 0%; IQR: 0-1.3%, 
p=0.0082). A 10-fold reduction in ADCC endpoint titers between 
baseline and week 96 was detected. Similarly, serum Env-specific 
antibody binding titers significantly decreased 10-fold after 96 weeks 
of cART (baseline: median: 5 log10, IQR: 4.5-5; week 96: median: 4 
log10, IQR: 3.5-4.5; 
Conclusion: A significant reduction in HIV-specific ADCC occurs 
in subjects following prolonged cART. ADCC-boosting therapeutic 
vaccines and/or modulation of ADCC effector functions could assist 
in the control of HIV and the ability to clear reactivated latently 
infected cells. 
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P03.36
p24-Specific Antibody Dependent Cellular 
Phagocytosis Is Associated with Antiviral 
Control in Chronic HIV-1 Subtype C Infection 
J.K. Maroa1, A. Chung2, A. Licht2, B. Ndlovu1, H. Robinson2,  
T. Ndung’u1, and G. Alter2
1University of KwaZulu-Natal, Durban, South Africa; 2Ragon 
Institute of MGH, MIT and Harvard, Cambridge, MA, USA 
Background: There are limited data describing the functional 
characteristics of non-neutralizing antibodies (Abs) in chronic HIV-1 
subtype C (HIV-1C) infection. However, mounting evidence suggests 
that functions such as antibody dependent cellular phagocytosis 
(ADCP) may have a critical role in control and prevention of infection.
Methods: The capacity of plasma Abs to mediate ADCP in the presence 
of fluorescent beads conjugated to HIV-1C p24 protein was examined 
in a THP-1 cell based in-vitro assay.  Correlations between p24- specific 
IgG subclass titers, IgA titers, ADCP responses and markers of disease 
progression were determined. 
Results: In an initial exploratory analysis involving 340 HIV-1C 
chronically infected antiretroviral-naïve participants, Gag-specific (p17, 
p24 and p55) but not envelope (gp120 and gp140) IgG titers correlated 
with lower viral loads (VL) and higher CD4 counts.  Based on these 
results, a subset of 122 patients with p24 antibody titers higher (n= 56) 
or lower (n=66) than the cohort median were selected to further dissect 
the functional profile of p24-specific Abs.  Plasma p24 specific IgG1 
titers but not others were highly correlated with the ADCP responses 
to both gp120 and p24 (p<0.0001).  We found no correlation between 
plasma gp120 IgA titers and gp120 ADCP responses (p=0.96) nor p24 
IgA titers and p24 ADCP responses (p=0.61). Plasma gp120-specific 
ADCP responses did not correlate with VL (p = 0.29) and CD4 count 
(p = 0.17).  In contrast, p24-specific ADCP responses were associated 
with lower VL (p= 0.02) and showed a trend towards association with 
higher CD4 count (p = 0.08).  
Conclusion: Our data suggest that p24-specific IgG1 Abs, in chronic 
HIV-1C infection, mediate ADCP responses that may contribute to viral 
control. There is need to investigate mechanisms by which Gag-specific 
Abs may contribute to viral control and how Ab-mediated phagocytosis 
may be harnessed in the context of vaccine design.
P03.35
Characterization of Broadly Neutralizing 
Antibodies (bNAbs) to HIV-1 Present in a Cohort 
of Long Term Non-Progressors (LTNPs)
N. Gonzalez1, R.M. Lynch2, K. McKee2, E. Yuste3, J.R. Mascola2, 
and J. Alcami1
1Centro Nacional de Microbiologia Instituto de Salud Carlos 
III, Madrid, Spain; 2Vaccine Research Center, NIAID, NIH, 
Bethesda, MD, USA; 3Hospital Clínic, IDIBAPS, HIVACAT, 
Barcelona, Spain
Background: One major obstacle to induce bNAbs resides in the high 
variability of the viral envelope and structural mechanisms hiding 
crucial epitopes for neutralization. Besides, maturation of bNAbs 
represents a major challenge for the immune system that can be 
impaired by the immune deficiency associated with HIV infection. We 
have explored the hypothesis that preserved B cell function in LTNPs 
could result in the production of a broad humoral response.
Methods: Samples (129) from the cohort of LTNPs were kindly 
provided by the HIV BioBank integrated in the Spanish AIDS Research 
Network (RIS). A population of 191 untreated typical progressors (TPs) 
from Hospital Clinic, Barcelona, was analyzed as control. Sera were 
preincubated with Env recombinant viruses harboring a luciferase gene 
and viral infection assessed by luciferase activity. bNAbs specificities 
were studied by ELISA using mutated gp120 that abrogates antibody 
binding; neutralization assays with mutated viruses and peptide 
competition neutralization assays. Epitope specificities were also 
elucidated from the serum pattern of neutralization against a panel of 
diverse HIV-1 isolates.
Results: Elite neutralizers (9.3%) were found among LTNPs. Broadly 
neutralizing sera were screened for the presence of epitope-specific 
antibodies. By ELISA techniques CD4 binding site antibodies were 
detected in 33% of LTNP and 57% of TPs. To determine whether 
these antibodies were responsible for the broad neutralization, 
competition neutralization assays by using RSC3 (antigenically 
resurfaced glycoprotein containing the CD4bs) were performed. RSC3 
addition inhibited neutralization mediated by 2 sera from LTNPs 
(17%) and no serum of normal progressors. Anti-MPER antibodies 
were detected in 50% of LTNPs and 57% of TPs, including several 
sera with 4E10 and Z13-like antibodies. Glycan-dependent HIV-
1 neutralizing antibodies were more abundant in LTNPs (75%) as 
compared to control population (43%).
Conclusion: LTNPs showed broad humoral immune responses against 
HIV-1 suggesting that other factors than antigenemia could drive the 
development of bNAbs.
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P03.38
Long CDR H3 of a Broadly-Neutralizing 
Antibody Is Present at Recombination
C. Schramm1, N.A. Doria-Rose2, J. Gorman2, P.L. Moore3,  
R.P. Staupe2, Z. Zhang1, Y. Yang2, J. Bhiman3, I. Georgiev2,  
N.L. Longo2, M. Pancera2, J.C. Mullikin4, S.A. Karim3, L. Morris3, 
P.D. Kwong2, J.R. Mascola2,and  L. Shapiro1
1Columbia University, New York, NY, USA; 2Vaccine Research 
Center, NIAID, NIH, Bethesda, MD, USA; 3National Institute 
for Communicable Diseases of the National Health Laboratory 
Service, Johannesberg, South Africa; 4NIH, Bethesda, MD, USA
Background: A family of highly-potent, broadly-neutralizing V1/
V2-directed antibodies has been isolated from an African donor. As 
with other known antibodies that target epitopes in this region, such 
as PG9 and PG16, the interaction depends on an unusually long 
antibody CDR H3 region. Up to this point it has been unclear whether 
such long CDR H3 loops are generated at recombination or whether 
they elongate over time by somatic hypermutation, beginning from 
shorter CDR H3 recombinants.
Methods: A longitudinal analysis was carried out using B cells isolated 
from the donor at several different time points. We used 454 next-
generation sequencing (NGS) to sequence cDNAs corresponding to 
the antibody variable regions from the cells. After processing with a 
standard antibodyomics pipeline to identify somatic variants of the 
isolated antibodies, a maximum-likelihood phylogenetic tree was 
constructed to infer the original unmutated common ancestor (UCA) 
and trace the development of the clonal lineage.
Results: The UCA sequence calculated from the maximum-likelihood 
tree contains a full-length (37 amino acid) CDR H3 loop. We also find 
several extremely-low divergence sequences in the 454 data with 37 
amino acid CDR H3 loops, supporting the conclusion that the long CDR 
H3 loop is formed whole by the recombination process, rather than 
elongating from a shorter recombinant through somatic hypermutation.
Conclusion: Broadly-neutralizing antibodies with low rates of somatic 
hypermutation are of particular interest in the search for an effective 
HIV-1 vaccine, as they should be easier to elicit. Here we have shown 
that long CDR H3 loops can be generated by the initial recombination 
event, indicating that V1/V2-directed antibodies may represent a 
promising pathway for vaccine development.
P03.37
TNFα Impairs Peripheral T Follicular Helper 
(pTfh) Cell Function In Vitro and Is Associated 
with Decreased Ab Response to Influenza 
Vaccine In Vivo
A. Parmigiani1, M.L. Alcaide1, D. Frasca1, M. Fischl1, and  
S. Pahwa1
1University of Miami Miller School of Medicine, Miami, FL, USA
Background: Peripheral T follicular helper cells (pTfh) have been 
shown to provide critical help to B cells in producing Ab in response to 
influenza vaccines. We investigated whether generalized inflammation 
and immune activation are associated with impaired antibody response 
to seasonal 2011/2012 influenza vaccine in a cohort of elderly HIV+ 
women, and examined the role of the pro-inflammatory cytokine TNFα 
for its influence on B cells.
Methods: Fifteen HIV+ virally suppressed post-menopausal women on 
ART (median CD4 count, 519 cells/mm3) and 12 age-matched HIV– 
controls,	all	recipients	of	2011/2012	influenza	vaccine	(Fluvarix®,	GSK),	
were investigated for Influenza Ab titers 4 weeks after vaccination, 
plasma TNFα and IL-21 levels and activation markers (CD38, HLA-DR) 
on pTfh (CD3+CD4+CD45RO+CXCR5+) cells. B cells and memory CD4 
T cells were isolated, co-cultured at a 1:1 ratio and stimulated with 
SEB in the presence of TNFα, IL-21, anti-TNFα or anti-IL-21R Abs. IL-21 
and immunoglobulin levels were analysed in culture supernatants by 
ELISA. Statistical methods included Student t-test and Pearson analysis, 
with P values <0.05 being considered significant.
Results: Protective Ab titers to influenza developed after vaccination 
in 75% of the HIV+ and 91% of the HIV– women. Plasma TNFα 
levels were inversely correlated with the post-vaccination Ab titers 
(r=-0.4686, p=0.0158), with the frequency of activated pTfh cells 
(r=0.4831, p=0.0198), and with the post-vaccination levels of plasma 
IL-21 (r=-0.4511, p=0.0207). In vitro TNFα blockade improved the 
ability of CD4 T cells to produce IL-21 (p=0.0203) and of B cells to 
secrete immunoglobulins (p=0.0399). 
Conclusion: Excessive immune activation of pTfh and elevated pro-
inflammatory cytokine TNFα can impair influenza vaccine-induced 
Ab responses. Chronically activated pTfh cells fail to help vaccine-
induced B cell Ab production. Interventions aimed at reducing chronic 
inflammation and immune activation in HIV+ patients, especially in 
the elderly, may improve their response to vaccination.
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P03.40
Eliminating Autoreactivity of Variants of 
Antibody VRC07 by Glycan Masking
G. Chuang1, B. Zhang1, K. Lloyd2, J. Eudailey2, J. Blinn2,  
K. McKee1, Y. Kwon1, J.R. Mascola1, B.F. Haynes2, I.S. Georgiev1, 
and P.D. Kwong1
1NIAID, NIH, Bethesda, MD, USA; 2Duke University Medical 
Center, Durham, NC, USA
Background: Antibody VRC07, a clonal relative of VRC01 identified 
from next-generation-sequencing analysis of PBMC’s from Donor 45, 
shows improved HIV-1 neutralization breadth and potency compared 
to VRC01.  Efforts are being made to further improve the potency of 
VRC07, and a number of mutations improve the potency of VRC07. 
Some of the more potent mutations, however, induce autoreactivity, 
which in turn negatively impacts effectiveness and safety.  Here 
we investigate the ability of introduced N-linked glycans to shield 
potency-enhancing mutations from auto-antigen and to eliminate the 
induced autoreactivity.
Methods: For three different autoreactive VRC07 antibody variants, 
we designed a total of five single glycan antibody mutants by 
computationally designing N-linked glycosylation sequons proximal 
to the antibody residues responsible for autoreactivity. The NGlycPred 
algorithm, a Random Forest-based classifier utilizing structural 
properties and patterns as attributes, was used to predict the glycan 
occupancy of the N-linked glycosylation sequons.  Three autoreactivity 
assays, Anti-cardiolipin ELISA, Luminex AtheNA Multi-Lyte ANA test, 
and HEp-2 ANA test were used to assess the autoreactivity of these 
glycan mutants.
Results: Gel analysis of intact and PNGaseF treated VRC07 glycan 
mutants demonstrated that N-linked glycans were successfully added 
for all five antibodies as predicted from the computational algorithm. 
Addition of a single N-linked glycan eliminated the autoreactivity 
generated from each of the potency-enhancing mutations, as assessed 
with the three autoreactivity assays.
Conclusion: We have demonstrated that adding an N-linked glycan 
proximal to autoreactive residues eliminated autoreactivity of VRC07 
variants. When potential therapeutic antibodies show autoreactivity, 
our protocol of N-linked glycan masking may be used to eliminate this 
autoreactivity and to improve the properties of promising therapeutic 
candidates for AIDS and other diseases.
P03.39
V2 Peptide Binding to HIV-1 Variants and 
Interaction of HIV-1 with α4β7 Integrin 
Receptor
K.K. Peachman1, E. Billings1, M. Rolland1, R. McLinden1,  
A. Chenine1, S. Tovanabutra1, J.H. Kim1, N. Michael1, C.R. Alving1, 
and M. Rao1
1U.S. MHRP, Silver Spring, MD, USA
Background: The mucosal homing integrin receptor α4β7 interacts 
with the HIV-1-gp120 second variable loop (V2).  Analysis of the 
RV144 samples showed that antibodies against the Env gp120 V1V2-
region, which contained the α4β7-binding site (aa 179-181) were 
associated with lower risk of infection. Sequence analysis showed that 
breakthrough viruses in vaccinees and placebos differed at two sites 
in V2, with an increased proportion of K169 and a lower proportion of 
I181X in vaccinees.   A critical unanswered question is the role of α4β7 
in transmission efficiency. 
Methods: Primary viruses and infectious molecular clones (IMC) were 
pre-incubated with α4β7-expressing RPMI8866 cells and then added 
to plates coated with either MAdCAM-1 or streptavidin-biotinylated 
linear-V2 peptide.  In separate experiments, RV144 plasma from 
infected vaccinees and placebos were added to peptide-coated plates 
followed by cells and binding/inhibition was determined. Seventy-eight 
infected samples were analyzed by Biacore for binding to four linear 
V2-92TH023-peptides (consensus, I181L, K169Q/Q170R, K169Q/
Q170R/I181L). 
Results: Primary viruses SF162 and BaL inhibited α4β7 binding 
(30%) to MAdCAM-1 in a dose-dependent manner (p<0.02), while 
US-1 and JRFL did not.  Acute IMCs A, C, and chronic IMC subtype C 
also inhibited binding (p<0.02), while acute/chronic CRF_01 AE IMCs 
showed a trend towards inhibition. None of the RV144 plasma showed 
significant differences in binding to the four peptides. Individuals 
infected with K169-containing viruses showed a 5-fold higher binding 
to V2-consensus peptides compared to individuals infected with 
K169X-variants (p=0.04). There was no difference among placebos 
(p=0.81).  Peptide binding did not differ between subjects who carried 
I181 or I181X-variants. Preliminary results with 16 samples showed no 
correlation between V2-length and α4β7-inhibition. 
Conclusion: V2-binding is affected by the viral sequence rather than 
the linear peptide sequence, suggesting a conformational determinant. 
Inhibition of α4β7-binding by certain viruses warrants further study to 
understand if there is a relationship between transmission efficiency 
and HIV-1 sequence. 
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P03.42
Biochemical, Immunological and Structural 
Characterization of a Panel of Novel Rabbit 
Monoclonal Antibodies Elicited by HIV-1 Env 
Vaccination
Y. Chen4, M. Vaine4, R. Pan1, X. Kong1, A. Wallace4, D. Han4,  
S. Wang4, M.S. Seaman2, D. Montefiori3, S. Wang4, and S. Lu4
1New York University School of Medicine, New York, NY, 
USA; 2Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA; 3Duke University Medical Center, 
Durham, NC, USA; 4University of Massachusetts Medical 
School, Worcester, MA, USA
Background: Until now, the monoclonal antibodies (mAbs) widely 
studied in the AIDS vaccine field have been generated from HIV-1 
infected individuals.  Given the vast difference between infection and 
prophylactic vaccination, study of the antibody profiles elicited by 
candidate AIDS vaccines is urgently needed.  
Methods: Here we report the development of a panel of novel rabbit 
mAbs (RmAbs) produced by HIV-1 Env-based DNA prime-protein 
immunization. Extensive analysis was conducted on the specificity 
and binding characteristics of these RmAbs. Furthermore, structural 
analyses were carried out by crystallization of three RmAbs in complex 
with their corresponding epitope peptides.
Results: These RmAbs revealed a broad diversity of Env epitopes, 
including not only the highly immunogenic V3 loop, but also several 
previously underappreciated epitopes in the C1, C4, and C5 regions. 
Overall, these RmAbs showed high binding affinities, a majority of 
them could cross-react with gp120 antigens from more than one 
subtype, and several had neutralizing activities. Furthermore, one of 
these RmAb, R20, targeting at the glycan rich V3 base, shares the same 
peptide region as that of the highly potent broadly neutralizing human 
mAb, PGT128.  
Conclusion: Our data indicates the feasibility of using vaccination to 
elicit high quality antibodies with protective potential.  Rabbit mAbs 
provide a much needed platform to dissect the specificity, quality, 
and affinity maturation of HIV-1 Env-specific antibody responses 
elicited by vaccines.
P03.41
Broad Neutralizing Antibody Responses in HIV-
1 Superinfected Women Do Not Target Known 
Epitope Specificities 
V.C. Cortez1, K. Ronen1, L. Goo1, D. Peterson1, and J. Overbaugh1
1Fred Hutchinson Cancer Research Center/University of 
Washington, Seattle, WA, USA
Background: We have shown that superinfection leads to a broader and 
more potent neutralizing antibody response when compared to single 
infection in a cohort of high-risk women. This suggests that exposure 
to antigenically diverse HIV-1 variants may contribute to the elicitation 
of broadly neutralizing antibodies. However, the antigenic targets of 
these broad responses observed after superinfection are not known. 
Here, we examined whether superinfection focuses the antibody 
response on epitopes that are recognized by recently characterized 
HIV-1 specific broadly neutralizing monoclonal antibodies.
Methods: Plasma samples obtained ~5 years after initial infection 
from 21 superinfected women identified from a seroincident cohort in 
Mombasa, Kenya were tested for antibodies directed to the CD4-binding 
site by ELISA and neutralization assays using RSC3 and ∆RSC371I 
mutant proteins. The effect of glycosylation residues at positions N160 
and N332 were examined by comparing the neutralization profiles of 
wildtype virus to mutant viruses with these residues removed. 
Results: One out of the 21 women’s antibody responses (5%) displayed 
differential binding affinity to RSC3 and ∆RSC371I mutant proteins. 
However, competition with these proteins in a neutralization assay did 
not indicate the presence of CD4-binding site neutralizing antibodies, 
suggesting that this woman has binding, but not neutralizing 
antibodies to this site. Neutralization assays using wildtype and 
mutants for N160K (Q461d1, Q23-17, DU156) or N332A (Q23-17) 
also did not show differential IC50s, demonstrating that these women 
did not develop responses to either of these residues, which would be 
indicative of PG and PGT-directed antibody specificities.
Conclusion: Overall, this study suggests that the broad and potent 
neutralizing antibody responses elicited following superinfection in 
these women is focused on epitopes that have yet to be identified. 
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P03.44
Threshold Mutation Rate Is Required for V3 
Antibodies Displaying Cross-Neutralization of 
HIV-1 Tier 2 Viruses
L. Li4, X. Wang1, C. Williams4, B. Volsky4, M.S. Seaman2,  
A. Nadas4, S. Zolla-Pazner3, and M.K. Gorny4
1Veterans Affairs New York Harbor Healthcare System, New 
York, NY, USA; 2Beth Israel Deaconess Medical Center, 
Boston, MA, USA; 3New York University School of Medicine 
Veterans Affairs New York Harbor Healthcare System, New 
York, NY, USA; 4New York University School of Medicine, 
New York, NY, USA
Background: The RV144 clinical vaccine trial showed that reduced 
HIV-1 infection in vaccine recipients was inversely correlated with 
higher levels of plasma anti-V2 antibodies (Abs).  Anti-V2, along with 
anti-CD4-binding site (CD4bs) and anti-V3, Abs are present in almost all 
HIV-infected subjects and can be relatively easily induced by vaccines; 
however, they exhibit rather weak neutralization. We have analyzed 
human monoclonal Abs (mAbs) with the same specificities to compare 
their neutralizing activities and determine a threshold of the mutation 
rate in Abs required for cross-neutralization of HIV-1.
Methods: Sixty-six human mAbs specific for CD4bs, V3 or V2 were 
produced by cellular and molecular methods from individuals infected 
with various subtypes of HIV-1. The percentage of mutations in the 
heavy chain variable fragment of each mAbs was analyzed and 
compared with neutralizing activity against a standard panel of 41 
pseudoviruses (psVs). 
Results: All 66 mAbs neutralized, with varying frequencies, a panel 
of sensitive tier 1 psVs, while the more resistant tier 2 psVs were 
neutralized sporadically and only by V3 mAbs. Mutation frequencies 
ranging from 2.4% to 18.1% in VH genes were comparable for CD4bs, 
V3 and V2 mAbs and had no correlation with the neutralization of tier 
1 viruses. However, neutralization of tier 2 viruses by anti-V3 mAbs 
correlated with the percentage of mutations suggesting they can be 
related to a higher affinity. Some mAbs had mutation rates comparable 
to the level observed in Abs induced by the HIV vaccine used in the 
RV144 trial and these mAbs displayed cross-neutralizing activity.
Conclusion: The results indicate that mAbs specific to three neutralizing 
sites with mutation frequencies comparable to vaccine-induced Abs, 
can neutralize sensitive tier 1 viruses. A higher level of mutations is 
required for neutralization of tier 2 viruses.
P03.43
Inhibition of B Cell Function by HIV-1 Envelope: 
Role of Binding to Integrin α4β7
C. Cicala1
1NIAID, NIH, Bethesda, MD, USA
Background: During the early stages of HIV infection the immune 
system of the infected individual is already somewhat impaired. 
Among the defects described is the impairment of normal B cell 
function that includes a significant delay in the development of the 
anti-HIV humoral immune response. The mechanisms underlying 
this delay are not fully understood. In the present study, we asked 
whether gp120-induced signaling through α4β7 on B cells could 
disrupt their function. 
Methods: Peripheral blood B cells were treated in vitro with gp120s 
derived from viral isolates that exhibited different affinity for α4β7. 
Treated B cells were tested for alterations in their transcriptional 
program as determined by RNA microarray analysis. CFSE proliferation 
assay and FACS analysis were also employed.
Results: gp120 signaling through α4β7 modified the expression of 
genes involved in chemotaxis, regulation of apoptosis, regulation of 
lymphocyte proliferation, immune/inflammatory response. Several of 
these genes have previously been associated with B cell dysfunction 
in HIV-infected patients. B cells were also tested for proliferative 
capacity and changes in the expression of surface receptors. gp120s 
with high affinity for α4β7 mediated a strong inhibition of B cell 
proliferation. Among the genes upregulated by gp120 was FCRL4, an 
inhibitory receptor. Increased FcRL4 expression is observed in HIV-
infected individuals, but its expression normalizes upon initiation 
of antiretroviral therapy. We observed induction of FcRL4 surface 
expression by treatment with soluble HIV-1 gp120 and by exposure of 
B cells to CD4+ T cells that had been infected in vitro. 
Conclusion: Taken together these results suggest that gp120s with a 
high affinity for α4β7 have the potential to disrupt B cell function. These 
studies have implications for understanding the immunopathogenic 
mechanisms of HIV-1 infection, particularly the ability of high levels 
of viremia observed during acute HIV infection to blunt an appropriate 
antibody response to the virus.
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P03.46
Analysis of Env Regions Important for Binding 
and Resistance to B404, a Potent Neutralizing 
Antibody Against SIV
T. Kuwata1, K. Takaki1, K. Yoshimura2, I. Enomoto1, F. Wu3,  
I. Ourmanov3, V.M. Hirsch3, M. Yokoyama2, H. Sato2, and  
S. Matsushita1
1Kumamoto University, Kumamoto, Japan; 2National Institute 
of Infectious Diseases, Japan; 3LMM, NIAID, NIH, Bethesda, 
MD, USA
Background: Inducing neutralizing antibodies (NAb) is the key to 
developing a protective vaccine against HIV-1. Although non-human 
primate models of SIV infection are commonly used to develop 
vaccines against HIV-1, epitopes for potent and broad neutralization of 
SIV remain unclear because few monoclonal NAbs have been available. 
Recently, we isolated NAbs from rhesus macaques infected with 
SIVsmH635FC, which causes a vigorous and potent antibody response 
in the infected macaques. To clarify the neutralization mechanism of 
SIV, we analyzed Env regions important for binding and resistance to 
B404, a representative NAb with potent and broad neutralizing activity.
Methods: Binding site for B404 was analyzed by competition ELISA 
with monoclonal antibodies and by examining reactivities to Env 
mutants by flow cytometry. B404-resistant variants were induced 
by passages of SIVmac316 in PM1/CCR5 cells in the presence of 
increasing concentrations of B404. The Env residues associated with 
the resistance to B404 were identified by genetic analysis of the env 
gene, molecular dynamics simulations of variants, and neutralization 
assay using mutant viruses.
Results: The V3 and V4 loops were critical for B404 binding. The 
reactivity to the B404 epitope on trimeric, but not monomeric, Env was 
enhanced by CD4 ligation. The B404-resistant variant accumulated 
amino acid substitutions in the C2 region of gp120, which could 
effectively alter the structural dynamics of the V3/V4 loops and their 
neighboring regions. The Q733stop mutation, which truncates the 
cytoplasmic tail of gp41, was also associated with resistance to B404, 
and increased infectivity in human cells.
Conclusion: A conformational epitope consisting of the V3 and V4 
loops is the target for B404 that potently and broadly neutralize 
various SIV strains. Conformational change of Env trimer conferred by 
the mutations in C2 and gp41 is important for the resistant to B404.
P03.45
New Insight on DNA Vaccination to Prime High 
Quality B Cell and Antibody Responses
K. Hollister1, J. Suschak2, Y. Chen2, K. Remington2, S. Wang2,  
K. Fitzgerald2, A. Dent1, and S. Lu2
1Indiana University School of Medicine, Indianapolis, 
IN, USA; 2University of Massachusetts Medical School, 
Worcester, MA, USA
Background: The use of DNA immunization to elicit high quality 
antibody responses is receiving more attention in HIV vaccine 
development.  If viral vector priming was effective in the RV144 trial, 
there is no scientific reason to suggest that DNA vaccine cannot be as 
effective, if not more so.  While we, along with others, have shown that 
DNA prime-protein boost is highly effective in eliciting cross-subtype 
binding and neutralizing antibodies in both animal and human studies, 
the uncertainty on DNA immunization’s mechanisms has prevented 
DNA vaccines from moving to more advanced studies.  
Methods: Two independent mice studies were conducted. First, using 
HIV-1 gp120 as model immunogen, wild type (WT) C57/BL6 mice 
were immunized with DNA prime-protein boost, DNA alone, and 
protein alone. T follicular helper (Tfh) and germinal center (GC) B cells 
responses were analyzed. Second, antigen specific IgG responses in 
Aim2 knockout and WT mice were studied. 
Results: Here out data indicated that DNA immunization can take 
advantage of recently identified novel intracellular mechanisms 
involved in both acquired and innate immune response pathways. 
First, DNA priming is able to effectively re-orchestrate germinal center 
responses.  At early phase (day 3) post final immunization, increased 
numbers of Tfh cells and GC B cells are observed in the DNA prime-
protein boost group compared to the group that did not receive DNA 
priming. Second, we discovered that Aim2, an important member of 
the inflammasome family responsible for IL-1β and IL-18 release, is 
involved in DNA immunization as Aim2 knockout mice demonstrated 
decreased antibody titers when compared to WT mice.  
Conclusion: Findings from these two independent studies not only 
link DNA immunization to critical intracellular immune pathways 
but also bridge the antigen-specific (acquired immunity) and non-
antigen-specific (innate immunity) arms of immune system, which are 
important for the development of effective HIV vaccines.  
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P03.48
Steric Access to the HIV-1 Co-Receptor Binding 
Site Is Manifest on the Virus Prior to CD4 
Engagement at the Target Cell Surface
B.K. Chakrabarti1 and R.T. Wyatt2
1IAVI/The Scripps Research Institute, Gurgaon, India; 2The 
Scripps Research Institute, La Jolla, CA, USA
Background: It is well known that classical co-receptor binding site 
(CoRbs)-directed antibodies (eg 17b IgG) do not neutralize HIV-1 
primary isolates. However, they can neutralize the lab-adapted virus 
HXBc2, suggesting that a more open conformation allows access on 
this virus that is not permitted on primary isolates. In contrast, single 
chains (sFvs) derived from CoRbs monoclonal antibodies (Mabs) can 
neutralize primary isolates, suggesting steric restriction. Restriction to 
the CoRbs was suggested to be steric occlusion to the viral Env once 
engaged with target cell CD4. Such engagement would form or expose 
the CoRbs.
Methods: To investigate neutralization dynamics mediated by the 
co-receptor-directed antibodies, 17b and 17b sFv (and/or X5) we 
performed antibody-virus “washout experiments” using viruses 
containing envelope glycoproteins derived from both lab-adapted and 
primary viruses. 
Results: We performed washout experiments on the lab-adapted virus, 
HXBc2 with CoRbs mAbs. As expected, the full length IgG, 17b could 
neutralize HXBc2 and this neutralization activity was not significantly 
reduced by antibody-virus washing, indicating direct access of 17b 
epitope on the virus. We performed similar experiments on primary 
isolates and observed that, also as expected, 17b IgG, is unable to 
neutralize primary viruses both in “no-wash” and “wash-out” conditions, 
presumably due to lack of access to its epitope. Next we performed 
wash-out analysis with the neutralizing 17b sFv and we observed that 
the sFv resisted washout from primary viruses, suggesting direct access 
to the CoRbs prior to CD4 engagement. 
Conclusion: The data indicate that for lab-adapted isolates, the CoRbs 
is exposed prior to CD4 engagement and that the induced conformation 
recognized by 17b is at least sampled prior to CD4 binding. The sFv 
“washout” data suggest that prior to target cell engagement, the co-
receptor binding site is sterically occluded for full IgG on the virus but 
the smaller sFv can access this region.
P03.47
Rapid Screening of Human Sera for the 
Presence of Neutralizing Anti-MPER Antibodies
L.M. Molinos1, J. Carrillo1, S. Marfil1, E. García1, B. Clotet1, and  
J. Blanco1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, Spain
Background: The definition of the mechanism(s) of elicitation of 
neutralizing antibodies against the membrane proximal extracellular 
region (MPER) of gp41 will benefit from the analysis of new antibodies 
isolated from individuals with high titers of these antibodies. To 
identify these individuals, we have developed a fast screening method 
to measure neutralizing anti MPER antibodies.
Methods: Sera from 78 HIV+ individuals with detectable viremia and 
10 uninfected individuals were analyzed. The presence of anti-MPER 
antibodies was screened by ELISA and by using a flow cytometric assay 
that measures IgG binding to 293 cells stably transfected with two 
different truncated forms of gp41 covering the HR2, the MPER and the 
transmembrane domains, differing in the N-terminal sequence. Control 
cells and competition assays with 2F5 antibody were performed to 
confirm specificity.
Results: Both cell-surface expressed truncated gp41 molecules properly 
exposed the MPER epitope, as assessed by staining with antibodies 
4E10 and 2F5, and were recognized by most sera from HIV infected 
individuals. While the binding to both cell surface expressed gp41 
truncated proteins strongly correlated (p<0.0001) it was unrelated 
to standard ELISA assays for MPER linear epitopes. In competition 
assays with labeled 2F5 antibody, sera from HIV infected individuals 
that strongly recognized gp41 truncated proteins showed significantly 
higher inhibitory activity than samples from weakly reactive HIV-1 
infected patients or  uninfected individuals (p<0.0001). Therefore, the 
level of recognition of cell surface expressed gp41 proteins, but not 
data from ELISA assay, showed a correlation with the ability of sera to 
compete with the 2F5 antibody.
Conclusion: Small proteins exposing the MPER on the cell membrane 
are useful tools for the analysis of 2F5-like neutralizing anti HIV gp41 
responses. This improved tool compared to ELISA assays, may facilitate 
large screening of serum samples to identify and characterize new anti 
MPER antibodies and to monitor neutralizing immune responses in 
vaccine trials.
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P03.50
Copy Number Variants (CNV) in the 
Immunoglobulin Heavy Chain Locus (IGH) and 
Tests for Association with Progression to AIDS
F. Breden1, C.T. Watson2, K.M. Steinberg3, J. Willsey4, F. Pereyra5, 
B. Walker5, M. Brockman1, and E.E. Eichler6
1Simon Fraser University, Burnaby, Canada; 2Icahn School of 
Medicine at Mount Sinai, New York, NY, USA; 3Washington 
University, St. Louis, MO, USA; 4Yale University, New Haven, CT, 
USA; 5Ragon Institute of MGH, MIT and Harvard, Cambridge, 
MA, USA; 6University of Washington, Seattle, WA, USA
Background: The immunoglobulin heavy-chain locus (IGH) encodes 
variable (IGHV), diversity (IGHD), joining (IGHJ), and constant (IGHC) 
genes and is responsible for antibody heavy-chain biosynthesis, which 
is vital to the adaptive immune response. Programmed V-(D)-J somatic 
rearrangement and the complex duplicated nature of the locus have 
impeded attempts to reconcile its genomic organization based on 
traditional B-lymphocyte derived genetic material. As a result, sequence 
descriptions of germline variation within IGHV are lacking, haplotype 
inference using traditional linkage disequilibrium methods has been 
difficult, and the human genome reference assembly is missing several 
expressed IGHV genes.
Methods: We obtained high-quality finished Sanger sequence from 
the IGH region of large insert clones of a haploid human hydatidiform 
mole library and from a panel of nine diploid genomes of diverse 
ethnic origin from the HapMap collection.
Results: We present the most complete haplotype of IGHV, IGHD, and 
IGHJ gene regions derived from a single chromosome, representing 
an alternate assembly of ~1 Mbp.   From this population panel, 
we characterized 11 large germline copy-number variants, several 
previously unmapped IGHV genes, and an additional 221 Kbp of 
insertion sequence. Based on this new haplotype information, we 
genotyped four CNVs by PCR in 425 individuals from nine human 
populations. We found that all four are highly polymorphic and show 
considerable stratification (Fst 0.3–0.5), with the greatest differences 
observed between African and Asian populations.  We are now testing 
for an increase in copy number of IGHV1-69 alleles associated with 
broadly-neutralizing anti-HIV antibodies, comparing spontaneous 
controllers of HIV infection to normal progressors.
Conclusion: Much of the CNV in the IGH locus and other immune loci 
remain uncharacterized, and high-throughput genomic assays (GWAS 
and NextGen Sequencing) do not properly genotype these regions, 
invalidating association studies searching for hidden heritability of 
susceptibility to autoimmune and infectious diseases, such as HIV/AIDS.
P03.49
Genetic and Functional Characterization of 
Somatic Variants of Vaccine-Induced HIV-1 
CD4bs-Directed Monoclonal Antibodies
G.E. Phad1, C. Sundling1, Z. Zhang2, M. Navis1, S. O’Dell3, Y. Li4, 
R. Wyatt4, J. Mascola3, L. Shapiro2, and G.B. Karlsson Hedestam1
1Karolinska Institutet, Stockholm, Sweden; 2Columbia 
University, New York, NY, USA; 3Vaccine Research Center, 
NIAID, NIH, Bethesda, MD, USA; 4IAVI Neutralizing Antibody 
Center at The Scripps Research Institute, La Jolla, CA, USA
Background: Recent studies of broadly neutralizing antibodies 
targeting the primary receptor binding site (CD4bs) of HIV-1 isolated 
from chronically infected individuals suggest that extensive affinity 
maturation is required to achieve broad neutralization. By comparison, 
CD4bs-directed antibodies elicited by vaccination are far less driven by 
somatic hypermutation (SHM), a feature that likely contributes to the 
comparably narrow range of neutralization these antibodies display. 
We recently isolated a set of CD4bs-specific monoclonal antibodies 
(MAbs) from rhesus macaques immunized with envelope glycoprotein 
(Env) trimers and described their genetic and functional properties. 
Methods: Here, we isolated somatic variants of selected MAbs using 
two complementary approaches for a more comprehensive analysis of 
these lineages. In one approach, we designed clone-specific primers 
that align to the DH and JH junctions to selectively amplify somatic 
variants of the respective heavy chain (HC) sequences. The somatic 
variants were cloned and expressed together with the original light 
chains and evaluated for CD4bs specificity by ELISA and for their 
neutralization activity. In the other approach, we subjected peripheral 
blood mononuclear cells to 454 sequencing to create a database 
of HC VDJ sequences from the same rhesus macaque. Sequences 
representing proposed somatic variants of the specific MAbs were 
identified and their frequencies and degree of SHM were determined.
Results: We identified HC sequences that displayed a higher degree of 
SHM (up to 18% at the aa level) than the original antibodies (12-13% at 
the aa level) compared to their germline counterparts. Furthermore, in 
at least one case we found that increased SHM translated to improved 
neutralizing capacity. Further, our results suggest that the size of each 
clonal family is relatively small.
Conclusion: This approach allows us to characterize clonal families of 
vaccine-elicited antibodies archived in the peripheral memory B cell 
compartment for an improved understanding of vaccine-induced B cell 
responses targeting the HIV-1 CD4bs.
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P03.52
Escape from HIV-1 Neutralising Antibodies 
Drives an Increase in Plasma Neutralisation 
Breadth Through Recognition of Multiple 
Epitopes and Immunotypes
C.K. Wibmer1, J.N. Bhiman1, E.S. Gray2, N.L. Tumba2,  
S.S. Abdool Karim3, L. Morris1, and P.L. Moore1
1National Institute for Communicable Diseases (National 
Health Laboratory Services) and the University of the 
Witwatersrand, Johannesburg, South Africa; 2National Institute 
for Communicable Diseases (National Health Laboratory 
Services), Johannesburg, South Africa; 3CAPRISA, University of 
KwaZulu-Natal, Durban, South Africa
Background: Identifying the targets of broadly cross-neutralising 
(BCN) antibodies and understanding how they develop is critical to 
the rational design of an HIV-1 vaccine. Four sites of vulnerability 
on the envelope are known: V2; V3/ the co-receptor binding site; 
the CD4 binding site (CD4bs); and the membrane proximal external 
region of gp41. Here we mapped the BCN antibody targets and escape 
mutations in one individual who developed exceptional breadth 
(>90% neutralisation breadth) over 4.5 years of infection.
Methods: Site-directed mutagenesis was used to map the targets of 
BCN antibodies. Single genome amplification of autologous envelope 
sequences from twelve time points (7 to 240 weeks post-infection) 
identified potential escape mutations, which were introduced into 
heterologous viruses to characterise their effects on BCN antibody 
kinetics. 
Results: After 6 months of infection early type-specific V2 neutralising 
antibodies targeted a PG9-like epitope. Escape from these antibodies 
through an N167D mutation was associated with the development 
of BCN antibodies targeting the same epitope. Subsequent escape 
mutations that deleted the N160 glycan one year later exposed a 
second vulnerability for BCN antibodies targeting a glycan-dependent 
epitope in the CD4bs. Early escape from this BCN specificity (eg: 
N279D) resulted in the emergence of CD4bs antibodies with reduced 
dependence on the mutated amino acids, and this correlated with an 
increase in neutralisation breadth. 
Conclusion: These data suggest that rare V2 immunotypes selected 
for by anti-V2 antibodies exposed the CD4bs to antibodies with a novel 
glycan-dependent mechanism of neutralisation, representing a major 
sub-epitope of the CD4bs that may be important for vaccine design. 
Additionally we identified the escape pathways from V2 and CD4bs 
antibodies that drove the development of neutralisation breadth. This 
information about the interactions between HIV-1 and its host identify 
templates for sequential immunisation strategies aimed at inducing 
BCN antibodies to both V2 and the CD4bs. 
P03.51
What Can Be Learnt About Broad ADCC 
Immunity to HIV from Influenza?
S.J. Kent1, S. Jegaskanda1, V. Madhavi1, L. Wren1, and I. Stratov1
1University of Melbourne, Melbourne, Australia
Background: HIV and Influenza are variable viruses and it is difficult 
for infected or vaccinated subjects to generate antibodies that 
neutralize the majority of field strains for both viruses. However, 
non-neutralizing antibodies with effector functions such as Antibody-
Dependent Cellular Cytotoxicity (ADCC) may be able to recognize 
a broader array of viral strains and help reduce infection or control 
disease. We studied the breadth of recognition of HIV and Influenza 
strains by ADCC antibodies.
Methods: Serum samples from cART-naïve HIV+ subjects (n=79) 
and influenza-seropositive healthy adults (n= 182) were studied for 
ADCC to multiple strains of HIV or Influenza using both killing-based 
ADCC assays (RFADCC for HIV and ADCVI for influenza) and antibody-
dependent NK cell activation assays.
Results: Influenza-specific ADCC antibodies were found in serum from 
over 90% of healthy adults and typically recognize multiple divergent 
strains including the hemagluttinin of seasonal H1N1 and H3N2 
strains. Over half of adults had ADCC antibodies to the swine-origin 
H1N1 strain PRIOR to the onset of that epidemic. Pandemic H1N1-
specific ADCC antibodies pre-2009 were most common in subjects 
>45 years of age (<0.01), an age group that was relatively protected 
from disease. ADCC recognition of HIV is also common and broad 
in HIV+ subjects, with ADCC recognition of HIV exceeding 90% of 
subjects and the majority of infected subjects recognizing multiple 
HIV-1 subtypes. ADCC recognition of the HIV protein Vpu was rarer 
(11%) and only found in subjects with slow HIV progression.
Conclusion: Striking parallels exist in the breadth of ADCC recognition 
of HIV and Influenza. Increased breadth of influenza ADCC antibodies 
likely represents stimulation from multiple prior infections. HIV 
vaccination strategies may be able to mimic this. The association of 
ADCC with reduced infection (for influenza) and disease progression 
(for HIV) suggests that ADCC-based vaccines or immunotherapies may 
hold promise for these infections. 
Topic 03: B Cell Immunology and Antibody Functions
136
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L1, Room 111 – 112.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L1, Room 111 – 112.
P03.54
A Mechanistic Understanding of Immune 
Escape Pathways in the HIV-1 Envelope 
Glycoprotein
G. Gnanakaran1, A. Sethi1, J. Tian1, C. Derdeyn2, and B. Korber1
1Los Alamos National Labs, Los Alamos, NM, USA; 2Emory 
University, Atlanta, GA, USA
Background: The extraordinary genetic diversity and the 
conformational plasticity of HIV-1 Env proteins, gp120 and gp41, 
present a formidable obstacle for effective immune control and vaccine 
design. Mutations that are distant from the antibody binding site can 
lead to escape, probably by changing the conformation or dynamics 
of Env; however, these changes are difficult to identify and define 
mechanistically. Here we develop a network analysis-based approach 
to identify potential long-distance immune evasion mechanisms using 
three known HIV-1 Env gp120 protein structures from two different 
clades, B and C.
Methods: First, correlation and principal component analyses of 
molecular dynamics simulations identified a high degree of long-
distance coupled motions that exist between functionally distant 
regions within the intrinsic dynamics of the gp120 core, supporting 
the presence of long-distance communication in gp120. Then, by 
integrating MD simulations with network theory, we identified the 
optimal and suboptimal communication pathways and modules within 
the gp120 core.
Results: We show that many different pathways exist for communication 
between spatially distant sites in gp120 and a suboptimal pathway in 
one strain can serve as the optimal pathway in another strain. While 
the long distance coupled motions are highly conserved across the 
three gp120 cores considered, the shortest route for communication 
between spatially distant sites in gp120 varied with the sequence. 
Our analysis indicates that HIV-1 gp120 could retain its function and 
escape from antibody through mutations that allow it to utilize one 
of the suboptimal paths if the optimal pathway becomes blocked. 
Hence, blocking or altering dominant and suboptimal pathways in 
gp120 should also be considered in vaccination strategies to increase 
exposure and/or immunogenicity of conserved epitopes.
Conclusion: The results unveil both strain-dependent and 
-independent characteristics of communication pathways in gp120. 
The identification of conserved elements within these communication 
pathways, termed inter-modular hotspots, presents a new opportunity 
for immunogen design.
P03.53
Arginine-Scanning of PG16 Paratope Defines 
Quaternary Epitope
M. Pancera1, J. Zhu1, S. O’Dell1, Y. Yang1, B. Zhang1, A. Changela1, 
J.S. McLellan1, X. Wu1, T. Zhou1, D.R. Burton1, W.C. Koff1,  
J.R. Mascola1, and P.D. Kwong1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: PG9 and PG16 are broad and potent neutralizing 
antibodies that target HIV-1, neutralizing 72-78% of viral strains with 
an average IC50 of 0.2 µg/ml. These somatic variants preferentially 
bind a quaternary epitope on the HIV-1 gp120 envelope glycoprotein, 
contained in V2 and possibly V3. Crystal structures of PG9 and PG16 
bound to scaffolded V1/V2 show they recognize a site of vulnerability 
comprising two glycans and a strand. The glycan at position Asn160, 
which is required for neutralization, is Man5GlcNAc2, whereas some 
diversity is allowed at a second site, located at Asn156 or Asn173. 
Methods: To define the PG16 paratope, we developed a method 
that bioinformatically identifies surface residues capable of being 
mutated to arginine without disturbing the PG16 structure, and used 
this method to define a collection of PG16 arginine mutants, each 
separated by ~5 Å. We individually mutated 34 residues from the 
PG16 combining site to arginine, produced the mutated antibodies, 
and performed neutralization assays on 9 HIV-1 strains. 
Results: Strain-dependent effects were observed, though the average 
arginine-defined paratope was contained in the long hammerhead-
shaped CDR H3 and in the CDR L2 and L3. This arginine-defined 
paratope closely matched the crystal structure of PG16 bound to a 
monomeric scaffolded V1/V2. However, there were a few differences 
at residues Tyr32, Ala96 and Tyr100s of the heavy chain and Val51 
of the light chain.  Remarkably, these residues were those predicted 
to interact with a neighboring Asn160 glycan, based on the recent 
cryoEM structure of PG9 bound to a trimeric BG505 gp140 protein. 
Conclusion: Our data provide a new method, arginine “pin-
cushioning”, to determine the interactive surface of a protein.  We 
show here how this method can be used to guide the definition of an 
antibody interacting with the HIV-1 viral spike, even if the epitope is 
quaternary in nature. 
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P03.56
Computational and Mutagenesis Analyses of 
the Epitope of Human V2 mAb 2158 
B. Spurrier1, C. Williams2, M.K. Gorny3, S. Zolla-Pazner4, and  
X. Kong2
1New York University Medical Center, New York, NY, USA; 
2New York University School of Medicine, New York, NY, 
USA; 3New York University, New York, NY, USA; 4New York 
University, Veterans Affairs New York Harbor Healthcare 
System, New York, NY, USA
Background: The RV144 correlates analysis indicated that antibodies 
targeting the V2 region of gp120 were associated with a lower risk of 
infection. Thus, structural mapping of all V2 epitopes will be crucial 
to the design of an effective V2 vaccine. A panel of human mAbs, 
including mAb 2158, target a conformational V2 region encompassing 
the α4β7 integrin binding site, and provide a unique opportunity for 
characterizing this V2 region which was not visualized in the V1V2/
PG9, V2/CH58, or V2/CH59 crystal structures.
Methods: We constructed a full-length V1V2 model based on the V1V2/
PG9 crystal structure using Rosetta 3.4, and systematically computed 
the in silico stability energy for each residue. The computational 
analysis identified a group of V2 residues that can either stabilize the 
epitope region or directly mediate mAb 2158 binding. We then cloned 
and expressed a set of mutants based on the computational data, and 
tested these mutants for mAb 2158 binding by an ELISA.
Results: Our extensive computational Monte Carlo simulation has led 
to a structural model of the missing V2 region in the V1V2/PG9 crystal 
structure, providing a complete V1V2 model with the integrin-binding 
site. Comparison of our energy stability data with our ELISA results 
allows us to group V2 residues into two sets which play key roles in the 
epitope of mAb 2158. The first set, consisting of residues F176, V181, 
Y191, and L193, forms a hydrophobic core stabilizing the V2 region for 
optimal mAb 2158 binding. The second set, including A172, P179, and 
D180, can directly mediate side chain interactions with 2158.  
Conclusion: These data provide a model of the binding surface 
recognized by mAb 2158 and insights for understanding the antigen 
binding of related V2 antibodies. Our results may contribute to the 
design of V2-targeted immunogens.
P03.55
Association Between HIV-1 Coreceptor Usage 
and Resistance to Some Broadly Neutralizing 
Antibodies
N. Pfeifer1 and T. Lengauer1
1Max Planck Institute for Informatics, Saarbruecken, Germany
Background: The recent discovery of broadly neutralizing antibodies 
against many different HIV-1 strains has revitalized hopes of 
developing a universal vaccine against HIV-1. HIV-1 variants that can 
only use the CCR5 coreceptor for cell entry are mainly responsible for 
new infections, while CXCR4-using variants can become dominant in 
later infection stages.
Methods: We performed a statistical analysis on two different 
previously published data sets. The first data set was a panel of 
199 diverse HIV-1 isolates for which IC50 neutralization titers were 
determined for the broadly neutralizing antibodies VRC01, VRC-PG04, 
PG9, and PG16. The second data set contained env sequences of viral 
variants extracted from HIV-1 infected humanized mice treated with 
the antibody PGT128 as well as from untreated control mice.
Results: We found a statistically significant association between 
viral resistance to the broadly neutralizing antibodies PG9 and 
PG16 and CXCR4 coreceptor usage (p-value = 0.0011 and p-value = 
0.0010, respectively) for the 199-isolate panel. This association was 
not present for antibodies VRC01 and VRC-PG04 targeting the CD4 
binding site. Furthermore, certain amino acids at specific positions 
of the Env protein sequence were associated significantly with viral 
sensitivity/resistance to PG9, overlapping partly with amino acids at 
certain positions significantly associated with coreceptor usage.
Additionally, our analysis on viral variants from HIV-1 infected 
humanized mice under treatment with the broadly neutralizing 
antibody PGT128 indicated that certain antibodies might drive 
a viral population towards developing CXCR4-coreceptor usage 
capability (p-value = 0.0011 for the comparison between PGT128 
and control measurement).
Conclusion: This analysis highlights the importance of accounting for 
a possible coreceptor usage bias for an HIV vaccine as well as for 
passive antibody transfer treatment. For a vaccine one would want 
antibodies that are best against CCR5-using viruses and for treatment 
of salvage patients one might exclude antibodies with a CCR5-bias to 
avoid a coreceptor switch.
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P03.58
Structural Characterization of Two Monoclonal 
Antibodies Targeting the Fourth Constant 
Domain in the Bridging Sheet of HIV-1 gp120
R. Pan1, Y. Chen2, M. Vaine2, S. Wang2, H.C. Kelker1, V.R. Itri1,  
F.T. Valentine1, S. Lu2, and X. Kong1
1New York University School of Medicine, New York, 
NY, USA; 2University of Massachusetts Medical School, 
Worcester, MA, USA
Background: The fourth constant domain (C4) of HIV-1 gp120 is 
a structural element important for the function of HIV-1 envelope 
complex; it involves in the bindings of the receptor CD4 and co-
receptor CCR5/CXCR4. This region is immunogenic to both T cell and 
B cell, and a number of monoclonal antibodies (Mabs) against this 
region, named CD4-blockers, have been isolated since 1990s and 
characterized biologically. However, there has not been any study on 
their antigen-antibody interactions at the atomic level.
Methods: We determined Fab/epitope complex crystal structures of 
two neutralizing anti-C4 antibodies, a rabbit Mab R53 and a mouse 
Mab 11a8. R53 was raised by immunization with recombinant gp120 
using a DNA prime-protein boost regimen, while 11a8 with multiple 
identical copies of covalently linked C4 peptides (MCPs). 
Results: Our data show that R53 and 11a8 target at the same epitope 
region in C4 with slightly different binding modes. The epitope of 
R53 (431GKAMYAPPIRG441) is shaped like a stretched spring, lying 
across on top of the light and heavy chains. Its N-terminal part lies in 
a groove on the heavy chain side while the C-terminal part straddles 
on a saddle formed by the light chain. The antigen binding site 
surface of R53 is negatively charged, complementing the epitope 
with a positively charge residue at each terminus. The epitope of 
11a8 (AMYAPPIE) is shaped like a hook, lying between the light chain 
CDRs and heavy chain CDRs. Although the 11a8 epitope has one 
negatively charged residue at the C-terminus, its side chain does not 
involve antibody binding. 
Conclusion: This is the first structural characterization of any anti-C4 
Mabs whose epitopes consist of a conserved C4 sequence motif 
AMYAPPI, which overlaps with known gp120 T cell epitopes T1 and 
PS05, thus a potential target for HIV vaccine development. 
P03.57
HIV-1 Infection and Systematic Lupus 
Erythematosus Display Distinct Igg H VDJ 
Profiles Defined by Pyrosequencing that Differ 
from Healthy Individuals
L. Yin1, J. Yao1, K. Chang1, B.P. Gardner1, X. Zhang1, Y. Chi1,  
C.A. Rodriguez2, P. Sriaroon2, J.W. Sleasman2, and  
M.M. Goodenow1
1University of Florida, Gainesville, FL, USA; 2University of 
South Florida, St. Petersburg, FL, USA
Background: IgM heavy chain (H) CDR3 transcriptome repertoire 
has reduced biodiversity in the peripheral blood (PB) in HIV-infection 
or systematic lupus erythematosus (SLE) reflecting restricted VDJ 
recombinants compared to healthy controls (HC). We hypothesized that 
HIV-infection and SLE will have distinct IgG profiles.
Methods: 454-deep sequencing of full-length IgG H VDJ transcriptome 
(~500 bp) in PB from 4 therapy-naïve or 4 treated HIV-infected young 
adults (HIV) was compared with 8 age-balanced HC or 3 counterparts 
with SLE. A customized bioinformatics software, IgSEQ, was developed 
to automate integrated analysis of somatic hypermutation (SHM) and 
VDJ allele plus reading frame (RF) use by IMGT system, metagenomics 
of antibody biodiversity by ESPRIT, and predicted response to antigen. 
Comparisons among groups were evaluated by Multivariate Analysis 
of Variance with p<0.05 as significant.
Results: IgG H VDJ transcriptome repertoire in HIV and SLE compared 
to HC showed a trend toward decreased biodiversity, diminished SHM, 
particularly nonsilent mutations in CDRs, and reduced proportion of 
sequences estimated to reflect antigen selection. Repertoire expression 
of VH3, DH3 with RF2, and JH4 predominated in HC and HIV, whereas 
SLE had increased use of VH4, DH5 and DH6 with RF3, and JH3. 
Longer CDR3 lengths (15 to 17 aa) predominated in SLE, in contrast to 
shorter CDR3 lengths (13 or 14 aa) in HIV, while predominant CDR3 
length varied from 13 to 19 aa among healthy individuals. Overall 
profiles of the IgG repertoire differed between HIV and SLE and were 
distinct from HC.
Conclusion: Decreased VDJ diversity in both SLE and HIV infection 
likely reflects polyclonal B cell activation. Mechanisms of VDJ 
recombination and generation of SHM are intact. Alterations in the IgG 
repertoire are clearly apparent using deep sequencing, which provides 
a unique means to monitor the B cell repertoire in health and disease, 
or following immunization. 
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P03.60
Systemic IgG and IgA Responses to gp70V1V2 
and C1 in HIV-Infected Elite Controllers Versus 
Controllers and Noncontrollers on HAART
R. Nabi5, Q. Wei1, Z. Moldoveanu1, E.T. Golub2, A.L. Landay3, 
G.D. Tomaras4, J. Mestecky1, and P.A. Kozlowski5
1University of Alabama at Birmingham, Birmingham, AL, 
USA; 2Johns Hopkins University, Baltimore, MD, USA; 3Rush 
University, Chicago, IL, USA; 4Duke University, Durham, NC, 
USA; 5Louisiana State University Health Sciences Center, New 
Orleans, LA, USA
Background: Identification of the immune mechanisms which enable 
HIV-infected elite controllers (EC) to inhibit viral replication will 
contribute to our understanding of protective immunity and vaccine 
development for HIV. Based on RV144 trial results, we hypothesized 
that EC may have greater systemic IgG responses to V1V2 and reduced 
serum IgA against the C1 domain of gp120 when compared to infected 
individuals who require highly-active antiretroviral therapy (HAART) to 
manage disease. 
Methods: Serum samples collected at a two year interval from age- 
and race-matched HIV negative women (n=20) and HIV-infected 
women were obtained from the Women’s Interagency HIV Study. 
Infected subjects were in one of the following groups: 1) EC (n=10) 
or 2) HAART controllers (HC; n=20) both with viral loads ≤ 80 RNA 
copies/ml and CD4 cells > 350/µl, and 3) HAART progressors (HP; 
n=19) with viral loads > 1000 and CD4 < 250/µl.  ELISA was used to 
measure Ig and specific antibodies to gp120, gp41, p24, gp70V1V2 
and C1 peptides.
Results: Many infected women, including EC, had IgG (but not 
IgA) hypergammaglobulinemia. EC had greater anti-p24 IgG and 
IgA responses when compared to HC and HP. Though IgG and IgA 
responses to gp120 or gp41 were similar in all infection groups, EC 
more frequently demonstrated anti-gp70V1V2 IgG than HC, and they 
had higher magnitude responses than HP. Anti-C1 IgA (but not IgG) was 
detected at low levels and was increased roughly 10-fold in all HIV 
groups after 2 years. In contrast, systemic IgG and IgA responses to 
other antigens did not change significantly during this time. 
Conclusion: These data support a beneficial role of anti-V1V2 IgG in 
control of HIV infection, but not a detrimental effect of anti-C1 IgA 
in disease. The results further suggest that B cell abnormalities and 
undetected viral replication may be occurring in many EC. 
P03.59
Fitness Cost of Viral Escape from Broadly 
Neutralizing CD4-Binding Site Antibodies
R.M. Lynch1, P. Wong1, X. Wu2, and J. Mascola1
1NIH, Bethesda, MD, USA; 2Aaron Diamond AIDS Research 
Center, New York, NY, USA
Background: The receptor-binding site on the HIV glycoprotein gp120 
is a highly conserved epitope, and certain antibodies directed against 
this CD4 binding site (CD4bs) such as VRC01 can potently neutralize 
the majority of HIV-1 isolates. Previous studies demonstrated that 
HIV can escape from an anti-CD4bs response by accruing mutations 
in the Loop D and V5 domains of gp120.  Although conservation of 
the CD4bs renders it an ideal target for broad neutralization, it also 
suggests that viral escape from CD4bs antibodies may reduce affinity 
for CD4 and lower viral replication.
Methods: Env-pseudoviruses and infectious molecular clones (IMC) 
were constructed using the near-full length gp160 env gene of YU2 
with 4 mutations at residues associated with VRC01 resistance made 
singly and in combination as well as from autologous env genes from 
the VRC01 donor (both sensitive and resistant to VRC01). Replication 
kinetics of IMCs were assessed by in vitro infection of primary CD4 
T cells.
Results: Two mutations in LoopD and two in V5, have been associated 
with resistance to VRC01. Introduction of these mutations into YU2 
Env resulted in complete resistance to six additional antibodies of the 
VRC01 class and this IMC displayed severely impaired replication. 
Singly, the G458D mutation in V5, which conferred resistance to some 
CD4bs antibodies, also lowered replication. An N279K mutation in 
LoopD did not affect replication though it conferred partial resistance 
to the VRC01 class mAbs. Analysis of VRC01-escaped autologous 
Envs from the donor revealed non-consensus residues at 279 and no 
replication deficit.
Conclusion: These data demonstrate escape from neutralization by the 
VRC01 class of antibodies can impair replicative fitness of HIV. Viral 
Envs from the VRC01 donor displayed no reduction in replicative fitness, 
suggesting that compensatory mutations can restore viral replication 
over time. The conserved CD4bs is a potentially important target for 
vaccine-induced antibodies aimed at preventing HIV infection.
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P03.62 LB D
Analysis of Vaccine-Elicited Antibodies to the 
HIV-1 gp120 CD4 Binding Site Reveals Distinct 
Modes of Env Recognition to Guide Immunogen 
Re-design
K. Tran1, C. Poulsen1, J. Guenaga1, N. de Val Alda1, C. Sundling2,  
R. Wilson1, Y. Li1, R. Stanfield1, I. Wilson1, A.B. Ward1, G.B. Hedestam 
Karlsson2, and R.T. Wyatt1
1The Scripps Research Institute, La Jolla, CA,, USA; 2Karolinska 
Institutet, Stockholm, Sweden USA
Background: Structure-function studies of broadly and non-broadly 
neutralizing antibodies directed toward the HIV-1 CD4 binding 
site (CD4bs) indicate that accessibility to the viral spike is a critical 
neutralization determinant. We cloned CD4bs-directed antibodies 
from non-human primates immunized with YU2 gp140-foldon trimers, 
which neutralize Tier 1, but not Tier 2 isolates.
Methods: To elucidate their limited functional capacity, the Fab 
fragments of two antibodies, GE136 and GE148, were crystallized, 
yielding the first high-resolution structures of vaccine-elicited CD4bs-
directed antibodies.
Results: Interaction of the antibodies with gp120 and the functional 
spike were further defined through paratope alanine scanning of 
their complementarity determining regions. These data, coupled with 
previous gp120 epitope scanning, were used to generate docking 
models of the Fabs in complex with gp120, revealing testable high-
resolution interactions. Targeted substitution in the mAb paratopes 
both decreased and enhanced neutralizing activity as predicted by the 
modeling. EM reconstructions of GE148 and GE136 in complex with 
gp120 and PGT122, compared to PGV04-gp120-PGT122 EM densities, 
revealed different angles of binding to the gp120 CD4bs. Fitting the 
complexes into both cryo-EM and SOSIP EM densities suggested that 
the vaccine-elicited NHP antibodies attempt to approach the trimeric 
Env from the “top of the spike” thereby engendering clashes with the 
glycosylated variable region cap of primary isolates. This angle of 
approach contrasts with the more “side approach” taken by the bNAbs 
VRC01 and PGV04. Subsequent EM analysis confirmed that the YU2 
gp140-foldon trimers are too open in conformation, suggesting the 
design of V loop-capped trimers to restrict access of B cells to the 
CD4bs by a “lateral only” mode of engagement. We have generated 
well-ordered 2nd generation soluble trimers as defined by EM and 
antigenicity (Guenaga et al Abstract).
Conclusion: We conclude that well-ordered trimers provide reagents 
to test the hypothesis whether faithful mimics of the native spike will 
elicit neutralizing antibodies.
P03.61 LB
Exploring the Human Genomic DNA Antibody 
Repertoire for Development of an Effective 
HIV-1 Vaccine
M. Zhang1, Y. Zhang1, J. Li1, J. Xu2, Y. Shao3, and Z. Chen1
1The University of Hong Kong, Pokfulam, China; 2Fudan 
University, Shanghai, China; 3National Center for AIDS/STD 
Control and Prevention, China CDC, Beijing, China
Background: Broadly neutralizing HIV-1 antibodies (bnAbs) are 
expected to be a key component of immune protection conferred by 
an effective HIV-1 vaccine. All known HIV-1 bnAbs were isolated from 
the human cDNA antibody repertoires of “elite controllers” and they 
exhibited uncommon characteristics. Vaccine immunogens designed 
based on some of the known bnAbs did not induce the same and 
similar bnAbs in vivo. The human genomic DNA (gDNA) antibody 
repertoire has not been investigated for HIV-1 vaccine development. 
Methods: Nonimmune (300 uninfected individuals) and three immune 
human gDNA antibody libraries and the corresponding cDNA antibody 
libraries were constructed and deep sequenced. Sequence results 
were analyzed and compared. The human gDNA and cDNA antibody 
libraries were furthered panned against an engineered envelope 
glycoprotein RSC3 by phage display.
Results: Human gDNA antibody repertoire was more diverse than the 
cDNA antibody repertoire in using IGHV lineages. The frequencies of 
heavy and light chain variable regions that had exactly the same V(D)
J recombinations and the same lengths of CDR3s as known HIV-1 
bnAbs were extremely low. We isolated a panel of RSC3-specific mAbs 
from the human gDNA antibody libraries, but did not isolate the same 
or similar mAbs from the corresponding cDNA libraries. The isolated 
mAbs competed with bnAbs VRC01 and b12 for binding to RSC3. But 
unlike VRC01 and b12, these mAbs used various IGHV lineages and 
have very low levels of somatic maturation, thus were incapable of 
neutralizing the virus.
Conclusion: Our results suggest that antibody diversity in the human 
antibody gene repertoire is not infinite, and immunogens designed 
based on known bnAbs may not elicit the same or similar bnAbs in 
human population for lack of the putative germline antibodies. The 
gDNA-derived RSC3-specific mAbs may have the potential to mature 
to VRC01-like bnAbs, but there may be obstacles to their further 
maturation in vivo.
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P03.64 LB
Neutralizing Antibody to HIV-1 gp41 MPER Alters 
Recognition Properties of the Infectious Spike
A. Kim1, D. Leaman1, and M. Zwick1
1The Scripps Research Institute, La Jolla, CA, USA
Background: Human antibody 10E8 exhibits potent cross-clade 
neutralization against HIV-1 that has been linked to a helix in the 
membrane proximal external region (MPER) of envelope glycoprotein 
(Env) gp41. However, the affinity of antibodies for MPER antigens 
does not correlate with neutralization suggesting that some feature is 
unaccounted for on native, trimeric spikes.
Methods: Mutations that have been shown to diminish 10E8 binding 
to MPER peptides were introduced into different HIV-1 Envs and tested 
in thermostability assays and neutralization assays in different formats. 
Various antibodies and inhibitors were also tested against HIV-1 in 
the presence or absence of 10E8. Binding of 10E8 to native Env was 
examined using gel mobility shift native PAGE and Western blot.
Results: Several MPER mutants showed complex behavior in 
neutralization assays with 10E8 in which low concentrations of 10E8 
partially neutralized viral infectivity but saturating concentrations did not 
fully block infection. Surprisingly, we find that when saturated with 10E8, 
such mutant viruses become less sensitive to other MPER antibodies 
and to soluble CD4 while becoming more sensitive to antibodies and 
inhibitors against distal sites on gp41. At saturation, 10E8 binds to 
wild-type and MPER mutant spikes with 3:1 and 1:1 stoichiometry, 
respectively. Hence, at partial occupancy by 10E8 mutant spikes can 
be infectious but have altered sensitivity to ligands. Moreover, 10E8 
accelerates functional decay and physical disruption of wild-type HIV-1 
Env but can stabilize MPER mutant Envs. Partial neutralization by 10E8 
is also shown to be modulated by Env glycosylation.
Conclusion: We describe a novel ability of an antibody to stabilize, 
partially neutralize and alter neutralization sensitivity of a virion spike. 
Our results identify quaternary structure-dependent features of HIV-1 
Env that are crucial to MPER recognition by antibody 10E8, which has 
implications for immunoprophylaxis and vaccine design.
P03.63 LB
Antibodies VRC01 and 10E8 Require Minimal 
Somatic Framework Mutations to Achieve High 
Neutralization Breadth and Potency
I.S. Georgiev1, R.S. Rudicell1, K.O. Saunders1, W. Shi1, T. Kirys1,  
K. McKee1, S. O’Dell1, G. Chuang1, Z. Yang1, G. Ofek1, J.R. Mascola1, 
G.J. Nabel1, and P.D. Kwong1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: The majority of broadly neutralizing antibodies (bNAbs) 
against HIV-1 are characterized by substantially increased frequencies 
of somatic mutations. Moreover, mutations within the antibody 
framework regions, which are typically less associated with direct 
antigen interactions, have been shown to be generally required for 
broad and potent neutralization.
Methods: We utilized a partial framework reversion approach for two 
bNAbs targeting two different epitopes on the HIV-1 envelope: CD4-
binding-site antibody VRC01 with 42% heavy/28% light and MPER 
antibody 10E8 with 22% heavy/17% light chain framework mutations. 
First, the mature CDR regions were transplanted onto a putative 
human germline gene. Next, a set of germline framework residues 
were selected for mutation to their mature counterparts based on 
structure and sequence considerations. Three constructs with different 
numbers of framework mutations were created for each of the heavy 
and light chains of VRC01 and 10E8. Partial revertants were tested for 
neutralization on a panel of 21 diverse HIV-1 strains.
Results: A total of ten constructs combining partially reverted and/
or mature heavy and light chains were created for each of VRC01 
and 10E8. The VRC01 variant with no framework mutations (100% 
framework reversion) showed complete loss of neutralization activity, 
whereas the analogous 10E8 variant had a ~10-fold loss in potency. 
Interestingly, variants with ~80% (VRC01) and ~90% (10E8) framework 
reversion had only a ~1.5-fold and ~3-fold loss in potency, respectively. 
For both VRC01 and 10E8, partial revertants with breadth and potency 
similar to the mature antibodies were identified. For VRC01, a light 
chain with ~50% reversion of framework mutations showed a ~2-fold 
improvement in potency over the mature antibody.
Conclusion: Our results indicate that many antibody mutations found 
in mature anti-HIV-1 antibodies may not be necessary for broad and 
potent neutralization. BNabs with lower numbers of mutations can be 
of utility as antibody therapeutics and as targets for immunogen design.
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P03.66 LB
Crystal Structure of a Cleaved, Stabilized HIV-1 
Env Trimer in Complex with a Glycan-Dependent 
Broadly Neutralizing Antibody at 4.7 Å
J. Julien1, A. Cupo2, D. Sok1, R.L. Stanfield1, D. Lyumkis1,  
M.C. Deller1, D.R. Burton1, R.W. Sanders3, J.P. Moore2, A.B. Ward1, 
and I.A. Wilson1
1The Scripps Research Institute, La Jolla, CA, USA; 2Weill 
Medical College of Cornell University, New York, NY, USA; 
3Academic Medical Center, Amsterdam, Netherlands
Background: The functional, cleaved HIV-1 Env trimer is central to 
vaccine design strategies due to its role in HIV-1 entry, the first step of 
the viral infection causative of AIDS. Although structures of portions 
of its individual core subunits, gp120 and gp41, has been achieved, 
structural characterization of an intact, soluble HIV-1 Env trimer has 
thus far remained elusive.
Methods: Here, we describe the crystal structure at 4.7 Å of an 
antigenically near-native, cleaved, stabilized recombinant HIV-1 Env 
construct of isolate BG505 (termed SOSIP.664) in complex with a 
glycan-dependent, broad and potent neutralizing antibody (bnAb), 
PGT122.
Results: In addition to corroborating previously described high-
resolution crystal structures of core gp120 and gp120 V1/V2, the 
cleaved, stabilized HIV-1 Env trimer crystal structure reveals unique 
features and organization of the gp120 V1/V2/V3 loops and insights 
into gp41 structure in the context of gp120. Furthermore, the co-crystal 
structure delineates the full epitope of PGT122, that includes gp120 
V1 and V3, in addition to several surrounding glycans. The cleaved, 
stabilized HIV-1 Env trimer structure also provides insights into the 
delineation of the complete epitopes for other bnAbs, where only 
partial information was previously available.
Conclusion: Together, structural details of the architecture of the 
antigenically near-native HIV-1 Env SOSIP.664 provide a blueprint for 
structure-based vaccine design strategies looking to re-elicit bnAbs 
with unusual features, as well as provide key insights into Env function.
P03.65 LB
High Proportion of Simian Immunodeficiency 
Virus gp120-Reactive Antibodies in B Cell 
Repertoire of Chronically Infected African Green 
Monkeys 
T. Arifin1, R. Zhang2, C. Stolarchuk 2, A. Fougler2, J. Amos2,  
M. Wang2, N. Vandergrift2, S. Smith2, L. Colvin2, K. Dewar3,  
N. Juretic3, J. Wasserscheid3, H. Liao2, and S. Permar2
1Duke University Medical Center, Duke-NUS Graduate Medical 
School Singapore, Durham, NC, USA; 2Duke University Medical 
Center, Durham, NC, USA; 3McGill University and Génome 
Québec Innovation Centre, Montreal, Canada
Background: Natural hosts of Simian Immunodeficiency Virus (SIV), 
such as African green monkeys (AGMs), rarely transmit the virus to 
their infant. Moreover, SIV-infected AGMs have strong autologous virus 
neutralizing antibody responses in milk, unlike humans and rhesus 
monkeys. Therefore, defining the SIV Envelope (Env)-specific B cell 
repertoire of AGMs could guide development of vaccines that elicit 
protective mucosal antibody responses. 
Methods: The constant and variable gene segments of immunoglobulin 
(Ig) heavy- and light-chain (VH and VL) were identified in the AGM 
genome using human and rhesus Ig gene sequences. The Ig genes 
were amplified by RT/PCR from single memory B cells sorted by flow 
cytometry from blood and milk of four SIV-infected lactating AGMs 
and used to produce recombinant monoclonal antibodies (mAbs) for 
characterizing their specificities. 
Results: We localized the constant and variable gene segments of 
IgH, IgK and IgL to AGM chromosomes 24, 14, and 19 respectively. 
Numbers of AGM VH, VK and VL gene segments were comparable to 
that of humans. We found a significantly higher proportion of memory 
B cells isolated from blood (18.3%) and milk (29%) of SIV-infected 
AGMs (n=4) produced Env-specific mAbs than that of memory B cells 
populations isolated from blood (0.6%); and milk (7.3%) of chronically 
HIV-infected individuals (n=7) (p<0.0001 and p=0.004, respectively, 
Fisher’s exact). Moreover, a higher proportion of the Env-specific AGM 
blood and milk antibodies were directed against gp120 (11.0% and 
10.0% respectively) than gp41 (3.7% and 5.0% respectively). Usage of 
the VH<4~59 human ortholog was overrepresented in both blood and 
milk Env-reactive (46.7% and 24.1% respectively) and non-reactive 
(17.9% and 23.9% respectively) AGM antibodies. 
Conclusion: A considerably larger proportion of the SIV-infected AGM 
B cell repertoire is committed to responding to the SIV Env than that of 
HIV-infected humans. Isolation of these AGM antibodies will facilitate 
exploration of their transmission-blocking properties.
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P03.68 LB
Investigation of Antibody Responses Induced 
in RV305 a Late Boost Vaccination of HIV-1 
Uninfected Volunteers that Participated in 
RV144, a Thai Trial
N. Karasavvas1, C. Karnasuta1, V. Ngauy1, S. Vasan1,  
R. Trichavaroj1, M.S. de Souza2, H. Savadsuk1, D. Inthawong1,  
S. Rittiroongrad1, S. Madnote1, S. Nitayaphan1, P. Pitisuttithum3,  
S. Rerks-Ngarm4, R.J. O’Connell1, N.L. Michael5, and J.H. Kim5
1Armed Forces Research Institute of Medical Sciences (AFRIMS), 
Bangkok, Thailand; 2Thai Red Cross AIDS Research Centre, 
Bangkok, Thailand; 3Mahidol University, Bangkok, Thailand; 
4Ministry of Public Health, Nonthaburi, Thailand; 5U.S. MHRP, 
Silver Spring, MD, USA
Background: RV305 is a randomized, double-blinded, placebo 
controlled study designed to investigate immune responses generated 
after a late boost in RV144 volunteers who completed the full vaccine 
series given 6-8 years earlier. Healthy, HIV uninfected volunteers 
from RV144 were enrolled and received 2 injections of ALVAC-HIV or 
AIDSVAX-B/E or a combination of ALVAC-HIV/AIDSVAX-B/E at day 0 
and 6 months.
Methods: IgG and IgA responses at baseline and 2 weeks post first 
and second vaccination were tested by ELISA against HIV-1 envelope 
protein, gp120 CRF01_AE (A244), and gp70V1V2 scaffolds subtype 
E (92TH023) and subtype B (CaseA2). Antibody responses were 
compared to those induced in RV144 at 2 weeks post last vaccination 
in the primary vaccination series.
Results: At baseline, antibodies to gp120 were similar in all vaccination 
groups (geometric mean titers (GMT) ranging 148-183). After the first 
vaccination, gp120 GMT in ALVAC-HIV/AIDSVAX-B/E group increased 
to 23,387 followed by AIDSVAX-B/E to 12,068 and ALVAC-HIV to 
279. Responses dropped 6 months post first vaccination in all groups, 
but increased again following the second injection, although lower 
than those following the first injection. After the first injection, ALVAC-
HIV/AIDSVAX-B/E group also provided higher responses against 
gp70V1V2 subtype E (GMT=7,903) and subtype B (GMT=610) as 
compared to AIDSVAX-B/E group, subtype E: GMT=3,294 and subtype 
B: GMT=400, and ALVAC-HIV group, subtype E: GMT=81 and subtype 
B: GMT=50. Weak gp120 IgA responses were induced in ALVAC-HIV/
AIDSVAX-B/E (GMT=70) and AIDSVAX-B/E (GMT=69) but not in the 
ALVAC-HIV group.
Conclusion: Residual antibody responses against gp120 were detected 
6-8 years post-vaccination in RV144. Late boosted IgG responses 
were highest following ALVAC-HIV/AIDSVAX-B/E vaccination followed 
by AIDSVAX-B/E and ALVAC-HIV alone. Although ALVAC-HIV alone 
generated weak responses, it potentiated antibody responses when co-
administered with AIDSVAX-B/E. IgA responses to all antigens tested 
were similar in ALVAC-HIV/AIDSVAX-B/E and AIDSVAX-B/E groups 
suggesting that ALVAC-HIV does not substantially contribute to IgA.
P03.67 LB
Distinct Changes in B Cell Subsets in Rhesus 
Macaques in Blood and Lymph Node During 
Chronic Viral Infections and Acute SIV Infection
E.E. Sparger1, W. Chang1, D.F. Gonzalez1, H. Kieu1, J. Deere1,  
B.L. Shacklett1, and P.A. Barry1
1University of California-Davis, Davis, CA, USA
Background: Studies in humans and rhesus macaques (RM) suggests 
that general B cell dysfunction including hypergammaglobulinemia, 
polyclonal B cell activation, and delayed antibody maturation are 
associated with HIV/SIV infection. Mechanisms for B cell dysfunction 
during HIV/SIV infection have not been thoroughly determined.
Methods: B cell subset profiles in blood were first compared between 
healthy RM and humans and between healthy SPF and non-SPF RM. 
Next changes in B cell compartments in blood were examined during 
acute SIV infection in the RM model for HIV. Adult female SPF RMs 
were challenged weekly intravaginally with a low dose of SIVmac251 
until animals demonstrated persistent plasma viremia. Peripheral blood 
samples were assessed longitudinally by flow cytometric analysis 
and ELISA. Dynamics of SIV antibody development and avidity were 
compared to antibody responses to other antigens including rhesus 
cytomegalovirus (RhCMV) during acute and early chronic SIV infection. 
The composition of peripheral B cells, including naïve B, resting 
memory B, activated memory B, and plasmablast subsets during the 
acute phase of infection was compared to the pre-SIV-infected state.
Results: Firstly, significant differences in B cell subsets were noted 
between healthy RM and humans and between SPF and non-SPF RM. 
Regarding SIV infection, peripheral CD20+ B cell counts exhibited a 
substantial drop corresponding with a peak in viral titer within the first 
two weeks of acute infection and rebounded subsequently. Acute SIV 
infection induced significant changes in distribution of B cell memory 
subsets and defects in SIV-specific antibody maturation. Additional 
findings regarding B cell and T follicular helper cell subsets in lymph 
nodes during early chronic infection will be presented.
Conclusion: Our findings demonstrate distinct patterns of B cell subset 
alterations in circulation caused by chronic infections in general and 
by SIV infection. These findings will contribute to understanding 
mechanisms of B-cell dysfunction in HIV-associated disease.
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P03.70 LB
HIV-1 Antibody Epitope Mapping of Individuals 
Treated with Antiretroviral Therapy During 
Acute/Early HIV-1-Infection
K.E. Stephenson1, N. Pawlowski2, P. von Hoegen2, U. Reimer2,  
E.S. Rosenberg3, and D.H. Barouch4
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2JPT 
Peptide Technologies GmbH, Berlin, Germany; 3Massachusetts 
General Hospital, Boston, MA, USA; 4Beth Israel Deaconess 
Medical Center and Ragon Institute of MGH, MIT and Harvard, 
Boston, MA, USA
Background: One vaccine strategy to overcome the challenge of 
HIV diversity is to elicit antibodies specific to multiple HIV sequence 
variants. To better characterize the potential diversity of HIV-specific 
antibodies in humans, we performed antibody epitope mapping in 
individuals treated with antiretroviral therapy during acute/early HIV-
infection both before and after treatment interruption.
Methods: Plasma from North American individuals treated during 
acute/early HIV-infection (N=20, undetectable viral load >6 months) 
and at 20 weeks following treatment interruption (N=8, mean viral load 
12,183 copies/ml) were incubated on peptide-microarrays containing 
6564 peptides covering 46-72% of all clades for Env, Gag, Nef, Pol, 
Rev, Tat, and Vif. Microarrays were incubated with labeled anti-IgG and 
imaged by GenePix scanner. Threshold for positivity was >5x noise 
signal distribution. Positive peptides overlapping >5 amino acids were 
considered one binding site. 
Results: Antibodies from individuals treated during acute/early HIV-
infection bound primarily to Env, Pol, and Gag (27, 12, and 9 average 
sites, respectively). Of all bound gp140 sites, 21% were shared by 
>85% of subjects (predominantly V3 and gp41 C-C loop). Following 
treatment interruption, there was significant expansion in average Env 
breadth (27 vs. 37 sites, P=.0036) and depth (6 vs. 12 peptides/site, 
P<0.0001). Binding to sequences that circulate outside North America 
increased (38 vs. 44% non-B peptides among all bound gp140 
peptides, P=.0157), as did the proportion of bound gp140 peptides 
shared by >85% of subjects (45%, predominantly V2 and gp41 HR2). 
Overall, there was a strong positive correlation between breadth and 
depth of antibody binding (R=0.65, P=.0002).
Conclusion: Individuals treated during acute/early HIV-infection had 
antibodies specific to dozens of sites along the HIV proteome, with 
similar binding patterns and substantial cross-clade binding. After HIV 
antigen levels increased, the average breadth and depth of Env binding 
expanded significantly. These observations suggest that vaccines 
designed to elicit diverse HIV-specific antibodies are feasible.
P03.69 LB
Genetic Assessment of B Cell Responses 
Following Immunization with HIV Env Protein 
and Adjuvants or Pathogenic SHIV Infection in 
Non-human Primates
J. Francica1, Z. Zhanhai2, S. Schmidt1, J. Mascola1, M. Singh3,  
D. O’Hagan3, M. Martin4, L. Shapiro2, and R. Seder1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2Columbia University, New York, NY, USA; 3Novartis Vaccines 
and Diagnostics, Cambridge, MA, USA; 4NIAID, NIH, Bethesda, 
MD, USA
Background: A highly effective preventive vaccine against HIV-1 
will require the generation of potent neutralizing antibody responses 
against the HIV envelope (Env). Recent evidence shows that broadly-
neutralizing antibodies from HIV+ individuals often have unique 
characteristics such as extensive somatic hypermutation (SHM), long 
CDRH3 regions and VH family restriction.
Methods: To prospectively study these functional characteristics, we 
characterized Env-specific B cells using sample barcoding and 454 
deep sequencing in nonhuman primates (NHP) following a highly 
pathogenic SHIV-AD8 infection or vaccination with HIV Env clade C 
protein with a variety of adjuvants.
Results: The initial analysis from a group of 8 NHP infected with 
SHIV shows progressively increasing levels of SHM after ~100 weeks 
of infection in only certain animals; this correlated with greater 
neutralization against a broad panel of HIV isolates. Indeed, SHM 
increased as high as 66% over basal levels. In contrast, animals with 
weak neutralization responses maintained basal levels of SHM of only 
~8% divergence from their putative germlines. Furthermore, greater 
SHM and neutralization correlated with higher viral loads and trended 
toward lower CD4+ T cell counts. To compare the genetic attributes of 
Env-specific B cells responding to vaccination, NHP were immunized 
four times with a Clade C trimeric Env protein alone, with alum or 
MF59 with or without a TLR4 or TLR7 agonist, polyIC:LC or ISCOMs. 
Robust Env-specific B cell responses- as high as 20% of IgG cells- 
were detected across multiple adjuvant groups. However, preliminary 
analysis suggests that the adjuvant formulations tested here do not 
significantly affect SHM. Differences in neutralization between adjuvant 
groups instead correlate with overall Env binding titers. Further studies 
assessing CDRH3 length and gene family usage are underway.
Conclusion: Taken together, we have developed NHP vaccine and 
infection models that utilize next-generation B cell sequencing to 
understand the development of broadly neutralizing antibody responses.
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P03.72 LB
Phylogenetic Conservation of a Dominant 
Antibody Light Chain HIV Env V2 Binding Motif 
in Human and rhesus Macaque Antibodies 
K. Wiehe1, D. Easterhoff2, K. Luo2, W. Williams2, N. Vandergrift2,  
E. Lloyd2, C. Stolarchuk2, R. Parks2, N. Nicely2, J. Kaewkungwal3,  
S. Nitayaphan4, P. Pitisuttithum3, S. Rerks-Ngarm5, N. Michael6,  
J. Kim6, G. Tomaras2, M. Bonsignori2, T.B. Kepler7, A.M. Moody2, 
H. Liao2, and B.F. Haynes2
1Duke University Medical Center, Durham, NC, USA; 2Duke 
University School of Medicine, Durham, NC, USA; 3Mahidol 
University, Bangkok, Thailand; 4Armed Forces Research Institute 
of Medical Sciences, Bangkok, Thailand; 5Ministry of Public 
Health, Nonthaburi, Thailand; 6US MHRP, Silver Spring, MD, 
USA; 7Boston University School of Medicine, Boston, MA, USA
Background: Antibodies against the first and second variable loops 
(V1V2) of HIV-1 gp120 were a correlate of transmission risk in the 
RV144 HIV-1 vaccine trial. One dominant antibody induced in the 
RV144 trial was centered on a region around lysine (K) at V2 position 
169. Four anti-V2 antibodies (CH58, CH59, HG107, HG120) from two 
RV144 vaccinees were isolated that utilized different Vλ segments 
(Vλ6-57 by CH58 and Vλ3-10 by CH59, HG107 and HG120). All four 
antibody light chains shared a Glu-Asp (ED) binding motif in the CDRL2 
encoded in their germline VLs that for CH58 and CH59 were shown to 
form salt bridges with two lysines in the V2 epitope. Env V2 K169 has 
been implicated in a viral genetic study as a site of immune pressure 
in the RV144 trial.  
Methods: To determine if the restricted ED motif usage for dominant 
V2 antibody K169 binding is conserved in rhesus macaques, we 
isolated antibodies from blood memory B-cells using antigen-specific 
flow cytometry single cell sorts from rhesus macaques immunized with 
RV144 vaccine Env proteins. 
Results: We isolated 19 antibodies in V2-reactive clonal antibody 
lineages from rhesus macaques immunized with RV144 A244 gp120 
Env. Remarkably all 19 V2 antibodies use Vλ3-17, the rhesus ortholog 
of human Vλ3-10 that contains the CDRL2 ED motif. 
Conclusion: The CDRL2 ED antibody light chain motif represents a 
restricted sequence required for antibody binding the K169 epitope 
of the HIV-1 V2 loop that is conserved between man and rhesus 
macaques. This motif is shared in all human and rhesus K169-targeted 
V2 antibodies isolated to date. Thus, the dominant antibody response 
to K169 V2 in both humans and rhesus macaques is highly restricted 
and limited to usage of two light chains in man and one light chain in 
rhesus macaques.
P03.71 LB
Structural Analysis of the Unmutated Common 
Ancestor Antibodies of the HIV Envelope V2 
Antibodies CH58 and CH59 Derived from RV144 
Vaccinees
N.I. Nicely1, K. Wiehe1, T.B. Kepler2, F.H. Jaeger1, S.M. Dennison1, 
H. Liao1, S.M. Alam1, S. Rerks-Ngarm3, S. Nitayaphan4,  
P. Pitisuttithum5, J. Kaewkungwal5, N.L. Michael6, J.H. Kim6, and 
B.F. Haynes1
1Duke University School of Medicine, Durham, NC, USA; 
2Boston University, Boston, MA, USA; 3Ministry of Public Health, 
Nonthaburi, Thailand; 4Armed Forces Research Institute of 
Medical Sciences, Thailand; 5Mahidol University, Bangkok, 
Thailand; 6U.S. MHRP, Silver Spring, MD, USA
Background: CH58 and CH59 are antibodies isolated from RV144 
vaccinees and bind at lysine (K) 169 of the HIV-1 Env gp120 V2 region. 
Both mAbs neutralize select tier 1 HIV-1 AE strains and mediate ADCC 
against virus-infected CD4 T cell targets. Previous crystal structures 
show that CH58 and CH59 recognize V2 in helical conformations 
(Immunity 38:176, 2013). The inferred clonal lineages leading to 
the CH58 and CH59 antibodies show that the mature antibodies are 
mutated ~2-3% from germline.
Methods: To study structural correlates of affinity maturation, crystal 
structures of the unmutated common ancestor (UCA) antibodies 
of CH58 and CH59 were determined and compared to published 
structures of the mature antibodies, respectively.
Results: Alanine-substituted peptide analysis demonstrated that the 
footprints of the CH58 and CH59 UCAs were broader than those of 
the corresponding mature mAbs. Structural analysis of the mature 
and UCA antibodies in their unliganded and liganded forms found 
conformational shifts associated with maturation in the cases of CDRL3 
in the CH58 lineage and CDRH1 in the CH59 lineage. A significant 
conformational shift occurs in CDR-H3 between the unliganded 
CH58UCA/mature and liganded CH58UCA/mature structures. Both 
CH58 and CH59 UCA epitopes included the V2 amino acid K169; 
however the CH58 lineage displayed additional contacts being made 
with K169 during maturation, whereas the CH59 lineage showed a 
pre-configured binding site for K169. The CH58 lineage also showed 
mutations during maturation that served to establish specific polar 
contacts with ligand.
Conclusion: The CH58 and CH59 epitopes narrowed with affinity 
maturation. Both the CH58 and CH59 lineages showed heavy and 
light chain CDR conformational changes associated with maturation. 
The CH58 lineage additionally displayed a CDRH3 conformational 
ordering associated with binding. Thus, several structural features 
observed in the mature antibodies are already present in the UCAs, 
while other features develop with maturation.
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P03.74 LB
Comparative Evaluation of Assays for Fc 
Receptor-Mediated Antibody Effector Functions 
Targeting HIV-1
M.E. Ackerman1, Y. Huang2, G. Alter3, G. Ferrari4, D. Forthal5,  
J. Kappes6, G. Lewis7, J.C. Love8, L. Harris2, B. Borate2, C. Trujillo2, 
S. Ramsey2, S. Woo2, K. Greene4, H. Gao4, and D. Montefiori4
1Dartmouth College, Hanover, NH, USA; 2The Statistical 
Center for HIV/AIDS Research and Prevention, Seattle, WA, 
USA; 3Ragon Institute of MGH, MIT and Harvard, Cambridge, 
MA, USA; 4Duke University, Durham, NC, USA; 5University of 
California-Irvine, Irvine, CA, USA; 6University of Alabama at 
Birmingham, Birmingham, AL, USA; 7University of Maryland, 
College Park, MD, USA; 8Massachusetts Institute of Technology, 
Cambridge, MA, USA
Background: The multiplicity of antibody-effector functions mediated 
through different receptors and divergent effector cell types has 
resulted in the development of numerous functional assays. These 
include antibody-dependent cellular cytotoxicity (ADCC), antibody-
dependent cellular viral inhibition (ADCVI), antibody-dependent 
cellular phagocytosis (ADCP) assays, as well as multi-parameter 
effector function arrays. In this study, ten such assays developed in 
seven different labs were evaluated on a common set of samples.
Methods: Labs were provided uniform reagents (when applicable) 
and performed assays on a total of 140 blinded IgG samples purified 
from chronic treated (n=31), chronic untreated (n=28), elite controllers 
(n=31), VAX004 vaccinees (n=30), seronegatives (n=20), 10 matching 
unfractionated plasma samples, and 12 IVIG, HIVIG and HIVIG-C 
control samples. Descriptive and inferential statistical analyses were 
performed on individual assays and across assays.
Results: Most assays incurred a low false positive rate based on the 
24 seronegative and IVIG samples. While different summary measures 
showed moderate-to-high correlations within each assay, readouts 
amongst different assay types showed weak-to-moderate correlations 
indicating that they may capture unique functional aspects of the 
antibody response. Good dynamic ranges were observed, with the 
ADCC response rate varying from 17% among vaccinees to 90% among 
chronic untreated subjects, ADCVI response rate from 3% among 
vaccinees to 29% among chronic treated subjects, and ADCP response 
rate of 3% among vaccinees and 17% among elite controllers. HIV-
specific antibodies exhibited potent binding to Fcγ receptors IIa, IIb, IIIa 
and IIIb. The levels of various antibody effector functions were similar 
among all infected subject groups, but considerably weaker among 
vaccinees. Contrastingly, IgG4 responses among Vax004 vaccinees 
were substantially higher than those of HIV infected subjects.
Conclusion: Comparisons among the assays tested here may be used 
to identify those that capture distinct antibody activities, facilitating 
assessment of functionally unique humoral responses in future HIV 
vaccine research efforts.
P03.73 LB
Genetic and Immunological Evidence for a Role 
of Env-V3 Antibodies in the RV144 Trial
M. Rolland1, P.T. Edlefsen2, R. Gottardo2, D.C. Montefiori3,  
S. Zolla-Pazner4, A. Moody3, L.H. Liao3, P. Liu3, G.D. Tomaras3,  
B.F. Haynes3, R.T. Bailer5, R.A. Koup5, J.R. Mascola5, X. Shen3,  
B.T. Korber6, S. Tovanabutra1, S. Rerks-Ngarm7, S. Nitayaphan8,  
P. Pitisuttihum9, J. Kaewkungwal9, M.L. Robb1, N.L. Michael1,  
J.I. Mullins10, P.B. Gilbert2, and J.H. Kim1
1US MHRP, Silver Spring, MD, USA; 2Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 3Duke University Medical 
Center, Raleigh, NC, USA; 4Veterans Affair and New York 
University, New York, NY, USA; 5Vaccine Research Center, 
NIAID, NIH, Bethesda, MD, USA; 6Los Alamos National Lab, 
Santa Fe, NM, USA; 7MOPH, Bangkok, Thailand; 8AFRIMS, 
Bangkok, Thailand; 9Mahidol University, Bangkok, Thailand; 
10University of Washington, Seattle, WA, USA
Background: The RV144 vaccine trial showed an estimated vaccine 
efficacy of 31%. The impact of vaccine-induced immune responses can 
be investigated through studying cases and controls (vaccinees who 
became infected or not) and breakthrough infections (infected vaccine 
and placebo recipients).
Methods: Studies in vaccinees (case/controls) included: 1) Detection 
of Env linear epitopes with PepStar peptide microarrays (JPT Peptide 
Technologies GmbH); 2) Assays of antibody functions such as 
neutralization (TZM-BL, A3R5 cells), binding, and capture; 3) Isolation 
of V3-specific mAbs from peripheral B. Cases-only studies included 
several sieve analysis methods aimed at detecting differences between 
proteome sequences from breakthrough infections (vaccine vs placebo).
Results: Among RV144 vaccinees, peptide microarrays identified a 
very frequently targeted epitope in V3 (AA304-AA320). When vaccine 
recipients had low gp120-specific plasma IgA, high responses to this 
V3 peptide were associated with a decreased risk of HIV infection 
(OR=0.49, p=0.007). Neutralization from vaccinees’s samples was 
weak, but due mostly to V3-specific antibodies. Two V3 mAbs were 
isolated: they bound to epitopes that included site 307 and mediated 
in vitro ADCC, infectious virion capture, and Tier 1 neutralization. 
Comparison of CRF01_AE breakthrough viruses from 43 vaccine 
and 66 placebo recipients showed that viruses differed significantly 
between the vaccine and placebo group at V3 site 317 (p=0.040), 
while site 307 was borderline significant (p=0.065). Vaccine efficacy 
was estimated at 52% against viruses with the consensus residue 
matching all the vaccine inserts at 307(I) (CI: 20-72%; p=0.003) and 
85% against viruses mismatching the vaccines at 317 (F317X) (CI: 
32-97%; p=0.004). Interestingly, sites 307 and 317 are part of the 
hydrophobic core of V3, which is recognized by multiple neutralizing 
V3-specific monoclonal antibodies.
Conclusion: Evidence of vaccine-specific genetic signatures and 
antibody targeting in V3 demonstrate how the combined analysis of 
viral genetics and immune responses can contribute to understanding 
potential mechanisms of vaccine protection.
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P03.76 LB
Distinct VH Gene Usage and HIV Envelope 
Specificity of Colostrum and Peripheral B 
Cell Monoclonal Antibodies of HIV-Infected, 
Lactating African Women
C.R. Sacha1, N. Vandergrift1, D.J. Marshall1, T.C. Gurley1, L. Stiegel1, 
J.F. Whitesides1, J. Friedman1, G.G. Fouda1, B. Liebl1, E. McGuire1, 
A. Foulger1, T.B. Kepler2, H. Liao1, B.F. Haynes1, M.A. Moody1,  
and S.R. Permar1
1Duke University School of Medicine, Durham, NC, USA; 
2Boston University School of Medicine, Boston, MA, USA
Background: A successful HIV vaccine must elicit immune responses 
that impede mucosal virus transmission, though functional roles of 
protective HIV Envelope (Env)-specific mucosal antibodies have 
yet to be established. Isolation and characterization of HIV Env-
specific antibodies produced by colostrum B cells could help define 
mucosal antibody responses that are protective against mucosal virus 
transmission via breastfeeding.
Methods: To examine the HIV Env-specific B cell repertoire in 
colostrum, single memory or HIV Env-specific B cells were sorted 
from colostrum and blood of 17 chronically HIV-1-infected, lactating 
women. Immunoglobulin heavy and light chain variable region genes 
(VH and VL) were amplified by nested RT-PCR to produce 49 blood and 
35 colostrum HIV Env-specific B cell monoclonal antibodies (mAbs).
Results: All HIV Env-specific colostrum B cell mAbs were IgG1 isotype, 
while those in blood were IgG1, IgG3, IgD, IgA, and IgM. There was 
no significant difference in CDR3 length or mutation frequency of 
VH genes derived from the HIV Env-reactive blood and colostrum B 
cells. However, VH gene subfamily 1~69 usage was more frequent 
among colostrum-derived (51.4%) than blood-derived (20.4%) HIV 
Env-reactive antibodies (p = 0.005, Fisher’s exact test). In addition, 
colostrum contained a higher percentage of gp120-directed antibodies 
and a lower percentage of gp41-directed antibodies than blood 
(65.7 and 14.3% gp120-specific, and 34.3 and 77.6% gp41-specific, 
respectively; p < 0.0001, Fisher’s exact test). One cross-compartment 
HIV Env-specific clonal B cell lineage was identified.
Conclusion: The IgG1 isotype predominance, more restricted VH gene 
usage, and higher percentage of gp120-specificity of HIV Env-specific 
antibodies isolated from colostrum B cells compared to peripheral B 
cells of HIV-1-infected women suggest selective homing of restricted 
populations of IgG-secreting memory B cells to the lactating mammary 
gland. Thus, effective maternal vaccination to eliminate postnatal virus 
transmission may require specific targeting of this distinct population 
of mucosal B cells.
P03.75 LB
The N276 Glycosylation Site Is Required for HIV-
1 Neutralization by the CD4 Binding Site specific 
HJ16 Monoclonal Antibody 
G. Vanham1, S. Balla-Jhagjhoorsingh1, D. Corti2, L. Heyndrickx1, 
and D. Davis3
1ITM, Antwerpen, Belgium; 2Institute for Research in 
Biomedicine, Bellinzona, Switzerland; 3Biomedical Primate 
Research Centre, Rijswijk, Netherlands
Background: Immunogen design for HIV-1 vaccines can be based on 
epitope identification of naturally occurring neutralizing antibodies in 
patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 has 
been described by us (Corti D et al. 2010 PloS one 5: e8805). We 
already established that it recognizes a new epitope in or near the CD4 
binding site (CD4bs) that only partially overlaps with the b12 epitope. 
Here, we identified the critical binding site by resistance induction in 
VI1090, a sensitive CRF02_AG HIV-1 
Methods: A 2000-fold resistance was induced by culturing VI1090 
in activated human mononuclear cells with escalating doses of HJ16. 
Resistance-associated mutations were revealed by sequencing and 
confirmed by site-directed mutagenesis. Possible cross-resistance with 
other gp120 inhibitors was analyzed in the TZMbl neutralization assay. 
Results: In 4 dose-escalation studies, the N276D mutation was the only 
alteration found and was confirmed to be responsible for resistance by 
site-directed mutagenesis in the homologous CRF02_AG, but also in a 
subtype A and a subtype C isolate. This mutation removes an N-linked 
glycosylation site. The effect of N276D was selective: it failed to confer 
resistance to several other entry inhibitors. Remarkably, sensitivity to 
the potent and broad CD4bs VRC01 mAb was increased in the N276D 
mutated viruses. 
Conclusion: The N276 glycan is essential for neutralization by the 
CD4bs-blocking HJ16, suggesting that its full epitope is a glyco-
peptide on gp120. This is similar to the PG9 and PGT128 mAbs, 
which also recognize glycopeptides near the CD4bs. Interestingly, 
N276 glycosylation hinders recognition and maturation of VRC01-like 
antibodies, while our data suggest that N276 glycan may be required 
for HJ16-like antibody induction. Therefore, our observations are of 
interest to design new Env immunogens aiming at induction of tier 
2-type CD4bs specific neutralizing antibodies. 
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P03.78 LB
Computational Analysis of Anti-HIV-1 Antibody 
Neutralization Panel Data to Identify Potential 
Functional Epitope Residues
A.P. West, Jr1, L. Scharf1, J. Horwitz2, F. Klein2, M.C. Nussenzweig2, 
and P.J. Bjorkman1
1California Institute of Technology, Pasadena, CA, USA;  
2The Rockefeller University, New York, NY, USA
Background: Advances in single cell antibody cloning methods have 
led to the identification of a variety of broadly neutralizing anti-HIV-1 
antibodies. Initial characterization of these antibodies often involves 
measurement of their neutralization activity against a panel of viruses, 
but such experiments do not generally lead to conclusive identification 
of an antibody’s epitope.
Methods: We developed a computational tool, Antibody Database, to 
help identify critical residues on Env whose natural variation affects 
antibody activity. Our simplifying assumption was that for a given 
antibody, a significant portion of the dispersion of neutralization 
activity across a panel of HIV-1 strains is due to the amino acid identity 
or glycosylation state at a small number of specific sites, each acting 
independently. A model of an antibody’s neutralization IC50 was 
developed in which each site contributes a term to the logarithm of the 
modeled IC50. The analysis program attempts to determine the set of 
rules that minimizes the sum of the residuals between observed and 
modeled IC50s.
Results: As a test case, we analyzed antibody 8ANC195, an anti-
gp120 antibody of unknown specificity. The model for this antibody 
indicated that glycosylation sites at Env positions 234 and 276 were 
critical for neutralization. We evaluated this prediction by measuring 
neutralization potencies of 8ANC195 against HIV-1 in vitro and in an 
antibody therapy experiment in humanized mice.
Conclusion: These experiments confirmed that 8ANC195 represents a 
distinct class of glycan-dependent anti-HIV-1 antibody and validated 
the utility of computational analysis of neutralization panel data. 
The Antibody Database program implements this analysis as well 
as providing an environment where sequence, neutralization, and 
structural data can be examined together.
P03.77 LB
Vaccine-Elicited B Cell Responses Against the 
HIV-1 Primary Receptor Binding Site
Y. Wang2, C. Sundling1, K. Dai2, R. Wilson2, S. O’Dell3, J. Zhu2,  
Y. Xiao4, J.R. Mascola3, G.B. Karlsson Hedestam1, R.T. Wyatt2,  
and Y. Li2
1Karolinska Institutet, Stockholm, Sweden; 2The Scripps Research 
Institute, La Jolla, CA, USA; 3Vaccine Research Center, NIAID, 
NIH, Bethesda, MD, USA; 4NIAID, NIH, Bethesda, MD, USA
Background: Due to the high level of structural variability of HIV-1 
Env, elicitation of neutralizing antibody (NAb) responses to conserved 
neutralizing determinants, such as the CD4 binding site (CD4bs), is a 
major focus of HIV-1 vaccine development. Accordingly, a detailed 
understanding of how trimeric Env immunogens activate the naïve 
primate B cell repertoire and how Env-elicited antibody responses 
evolve during the course of the immunization schedule may indicate 
how to direct the response toward desired neutralizing targets. 
Methods: Recently, we established methodology to characterize NAb 
responses elicited by soluble Env immunogens in rhesus macaques 
by antigen/epitope-specific single B cell sorting, RT-PCR to recover 
immunoglobulin G (IgG) heavy/light chain genes, in vitro expression 
of IgG, and epitope fine-mapping to the conserved CD4bs. Here, we 
extend the use of this methodology to conduct a comprehensive 
analysis of the evolving vaccine-elicited CD4bs-specific B cell response 
at the clonal level. 
Results: We interrogated the Ab repertoires from two rhesus macaques 
following a total of five inoculations with trimeric Env. We observed 
similar VH gene usage in the CD4bs- and Env-specific memory B 
cell repertoires while the level of somatic hypermutation was higher 
following the 5th immunization compared to following the 2nd 
immunization in both compartments. Interestingly, the heavy chain 
CDR3 regions from the CD4bs-specific B cells were on average longer 
than those from the total Env-specific cells and the CD4bs-specific B 
cell subset has higher level of clonality than that of the Env-specific 
subset. However, only a small portion of the CD4bs-specific Ig 
repertoire following the 2nd immunization is maintained following 
the 5th immunization, which suggests that clonality is only partially 
maintained and the repertoire is dynamically recruiting new B cells to 
generate diversity. 
Conclusion: These data provide an improved understanding of the 
evolving B cell response following Env immunization.
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P04.02 D
Enhanced HIV-Specific CD8+ T Cell Responses 
Following Polytopic Administration of VRC 
rAd5 gag-pol/env A/B/C in HIV-Uninfected 
Healthy Adults 
I. Frank1, N. Grunenberg2, J. Hural2, P. Edlesfsen2, A. DeCamp2,  
M. Allen3, P. Spearman4, K. Bar1, S. Kalams5, L. Baden6, M. Keefer7, 
J. Fuchs8, R. Novak9, B. Graham10, M. Enama10, and N. Frahm2
1University of Pennsylvania, Philadelphia, PA, USA; 2University 
of Washington, Seattle, WA, USA; 3NIAID, NIH, Bethesda, 
MD, USA; 4Emory University, Atlanta, GA, USA; 5Vanderbilt 
University, Nashville, TN, USA; 6Brigham and Women’s 
Hospital, Boston, MA, USA; 7University of Rochester, 
Rochester, NY, USA; 8San Francisco Department of Public 
Health, San Francisco, CA, USA; 9University of Illinois, 
Chicago, IL, USA; 10Vaccine Research Center, NIAID, NIH, 
Bethesda, MD, USA
Background: HIV-specific CTL responses help control HIV replication. 
Immunodominance towards certain antigens may limit the breadth 
of responses.  We evaluated whether polytopic vaccination – 
administration of immunizations in multiple anatomical sites – alters 
HIV-specific immunity.
Methods: We conducted a randomized, double-blind trial comparing 
three vaccine administration strategies at one time point: Group 1) 
VRC rAd5 Gag-Pol/Env A/B/C (1x10e10 PU) was administered in 
one deltoid; Group 2) the four vaccine antigenic components were 
administered separately in each deltoid or thigh; and Group 3) the 
vaccine was administered at one-quarter dose (0.25 x10e10 PU) in 
each of four anatomic sites. T cell responses to six peptide pools 
matching the vaccine inserts were assessed by intracellular cytokine 
staining. 
Results: 90 participants were enrolled, including 56 men and 34 
women; primary immunogenicity data at week 4 post-immunization 
were available on 87.  CD8+ T cell responses to any peptide pool 
were seen in 87%, 83%, and 82% of Groups 1, 2, and 3, respectively. 
However, there were more responders in Group 3 vs Group 1 to Pol 
(81% vs 45%, p=0.01) and EnvA (68% vs 40%, p=0.04), and more in 
Group 2 vs Group 1 to EnvC (66% vs 37%, p=0.04).  The magnitude 
of CD8+ T cell responses was greater in Group 3 than Group 1 against 
any peptide pool and any Env pool (p=0.002 and 0.014).  There were 
no differences in magnitude of CD8+ T cell responses between Groups 
2 and 1.  The breadth of CD8+ T cell responses was greater in Group 3 
than Group 1 (responses to 3.5 vs 2.8 of 6 pools, p=0.03), but did not 
significantly differ between Groups 2 and 1.
Conclusion: Polytopic administration can modify the proportion 
of vaccine responders, and measures of magnitude and breadth of 
cellular immune responses.  Epitope mapping and antibody binding 
studies are underway to characterize differences further. 
P04.01 D
Phase I Safety and Immunogenicity of 
Electroporated HIV DNA with or Without 
Interleukin 12 in Healthy HIV-Seronegative 
African Volunteers
E. Karita1, J. Mpendo2, O. Anzala3, J. Nyombayire1,  
A. Namvumbya2, G. Mutua3, C. Schmidt4, J. Cox5, J. Gilmour5,  
B. Rasmussen4, J. Lehrman4, J. Eldrige6, M. Egan6, D. Hannaman7, 
L. Dally8, C. Smith8, S. Allen9, F. Priddy4, and P. Fast4
1Projet San Francisco, Kigali, Rwanda; 2UVRI-IAVI HIV Vaccine 
Programme, Entebbe, Uganda; 3KAVI-Kangemi, University 
of Nairobi, Nairobi, Kenya; 4 IAVI, New York, NY, USA; 5IAVI 
Human Immunology Laboratory, London, UK; 6Profectus 
BioSciences, Inc., Tarrytown, NY, USA; 7ICHOR Medical 
Systems, Inc., San Diego, CA, USA; 8The EMMES Corporation, 
Rockville, MD, USA; 9Emory University, School of Medicine, 
Atlanta, GA, USA
Background: DNA vaccines have typically been safe in clinical trials, 
but weakly immunogenic. Strategies to enhance their immunogenicity 
include i) co-administration of adjuvants and ii) intramuscular 
administration by in vivo electroporation (IM/EP).
Methods: Seventy five HIV-uninfected healthy adults were enrolled into 
a randomized, double blind, placebo controlled trial. Multi-antigenic 
HIV plasmid DNA (HIVMAG) vaccine encoding clade B gag-pol, env, 
nef-tat-vif(3mg/dose), alone or co-administered with pDNA IL12 given 
IM/EP using TriGridTM Delivery System, and recombinant Ad35 
vaccine containing HIV-1 subtype A gag, RT, int, nef and gp140 env 
genes (Ad35-GRIN/ENV; 2x1010 vp) given IM were tested in different 
prime-boost regimens (M0,1,2 +M6 or M0+M4). Group 1: HIVMAG 
(x3)-Ad35 (x1), Group 2: HIVMAG+100ug IL12 (x3)- Ad35 (x1), Group 
3: HIVMAG+1000ug IL12 (x3)- Ad35(x1), Group 4: HIVMAG+1000ug 
IL12 (x1)- Ad35 (x1), Group 5: Ad35 (x1)-HIVMAG+1000ug IL12 (x1). 
All IM/EP vaccinations required bilateral administrations, one into 
each deltoid. Safety, tolerability and immunogenicity were assessed at 
predetermined time points.
Results: Both vaccines were safe and well-tolerated. All but one 
local and all systemic reactogenicity events were mild or moderate 
in severity. No SAEs were reported. Preliminary group un-blinded 
IFNy ELISPOT results show that 2 weeks post 3 rd DNA prime the 
proportions of volunteers in Groups 1-3 responding to any peptide 
were 82, 64 and 42% and 2 weeks post Ad35 boost73, 82 and 89%, 
with corresponding increases in magnitude post boost. Response 
rates in Groups 4 and 5 were 50% and 46%, respectively, after last 
(second) vaccination. An average of 4 out of 12 peptide pools per 
vaccinee was recognized; further studies to assess epitope breadth and 
polyfunctionality are in progress. 
Conclusion: Repeated administration of HIV MAG +/-IL12 by IM/EP 
was acceptable among African volunteers. Preliminary ELISPOT data 
showed that HIVMAG by IM/EP was immunogenic but currently there 
is no clear indication that pDNA IL12 enhanced the immune responses. 
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P04.04 D
Feasibility of Enrolling Female Commercial Sex 
Workers at High Risk of HIV Infection for HIV 
Vaccine Trials in the Caribbean
M. Deschamps1, C. Morgan2, C. Zorrilla3, B. Metch2, Y. Donastorg4, 
P. Joseph1, E. Swann5, T. Madenwald2, G. Escamilla2, J.W. Pape1, 
and H. Protocol Team2
1Groupe Haitien d’Etude du Sarcome de Kaposi et des 
Infections Opportunistes (GHESKIO), Port au Prince, Haiti; 
2Fred Hutchinson Cancer Research Center, Seattle, WA, 
USA; 3Maternal and Infant Studies Center (CEMI), University 
of Puerto Rico School of Medicine, San Juan, Puerto Rico; 
4Unidad de Vacunas IDCP-COIN-DIGECITSS, Santo Domingo, 
Dominican Republic; 5NIAID, NIH, Bethesda, MD, USA
Background: Identifying women with sufficient clade B HIV infection 
rates for HIV vaccine efficacy trials has been challenging. The 
Caribbean has higher HIV incidence among regions where clade B 
predominates and a higher proportion of females living with HIV than 
males. HVTN 907 evaluated the feasibility of identifying and retaining 
women at high risk of HIV infection.
Methods: HIV-uninfected, age 18-45, nonpregnant females were 
enrolled in an observational study in Haiti, Puerto Rico, and Dominican 
Republic. Minimum risk eligibility criteria included exchanging sex 
for goods/services/money and unprotected vaginal or anal sex with 
a man in the previous 6 months. Each site applied more stringent 
criteria using local epidemiology. Visits every 6 months for 18 months 
included HIV and pregnancy testing, risk-reduction counseling, and 
HIV-risk assessments.
Results: 799 female sex workers enrolled with a 93% retention rate. 
Reporting at screening being unlikely to live in the same place for 6 
months was a predictor of drop-out (odds ratio = 2.2, 95% CI 1.1%, 
4.3%). The median number of male partners over 6 months declined 
from 200 at screening, 121 at 6 months, 70 at 12 months and 17 
at 18 months (p <0.001 screening-18 months). Statistically significant 
declines in unprotected sex and heavy alcohol and drug use also were 
observed. Among the 634 women who reported not being surgically 
sterilized, pregnancy incidence was 22.5% (95% CI 21.9%, 29.5%). 
The HIV incidence was 1.07% (95% CI 0.55%, 1.87%). Co-factors 
associated with increased HIV infection were exchanging sex on the 
street and having a partner who forced sex.
Conclusion: Strategies identified women at higher risk of HIV and 
were successful in maintaining high retention. Counseling seemed 
to have a positive impact on risk behavior, though pregnancy rates 
indicated having unprotected sex. HIV incidence was higher than 
previous efforts to enroll high-risk women in clade B regions.
P04.03 D
Distinct HIV-Specific Antibody Fc-Profiles in 
RV144 and VAX003 Vaccinees
A.W. Chung1, M. Ghebremichael1, H. Robinson1, E. Brown2, I. Choi2, 
M. Rolland3, A. Dugast1, T.J. Suscovich1, L. Liao4, A.E. Mahan1, 
H. Streeck3, S. Rerks-Ngarm5, S. Nitayaphan6, M.S. de Souza6, 
P. Pitisuttithum7, D. Francis8, N.L. Michael3, J.H. Kim3, C. Bailey-
Kellog2, M.E. Ackerman2, and G. Alter1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Dartmouth College, Hanover, NH, USA; 3U.S. MHRP, 
Silver Spring, MD, USA; 4Duke University, Durham, NC, USA; 
5Ministry of Public Health, Nonthaburi, Thailand; 6Armed Forces 
Research Institute of Medical Sciences, Bangkok, Thailand; 
7Mahidol University, Bangkok, Thailand; 8Global Solutions for 
Infectious Diseases, South San Francisco, CA, USA
Background: The	 RV144	 ALVAC-HIV/AIDSVAX®	 B/E	 regimen	 (2	
vaccinations prime and 2 protein boosts) showed an estimated 
31.2% efficacy against HIV infection, whereas VAX003, consisting 
of	 only	 AIDSVAX®	B/E	 (7	 protein	 vaccinations),	 was	 not	 protective.	
As protection in RV144 was observed in the absence of neutralizing 
antibody (Ab) activity or cytotoxic T cell responses, but was 
associated with Ab binding to specific viral variants across the V2-
loop, we speculated that qualitative differences in the specificity and/
or Fc-effector profiles of Abs may have accounted for the observed 
differences in the two trials.
Methods: Abs were purified from 100 RV144 study subjects (80 
vaccine and 20 placebo recipients taken weeks 0 and 2 weeks post 
final vaccination), 50 Vax003 vaccinees (taken 2 weeks post 2nd , 
3rd and final vaccination) and 10 Vax003 placebos recipients (taken 
2 weeks post final vaccination). IgGs were assayed for gp120-specific 
ADCC, ADCP, NK degranulation and cytokine production and Ab 
isotype selection to specific HIV-1 proteins and V2-loop breakthrough 
viral epitope sequences.
Results: Here we show that the RV144 regimen elicited highly 
coordinated Fc-mediated effector responses, with the selective 
induction of highly functional IgG1 and IgG3 Abs. By contrast, 
VAX003 elicited monofunctional Ab responses influenced by IgG4 
selection. Significantly weaker IgG titers and Fc-mediated immune 
responses were observed from VAX003 subjects post 2nd vaccination. 
Additional VAX003 protein vaccinations did, however, increase Fc-
mediated responses, and IgG1 and IgG4 subclass titers, but not IgG3 
titers, which remained low despite an additional protein vaccination. 
Moreover, only RV144 induced IgG1 and IgG3 Abs targeting the 
crown of the HIV envelope V2-loop, albeit with low coverage of 
breakthrough viral sequences.
Conclusion: These data suggest that subclass selection differences 
associated with coordinated humoral functional responses targeting 
strain-specific protective V2-loop epitopes may underlie differences in 
vaccine efficacy observed across the trials.
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P04.06
Baseline Predictors of Immunogenicity in 
HVTN 204
B. Adamson1, T. Hertz2, A. Duerr1, C. Morgan1, M. Keefer3,  
G. Churchyard4, B. Graham5, P. Gilbert2, J. Kublin1 and the 
NIAID HIV Vaccine Trials Network1
1HIV Vaccine Trials Network, Seattle, WA, USA; 2Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; 
3University of Rochester, Rochester, NY, USA; 4The Aurum 
Institute for Health Research, Klerksdorp, South Africa; 
5Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: Identifying baseline predictors of immunogenicity 
could increase statistical power when designing future clinical trials. 
This in turn may allow reduction in sample sizes needed to assess 
vaccine efficacy and correlates of immune protection. Demographics, 
reactogenicity, and MHC type have been considered potential 
predictors of immune responses to HIV vaccines.
Methods: This analysis included data from 90 U.S. participants in 
HVTN 204 vaccinated with a regimen from the NIH Vaccine Research 
Center comprising a 6-plasmid HIV-1 DNA prime (envA, envB, envC, 
gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 
(rAd5) HIV-1 with largely matching inserts.  Gender, age, race, baseline 
log (Ad5 neutralizing antibody titer), local and systemic reactogenicity 
(24 hours after the Ad5 boost), and MHC efficiency score (a correlation 
between the conservation score and the binding prediction score 
based on molecular HLA typing) were analyzed as predictors of HIV-
specific CD4+ and CD8+ T cell responses measured by intracellular 
cytokine staining (ICS) 6 weeks after the Ad5 boost.  Predictors of 
immune response were assessed using linear and multivariate logistic 
regression modeling and forward stepwise selection. MHC efficiency 
scores were calculated for the 56 vaccine recipients with HLA sequence 
data.
Results: Baseline log (Ad5 nAb titer) was negatively associated with 
CD8+ ICS responses in the univariate and forward stepwise selection 
models (OR 0.91; 95% CI 0.84, 0.99) for an Ad5 titer increase of one 
tertile.  No other variables were significantly associated with HIV-specific 
CD4+ or CD8+ ICS responses in the linear or multivariate models.
Conclusion: Only baseline Ad5 nAb titer was correlated with immune 
responses elicited.  However, the small sample size in this analysis 
may have precluded detection of small effects.  Analysis of baseline 
demographics and reactogenicity data from larger studies may reveal 
response differences based on region, demographics such as BMI, host 
genetics, or effects seen only with certain vaccine types.
P04.05 D
Phase I Clinical Trial HIV-CORE002 of a 
Universal T-cell Vaccine: One Year Follow On 
and Epitope Mapping
N.Borthwick1, T. Ahmed1, B. Ondondo1, E. Hayton1, A. Nicosia2,  
A. McMichael3, L. Dorrell3, and T. Hanke1
1Oxford University, Jenner Institute, Oxford, United Kingdom; 
2CEINGE, Naples, Italy; 3Weatherall Institute of Molecular 
Medicine, Oxford, United Kingdom
Background: To overcome the problems of HIV-1 diversity in the 
development of an effective vaccine, we have designed a universal 
immunogen HIVconsv utilizing the most conserved regions of the HIV-
1 proteome across the major clades.
Methods: A gene coding for HIVconsv was inserted into plasmid 
(DNA; D), modified vaccinia virus Ankara (MVA; M) and non-replicating 
chimpanzee adenovirus (ChAdV-63; C) and used in heterologous 
prime-boost vaccine regimens in HIV-1-negative healthy adults in 
Oxford. Here, we determined the T cell response breadth at last bleed 
of the clinical trial (week 28) and employed fresh ex vivo responses at 
1 year after the last vaccine administration to determine the longevity 
of these responses.
Results: Frozen PBMC from 17 participants (CM: 7 and DDDCM: 10) 
were used to map specificity using a panel of 199 overlapping peptides 
corresponding to the entire HIVconsv immunogen. Cells were expanded 
for 10 days using six peptides pools and then tested in IFN-γ ELISPOT 
assays against individual pool peptides. Participants responded to a 
median of 13 individual peptides (range: 4-30) and 10 (range 3-19) 
individual epitopes, of which approximately 10% and 59% were 
derived from Gag and Pol proteins. 20% were junctional, spanning two 
adjacent conserved regions. 60% of the responses were to peptides 
that contained known T cell epitopes matching the participants HLA 
types.Follow up samples were obtained from 12 participants (CM: 5 
and DDDCM: 7). Fresh, ex vivo IFN-γ ELISpot responses measured 
against six peptide pools showed detectable responses in both groups 
with median 600 and 1535 total SFU/106 PBMC, respectively. In both 
groups the pattern of responses to individual pools was maintained 
with reference to peak responses.
Conclusion: HIVconsv vaccination induced T cell responses that 
lasted at least one year. Vaccinees’ T cell responses map to epitopes, 
including previously identified CD8+ CTL epitopes, across the length 
of HIVconsv.
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P04.08
HVTN Mentored Research Program for Black 
and Latino/a Medical Students Increases 
Intent to Pursue a Career in HIV/AIDS Vaccine 
Research
B. Adamson1, S. Wakefield1, D. Flood1, D. Stoff2, C. Sopher1,  
R. Cook1, N. Pemberton1, J. Kublin1, J. Fuchs3, and the NIAID HIV 
Vaccine Trials Network1
1HIV Vaccine Trials Network, Seattle, WA, USA; 2National 
Institute of Mental Health, Bethesda, MD, USA; 3San Francisco 
Department of Public Health, San Francisco, CA, USA
Background: Blacks and Latino/as are disproportionately affected 
by the HIV epidemic, yet clinician scientists of color are severely 
underrepresented in the HIV/AIDS vaccine trial community.
Methods: The National Institute of Allergy and Infectious Diseases 
(NIAID)-funded HIV Vaccine Trials Network (HVTN) conducted formative 
research with Black and Latino/a senior HIV researcher, assembled an 
advisory group, developed a program logic model, and designed the 
Research and Mentorship Program (RAMP) for U.S. medical students. 
In September 2010, HVTN released the first RFA, with subsequent 
releases in 2011 and 2012. For all three releases combined, HVTN was 
contacted by 196 interested medical students of color, 59 competitive 
applications were received and reviewed, and 21 scholars were 
selected and awarded support from NIAID and the National Institute of 
Mental Health (NIMH) through the HVTN. Evaluation results presented 
here include pre- and post-program surveys, knowledge assessments, 
and hour-long semi-structured interviews with the 6 scholars and 9 of 
11 mentors from the pilot year.
Results: Scholars conducted 3-12 month mentored research projects 
at global HVTN clinical research sites and presented their results at 
an HVTN conference.  Training workshops included orientations 
for scholars and mentors, introduction to HIV vaccines, cultural 
responsiveness, and professional development.  Compared to baseline, 
scholars’ self-reported skill in research methods increased 29%.  Their 
knowledge of career opportunities in HIV vaccine research more than 
doubled and intent to pursue a career in HIV/AIDS vaccine research 
increased 64%.  All mentors agreed or strongly agreed that they 
expected to maintain a relationship with their scholar in the future.
Conclusion: HVTN with NIMH strategically designed and implemented 
a mentored research program to increase the number of future Black 
and Latino/a HIV vaccine investigators by reaching early into the career 
pipeline and providing strong mentorship through a structured research 
project. Continued follow-up of scholars will provide additional data on 
HIV vaccine career outcomes.
P04.07
In Vivo Targeting of HIV Gag to Dendritic 
Cells Given with Poly ICLC Is Safe and Induces 
Durable CD4 T Cell and B Cell Responses in 
Healthy Volunteers
M. Caskey1, C. Trumpfheller1, S. Schlesinger1, S. Pollak1,  
L. Sinnenberg1, J. Pring1, A. Hurley1, I. Shimeliovich1, P. Sarma1,  
B. Yipp1, S. Mehandru1, N. Anandasabapathy1, R. Steinman1,  
T. Keler2, R. Koup3, R. Bailer4, G. Tomaras5, and A. Sato6
1The Rockefeller University, New York, NY, USA; 2Celldex 
Therapeutics, Phillipsburg, NJ, USA; 3Vaccine Research Center, 
NIAID, NIH, Bethesda, MD, USA; 4NIAID Vaccine Immune T Cell 
and Antibody Laboratory, Bethesda, MD, USA; 5Duke 
University, Durham, NC, USA; 6Statistical Center for HIV/AIDS 
Research, Seattle, WA, USA
Background: In vivo delivery of HIV antigens within α-DEC 205 
antibodies to maturing dendritic cells in combination with maturation 
stimuli is a potential new vaccine platform. This phase-I study evaluates 
the safety and immunogenicity of DEC-targeting of HIV gag p24 in 
combination with poly ICLC in healthy volunteers. 
Methods: 45 volunteers aged 18-60 were enrolled.  9 volunteers 
per dosage group (low: 0.3mg; mid: 1.0mg; high: 3.0mg) received 
α-DEC205-HIVp24 mAb plus 1.6 mg of poly ICLC s.c., 3 received poly 
ICLC only, and 3 received saline. Volunteers were vaccinated at weeks 
0, 4, 12 and followed for 12 months.
Results: Transient local and systemic reactogenicity occurred, without 
vaccine-related serious adverse events to date. Gag p24-specific IgG 
was induced in 9/15 (60%, 9 received vaccine plus adjuvant) volunteers 
in all groups. Responses persisted at least for 12 months after last dose 
in most responders. After last immunization, response rates by IFN-γ 
ELISPOT were 44%, 56% and 33% in the low, mid and high dose 
groups, respectively. Responses were detected in 10-25% of vaccines 
12 months after last dose. Blinded intracellular cytokine staining data 
showed that IL-2 and TNF-α were the predominant cytokines. For CD4+ 
cells producing IL-2 or TNF-α, response rates ranged from 33 to 40% 
(5-6/15 volunteers, 9 received vaccine plus adjuvant), 20 to 27% (3-
4/15 volunteers) and 43-50%(6-7/15 volunteers) in the low, mid and 
high dose groups respectively. Among positive responders, the median 
magnitude across dose groups were similar, with median magnitudes 
ranging from 0.06 to 0.16% for IFN-γ+ cells, 0.08 to 0.23% for IL2+ 
cells, and 0.06 to 0.16% for TNF-α+ cells. 
Conclusion: This novel DC-targeted protein HIV vaccine in combination 
with poly ICLC is safe and immunogenic in humans. Cellular and 
humoral immune responses are induced. Antibody responses remain 
detectable at 12 months after last immunization in most responders.
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P04.10
Building Community Support for the NICCAV 
Project: Experience on the Field
F.C. Durueke1, C. Okonkwo1, G. Odemujie2, W. Gofwen3,  
M. Ukpong1, and the NICCAV Community Study Team4
1New HIV Vaccine and Microbicides Advocacy Society, 
Lagos, Nigeria; 2Radio Nigeria, Abuja, Nigeria; 3Plateau Radio 
and Television Commission, Jos, Nigeria; 4Jos Community, 
Jos, Nigeria
Background: The Nigerian Canadian Collaboration on AIDS Vaccine 
(NICCAV) community engagement programme developed a model 
to enable it achieve its four objectives of ensuring communities are 
actively engaged with the HIV Vaccine demonstration project. These 
are: to constitute a CAB that shall  effectively engage with the research 
team; Build the capacity of identified CSOs to enable them address 
the research literacy needs of potential research volunteers; Build the 
capacity of the media to effectively educate the general public and 
other stakeholders on HIV vaccine research; and implement the GPP 
for the NICCAV project.
Methods: An independent Community Organisation was engaged 
on the project to facilitate the community engagement programme. 
Community mapping was conducted; identified community 
stakeholders and leaders were then reached through advocacy visits. 
Sixteen volunteer CSOs working within Jos metropolis had their 
capacity built to enable them conduct research literacy within their 
constituencies. Through community support, a CAB was constituted to 
play an advisory role to the project.  Identified media persons were 
enrolled in a capacity building programme to enable them disseminate 
culturally and linguistically appropriate information on HIV vaccine 
research.
Results: The community mapping led to the zoning of the Jos 
metropolis, identification of populations, groups to be engaged with 
the project, locations where potential volunteers can be identified 
for educational and recruitment efforts. Advocacy visits to identified 
stakeholders was conducted. The structured capacity building efforts 
for CAB and CSO enables them to conduct community education and 
ensure research literacy. The strategic efforts to build the capacity 
of identified media partners led to more publications on new HIV 
prevention technology in the country. In 7 months, the project had 
reached over 10,000 persons in the community with HIV prevention 
research literacy information. 
Conclusion: Investment in a structured community engagement 
programme results in sustainable project impact especially with 
respect to research literacy.
P04.09
Acceptability and Quality of New Mucosal 
Secretion Collection Procedures in an HIV 
Vaccine Trial in Thailand
A. Limwattanayingyong1, T. Arun-Ngamwong2,  
J. Wattanakitwichai3, D. Yamoon2, T. Debyasuvarn4,  
J. Dhitarat3, J. Kaewkungwal5, C. Namwat4, N. Premsri6,  
N. Churikanont6, J. Excler7, R. O’Connell6, C. Eamsila6, J. Kim6, 
N. Karasavvas6, S. Vasan8, V. Ngauy6, P. Pitisuttithum3, and  
S. Rerks-Ngarm4
1HIV Vaccine Trial Center, Bangkok, Thailand; 2Banglamung 
Hospital, Chonburi, Thailand; 3Mahidol University, Bangkok, 
Thailand; 4Ministry of Public Health, Nonthaburi, Thailand; 
5BIOPHICS, Mahidol University, Bangkok, Thailand; 6Armed 
Forces Research Institute of Medical Sciences, Bangkok, 
Thailand; 7U.S. MHRP, Silver Spring, MD, USA; 8Armed Forces 
Research Institute of Medical Sciences, Henry M. Jackson 
Foundation, Bangkok, Thailand
Background: The assessment of vaccine-induced mucosal immune 
responses may be critical for the development of a successful HIV-1 
vaccine. RV305, conducted in previously vaccinated RV144 volunteers, 
aims at assessing the effect of late boosts on systemic and mucosal 
immunological responses. This study assessed the acceptability, 
tolerability, and quality of mucosal secretions in a population where 
use of intra-vaginal devices and rectal exams are uncommon.
Methods: RV305 enrolled 162 healthy volunteers who previously 
received the RV144 vaccine regimen. Women were asked to provide 
only cervico-vaginal secretions by insertion of a cervical soft cup and 
men to provide semen (masturbation) and rectal secretions (sponge 
via anoscope). Female volunteers underwent Pap smears and all were 
tested for genital infections prior mucosal collection. Samples were 
tested for microscopic blood contamination. Counseling notes and 
source documents were reviewed to assess reasons for participation or 
refusal in these collection procedures.
Results: Acceptability rates were 89.7%, 86.1% and 23.4% for 
cervico-vaginal, semen and rectal secretions, respectively. Factors 
contributing to high acceptability rates included comprehensive 
counseling and education and prior relationship between the staff and 
RV144 volunteers enrolled in this trial. Up to 90% of cervico-vaginal 
and rectal specimens collected were suitable for immunological 
testing and were not contaminated with blood. Overall, acceptability 
for cervico-vaginal secretion collection using the soft cup method and 
for semen collection was high, but acceptability of rectal secretions 
was low. 
Conclusion: These findings demonstrate that uncommon methods for 
mucosal secretion collection can be introduced to healthy volunteers 
with appropriate education and counseling. However, the acceptability 
of more uncomfortable procedures such as rectal secretions collection 
remains low.
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P04.12
Dynamics of Viral Load (VL) Rebound After 
cART Interruption in Chronic HIV Infected 
Patients Receiving MVA-B plus Disulfiram
B. Mothe1, S. Sanchez4, S. Corral2, N. Climent4, A.C. Guardo4,  
L. Leal4, B. Torres4, J.L. Jimenez2, J. Pich4, J.A. Arnaiz4, A. León4, 
M. Muñoz-Fernandez2, J.M. Gatell4, B. Clotet1, M. Esteban3,  
M. Plana4, J. Lopez Bernaldo de Quiros2, C. Brander1, and   
F. García4
1IrsiCaixa Institute for AIDS Research, HIVACAT, Hospital 
Universitari “Germans Trias i Pujol”, Barcelona, Spain; 
2Hospital Gregorio Marañón, Madrid, Spain; 3Centro Nacional 
de Biotecnología, Madrid, Spain; 4Hospital Clínic, IDIBAPS, 
HIVACAT, Barcelona, Spain
Background: In vitro data suggest that stimulation of HIV-1-specific T 
lymphocytes with a therapeutic vaccine could facilitate elimination of 
latent viral reservoir after virus reactivation with drugs (i.e disulfiram). 
We present the results of a substudy of a phase I, doubled blind 
placebo-controlled trial of an MVA-B therapeutic trial combined with 
disulfiram virus-reactivation treatmentt in successful cART-treated HIV-
infected patients.
Methods: Patients were randomly allocated to receive 3 intramuscular 
injections of MVA-B at 0, 4 and 16 weeks (n=20) or placebo (n=10). 
Twelve patients (9 MVA-B, 3 placebo vaccinated) received a 4th dose 
of MVA-B at week 36 followed by 2 months of disulfiram (250 mg qd). 
cART was discontinued in all 30 patients 8 weeks after the last dose of 
MVA-B and viral rebound dynamics were assessed during the first 12 
weeks of cART interruption.  
Results: VL was maintained below detectable levels in all patients 
while receiving MVA-B or MVA-B/disulfiram on ART but rebounded 
in all patients after cART interruption. The dynamics of VL rebound 
were not significantly different between the disulfiram treated/
untreated groups. Proportion of patients with VL rebound at weeks 
2 and 4 after cART interruption was similar between groups (w2: 
7/12 (58%) and 8/16 (50%), w4: 11/12 (92%) and 15/17 (88%), in 
MVA-B/disulfiram vs MVA-B, P = 0.66 and 0.74), respectively). At 
week 12 after cART interruption, mean (SE) change VL (as compared 
with set-point VL before any cART) was −0.72 (0.4) vs −0.35 (0.3) 
in MVA-B/ disulfiram vs MVA-B, respectively (P = 0.46). CD4 T cell 
counts declined similarly between groups after cART interruption. 
Changes in immunogenicity and latent viral reservoir before and 
after MVA-B/disulfiram are being assessed. 
Conclusion: A combination strategy of a therapeutic vaccine 
(MVA-B) plus disulfiram treatment neither  prevented nor delayed 
viral load rebound after cART interruption as compared with MVA-B 
vaccination alone
P04.11
Strategy to Conduct Vaccine Trials: The 
GHESKIO Experience
M. Deschamps1, P. Joseph1, K. Severe1, T. Dadaille1, N. Dorvil1,  
J. Pape2, and HIV Vaccine Trial Network3
1GHESKIO Centers, Port au Prince, Haiti; 2Division of Global 
Health, Weill Medical College of Cornell University, New York, 
NY, USA; 3HIV Vaccine Trial Network, Seattle, WA, USA
Background: GHESKIO has developed an integrated, holistic model 
of prevention and care for HIV and other infectious diseases based 
on research conducted in Haiti. GHESKIO is one of the largest sites 
working in the community to conduct HIV vaccine trials in the region. 
We describe the implementation strategy and outcomes of 10 vaccines 
studies conducted with support of HIV Vaccine Trials Network (HVTN) 
and the Haitian Ministry of Health.
Methods: The vaccine interventions included: 1) Preparation phase: 
Political support, community and staff training, development of 
educative materials, recruitment and retention plans; assessment of 
volunteers’ critical needs for incentives and services; laboratory capacity 
building and contingency plan development. 2) Implementation Phase: 
Multidisciplinary team approach comprised of physician, social worker, 
peer educators, nurses, data manager, laboratory, psychologist, site 
coordinator, and ethical review board and community advisory board 
(CAB) representatives. 3) Monitoring and Retention:  Regular site 
monitoring and evaluation; contingency plan to enroll and retain 
participants during crisis; telephone cards, home visits and incentives 
to maintain high retention. 
Results: From 2001 to 2012, 10 preventive HIV vaccine protocols 
were conducted at GHESKIO. Of those, 4 were HIV vaccine trials 
(HIVNET 026, HVTN 050, 204,502), 6 non-vaccine trials (HVTN 
903,504,404,802,907, 910). A total of 1,082 subjects were enrolled 
to evaluate site capacity to recruit and retain volunteers and test 
promising HIV vaccines in phase I/II and phase II-B trials. High retention 
rates (98-100%) have been observed among all trials.
Conclusion: In collaboration with HVTN and support of the Ministry 
of Health and other partners, GHESKIO has been able to develop 
an effective, multidisciplinary model of vaccine implementation. 
GHESKIO’s ability to continue providing prevention and care services 
throughout periods of crisis reflects its capacity to respond and 
intervene in conducting large vaccine trials.  
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P04.14
Early and Continuous Engagement of the CAB 
Is Essential to the Successful Implementation of 
Invasive Procedures in Clinical Trials
P. Charuthamrong1, W. Kaeratiswetanun2, T. Yamkram2,  
L. Sarovat3, T. Sawangying3, N. Thaitawat2, U. 
Likhitwonnawut3, S. Vasan2, M. Robb4, N. Churikanont2,  
S. Getchalarat2, E. Kroon2, S. Nitayaphan5, C. Eamsila5,  
S. Sriplienchan2, and V. Ngauy2
1Armed Forces Research Institute of Medical Sciences (MHRP-
AFRIMS), Rayong, Thailand; 2Armed Forces Research Institute 
of Medical Sciences, Banglamung District, Thailand; 3CAB, 
Bangkok, Thailand; 4U.S. MHRP, Silver Spring, MD, USA; 
5Royal Thai Army-AFRIMS, Bangkok, Thailand
Background: The Department of Retrovirology, AFRIMS, located in 
Bangkok, Thailand conducts acute cohort and HIV vaccine trials. As part 
of these studies, invasive procedures such as cervical and/or sigmoid 
biopsies, bone marrow aspirate, leukapheresis and lumbar puncture 
are performed to assess immune responses to vaccine or HIV infection. 
Efforts to assess volunteer acceptability of these novel procedures 
were initiated early in protocol development through engagement and 
education of the Retro Community Advisory Board (Retro CAB). Opinions, 
concerns, and advices were solicited to aid in the development of the 
protocol, informed consents, and educational materials.
Methods: Retro CAB membership represents and reflects the 
community and target population in which the trials are conducted. 
CAB members received GCP and GPP training and emphasis was placed 
developing research and social competency.Education on the protocols 
and invasive procedures was provided in advanced lay language.  A 
variety of media and educational methods were employed.CAB 
members with more advanced research or medical training helped to 
educated peers with less scientific backgrounds.
Results: Six protocols employing invasive procedures were discussed in9 
of 13 CAB meetings.CAB members reviewed the Test of Understanding, 
Informed Consent, study recruitment and education materials, and 
volunteer risk, benefits and compensation. A key concern raised by the 
CAB was the provision of medical care for volunteers in the event of 
complications arising from invasive procedures, particularly in healthy 
volunteers.  Researchers negotiated, developed, and purchased 
a novel Clinical Trials Insurance policy to provide coverage for 
serious complications arising from these procedures. Instituting CAB 
recommendations for consenting and volunteer education increased 
acceptability for cervical biopsy, sigmoid biopsy and leukapharesis 
from zero to just under enrollment goal.
Conclusion: Early, dedicated, and continual engagement of the 
community and pursuit of CAB guidance allowed for the successful 
implementation of invasive procedures that had previously never been 
performed in healthy volunteers in our protocols.
P04.13
Transgender Participants in Phase 1-2a Trials 
of the HIV Vaccine Trials Network (HVTN): A 
Descriptive Analysis
S.T. Karuna1 and M.P. Andrasik1
1HIV Vaccine Trials Network, Seattle, WA, USA
Background: The US Institute of Medicine (2011) noted a dearth of 
information on transgender individuals and called for more data. 
We respond by describing transgender individuals in HVTN trials, a 
population of unique import as they stand to benefit greatly from an 
HIV vaccine.  HIV prevalence in the US transgender population (2.64%) 
is five times the national average (0.45%).
Methods: Case report forms were analyzed for individuals who 
reported their gender identity differing from birth sex and who enrolled 
in 1-2a HVTN trials enrolling low-risk participants since 2009.
Results: Twelve transgender individuals (1.7% of 694 participants 
across six trials) were included, 9 (75%) male-to-female transgender 
participants (reporting male sex and female gender) and 3 (25%) 
female-to-male participants. The mean age was 25.8 years 
(SD=3.81). 25% identified as Hispanic, 83.3% as White, 8.3% as 
African-American, and 8.3% as “other.” The most common reasons 
for enrolling in an HIV vaccine trial were to: help find an effective 
vaccine (100%); help their community (100%); be informed about 
HIV research (88.3%); and because they know someone with HIV 
(66.7%). Fifty-seven pre-existing conditions were reported (mean 
4.75, SD=3.02). Fifty-seven adverse events were reported (mean 
4.75, SD=4.09), two deemed related to vaccine. 83.3% reported 
hormone therapy for a gender identity indication; 50% reported 
mental health medication. Retention was excellent with only one 
missed visit. Three participants requested interim HIV tests, two 
for possible HIV exposure. One participant became HIV-infected. 
No social impacts were reported; all participants reported benefits 
of participation, including: feeling good helping others (75%); risk 
reduction counseling (25%); and medical care (16.7%).
Conclusion: Primary reasons for HIV vaccine trial participation were 
altruistic. Mental illness incidence approximated that reported from 
other surveys of transgender individuals and was not accompanied by 
social impacts or missed visits. HIV incidence was 12.7/100 person-
years. Future analyses will include comparisons with non-transgender 
(cisgender) participants.
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P04.16
Mucosal Specimen Collection, Processing and 
Assay—Experience from a Resource-Limited 
Setting in Kenya
G.S. Omosa-Manyonyi1, B. Farah1, P. Bergin2, O. Anzala1,  
J. Gilmour3, G. Ouattara1, G. Mutua1, J. Lehrman4,  
H. Ogutu1, S. Ogola1, C. Verlinde3, R. Ndambuki1, E. Mutisya1, 
K. Chinyenze3, J. Nyange1, R. Langat1, D. Laufer3, H. Park3, and 
P. Fast3
1Kenya AIDS Vaccine Initiative (KAVI), University of Nairobi, 
Nairobi, Kenya; 2Imperial College, London, UK; 3IAVI, London, 
UK; 4IAVI, New York, NY, USA
Background: HIV-1 infection occurs most commonly through sexual 
intercourse.  Induction of mucosal immune responses will likely be 
necessary for an effective HIV vaccine.  KAVI embarked on building 
capacity for mucosal immunological work and disseminating this to 
other African research sites.   
Methods: With support from IAVI, KAVI clinical and laboratory teams 
designed SOPs for collection, processing and assay of cells and 
secretions from gastrointestinal, genital and upper respiratory mucosal 
surfaces over the course of 4 years and several studies.  Specimens 
analyzed for humoral immune responses included saliva, nasal 
turbinate, nasopharyngeal, cervical-vaginal and rectal secretions. 
Cervical-vaginal and rectal cytobrush samples, and rectal and sigmoid 
biopsies were stained and analyzed by flow cytometry.  Participants 
were free to opt out of any collection.  Reasons for refusal and 
other acceptability/tolerability data were collected. Depending on 
acceptability/tolerability and assay results, collection methods were 
dropped or SOPs improved as needed.  A curriculum was developed 
for training other African sites involved in HIV research on mucosal 
sample collection and processing.
Results: Four mucosal studies were conducted at KAVI, one involving 
participants from three HIV vaccine trials. Repeated mucosal sampling 
in both high and low risk participants was generally well accepted/
tolerated (AIDS Vaccine 2010 and 2012, P10.07 and P122 respectively). 
Cellular and humoral immune responses to HIV were detectable in 
various mucosal compartments including relatively easier sampling 
sites like the mouth and nose. One site in Rwanda received training 
and subsequently conducted a mucosal study; training of more sites 
is being planned.
Conclusion: Mucosal sample collection and processing from various 
mucosal compartments and by various sampling techniques is possible 
in a resource-limited setting.  HIV-relevant immunological responses 
are detectable in both genital and non-genital mucosal compartments. 
South-to-south collaborations for technology transfer in mucosal 
immunological studies is feasible and should be encouraged.
P04.15
Recruitment, Enhanced Retention Strategies 
and Willingness to Participate Among Hard-
to-Reach Female Sex Workers in Barcelona for 
HIV Vaccine Trials
M. Etcheverry1, J.L. Evans2, E. Sanchez3, E. Mendez Arancibia1, 
M. Meroño4, J. Gatell1, K. Page2, and J. Joseph1
1Hospital Clínic, IDIBAPS, HIVACAT, Barcelona, Spain; 2HIV/
AIDS Division at San Francisco General Hospital, University 
of California, San Francisco, CA, USA; 3Blanquerna School 
of Health Science, Ramon Llull University, Barcelona, Spain; 
4Àmbit-Prevenció Foundation, Barcelona, Spain
Background: Studies assessing prevention interventions, including 
prophylactic vaccines, require recruitment, long-term follow-up and 
high retention rates of HIV high risk volunteers who are willing to 
participate in future vaccine trials.  The potential for implementation of 
HIV vaccine trials in hard-to-reach female sex workers in an inner city 
area of Barcelona, Spain was assessed.
Methods: Baseline demographic, risk behavior, HIV testing and 
willingness to participate were recorded among 869 female sex 
workers, using an interviewer administered questionnaire.  Moreover, 
we evaluated retention outcomes over 24 month’s period of follow-
up between two groups in which different strategies were applied: 
enhanced retention (ER/n=130) and control retention (CR/n=121). In 
addition, risk behaviors over time, HIV seroincidence, and correlates of 
willingness to participate in future vaccine trials were assessed among 
the enhanced retention (ER) group.
Results: From 2005 to 2012 869 female sex workers who attended 
Ambit Prevencio center were enrolled. Overall, HIV baseline 
seroprevalence was 3% and 93% were willing to participate in HIV 
vaccine trials at baseline. At 6 months 76% of particpants in the ER 
group and 16 % in the CR group remain in follow-up; 69 % and 13 
% at 12 months respectively. Willingness was significantly associated 
with higher HIV risk exposure, and higher education level. Overall, 5 
new HIV-1 infections were found, yielding an estimated seroincidence 
rate of 1.1/100 PYO (95% CI: 0.3-4.3). 
Conclusion: Our results indicate that recruitment, retention, and 
willingness to participate are feasible in vaccine preparedness studies 
among hard-to-reach populations. To ensure broad participation in HIV 
vaccine clinical trials and cohort studies including women at high risk 
for HIV infection, modifications of the retention strategies may also be 
required. Furthermore, the fact that retaining hard-to-reach populations 
is difficult should not exclude this target population for HIV vaccine 
and prevention trials.
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P04.18
Immunogenicity of Homologous and 
Heterologous Regimens of Ad26-Enva.01 and 
Ad35-Enva HIV Vaccines in HIV-Uninfected 
Volunteers in the U.S. and Africa
J. Gilmour1, L.R. Baden2, N. Frahm3, D. Laufer1, P. Hayes4,  
L. Peter5, M.S. Seaman5, E. Cormier1, J. Hural3, E. Karita6,  
G. Mutua7, L. Gail-Bekker8, G. Gray9, L. Page-Shipp10, P. Fast1, 
J.H. Cox1, and D.H. Barouch5
1IAVI, London, UK; 2Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA, USA; 3Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 4Imperial College, London, 
UK; 5Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA; 6Projet San Francisco/Rwanda-
Zambia HIV Research Group, Kigali, Rwanda; 7University 
of Nairobi, Nairobi, Kenya; 8The Desmond Tutu HIV Centre 
Institute of Infectious Disease and Molecular Medicine Faculty 
of Health Sciences, Cape Town, South Africa; 9Perinatal HIV 
Research Unit, Cape Town, South Africa; 10The Aurum Institute 
for Health Research, Klerksdorp, South Africa
Background: Heterologous prime boost vaccine regimens offer a 
promising approach to improving T cell and antibody responses. 
Homologous and heterologous prime boost regimens were compared 
using two low seroprevalence Adenovirus vectors expressing two HIV-
1 subtype A Envs.
Methods: Ad26.EnvA.01 and/or Ad35-EnvA were administered at 5 x 
10 10 viral particles intramuscularly in 217 volunteers (173 vaccine: 44 
placebo) in three regions (US, East and South Africa) with two different 
intervals.  US volunteers (Groups A-D) received heterologous (Ad26.
EnvA.01+Ad35-EnvA or Ad35-EnvA+Ad26.EnvA.01) regimens at 0/3- 
or 0/6-month intervals.  African volunteers (Groups E-L) received the 
same heterologous regimens or homologous regimens consisting of 
two Ad26-EnvA.01 or two Ad35-EnvA at 0/3 months.
Results: Vaccine regimens were well tolerated.  IFN-gamma ELISPOT 
responses were detected in  44-100% of subjects (A-D), 6-62% (E-L) 
at 2 weeks and 78-100% (A-D), 47-88% (E-L) at 4 weeks after second 
vaccination for Ad26.EnvA.01 matched peptide pools and 11-75% (A-
D), 0-69% (E-L) at 2 weeks and 33-100% (A-D) and 0-87% (E-L) at 
4 weeks for Ad35-Env A matched peptide pools.  Env-specific CD4 
and CD8 response rates were up to 70% (CD4) and 80% (CD8) for 
IFN-gamma and/or IL2 expressing T cells in Groups I-L (South Africa) 
at 4 weeks post second vaccination.  T cell response magnitudes 
by ELISPOT and flow cytometry were modest; differences between 
heterologous or homologous regimens were dependent on peptide 
sets.  Env antibody responses were 93-100% in all groups with >10-
fold boost in magnitude at 4 weeks post second vaccination.  Baseline 
and vaccine-elicited Ad26 and Ad35 neutralizing antibodies were 
observed with marked regional differences; East Africa > South Africa 
> US and Ad26 > Ad35 titers.
Conclusion: Env antibody and T cell responses were detected in all 
groups and no correlation was detected between baseline vector-
specific neutralizing antibodies and Env-specific humoral or cellular 
immune responses across all regions.  Immunogenicity in heterologous 
and homologous regimens was comparable
P04.17
Pride of Fulfillment and Self-Respect: A Follow-
Up Study Among Volunteers Who Completed 
Phase I/II HIV Vaccine Trial in Dar es Salaam, 
Tanzania
E.A. Tarimo1, M. Ngatoluwa1, P. Munseri1, S. Aboud1, M. Bakari1, 
F. Mhalu1, and E. Sandstrom2
1Muhimbili University of Health and Allied Sciences, Dar 
es Salaam, United Republic of Tanzania; 2Sodersjukhuset, 
Stockholm, Sweden
Background: Enrolment in HIV vaccine trials is important for 
subsequent development of an affordable and effective vaccine. In the 
HIVIS-03 HIV vaccine trial, a total of 60 volunteers were randomized 
to receive either placebo or active vaccine (DNA priming, followed 
by boosting with MVA and rgp-140/GLA). Following completion of all 
vaccinations and follow up, all volunteers were un-blinded.  We hereby 
describe the experiences of volunteers after un-blinding. 
Methods: A follow up study was conducted in Dar es Salaam, Tanzania 
about 3 years after un-blinding of volunteers who received the active 
vaccine. Of the 33 volunteers, 21 (63.6%) were available during this 
follow up study. A self-administered questionnaire with both open and 
closed ended questions was completed by the volunteers. Content 
analysis was used to analyze the data.
Results: The majority (18/21; 85.7%) reported that participation in a 
vaccine trial was a good experience in the sense that they were able 
to: accomplish their dreams as volunteers, experience comfort about 
their decision, and experience safety of the vaccine. However, minority 
(3/21) were doubtful about their future in terms of possible long term 
vaccine side effects. About two third (13/21; 61.9%) of the volunteers 
informed their spouses about the outcome of un-blinding; five (5/21) 
informed their parents, relatives and friends; three (3/21) did not 
inform anybody. The reactions of those who were informed ranged 
from acceptance of volunteers’ decision to anxiety suspecting that 
the vaccine could be fatal.  However, none of the volunteers reacted 
negatively towards these reactions; they stated that participation in the 
vaccine trial was a personal decision.
Conclusion: Participation in phase I/II HIV vaccine trial in a Tanzanian 
context may be a rewarding experience. However, doubts from the 
surrounding community and some volunteers may persist. Therefore, 
follow up studies after un-blinding are important to address the 
volunteers’ and the community’s concerns.
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P04.20
Recruitment and Retention of Urban 
Population in Vaccine Trials in Uganda
H.N. Kibuuka1, L. Mutengu1, J. Nanyondo1, G. Kawooya1,  
S. Wakabi1, A. Sekiziyivu1, M. Millard1, J. Ledgerwood2,  
N. Michael3, and M. Robb3
1Makerere University-Walter Reed Project, Kampala, Uganda; 
2Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
3U.S. MHRP, Silver Spring, MD, USA
Background: Successful recruitment and retention of study participants 
is essential to the conduct of clinical trials.  Makerere University Walter 
Reed Project has conducted three Phase I/II HIV vaccine trials and 
a Phase Ib Ebola/Marburg vaccine trial recruiting participants from 
Kampala and its suburbs. We describe the experience and lessons 
learnt in recruiting low risk HIV uninfected participants and strategies 
for their retention.
Methods: Participants responding to various recruitment methods to 
include radio announcements, newspaper adverts, posters, brochures 
and word of mouth were screened after obtaining informed consent. 
A computerised clinic appointments tracking system, telephone 
reminders, home visits and invitations to functions were methods 
utilized to improve retention.
Results: Approximately 1744 participants were screened to enrol 325 
participants at a ratio of 5.4:1 (6.3: 1 for HIV vaccine studies and 
3.5:1 for the Ebola/Marburg study).  Screening to enrolment ratios 
were initially 7:1 and recently 5:1 for HIV vaccine studies with similar 
eligibility criteria.  The majority (79.7%) of enrolled participants were 
males (259/325) while 20.3% (66/325) were females.  All four studies 
included a greater number of men. While laboratory abnormalities 
were the most common cause of screen outs in the first trial as a 
complete set of local normal laboratory values was not available for 
use, other reasons such as health related exclusions and not returning 
for further screening visits were also common causes of screen outs 
overtime. High retention rates of 100% and 98% were achieved 
during one year of follow up for the first 2 HIV vaccine studies while 
the third is still ongoing. The overall retention for the two-year Ebola/
Marburg study was 92.6%.
Conclusion: The urban population surrounding Kampala is enthusiastic 
to participate in vaccine trials and can obtain high retention rates in 
Phase I/II studies. Emphasis should be placed on increasing female 
enrolment in vaccine trials. 
P04.19
Attracting, Equipping and Retaining Young 
Investigators in HIV Vaccine Research in South 
Africa
D. Flood2, M. Wallace1, K. Racow1, J. Kublin2, and L. Bekker1
1University of Cape Town, Cape Town, South Africa; 2HIV 
Vaccine Trials Network/Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA
Background: Upcoming HIV vaccine efficacy trials will require 
extensive research capacity, including at the investigator level. While 
senior level South African HIV vaccine researchers have developed 
tremendous expertise, junior clinician investigators are not being 
developed at the same rate. In 2010, the HIV Vaccine Trials Network 
(HVTN) with support from the National Institute of Allergy and 
Infectious Diseases (NIAID), collaborated with the Fogarty International 
Center to establish SHAPe (South African/HVTN AIDS Vaccine Early 
Stage Investigator Program), a peer reviewed MD/PhD program that 
recruits and supports young clinician investigators as they become 
independent investigators. Formative research was conducted to 
identify barriers and facilitators to attracting, equipping and retaining 
young investigators; develop recommendations to address challenges; 
and inform development of the SHAPe Program.
Methods: Qualitative data exploring the abovementioned issues 
were collected from interviews and focus groups with 5 senior and 6 
junior HIV vaccine investigators, and 7 medical doctors not involved 
in research.  Participants were recruited from clinical research sites and 
by referral throughout South Africa. Target participants comprised a 
small group of specialized individuals, and thus purposive sampling 
with specific criteria was used. Sessions were recorded and transcribed. 
Data were analyzed using ATLAS.ti software.  
Results: Participants recommended: 1) greater focus on fostering 
interest and developing research skills during medical training; 2) a 
more clearly defined investigator career development pathway; 3) 
stable funding and support for additional mentored research programs; 
4) better integration of research and academia; 5) targeted training; 
and 6) young investigator conference participation and networking. 
Conclusion: Expanding programs that provide young investigators 
with funded independent research, mentoring, and professional 
development may contribute to building South Africa’s next generation 
of HIV vaccine scientists. Researchers should consider creating a 
consortium to address challenges, and appeal to the local/national 
government for increased research support.   
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P04.22
ABSTRACT WITHDRAWN
P04.21
Construction of an Optimized Multi-Arm 
Phase I-II Trial Design to Evaluate the Safety 
and Immunogenicity of Different HIV Vaccine 
Strategies
L. Richert1, A.  Doussau2, J. Lelièvre3, V.  Arnold1, Y.  Lévy3,  
G. Chêne1, and R. Thiébaut1
1Centre INSERM U897, ISPED, University Bordeaux, Bordeaux, 
France; 2CHU Bordeaux, Pôle de Santé Publique, Bordeaux, 
France; 3INSERM U955, Vaccine Research Institute (VRI), 
UPEC, Créteil, France
Background: To accelerate HIV vaccine development, optimized trial 
designs are needed. We propose an optimized early stage design 
to evaluate four preventive prime-boost HIV vaccine strategies in 
parallel, aiming at rapidly discarding those that are unsafe or non-
immunogenic.
Methods: A multi-arm phase I/II trial is planned to study the safety and 
immunogenicity of four prime-boost strategies. One of the vaccines 
used as prime and boost in different strategies (vaccine 1) has yet to be 
tested in humans, thus requiring a phase I safety evaluation. However, 
its toxicity risk is considered minimal based on data from similar 
vaccines. We newly adapted a randomized phase II trial by integrating 
an early safety decision rule to emulate the phase I evaluation. 
Frequentist operating characteristics of the proposed design and 
scenarios for Bayesian analyses were evaluated in simulation studies. 
Timelines for the trial were projected.
Results: We propose a randomized four-arm phase I/II design 
with two independent binary endpoints for evaluating safety and 
immunogenicity. For immunogenicity screening in each arm at trial 
end, the observed proportion of interferon-γ ELISpot responders is 
compared to an unacceptably low proportion. No direct comparisons 
between arms will be made, but randomisation limits heterogeneity in 
volunteer characteristics between arms. To avoid exposure of additional 
participants to an unsafe vaccine during the vaccine boost phase, a 
stringent early stopping rule is imposed on the trial arm starting with 
injections of vaccine 1. In simulations of the frequentist operating 
characteristics of the design, the risk of erroneous conclusions was 
controlled at <15%. A 12-month gain in timelines is expected by this 
optimized design.
Conclusion: The proposed optimized design allows for accelerating 
early stage clinical development of HIV vaccine strategies by combining 
phase I and phase II evaluations in several arms in parallel. The set-up 
of a HIV vaccine trial using this design is currently ongoing.
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P04.24
Low Rates of ARV Use and Uptake Among 
Discordant Couples Followed in Government 
Clinics in Zambia
C. Dinh1, C. Kwok1, E. Dissen1, T. Sharkey1, N. Munir1, P. Chadd1, 
K. Parris1, W. Kilembe1, M. Inambao1, A. Tichacek2, and  
S. Allen2
1Zambia Emory HIV Research Project, Lusaka, Zambia; 
2Rwanda Zambia HIV Research Group, Atlanta, GA, USA
Background: Zambian National Guidelines include ARV for HIV+ 
individuals with CD4 counts less than 350 cells/mm 3, and for 
discordant couples. Couples’ Voluntary HIV Counseling and Testing 
(CVCT) has also been endorsed by the Zambian government. 
Acceptability of “treatment as prevention” has not been evaluated 
among discordant couples. In addition, given the high HIV prevalence 
and declining budgets, access to ARV may be limited.
Methods: Couples are invited to take part in CVCT services at 
Zambia government clinics. Data regarding history of prior testing, 
pregnancy, and ARV use was collected anonymously from January 
2008 to March 2013. ARV referrals were provided to those who were 
HIV-infected. In 2011, follow-up testing and counseling was instituted 
for discordant couples. 
Results: 11,277 discordant couples were identified in government 
clinics in Lusaka, Copperbelt, and Southern Provinces. Although more 
than half of HIV+ parners in discordant couples reported having been 
previously tested as individuals, only 1829 (16.2%) had initiated ARVs 
prior to CVCT. Follow-up testing rates were low, ranging from 10%-
25% across cities. Of 1161 HIV-infected partners who were not on 
ARVs at the initial CVCT visit, 980 (84.4%) had not initiated ARVs at 
subsequent follow-up visits. Higher rates of ARV use were observed in 
discordant couples where the woman was HIV-infected.
Conclusion: Couples’ HIV testing and counseling with follow-up 
testing for HIV discordant couples should be provided and promoted 
in government clinics. Obstacles to ARV uptake among Zambian 
discordant couples should be investigated and may include fear of 
stigma, unwillingness to take medication if asymptomatic, and limited 
ARV stocks with priority given to those with more advanced disease. 
Discordant couples benefit from reduced HIV transmission after CVCT 
whether or not they initiate ARV. Future HIV vaccine efficacy trials 
should include discordant couples.
P04.23
Benefits of a Comprehensive, Semi-
Automated Quality Program for 
Cryopreserved PBMC Covering 29 Globally 
Distributed Clinical Trials Sites
C. Ducar1, D. Smith1, M. Stirewalt1, J. McElrath1, and J. Hural1
1HIV Vaccine Trials Network, Seattle, WA, USA
Background:  The HVTN is a global network of clinical trial sites 
dedicated to identifying an effective HIV vaccine.  Immunologic 
evaluation of experimental vaccines requires cryopreservation of 
peripheral blood mononuclear cells (PBMC) for the assessment 
of vaccine-induced cellular functions. The HVTN PBMC Quality 
Management Program is designed to ensure viable PBMCs are 
processed, stored and shipped for clinical trial assays from all HVTN 
clinical trial sites. The program has evolved by developing and 
incorporating best practices for laboratory and specimen quality and 
implementing automated, web-based tools.  These tools allow both 
the site-affiliated processing laboratories and the central Laboratory 
Operations Unit to rapidly collect, analyze and report PBMC quality. 
Methods: The HVTN PBMC Quality Management Program includes 
five key components: 1) Laboratory Assessment, 2) PBMC Training 
and Certification, 3) Internal Quality Control (IQC), 4) External 
Quality Control (EQC), and 5) Assay Specimen Quality Control (AQC). 
Fresh PBMC processing data is uploaded from each clinical site 
processing lab to a central database at the HVTN Statistical and Data 
Management Center (SDMC) for access on a web portal called Atlas. 
Samples are thawed at a central laboratory for assay or specimen 
quality control and sample quality data is uploaded directly to the 
Atlas database by the central. 
Results: Two year cumulative data covering 13,853 blood draws 
reveals an average fresh PBMC yield of 1.43x10 6 ± 0.48 cells per 
milliliter of whole blood. Two year cumulative data covering 1818 
randomly selected clinical trial specimens shows that 99.6% of 
specimens tested had acceptable viabilities (>75% live cells) with a 
mean viability of 89.3% ± 5.06%, and  97.0% of specimens tested 
had acceptable recoveries (70%-130%) with a mean of recovery of 
87.3% ± 17.3% of the cryopreserved. 
Conclusion: These data support the benefits of implementing a 
comprehensive, semi-automated, web-based PBMC quality program 
for large clinical trials networks.
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P04.26
PENNVAX-B DNA Vaccine via Electroporation 
Drives Potent Cellular Immune Responses and 
Synthesis of Granzyme B, Perforin:  Data from 
3 Clinical Trials
N.Y. Sardesai1, M.P. Morrow1, J. Yan1, L. Ramirez2, J. Lee1, J. Boyer2, 
P. Tebas2, D.B. Weiner2, and M. Bagarazzi1
1Inovio Pharmaceuticals, Inc., Blue Bell, PA, USA; 2University 
of Pennsylvania, School of Medicine, Philadelphia, PA, USA
Background: Together with the HVTN, we recently reported the 
safety and comparative immunogenicity data from two clinical trials 
(HVTN-070/080)	 of	 the	 PENNVAX®-B	 DNA	 vaccine	 (PVB;	 SynCon®	
HIV Gag, Pol, and Env) with plasmid IL12 and impact of intramuscular 
electroporation	(EP)	using	the	CELLECTRA®	device	for	delivery.	In	HIV	
negative cohorts, PVB+IL12 via EP provided superior immunogenicity 
to the non-EP trial and had a significant dose-sparing effect. 71.4% of 
the vaccinees with EP produced a CD4+ or CD8+ T cell response after 
only 2 vaccinations rising to 88.9% after 3.  High levels of CD8+ T 
cells in the majority of subjects were a notable impact of EP delivery 
likely in combination with IL12.  Importantly, 85.7% of the responders 
with CD8+ and 71.4% with CD4+ T cells had memory responses 
persisting over 6 months.
Methods: Induction of potent and sustained levels of anti-HIV CD8+ 
T cells could lead to successful immunotherapy for infection. We 
therefore evaluated PVB + EP (weeks 0, 4, 8, 16) in 12 HIV infected 
volunteers on HAART in a Phase I study.  Enrollment criteria included 
HIV RNA<75 copies/mL, CD4 > 400/µL with nadir >200/µL. This study 
did not include IL12.
Results: All 12 subjects showed strong vaccine-specific T cell responses 
(IFN-γ ELISpot) to at least one antigen. Furthermore 9 of 12 subjects 
responded to 2 antigens; 4 subjects to all 3 antigens.  Flow cytometry 
showed that vaccination led to increased HIV specific CD8+ T cell 
activation after peptide stimulation (CD137 expression) and increased 
frequency of CTL-related markers Granzyme B and Perforin.
Conclusion: Vaccinations in all 3 trials were safe and well tolerated. 
These trials illustrate that improved DNA vaccination with CELLECTRA 
EP can drive the expansion of HIV-specific CD8+ T cells with a 
CTL phenotype and suggest this as a viable approach for HIV 
immunotherapy in combination with HAART or PrEP regimens.
P04.25
Integration of Prevention, Screening, and 
Treatment for Common Diseases for Vaccine 
Trial Target Populations: The Good Health 
Package in Zambia
E.K. Dissen1, C. Kwok1, N. Munir1, N. Ahmed2, J. Abdallah3,  
T. Sharkey1, C. Dinh1, A. Tichacek3, M. Inambao1, W. Kilembe1, 
and S. Allen3
1Zambia Emory HIV Research Group, Ndola, Zambia; 2Rwanda 
Zambia HIV Research Group, Kigali, Rwanda; 3Emory 
University, Atlanta, GA, USA
Background: In addition to the high HIV prevalence in Sub-Saharan 
Africa, the region is burdened with a majority of the world’s neglected 
tropical diseases (NTDs). Millions of people live without access to 
clean water, and non-communicable diseases (NCD) are an emerging 
problem. The Good Health Package (GHP) offers prevention, screening, 
and treatment for common diseases to couples seeking HIV testing.
Methods: Zambia Emory HIV Research Project (ZEHRP) has established 
Couples’ Voluntary HIV Counseling and Testing (CVCT) services in 50 
Zambian government clinics.  Sero-concordant negative and sero-
discordant couples are invited for HIV retesting at regular intervals 
and referred to ZEHRP for vaccine trials and studies.  In 2012, ZEHRP 
began offering blood pressure screening, chlorine for drinking water, 
deworming medication for household members, rapid syphilis testing, 
antibacterial hand soap, and urine dipstick screening for diabetes and 
schistosomiasis. Couples choose one service at each follow up visit.
Results: In 16 months, more than 7,500 services have been received 
by couples returning for follow-up.  The top three choices were soap 
(76%), chlorine (12%), and deworming (7%); the least popular was 
urinalysis (<1%).  Thirteen percent of individuals who had blood 
pressure tested were referred to clinics for hypertension treatment and 
20% tested for syphilis were positive and received free treatment.
Conclusion: The GHP provided an opportunity to teach proper hand-
washing, correct chlorine use, and periodic household deworming. 
Hypertension and diabetes are on the rise; education is needed as 
they are not recognized as important problems. Couples appreciated 
syphilis screening as it is otherwise available only to pregnant 
women.  Although 4/26 HIV vaccine trial participants referred from 
ZEHRP CVCT were diagnosed with active schistosomiasis during this 
time frame, neither couples nor clinic health care providers are aware 
of the high prevalence in urban adults. Prevention, screening, and 
treatment for common diseases should be offered to potential HIV 
vaccine trial participants.
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P04.28
Long-Chain Peer Referral to Recruit Black MSM 
and Black Transgender Women for an HIV 
Vaccine Efficacy Trial
A. Coombs1, W. McFarland2, T.O. Ick3, V. Fuqua3, S.P. Buchbinder2, 
J.D. Fuchs2, and HIV Vaccine Trials Network1
1Tufts University School of Medicine, Boston, MA, USA; 2San 
Francisco Department of Public Health, University of California-
San Francisco, San Francisco, CA, USA; 3San Francisco 
Department of Public Health, San Francisco, CA, USA
Background: Face-to-face outreach and online recruitment strategies 
for biomedical HIV prevention trials have identified limited numbers 
of black men who have sex with men (MSM) and black male-to-
female transgender women (transwomen) enrollees, two populations 
disproportionately affected by HIV. Long-chain peer referral (LCPR) 
has been used effectively to recruit hard-to-reach populations into 
cross-sectional and longitudinal studies. We therefore evaluated the 
feasibility of LCPR to recruit black MSM and transwomen into an 
ongoing HIV vaccine efficacy trial.
Methods: We conducted key-informant interviews, focus groups, and 
community consultations to develop an LCPR recruitment protocol and 
educational materials, and to identify initial participants to encourage 
black MSM and transwomen in their social networks to undergo vaccine 
study screening. From August 2012-March 2013, initial participants 
from San Francisco and Alameda counties were asked to refer peers 
who were ages 18-50 years and HIV uninfected or of unknown status.
Results: An initial 11 MSM and 6 transwomen participants were 
identified. Fifteen 1st or 2nd wave recruits underwent prescreening. 
Seven recruits advanced to medical screening. Of these, 3 were eligible 
for the trial (20%) and 2 enrolled. Two others were HIV-infected 
but previously unaware of their status; 1 was ineligible due to high 
adenovirus titers (the candidate vaccine vector), and 2 did not return 
to complete screening.
Conclusion: While we had limited success enrolling black MSM and 
transwomen in this application of LCPR, the recruitment strategy 
remains promising given its ability to tap into at-risk populations 
as seen by presentation of participants who were HIV-infected 
but unaware of their status. LCPR may be enhanced by increasing 
community awareness of HIV vaccine trials, by directing participants 
into efficacy trials with study phase-appropriate eligibility criteria, 
and by recruiting both HIV- infected and uninfected individuals 
to initial studies where comprehensive education about HIV 
research may encourage potentially eligible individuals to consider 
longitudinal follow-up. 
P04.27
Eligibility Assessments of Healthy Adults for 
Eleven HIV Vaccine Clinical Trials Conducted 
Through a Screening Protocol: 2002–2013
M.E. Enama1, L. Novik1, C.S. Hendel1, L. Holman1, S. Plummer1, 
I. Gordon1, O. Vasilenko1, B.S. Graham1, and J.E. Ledgerwood1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: The VRC/NIAID screening protocol, NIH #02-I-0127 
(NCT00031304), was developed to offer a well-structured process 
through which recruitment of potential participants could occur, with 
opportunity for volunteers to learn about investigational HIV vaccines 
and to be evaluated for eligibility.
Methods: The protocol was IRB-approved at the NIH Clinical Center 
(Bethesda, MD). Participation began after informed consent to be 
screened for an HIV vaccine study was obtained. Evaluations included 
medical history, physical exam, laboratory tests and collection of 
research samples. Subjects could screen for more than one HIV 
vaccine protocol. Screening outcomes and reasons for ineligibility were 
documented. After receipt of placebo in an HIV vaccine study or if 
potentially eligible for an HIV vaccine booster study, subjects could 
re-enroll in the screening protocol.
Results: Eligibility screening for 11 HIV vaccine protocols was 
completed 2002-2013. Cumulatively, 1324 adults enrolled one or 
more times for 1359 enrollments total. The study population included 
425 (32%) women and 899 (68%) men. Distribution by race was 69% 
white, 23% black/African American, 4% Asian, and 4% other races; 
overall, 6% were Hispanic/Latino. Of 1494 screening assessments, 
29% resulted in enrollment into an HIV vaccine protocol. Other 
outcomes were ineligibility (44%), withdrawal (19%), lost to follow-up 
(7%) and closed-out (1%).  Reasons for HIV vaccine study ineligibility 
included abnormal laboratory test (53%), medical history (22%), 
physical exam (10%), protocol-specific HIV risk criteria (8%) and 
other (7%).  After 2007, pre-existing immunity to a candidate vaccine 
vector, adenovirus serotype5, was the most common laboratory test 
associated with ineligibility.
Conclusion: The screening protocol was successful in facilitating 
enrollment of 11 VRC HIV vaccine protocols over 11 years at the NIH 
Clinical Center and allowed vaccine protocols to begin accrual quickly 
after IRB approval. Careful attention to screening outcomes improves 
the study education process and ensures a well-informed pool of 
volunteers for HIV vaccine protocols.
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P04.30
Performance of the Determine HIV 1/2 Ag/Ab 
Combo Rapid Test on Serial Samples from an 
Acute Infection Study (RV217) in East Africa and 
Thailand
L. Eller1, M. Manak1, A. Shutt1, J. Malia1, R. Trichavaroj2,  
B.  Danboise3. Lueer4, F.  Jallow5, M.  Hoelscher4,  
C.  Geldmacher4, N. Michael1, M. Robb1, and S. Peel1
1U.S. MHRP, Silver Spring, MD, USA; 2Armed Forces Research 
Institute of Medical Sciences (AFRIMS), Bangkok, Thailand; 
3Walter Reed Project-Kericho, Kericho, Kenya; 4Mbeya Medical 
Research Center, Mbeya, United Republic of Tanzania; 
5Makerere University Walter Reed Project, Kampala, Uganda
Background: Several small studies have demonstrated low sensitivity 
of the Determine HIV 1/2 Ag/Ab Combo Rapid Test (Combo RT) during 
acute HIV infection (AHI). We evaluated Combo RT performance 
on well-defined panels of serial samples collected from AHI cases 
identified by the Early Capture HIV Cohort (ECHO) Study, RV217.  
Methods: Individuals at high risk of HIV infection from Tanzania, 
Uganda, Kenya and Thailand were screened twice-weekly by Aptima 
HIV-1 Qualitative RNA assay (Gen-Probe, Inc. San Diego, CA). Following 
a reactive Aptima result, serial samples were collected twice weekly 
from consenting participants.  Serial specimen panels were screened 
with Combo RT (Alere, Inc), HIV-1 p24 Antigen (Ag) Test, GS HIV-1/2 
Plus O EIA (3th Gen), and HIV1/2 Multispot (Bio-Rad Laboratories, 
Redmond, Washington).
Results: Antigen and antibody (Ab) performance of the Combo RT 
were evaluated separately. Of 29 AHI cases, only four (13.7%) were 
identified by p24 target alone (Ag range: 210-5,500 pg/ml) despite 
device claims of a limit of detection of 12.5-25 pg/ml.  Anti-HIV Ab 
detection by Combo RT was highly sensitive. 24/29 (82.7%) cases 
were identified either before, or at the same time point as a 3rd 
generation EIA. Combo RT Ab was reactive on median day 14 (range 
3-25) while 3rd generation EIA reactivity occurred at day 16 (range 
10-33) (p=0.76).   In 23/29 (79.3%) cases, the Combo RT antibody test 
was reactive before Multi-spot, which was reactive on median day 20 
(range 14-40)(p<0.0001).
Conclusion: Combo RT performance for AHI case detection was 
poor as previously described and is likely due to omission of a p24 
Ab/Ab dissociation step.  Anti-HIV Ab detection was comparable 
with 3rd generation EIA and showed improved sensitivity over the 
Multi-spot rapid test. Ag detection sensitivity and, thus, enhanced 
AHI case detection may be vastly improved by addition of a p24 
dissociation step.
P04.29
Retention, ARV Use, and Dual Contraception 
in Discordant Couples in Government Clinics in 
Kigali, Rwanda
R. Ingabire1, E. Karita1, J. Nyombayire1, J. Mukamuyango1,  
R. Sinabamenye1, N. Ahmed1, J.N. Nduwamungu1,  
H. Uwamahoro1, S. Nouri1, S. Strunk1, A. Tichacek2, and S. Allen2
1Rwanda Zambia HIV Research Group/Projet San Francisco, 
Kigali, Rwanda; 2Rwanda Zambia HIV Research Group/Emory 
University School of Medicine, Atlanta, GA, USA
Background: HIV discordant couples benefit from joint HIV testing, 
with seroconversion rates of 3-4%/year in Rwanda compared 
with 11%-12%/year among uncounseled discordant couples in 
the region. Treatment-as-prevention (TAP) with ARV has been 
recommended for discordant couples. HIV- women participating in 
vaccine trials are asked to avoid pregnancy, ideally with long acting 
under independent contraceptives (LARC) such as the copper IUD 
and the contraceptive implant.  
Methods: Projet San Francisco provides training, monitoring and 
evaluation, and reporting of discordant couple management and LARC 
insertion in government clinics in Kigali, Rwanda. We describe follow-
up rates, ARV uptake, and LARC use among HIV discordant couples. 
Results: Of 2322 discordant couples identified during routine CVCT 
in antenatal clinics, 53% (1220) were on ARV. Sixty three percent 
(1452) of couples enrolled in the follow-up program. Of these, 
54% (777) were on ARV at first couples testing and 51% (347/675) 
initiated ARV after CVCT. It is not clear why more than a third of 
discordant couples did not enroll in follow-up, nor why 328 who did 
enroll in followup did not initiate ARV. Following an intensive LARC 
training program, the proportion of family planning clients choosing 
LARC increased from <2% to >55%. However, only 9% of discordant 
couples in the followup program report LARC use (7% implant, 2% 
IUD): 9% use depo-provera, 2% use oral contraceptives, and 80% 
use condoms alone. 
Conclusion: Rwanda is the only country in Africa to implement CVCT on 
a national scale, with >90% of pregnant women now tested with their 
partners. Even in the capital city however, many discordant couples 
do not avail themselves of followup services or ARV. Integrating full-
service family planning with dual-method counseling into discordant 
couple follow-up would help couples avoid unplanned pregnancies 
and provide an added benefit to those participating in future HIV 
vaccine efficacy trials. 
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P04.32
A Recombinant Vesicular Stomatitis Virus 
(rVSV) HIV-1 Gag Vaccine Is Safe and 
Immunogenic in Healthy, HIV-1 Uninfected 
Phase I Trial Participants
J.D. Fuchs1, I. Frank2, M. Elizaga3, N. Kochar3, M. Allen4,  
N. Frahm3, D.K. Carter3, S. Li3, S. Edupuganti5, S. Kalams6,  
R. Sheets4, M. Pensiero4, T. Latham7, M. Egan7, D. Clarke7, 
and J. Eldridge7
1San Francisco Department of Public Health, San Francisco, 
WA, USA; 2University of Pennsylvania, Philadelphia, PA, 
USA; 3Fred Hutchinson Cancer Research Center, Seattle, WA, 
USA; 4NIAID, NIH, Bethesda, MD, USA; 5Emory University, 
Atlanta, GA, USA; 6Vanderbilt University, Nashville, TN, USA; 
7Profectus BioSciences, Inc., Tarrytown, NY, USA
Background: Highly attenuated recombinant vesicular stomatitis 
virus (rVSV) is a replicating viral vector-based vaccine which takes 
advantage of limited seroprevalence to VSV. Here we present safety 
and immunogenicity data from a phase 1a first-in-human trial.
Methods: HVTN 090 enrolled sixty healthy, HIV-1-uninfected adults 
in a randomized, double-blinded, placebo-controlled dose escalation 
study. Groups of 12 participants received rVSV HIV-1 Gag vaccine at 
5 dose levels (4.6 x 10 3 to 3.4 x 10 7 PFU) (N=10/group) or placebo 
(N=2/group), delivered intramuscularly as bilateral injections at 0 
and 2 months. Reactogenicity over 7 days, adverse events (AEs), and 
VSV cultures from blood, urine, saliva and swabs of oral lesions were 
assessed. HIV-1-specific CD4+ /CD8+ T cell responses to Gag peptides 
were measured at 2 weeks post-boost by intracellular cytokine staining 
(ICS) and by IFN-γ ELISpot. Neutralizing antibody responses to the 
rVSV vector were also assessed.
Results: The median age was 24; 45% were female and 37% were 
non-white. Local and systemic reactogenicity symptoms were mild 
to moderate and increased with dose.  No severe reactogenicity, 
encephalitis, or product-related SAEs were reported. All rVSV cultures 
were negative.  All vaccine recipients became seropositive for VSV 
after 2 vaccinations indicating successful vaccine ‘take’. Gag-specific T 
cell responses were detected in 63% of participants by IFN-γ ELISpot 
at the highest dose post-boost. ICS revealed that responses were 
predominantly mediated by CD4+ T cells expressing CD40L, showing 
a clear dose-response from 11% of participants responding at the 
second dose level to 50% at the highest dose. 
Conclusion: A replication-competent rVSV Gag vaccine has an 
acceptable safety profile in healthy adults. Gag-specific T cell responses 
were detected in ~60% of study participants after 2 vaccinations at the 
highest dose. HVTN 087 is currently exploring whether priming with 
a multigene HIV-1 DNA vaccine given with plasmid IL-12 adjuvant by 
electroporation will increase the immunogenicity of the rVSV vaccine.
P04.31
Discordant Couples Cohort Is Still Relevant for 
HIV Vaccine Studies Despite Low Transmission 
Rates; Canadian–Nigerian Experience 
S. Osawe1, E. Okpokoro2, R. Datiri3, G. Choji3, F. Okolo3,  
P. Datong3, and A. Abimiku4
1Institute of Human Virology, Nigeria, Jos, Nigeria; 2Institute 
of Human Virology, Nigeria, Abuja, Nigeria; 3Plateau State 
Human Virology Research Centre, Jos, Nigeria; 4School of 
Medicine, University of Maryland, Baltimore, MD, USA
Background: Discordant couples have been known to be medium risk 
group for HIV transmission.  This group is suitable for HIV vaccine 
trials due to the natural exposure and high retention rates recorded in 
the past. A cohort of discordant couples is being developed in Nigeria 
to record HIV incidence, STI infections, retention rates, risk factors 
and behavioral data. The data collected from this cohort will establish 
baseline information on the general Nigerian population.
Methods: A prospective cohort study to enroll and follow up 500 HIV 
serodiscordant couples for 2 years was established in Jos, Nigeria. 
Relevant ethical approvals were obtained. Following informed consent, 
standardized questionnaires were administered, clinical examinations 
done, and samples collected. Data on risk behavior from participants; 
and CD4 counts and viral from their partners were collected. 
Results: A total of 540 HIV negative volunteers were enrolled, 282 
(52.2%) females and 258 (47.8%) males. 215 enrollees (39.8%) 
reported use of condoms at all times while 159 (29.4%) reported 
non-frequent use and 164 (30.4%) never use condoms. The average 
CD4 count was 428 cells/µl. Most importantly, 258 (69.4%) of the 
HIV positive partners had detectable viral load levels with 67 (26.0%) 
having >10,000 copies/ml. Three of the 540 volunteers seroconverted 
giving this cohort an incidence of 0.56%. 
Conclusion: Our study indicates that despite the scale up of 
antiretrovirals, seronegative partners continue to be at risk of being 
infected by their HIV+ partners in resource limited settings. Our study 
recorded detectable virus in the seropositive partners and inconsistent 
condom use despite risk reduction counseling. In addition, this fairly 
healthy serodiscordant couple cohort is an important natural adult 
model to study immune responses in HIV exposed adults. This baseline 
immune response might impact the interpretation of the effectiveness 
of HIV vaccine trials.
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P04.34 LB
Immunogenicity of MVA-B in HIV-1-Infected 
Volunteers
M. Esteban1
1Centro Nacional de Biotecnología/CSIC, Madrid, Spain
Background: Previous studies suggested that poxvirus-based vaccine 
regimens may be instrumental in the therapeutic HIV field. Here, we 
have characterized the T cell mediated immunity elicited in 22 chronic 
HIV-1-infected patients undergoing highly active antiretroviral therapy 
(HAART) pre- and post-vaccination with a clade B-based HIV-1 vaccine 
candidate expressing Env, Gag, Pol and Nef antigens (MVA-B).
Methods: A total of 30 chronic HIV-1-infected patients on HAART 
with CD4 cell counts above 450 cells/mm3 and undetectable viremia 
were enrolled in a phase I, double-blind, placebo-controlled trial. The 
volunteers were randomly allocated to receive three injections of 
MVA-B (108 PFU/ dose) (n=20) or placebo (n=10) by intramuscular 
route at weeks 0, 4 and 16 followed by interruption of the HAART 
therapy at week 24. The magnitude, quality and phenotype of the 
cellular immune responses were assayed in 22 out of 30 volunteers 
by polyfunctional flow cytometry (IL-2/IFN-_/TNF-_/CD107a) on 
cryopreserved peripheral blood mononuclear cells (PBMC) at weeks 
0, 6, 18 and 24.
Results: High, broad and polyfunctional HIV-specific CD8 T cell 
responses with effector memory (TEM) phenotype were detected in 
all of the 22 seropositive individuals pre- and post-vaccination, with 
preference in the order of GPN=Gag>Env. A significant increase in the 
frequencies of HIV-specific CD4+ T cell responses with TEM phenotype 
were detected after 2 (p-value=0.0014) or 3 (p-value=0.008) doses 
of MVA-B in vaccine group compared with placebo. At all the time 
points assayed the CD4+ T cell responses were polyfunctional, with 
preference in the order of Gag>GPN>Env.
Conclusion: MVA-B vaccination represents a feasible strategy to improve 
T cell responses in individuals with existing HIV-specific immunity
P04.33
Performance of HIV Rapid and HIV ELISA 
Test Kits on Samples from a Preventative HIV 
Vaccine Trial to Evaluate Vaccine Induced Sero-
Reactivity (VISR) 
P. Chetty1, G. Stevens1, B. Farah2, I. Mwangi2, S. Wangui2,  
C. Schmidt1, D. Laufer1, and O. Anzala2
1IAVI, South Africa; 2Kenya AIDS Vaccine Initiative, Nairobi, Kenya
Background: HIV uninfected participants in HIV vaccine trials may 
develop HIV-specific antibodies as a result of receipt of HIV vaccine, 
which can lead to vaccine induced sero-reactivity (VISR), i.e. reactive 
results by standard HIV diagnostic test kits. Correct HIV diagnosis 
therefore requires confirmatory testing. It is essential to determine 
the best suited HIV testing algorithm for a particular HIV vaccine to 
facilitate appropriate HIV test counselling, avoid mis-diagnosis and 
mitigate social harm. The performance of 4 HIV test kits for detection of 
VISR was determined using stored sera from post vaccination samples.
Methods: Study participants were HIV-uninfected and had received 
either Ad26-ENVA or Ad35-ENV product or both or placebo in a 
prime-boost regimen. Samples stored from 32 vaccine and 8 placebo 
recipients at 2 months and 9 months post last vaccination visit were 
tested on 4 different HIV test kits at a research centre in Nairobi.   
Results: 96.9 (31/32) of vaccine recipient samples showed reactive 
results on both the 4th generation BioMerieux Vironostika Ag/
Ab Microelisa kit and Mini-VIDAS HIV Ultra Duo Ag/Ab kit for both 
post vaccination visits. 37.5% (12/32) 2 months and 9.4% (3/32) 9 
months post last vaccination samples were reactive when using the 
3rd generation Alere HIV 1/2 Rapid test. 50.0% (16/32) 2 months and 
3.1% (1/32) 9 months post last vaccination visit were reactive when 
using the 3rd generation Trinity Unigold 1/2. No placebo recipients 
tested positive on any assay for VISR. 
Conclusion: Selection of optimal kits for HIV testing algorithm(s) 
following receipt of HIV vaccine may be challenging. 3rd generation 
HIV Rapid test kits were much less sensitive in detecting VISR 
compared to 4th Generation ELISA kits. Post vaccination samples from 
HIV vaccine trials are useful when designing HIV testing algorithms for 
subsequent trials and following up of persistence of VISR.
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P04.36 LB
Boosting Antibody Responses with gp140 
Protein Two Years After DNA/MVA Priming: 
Results from the HVTN 073E Phase I Vaccine 
Trial 
L. Morris1, N.N. Mkhize1, T. Hermanus1, E. Chung1, A. Sato1,  
S. Grant1, N. Gu1, C. Williamson1, A. Williamson1, S. Barnett1,  
L. Bekker1, M. Allen1, M.N. Pensiero1, J. Hural1, J. McElrath1,  
M. Elizaga1, K. Mayer1, G. Tomaras1, D. Montefiori1, and G. Gray1
1National Institute for Communicable Diseases, Johannesburg, 
South Africa
Background: HVTN 073E, an extension of the HVTN 073/SAAVI 102 
phase 1 study, was designed to explore whether antibody responses 
to a DNA/poxvirus vaccine can be improved with the addition of an 
envelope protein vaccine. 
Methods: 27 HIV-1-uninfected adult participants, who 2 years prior 
had been vaccinated with SAAVI DNA-C2 vaccine and SAAVI MVA-C 
vaccine, were boosted twice, 3 months apart, with 100 mcg of Novartis 
subtype C oligomeric V2 loop-deleted TV1 gp140 formulated with 
MF59 adjuvant. Altogether, participants received either DNA/MVA 
with a protein boost (T1/T2, n=16), DNA/MVA with a placebo boost 
(T1/C2, n=6), placebo with a protein boost (C1/T2, n=1), or double 
placebo (C1/C2, n=4). Serum samples from 2 weeks after the 1st and 
2nd protein boosts (visits 19 and 22) and 6 month later (visit 24) were 
tested for binding and neutralizing antibodies.
Results: No neutralizing antibodies were detected following DNA/
MVA vaccination. After gp140 boosting neutralizing antibodies to 
MW965.26, a Tier 1A clade C virus, were detected in 53%, 100% 
and 75% of individuals at visits 19, 22 and 24, respectively. For 
all 3 Tier 1 viruses, the area under the magnitude-breadth curve 
was significantly higher in T1/T2 versus T1/C2 at visits 22 and 24 
(p<0.0001 and p=0.0052). No responses were seen to Tier 2 viruses 
in this TZM-bl assay. In contrast, neutralization of the Tier 2 virus 
TV1.21 was seen in the A3R5 assay with an 80% response rate in the 
T1/T2 group. Similarly, the area under the magnitude-breadth curve 
was significantly higher in T1/T2 versus T1/C2 at visit 22 (p=0.0098). 
The C1/T2 and C1/C2 groups showed no responses at v22. High titer 
binding antibodies to TV1dV2 gp140 proteins were detected in all T1/
T2 vaccinated individuals after the first boost. 
Conclusion: Protein boosting after DNA/MVA vaccination resulted in 
good neutralizing antibody responses despite a 2-year interval. 
P04.35 LB
Autologous Dendritic Cell-Based Therapy 
Modulates Proviral DNA Levels in Chronically 
HIV-Infected Subjects
I. Tcherepanova1, J. Harris1, J. Horvatinovich1, M. DeBenedette1,  
S. Vezina2, C. Tremblay3, M. Loufty4, J. Gill5, J. Baril6, F. Smaill7,  
J. Angel8, J. Routy9, and C. Nicolette1
1Argos Therapeutics, Durham, NC, USA; 2Clinique Médicale 
l’Actuel, Montreal, Canada; 3Centre de Recherche du Centre 
Hospitalier de l’Université de Montréal, Montreal, Canada; 
4Maple Leaf Clinic, Toronto, Canada; 5Southern Alberta Clinic, 
Calgary, Canada; 6Medical du Quartier Latin, Montreal, Canada; 
7McMaster University Medical Center, Hamilton, Canada; 
8Ottawa Hospital Research Institute, Ottawa, Canada; 9McGill 
University Health Centre, Montreal, Canada
Background: Strategies for HIV eradication will hinge on the ability to 
purge latently infected cells. The levels of HIV DNA (pDNA) in chronic 
patients on ART are stable for years but serve as a reservoir for re-
emergence of HIV in the absence of ART. 
Previously we reported results of a clinical study testing AGS-004 
in chronic HIV patients. AGS-004 is an autologous immunotherapy 
consisting of dendritic cells expressing autologous HIV RNAs. Twenty-
five subjects received four immunizations in combination with ART 
followed by an analytic treatment interruption (ATI). Twenty-one 
subjects reached the primary endpoint with 16 of 21 demonstrating 
a mean reduction in viral load set point of 1.21 logs. In this study we 
evaluated the impact of AGS-004 on the pDNA levels. 
Methods: The pDNA was measured by repetitive sampling PCR. 
Samples at a baseline (week 0) and after four immunizations with 
AGS-004 (week 14) for this analysis were available from 20 of 21 
subjects meeting the primary endpoint. Samples from 10 subjects were 
available after 10 weeks of ATI (week 24).
Results: In the analysis of week 14 versus baseline, 5 of 20 subjects 
had an increase, 8 had stable levels and 7 had decreased in pDNA 
levels. Subjects with lower baseline levels of pDNA were more likely 
to experience a decrease in pDNA levels at week 14. In the analysis 
of samples after 10 weeks of ATI, 8 of 10 had increased pDNA levels 
coinciding with elevated plasma VL. However, in 2 of 10 subjects 
measured, pDNA levels continued to decline during ATI coinciding with 
longer VL control without ART. 
Conclusion: We believe this is the first report of the HIV pDNA levels 
modulated in response to DC-based therapy. Thus AGS-004 is a good 
candidate for combination with ART and latency re-activating agents in 
pursuit of HIV eradication.
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P04.38 LB
HVTN 505: Efficacy of a Multi-Gene DNA Prime/
Recombinant Adeno 5 (rAd5) Vector Boost 
Vaccine in Men & Transgender Women (TGW) 
Who Have Sex with Men
S. Hammer1, M. Sobieszczyk1, H. Janes2, P. Gilbert2, S. Karuna3,  
D. Grove2, S. Ramirez3, C. Bentley3, C. Anude4, M. Mulligan5,  
B. Koblin6, S. Buchbinder7, M. Keefer8, J. Hural3, J. McElrath3,  
N. Frahm3, G. Tomaras9, B. Graham10, M. Enama10, G. Broder3,  
J. Maynard3, S. Wakefield3, R. Holt3, E. DeJesus11, I. Frank12,  
R. Novak13, A. Martinez4, J. Kublin3, L. Corey3, and HIV Vaccine 
Trials Network1
1Columbia University, New York, NY, USA; 2SCHARP, Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; 3Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; 4DAIDS, 
NIAID, Bethesda, MD, USA; 5Emory University, Atlanta, GA, USA; 
6New York Blood Center, New York, NY, USA; 7San Francisco 
Department of Public Health, San Francisco, CA, USA; 8University 
of Rochester, Rochester, NY, USA; 9Duke University, Durham, 
NC, USA; 10Vaccine Research Center, NIAID, NIH, Bethesda, 
MD, USA; 11Orlando Immunology Center, Orlando, FL, USA; 
12University of Pennsylvania, Philadelphia, PA, USA; 13University 
of Illinois, Chicago, IL, USA
Background: The DNA/rAd5 vaccine regimen developed by VRC/NIAID 
elicits HIV-specific, multifunctional CD4+/CD8+ T-cell responses and 
antibodies (Ab) to HIV Env. Preclinical and clinical data demonstrated 
safety and immunogenicity and supported efficacy potential. 
Methods: Primary objectives of this multicenter (U.S.), double-blind, 
placebo-controlled, randomized trial were vaccine efficacy (VE) for 
HIV acquisition (diagnosed between Wk 28 through month 24), viral 
load (VL) setpoint (mean HIV-1 RNA level obtained Wks 10-20 post 
diagnosis), and safety. Eligibility included being Ad5 Ab seronegative, 
circumcised, MSM or TGW, 18-50 years, and meeting behavioral risk 
criteria. The 6-plasmid DNA vaccine [Gag, Pol, Nef (clade B) and gp145 
Envs (clades A, B, C)] was administered at Wks 0, 4, 8. The rAd5 boost 
[4-valent vector with full E1 and E4 and partial E3 deletions, encoding 
Gag/Pol fusion protein (clade B) and gp140 Envs (clades A, B, C)] was 
administered at Wk 24. 
Results: 2504 participants enrolled 6/11/09 through 3/27/13 with 
1253 randomized to vaccine (V) and 1251 to placebo (P). Characteristics 
included median age 29; 70% White, 16% Black; 8% Hispanic; risk 
factors balanced across arms. On 4/22/13 the DSMB recommended 
halt of vaccinations based on pre-specified efficacy futility criteria. 
Primary analysis at end of blinded follow-up showed 27 (V) and 21 (P) 
Wk 28+ HIV infections [VE -25.0%; (95%CI -121.2,29.3); p = 0.44]. 
Mean VL setpoints were 4.46 (V) and 4.47 (P) log RNA copies/mL. 
MITT analysis, including all infections [41 (V);31 (P), p = 0.28] was 
concordant with the primary analysis. The vaccine regimen was well 
tolerated and immunogenic for both T and B cell responses.
Conclusion: The VRC DNA/rAd5 regimen neither reduced HIV 
acquisition nor post-acquisition VL setpoint in MSM and TGW. The 
greater number of infections in the vaccine compared to the placebo 
arm is not statistically different but unblinded follow-up continues for 
further assessment.
P04.37 LB
Safety, Immunogenicity and Dynamics of 
Viral Load Rebound After cART Interruption in 
Chronic HIV Infected Patients Receiving MVA-B 
Vaccination
B. Mothe1, N. Climent2, M. Plana2, M. Rosas1, J. Jiménez3,  
M. Muñoz-Fernandez3, J. Pich2, J. Arnaiz2, J. Gatell2, B. Clotet1,  
M. Esteban4, J. López Bernaldo de Quirós3, F. García2, and  
C. Brander1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2Hospital Clínic, IDIBAPS, HIVACAT, Barcelona, Spain; 
3Hospital General Universitario Gregorio Marañón, IiSGM, 
Madrid, Spain; 4Centro Nacional de Biotecnología, Madrid, 
Spain
Background: Poxvirus-based vaccines have shown great potential as 
HIV vaccines. We present the safety and immunogenicity results of a 
phase I, double blinded, placebo-controlled therapeutical vaccine trial 
of an MVA vector expressing HIV-1 antigens from clade B (MVA-B) in 
successfully cART-treated HIV-infected patients who underwent cART 
interruption.
Methods: Patients were randomly allocated to receive 3 intramuscular 
injections of MVA-B at 0, 4 and 16 weeks (n=20) or placebo (n=10). 
cART was discontinued in all patients 8 weeks after the last dose of 
MVA-B and viral rebound dynamics were assessed during the first 12 
weeks of cART interruption. Immunogenicity to the vaccine insert and 
the rest of the HIV proteome was assessed using IFNg ELISPOT.
Results: Vaccinations were well tolerated with no grade 3 or 4 side 
effects reported and viral load (VL) was maintained below detectable 
levels in all patients while receiving cART and MVA-B challenges. No 
major changes in total magnitude or breadth of HIV-specific responses 
were detected between vaccinees and placebos. Only a minor 
significant increase in the responses targeting vaccine inserts of Gag 
and Env-gp120 was seen after 2 vaccinations and was maintained over 
time (median Gag responses of 290, 403 and 435 SFC/M PBMC at 
baseline, w6 and w24 respectively, p=0.02 and p=0.04). However, 
all patients rebounded after cART interruption. At week 12 after 
cART interruption, median reduction in VL (as compared to setpoint 
VL before any cART) was -0.24 vs -0.53 log copies/ml in MVA-B vs 
placebo, respectively (p=0.74). CD4 T cell counts declined similarly 
between groups. The dynamics of VL rebound did not correlate with 
the responses detected before cART interruption.
Conclusion: MVA-B vaccination was a safe strategy to increase Gag 
and Env-gp120 specific T cell responses in individuals with existing 
HIV-specific immunity but did not avoid nor impact VL rebound after 
cART interruption.
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P04.40 LB
Preliminary Results of a Brazilian Clinical Trial 
for DC-Based Immunotherapy Against HIV-1
A.D. Almeida1, T.M. Oshiro1, L.T. Silva1, W.C. Silva1, J.A. Barbuto1, 
and A.J. Duarte1
1University of São Paulo, São Paulo, Brazil
Background: Immunotherapy based on monocyte-derived dendritic 
cells (moDC) is a promising strategy for treating HIV-infected 
individuals. Clinical trials using this product have shown to be safe 
and well tolerated, but individual response is variable. Currently, we 
are conducting a phase I/II clinical trial aiming to test the effect of 
moDC pulsed with chemically inactivated autologous HIV in a Brazilian 
cohort. We present preliminary results concerning safety and evolution 
of plasma viral load during the first 90 days after vaccination.
Methods: Nineteen chronically HIV-infected patients, naïve for 
antiretroviral treatment, were randomized in three groups (G1-G3) to 
received three doses (15 days intervals) of 3x107 un-pulsed DCs (G1, 
n=4), 3x106 HIV-pulsed DCs (G2, n=9) or 3x107 HIV-pulsed DCs (G3, 
n=6). Safety and immunovirological parameters will be monitored for 
one year.
Results: We hereby report data from the first 90 days of follow up. Forty-
five days after the first dose of vaccination, two out of three patients in 
G1 and four out of six in G3 have shown a decrease in plasma viral load 
(PVL) (mean of 0.056 log 0.323 log in G1 and G3 respectively). 
Ninety days after vaccine initiation, 3/3 subjects in group G1, 2/7 in 
G2, and 3/6 in G3 presented reduced PVL (mean 0.124; 0.084 and 
0.16 log respectively).
As for the CD4 and CD8T cell counts, so far, we have not observed 
significant changes after vaccination.
Conclusion: Until now, our results have demonstrated that the vaccine 
is safe, for no major adverse–related events have been reported. 
These preliminary results suggest a slight advantage for subjects 
under the 3x107 HIV-pulsed DCs regimen with respect on PVL. A more 
conclusive response to this immunotherapy will be better defined once 
the ongoing follow-up is concluded.
P04.39 LB
Vaccination with Heterologous HIV Envelope 
Sequences and Heterologous Adenovirus 
Vectors Increases T Cell Responses to Conserved 
Regions: HVTN 083 
J. Hural1, S. Walsh2, Z. Moodie1, N. Frahm1, A. Gartland1,  
D. Friedrich1, T. Hertz1, H. Ahmed1, M. Wilck3, C. Morgan1,  
E. Swann4, H. Wang1, B. Manso1, S. Self1, B. Graham5, and X. Jin6
1HIV Vaccine Trials Network, Seattle, WA, USA; 2Brigham and 
Women’s Hospital, Boston, MA, USA; 3Hospital of the University 
of Pennsylvania, Philadelphia, PA, USA; 4NIAID, NIH, Bethesda, 
MD, USA; 5Vaccine Research Center, NIAID, NIH, Bethesda, MD, 
USA; 6University of Rochester, Rochester, NY, USA
Background: Several approaches have been proposed to improve 
the ability of HIV vaccine-induced responses to recognize diverse 
circulating HIV strains, among them increasing the breadth of immune 
responses or directing them towards conserved regions. HVTN083 
tested how prime-boost strategies employing heterologous vectors, 
heterologous inserts or combinations thereof affect the breadth and 
specificity of cellular immune responses.
Methods: 180 subjects were randomized among five prime-boost 
combinations of vectors (Ad5 or Ad35) and HIV-1 Env inserts (clade 
A or B). T-cell responses to individual 15mers were mapped by IFN-g 
ELISpot using insert-matched peptides. Shared epitopes were defined 
as sequences ≥8 amino acids (AA) with ≥6 identical AA for EnvA and 
EnvB. Alternatively, optimal 8-10 AA epitopes were predicted using a 
computational HLA binding predictor (NetMHCpan) and participants’ 
HLA class I types with similar results.
Results: All regimens were well tolerated with no vaccine-related 
serious adverse events. Response rates to EnvA (included in all 
groups) were similar across groups (58.1%-75.9%). Heterologous 
and homologous insert regimens elicited responses to similar total 
numbers of epitopes (ratio of means=1.0, 95% CI=[0.6, 1.6], p=0.91), 
however, heterologous insert regimens targeted more epitopes shared 
between EnvA and EnvB than homologous insert regimens (ratio of 
means=2.7, 95% CI=[1.2, 5.7], p=0.01). Shared responses included 
responses to regions conserved between EnvA and EnvB, or cross-
reactive T cells targeting variant EnvA and EnvB epitopes. Heterologous 
vector regimen responses had significantly higher numbers of total, 
EnvA, EnvB and shared epitopes than homologous vector regimen 
responses (p=0.02, 0.044, 0.045, 0.065 respectively).
Conclusion: Combinations of Ad5-EnvA, Ad5-EnvB, and Ad35-EnvA 
appeared safe and immunogenic. Vaccination with heterologous vector-
insert pairs has minimal impact on overall response rates; however, 
heterologous vector regimens increased the total number of targeted 
epitopes. Notably, heterologous insert prime-boosting increased T-cell 
responses to shared epitopes. Increased responses to conserved epitopes 
may translate into better coverage of circulating viruses.
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P04.42 LB
Transcriptional Profiling of RV144 Participants 
Reveals a Gene Expression Signature that 
Correlates with Immunogenicity 
M. Cameron1, A. Sabnis1, F. Lefebvre1, R. Gottardo2, N. Frahm2,  
S. De Rosa2, P. Wilkinson1, N. Michael3, J. Kim3, M. McElrath2,  
and R. Sekaly1
1Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, FL, 
USA; 2Fred Hutchinson Cancer Research Center, Seattle, WA, 
USA; 3US MHRP, Bethesda, MD, USA
Background: The Thai HIV Vaccine Clinical Trial (RV144) showed partial 
protection from infection. Our objective was to define transcriptional 
correlates of immunogenicity in the trial via antigen-specific stimulation 
of participant peripheral blood mononuclear cells (PBMCs).
Methods: We used Illumina HumanHT-12 BeadChips to produce two 
microarray datasets, initially on samples from 40 RV144 vaccinees 
and 10 placebo subjects. PBMCs collected at pre-vaccine, 26wk and 
52wk post-enrollment were stimulated for 15h using 92TH023ENV 
peptide pools or DMSO control. We also arrayed 426 case-control 
study samples from 213 participants after 15h stimulation with ENV 
or DMSO at 26wk post-enrollment. Because our group was blinded to 
case-control status, our bioinformatic analysis was performed on both 
datasets with the purpose of identifying transcriptional profiles that 
correlate with intracellular cytokine staining (ICS) data.
Results: We compared responses to ENV in vaccinees after subtracting 
the DMSO baseline between pre-vaccine and 26wk revealing a 119 
gene signature (P<0.01, <20% False Discovery Rate) that distinguished 
a cluster of vaccinees from placebo subjects. This signature was 
associated with response status upon correlation with ICS data (Fisher’s 
exact test, P<10-5). To validate this signature, we analyzed the case-
control cohort dataset by regressing ICS data with differential gene 
expression (P<0.05, Fold Change>1.3) for stimulated vaccine-recipient 
PBMCs (DMSO background subtracted). Hierarchical clustering of 
the top genes by r2 value that most significantly correlated with ICS 
revealed clusters of putative responding and non-responding subjects. 
Genes highly associated with the ICS data included interferon 
response genes (STAT1, CXCL9/10, SERPING1, TAP1/2, WARS) and 
TNFA (inflammasome) in the case-control dataset.
Conclusion: Our study represents the first functional genomics 
analysis of RV144 trial subject samples and has identified potential 
mechanisms underlying the development of protective immune 
responses in RV144 participants. Funding by NIAID/DAIDS (HVTN) and 
the Henry M. Jackson Foundation.
P04.41 LB
Immunogenicity and Efficacy of a Therapeutic 
HIV-1 Vaccine (HIVAX™) in HIV Patients on 
HAART 
F. Tung1, J.K. Tung1, J. Castro2, H. Boliva2, and M.A. Fischl2
1GeneCure Biotechnologies, Norcross, GA, USA; 2University of 
Miami, School of Medicine, Miami, FL, USA
Background: HIV-1 specific cellular immunity contributes to the control 
of viral replication. In this first-in-human therapeutic vaccination study, 
a replication-defective HIV-1 vaccine was tested in HIV-1 infected 
subjects under antiretroviral 
Methods: A010 is a randomized, placebo-controlled dose-escalation 
trial to evaluate the safety and immunogenicity of two doses of a 
replication defective HIV-1 vaccine (HIVAX™) in subjects receiving 
stable highly active antiretroviral therapy (HAART) who have an HIV-
1 RNA <50 copies/ml and CD4 cell count >500 cells/mm3. Fifteen 
subjects were randomized 2:1 to vaccine or placebo in low dose group. 
Following the randomized 24-week vaccination phase, subjects who 
received active vaccine and who met eligibility underwent a 12-week 
analytical antiretroviral treatment interruption (ATI). Subjects with viral 
load less than 5,000 copies/ml and stable CD4 cell count at week 
36 have option to continue ATI. Cellular immunity was measured 
by ELISPOT assay. Plasma cytokines were monitored during the 
vaccination phase. CD4 cell count and viral load were monitored 
throughout the trial. 
Results: HIVAX™ was well tolerated. Mild injection site reaction with 
transient induration occurred in 9 subjects. High levels of cell-mediated 
immune response, measured by ELISPOT assay, were observed in 
all subjects receiving HIVAX. Subjects receiving placebo have low 
background of ELISPOT responses. Surprisingly, pro-inflammatory 
cytokines (IL-6, IL-1β, TNFα, LTα, IL-4, IL-8, IL-15) were all significantly 
reduced in vaccine recipients compared to pre-vaccination level. The 
median viral load set point (2,841 copies/ml) was significantly lower 
in subjects following a 12-week ATI as compared to previous placebo 
set point level (40,000 copies/ml). Two subjects who continue ATI for 
over 10 months still maintain low viral load and stable CD4 cell count. 
Conclusion: HIVAX™ vaccine is safe and highly immunogenic in these 
HIV-1 infected subjects. HIVAX™ was effective in controlling viral load 
during ATI warranting further evaluation of protective efficacy by this 
therapeutic vaccine. 
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P04.44 LB
A Phase I/II Trial of Preventive HIV Vaccination 
with DNA and Poxviral-Vector in Healthy 
Subjects EV03/ANRS VAC20: Cytokine 
Production by T Cells
C. Lacabaratz1, A. Wiedemann1, C. Boucherie2, L. Richert2,  
A. Babiker3, A. Harari4, P. Bart4, J. Weber5, S. McCormack3,  
H. Wolf6, G. Chêne2, R. Thiébaut2, G. Pantaléo4, and Y. Lévy7
1INSERM U955, Créteil, France; 2INSERM U897, Clinical Trials 
Unit, Bordeaux, France; 3MRC, Clinical Trials Unit, London, 
UK; 4Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland; 5Imperial College, St Mary’s Hospital, London, 
UK; 6University of Regensburg, Regensburg, Germany; 7Centre 
Hospitalier Universitaire Henri Mondor, Créteil, France
Background: The EV03/ANRS Vac20 phase I/II trial investigated the 
optimal prime/boost strategy using DNA/NYVAC combination, both 
expressing HIV-1 clade C Env and Gag/Pol/Nef. 147 healthy volunteers 
were randomized in 8 European centres to 3 DNA/1 NYVAC (weeks 
0/4/8/24; group 1) or 2 DNA/2 NYVAC (weeks 0/4/20/24; group 
2). At week 26 and/or 28, T cell responses (IFNγ Elispot assay) were 
present in 91% and 80% of volunteers in group 1 and 2, respectively 
(P=0.053). The magnitude of responses was higher in group 1 than in 
group 2 (P<0.001).
Methods: Functionality of T cell responses was assessed using ICS 
assay performed at week 26/28 in responders to Env plus at least to 
one of the Gag/Pol/Nef pools. Cells were stimulated 6h with the same 
pools used for IFNγ Elispot in the presence of anti-CD28 antibody and 
BFA, and stained with mAb CD3/CD4/CD8/IL2/IFNγ/TNFα. Responses 
were defined as % cytokine+ in CD4+ or CD8+ T cells > 0.03% and 
3 fold background.
Results: Among 66 Elispot responders (n=43 group 1, n=23 group 
2), the frequency of CD4+ T cell responders to at least one HIV pool 
was 68%. The magnitude of CD4+ T cell responses (median [IQR]) was 
0.62% [0.55-0.86] without difference between groups. The majority 
of CD4+ T cell responses were directed against Env (72% and 56% 
in groups 1 and 2, respectively) while only 9% were directed to Gag/
Pol/Nef. 38% of vaccinees were CD8+ T cell responders and the 
magnitude (median [IQR]) was 0.50% [0.40-0.72] without difference 
between groups. In each group, 28-30% of vaccinees responded to 
Env and 13-16% to Gag/Pol/Nef. Among HIV-specific CD4+ and CD8+ 
T cells, 33% and 17% produced at least 2 cytokines, respectively.
Conclusion: DNA/NYVAC combination elicits both polyfunctional 
CD4+ and CD8+ T cell responses with a majority of CD4+ T cells 
directed against Env protein. 
P04.43 LB
A Late Third HIV-MVA Vaccination Boosted 
Strong and Potent Immune Responses in 
Tanzanian Volunteers Previously Immunized 
with HIV-DNA and HIV-MVA
A. Joachim1, P. Munseri1, C. Nilsson2, M. Bakari3, S. Aboud3,  
E.F. Lyamuya3, C. Moshiro3, M. Robb4, M. Marovich4, P. Earl5,  
B. Moss5, D. Buma6, M. Janabi6, B. Wahren7, F. Mhalu6, G. Ferrari8, 
E. Sandstrom7, and G. Biberfeld3
1Muhimbili University of Health and Allied Sciences and 
Karolinska Institute, Stockholm, Sweden, Dar es Salaam, 
United Republic of Tanzania; 2Karolinska Institutet and Swedish 
Institute for Communicable Disease Solna, Stockholm, Sweden; 
3Muhimbili University of Health and Allied Sciences, Dar 
es Salaam, United Republic of Tanzania; 4US MHRP, Silver 
Spring, MD, USA; 5NIAID, NIH, Bethesda, MD, USA; 6Muhimbili 
National Hospital, Dar es Salaam, United Republic of Tanzania; 
7Karolinska Institutet, Stockholm, Sweden; 8Duke University 
Medical Center, Durham, NC, USA 
Background: A successful vaccine against HIV requires effective and 
long-lasting cellular and humoral immune responses. We explored 
the duration of immune responses and the effect of a third HIV-
modified vaccinia Ankara (MVA) boost in HIV-DNA and HIV-MVA 
Tanzanian vaccinees. 
Methods: Twenty healthy volunteers previously primed with HIV-
DNA plasmids encoding HIV-1 subtypes A, B, and C at months 0, 1 
and 3 and boosted with HIV-MVA expressing CRF01_AE at months 
9 and 21 were given a third HIV-MVA boost three years after the 2nd 
HIV-MVA. Samples were tested before and at 2-4 weeks post the 3rd 
HIV-MVA boost. Cellular responses were assessed using IFN-γ ELISpot 
and lymphoproliferation assay(LPA). Binding antibodies to gp140 
were tested by enzyme-linked immunosorbent assay. Antibody-
dependent cellular cytotoxicity (ADCC) antibodies were tested using 
HIV-1 recombinant gp120-coated and infected cells. Anti-vaccinia 
neutralizing antibodies were determined by plaque reduction of 
vaccinia strain-Elstree. 
Results: At the time of the 3rd HIV-MVA, three years after the 2nd HIV-
MVA, 15/19 (79%) vaccinees had IFN-γ ELISpot responses, 11 (58%) 
to Gag and 6 (32%) to Env. Two weeks after the 3rd HIV-MVA, 19/20 
(95%) vaccinees had IFN-γ ELISpot responses, 17 (85%) to Gag and 
16 (80%) to Env whereas 15/16 (94%) had positive LPA response. The 
anti-gp140 subtype C antibody titers were significantly higher after the 
third HIV-MVA p=0.001. ADCC responses to subtype-E gp120-coated 
cells were detected in 16/19 (84%) vaccinees before and in 18/19 
(95%) after the 3rd HIV-MVA where 14/20 (70%) vaccinees had ADCC 
activity to CM235 infected cells. Anti-vaccinia neutralizing antibodies 
were detected in all vaccinees before the 3rd HIV-MVA. 
Conclusion: Anti-HIV immune responses were still detectable three 
years after the second HIV-MVA immunization. Despite pre-existing 
immunity to vaccinia, a late third HIV-MVA vaccination boosted 
strong and potent anti-HIV cellular and humoral immune responses in 
previously HIV-DNA and HIV-MVA immunized volunteers. 
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P04.46 LB
Targeting HIV Env gp140 to LOX-1 in 
Combination with Replication Competent 
NYVAC-C Elicits Humoral and Cellular 
Responses in Rhesus Macaques
Y. Lévy1, S. Zurawski2, C. Lacabaratz1, A. Flamar2, C. Peltekian1,  
A. Salazar3, S. Reed4, G. Pantaléo5, and G. Zurawski2
1INSERM U955, Université Paris-Est, Centre Hospitalier 
Universitaire Henri Mondor, Créteil, France; 2Baylor Institute 
for Immunology Research, INSERM U899, Dallas, TX, 
USA; 3Oncovir, Washington, WA, USA; 4Infectious Disease 
Research Institute, Washington, WA, USA; 5Centre Hospitalier 
Universitaire Vaudois, Lausanne, France
Background: Protective immunity against HIV will likely require 
vaccination with a combination of a viral or DNA vector with HIV 
Env protein plus adjuvant. To this end, we have developed as a 
candidate protein component αLOX-1.HIV Env gp140, a dendritic cell 
(DC)-targeting vaccine bearing gp140 from clade C ZM96 fused to a 
humanized αLOX-1 monoclonal antibody.
Methods: Non-human primates (NHP), either naïve (4 per group) or 
primed twice (wk0, 4) (6 per group) with NYVAC-KC viruses encoding 
CN54 Gag, Nef, Pol and ZM96 Env gp140 sequences, were injected 
three times (wk12, 16, 20) intradermally with 250 micrograms of 
αLOX-1.HIV Env gp140 plus 1 milligram poly ICLC (Hiltonol) or 20 
micrograms of GLA as adjuvant. ELISA was used to assay Env-specific 
antibody responses, while IFNγ ELISPOT was used to detect Env-
specific T cell responses.
Results: In the naïve NHP groups, anti-Env IgG titers were elicited 
to maximal levels at 2 weeks after the third vaccination and were 
significantly more robust with poly ICLC (-log EC50 2.33) vs. GLA 
(-log EC50 6.42) adjuvant. Env-specific T cell responses were maximal 
(~400 spots per 106 cells) at 2 weeks after the second vaccination 
and were only observed with poly ICLC adjuvant. In the NYVAC-C-
primed groups, anti-Env IgG titers were maximal (-log EC50 2.3-3.13) 
2 weeks after the first αLOX-1.HIV Env gp140 vaccination and were 
similar with both adjuvants. However, Env-specific T cell responses 
were more robust (200-300 spots per 106 cells) in the poly ICLC group. 
Overall, the DC-targeting vaccines elicited both CD4+ and CD8+ T cell 
responses against multiple ENV epitopes, and especially for the CD4+ 
T cell responses, the quality was high.
Conclusion: Thus, αLOX-1.HIV Env gp140 plus poly ICLC is a 
promising protein and adjuvant combination for eliciting potentially 
protective Env-specific antibody and T cell responses in both priming 
and boost settings.
P04.45 LB
A Mixed-Methods Assessment of Understanding 
(AoU) Tool for HIV Vaccine Trials: Results from a 
Comparative Study in South Africa and Uganda
S. Welsh6, G. Lindegger1, M. Quayle1, D. Mark2, M. Wallace3,  
L. Bekker3, S. Roux3, U. Bahemuka4, E. Ruzagira4, T. Mebrahtu5,  
P. Fast6, F. Priddy6, S. Singh7, J. Mbogua6, P. Bahati6, and  
B. Bender6
1University of KwaZulu-Natal, Pietermaritzburg, South Africa; 
2University of Cape Town, Cape Town, South Africa; 3Desmond 
Tutu HIV Foundation, Cape Town, South Africa; 4MRC/
UVRI Uganda Research Unit on AIDS, Masaka, Uganda; 5US 
MHRP, Bethesda, MD, USA; 6IAVI, New York, NY, USA; 7GHAR 
Consulting Inc., New York, NY, USA
Background: Closed-ended methods, such as true/false tests, 
for assessment of understanding (AoU) may not measure true 
understanding of important trial concepts. For HIV vaccine trials, 
complex concepts require more comprehensive assessment methods. 
Methods: Eighty men and women were enrolled at two clinical 
research centers in South Africa and Uganda, which were recruiting 
for phase I HIV vaccine trials. A within-subjects, repeated measures 
design was used. Consenting volunteers were given three AoUs with 
different formats: a true/false test, a narrative, and a mixed-method 
approach using true/false questions and scenarios. Performance was 
compared using correlations and repeated-measure t-tests, and inter-
rater reliability analysis. Interviews were recorded and transcribed. 
Volunteer feedback on the AoUs was collected with a questionnaire. 
Focus groups with study staff investigated experiences implementing 
the different formats. AoU transcripts were scored by multiple raters 
using standardized criteria.
Results: The true/false and the narrative scores differed significantly, 
as did the true/false and scenario scores. Narrative and scenario scores 
were well correlated. The true/false test appeared to overestimate 
understanding, compared to the qualitative measures. Inter-rater 
reliability scores showed a significant variance. Results from the 
volunteer questionnaires and staff focus groups showed that the 
scenario format was preferred because of volunteer comfort level and 
increased dialogue about the trial between volunteers and staff. 
Conclusion: The results suggest that qualitative methods may be 
better suited to assessing volunteer understanding in clinical trial 
settings, particularly for concepts that are considered essential 
for genuine informed consent. Given that the inter-rater reliability 
showed significant differences in how scorers were evaluating the AoU 
responses, it seems prudent to incorporate more training for individuals 
who administer and score AoUs in order to increase consistency. An 
AoU toolkit is being developed that will incorporate findings from this 
study and additional experience using the tool in recent HIV vaccine 
clinical trials.
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P05.02 D
Mechanism of HIV Entry into the Columnar 
Epithelium of the Female Genital Tract
A. Carias1, M. Anderson1, and T. Hope1
1Northwestern University, Chicago, IL, USA
Background: During male-to-female transmission HIV must bypass 
the mucosal epithelium of the female reproductive tract and gain 
access to underlying target cells.  Previously, we illustrated that HIV 
is able to penetrate intact columnar and squamous genital epithelia 
in both ex vivo and in vivo systems.  Furthermore, we also previously 
illustrated that virus enters the squamous epithelium in a diffusion-
based mechanism.  By utilizing a similar series of approaches, we 
illustrate endocytosis as a possible mechanism of HIV entry into the 
simple columnar epithelium of the endocervix.
Methods: Human cervical explants were exposed to V-ATPase 
inhibitor Bafilomycin A1 (BafA1) and cell-free PA-GFP HIV of various 
tropisms.  Control samples were incubated with virus in the absence 
of BafA1 treatment. Following, samples were removed, snap frozen, 
sectioned, stained and imaged accordingly through deconvolution 
fluorescent microscopy. Comparison of the image z-stacks pre and 
post-photoactivation revealed viral signal, accounting for background. 
Results: In our human ex vivo control samples, PA-GFP HIV was 
found to enter the simple columnar epithelium of the endocervix to 
depths up to 50 microns.  We also confirmed that virions penetrated 
to depths were target cells reside.   In contrast, BafA1 treated 
samples, independent of viral tropism, had a smaller number of 
penetrating virions.  Likewise, deep penetrators (>20 microns) were 
rarely observed with the majority of virions seen within the simple 
columnar barrier itself.
Conclusion: Overall, our control samples confirmed PA-GFP HIV is able 
to penetrate the intact columnar epithelium, to depths of 50 microns, 
thereby gaining access to underlying target cells. In contrast, virions 
in BafA1 treated samples were less likely to be observed past the 
columnar barrier, within the lamina propria.  In BafA1 treated samples, 
a trend in the decrease of the number of penetrating virions was 
also noted.  Collectively, this data may suggest a transcytosis-based 
mechanism for HIV-1 entry into the endocervical columnar barrier.
P05.01 D
Rapid Detection of Early HIV-1 Infections by 
Direct Sequencing of a Hypervariable Segment 
of the Viral Env Gene
G. Damilano1, E. Socias2, C. Magneres2, G. Turk1, O. Sued2, J. Ruiz1, 
M. Gomez-Carrillo1, H. Salomon1, and D. Dilernia3
1Institute for Biomedical Research on Retroviruses and AIDS, 
Buenos Aires, Argentina; 2HUESPED Fundation, Buenos Aires, 
Argentina; 3Emory Vaccine Center, Atlanta, GA, USA
Background: In the 75% of HIV transmission events, only one viral 
variant establishes the infection.To know this specific variant allows 
performing studies to increase our understanding of transmission. 
Clinical data analysis can identify patients with evidence of recent 
infection but are unable to define whether a high degree of viral 
diversification have already occurred. Here, we propose that direct 
sequencing of a short hypervariable segment of env allows rapid 
identification of newly infected patients with very early infection times.
Methods: We studied 44 newly diagnosed individuals with clinical 
evidence of infection time (30-270 days). Blood samples were collected 
and the viral RNA was extracted from plasma with QIAamp Viral RNA 
Kit. An hypervariable segment of the env gene (nt. 6858 to 6883 of 
HXB2) was amplified by nested RT-PCR and sequenced with “Big Die 
terminator Kit” and ABI Prism 3100 sequencer. Chromatograms were 
analyzed with Sequencher 4.10.
Results: From the analysis of the sequences of the segment we found 
that the number of ambiguities present in the sequences increased with 
the number of days estimated post-infection. The average number of 
ambiguities was 0.125 in patients with less than 60 days of infection, 
3.71 for 90 days, 13.6 for 120 days, 17.33 for 150 days and largely 
superior than 17.3 for 270 days post-infection. In addition, in a set of 
5 patients we observed that the intra-host diversity of the gag gene 
(assessed by cloning and sequencing of the quasiespcies) was also 
correlated with the number of ambiguities in the env segment. 
Conclusion: We show that it is possible to rapidly identify patients 
where the founder virus might still be present by sequencing of an 
hypervariable region of the env gene, which provides an accurate 
correlate with the infection time estimated from clinical and 
serological data.
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P05.04 D
The V1V2 Domain Preserves Envelope 
Functionality During Free Virus Transmission 
but Is Largely Dispensable for Cell-Cell 
Transmission
O.F. Brandenberg1, P. Rusert1, C. Magnus1, J. Weber1, R.R. Regoes2, 
and A. Trkola1
1University of Zurich, Zurich, Switzerland; 2ETH Zurich, Zurich, 
Switzerland
Background: The variable loop 1 and 2 (V1V2) domain of the HIV-1 
envelope glycoprotein gp120 has a dualistic role in the envelope’s 
functionality. Its high variability allows tailored shielding against 
evolving neutralizing antibodies (nAbs) rendering it the key regulator 
of neutralization escape. Yet, V1V2 has been indicated to play also an 
important role in conserving entry functionality of the envelope trimer, 
largely attributed towards its influence on trimer stability. Here, we 
aimed to precisely dissect the steps in the HIV-1 entry process steered 
by the V1V2 domain during both free-virus and cell-cell transmission.
Methods: We generated 12 subtype B and C HIV-1 envelope mutants 
with V1V2-deletion or specific point mutations, including mutants of 
the glycosylation site at position 160, and compared wt and mutant 
envs for entry fitness and nAb shielding capacity during free-virus and 
cell-cell transmission. 
Results: We found that key point mutations or deletion of V1V2 
strongly reduced free-virus but not cell-cell transmission. By long-term 
passaging of a replication-competent V1V2-deleted strain we derived 
a series of envelope mutants that allowed a detailed characterization 
of the adaptation strategy HIV chooses to overcome loss of V1V2. We 
found that V1V2 steers trimer stability, virus entry kinetics and the 
number of trimers required for entry into target cells. Of note, shielding 
from nAbs is compromised during both free-virus entry and cell-cell 
transmission if V1V2 integrity is lost. 
Conclusion: Our results underline the role of V1V2 as a major regulator 
of the HIV-1 entry process during free-virus transmission. The fact that 
cell-cell transmission is less affected by changes in V1V2 highlights a 
further possible survival route of the virus. V1V2 mutations required 
for neutralization escape that render the virus less fit for free-virus 
transmission may replicate strictly in a cell-cell transmission manner 
until compensation mutations emerge which ensure both neutralization 
escape and entry fitness.
P05.03 D
Impact of Host Cell-Specific Glycosylation 
Differences on SIV Infectivity and Mucosal 
Transmission
C.B. Karsten1, F.F. Buettner2, I. Nehlmeier1, U. Sauermann1,  
B. Neumann1, C. Stahl-Hennig1, R. Gerardy-Schahn2, and  
S. Pöhlmann1
1German Primate Center, Göttingen, Germany; 2Institute for 
Cellular Chemistry, Hannover Medical School, Hannover, Germany 
Background: The dense glycosylation of the human immunodeficiency 
virus (HIV) envelope protein (Env) shields potential epitopes from 
neutralizing antibodies. Furthermore, the interaction of Env glycans 
with immune cell lectins can enhance viral transmission to target cells. 
The major viral target cells, macrophages and T cells, glycosylate Env 
differentially, but the consequences of these glycosylation differences 
for HIV biology are unknown. We seek to identify host cell specific 
Env glycosylation differences on a molecular level and to elucidate 
their impact on infectivity and transmission in vivo using the simian 
immunodeficiency virus (SIV)/rhesus macaque model.
Methods: SIVmac239/316ENV produced in primary rhesus 
macrophages (M-SIV), primary rhesus CD4+ T cells (T-SIV), HEK293 
(293-SIV) and 293S GnTI -/- cells (GNTI-SIV) was characterized 
for glycan composition by EndoH and PNGaseF digest and virion 
incorporation of gp120. Viral infectivity and interactions with dendritic 
cell lectins were analyzed in standard assays. Mucosal transmission 
was determined by rectal challenge of rhesus macaques (n=3/virus).
Results: Western blot analysis revealed that M-SIV and T-SIV 
incorporated similar amounts of Env. Nevertheless, T-SIV Env contained 
more oligomannose glycans and the virus was less infectious in vitro 
than M-SIV, indicating that oligomannose glycans might negatively 
impact infectivity. Similarly, GNTI-SIV, which bears exclusively 
oligomannose glycans, was markedly reduced in infectivity relative 
to 293-SIV. However, decreased Env incorporation of GNTI-SIV and 
not differential glycosylation might explain this phenotype. M-SIV was 
better transmitted by dendritic cell lectins than T-SIV suggesting that 
specific glycan motifs might be more important for lectin interactions 
than high amounts of oligomannose. We are currently investigating 
whether differential lectin interactions result in differential mucosal 
transmission of SIV in rhesus macaques. The results of these studies 
will be presented. 
Conclusion: We show that host cell specific glycosylation differences 
impact SIV infectivity and transmission by lectins. Mass spectrometry 
must reveal the position and nature of the responsible glycans.
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P05.06
Incidence of HIV-1 Superinfection Is Similar to 
Primary HIV-1 Incidence in a Cohort of Female 
Sex Workers in Uganda
A.D. Redd1, D. Ssemwanga2, S.K. Wendel1, N. Ndembi3,  
J. Vandepitte2, H. Grosskurth4, C.M.  Parry2, C. Martens5,  
D. Bruno5, S.F. Porcella5, T.C. Quinn1, and P. Kaleebu2
1NIAID, NIH, Baltimore, MD, USA; 2MRC/UVRI Uganda 
Research Unit on AIDS, Entebbe, Uganda; 3Institute of 
Human Virology, Abuja, Nigeria; 4London School of Hygiene 
and Tropical Medicine, London, UK; 5Rocky Mountain 
Laboratories, NIAID, NIH, Hamilton, MT, USA
Background: Understanding the host, viral and immunological 
correlates of HIV-1 superinfection are crucial for vaccine design and 
development. Several studies have shown varying incidence rates of 
superinfection among different risk behavior populations. We report 
on the incidence of HIV-1 superinfection in a cohort of female sex 
workers in Kampala, Uganda.
Methods: In 2008, the Good Health for Women Project (GHWP) 
recruited a cohort of 1027 women involved in commercial sex work in 
Kampala, Uganda. The baseline HIV-1 prevalence was 37% and HIV 
incidence rate in the first 3 years was 3.7/100-person years. A validated 
next-generation sequencing technique was used to determine the rate 
of HIV superinfection by examining two regions of the viral genome 
(p24 and gp41) in two longitudinal samples from women who entered 
the cohort as HIV prevalent cases (n=125).
Results: 70% (88/125) of the women screened had amplifiable 
sequences from at least one genomic region for both time-points 
analyzed (204.2 total person years). The samples amplified well with 
good sequence coverage for time-point 1 (mean of total sequence 
reads for p24=8901, gp41=9606) and time-point 2 (p24=12625, 
gp41=8301). Seven cases of superinfection and eight cases of women 
initially diagnosed with dual HIV-1 infection were identified. The rate 
of superinfection in this population was calculated to be 3.4/100 
person years.  Together with the dual infections, 17% of the women 
in the cohort experienced infection with multiple strains of HIV during 
the study. The rate of superinfection was more than double the rate 
observed in a lower-risk rural general population in Uganda (IRR=2.4 
95% CI=0.7-7.9; p=0.06).
Conclusion: The rate of superinfection was highly similar to the 
primary HIV incidence rate in this high-risk population, which agrees 
with previous data from a lower-risk general rural population. The high 
rate of superinfection is most likely a reflection of continued risky 
behavior in this population.
P05.05
Genetic Characteristics of HIV-1 Env in 
the Genital Tract of African Heterosexual 
Transmission Pairs
M.S. Campbell1, A.L. Lam1, R. Payant2, H. Zhao1, C. Williams2,  
H. Huang2, J.I. Mullins1, A. Wald3, W. Stevens4, G. Gray5,  
C. Farquhar1, H. Rees5, C. Celum1, L.M. Frenkel6, and  
J.R. Lingappa1
1University of Washington, Seattle, WA, USA; 2Seattle 
Children’s Research Institute, Seattle, WA, USA; 3University 
of Washington and Fred Hutchinson Cancer Research Center, 
Seattle, WA, USA; 4University of the Witwatersrand and 
Contract Laboratory Services, Johannesburg, South Africa; 
5University of the Witwatersrand, Johannesburg, South 
Africa; 6Seattle Children’s Research Institute and University of 
Washington, Seattle, WA, USA 
Background: A better understanding of characteristics that define 
mucosally-transmitted HIV-1 may inform vaccine design.  Commonly, 
a single CCR5-tropic virus establishes infection. In cross-sectional 
studies, histidine in Env leader peptide position 12 (His-12) is more 
frequent in blood-derived subtype B viruses from early compared to 
chronic infection, but few data exist for non-clade B or genital tract-
derived viruses.
Methods: Full-length HIV-1 env was sequenced from multiple viral 
templates in seminal plasma and endocervical swabs from 9 African 
male-to-female transmission pairs in the Partners in Prevention HSV/
HIV Transmission Study.  Viral genetic diversity, chemokine co-receptor 
usage, and Env position 12 residues were evaluated.
Results: A mean of 14 sequences (SD = 6) was obtained from each 
participant. Couples were infected with HIV-1 subtypes A or A1/C 
(N=4), C (N=3), and D (N=2).  Seroconverters had less variable 
sequences compared to transmitters (pairwise genetic distance 0.5% 
versus 1.4%, Student’s t-test p = 0.007).  Within transmission pairs, 
mean pairwise distance between the most closely related sequences 
was 1.3% (SD = 0.7%).  Viruses were predicted to be CCR5-tropic, 
except in one transmitter with 7/16 CXCR4-tropic viruses. At Env 
position 12, 17 participants had homogenous viral templates, 
encoding glutamine (N = 8), asparagine (N = 3), histidine (N = 4), 
and arginine (N = 2). Partners in these transmitting couples shared 
Env position 12, with the exception of one couple with asparagine in 
15/15 seroconverter and 17/19 transmitter sequences, and aspartate 
in 2/19 transmitter sequences.
Conclusion: Genital tract viruses within African male-to-female HIV-
1 transmission pairs show evidence of a genetic bottleneck and 
predominant CCR5 co-receptor usage.  In this small study, multiple 
variants were rarely observed at Env position 12 in transmitters and 
His-12 was not found with increased frequency in seroconverters. 
Further studies are underway to determine the significance of Env 
position 12 in transmission of non-clade B viruses.
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P05.08
Transmission and Ultradeep Sequence 
Evolution of CXCR4 Using HIV-1 in an 
Individual Homozygous for the CCR5 Delta-32 
Mutation
A. Le2, R. McGovern1, J. Taylor1, R. Danroth2, C.J. Brumme1,  
T. Kerr1, M. Milloy1, P.R. Harrigan1, A.F. Poon1, and Z. Brumme2
1British Columbia Centre for Excellence in HIV/AIDS, Vancouver, 
Canada; 2Simon Fraser University, Burnaby, Canada
Background: Following an explosive mid-1990s HIV-1 outbreak, the 
incidence of X4 infections among Vancouver injection drug users was 
13%, one-half of which mapped to a single phylogenetic cluster. Within 
this cluster, we identified a putative case of X4-HIV transmission from 
a CCR5wt/wt donor to a CCR5Δ32/Δ32 recipient, and characterized 
this rare event using deep-sequencing.
Methods: Phylogenetic relatedness of donor and recipient HIV was 
confirmed by bulk sequencing of plasma RNA gag, pol, nef and 
env-V3.  Host CCR5 genotyping was performed using sequence-based 
methods. The donor’s estimated infection date was Mar/00; plasma/
PBMC were available 10, 16 and 50 months thereafter.  The estimated 
transmission event occurred Aug/01; recipient plasma/PBMC were 
available 5, 6 and 12 months thereafter. Env-V3 from plasma-RNA and 
PBMC-DNA were triplicate amplified, pooled and deep-sequenced. 
Results: V3 deep-sequencing suggested transmission of a minimum of 
two highly related variants in both donor and recipient. Exact matches 
for the recipient’s two predominant variants were not observed in 
donor plasma at any timepoint; instead, one matched a minority 
(0.04%) PBMC variant 8 months earlier. Whereas the CCR5wt/wt 
donor exhibited rapid progression (Log10pVL>5.1 copies/ml and 
CD4=20 cells/mm3 within 1.5 years of infection), the CCR5Δ32/Δ32 
recipient’s CD4 counts remained >400 cells/mm3 for two years with 
Log10pVL~4.2. Whereas the donor’s coreceptor genotype evolved 
towards increased CCR5 usage in the first year (X4 prevalence from 
100% to 52% by the time of transmission), the recipient’s HIV 
evolution appeared constrained and remained consistently X4. Within 
one year, the recipient’s dominant virus population was replaced with 
a single V3 R25K variant, with novel X4 minority variants exhibiting 
positively-charged residues at codon 24 and others, also emerging. 
Conclusion: Results highlight HIV’s extensive capacity for host 
adaptation.  Discordant clinical progression in the donor vs. recipient 
despite infection with a highly similar virus underscore the influence of 
host genetics on HIV pathogenesis.
P05.07
Phenotypic and Functional Characterization of 
CD4+ T Cells in the Foreskin
A. Ssemaganda1, J.L. Prodger2, A. Ssetaala1, A. Nanvubya1,  
M. Wambuzi1, P. Kato1, J. Mpendo1, L.E. Nielsen3, N. Kiwanuka4, 
and R. Kaul2
1UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda; 
2University of Toronto, Toronto, Canada; 3IAVI, New York, NY, 
USA; 4Makerere University College of Health Sciences, School 
of Public Health, Kampala, Uganda
Background: Male circumcision is known to reduce HIV incidence 
by ~60% in heterosexual men from Sub-Saharan Africa. Therefore, a 
better understanding of the immune correlates of HIV acquisition in the 
foreskin is needed to design additional male-focused HIV prevention 
strategies. We characterized putative HIV target cells in the foreskin 
using multi-parameter flow cytometry. 
Methods: We collected foreskin tissue and blood from 34 HIV-
uninfected Ugandan men. Foreskin T cells were isolated using 
previously described mechanical and enzymatic digestion. Phenotyping 
was performed using the following antibodies: CD3, CD4, CCR5, CD69, 
HLA-DR, CD38, CCR6, IL17a, IL22, IFNγ, α4, β7, and CLA.
Results: The phenotype of CD4+ T cell subsets differed between blood 
and foreskin. As previously described, foreskin CD4+ T cells expressed 
much more CCR5, CD69 and HLA-DR than blood cells (p<0.0001). 
Th1, Th17, and Th22 cells from the blood all expressed higher levels of 
CCR5 than did bulk CD4 T cells, with highest expression on Th17 cells 
(CCR6+/IL17a+). In the foreskin, CCR5 expression was greatest on Th1 
cells (p=0.003), elevated to a lesser extent on Th17 cells (p=0.001), 
and decreased on Th22 cells (p=0.008) compared to bulk CD4 T 
cells.  Foreskin CD4 T cells were more polyfunctional than blood, with 
a higher proportion of cells producing ≥2 cytokines. Foreskin CD4+ 
T cells expressed low levels of α4β7 compared to blood (1.68% vs. 
6.93%, p<0.0001), but very high levels of the skin homing marker 
CLA (59.0% vs. 18.45%, p<0.0001).
Conclusion: The phenotype of functional CD4+ T cell subsets differs 
substantially between the blood and foreskin, with implications 
for HIV susceptibility. Homing marker expression in the foreskin is 
more characteristic of skin than mucosal-homing T cells. Further 
characterization of foreskin T cells may assist the development of 
better HIV prevention tools.
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P05.10
Human Leukocyte Antigen Class I (HLA-I) 
Adapted Epitopes Can Induce Functional 
Primary CD8+ T Cell Responses During Acute 
HIV-1 Infection
V.Y. Du1, A. Bansal1, J. Carlson2, J. Salazar-Gonzalez1,  
M. Schaefer3, W. Kilembe3, J. Sidney4, S.L. Heath1, E. Hunter3, 
and P.A. Goepfert1
1University of Alabama at Birmingham, Birmingham, AL, USA; 
2Microsoft Research, Los Angeles, CA, USA; 3Emory University, 
Atlanta, GA, USA; 4La Jolla Institute for Allergy & Immunology, 
La Jolla, CA, USA
Background: HIV CD8+ T cell escape mutations can be predicted 
based on the human leukocyte antigen class I (HLA-I) allele of the 
infected individual, whereby the epitope adapts to HLA-restricted 
pressure.  Although these adapted epitopes may still be able to induce 
CD8+ T cell responses, the extent to which this occurs has not been 
accurately assessed. 
Methods: We derived the transmitted founder virus (TFV) from 13 
clade B HIV acutely infected patients.  This strategy allowed us to 
differentiate primary vs. cross-reactive responses, which is not possible 
when studying chronic patients.  Using IFN- γ ELISPOT assay, we 
compared the ability of TFV-encoded adapted or non-adapted epitopes 
to induce primary CD8+ T cell responses. 
Results: Non-adapted epitopes were more likely to elicit a primary 
response (p=0.046).  Similarly, individuals with more non-adapted 
epitopes encoded by their TFV had a greater breadth of primary 
responses (p=0.028).  Furthermore, in a cross-sectional study of a 
larger cohort of Zambian patients with acute clade C HIV infection, 
those with TFV encoding fewer adapted epitopes had lower set point 
viral loads (p=0.007).  Thus, protective CD8+ T cell responses may 
be maintained in an individual who’s TFV contains more non-adapted 
epitopes.  Although responses to adapted epitopes were seen less 
frequently, they shared similar magnitude, functional avidity, and 
polyfunctionality compared to those elicited to the non-adapted 
counterparts.  Interestingly, the few adapted epitopes that elicited 
a response were predicted to exhibit higher HLA binding affinity 
compared to the non-responsive ones (p<0.0001).  Testing these non-
responsive adapted epitopes in a larger cohort of chronic patients 
confirmed the lack of specific HLA-restricted responses.  
Conclusion: Therefore, while some adapted epitopes induced 
primary CD8+ T cell responses that were indistinguishable from their 
non-adapted counterparts, the majority did not elicit any response. 
These results have important implications for T cell-based HIV 
vaccine strategies.
P05.09
Evidence of Selection During HIV-1 Transmission 
in Heterosexual Couples in Zambia
D.C. Mónaco1, J. Carlson2, M. Schaeffer1, D. Claiborne1, J. Prince1, 
D. Dilernia1, K. Denis1, W. Kilembe3, S. Lakhi3, J. Tang4, P. Farmer1, 
R. Kaslow4, S. Allen5, P. Goepfert4, D. Heckerman2, and E. Hunter1
1Emory Vaccine Center, Atlanta, GA, USA; 2Microsoft Research, 
Redmond, WA, USA; 3Zambia Emory HIV Research Project, 
Lusaka, Zambia; 4University of Alabama at Birmingham, 
Birmingham, AL, USA; 5Emory University, Atlanta, GA, USA
Background: HIV infection occurs by the transmission of one or a few 
of the variants present in the donor. This process is poorly understood 
and it is not known if this transmission bottleneck is mediated by an 
active selection process or is the consequence of a random event.
Methods: In a group of 169 epidemiologically-linked transmission 
pairs from a Zambian cohort, we studied the frequency and dynamics 
of HIV polymorphisms in Gag, Pol and Nef. The frequency of each 
residue (based on 350 chronically-infected patients) was correlated 
with the rate of transmission in the transmission pairs.
Results: Gag, Pol and Nef proteins of transmitting partners had a large 
number of non-consensus amino acid polymorphisms (medians of 
36, 41 and 24, respectively) and the majority of them (80%) were 
transmitted to the epidemiologically-linked partner. Overall, the odd 
of transmission was significantly correlated with the polymorphism 
frequency in the cohort, with residues present in 95% of donors 
transmitting with 99% frequency vs 87% transmission frequency for 
rare polymorphisms. A similar bias was observed at positions where 
there was a mixture of polymorphism and consensus residues, with 
polymorphisms being transmitted at a significantly lower frequency 
than predicted (43% vs 50%; p<10-10). Polymorphisms were 1.6x 
more likely to be transmitted from male-to-female than from female-
to-male (p=4x10-11) and, in the female-to-male transmission pairs, 
we identified 9 positions among Gag, Pol and Nef where the rate 
of transmission was significantly different than expected from the 
frequency of the residues (p<0.005;q<0.2).
Conclusion: While a majority of Gag, Pol and Nef polymorphisms 
are transmitted, there is a dose dependent relationship between 
cohort prevalence of a residue and odds of transmission. Moreover, 
female-to-male transmission results in higher negative selection 
on polymorphisms. These observations argue in favor of a selective 
transmission process that favors certain residues.
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P05.12
Cryptic Determinant of α4β7 Binding in the V2 
Loop of HIV-1
B. Tassaneetrithep1, D. Tivon2, J. Swetnam2, J.H. Kim1,  
N.L. Michael1, M.A. Marovich1, and T. Cardozo2
1U.S. MHRP, Silver Spring, MD, USA; 2New York University 
School of Medicine, New York, NY, USA
Background: The peptide segment spanning positions 166-181 of the 
V2 loop of HIV-1 has been found to harbor two functionally important 
sites.  The first, spanning positions 179-181, binds the human α4β7 
integrin receptor that plays a role in dissemination of infecting HIV-
1 virions to gut-associated lymphoid tissue (GALT).  The second, at 
positions 166-178, is the target of anti-V2 antibodies elicited by the 
vaccines used in the RV144 clinical trial.  Here, we present evidence 
that this second site affects the functionality of the first site.   
Methods: We generated short V2 peptides mimicking the A244/
TH023 and MN strains of HIV-1, the immunogens tested in the RV144 
trial, and measured the interaction of these peptides with the α4β7 
integrin receptor on the surface of CD4 + and CD8 + T cells in an  in 
vitro cellular assay. We also generated a set of diverse V2 peptides with 
and without key amino acids within V2 165-185 and analyzed the 
pattern of their binding to the α4β7 integrin receptor.
Results: Peptides bearing the same sequence at positions 173-185 as 
RV144 immunogens did not bind α4β7 on both CD4 + and CD8 + T 
cells.  However, the addition of amino acids QRV at positions 170-172 
restored binding.  Specific amino acids at 170-172 were also required 
for binding of diverse V2-derived peptides. 
Conclusion: We identified a second, cryptic determinant of α4β7 
binding located at positions 170-172 of the V2 loop. Interestingly, the 
anti-V2 antibody response elicited by the RV144 vaccine, along with 
immune pressure inferred from a sieve analysis, is directed specifically 
to these same amino acids within the V2 loop.  The anti-V2 antibodies 
that apparently reduced the risk of infection in the RV144 trial may 
have functioned by neutralizing α4β7-mediated dissemination to GALT 
via this cryptic determinant.  
P05.11
Impact of Training Peer Educators Ex-Fighters 
BURUNDI as a Strategy to Reduce Risk 
Behaviors Favoring the Transmission of HIV/
AIDS
F. Ndayimirije1
1Forum des anciens combattants pour la lutte contre le VIH/SIDa 
l’Amélioration de la Santé et del’Education, Bujumbura, Burundi
Background: AIDS affects not only the physical health of individuals 
but also their family and community identity. Indeed, the stigma and 
discrimination surrounding the disease are equally destructive as the 
disease. This stigma is so strong in groups that have been affected by 
armed groups such as ex-combatants conflict. To improve the status 
of veterans in their home communities in reducing risk behaviors 
favoring the transmission of HIV / AIDS, FACOSASE wished form 360 
PEEXC to fight against this scourge and the objective Show is PEEXC 
on how to improve the strategy of reducing risk behaviors favoring the 
transmission of HIV / AIDS.
Methods: To implement this strategy as training PEEXC reduction 
of risk behaviors facilitating the transmission of HIV / AIDS, we 
first conducted a raid on land in order to identify PE EXC who will 
participate in the training.
Results: At the end of training, there is the development of knowledge 
of older PEEXC 20 to 35 years on a better integration to reduce risk 
behaviors favoring the transmission of HIV / AIDS educators -A general 
awareness of the issue of this strategy through media coverage.
Conclusion: This training helped PEEXC on developing knowledge 
PEEXC as a strategy to reduce risk behaviors facilitating the 
transmission of HIV / AIDS.
It was anticipated identification of best practices that could be applied 
elsewhere in order to reduce risk behaviors favoring the transmission 
of HIV / AIDS among groups that have been affected by armed conflict 
in general and in particular the ex-combatants BURUNDI and drive 
in the psycho-social care and the medical PEEXC having made  a 
voluntary tracks and living with HIV / AIDS to improve their quality 
of life and more of the 360 who have been trained and have the 
screening 60% were seropositive
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P05.14
Altered Immune Activation in HIV-Negative 
High-Risk Men Who Have Sex with Men (MSM) 
Compared to Low-Risk HIV-Negative Men
C.D. Palmer1, J. Tomassilli2, M. Sirignano1, K.F. Benedict3,  
T. Allen1, K.H. Mayer2, and M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Fenway Health, Beth Israel Deaconess Medical Center, 
Boston, MA, USA; MIT, Cambridge, MA, USA
Background: Sexually transmitted infections and inflammation in the 
female genital tract can the risk of HIV acquisition in women. Men who 
have sex with men (MSM) are often at increased risk of HIV infection 
due to behavioral and biological factors. In order to assess whether 
high-risk behavioral preferences associated with increased markers 
of immune activation, we recruited a cohort of high-risk HIV-negative 
MSM (unprotected sex, intravenous drug use) and compared markers 
of immune activation to low-risk HIV-negative males. 
Methods: HIV-negative MSM at high risk for HIV-1 acquisition (HR-
MSM) and HIV-negative low-risk males (controls) were enrolled at the 
Fenway Health Center and the Ragon Institute, respectively. Peripheral 
blood mononuclear cells isolated from blood samples were analyzed 
for markers of T lymphocyte activation by flow cytometry. Plasma 
samples were analyzed for soluble markers of inflammation by bead-
based multiplex assay. 
Results: Subject demographics were as follows: HR-MSM (n=20; mean 
age=35.7[20-57]; 50% Caucasian, 30% Black/African American, 
20% other/unknown), controls (n=11; mean age=40.9[23-63]; 91% 
Caucasian, 9% Black/African American). The percent of CD4+ and 
CD8+ T cell populations followed a Gaussian distribution in controls 
but not in HR-MSM, with the latter also displaying a significantly 
lower CD4/CD8 ratio owing to a significantly higher proportion of 
CD8+ lymphocytes (p<0.05). Furthermore, HR-MSM presented with 
decreased percentage of CD38+CD4+ and CD25+CD8+ lymphocytes. 
Soluble marker analysis revealed significantly higher levels of IP-10 
(p<0.05), as well as a trend towards increased IL-12p40 and IL-12p70 
in HR-MSM. Several of the measured inflammatory makers showed a 
Gaussian distribution in controls, but not in HR-MSM. 
Conclusion: Our preliminary observations suggest increased 
immunological heterogeneity and altered levels of immune activation 
in HIV-negative HR-MSM compared to low-risk controls. These 
differences could potentially indicate a subset of MSM who are at an 
increased risk of HIV acquisition following exposure due to an altered 
inflammatory state. 
P05.13
Siglec-1 Expressed on Activated Monocytes 
Captures and Transfers HIV-1 Through 
Recognition of Sialyllactose Exposed on Viral 
Membrane Gangliosides
M. Pino1, I. Erkizia1, J. Dalmau1, E. Erickson2, B. Clotet1,  
O.T. Keppler2, A. Telenti3, H. Kräusslich2, J. Martinez-Picado4, and 
N. Izquierdo-Useros1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2Universitätsklinikum Heidelberg, Heidelberg, Germany; 
3University Hospital Center and University of Lausanne, 
Lausanne, Switzerland; 4IrsiCaixa Institute for AIDS Research, 
HIVACAT, and Institució Catalana de Recerca i Estudis 
Avancats, Barcelona, Spain
Background: HIV-1 cell-to-cell transmission is a potent infectious 
pathway that could boost viral dissemination in tissues. We have 
recently identified that the Sialic acid-binding Ig-like lectin 1 
(Siglec-1, CD169) expressed on dendritic cells captures HIV-1 through 
recognition of sialyllactose exposed on viral membrane gangliosides. 
Siglec-1 is up-regulated upon dendritic cell exposure to immune 
activation signals, such as interferon-alfa (IFNα) or lipopolysaccharide 
(LPS). However, if other myeloid cells, such as activated monocytes, 
mediate HIV-1 transmission via Siglec-1/sialyllactose recognition, is 
still not known.
Methods: Monocytes from seronegative donors were treated or 
not with LPS or IFNα and analyzed for Siglec-1 expression by 
flow cytometry. Fluorescent HIV-1 viral like particles lacking the 
envelope glycoproteins were used to monitor Siglec-1 viral capture 
via sialyllactose recognition of viral membrane gangliosides. HIV-
1 trafficking in activated monocytes was followed by confocal 
microscopy. Siglec-1 role during HIV-1 transmission was further 
assessed in functional blocking assays. Finally, the expression of 
Siglec-1 on monocytes of HIV-1 infected patients was detected before 
and after antiretroviral treatment. Statistical analysis was performed 
using paired. 
Results: Both LPS and IFNα-activated monocytes increased Siglec-1 
expression compared to non-activated cells. Siglec-1 on IFNα-activated 
monocytes increased viral capture and transmission to target cells 
(P<0.0001 and P=0.021, respectively). Moreover, pre-treatment 
of IFNα-activated monocytes with a monoclonal antibody against 
Siglec-1 diminished HIV-1 capture and transmission (P<0.0001 and 
P=0.0013, respectively). Confocal microscopy revealed trafficking of 
Siglec-1 and HIV-1 to the same cytoplasmic sac-like compartment. 
Finally, antiretroviral treatment in HIV-1 patients decreased Siglec-1 
expression (P=0.0024). 
Conclusion: Both LPS and IFNα-mediated immune activation in 
response to HIV-1 infection induce Siglec-1 expression on monocytes. 
Siglec-1 expressed on activated monocytes recognizes sialyllactose 
exposed on HIV-1 membrane gangliosides, facilitating infection 
of target cells. Thus, Siglec-1 expressed on myeloid cells, such as 
monocytes and dendritic cells could boost HIV-1 dissemination in 
inflamed immune tissues.
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P05.16
HIV-1 Naturally-Occurring BF Intersubtype 
Recombination in Gag-Protease Is Associated 
to Reduction in Viral Replication Capacity
C. Espada1, F. Melo2, P.M. Zanotto3, L. Martínez Peralta1, and 
M.G. Carobene4
1Instituto de Investigaciones en Microbiología y Parasitología 
Médica, Buenos Aires, Argentina; 2Universidade de Brasilia, 
Brasilia, Brazil; 3Universidade de São Paulo, São Paulo, Brazil; 
4Instituto de Investigaciones Biomedicas en Retrovirus y SIDA, 
Buenos Aires, Argentina
Background: HIV-1 recombination may have a major impact on the 
global epidemic since the intersubtype recombinant variants might 
exhibit differential biological behaviors. gag and pol are closely 
related genes as both polyproteins precursors are cleaved by the viral 
protease. Gag is known to be targeted by the host CTL response and 
to be involved in the antiretroviral treatment outcome. We evaluated 
the consequences of intersubtype recombination in gag-protease 
by comparing the in vitro viral replication of pure subtype B vs BF 
recombinants variants, highly represented in South America.  
Methods: CRF12_BF-like and CRF28_BF-like gag-protease sequences 
from two HIV-infected subjects were used to construct chimeric NL4-3-
derived viral variants: pNL-Bst (subtype B), pNL-CRF12_BF-like and pNL-
CRF28_BF-like. Viral stocks were generated by transfecting HEK293T 
cells using Lipofectamine 2000 (Invitrogen). MT2 cell cultures were 
infected with equal amounts of p24 antigen (300 ng) of each viral 
stock. Viral replication capacity (RC) was examined by quantifying 
p24 antigen (Murex, Abbot) in cell culture supernatants every 24 h. 
Statistical analysis was performed using GraphPad software.
Results: Although at 24 h pi, NL-CRF12_BF-like RC was significantly 
higher than that of NL-Bst (p24= 1.7 vs. 0.55 ng/ml, p=0.0001), at 
48 and 72 h pi no statistically differences were observed (p>0.05). 
Surprisingly, at 96 h, NL-CRF12_BF-like showed significantly lower RC 
than NL-Bst (p24= 749333 vs. 1672000 ng/ml, p=0.002). In contrast, 
the RC of the NL-CRF28_BF-like variant was lower than both, NL-Bst 
and NL-CRF12_BF-like at all times points (p24= 0.4, 0.6, 2.1 and 10 
ng/ml, p<0.001). 
Conclusion: Our results show for the first time that intersubtype 
recombination in the gag-protease region affects viral RC, as well as a 
replicative advantage associated to gag-protease region of the CRF12BF-
like over the CRF28_BF-like. This study underscores the relevance of 
the natural variation between subtypes in the epidemiological context 
and future development of new antiretroviral drugs.
P05.15
Construction and Phenotypic Characterization 
of Functional Envelope Clones Derived from 
HIV-1 Subtype A Viruses Circulating in Russia
A. Revilla6, A. Fernández-García6, A. Chand1, A. Robles1,  
E. Delgado6, P. Nebreda6, C. Carrera6, A. Vinogradova2,  
A. Rakhmanova3, E. Karamov4, L. Pérez-Álvarez6, S. Osmanov5, 
R. Nájera6, M.S. Seaman1, and M.M. Thomson6
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2St. 
Petersburg AIDS Center, St. Petersburg, Russian Federation; 
3Botkin’s Infectious Diseases Hospital, St. Petersburg, Russian 
Federation; 4D.I. Ivanovsky Institute of Virology, Moscow, 
Russian Federation; 5WHO-UNAIDS, Geneva, Switzerland; 
6Instituto de Salud Carlos III, Majadahonda (Madrid), Spain
Background: The HIV-1 epidemic in former Soviet Union (FSU) 
countries is dominated by a monophyletic subtype A variant (AFSU). In 
spite of its epidemic importance, no functional envelope clones of this 
variant have been reported in the literature. Here we aim to obtain a 
panel of functional AFSU envelope clones from plasma of HIV-1-infected 
individuals and to characterize their neutralization properties and 
coreceptor usage.
Methods: Plasma samples collected in Russia from 28 HIV-1-infected 
individuals were used. Full-length HIV-1 envelopes were RT-PCR-
amplified using a single genome amplification assay and cloned into 
an expression vector. Envelope clones were cotransfected with an 
Env-deficient HIV-1 plasmid, generating pseudovirions, which were 
tested for envelope functionality in TZM-bl cells. Clones yielding 
a signal/background luminiscence ratio >50 were considered 
highly functional. Susceptibility to broadly neutralizing monoclonal 
antibodies (mAbs) b12, 2G12, 2F5, 4E10 and VRC01 was measured 
in TZM-bl cells. Phenotypic determination of coreceptor usage was 
done using GHOST cells. Phylogenetic sequence analyses were done 
via maximum likelihood.
Results: Highly functional envelope clones of the AFSU   variant were 
obtained from 18 individuals. All 18 pseudoviruses were sensitive to 
VRC01 (mean IC50, 0.54 µg/ml); most were sensitive to 2F5 (n=17; 
mean IC50, 11.49 µg/ml) and 4E10 (n=16; mean IC50, 11.24 µg/
ml); and a few were sensitive to b12 (n=5) and 2G12 (n=2). Of 15 
pseudoviruses tested for coreceptor usage, 14 were of R5 and 1 was 
of R5X4 phenotypes.
Conclusion: We report the first panel of highly functional HIV-
1 envelope clones of the AFSU   variant with characterization 
of neutralization properties and phenotypic coreceptor usage. 
Neutralization sensitivities to broadly neutralizing mAbs were similar 
to those reported for African subtype A-enveloped pseudoviruses. 
Most clones were of R5 phenotype. These clones may be useful for 
neutralization assays in vaccine-related studies and for analyses of 
coreceptor usage and of efficacy of cell entry inhibitor drugs
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P05.18
The Impact of HLA-Class-I-Mediated Control of 
HIV-1 in a Japanese Cohort
K. Sakai1, T. Chikata1, M. Hasegawa1, H. Gatanaga2, S. Oka2, 
and M. Takiguchi1
1Kumamoto University, Kumamoto, Japan; 2AIDS Clinical 
Center, National Center for Global Health and Medicine, Japan
Background: HIV-1 immune evasion from cytotoxic T lymphocytes 
(CTLs) causes the emergence of escape mutations, resulting in 
persisting escape variants that shape HLA-associated viral diversity 
at the population level. Recent studies with Caucasian and African 
cohorts showed that HLA-associated escape mutations in Gag impose 
fitness cost and that Gag-mediated viral replication capacity (Gag RC) 
is compromised in patients with protective HLA alleles. However, the 
protective alleles well-studied in Caucasian/Africa cohorts, including 
B*57:01, are not prevalent in Japan, and some studies suggested an 
important role of Pol as an immune target by CTLs in Asian cohorts. To 
address these issues, we investigated HLA-associated changes Gag RCs 
in treatment-naive HIV+ Japanese patients.
Methods: Gag RCs were examined by generating chimeric HIV-1 NL4-3 
encoding plasma-derived gag-protease from 350 untreated Japanese 
patients chronically infected with HIV-1 subtype B. RCs were examined 
in vitro by infecting a GFP+ T cell line.
Results: We examined HLA-associated changes in Gag RCs in vitro. 
Unlike Caucasian/African cohort studies, Gag RCs showed only a weak 
association with CD4 count and none with plasma viral load (pVL) in 
our Japanese cohort even though CD4 count and pVL were strongly 
associated. In addition, Gag RCs for individual HLA alleles did not 
reflect lower or higher pVL associated with particular HLA alleles and 
no advantage of rare HLA alleles or disadvantage of homozygosity at 
HLA class I loci.
Conclusion: Even though African and Caucasian-cohort studies 
previously indicated a significant association between Gag RCs and 
patients’ clinical outcome, Gag RCs were not predictive of disease 
prognosis in our Japanese cohort. Our observations suggested a 
possibility that immune responses against Gag may not play a 
dominant role in HIV+ Japanese patients, unlike African/Caucasian 
cohorts, possibly due to different HLA prevalence and unique HLA 
footprints on the viral evolution.
P05.17
Dissecting HIV-1 Quasispecies Dynamics 
Within Intestinal Mucosal Tissues from Primary 
Infected MSM Subjects 
D.C. Tully1, S. Moore1, C.B. Ogilvie1, K.A. Power1, T.M. Allen1, and 
D.S. Kwon1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Background: The global spread of HIV-1 has been fueled by mucosal 
infection through sexual transmission. Gut associated lymphoid 
tissue (GALT) contains the majority of the body’s CD8+ T cells and is 
the primary site of viral replication in early HIV-1 infection. Despite 
recognition of its importance in HIV-1 pathogenesis, characterization 
of the HIV-1 quasispecies in the GALT during early HIV-1 infection is 
limited. This understanding may be critical in revealing determinants 
for viral entry and for a general understanding of virus trafficking and 
virus turnover. 
Methods: Endoscopic intestinal biopsies from the colon, ileum and 
duodenum were obtained from two HIV infected subjects during 
acute infection (Fiebig III and IV) and 6-months later. Whole-genome 
amplification coupled with 454 deep sequencing allowed the 
characterization of intra-host diversity across the entire HIV genome 
from longitudinal biopsy specimens, plasma and PBMCs. 
Results: Colon demonstrated the highest viral diversity, with its spectra 
of variants temporally following those in plasma, including a number 
of likely CTL escape mutations. Duodenum appeared to harbor unique 
variants demonstrating a strong preference for the minority variant in 
plasma. Conversely, ileum was more homogenous, lagging behind the 
pace of diversification of other tissue compartments and plasma. We 
also observed a number of tissue-specific viral variants over time. 
Conclusion: This study highlights the complex dynamic interplay 
between plasma and mucosal resident virus early after infection. Deep 
sequencing revealed sequestration of minority variants residing within 
each tissue compartment, which appeared transient in nature, and 
may be attributed to local bursts of viral replication. The longitudinal 
analysis of CTL escape mutants suggests that the intestinal tissues may 
represent sequestered immunologic compartments that are distinct from 
one another and the systemic circulation.  The compartmentalization 
of immune pressure may then lead to development of unique tissue-
specific viral populations. 
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P05.20
HIV-1 Gag Evolution During Dual Selective 
Pressure by Drugs and HLA- Class I Immune 
Responses in Long-Term Treated Patients
E. Jimenez1, R. Peña1, F.M. Codoñer2, T. Vollbrecht3, B. Clotet1, 
J. Martinez-Picado1, R. Draenert3, and J. G Prado1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2Lifesciences, Valencia, Spain; 3Medizinische Poliklinik, 
Klinikum der Ludwig-Maximilians-Universität, Germany
Background: Although HLA class I immune pressure is the stronger 
contributor to HIV-1 evolution. The generalized introduction of 
antiretroviral treatment (ART) to control virus replication, will favour the 
convergence of drug and immune selective pressures against HIV-1. In 
this scenario, dual drug/immune pressure could modify the patterns 
of natural HIV-1 evolution at important immunogenic and enzymatic 
sites. The accurate understanding of the evolutionary pathways of 
HIV-1 under ART would be crucial to optimize immunotherapeutic 
strategies directed to treated individuals.
Methods: Viral RNA was extracted from plasma samples in four 
patients before and a media of four years after ART introduction. A 
total of 50 viral clones covering HIV-1 Gag and Protease (Gag-PR) 
were obtained per patient by Single-Genome Amplification (SGA) and 
sequence. Selection of HIV-1 drug resistance mutations in the PR and 
CD8+ T cell epitope variation in Gag was monitored overtime. All 
subjects were HLA-class I typed and CD8+ T cell responses measured 
by Elispot against a panel of Gag and Protease overlapping peptides.
Results: Longitudinal HIV-1 Gag-PR sequencing reveals a concomitant 
accumulation of mutations in Gag and Protease during long-term 
antiretroviral treatment. However, SGA data demonstrate differences 
in HIV-1 evolution between patients. For patient 1, HIV-1 Gag evolution 
was fast and marked by the absence of measurable CD8+ T cells 
responses during ART. Meanwhile, patients 2, 3 and 4 maintained 
measurable Gag CD8+ T cells responses during ART and have a 
low accumulation of Gag mutations with overall lower viral loads. 
Appearance of drug resistance mutations in the protease was observed 
in all patients.
Conclusion: Our data demonstrate concomitant Gag-PR evolution 
and suggest that CD8+ T –cell responses against Gag may contribute 
to slow viral evolution during ART. These findings provide a better 
understanding of the evolutionary events during long-term ART and 
are crucial for the accurate design of immune therapeutic strategies 
in treated patients.  
P05.19
No Evidence for Selection of HIV-1 with 
Enhanced Gag-Pro or Nef Function Among 
Breakthrough Infections in the CAPRISA 004 
Tenofovir Microbicide Trial
D.R. Chopera1, J. Mann1, P. Mwimanzi2, S. Omarjee1, X. Kuang2, 
N. Ndabambi3, S. Goodier3, E. Martin2, V. Naranbhai1,  
S.S. Abdool Karim1, Q. Abdool Karim1, Z. Brumme2, T. Ndung’u1, 
C. Williamson3, and M. Brockman2
1CAPRISA, University of KwaZulu-Natal, Durban, South Africa; 
2Simon Fraser University, Burnaby, Canada; 3University of 
Cape Town, Cape Town, South Africa
Background: The use of antiretroviral drugs for HIV-1 prophylaxis 
could provide partial protection that inadvertently selects for more fit 
viral variants among incident infections. To examine this, we assessed 
in vitro Gag-Protease and Nef protein function in early viral sequences 
obtained from the CAPRISA 004 1% tenofovir gel microbicide trial.
Methods: Baseline plasma samples (median [IQR] 37.5 [23.9-62.6] 
days post-infection) were studied for 31 treated and 51 placebo 
participants (84% of total study infections).  Gag-Protease recombinant 
viruses were constructed (30 treated and 45 placebo participants). 
Viral replication capacity (RC) was assessed using a GFP reporter T cell 
assay and results normalized to WT NL4-3.  One representative Nef 
plasma sequence per patient was cloned into pSELECT-GFP vector (31 
treated and 48 placebo). Nef clones were transfected into CEM T cells 
expressing CD4 and HLA-A*02. CD4 and HLA down-regulation were 
assessed by flow cytometry, and results normalized to control SF2 Nef. 
Nef expression was confirmed by Western blotting.
Results: No major phylogenetic clustering and no differences in Gag-
Protease (p=0.2) or Nef CD4 down-regulation function (p=0.2) were 
observed in sequences from participants who received tenofovir vs. 
placebo gel prophylaxis. There was a trend towards tenofovir recipients 
having lower HLA down-regulation function (p=0.06). Nef CD4 and 
HLA down-regulation functions were strongly correlated (Spearman’s 
r=0.007); however, neither function correlated with Gag-Protease 
replication capacity. We observed a modest association between 
Gag-Protease replication capacity and plasma viral load set-point 
(Spearman’s r=0.2; p=0.05).
Conclusion: In vitro Gag-Protease and Nef function was similar in 
breakthrough viruses obtained from individuals in the tenofovir and 
placebo arms of the CAPRISA 004 study.  Results suggest that the 
1% tenofovir microbicide gel did not select for founder viruses with 
significantly altered functional characteristics in these genes.
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P05.22
Siglec-1 on Macrophages Is a Major Infectivity 
Receptor for HIV-1: Differential Effects of GM-
CSF and M-CSF on HIV-1 Entry and Replication
O. Jobe1, S. Tovanabutra1, P. Ehrenberg1, K. Poltavee1,  
K.K. Peachman1, A. Chenine1, R. McLinden1, R. Thomas1,  
J. Kim1, N.L. Michael1, C.R. Alving1, and M. Rao1
1U.S. MHRP, Silver Spring, MD, USA
Background: The environmental milieu around macrophages has a 
profound influence on their phenotype, and permissiveness to HIV-
1 infection and replication. The effect of granulocyte macrophage 
colony-stimulating factor (GM-CSF) and macrophage colony-stimulating 
factor (M-CSF) on the phenotypic profiles and permissiveness to HIV-1 
infection of primary human monocyte-derived macrophages (MDM) 
were evaluated.
Methods: MDM were generated from PBMCs of HIV-1 seronegative 
donors following in vitro culture in media supplemented with GM-
CSF or M-CSF. Expression of cell surface markers and intracellular 
p24 were determined by flow cytometry. Chemokines were assayed 
by ELISA. HIV-1 gp120 sequences derived from infected MDM were 
characterized using single genome amplification. Virus entry and 
intracellular replication were assessed by PCR using strong stop and 
LTR/Gag primer/probe sets. 
Results: MDM cultured in GM-CSF induced high levels of β-chemokines 
(80-120 pg/ml) compared to M-CSF (p <0.001). Incubation of M-CSF 
cells with supernatants from GM-CSF cultures reduced the infectivity 
by 85% (p <0.002). Blocking CD4 or CCR5 receptors with monoclonal 
antibodies did not prevent HIV-1 infection.  However, blocking Siglec-1 
(CD169) receptor with anti-CD169 abrogated HIV-1 infection. Siglec-1 
expression was decreased by 50% in GM-CSF cultured MDM. MDM 
from three donors differentiated in GM-CSF were 8-10-fold less 
permissive to primary viruses compared to MDM grown in M-CSF 
(p <0.001). Differences in HIV-1 infectivity were not due to genetic 
differences in viral sequences (p = 0.1845). Infected GM-CSF cultures 
showed decreases in HIV-1 entry (3-128-fold) and replication (8-64-
fold) at 24 and 96-hr time points relative to corresponding M-CSF 
infected cultures (p <0.01). 
Conclusion: The differences in infectivity observed in these two 
models were not due to selective virus variation or fitness, but due to 
decreased entry and replication of HIV-1 in GM-CSF cultured MDM. The 
decreased expression of Siglec-1 and the presence of soluble factors in 
the GM-CSF cultured MDM could have contributed to decreased entry. 
P05.21
Models of HIV-1 gp120 Complexed with CXCR4 
and CCR5 
A. Agarwal1, R.A. Stein1, and T. Cardozo1
1New York University School of Medicine, New York, NY, USA
Background: During cellular entry, the HIV-1 gp120/gp41 viral 
envelope glycoprotein mediates the sequential attachment of HIV-1 to 
the CD4 host immune cell receptors, which are the primary receptors, 
and to the CCR5 or CXCR4 chemokine co-receptors. While X-ray 
crystallography studies provided details of the interaction between 
the gp120 core and a two-domain fragment of human CD4, a three-
dimensional model in which gp120 simultaneously binds CD4 and 
either CCR5 or CXCR4 does not exist at this time. 
Methods: We used in silico molecular docking to find the optimal 
3D structural fit between the crown of gp120’s V3 loop and pockets 
on the molecular surface of the core of gp120 in its liganded 
conformation.  Based on the location of optimal fit, molecular 
modeling was used to connect the loops between the V3 loop crown 
and the V3 stem emerging from the core. This new conformation of 
gp120 was then docked to molecular models and crystal structures 
of CXCR4 and CCR5.
Results: The V3 loop crown exhibited a strong structural preference 
for a particular docking site on the molecular surface of the gp120 
core domain, near a region known as the “bridging sheet”. Using 
this location to guide the modeling of the complete CD4-liganded 
conformation of gp120, we found that the new conformation is 
structurally compatible with the N-terminal sulfated helix of CCR5 
and with the ligand-binding surface of the crystallographic surface of 
CXCR4. Models of the whole complex of gp120 with CXCR4 and CCR5 
were refined from this starting point.
Conclusion: The interface of gp120 and CCR5/CXCR4 is primarily 
between the V3 loop crown and the N-terminal helix of the chemokine 
receptors, which exhibits sulfated tyrosines that make critical V3 loop 
and gp120 core contacts. According to our model, the C-terminal beta-
strand of the V3 crown docks into the central surface extracellular 
pocket of CCR5/CXCR4.
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P05.24
HIV-1 Polymorphisms Associated with 4-Digit 
HLA Alleles in Japanese Individuals Chronically 
Infected with the Clade B Virus
T. Chikata1, J.M. Carlson2, Y. Tamura1, M.A. Borghan3, T. Naruto1,  
M. Hashimoto1, H. Murakoshi1, S. Mallal4, M. John4, H. Gatanaga5, 
S. Oka5, Z.L. Brumme6, and M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan; 2Microsoft Research, Los Angeles, CA, USA; 3Oman 
Medical College, Sohar, Oman; 4Murdoch University, Murdoch, 
Australia; 5National Center for Global Health and Medicine, 
Tokyo, Japan; 6Simon Fraser University, Burnaby, Canada
Background: The appearance of HLA-associated HIV-1 polymorphisms 
(HLA-APs) represents an HLA footprint effect. Since the distribution of 
HLA alleles is quite different between regions or races, it is assumed 
that the comparison of HLA-APs between Asian and Caucasian 
individuals infected with the clade B virus can clarify HIV-1 evolution 
between both populations. However, there are no large-scale HLA-AP 
studies in Asian individuals.
Methods: We analyzed the sequence of Gag, Pol, and Nef genes 
in 430 treatment-naïve Japanese chronically infected with HIV-
1 clade B. Identification of associations between HIV-1 amino acid 
polymorphisms and 4-digit HLA class I alleles was performed by using 
a phylogenetically corrected logistic regression model and multiple 
tests were corrected by using q-value. Then, we compared our results 
with those for the Caucasian cohort (IHAC).
Results: We completely determined 397, 363, and 306 sequences 
of Gag, Pol, and Nef, respectively, and then analyzed polymorphism 
associated with 37 4-digit HLA alleles. At the threshold of q<0.2, we 
identified 284 HLA-APs (94 in Gag, 86 in Pol, and 104 in Nef). These 
HLA-APs were more frequently detected in Nef codons (21.8%; 45 
of 206) than in Gag (10.2%; 51 of 500) or Pol (5.1%; 51 of 947). 
Furthermore, we found that the number of HLA-associated mutations 
in Pol was inversely correlated to viral load. Analysis of HLA-APs 
among HLA subtypes demonstrated different HLA-APs between 
HLA subtypes among which substitutions were found outside the 
peptide-binding groove. Comparative analysis between Japanese and 
Caucasian cohorts showed that 85 (53.5%) of 159 HLA-APs associated 
with 18 HLA alleles shared in both populations were not observed 
in the IHAC. Approximately 66% of HLA-APs were identified only in 
Japanese individuals.
Conclusion: This study demonstrated the different HIV-1 evolution 
between Japanese and Caucasian individuals and highlighted 
the complexity of HLA-AP formation and the existence of novel 
mechanisms forming HLA-APs.
P05.23
Impaired Early HIV-1 Nef Function in 
Spontaneous Viremic Controllers
X. Kuang1, A. Le1, P. Mwimanzi1, G. Anmole1, T. Ueno2,  
T. Miura3, E. Connick4, E.S. Daar5, A. Kelleher6, H. Jessen7,  
S. Little8, M. Markowitz9, F. Pereyra10, E. Rosenberg11,  
B. Walker10, and Z. Brumme1, and M. Brockman12
1Simon Fraser University, Canada; 2Kumamoto University, 
Japan; 3University of Nagasaki, Japan; 4University of 
Colorado-Denver, CO, USA; 5University of California-Los 
Angeles, Los Angeles, CA, USA; 6University of New South 
Wales, Australia; 7Jessen Praxis, Germany; 8University of 
California-San Diego, San Diego, CA, USA; 9Aaron Diamond 
AIDS Research Center, New York, NY, USA; 10Ragon 
Institute of MGH, MIT and Harvard, Cambridge, MA, USA; 
11Massachusetts General Hospital, Boston, MA, USA; 12Simon 
Fraser University, Burnaby, Canada
Background: Nef clones derived from HIV-1 elite controllers display 
reduced activity compared to those from chronic progressors, but 
the relevance of host and viral factors to this phenotype remain 
unknown. To investigate this, we assessed the CD4 and HLA class 
I down-regulation activities of acute/early Nef clones derived from 
individuals who suppressed plasma viremia to <2000 RNA copies/
mL in the first year (Acute Controllers [AC]) and those who did not 
(Acute Progressors [AP]).
Methods: Nef sequences were cloned from N=10 AC (median [IQR] 
72 [57-99] days post-infection [DPI]) and N=56 AP (54 [35-73] DPI). 
Clones were transfected into CEM T cells expressing HLA-A*02, and 
surface CD4 and A*02 levels were quantified at 24h using flow 
cytometry. The ability of each Nef clone to down-regulate CD4 and 
HLA was normalized to Nef-SF2 control.
Results: Nef sequences from AC and AP displayed no substantial 
phylogenetic clustering or significant imbalance in amino acid 
frequency. Nevertheless, Nef clones from AC had reduced ability 
to down-regulate CD4 (median [IQR] 0.94 [0.87-0.99]) vs. AP (0.99 
[0.98-1.02]), p=0.004. Similarly, HLA down-regulation activity was 
lower in AC (0.83 [0.67-0.95]) vs. AP (1.01 [0.98-1.06]), p=0.001. The 
frequency of protective HLA alleles (B*13, B*1516/17, B*27, B*51, B*57, 
and B*5801) was comparable between AC (5/10 [50%]) and AP (19/56 
[34%]), p=0.5; however, reduced CD4 down-regulation function 
appeared to be driven by AC possessing protective HLA. Follow-up 
samples from 3 AC and 3 AP indicated that CD4 down-regulation 
activity diminished in 2 AC and 1 AP over the first year of infection, 
while HLA down-regulation activity diminished in all 6 participants 
over the same period.
Conclusion: Acute/early Nef clones derived from AC displayed 
lower CD4 and HLA down-regulation activities. Impaired CD4 down-
regulation in AC expressing protective HLA supports the contribution 
of both host and viral factors to this phenotype.
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P05.26
CD25+FoxP3+ Memory CD4 T Cells Are 
Frequent Targets of HIV Infection In Vivo
M. Chachage1, L. Podola2, O. Kuffour3, O. Mgaya1, P. Clowes1,  
D. Kowour1, M. Schiemann4, L. Henkel4, A. Bauer1, L. Maboko1, 
M. Hoelscher2, F.S. Sarfo5, K. Eberhardt6, T. Feldt6, E. Saathoff2, 
and C. Geldmacher2
1NIMR-Mbeya Medical Research Centre, Mbeya, United 
Republic of Tanzania; 2Medical Center of the University of 
Munich (LMU), Munich, Germany; 3Charite University of 
Medicine, Berlin, Germany; 4 Universität München, Munich, 
Germany; 5Komfo Anokye Teaching Hospital, Kumasi, 
Ghana; 6Bernhard Nocht Institute for Tropical Medicine, 
Hamburg, Germany
Background: Interleukin 2 (IL2) facilitates homeostatic proliferation 
and maintenance of IL2 receptor alpha chain+ (CD25) FoxP3+ CD4+ 
regulatory T cells (Tregs). In vitro, IL2-dependent cell cycle induction 
and CD25 expression is closely linked to HIV replication in CD4 T cells. 
We hence hypothesized that Tregs may constitute a highly suitable 
target for HIV infection in vivo.
Methods: Using polychromatic flow cytometry, Treg frequencies, 
absolute numbers, CCR5 expression (n=381) and markers of cell 
proliferation (Ki67, n=38) were studied ex vivo in relation to HIV 
infection status. HIV-DNA content was then quantified in different sorted 
CD45RO+  memory CD4 T cell populations, including CD25+FoxP3+ 
Tregs, from HIV+ PBMC samples (n=22).
Results: Tregs cell numbers in HIV+ subjects were depleted (10 cells/
µl) compared to HIV- subjects (18 cells/µl, p<0.0001), with a linear 
correlation between Treg and total CD4 T cell counts (p=0.0009). 
Independent of HIV infection, a substantial fraction of Tregs 
(median>50%) expressed the HIV co-receptor CCR5, potentially 
supporting viral entry into Tregs. Importantly, chronic HIV infection 
was associated a substantial increase of proliferating (Ki67+) Tregs 
cells (median: 27.6% (HIV+) and 18% (HIV-); p=0.004) and memory 
CD4 T cells (4.1% (HIV+) versus 1.3% (HIV-), p<0.0001). Finally, sorted 
CD45RO+ Treg cells had a 15- fold HIV-DNA content compared to 
memory CD4 T cells (p=0.0032).
Conclusion: Our data demonstrate that during chronic HIV infection, 
a large proportion of Treg cells express the CCR5 and are actively 
proliferating, which might facilitate HIV infection of memory CD25+, 
FoxP3+ CD4 T cells in vivo. These data support the hypothesis that 
specific cellular characteristics of the Treg cell life cycle make then a 
highly suitable target for HIV replication in vivo.  
P05.25
Envelope Gene Analysis Shows Migration of 
HIV-1 A to India from East Africa Early During 
Epidemic
S.S. Pandey1, A. Walimbe1, S. Cherian1, and R. Paranjape1
1ICMR, Pune, India
Background: The global diversity of HIV-1 poses an alarming challenge 
to HIV vaccine development. Subtype A of HIV-1 is the second globally 
most prevalent variant (12%) and its recombinants CRF02_AG and 
CRF01_AE contribute 8% and 5% respectively. The subtype is mainly 
found in Africa, Europe and Asia. Among the five sub-clades (A1-A5) 
of HIV-1A, A1 is the most predominant. Although reported for last two 
decades, HIV-1 subtype A represents a small proportion of circulating 
HIV viruses in India.  We report the results of analysis of env sequences 
from Indian HIV1 A to study genetic diversity and original source of 
infection in India.
Methods: Phylogeographic analysis was carried out using the Bayesian 
MCMC approach based on 233 globally representative env sequences 
including 6 isolates (1998–2011) from Western India. MCC tree was 
generated under the relaxed uncorrelated lognormal clock model with 
Bayesian skyline tree prior. 
Results: The evolutionary rate of HIV1-A was estimated as 4.3x10  -3 
substitutions/site/year with time to the most recent common ancestor 
at ~1950. All Indian sequences formed a monophyletic cluster within 
sub-clade A1. The genetic diversity within HIV-1A1 was found to be 
10.3% and within Indian cluster, 6.5%. Though, Central Africa was 
determined to be the ancestral origin of A (A1-A5), the Indian A1 
cluster had Eastern Africa as the ancestral source and dated to 1979 
(1976–1982).  
Conclusion: The age of HIV-1A is comparable to an earlier estimate 
(~1945) based on multi-subtype analysis. The introduction of subtype 
A into India may be subsequent to HIV-1C reported to be ~1975. The 
ancestral origin of Indian subtype A viruses was determined to be East 
Africa. This analysis was based on small number of available data and 
needs to be confirmed with larger dataset.  
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P05.28
First Cell(s) Infected by Vaginal Transmission of 
Immunodeficiency Virus in Rhesus Macaques 
D. Stieh2, D. Maric2, M. Anderson2, R.S. Veazey1, and T.J. Hope2
1Tulane National Primate Research Center, Covington, LA, 
USA; 2Northwestern University, Feinberg School of Medicine, 
Chicago, IL, USA
Background: Male-to-female HIV infection occurs after exposure of 
the female reproductive tract (FRT) to viral inoculum in semen.  The 
initial target cells infected and their specific localization remain to 
be defined. 
Methods: To identify the initial sites of infection we have developed 
a single round infection system where a SIV based vector expressing 
luciferase and fluorescent protein reporters are pseudotyped with 
different envelopes.  High titre vector is administered intravaginally 
and/or intrarectally and animals are sacrificed after 48 hours. 
The luciferase expressing cells are identified in a photon detector, 
then dissected into foci of infection and frozen for imaging of thin 
sections.  Individual transduced (infected) cells within the tissue can 
be unequivocally identified by the spectrum specific to the fluorescent 
protein and staining for luciferase.
Results: Examination of the target cells reveals that they are primarily 
CD4+, CD3+ T cells.  However, CD3-, CD4+ cells are also detected. 
The ratio of CD3+/CD3- cells varies between animals.  Characterization 
of the infected CD3- cells is ongoing, but some of them have been 
identified to be tissue resident macrophages.  Foci of transduced cells 
identified in 7 animals are distributed throughout the FRT. Most infected 
cells are found in the vaginal vault.  Unexpectedly, we find that ovaries 
are commonly infected under the conditions of exposure in this model. 
The infection of cells within the endocervix is also detected, but it is 
not the predominant site of infection as proposed by some models.  
Conclusion: This system reveals that after vaginal exposure of 
virus, all aspects of the upper and lower FRT are susceptible to 
infection.  These studies provide important new insights into the 
interaction of the mucosal exposure of SIV after rhesus macaque 
vaginal challenge.  A better understanding of the initial steps of HIV 
transmission will inform and facilitate efforts to develop a vaccine 
to block HIV sexual transmission.  
P05.27
Enrollment Characteristics in a Potential HIV 
Vaccine Efficacy Population Among Fishing 
Communities Around Lake Victoria, Uganda
A. Nalutaaya1, A. Ssetaala1, J. Mpendo1, A. Nanvubya1,  
M. Wambuzi1, S. Sigirenda1, P. Kato1, and N. Kiwanuka2
1UVRI-IAVI HIV Vaccine Program, Entebbe and Kampala, 
Uganda; 2Makerere University College of Health Sciences, 
School of Public Health, Kampala, Uganda
Background: HIV vaccine efficacy trials will require high levels of 
participant enrollment and retention in order to maximize power to 
detect differences in endpoints. We conducted a randomized study to 
assess participant retention in a potential efficacy population of fishing 
communities of Lake Victoria, Uganda.
Methods: HIV negative individuals aged 13-49 years, resident 
in 4 fishing communities around Lake Victoria, Entebbe, Uganda, 
were enrolled and randomized to either mobile phone reminder or 
physical contact tracing arm. Participants were followed up at 1, 2, 3, 
6, 12, and 18 months post-baseline and data on socio-demographic 
characteristics, and HIV/STI risk behavior were collected using 
interviewer administered questionnaires. Venous blood was drawn for 
HIV testing.
Results: A total of 879 participants were screened (41.7% females), of 
which 662 (75.5%) were enrolled, giving a screening/enrollment ratio 
of 1.3:1. The overall mean (SD) and median (IQR) age were 28.2(6.8) 
and 27(23-32) years respectively.   94.3% had attained formal 
education, majority (57.8%) having attained primary education. 45.3% 
had spent less than 5 years in fishing communities. Only 35.9% were 
spending most of their time in fishing activities including fishing, fish 
selling and processing. 47% reported monogamous marriages. Only 
2.8% reported consistent condom use in the past 3 months in extra 
marital affairs. 71% reported having less than 5 new partners in the 
past 3 months, among these, only 4.8% consistently used condoms 
(p<0.0001). 18.4% (162/879) reported STI symptoms of which 61.1% 
(99/162) reported having sex while having STI symptoms.
Conclusion: Enrollment characteristics for this cohort show that fishing 
communities along Lake Victoria, Uganda are a diverse population 
with different social and economic status and at a higher risk for HIV 
infection and other STIs.  Research and medical interventions in this 
population should cater for this diversity.
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P05.30
Evidence of a Less Pathogenic HIV Infection 
Associated with High Adaptation to HLA-I 
Mediated Immune Response in a South 
American Native Community
D.A. Dilernia1, D.C. Monaco1, M. Quipildor2, A. Di Paolo2, L. Yue1, 
S. Kaur1, C. Ibegbu1, J. Altman1, H. Salomon3, and E. Hunter1
1Emory University, Atlanta, GA, USA; 2Hospital San Vicente de 
Paul de la Nueva Oran, San Ramon de la Nueva Oran, Argentina; 
3Universidad de Buenos Aires, Capital Federal, Argentina
Background: HIV escapes cellular immune response by selecting 
mutations that are associated to the HLA alleles carried by an 
individual. Our objective was to study the impact that selection of 
escape mutations has on disease progression in a native HIV-positive 
population from Oran, Argentina that exhibits a restricted HLA profile. 
Our initial hypothesis was that HIV would rapidly select escape 
mutations to the limited number of HLA alleles and impair the immune 
response against the infection.
Methods: We performed high-resolution HLA-I typing and near-full 
length HIV genome sequencing on 65 chronically infected individuals. 
Escape mutations linked to the most frequent HLA alleles (considered 
signatures of viral adaptation) were identified and correlated with 
viral load and CD4 count. CD8 subsets and immune activation were 
assessed by flow-cytometry.
Results: The phylogenetic analysis of the HIV genomes showed 12 
monophyletic clades (3-9 sequences/clade; bootstrap support=100), 
suggesting highly circulating strains, as well as virus sequences located 
in isolated branches of the tree. We identified 24 HLA-linked escape 
mutations (p<0.05; q<0.1) that showed to be more prevalent in the 
viruses present in clades than in the isolated ones (p=0.0114). In 
addition, patients infected with the former viruses exhibited a higher 
proportion of CD8+ naïve cells (CD45RA+CCR7+) and a less exhausted 
(PD-1+) phenotype. Moreover, in a subset of 41 antiretroviral-naïve 
patients, we found that the number of escape mutations was positively 
correlated with the CD4 count (p=0.044) and negatively correlated 
with the viral load (p=0.023). 
Conclusion: Adaptation of HIV to the HLA-I mediated immune response 
in the native community of Oran is leading to a less pathogenic 
infection. Our current hypotheses are focused on a potential negative 
impact of escape mutations on viral fitness and/or redirection of the 
immune response to novel/subdominant epitopes where escape is 
more difficult.
P05.29
HIV-1 Replicative Capacity Independently 
Predicts CD4+ T Cell Decline and May Play a 
Role in Early Immune Activation and Memory 
Cell Depletion
J.L. Prince1, D. Claiborne1, T. Yu1, J. Tang2, J. Carlson3,  
W. Kilembe4, J. Mulenga4, S. Lakhi4, J. Gilmour5, M.A. Price5,  
S.A. Allen1, and E. Hunter1
1Emory University, Atlanta, GA, USA; 2University of Alabama 
Birmingham, Birmingham, AL, USA; 3Microsoft Research, 
Los Angeles, CA, USA; 4Zambia Emory HIV Research Project, 
Lusaka, Zambia; 57IAVI, London, UK
Background: Determining host and viral factors of HIV-1 pathogenesis 
is paramount for rational vaccine design.  In individuals recently 
infected with HIV-1 subtype C, viral replicative capacity (vRC), 
determined by the transmitted Gag sequence, was correlated with both 
early set point viral load (VL) and CD4+ T cell (CD4) decline.  However, 
it was unclear if vRC impacts HIV-1 pathogenesis beyond its effect on 
early set point VL.
Methods: To answer this question, we doubled the size of the cohort 
under study.  vRC was assessed for 127 acutely infected Zambians with 
longitudinal CD4 counts up to 6 years post-infection.  Kaplan-Meier 
survival curve analysis and Cox proportional hazard models were 
utilized to identify independent correlates of CD4 decline.
Results: Individuals with low vRC viruses exhibit significantly slower 
disease progression up to 5yr post-infection for CD4 counts <350 (p 
= 0.02), < 300 (p = 0.002), and <200 (p = 0.033).  After statistical 
adjustment for set point VL, vRC remains an independent predictor of 
accelerated CD4 decline (hazard ratio = 2.05, p = 0.005). Individuals 
with the slowest CD4 decline were infected with low vRC viruses and 
controlled their early set point VL to less than 10 5.  This effect on CD4 
decline was also independent of host factors known to mediate control 
of set point VL, including HLA-B*57, gender, and HLA-B allele sharing 
between source and recipient partners.
Conclusion: It is possible that HIV-1 isolates with low vRC scores 
deplete memory T cell subsets to a less severe extent and/or do not 
induce high levels of immune activation, which may delay disease 
progression. Ongoing studies evaluating the levels of inflammatory 
cytokines in plasma, cellular activation, and memory T cell depletion 
should uncover the mechanistic basis for vRC’s contribution to early 
stage pathogenesis and further our understanding of the complex 
interactions between HIV-1 and the human immune system.
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P05.32 LB
Are Fishing Communities in Uganda Potential 
HIV Vaccine Efficacy Trial Populations? Results 
on HIV Incidence, Retention and Willingness to 
Participate
N. Kiwanuka1, A. Ssetaala1, J. Mpendo1, A. Nanvubya1,  
M. Wambuzi1, A. Nalutaaya1, P.K. Kitandwe1, and P. Kaleebu2
1UVRI-IAVI HIV Vaccine Program, Kampala, Uganda; 2Uganda 
Virus Research Institute, Entebbe, Uganda
Background: HIV prevention efficacy trials (including vaccine trials) 
require populations with high incidence, retention rates and willingness 
to participate levels
Methods: A community-based cohort study in 8 fishing communities 
and a randomized controlled trial (RCT) in 4 fishing communities 
were conducted, to determine population representative HIV rates, 
willingness to participate in hypothetical HIV vaccine trials (WTP) and 
retention. A cohort random sample of 2191 consenting participants 
aged 18-49 years were enrolled at baseline and followed up ~12 
months later. Data were collected on HIV risk behaviors and WTP, 
and venous blood was collected for HIV testing using rapid HIV tests 
with EIA confirmation. In the RCT, retention rates were determined in a 
simulated vaccine efficacy follow up schedule with visits at 0, 1, 2, 3, 
6, 12, and 18 months. Adjusted incidence rate ratios (Adj.IRR) of HIV 
acquisition were estimated by multivariable Poisson regression
Results: HIV incidence was 3.4/100py overall but among those who 
drank alcohol it was 7.67/100py (95% CI;4.62 - 12.7) in the 25-29 
year olds and 5.67/100py (95%CI;3.14 - 10.2) among 18-24 year 
olds. Compared to non-drinkers, the adj.IRR was 3.18 (95%CI;1.18 - 
8.57) and 4.93 (95%CI;1.91 - 12.8) among non-regular and regular 
drinkers respectively. Cohort follow up was 77% and was significantly 
higher among HIV negative at baseline (80%), age 30+ years (82.2%), 
and those with 5+ years of stay in the community (88.5%). WTP was 
89.3%, higher in men than women (91.2% vs 87.3%, p=0.004) and 
among island communities than lakeshore ones (90.4% vs 85.8%, 
p=0.004). Retention rates in RCT were 78.9%, 87.5%, 85.1% and 
85.1% at 1, 2, 3, and 6 months respectively.
Conclusion: With high HIV incidence, retention and WTP, fishing 
communities along L.Victoria, Uganda, appear to be a potential 
population for HIV prevention efficacy trials including vaccine trials.
P05.31 LB D
Relative Contribution of Gag, Nef, and Env to 
Minority Variant Transmission Revealed by 
Deep Sequencing of Transmission Pairs 
R. Batorsky1, M. Schaefer2, K. Power1, D. Tully1, E. Hunter2,  
T. Allen1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Emory University, Atlanta, GA, USA
Background: A single transmitted/founder (T/F) virus initiates infection 
in the recipient in over 70% of heterosexual transmissions; a few 
transmitted variants are detected in the remaining cases. Several 
studies suggest that there is selection for certain envelope features 
upon transmission, e.g. viruses with shorter and less glycosylated 
envelopes are preferentially transmitted, and the vast majority of 
T/F variants use CCR5 for entry into the host cell. It is important to 
identify what features may be selected upon transmission, in order to 
target vaccines to those features which may be more likely to establish 
infection in new hosts.
Methods: We performed full-genome HIV 454 deep sequencing of 
plasma virus from five epidemiologically linked transmission pairs 
from a Zambian cohort. In all cases a single T/F virus in the recipient 
could be inferred. Using global haplotype reconstruction for gp120, 
gp41, Nef, p24 and p17 we tested whether the T/F virus was likely to 
be selected by chance from the donor population. We combined our 
observations across all five pairs to identify regions of the genome 
potentially under selection at transmission. 
Results: In gp120 the T/F variant in the recipient is distinct from 
the majority donor population across all transmission pairs, and 
not selected at random from the donor population (Test of Random 
Transmission, p < 0.05). There were signatures of non-random 
transmission in 4/5 pairs in the gp41 fusion domain and in 3/5 pairs in 
p24, however the probability of minority variant transmission was not 
significant in these proteins.
Conclusion: Our study shows (1) deep sequencing, together with 
global haplotype reconstruction can be used to analyze the genetic 
signatures of selection upon transmission (2) the T/F variant is not 
randomly selected from the donor population (3) both gp120 and 
gp41 are likely to influence the ability of of a virus to initiate infection.
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P05.34 LB
New Insight in HIV-1 Evolution During Acute 
Infection Gained Through Dense Sampling and 
Targeted Deep Sequencing (TDS)
G. Kijak1, E.E. Sanders-Buell1, N. Goonetilleke2, M.A. Eller1,  
M. Rolland1, H. Li2, E.A. Harbolick1, M. Bose1, A. O’Sullivan1,  
P. Pham1, R. Thomas1, L. Eller1, R.J. O’Connell1, G. Shaw3,  
N.L. Michael1, M.L. Robb1, J.H. Kim1, and S. Tovanabutra1
1US MHRP, Silver Spring, MD, USA; 2University of Oxford, 
Oxford, UK; 3Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA, USA
Background: Initial adaptive immune responses to HIV-1 can be 
detected during the first weeks post-infection and viral escape variants 
can emerge soon after. Due to technical and logistical obstacles these 
processes are hard to define. Here we combine frequent sampling with 
targeted deep sequencing (TDS) to study viral evolution during very 
early acute HIV-1 infection (AHI).
Methods: A consented volunteer from RV217/ECHO with documented 
nucleic acid testing(NAT)-conversion and seroconversion was 
studied(day0:first NAT-positive time-point). Nine consecutive plasma 
samples (days2-31; mean sampling interval=3.6 days) were studied 
by combination of full- and partial-genome SGS and TDS(Ion Torrent). 
Ex vivo CTL responses to autologous peptides were analyzed at days 
7,17, and 53. TDS sequences were analyzed using Nautilus (Kijak et 
al., ARHR2013).
Results: The individual was originally infected with two highly-related 
T/F variants (genetic distance:1.5%;minor variant frequency:3%). Peak 
viremia occurred at day10. The peak CTL response to immunodominant 
LV9epitope (gp41;HXB2:814-822) was detected on day 17. The 
first evidence of escape at this epitope was also detected at day 17 
(frequency:0.8%). By day 21, there were 16 different escape variants 
(frequencies:0.6%-13.9%) all of them defined by a single non-
synonymous substitutions in any of 8 positions of the nonamer. 
Between day 17 and day 31 plasma viral load remained constant 
(range:5.71-6.04 log10copies/ml); the original variant decreased 
exponentially from 99.2% to10.5%, while the two major escape variants 
grew exponentially to 12.8% and 33.7%, respectively. The original 
sequence of both T/F variants was identical at the epitope and flanking 
regions, and escape variants emerged simultaneously on both variants. 
Six months post-infection a severe genetic bottleneck was observed: the 
dominant variant (frequency:79.5%) was one that at day 31 had been 
found at 7.4%, followed by the first detected escape variant (frequency: 
18.2%), while the original variant was present at 0.3%.
Conclusion: During very early AHI viral escape variants can emerge 
very rapidly and by exploration of a vast genetic landscape, which 
calls for the combined use of dense sampling and TDS. This data can 
be used to more accurately model dynamics of immune escape and 
inform vaccine design.
P05.33 LB
Development of Advanced Oligonucleotide-
Based Microbicides: Driving HIV into Suicide 
M. Voges1, J. Hauber1, and K. Mölling2
1Heinrich Pette Institute Leibniz Institute for Experimental 
Virology, Hamburg, Germany; 2Max Planck Institute for 
Molecular Genetics, Berlin, Germany
Background: HIV is globally transmitted primarily by sexual 
intercourse. Therefore, a major unmet medical need is seen in the self-
protection of women, particularly in societies where condoms are not 
accepted. Thus, user-controlled microbicides may represent promising 
intervention strategies that are currently being developed.
Methods: We are performing methods like RT/RNase H cleavage assay 
in vitro to show directly the specific oligodeoxynucleotide-dependent 
cleavage of the viral RNA sequence via viral RNase H in the highly 
conserved polypurin tract. Furthermore we are using luciferase-based 
infection assays to demonstrate reduced ability of the virus to infect 
cells after treatment with the oligodeoxynucleotides.
Results: We previously designed a short hairpin-looped 
oligodeoxynucleotide (ODN) that activates HIV-1 RNase H by mimicking 
ongoing reverse transcription, leading to efficient degradation of the 
viral RNA genome. ODNs have been shown to target cell-associated 
as well as free viral particles. Moreover, pronounced antiviral activity 
has been demonstrated in vitro and in several in vivo (animal) models. 
Therefore, current development focuses on strategies to increase 
overall ODN stability and to investigate different strategies of ODN 
delivery by chemical modifications of the ODNs. We could show that 
different chemical modifications of the ODNs did not alter the effect on 
RNase H dependent RNA cleavage and uptake of the ODNs into cells.
Conclusion: Taken together, these data suggest that ODNs may be 
valuable components of advanced antiviral microbicides that literally 
drive HIV into suicide.  
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P05.36 LB
Low Antibody-Dependent Cellular Cytotoxicity 
in HIV-1 Intrasubtype C Superinfected Zambian 
Seroconverters
D. Basu1, P. Xiao1, Z. Ende1, A. Bere1, W.J. Britt2, E. Chomba3,  
J. Mulenga3, W. Kilembe3, S.A. Allen1, C.A. Derdeyn1, and  
E. Hunter1
1Emory University, Atlanta, GA, USA; 2University of Alabama 
at Birmingham, Birmingham, AL, USA; 3Zambia Emory HIV 
Research Project, Lusaka, Zambia
Background: Although the role of antibody-dependent cellular 
cytotoxicity (ADCC) in HIV-1 superinfection and vaccine-elicited 
protection is unclear, this effector activity can result in early control 
of virally-infected target cells. Previous studies of superinfected 
Zambian seroconverters showed poor anti-HIV-1 humoral responses, 
including low autologous neutralizing antibodies, gp120- and V1V2-
binding antibodies prior to superinfection. Here, we compared ADCC 
responses between superinfected and non-superinfected groups, 
prior to superinfection. We also investigated CMV-specific antibody 
responses to evaluate potential global antibody defects.
Methods: We tested pre-superinfection antibodies for the ability to 
elicit ADCC killing in the presence of Subtype C env-coated target 
cells and unstained effector cells. We used flow-cytometry to measure 
killed targets and compared these responses between groups. We 
measured CMV-specific IgG responses approximately 3-months after 
seroconversion via a CMV-specific ELISA.
Results: ADCC responses prior to superinfection were significantly 
lower in the superinfected group as compared to the non-superinfected 
group. Two of three superinfected individuals had no measurable ADCC 
activity, compared to 1/10 non-superinfected controls. ADCC responses 
also directly correlated with gp120-specific IgG binding titer, viral load, 
and autologous neutralization titer, prior to superinfection. All study 
participants showed CMV seropositivity with no significant difference 
in CMV-specific binding IgG antibody reactivity between superinfected 
and non-superinfected groups.
Conclusion: Superinfected individuals exhibited lower levels of 
HIV-specific ADCC, but similar CMV-specific binding IgG antibody 
responses, as compared to non-superinfected controls. This, with our 
previous data, suggests that HIV-specific antibody responses may be 
compromised prior to superinfection, leading to potentially higher 
susceptibility to reinfection, yet superinfected individuals do not 
seem globally defective in antibody responses to viral pathogens. 
Moreover, it implies that within an area with a predominant subtype 
infection (subtype C), primary HIV-1 infection may induce some level 
of protection from superinfection. 
Research is supported by the NIH R37 AI-51235 (EH), FIC 2D43 
TW001042 (WK), P30 AI050409, and IAVI (SA).
P05.35 LB
Impact of HLA Selection Pressure on HIV-
1 Evolution and Fitness During the North 
American Epidemic
L. Cotton8, X.T. Kuang8, A.Q. Le8, J.M. Carlson1, B. Chan8,  
D.R. Chopera8, C.J. Brumme2, T.J. Markle8, E. Martin8, A. Shahid8,  
G. Anmole8, P. Mwimanzi8, P. Nassab8, K.A. Penney8,  
M.A. Rahman8, M. Milloy2, M.T. Schechter3, B.D. Walker4,  
T. Wagner5, S. Buchbinder5, J. Fuchs5, B. Koblin6, K. Mayer7,  
P. Harrigan2, M.A. Brockman8, A.F. Poon2, and Z.L. Brumme8
1Microsoft Research, USA; 2BC Centre for Excellence in HIV/
AIDS, Canada; 3University of British Columbia, Canada; 4Ragon 
Institute of MGH, MIT and Harvard, USA; 5San Francisco 
Department of Public Health, San Francisco, CA, USA; 6New 
York Blood Center, New York, NY, USA; 7Harvard Medical 
School, Southborough, MA, USA; 8Simon Fraser University, 
Burnaby, Canada
Background: Despite HIV’s extraordinary mutational capacity, immune 
escape pathways are broadly predictable based on host HLA. However, 
the extent to which HIV has adapted to HLA-driven selection over the 
pandemic’s course, and its pathogenic implications, remain unclear. 
Persistence of escape mutations following transmission could facilitate 
their gradual accumulation in circulating sequences, compromising 
host immunologic capacity as the epidemic progresses. A paucity of 
historic host/viral genotypes, combined with incomplete knowledge of 
epidemic founder viral sequences, render these challenging questions 
to answer.
Methods: We investigate immune-driven HIV-1 evolution in North 
America, and its functional implications, by genotypically and 
functionally comparing Linked host (HLA) and HIV (Gag/Nef) sequences 
from >350 novel historic specimens spanning 1979-1989, to a 
modern dataset spanning 2000-2011. Specimens derive from four key 
epidemic cities (New York, Boston, San Francisco and Vancouver). To 
minimize bias, HIV-1 sites under HLA-mediated selection were defined 
using independent sources.
Results: Reconstructed North American ancestral (founder) sequences 
are consistent with a late’60s/early’70s epidemic origin and are nearly 
identical to the continental consensus, arguing against widespread fixation 
of escape mutations in circulating sequences. Nevertheless, an observed 
~3-4 fold increase in HIV diversity over the past >30+ years appears to 
be driven in large part by HLA-mediated selection. Furthermore, median 
“background frequencies” of HLA-associated polymorphisms increased 
by 35-50% during this time. Though our estimates of the time to 
accumulation to dominance are on the order of centuries for most escape 
mutations, we identify an A*02-associated polymorphism in Gag that has 
increased to near-dominance in the past decades.
Conclusion: Results provide direct evidence supporting the 
accumulation of HLA-associated polymorphisms during an epidemic 
affecting an immunogenetically diverse host population. Furthermore, 
though no major temporal changes in Gag function were noted, 
increases in Nef-mediated HLA class I (and CD4) downregulation over 
time suggests HIV adaptation towards enhanced immune evasion via 
mutational and non-mutational means.
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P05.37 LB
Enhanced Fusion and Virion Incorporation for 
HIV-1 Subtype C Envelope Glycoproteins with 
Compact V1/V2 Domains
M. Cavrois1, J. Neidleman1, M.L. Santiago2, and C. Derdeyn3,  
E. Hunter3, W.C. Greene1
1Gladstone Institute, San Francisco, CA, USA; 2University of 
Colorado, Denver, CO, USA; 3Emory University, Atlanta, GA, USA
Background: HIV-1 encodes an envelope glycoprotein (Env) that 
triggers the fusion of viral and cellular membranes while minimizing 
exposure of its key protein domains to the adaptive immune system. 
Envs with long variable domains are generally less sensitive to antibody 
neutralization but also appear less fit to establish a de novo infection. 
By exchanging the V1/V2 domains between Envs of the same infected 
person or between two persons linked by a transmission event, we 
investigated the links between V1/V2 length, Env incorporation and 
fusion to primary CD4 T-cells or monocyte-derived dendritic cells. 
Methods: From a set of cloned Envs from four male-to-female 
transmission pairs (Lusaka cohort), we engineered 19 mutants in which 
sequences from V1 or V2 domains were exchanged between different 
Envs sequences from the same person or within the same transmission 
pair. The impact of V1/V2 domain length on Env incorporation was 
measured by Western blot while viral fusion was measured using the 
FRET-based fusion assay, which specifically quantifies fusion of HIV-1 
virions containing β-Lactamase-Vpr to primary cells. 
Results: Envs with compact V1/V2 domains mediated higher levels 
of fusion to both cell types while Envs with longer V1/V2 domains 
fused with lower efficiency. Unexpectedly, the length of V1/V2 greatly 
impacted Env incorporation into HIV-1 virions. Long V1/V2 domains 
in Env were associated with lower levels of virion Env. The number of 
potential N-glycosylation sites in V1 or V2 also inversely correlated to 
Env incorporation and fusion.
Conclusion: Our study points to Env incorporation into virions and 
fusion as limiting steps for transmission of HIV-1 to a new host, and 
suggests that the length and/or the N-glycosylation profile of V1/V2 
domain influences these steps. Exploiting the fitness cost incurred by 
long V1/V2 could lead to the development of more effective vaccine 
interventions to curb the HIV-1 epidemic.
Topic 05: HIV Transmission and Viral Diversity
Posters
P
O
ST
ER
S
191AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P06.02
Analysis of 100 African Whole Genome 
Sequences for Natural Host Resistance to HIV-1 
Infection
R. Mackelprang1, M. Emond1, J. Chong1, S. Hou1, T. O’Connor1, 
M. Bamshad1, T. Louie1, J. Mullins1, G. deBruyn2, N. Mugo3, and 
J.R. Lingappa1
1University of Washington, Seattle, WA, USA; 2University of 
the Witswatersrand, Johannesburg, South Africa; 3University 
of Nairobi, Nairobi, Kenya 
Background: HIV-1 exposed seronegative individuals (HESN) have 
been documented in diverse cohorts. Recent genome-wide studies 
capturing common genetic variation in European populations failed to 
identify HESN-associated single nucleotide polymorphisms (SNPs). We 
compared whole genome sequences (WGS) of African HESN and HIV-1 
seroconverters (SC) in order to identify genetic variation underlying an 
HESN phenotype.
Methods: HIV-1 exposure scores (ES) were generated through 
regression modeling of SC and HESN in the context of prospective 
follow-up of 3893 African HIV-1 serodiscordant couples. We selected 
50 HESN with consistently high ES matched to 50 SC by gender 
and self-reported ethnicity. Complete Genomics, Inc. generated 
100 WGS with a median of 49 reads per base obtained over these 
genomes. We evaluated 38 candidate SNPs previously reported as 
associated with HESN versus SC.  We also evaluated 1) single SNP 
associations with HIV-1 acquisition using logistic regression, and 
2) gene-level associations using two distinct algorithms (SKAT and 
Morris-Zeggini).  All analyses controlled for population stratification 
using the first 3 principal components.  P-values are uncorrected for 
multiple comparisons.
Results: Nearly 22 million high quality autosomal SNPs (454,176 
exonic SNPs) were identified across 100 African WGS.  Only one 
candidate (CCL2, rs1024610) was significantly associated with HESN 
compared to SC (P=0.01, identified in 1 SC and 11 HESN); although, 
the power to evaluate some candidate variants was limited. The by-
variant analysis identified 13 variants having 10 -5P>1.8x10 -7; the 
by-gene analysis identified 36 genes with 10 -3P>1.34x10 -7 (SKAT) 
or 28 genes with 10 -3P>4.2x10 -5 (Morris-Zeggini).  
Conclusion: Our WGS analysis of African HESN and SC has identified 
variants not previously associated with HIV-1 acquisition phenotypes 
that are of high priority for further study.  Among 38 candidate SNPs 
tested, only one was significantly associated with protection from HIV-
1. We are currently validating these associations through genotyping 
in an independent cohort of HESN and SC. 
P06.01
The Expression Analysis of Glucose Transporter 
1 Gene in the Pumwani Commercial Sex 
Worker Cohort, Nairobi, Kenya
W.A. Apidi1, R.C. Su1, J. Kimani2, F. Plummer3, and B. Ball1
1University of Manitoba, Winnipeg, Canada; 2University of 
Nairobi, Nairobi, Kenya; 3Public Health Agency of Canada, 
Winnipeg, Canada
Background: Altered susceptibility to HIV1 infection has been observed 
in multiple cohort studies. One of the best characterized HIV1 exposed 
yet uninfected groups is a commercial sex worker cohort from Nairobi, 
Kenya. (Fowke, et al, 1996; Plummer, et al, 1999; Ball, et al, 2007) 
A gene expression analysis conducted showed differential regulation 
of the glycolysis/gluconeogenesis pathway in HIV-1 exposed yet 
seronegative CSWs. (Songok, et al, 2012) 
Glucose is utilized by lymphocytes as their primary fuel source for 
cell survival, size, activation and cytokine production. The first critical 
regulatory step in glucose metabolism is glucose entry into cells 
through facilitated diffusion by proteins of the glucose transporter 
(GLUT) family. (Fox et al, 2005; Jacobs, et al, 2008) Over-expression 
of GLUT1 leads to increased glucose uptake and glycolysis which is 
required to mount a functional immune response necessary for rapid 
cell growth and proliferation in T lymphocytes. (Maclver et al, 2008) 
Methods: The study population was drawn from the Pumwani Sex 
Worker Cohort, Nairobi including: HIV highly exposed yet seronegative 
(HESNs) CSWs (>7 years); newly enrolled HIV-uninfected (<7 years); 
HIV-infected and lowly-exposed HIV negative antenatal clinic attendees 
(low risk group).Total RNA was extracted from PBMCs using Trizol; 
cDNA was synthesized and relative mRNA expression determined 
using SYBR Green by quantitative real time PCR. 
Results: Each assay was normalized using 18s rRNA gene. We observed 
a significant difference between highly exposed yet uninfected (HESNs) 
and newly enrolled HIV uninfected CSWs. (p=0.0056) There was no 
significant difference between HESNs with the HIV negative antenatal 
clinic attendees (p=0.8628) and HIV infected CSWs (p=0.5399).
Conclusion: We observed significantly lower mRNA expression of 
Glut1 in HESNs when compared to their uninfected yet susceptible 
counterparts. Following studies of Glut 1 protein expression and 
uptake studies are underway to understand the role Glut1 in glucose 
metabolism in HIV resistance.
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P06.04
HLA-Associated Variation in HIV Viral Load 
in a South American Native Community with 
Limited HLA Diversity
D.C. Mónaco1, M. Quipildor2, A. Di Paolo2, R. Coloccini3,  
G. Theiler4, M. Pando3, L. Fainboim4, E. Hunter1, H. Salomon3, 
and D. Dilernia1
1Emory Vaccine Center, Atlanta, GA, USA; 2Hospital San 
Vicente de Paul, Oran, Argentina; 3INBIRS, Buenos Aires, 
Argentina; 4Hospital de Clinicas, Buenos Aires, Argentina
Background: Pathogen-driven balancing selection has been proposed 
as an explanation for the high diversity of the HLA system. Different 
HLA alleles have been associated with variations in HIV viral load. Our 
aim was to determine the HLA-A and -B diversity in a South American 
native HIV-positive community and their association with clinical 
markers of disease progression.
Methods: We developed and validated a sequence-based technique 
for high resolution typing of HLA-A and –B genes. This technique was 
implemented to determine the diversity of these genes in a group of 65 
HIV-positive native individuals from Oran, Argentina. The comparison 
between the patient’s HLA alleles and the HIV viral load was made by 
Mann-Whitney test and the False-Discovery Rate approach was applied 
to correct for multiple comparisons.
Results: The HLA profile of the population under study was 
consistent with that observed for other native communities from 
South America. HLA-A diversity was restricted at both group 
(Heterozygosity Index (H)=0.791) and subtype (H=0.841) level. 
Alleles A*02:01:01:01, A*24:02:01 and A*31:01:02 accounted for 
the 83.4% of the genetic frequency. HLA-B diversity was found 
to be restricted at the group level (H=0.870) but highly diverse at 
the subtype level (H=0.969). The analysis of the viral load in each 
HLA allele group showed that HLA-B*35Px-positive patients exhibit 
significantly higher viral loads (p=0.038, q=0.17) while HLA-B*39-
positive patients exhibit significantly lower viral loads (p=0.014, 
q=0.13) than the negative counterparts.
Conclusion: The HLA profile of the HIV-positive native community of 
Oran showed to be restricted except at the subtype-level in HLA-B, 
consistent with the high prevalence of endemic infectious diseases in 
the area. In particular, B*39 is a native allele that mediates a novel 
association with a better control of the HIV infection.
P06.03
Higher DEFA1A3 Gene Copy Number and 
α-Defensins 1-3 Secretion by Dendritic Cells 
Are Associated with HIV Protection
V. Casanova1, I. Naval-Macabuhay1, F. Garcia2, A. Leon2,  
E. Fernandez2, C. Gil2, L. Miralles2, C. Rovira2, P. McCormick1,  
J. Gatell2, M. Plana2, T. Gallart2, and N. Climent2
1IDBAPS, Barcelona, Spain; 2Institut d’Investigació Biomèdica 
Pi i Sunyer IDIBAPS-AIDS Research Group, HIVACAT, 
Barcelona, Spain, Barcelona, Spain
Background: Some exceptional individuals are exposed to HIV 
virus but remain uninfected (HIV-exposed uninfected, EU). Higher 
α-defensins1-3 (HNP-1-3) secretion is known to be one of the innate 
host-resistance factors to HIV-1-infection. HNP-1-3 are peptides 
expressed mainly in neutrophils, but also in DCs, which display anti-
HIV-1 activities. DEFA1A3, the gene coding for HNP1-3 is present in a 
copy number variation (CNV).We hypothesize that an increased CNV 
would be a key factor inducing a protective HIV-1-immune response.
Methods: Healthy as well as EU monocyte-derived DCs supernatants 
were collected and HNP1-3 protein and 25 cytokine were quantified. 
DEFA1A3 CNV was addressed trough Duplex qRT-PCR. HIV-DCs-
infectionassays were performed in healthy individuals with high CNV 
(≥ 9) versus low CNV (≤ 4) being DCs infected at low dosesand P24 and 
maturation levels quantified. HIV-1-pulsed-DCs were co-cultured with 
autologous-monocyte-depleted PBMCs and HIV-specific responses 
were analyzed.
Results: EU individuals display a higher DEFA1A3 copy number 
variation (CNV), resulting in a higher HNP1-3 secretion in their 
immature dendritic cells (iDCs). Higher DEFA1A3 CNV and levels of 
HNP1-3 in iDCs correlate with the amount of virus EU-individuals 
are exposed to, suggesting a protective role (p<0.01). CNV critically 
and significantly modulate iDCs functions, as observed with healthy 
individuals with high CNV (≥9) who display a more mature DC status, 
including increased cytokine and chemokine (IL-8, IL-6, IL-1β, MCP-1 
and MIP-1β) secretion. These DCs have a decreased capacity to be 
HIV-1-infected and are able to induce a higher HIV-specific CD8+ T cell 
response than their lower CNV counterparts (p<0.05).
Conclusion: Elevated DEFA1A3 CNV genotype confers HIV-1 
protection while DCs from these individuals secrete higher amounts 
of HNP1-3 which by its antiviral activities and immune-mediators 
induction inhibit HIV replication on DCs. Taken together, elevated 
HNP1-3 CNV and HNP1-3 secretion potentiate and improve DC-HIV 
presentation lowering the risk of infection and providing an enhanced 
HIV-1-specific response.
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P06.06
Predictors of HVTN 503 MRK AD5 HIV-1 Gag/
Pol/Nef Vaccine-Induced Immune Response
K. Cerwensky1, F. Laher1, K. Otwombe1, G. Churchyard2, L. Bekker3, 
M. Nchabeleng4, K. Mlisana5, J. Kublin6, and G. Gray1
1University of the Witwatersrand, Soweto, South Africa; 2The 
Aurum Institute for Health Research, Johannesburg, South 
Africa; 3University of Cape Town, Cape Town, South Africa; 
4University of Limpopo, South Africa; 5CAPRISA, University 
of KwaZulu-Natal, South Africa; 6Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA
Background: Phambili, the HVTN 503Phase IIb efficacy study of 
MRK-Ad5 HIV-1 clade B vaccine conducted in South Africa, neither 
prevented HIV-1 infection nor lowered viral load setpoint. However, 
immune responses recognizing Clades B and C HIV-1 subtypes were 
elicited.We investigated predictors of vaccine-induced HIV-1 specific T 
cell immune responses.
Methods: An analysis of vaccine-induced immunogenicity by 
interferon-γ ELISPOT assays was conducted on the first 186 enrolled 
vaccine and placebo recipients four weeks post second vaccination. 
Descriptive and frequency analysis stratified by study arm and gender 
were performed on baseline demographics (gender, age, BMI, study site, 
Ad5 titre, HSV2, circumcision status) and risk behaviours. Multivariate 
logistic regression determined predictors of immune response to any 
Clade B or C antigens in the vaccine arm using backward selection. 
Each analysis was two-sided with 5% level of significance. 
Results: Of the 186 participants, 53.7% (n=100) were female, median 
age was 23 years [IQR:21-27], median BMI was 22.5 [IQR:20.4-
27.0], 53.7% (n=100) were from Soweto, 85.5% (n=159) were 
Ad5-seropositive, 18.8% (n=35) were heavy drinkers; 31.7% (n=59) 
reported drinking/drug use with sex, 61.3% (n=114) had unprotected 
vaginal sex and 79% (n=147) reported a main partner. All participants 
in the vaccine arm (n=93, 50%) developed T cell responses to either 
Clade B (n=87, 47%) and/or Clade C antigens (n=74, 40%), p=0.17. 
In multivariate analysis, normal/underweight BMI [AOR: 5.926, CI: 
1.069-32.84, p = 0.0417], female gender [AOR: 0.172, CI: 0.033-
0.883, p=0.0350], and one-log increase of Ad5 titre [AOR: 0.374, CI: 
0.164-0.850, p=0.0189] significantly predicted immune response to 
any Clade C antigens. Heavy drinking [AOR: 0.224, CI: 0.056-0.891, 
p=0.0336] inhibited immune response.
Conclusion: Gender, BMI, Ad5 titre and heavy drinking affected 
vaccine-induced HIV-1 specific immune responses to Clade C antigens. 
The role of BMI in blunting these immune responses requires 
elucidation. Whether these factors affect HIV vaccine efficacy remain 
to be determined. 
P06.05
IL-4, IL-10 and TNF-α Promotor Gene 
Polymorphism in North-Eastern Ukrainian 
HIV-1 Infected Individuals
A.I. Piddubna1
1Sumy State University, Sumy, Ukraine
Background: The objective of the research was to study distribution 
character of the allel variants of IL-4 promoter gene area in position 
-590, IL-10 in position -592, TNF-α in position -308 in HIV-1 infected 
Ukrainians of North-Eastern region. 
Methods: Data for the study were DNA samples, received from 
peripheral blood leukocytes of 200 inhabitants of North-Eastern region 
of Ukraine: 78 HIV-infected, 22-HIV-negative individuals from the 
group of high risk of contamination, 100 healthy blood donors. Gene 
polymorphism detection was made with PCR-RLFP method. 
Results: IL-4 (rs 2243250), IL-10 (rs 1800872) and TNF-α (rs 1800629) 
gene polymorphism has been studied for the first time in the population 
of HIV-infected Ukrainians. By analysis of frequency of IL-4 gene allel 
variants it has been discovered that homozygotes by the main allel 
were the dominant variant. It has been found out that among people 
with HIV there were 9.0 % of T/T minor gene carriers and were 4.5 
more often met in comparison with control group (p<0.05) that can 
prove the tendency to association of the mentioned genotype with 
infection. Distribution of allel variants of IL-10 gene promoter region in 
position -592 is characterized by homozygote dominance by the main 
gene. It has been established that among the individuals with HIV A/A 
minor allel carriers were 3.4 more often met in comparison with control 
group (p<0.05). The occurrence of the homozygous combination of 
the allel variant G/G of the promoter of TNF-α has been shown to 
prevail almost twofold over the occurrence of the variant G/A among 
all groups. High frequency of heterozygote by the main allel has been 
recorded among the individuals with HIV.
Conclusion: Our data suggest that IL-4, IL-10, TNF-α variations may 
contribute to the acquisition of HIV infection and encourages carrying 
out of further populations studies in this sphere of HIV-infection 
immunogenetics.
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P06.08
HLA Class I and KIR Polymorphisms Associated 
with Protection from HIV Infection and Disease 
Progression in a MSM Cohort in Lima, Perú
A. Olvera1, S. Perez-Alvarez1, C. Ganoza2, J.R. Lama2, J. Sanchez2, 
and C. Brander1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2IMPACTA, Lima, Peru
Background: Increasing data suggest that highly-exposed subjects 
can remain HIV uninfected despite prolonged viral exposure. It is also 
well known that relative viral control can be achieved by some infected 
individuals, especially those expressing particular HLA class I alleles 
and KIR genes.
Methods: To assess potential associations between particular genetic 
markers and risk of HIV infection or HIV viral load and CD4 counts, we 
followed a cohort of 468 individuals (222 HIV-, 246 HIV+) with high-
risk sexual behaviour in Lima (Perú), who were typed for HLA class I 
alleles. Of these, KIR genotypes were available for 73 HIV- and 170 
HIV+ subjects, with 35 of the latter also being assessed for the HLA-C 
upstream -35 variant.
Results: Three HLA class I allele (A*2301, B*3543, B*5703) and 1 KIR 
gene (2DS1) were significantly enriched among the HIV infected group, 
while one HLA allele (B*4002) was associated with relative protection 
from HIV infection. Eight HLA alleles (A*0201, B*0801, B*1801, B*3501, 
B*3505, B*3509, C*0401, C*0702) and one KIR gene (2DS4) were 
associated with higher viral loads and/or reduced CD4 counts in the HIV 
infected group while 11 HLA alleles (A*0222, A*1101, A*3303, B*1501, 
B*1516, B*3903, B*3913, B*3914, B*4004, B*5703, C*0801) and 2 KIR 
genes (2DP1 and 2DL1) were associated with lower viral loads and/or 
higher CD4 counts (all based on uncorrected p-values < 0.05).  
Conclusion: Despite Peruvian cohorts being well represented in past 
and current HIV vaccine trials; this is the first study to define high-
resolution HLA and KIR typing for this population. The description of 
the genetic background of this population will be of importance for 
immunopathological studies and to interpret disease outcome and HIV 
vaccine trial data in this country and the rest of South America.
P06.07
The Molecular Interaction of HIV’s Nef Protein 
with ß-catenin in the Wnt Signaling Pathway
K. Weiser1, J. Fuller1, R. Dasgupta 1, and T.J. Cardozo1
1New York University School of Medicine, New York, NY, USA
Background: The Wnt signaling pathway is implicated in major 
physiologic cellular functions such as proliferation, migration, cell 
fate specification, maintenance of pluripotency and induction of 
tumorigenicity. Proliferation and migration are important responses of 
T cells, which are major cellular targets of HIV infection. 
Methods: Using an informatics screen, we identified a previously 
unsuspected interaction between HIV’s Nef protein and β-catenin, a 
key component of the Wnt pathway. The three-dimensional structural 
compatibility of Nef peptides with the β-catenin ligand binding 
site was then tested more stringently by computational molecular 
docking. A pull-down assay using purified recombinant proteins and 
co-immunoprecipitation experiments in HEK293 cells were also used 
to confirm the Nef/β-catenin interaction. Finally, we used a β-catenin 
responsive luciferase reporter assay to determine if Nef inhibited the 
Wnt signaling pathway in cells.
Results: A segment in Nef contains identical amino acids at key positions 
and structurally mimics the β-catenin binding sites on endogenous 
β-catenin ligands. The interaction between Nef and β-catenin was 
confirmed in vitro and in cells. Moreover, the introduction of Nef into 
cells specifically inhibited a Wnt pathway reporter in cell-based assays. 
Conclusion: Structural and biochemical observations confirm that 
HIV’s Nef protein interacts with human β-catenin. This interaction 
is functionally significant in cells. The association of Nef with 
β-catenin potentially implicates the Wnt signaling pathway in T cell 
transmigration and immune activation phenomena characteristic of 
HIV infection and AIDS.
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P06.10
KIR2DS4 Confers Susceptibility in Mother-to-
Child HIV-1 Transmission
H.A. Hong1, M. Paximadis1, G.E. Gray2, L. Kuhn3, and  
C.T. Tiemessen1
1University of the Witwatersrand, Johannesburg, South Africa; 
2Chris Hani Baragwanath Hospital, South Africa; 3Mailman 
School of Public Health, Columbia University, New York, USA
Background: HIV-1 mother-to-child transmission (MTCT) remains the 
primary source of HIV-1 acquisition amongst children and can take 
place in utero (IU), intrapartum (IP) or postnatally through breastfeeding. 
Killer cell immunoglobulin-like receptors (KIRs) present on natural killer 
(NK) cells have previously been associated with HIV-1 transmission. 
KIR genes can be classified into A or B haplotypes, which respectively 
contribute to a more inhibitory or activating NK cell potential. KIR2DS4 
is the only activating KIR gene within the A haplotype, and alleles of 
KIR2DS4 can be divided into functional receptors (KIR2DS4-f) or non-
functional variants (KIR2DS4-v) devoid of a transmembrane region. 
This study questions the role of KIR2DS4 in the context of MTCT.
Methods: We KIR and HLA-C genotyped 217 Black South African 
mother-infant pairs: 145 were HIV-1 non-transmitting mothers (NT) 
and their exposed uninfected infants (EU); 72 were HIV-1 transmitting 
mothers (TR) and their infected infants [IU, IP or IU-2 (an IU enriched 
infected group)].
Results: KIR2DS4-v gene frequency was significantly higher in IU-2 
infants compared to EU infants (P=0.010, OR=3.41). This association 
was more significant when comparing infants homozygous for the A 
haplotype (P=0.004, OR=18.4). Mother-infant concordance (M+I+) 
for KIR2DS4-f, KIR2DS4-fv or KIR2DS4-v were not associated with an 
increased risk of HIV-1 transmission. However in M+I- discordance, 
KIR2DS4-f was associated with a higher risk of IP transmission (P=0.005, 
OR=3.84); whilst in M-I+ discordance, KIR2DS4-v was associated with 
an increased risk of IU transmission (P=0.002; OR=6.40). Comparisons 
involving the described HLA-C ligands for KIR2DS4-f did not reveal 
any significant associations.
Conclusion: Our findings add to studies of discordant couples 
identifying KIR2DS4-f as associated with risk of transmission through 
mucosal routes, and further identify the lack of a surface KIR2DS4 as 
a risk factor in IU HIV-1 acquisition. This study highlights an important 
role for KIR2DS4 in HIV-1 susceptibility/protection.
P06.09
Mechanisms of Abrupt HIV Disease Progression 
in a Cohort of Previous Elite and Viremic HIV 
Controllers
M. Rocafort6, R. Bellido6, M. Crespo1, J. Puig2, M.T. Orodea2,  
A. Marco3, L. Ruiz6, J. Alcamí4, B. Clotet6, R. Paredes6, C. Brander5, 
and B. Mothe6
1Hospital de la Vall d’Hebrón, Barcelona, Spain; 2‘Lluita 
contra la sida’ Foundation, Hospital Germans Trias i Pujol, 
Barcelona, Spain; 3Programa VIH/SIDA, Centre Penitenciari 
d’Homes de BCN, Barcelona, Spain; 4Centro Nacional 
de Biotecnología, Madrid, Spain; 5IrsiCaixa Institute for 
AIDS Research, HIVACAT, Hospital Germans Trias i Pujol; 
Universitat Autònoma de Barcelona, ICREA, Barcelona, 
Spain; 6IrsiCaixa Institute for AIDS Research, HIVACAT, 
Hospital Germans Trias i Pujol, Barcelona, Spain
Background: Extensive cross-sectional immune data from individuals 
able to control HIV replication to undetectable or low levels and 
with normal CD4+ T cell counts in the absence of cART (elite and 
viremic controllers) is already available. However, a small proportion 
of controllers end up progressing and relatively little is known about 
the factors responsible for the abrupt loss of HIV control (LoC) in these 
individuals.   
Methods: We identified 14 HIV patients who experienced an abrupt 
transition from a non-progressive to progressive HIV infection defined 
as > 1 log VL increase and loss of >30% CD4 cell counts or drop below 
350 cells/ml within 1 year. All individuals were screened longitudinally 
for T cell responses to the entire HIV proteome by ELISPOT and 
flow cytometry. Emergence of CXCR4-using virus and presence of 
HIV superinfection were evaluated. Presence of HLA footprints in 
the autologous viral population pre- and post-LoC was assessed. All 
immune data was compared to long-term Elites (n=32) and Viremic 
Controllers (n=19) without signs of HIV disease progression. 
Results: Tested individuals had stable viremia <3log copies/ml before 
LoC without protective HLA alleles being overrepresented. CXCR4-
tropic plasma virus was detected in 4 individuals’ post-LoC of which 2 
had R5 virus pre-LoC. There was no evidence for superinfection except 
one individual who is being investigated further. In 7/9 individuals 
tested to date, HLA footprints were maintained after LoC or even 
emerged newly post-LoC. Only one patient showed reversal of pre-LoC 
HLA footprints at the post-LoC timepoint. Immune analysis of detailed 
CTL escape mutations as well as changes in polyfunctionality is being 
currently assessed.
Conclusion: With a number of analyses still ongoing, emergence of 
CXCR4-using HIV, but not HIV superinfection nor reversion of viral 
adaptation to immune pressure, might be involved in loss of HIV control 
in subjects with previous spontaneous control of HIV-1 infection.
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P06.12
Host Genetics and Susceptibility to HIV-1 
Infection: Novel MHC Associations Among 
Serodiscordant Couples
H.A. Prentice1, N.M. Pajewski2, T. Porter1, K. Zhang1, E.E. Brown1, 
S. Allen3, E. Hunter3, R.A. Kaslow1, and J. Tang1
1University of Alabama at Birmingham, Birmingham, AL, USA; 
2Wake Forest University, Winston-Salem, NC, USA; 3Emory 
University, Atlanta, GA, USA
Background: Human genetic variations known to influence HIV-
1 acquisition have been restricted primarily to the CCR5 gene that 
encodes a major HIV-1 coreceptor. Two recent genome-wide association 
studies of African cohorts have failed to identify additional genetic 
loci. Our analyses of HIV-1 serodiscordant couples suggest that further 
investigation of variants within the human major histocompatibility 
complex (MHC) may help identify novel factors.
Methods: Single nucleotide polymorphisms (SNPs) within the extended 
human MHC region were genotyped using the ImmunoChip. Two 
alternative analytical methods, single marker models and penalized 
(HyperLasso), were applied to detect SNPs differentially distributed 
between either recent seroconverters (SCs) or seroprevalent partners 
(SPs) and HIV-1-exposed seronegative subjects (HESNs) with adequate 
follow-up and testing. Both types of models assumed additive effects 
adjusted for sex, age, visit interval, and previously reported risk factors 
in index and recipient partners. For Bonferroni correction, the number 
of independent comparisons was determined by simpleM.
Results: Analyses focused on 6,865 MHC SNPs with minor allele 
frequency >2.5% among 212 SCs, 437 SPs, and 227 HESNs. 
When SCs were compared to HESNs, single marker models failed 
to identify any variant associated with acquisition at a significance 
threshold of p=2.8x10 -5 . Penalized regression models revealed 
three independent association signals: rs2451731 (intergenic 
between ABT1 and ZNF322A) (OR=0.55, p=0.001), rs7744381 
(ncRNA within HLA-DPB2) (OR=0.56, p=0.002), and rs9469003 
(intergenic, between MICA and HLA-X) (OR=2.04, p=0.0008). Further 
comparison between SPs and HESNs identified one haplotype block 
between IER3 and DDR1 (tagged by rs2535335) as another region 
of interest (OR = 1.72, p = 0.0006).
Conclusion: High-dimensional statistical approaches may identify 
novel relationships between HIV-1 acquisition and variants in the MHC 
where their potential for functional contribution is considerable.
P06.11
May Host Genome Affect the Response to 
Dendritic Cell Based Immune Treatment 
Against HIV-1? 
R. Moura1, A. Pontillo2, P. D’Adamo3, and S. Crovella1
1Federal University of Pernambuco, Recife, Brazil; 2ICB/USP, 
São Paulo, Brazil; 3IRCCS “Burlo Garofolo,” Trieste, Italy
Background: Background. Promising studies have been made in recent 
years around the world, addressing the epidemic of Acquired Immune 
Deficiency Syndrome (AIDS) and including a new line of treatment 
against HIV-1 by using autologous dendritic cells (DC) vaccination. 
In December 2004, the Brazilian phase I clinical trial of DC-based 
immune therapy against HIV-1 was published, reporting the data of 18 
untreated HIV+ patients vaccinated with autologous DC pulsed with 
autologous inactivated HIV showed that half of the patients presented 
a good control of viral load. DC-based vaccine was demonstrated to 
increase HIV specific cellular immune response; however, in some 
HIV-infected patients, the response to the vaccine resulted to be not 
fully effective. In order to understand if the outcome of the vaccination 
may be influenced by the host’s genome, we studied the genetic 
background of 18 HIV-infected patients previously vaccinated with DC. 
Methods: Methods. Genomic DNA of 18 HIV-infected patients included 
in the Brazilian phase I clinical trial were analysed through Illumina 
Exome chip and Taqman SNP genotyping assays. SNPs frequencies 
distribution was compared between good- and bad- responder to the 
immune treatment.
Results: Results. We identified genes (PARD3B, PCDHB6 and B9, 
PKD1L2, SPOCK3, OR8U8 and U1, FOLR4, WDR66) and Single 
Nucleotide Polymorphisms (SNPs) potentially associated with the 
response to the immune-treatment.
Conclusion: Conclusion. Our findings suggest that, independently and/
or in addition to other variables, the host’s genome could significantly 
contribute to the modulation of the response to the DC vaccine. It will 
be interesting to investigate the distribution of these SNPs in other 
immune therapies trials.
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P06.14
Copy Number Variation of the Immunoglobulin 
Heavy Chain Variable Gene 1-69 in HIV-1 
Infected Individuals 
B. Lambson1, C. Mitchell1, E. Gray1, S.S. Abdool Karim2, and  
L. Morris1
1National Institute for Communicable Diseases of the National 
Health Laboratory Services, Johannesburg, South Africa; 
2Centre for the AIDS Programme of Research in South Africa, 
Durban, South Africa
Background: Immunoglobulin heavy chain variable region gene 
IGHV1-69 is commonly used by anti-HIV-1 antibodies including 
those to the CD4i epitope and the neutralizing antibodies 4E10, 
8ANC195 and CH12, from a participant in the CAPRISA Acute 
Infection Cohort, CAP206. IGHV1-69 can vary from 2 to 4 copies 
per genome because of duplications on 14q, which occur in an 
estimated 50% of people. IGHV1-69 usage has been shown to be 
linked to the number of gene copies. 
Methods: We developed a droplet digital PCR assay in which copy 
number was determined by counting the absolute number of target 
and reference DNA molecules. Reaction mix was partitioned into 
droplets and amplified to endpoint with primers and fluorescently 
labeled probes. The IGHV1-69 reverse primer was positioned 
in the 3’ flanking region to ensure that only germline DNA was 
amplified. The DNA from 12 CAPRISA participants, whose IGHV1-
69 allele number is known from cloning and ultra-deep sequencing 
experiments, was used. 
Results: Copy number among the 12 participants varied from 2 to 
4 per diploid genome. When compared to the allele numbers, copy 
number equaled these values in 10 cases but exceeded these values in 
2 participants.  Five individuals had a copy number of 3, four had a copy 
number of 2 and three had a copy number of 4. All three individuals 
with 4 copies produced broadly cross-neutralizing antibodies against 
HIV. CAP206 had 3 copies and 3 alleles, all of which were confirmed 
by antibody isolation, including IGHV1-69*02 used by CH12.  
Conclusion: The IGHV1-69 insertion polymorphism of 14q is common 
in the South African population with 67% (8/12) CAPRISA women 
having more than 2 copies. Isolation of neutralizing antibodies from 
these individuals, including those with 4 copies of IGHV1-69, will 
determine whether increased copy number is associated with a greater 
likelihood of IGHV1-69 neutralizing antibodies. 
P06.13
APOBEC3G and -3F Induced Cytidine 
Deamination and Association with Viral Control 
in a Population with High Frequency of the 
APOBEC3G H186R Variant
K. Reddy1, C. Winkler2, L.  Werner1, K. Mlisana1, S.S. Abdool Karim1, 
and T. Ndung’u1
1CAPRISA, University of KwaZulu-Natal, Durban, South Africa; 
2National Cancer Institute, NIH, Frederick, MD, USA 
Background: In the absence of HIV-1 Vif, APOBEC3G mutates the viral 
DNA during viral reverse transcription. Previous data suggests that the 
polymorphic variant, APOBEC3G H186R, may predispose to accelerated 
HIV-1 disease progression, however the mechanism remains unknown. 
It is possible that genetic variation within APOBEC3G may hinder HIV-1 
DNA editing in vivo. 
Methods: Participants in this study were twenty two females recruited 
with known acute or recent HIV-1 infection in Durban, South Africa. 
Participants were genotyped for the APOBEC3G H186R polymorphism 
by Taqman genotyping. The HIV-1env gene was amplified from proviral 
DNA samples obtained from participants at 36 months post-infection 
and directly sequenced.  The Hypermut 2.0 Tool (Los Alamos HIV 
Sequence Database) was used to detect APOBEC3G- and -3F induced 
hypermutations relative to a consensus subtype C reference sequence.
Results: There was no difference in viral DNA hypermutation according 
to APOBEC3G genotype.  Interestingly, HIV-1 env sequences contained 
a higher number of APOBEC3F compared to APOBEC3G-induced 
mutations (p=0.003), however, there was significant correlation 
between the numbers of APOBEC3G and -3F-induced mutations that 
were present (r=0.5, p=0.03). Additionally, the number of APOBEC3F- 
but not APOBEC3G-induced mutations correlated negatively with 
viral load (r= -0.6, p=0.006) and positively with CD4 T cell counts 
(r=0.6, p=0.004). One participant, homozygous for the 186H variant 
and a viremic controller (HIV-1 RNA copies below 2,000 copies/ml) 
at evaluation had extensive APOBEC3G-induced hypermutations, 
resulting in multiple stop codons across the gene.  
Conclusion: Our findings suggest that in our study population with a 
high frequency of the detrimental APOBEC3G H186R polymorphism 
that occurs predominantly within African populations there may be 
more significant contribution of APOBEC3F to viral hypermutation 
and viral control.  Further studies are needed on the contribution and 
mechanisms of viral control by diverse cytidine deaminases in heavily 
burdened countries.
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P06.16
Functional Comparison of the Promoters of the 
Two Genes (CCL3; CCL3L) that Encode for CCL3, 
the Natural Ligand of CCR5
M. Paximadis1 and C.T. Tiemessen1
1National Institute for Communicable Diseases and the 
Witswaterand University, Johannesburg, South Africa
Background: The CCL3 chemokine is encoded by two functional 
genes, CCL3 and CCL3L. Numerous studies have shown a role for 
CCL3 in HIV-1 disease, however the individual contributions of the two 
genes to CCL3 production is largely unknown since the two isoforms 
cannot be easily differentiated. The 5’UTR regions of CCL3 and CCL3L 
share a 77% nucleotide similarity even though the two genes share 
a 96% amino acid similarity; this is largely due to CCL3L 5’UTR 
harbouring a ~310bp Alu element absent in the CCL3 5’UTR.
Methods: We compared the function of the 5’ UTR regions of CCL3 
and CCL3L using an in vitro luciferase assay. Six representative CCL3 
promoters and two variations of the CCL3L promoter were amplified, 
sequenced and cloned upstream of the firefly luciferase gene in the 
pGL4.10 vector. HEK 293-T and four blood cells (Jurkat, K562, U937 
and THP-1) were transfected with the constructs and relative luciferase 
activity was taken as a measure of promoter strength/function.
Results: Promoter strengths differed substantially depending on cell 
type suggesting differences in transcription factor usage between the 
cell types. The two CCL3L promoters did not differ significantly from 
each other or from the wildtype (WT) CCL3 promoter in the blood cell 
lines. In HEK 293-T cells however, the CCL3L promoter was significantly 
(P<0.001) 1.7 to 1.9 fold stronger than CCL3 WT promoter. This result is 
suggestive of a transcriptional interaction of the SV40 large T antigen 
in 293-T cells and the CCL3L promoter, and we hypothesise that the 
Alu element is a likely site for this interaction.
Conclusion: This result may explain why certain viral infections (e.g. 
HTLV-2) selectively up-regulate CCL3L and why certain viral-HIV-1 
co-infections have been reported to exert a protective effect in HIV-1 
disease. This study forms the basis for investigating the role of the 
CCL3L Alu element on promoter function.
P06.15
Polymorphisms in the IRF1 Gene Associated 
with Reduced HIV Susceptibility and Their 
Impact on Mrna Splicing and IRF1 Protein 
Expression 
A. Sivro1, R. Su1, G. Liu1, J. Xie1, J. Kimani2, F.A. Plummer3, and 
T.B. Ball3
1University of Manitoba, Winnipeg, Canada; 2University of 
Nairobi, Nairobi, Kenya; 3University of Manitoba, Public Health 
Agency of Canada, Winnipeg, Canada 
Background: Interferon regulatory factor 1 (IRF1) is induced by HIV 
early in the infection process and serves two functions: transactivation 
of the HIV-1 genome and thus replication, and eliciting antiviral innate 
immune responses. Previous work has shown association of three 
polymorphisms in IRF1, located at 619, the microsatellite and 6516 of 
the gene, with decreased susceptibility to HIV-1 infection and a reduced 
likelihood of seroconversion. Peripheral blood mononuclear cells from 
individuals with protective IRF1 genotypes exhibited significantly 
lower basal IRF1 expression and lower HIV-1 LTR transcription 
during initial stages of infection. DNA sequence variations can cause 
phenotypic changes by multiple mechanisms, including mRNA splicing 
and turnover. This study will further characterize the effect of identified 
polymorphisms on IRF1 expression and its effect on HIV-1. 
Methods: Alternative splicing and the functional impact of IRF1 
polymorphisms on expression of IRF-1 regulated genes was analysed 
using the Affymetrix Human Exon 1.0 ST microarray. Exon splicing 
assay was performed in order to establish a direct link between 
identified polymorphisms and alternative splicing of the IRF1 mRNA.
Results: Data from this work shows an association of protective IRF1 
polymorphisms with increased expression of exon 7/8 and decreased 
IRF-1 protein stability. IRF1 polymorphism (microsatellite GT repeat) 
was shown to directly regulate mRNA splicing. Overall our results show 
a direct link between identified IRF1 polymorphisms and alternative 
splicing of the IRF1 gene, leading to altered IRF1 protein levels. 
Additionally, we observed an increase in antiviral immune responses 
in cells from individuals with protective IRF1 genotypes. 
Conclusion: Individuals with protective IRF1 genotypes are able 
to regulate the nature and strength of the immune response to HIV 
through altered IRF1 mRNA splicing. Resulting decrease in IRF1 protein 
stability and associated increase in antiviral immune responses could 
represent an important mechanism in preventing the establishment of 
HIV infection. 
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P06.18
Host Factors, Viral Replicative Capacity, and 
Viral Adaptation Work in Concert to Define 
HIV-1 Subtype C Disease Progression
D. Claiborne1, J. Prince1, T. Yu1, J. Tang2, J. Carlson3, S. Lakhi4, 
W. Kilembe4, J. Gilmour5, M. Price5, S. Allen1, and E. Hunter1
1Emory University, Atlanta, GA, USA; 2University of Alabama 
at Birmingham, Birmingham, AL, USA; 3Microsoft Research, 
Los Angeles, CA, USA; 4Zambia-Emory HIV Research Project, 
Lusaka, Zambia; 5IAVI, London, UK
Background: Efforts to elucidate protective host factors often rely 
on cross-sectional viral loads (VL) or CD4 T cell counts to determine 
factors influencing pathogenesis. Here, we study a cohort of 127 
acutely infected Zambians with longitudinal plasma VL and CD4 
counts up to 5 years post infection as a more sensitive method to 
identify novel host and viral characteristics directly associated with 
disease progression. 
Methods: Plasma VL and CD4 counts were assessed at 3-month 
intervals after seroconversion for 127 acutely infected Zambians 
for up to 5 years. HLA genotyping was performed using genomic 
DNA and PCR-based techniques. Viral replicative capacity (vRC) was 
assessed by cloning the gag gene from acute time points into MJ4, a 
subtype C proviral vector, and infecting a CEM T cell line with Gag-
MJ4 chimeric viruses. 
Results: Kaplan-Meier analyses and Cox proportional hazard models 
with an end-point defined by CD4 counts <300 were used to investigate 
protective and deleterious HLA class I and II alleles. HLA-B*1401, B*81, 
B*57/C*18, DQB1*02, and DRB1*15 were found to provide significant 
protection from CD4 decline, while HLA-A*03, A*24, and C*17 were 
deleterious.  Moreover, the effects of these alleles were found to 
be additive, such that individuals with 2 or more protective alleles 
experienced significantly slower CD4 decline. Meanwhile, sharing 
HLA-B alleles with a transmitting partner resulted in a significant risk 
for accelerated CD4 decline, reflecting the impact of pre-transmission 
viral adaptation on immune control. In multivariable models, HLA-I/
II, set point VL, gender, HLA-B sharing and vRC were found to be 
independent predictors of time to CD4 <300.
Conclusion: This study of a well-characterized cohort of acutely infected 
individuals provides unique insight into the independent contributions 
of host immunogenetics, viral characteristics, and viral adaptation to 
HIV-1 pathogenesis and will help to elucidate mechanisms of control, 
which may in turn define correlates of protection.
P06.17
Novel HLA Associations with HIV Control in 
Two Different Immunogenetic Contexts: A 
Multivariable Analysis
H. Valenzuela Ponce1, C.J. Brumme2, S. Ávila-Ríos1, Z.L. Brumme3, 
D. Garrido-Rodríguez1, T. García-Téllez1, C. García-Morales1,  
R. Hernández-Juan1, J.M. Carlson4, M. Brockman3, A. Shahid3,  
A. Murakami-Ogasawara1, C. Mejía-Villatoro5, R. Mendizabal5,  
A. Girón5, I. Escobar5, G. Reyes-Terán1, and M. Project Group1
1Instituto Nacional de Enfermedades Respiratorias (INER), 
Mexico City, Mexico; 2BC Centre for Excellence in HIV/AIDS, 
Vancouver, Canada; 3Simon Fraser University, Burnaby, 
Canada; 4Microsoft Research, Redmond, WA, USA; 5Roosevelt 
Hospital, Guatemala City, Guatemala
Background: Associations between HLA and HIV control have 
been well characterized. Unique HLA frequency distributions in 
uncharacterized populations represent an opportunity of finding 
novel factors for HIV control. We aimed to study HLA effects on HIV 
control in a previously uncharacterized cohort comparing with a large 
Caucasian cohort.
Methods: HLA-A, -B and -C sequence-based typing was performed 
on 1187 and 1500 chronically HIV-1 B clade-infected, ART-naïve 
individuals from Mexico/Guatemala and from the mainly Caucasian 
British Columbia HOMER cohort. Associations between HIV plasma 
viral load (pVL) and expression of HLA alleles were evaluated using 
false discovery rate analyses. Univariable and stepwise multivariable 
linear regression were used to identify factors associated with pVL in 
the Latin American cohort.
Results: There were significant differences between HLA frequencies 
of two cohorts reported here and the HOMER cohort. The universal 
associations between B*5701 and B*2705 and HIV control were 
evident in both cohorts. As previously describe for B-infected 
Caucasian cohorts, B*0702 and B*5501 were associated with higher 
pVL, while B*1401, B*1302 and B*5101 showed a protective effect 
in HOMER cohort. In the Mexican/Guatemalan cohort, B3501/02 
showed a risk effect and B*4102/1401/1402 showed a protective 
effect. New associations between HLA and HIV control were also 
observed in the Mexican/Guatemalan cohort, including B*39:02 
and C*08:01/02 associated with lower pVL and B*35:12 associated 
with higher pVL (all p<0.05, q<0.15). We have found a multivariable 
model that explains the variation in pVL in Mexico/Guatemala with 
the variables: CD4 count, being male, number of protective HLA-A and 
HLA-B alleles associated with pVL, age and B*5701/3502/4001 alleles 
by themselves. Finally, HLA frequency-dependent effects in Mexico/
Guatemala were observed.
Conclusion: Our data confirms previous associations between HLA 
alleles and HIV viral control, but also suggests the existence of new 
protective and risk associations and mechanisms in the context of a 
previously uncharacterized population. 
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P06.20 LB 
Association of FcγRIIC Polymorphism with 
Vaccine Efficacy and Correlates of HIV-1 
Infection Risk in RV144
S.S. Li1, P.B. Gilbert1, G.D. Tomaras2, G. Kijak3, G. Ferrari2,  
R. Thomas3, S. Zolla-Pazner4, D.T. Evans5, Y. Li1, R. Gottardo1, 
J.Y. Dai1, H. Janes1, D. Morris1, Y. Fong1, P.T. Edlefsen1, F. Li1,  
C.A. Magaret1, N. Frahm1, M.D. Alpert6, S. Rerks-Ngarm7,  
P. Pitisuttithum8, J. Kaewkungwal8, S. Nitayaphan9, M.L. Robb3, 
R.J. O’Connell3, N.L. Michael3, J.H. Kim3, M.J. McElrath1, and 
D.E. Geraghty1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Duke University School of Medicine, Durham, NC, USA; 3US 
MRHP, Silver Spring, MD, USA; 4Veterans Affairs New York 
Harbor Healthcare System and New York University School 
of Medicine, New York, NY, USA; 5University of Wisconsin, 
Madison, WI, USA; 6Harvard Medical School, Southborough, MA, 
USA; 7Ministry of Public Health, Nonthaburi, Thailand; 8Mahidol 
University, Bangkok, Thailand; 9Royal Thai Army, Armed Forces 
Research Institute of Medical Science, Bangkok, Thailand
Background: HIV infection risk in RV144 vaccinees was directly 
correlated to IgG binding antibodies (Abs) to HIV-1 envelope V1/V2 and 
inversely correlated to high plasma IgA Abs, supporting their role as 
correlates of the observed 31% vaccine efficacy (VE). ADCC responses 
inversely correlated with infection risk in the subgroup of vaccinees 
with low IgA. These data suggest that vaccine-induced Fc receptor 
(FcR)-mediated Abs function could play an important role in lowering 
infection risk. Thus, we hypothesize that the FcR genotypes may also 
influence VE because they affect Abs binding affinity. Furthermore, 
sieve analysis showed that VE against CRF01_AE HIV-1s expressing 
lysine at position 169 (169K) increased to 48%.
Methods: We sequenced the extracellular domains of six FcRs and 
identified 190 SNPs. Twenty-eight SNPs were selected with minor 
allele frequencies≥5% and correlation with other SNPs (r2<0.8). The 
case-only statistical method was used to assess the association of SNP 
genotypes with VE based on 125 infected cases. Logistic regression 
models were used to assess whether and how FcR genotypes modified 
the correlation between Week 26 immune responses and HIV-1 
infection based on the 41 infected vaccine recipients and the 205 
uninfected vaccine recipients.
Results: FcγRIIC-T118I (rs138747765) was significantly associated with 
VE against CRF01_AE HIV-1s containing 169K residue (VE = 15% in 
TT vs. 91% in TI/II, P=0.004, Family-Wise Error Rate (FWER)-adjusted 
P=0.05) and several vaccine-induced responses were associated with 
decreased risk of infection by viruses containing 169K residue in the 
FcγRIIC-118 TI/II recipients. The direct correlation of IgA with risk 
was restricted to the FcγRIIC-118 TT recipients. VE against all HIV-1s 
differed by FcγRIIC-T118I (VE = 11% in TT vs. 64% in TI/II, P=0.04) but 
was not FWER-significant. 
Conclusion: These results demonstrate the potential role of FcR 
genetics in predicting VE and suggest extended study could provide 
further insights into mechanistic correlate of protection.
P06.19 LB
HLA Class II Genes Interact with the Immune 
Correlates from the RV144 Vaccine Efficacy Trial 
and Impact HIV-1 Acquisition 
H. Prentice7, D.E. Geraghty1, G.D. Tomaras2, Y. Fong1, W. Nelson1, 
G.H. Kijak7, S. Zolla-Pazner3, S. Nitayaphan4, S. Rerks-Ngarm5,  
J. Kaewkungwal6, P. Pitisuttithum6, P.B. Gilbert1, B.F. Haynes2,  
J.H. Kim7, N. Michael97, and R. Thomas97
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Duke University School of Medicine, Durham, NC, USA; 3New 
York University School of Medicine, New York, NY, USA; 4US 
Army Medical Component, AFRIMS, Bangkok, Thailand; 5Ministry 
of Public Health, Nonthanburi, Thailand; 6Mahidol University, 
Bangkok, Thailand; 7US MHRP, Silver Spring, MD, USA
Background: RV144 is the first HIV-1 vaccine clinical trial to show an 
effect on HIV-1 acquisition. A follow up study discovered two immune 
correlates as predictors of risk of infection. Binding of plasma IgA 
antibodies to HIV-1 envelope (Env) correlated directly with acquisition 
whereas binding of IgG antibodies to the variable regions 1 and 2 
(V1V2) of Env correlated inversely with acquisition. We hypothesized 
that HLA class II molecules expressed on antigen presenting cells 
modulate CD4 T cell stimulation of antibody production by B cells 
involved in vaccine-induced responses. 
Methods: HLA class II genes were genotyped in the case-control group 
of 205 uninfected and 41 infected RV144 vaccinated volunteers. The 
interaction of HLA-DPB1, DQB1 and DRB1 alleles with IgA and IgG immune 
responses was tested for an effect on acquisition by logistic regression. 
Results: DQB1*06 had a significant interaction with IgA antibody 
responses (interaction p=0.002, q=0.089) on acquisition. Increased 
IgA antibody levels associated with increased risk for infection in 
the presence of DQB1*06, while no association was observed in the 
absence of DQB1*06 (OR=9.35, p=0.002 and OR=1.08, p=0.704, 
respectively). Corroborating this finding, in a categorical analysis 
DQB1*06 had a significant effect on HIV-1 infection only among the 
high IgA responders (OR=7.14, p=0.004). The observed DQB1*06 
interaction with IgA on acquisition also remained significant in a 
multivariable model, when testing other primary variables including 
IgG avidity, antibody-dependent cellular cytotoxicity, neutralizing 
antibodies, IgG binding to V1V2, and Env-specific CD4+ T cells 
(interaction p=0.004, q=0.029).
Conclusion: Evidence herein suggests that HLA class II genes are 
modulating the effect of antibody responses to the vaccine and impact 
HIV-1 acquisition. A next step may be to define the CD4 T cell clones 
that could mediate these HLA/antibody interactions. Understanding 
the mechanism of HLA class II effects on antibody responses to this 
vaccine will enable improved HIV vaccine 
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P06.21 LB
Host and Viral Factors Associated with HIV-1 
RNA Set-Point Among HIV-1 Seroconverters 
from sub-Saharan Africa
R. Mackelprang1, M. Carrington2, K. Thomas1, J.P. Hughes1,  
J.M. Baeten1, A. Wald1, C. Farquhar1, K. Fife3, M.S. Campbell1,  
S. Kapiga1, J.I. Mullins1, and J.R. Lingappa1
1University of Washington, Seattle, WA, USA; 2National 
Cancer Institute, NIH, Frederick, MD, USA; 3Indiana University, 
Bloomington, IN, USA
Background: HIV-1 set-point predicts disease progression and is 
partially determined by the source partner’s HIV-1 level and adaptive 
immune responses. However, these factors fail to capture most set-point 
variation. We quantified the collective impact of virus characteristics, 
human leukocyte antigen (HLA) alleles, and innate responses through 
toll-like receptor (TLR) alleles on HIV-1 set-point.
Methods: We analyzed data from HIV-1 seroconverters and their 
HIV-source partners in a large African HIV-1 serodiscordant couples 
cohort. Linear regression was used to determine associations with 
seroconverter set-point and R2 to estimate variation explained by HLA 
and TLR alleles, transmitting partner virus levels and other factors. 
Results: Among 128 HIV-1 seroconverters, the strongest predictors of 
set-point were HLA alleles and HIV-1 level of the transmitting partner, 
but HLA concordance between partners and TLR variation were also 
associated with set-point. Specifically, each log10 increase in source 
partner plasma HIV-1 RNA was associated with 0.4 log10 copies/
mL increased set-point (95% CI:0.2-0.5;p<0.001). HLA-B*5301 was 
associated with 0.6 log10 copies/mL higher (95% CI:0.3-0.9;p<0.001), 
and B*1401 and B*2703 with 1.1 (95% CI:0.4-1.9;p=0.002) and 0.7 
(95% CI:0.1,1.6;p=0.07)  log10 copies/mL lower set-point, respectively. 
HLA-A allele sharing between partners was associated with 0.5 log10 
copies/mL increase (95% CI:0.4,1.0;p<0.001). Finally, TLR2-rs3804100 
was associated with 0.4 (95% CI:-0.33-1.0;p=0.3) log10 copies/mL 
higher and TLR7-rs179012 with 0.4 (95% CI:0.2,0.7;p=0.001) log10 
copies/mL lower set-point. HLA alleles and transmitter HIV-1 level 
accounted for 13% and 10% of set-point variation, respectively, and 
HLA-A concordance and TLR polymorphisms contributed 6% and 5%. 
Overall, these factors and genital factors of the transmitter explained 
46% of variation in set-point.
Conclusion: We found that both innate immune responses, as captured 
by TLR variants, and acquired immune response, as determined by HLA 
alleles and HLA concordance with the transmitting partner, together 
with plasma HIV-1 levels of the transmitting partner, explain almost 
half of the variation in viral load set-point.
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P07.02
The Canarypox-Based Vector ALVAC Induces 
Higher Cytokine Responses Following 
Vaccination Compared to the Vaccinia-Based 
Vectors MVA and NYVAC
J.E. Teigler1, D.H. Barouch1, and N.L. Michael2
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2U.S. 
MHRP, Silver Spring, MD, USA
Background: Poxviral vectors have shown promise as novel vaccine 
systems against viral diseases as well as many tumor types. However, 
differences among these vectors in their innate immune activation 
remain poorly characterized.
Methods: Rhesus monkeys were inoculated IM with 1x10 8 pfu of 
the canarypox-based vector ALVAC, or a vaccinia-based vector MVA or 
NYVAC expressing SIV transgenes. Animals were bled longitudinally 
following vaccination. Naïve Rhesus and healthy human PBMC were 
isolated by the Ficoll-Hypaque gradient method and stimulated with 
MOI=1 or 10 pfu, respectively, of ALVAC, MVA, or NYVAC. Cytokines 
in serum and culture supernatant were measured by Luminex/ELISA. 
Differences between groups were assessed by Mann-Whitney U Tests.
Results: Animals which received ALVAC relative to animals which 
received MVA or NYVAC showed markedly higher-fold induction at 
d1 of the proinflammatory cytokines IL-1β (411- and 408-fold higher, 
respectively; p=0.0002, p<0.0001, respectively), IL-6 (83- and 6.3-
fold higher, respectively; p=0.0003, p=0.0043, respectively), and 
TNFα (48- and 29-fold higher, respectively; p=0.0002, p<0.0001, 
respectively). In Rhesus PBMC in vitro ALVAC, relative to MVA and 
NYVAC 24h post-infection, induced higher levels of IL-1β (66- and 
125-fold higher, respectively; p=0.0286 both), IL-6 (7.9- and 21-fold 
higher, respectively; p=0.0286, both), and TNFα (6.8- and 12-fold 
higher, respectively; p=0.0286, both), as well as the antiviral cytokines 
MIP-1α (7.2- and 30-fold higher, respectively, p-0.0286, both) and 
IFNγ (109- and 166-fold higher, respectively; p=0.0286, both). ALVAC 
induced higher fold-change responses in human PBMC 24h post-
infection compared to MVA and NYVAC both for proinflammatory, 
e.g. IL-1β (68- and 310-fold higher, respectively; p=0.0286, both) and 
anti-viral cytokines e.g. IFNγ (41- and 334-fold higher, respectively; 
p=0.0286, both).
Conclusion: The canarypox-based vector ALVAC and the vaccinia-
based vectors MVA and NYVAC show distinct cytokine induction profiles 
in several systems. These differences in innate immune activation may 
influence observed differences in their adaptive immune phenotypes.
P07.01
Differential Late Endosomal Trafficking by 
Adenovirus Vector Serotypes Confers Increased 
Stimulation of Innate Sensing Pathways
J.E. Teigler1 and D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: Multiple Adenovirus (Ad) vectors are currently being 
evaluated for clinical development and have been shown to differ 
in their innate stimulation profiles. The mechanism by which Ad26 
and Ad35 differentially stimulate greater innate responses than 
Ad5 remains poorly characterized. We therefore assessed the innate 
pathways stimulated by these Ad vectors and the influence of Ad 
vector trafficking. 
Methods: Human PBMC were pre-incubated with acidification or 
cathepsin inhibitors and then infected with 10 3 vp/cell Ad5, Ad35, 
or Ad26. Supernatant cytokines were measured by luminex. A549 
cells were cold-synchronized and infected with 5x10 3 -5x10 4 vp/cell 
Ad5, Ad26, Ad35, or fiber/knob chimeric vectors. Cells were analyzed 
by immunofluorescence histochemistry for EEA1, LAMP1, Mannose-6 
Phosphate Receptor (M6P) and nuclei (DAPI).
Results: Pre-incubation of PBMC with acidification and cathepsin 
inhibitors (Bafilomycin A1, Chloroquine, Ammonium chloride, Ca-
074Me, CAA0225, z-FA), which block essential events in late endosomal 
innate immune sensing, inhibited induction of IFNα2 (Ad5, ns; Ad35 
p=0.0286; Ad26, p=0.0286; Kruskal-Wallis Tests), IFNγ (Ad5: BafA 
p=0.0286, all others p=ns; Ad35, p=0.0286; Ad26, p=0.0286), 
and TNFα Ad5, p=ns; Ad35, p=0.0286; Ad26, p=0.0286) by Ad5, 
Ad35, and Ad26, suggesting that innate triggering may be occurring 
in late endosomes. Following infection, Ad5 localized to the nucleus 
greater than both Ad35 (1.84x greater colocalization 1h post-infection; 
p<0.001, Student’s t tests) and Ad26 (3.94x greater; p<0.001). Two 
hours post-infection, Ad35 and Ad26 localized more than Ad5 to 
late endosomes as shown by both LAMP1 (3.03x and 5.27x greater 
colocalization, respectively; both, p<0.01) and M6P (7.74x and 12.65x 
greater colocalization respectively; both, p<0.001).
Conclusion: Our results suggest that the differential innate stimulation 
by Ad vectors occurs by triggering innate signaling pathways accessed 
preferentially in late endosomes by Ad35 and Ad26. Trafficking to late 
endosomes is influenced by both vector fiber and capsid components. 
These data demonstrate a mechanism by which various Ad serotypes 
differentially trigger innate immunity.
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P07.04
Vaccine Adjuvants Induce Distinct Innate 
Immune Activation Profiles In Vivo
F. Liang3, K.J. Sandgren3, G. Lindgren3, E.A. Thompson1,  
H. Fausther-Bovendo1, D. O’Hagan2, A. Seubert2, E. De Gregorio2, 
S. Rao1, N.J. Sullivan1, R.A. Seder1, R.A. Koup1, and K. Loré3
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
2Novartis Vaccines and Diagnostics, Cambridge, MA, USA 
3Karolinska Institutet, Stockholm, Sweden
Background: Understanding the innate mechanisms dictating vaccine 
responses and why some adjuvants induce more potent responses than 
others would help optimize the design of new vaccine formulations. 
Here, utilizing a non-human primate (NHP) model we investigated the 
activation and recruitment of immune cells to the injection site as well 
as vaccine uptake efficiency after administration of three distinctly 
different adjuvants in vivo. 
Methods: Rhesus macaques received intramuscular injections of 
fluorescently-labeled HIV-1 envelope glycoprotein (Env) alone or 
together with one of the adjuvants; alum (benchmark), alum containing 
a TLR7 ligand or MF59 (emulsion). Muscle tissue, lymph nodes (LNs) 
and blood were collected for flow cytometry and confocal analysis.
Results: Robust infiltration of multiple immune cells into the muscle at 
the site of injection was seen with all adjuvants at 24 hrs. Neutrophils 
were the most frequent infiltrating cell type with all the adjuvants. 
Monocytes, myeloid and plasmacytoid dendritic cells (DCs) were also 
recruited. Env uptake was readily detectable in these cell populations 
in the muscle and in the draining, but not in non-draining, LNs. While 
alum-TLR7-ligand exclusively induced strong DC maturation and type 
I interferon responses, MF59 promoted neutrophil migration to LNs. 
Env+ neutrophils isolated from the LNs were found to present Env to 
memory T cells although at much lower capacity than did DCs. 
Conclusion: In line with findings that both MF59 and alum-TLR7-ligand 
are more potent adjuvants compared to alum in immunogenicity 
studies, our data indicate that these adjuvants induce stronger innate 
immune activity than alum. Therefore, a more comprehensive picture 
of how adjuvants regulate innate immune processes can assist in a 
more rational selection of adjuvants that are best suited for a given 
vaccine. As NHP cell subsets are similar to humans, this is a powerful 
model for translating data into optimizing future vaccine formulations 
and delivery strategies. 
P07.03
Antigen Presenting Cells Characterization at 
Local Site of Injection After MVA and Poly (I: 
C) Intramuscular Vaccination in Non-human 
Primates
L. Gosse1, P. Rosenbaum1, O. Epaulard2, R. Le Grand1, and  
F. Martinon1
1CEA, Fontenay-aux-Roses, France; 2Grenoble University 
Hospital, Grenoble, France
Background: Better understanding of early events at site of 
intramuscular vaccine injection is needed for a rational design of 
future vaccines.
Methods: The attenuated vaccinia virus Ankara (MVA) is an ideal 
replication-deficient viral vector for HIV-1 vaccines due to the excellent 
safety profile in humans and Polyinosinic:polycytidylic acid (Poly(I:C)) 
is an adjuvant known for its high tolerance and immunogenicity 
in animal trials. Cynomolgus macaques were immunized by the 
intramuscular route with either PBS, MVA (5x107 plaque-forming-
unit) or Poly(I:C) (200µg). Muscle biopsies were sampled at 24h after 
injection for Poly(I:C) and at 48h after injection for MVA to assess 
antigen presenting cells (APC) characterization by flow cytometry and 
APC localization by immunohistology.
Results: Perimysium inflammation due to massive APC arrival (mainly 
macrophages and polynuclear cells) was observed by HES coloration 
and immunohistofluorescence, at the injection site, after MVA or 
PolyI:C intramuscular injection. In muscle biopsies of immunized 
animals, leukocyte (CD45+) frequency was increased (49.6%±5.1 
and 54.4%±21.8 of total alive cells for PolyI:C and MVA, respectively; 
mean±SEM) compare to non-immunized animals (16.8%±9.0). 
Interestingly, macrophages (CD45+HLADR+CD163+) were the 
most abundantly recruited cells (46.7%±10.3 and 39.6%±1.1 of 
total CD45+ cells with PolyI:C and MVA, respectively) whereas 
dendritic cells (CD45+HLADR+CD163-CD11c+) were recruited in 
lower proportion (6.7%±5.7 or 0.5%±0.4 of CD45+ cells for PolyI:C 
and MVA, respectively). Moreover, MVA injection leaded to more 
prominent polynuclear cells recruitment (25.5%±8.2 of total CD45+ 
cells) compare to PolyI:C (1.9%±0.8).
Conclusion: Our results highlight the importance of macrophages 
following intramuscular vaccination and their possible role in the 
antigen-specific immune response induction, suggesting the potential 
benefit of a vaccine targeting macrophages as candidate against HIV.
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P07.06
DC-SIGNR Polymorphism and Expression: 
Correlation with Dendritic Cell Count and 
Subsets in Indian HIV-1 Infected Patients and 
Injecting Drug Users
O. Chaudhary1, S. Kumar1, M. Makhdoomi1, M. Bala2, J. Singh3, 
A.  Hazarika1, R. Kumar4, and K. Luthra1
1All India Institute of Medical Sciences, New Delhi, India;  
2Safdarjung Hospital, New Delhi, India; 3Kurukshetra 
University, Kurukshetra, India; 4Society for Promotion of Youth 
and Masses Center, Vasant Kunj, New Delhi, India
Background: DC-SIGNR is a C-type lectin receptor that interacts with a 
plethora of pathogens including HIV-1. DC-SIGNR is proposed to play 
a vital role in binding to HIV-1 gp120 thereby facilitating transmission 
of HIV to CD4+ T cell targets. To determine dendritic cell count and 
its subsets and study the expression of DC-SIGNR on PBMCs and its 
polymorphic variants.
Methods: Blood from 230 seronegative healthy individuals, 200 
injecting drug users, and 230 patients infected with HIV-1 was collected. 
The repeat region polymorphism in DC-SIGNR was performed by PCR. 
Peripheral blood DC count and its subsets was determined by flow 
cytometer. DC-SIGNR expression on PBMCs was determined by real 
time PCR and flow cytometer in antiretroviral naïve HIV-1 infected 
patients and healthy individuals and in culture of monocyte derived 
dendritic cells from healthy individuals.
Results: The frequency of DC-SIGNR 7/7 genotype was significantly 
higher in patients infected with HIV-1 and DC-SIGNR 7/5 genotype 
was significantly higher in injecting drug users. A salient finding of this 
study was the association of the heterozygous 7/5 DC-SIGNR genotypes 
with higher percentage of DC and their subsets and higher CD4+ T 
cell counts and lower viral load compared to the homozygous 7/7 
DC-SIGNR genotypes in patients infected with HIV-1. The expression 
of DC-SIGNR was higher in patients infected with HIV-1 with positive 
correlation with CD4+ T cells as compared to healthy individuals. 
Dendritic cells in culture, on infecting with HIV-1 virus (AIIMS 53), 
showed up regulation of DC-SIGNR and co-stimulatory molecules.
Conclusion: This is the first study to assess the DC subsets, and its 
association with DC-SIGNR polymorphism in injecting drug users and 
HIV-1 infected patients and DC-SIGNR expression in HIV-1 infected 
patients. This study suggests the protective role of 7/5 DC-SIGNR 
genotype in HIV-1 infection and the higher expression of DC-SIGNR in 
HIV-1 infection suggest possible role DC-SIGNR in activated dendritic 
cells during HIV-1 infection and needs to be  studied. 
P07.05
In Vivo Imaging Study of Innate Immune 
Response in Non-human Primates Following 
DNA Vaccination Associated with Skin 
Electroporation 
B. Todorova2, L. Adam2, F. Martinon2, R. Boisgard1, T. Kortulewski2, 
R. Le Grand2, and C. Chapon2
1CEA, SHFJ, Orsay, France; 2CEA, Fontenay-aux-Roses, France 
Background: DNA vaccines are a new promising approach in the 
research of preventive and therapeutic vaccination against chronic 
infections such as HIV. However, despite their effectiveness reported in 
small animal studies, DNA vaccines showed lower immunogenicity in 
humans. In a previous study, we demonstrated that auxoGTU-multiHIV 
DNA vaccine immune response is strongly improved by electroporation 
(EP) treatment of the injection site in non-human primates (NHP).  A 
better understanding of cellular behavior at the injection site during 
the first hours after vaccination is needed to increase and direct the 
immune response to DNA vaccines. In this study we used in vivo 
fluorescence imaging to visualize skin antigen presenting cells (APC) 
and monitor their spatio-temporal dynamics in NHP after vaccination.
Methods: AuxoGTU-multiHIV plasmid was injected intradermally and 
associated with noninvasive EP at vaccinated sites in anesthetized 
NHP (n=3).  Fluorescent labeled anti-HLADR antibody was injected at 
vaccinated sites before in vivo fluorescence imaging. Epidermal APCs 
were tracked with noninvasive in vivo fibered confocal fluorescence 
microscopy at 24h, 48h, 72h, and 96h post vaccination. Furthermore, 
epidermal and dermal APCs were monitored continuously for 24h by 
confocal fast laser scanning microscopy on skin explants.
Results: When electroporation was associated to intradermal injection 
of DNA plasmid, the density of epidermal APCs decreased significantly 
between 48h and 96h after vaccination. Experiments on skin explants 
confirmed the epidermal APC departure associated to a rise of dermal 
APC number. Moreover, we showed an increase of APC velocity and 
displacement in this condition.
Conclusion: Using in vivo fluorescence imaging approaches, we 
monitor epidermal APC behavior changes, induced by DNA vaccination 
associated with EP. In vivo imaging experiments on distinct innate 
immune cell populations are ongoing, in order to understand the 
cellular orchestration that shapes the adaptive immunity and thus 
optimize the DNA vaccines efficacy.
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P07.08
HIV Exposed Seronegative Have Distinct Type I 
and Type II Interferon Responses to TLR7 and 
TLR8 Stimulation Compared to Susceptible 
Women
W.R. Omange1, R.C. Su1, A.F. Meyers1, A. Maingi2, J. Nyakio3,  
C. Mesa3, I.A. Onyango2, J. Kimani2, F.A. Plummer4, and T.B. Ball5
1University of Manitoba, Winnipeg, Canada; 2University of 
Nairobi, Nairobi, Kenya; 3Public Health Agency of Canada, 
Winnipeg, Canada; 4University of Manitoba, University 
of Nairobi NML, PHAC, Winnipeg, Canada; 5University of 
Manitoba, Public Health Agency of Canada, Winnipeg, Canada
Background: Toll-Like Receptor 7 and 8, recognizes the single strand 
RNA from the HIV virus. A group of commercial sex workers (CSWs) 
are thought to be repeatedly exposed to the HIV virus in the course of 
their work yet remain uninfected. 
Methods: The CSWs studied were grouped into two based on years of 
enrollement in cohort, HIV negative status and continuous engagement 
in sex work. The two groups were, HESN who had been enrolled in 
cohort for more than 7 years, and a second group was called New 
Negatives (NN) who were in cohort for less than 7 years. Freshly 
isolated PBMCs were stimulated overnight with ssRNA40 (TLR7/8) and 
Imiquimod (TLR7). Changes in  expression of phenotypic and activation 
markers was done using flow cytometry and TLR signaling pathways 
analysis done using PCR arrays.Solubles cytokine were quantified 
using cytokine bead arrays from culture supernatants.
Results: T cells of HESN were activated more and produced high 
amounts of IFN-γ in response to TLR7 and TLR8 stimulation compared 
to those of NN women. Overall PBMCs of HESN produced higher 
quantities of of TNF-α and IL-1β after ssRNA stimulation, but lower 
quantities of IL-1 β and IL-10 after Imiquimod stimulation compared to 
NN women. PBMCs from HESN women produced higher amounts of 
IFN-γ in response to ssRNA, but lower amounts of IFN-a2 and CXCL10 
in response to Imiquimod a TLR7 ligand, as compared to NN women. 
An evaluation of the regulation or balance of cytokines in the millieu 
before and after TLR stimulation revealed a more regulated cytokine 
environment in HESN culture but a dysregulated millieu in NN women. 
An analysis TLR signalling pathway following stimulation revealed 
differences in activation of intracellular pathways between the two 
groups of women and between TLR7 and TLR8 ligands.
Conclusion: Differences exist in cellular activation, cytokine production 
and TLR signaling between HESN and NN CSWs.
P07.07
Coculture of HIV-1-Infected Dendritic Cells with 
Lymphocytes Impairs Host Restriction Factor 
SAMHD1 and Activates Immune Defenses
B. Su1, M.E. Biedma1, T. Decoville1, A. Lederle1, M. Peressin1,  
M. Lambotin1, A. Proust1, S. Schmidt1, G. Laumond1, V. Holl2, 
and C. Moog1
1INSERM U1110, Université de Strasbourg, Strasbourg, France; 
2Covance CLS SA, Geneva, Switzerland
Background: HIV-1 replication in dendritic cells (DCs) is restricted 
by SAMHD1. This factor is counteracted by the viral protein Vpx of 
HIV-2 or SIVsmSIVmac, but is absent in HIV-1. We previously observed 
a stimulation of HIV-1 replication in immature DCs cocultured 
with primary CD4 T or B lymphocytes. This suggests that HIV-1 
restriction in DCs may be overcome in coculture conditions. The aim 
of this study was to decipher SAMHD1-mediated restriction in DC/
lymphocyte coculture.
Methods: Primary monocyte-derived immature DCs were incubated 
with various R5 HIV-1 primary isolates during 2h, and then cocultured 
with autologous CD4 T and B lymphocytes. After 48h and 72h, the 
percentages of infected DC-SIGN+/CD3- MoDCs were detected by 
intracellular p24 antigen staining. Simultaneously, the expression of 
intracellular SAMHD1 and the maturation phenotype were quantified. 
IFN-α production was measured in the supernatants. Virus-like particles 
containing Vpx (VLP-Vpx) and exogenous dNTPs were used as control.
Results: SAMHD1 expression in DCs was significantly decreased from 
80% to 10% when DCs were cocultured with CD4 T or B lymphocytes 
for 48h and 72h (n≥9 donors). This decreased SAMHD1 was correlated 
with an increase HIV-1 replication in cocultured DCs. In addition, IFN-α 
production was detected in the supernatant of infected DC/CD4 T 
lymphocytes coculture and DCs acquired their maturation status 
48h and 72h post-infection. As controls, VLP-Vpx increased HIV-1 
replication and IFN-α release, and decreased SAMHD1. Addition of 
exogenous dNTPs increased HIV-1 replication but without modifying 
SAMHD1 and IFN-α release. 
Conclusion: These results demonstrate that coculture with 
lymphocytes decrease the expression of SAMHD1 in DCs leading to 
a significant increase of HIV-1 replication in DCs and triggering an 
antiviral immune response. The innate sensing of HIV-1-infected 
immature DCs, observed in coculture conditions further suggest that 
HIV-1 replication and restriction in DCs should be studied in more 
physiologically relevant models of DC/lymphocyte coculture.
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P07.10
Dynamics of Immune Cells Recruitment and 
Mobilization in Skin After DNA Vaccination 
with auxoGTUmultiSIV Plasmid in Non-human 
Primates
L. Adam1, O. Epaulard2, K. Reijonen3, R. Le Grand1, and  
F. Martinon1
1CEA, Fontenay-aux-Roses, France; 2Grenoble University 
Hospital, Grenoble, France; 3Fit Biotech, Tampere, Finland
Background: Because of HIV biology, classical vaccination strategies 
failed to induce protective responses. For this virus, it is necessary to 
turn to new strategies. DNA vaccine presents some advantages such 
as his safety (no viral agent used) and the mimicry of natural virus 
infection. The DNA auxoGTUmultiSIV vaccine in association with 
electroporation (EP) induces strong and persistent cellular responses in 
cynomolgus macaques.
Methods: Cynomolgus macaques were injected with auxoGTUmultiSIV 
(1mg/ml) or with PBS (control) by intradermal route with EP. Skin 
biopsies of injection sites were performed at different time points and 
cells were extracted to study early cellular events involved in the local 
immune responses. 
Results: At steady state, Langerhans cells (LC) (HLADRhiCD1ahiCD207+CD1c-) 
are the only antigen presenting cells in epidermis (1.6±0.9%). In dermis, a 
population of resident macrophages (HLADR+CD163+CD11b+CD11clow) 
(1.98±1.09%) and a population of HLADR+CD11c+CD1a+ dermal DC have 
been characterized. The latter can be separated in 2 subsets: CD1a+CD1c- 
and CD1a+CD1c+. In epidermis, 24h after injection, we observed an initial 
increase of LC with an up-regulation HLADR, suggesting their activation. 
At 72h, LC decreased to their baseline level. Interestingly, a population of 
HLADR+CD1aintCD1c+ cells appeared as soon as 24h and reached a peak 
at 72h. This population seems to up-regulate CD1a and down-regulate CD1c 
over time and presents an intracellular expression of CD207, an exclusive 
marker of LC in human. A recruitment of granulocytes (HLADR-CD66+) and 
inflammatory macrophages (HLADR+CD163midCD11bhi) was observed in 
epidermis and dermis, mainly at 24h after injection. These observations 
were rather attributed to EP than to vaccine injection.
Conclusion: Our results suggest that EP, independently of the presence 
of DNA, is sufficient to induce danger signals and cells recruitment. 
These early events could facilitate antigen uptake and presentation. This 
work provides important clues to the local mechanism of inflammation 
and opens up new possibilities for vaccine strategies.
P07.09
Long-Term Non-Progressors Display Expansion 
of T Cells Expressing NK Cell Receptors that 
Associates with CD4 T Cell Count and Viral Load 
S. Shalekoff1, P. Ive1, D. Spencer2, and C.T. Tiemessen1
1University of the Witwatersrand, Johannesburg, South Africa; 
2Helen Joseph Hospital, Johannesburg, South Africa
Background: Increased expression of inhibitory NK cell receptors 
(iNKRs), and decreased expression of activating NKRs (aNKRs) has 
been documented on NK cells in HIV-1 infection. As little is known 
regarding the expression or role of NKRs on T cells, we analysed the 
expression of various NKRs on T cells in HIV-1 infected long-term non-
progressors (LTNPs). 
Methods: The proportions and intensity of expression of killer cell 
immunoglobulin-like receptor (KIR) (KIR2DL1, KIR2DL3, KIR2DL4, 
KIR3DL1 and KIR2DS4), C-type lectin (NKG2A, NKG2C and NKG2D) 
and natural cytotoxicity receptors (NCR) (NKp30 and NKp46) on CD8 
and CD4 T cells were analysed in the peripheral blood of 14 LTNPs 
(viral load range, 1.59-4.86 log copies/ml and CD4 range, 327-2000 
cells/µL) and 14 race, gender and age-matched healthy controls. 
Results: LTNPs displayed relative to controls: (i) Increased proportions 
of KIR2DL1, KIR2DL3, KIR2DS4 and NKp46 expressing CD8 and 
CD4 T cells, and increased proportions of KIR2DL4, KIR3DL1, NKG2C 
and NKG2D expressing CD4 T cells; (ii) Lower fluorescence intensity 
of KIR2DL3, KIR2DL4, NKG2C and NKp46 on CD8 and CD4 T cells, 
as well as NKp30 on CD8 and KIR2DL1, KIR3DL1, KIR2DS4 and 
NKG2D on CD4 T cells. Importantly, in the LTNPs, higher CD4 T cell 
counts associated with lower proportions and higher intensity of 
NKp46 expression on CD8 T cells (r=-0.692, P=0.006 and r=0.609, 
P=0.021, respectively), as well as lower proportions of KIR3DL1 (r=-
0.745, P=0.002) and NKp46 (r=-0.552, P=0.041) expressing CD4 T 
cells. Furthermore, lower viral loads associated with higher intensity 
of KIR3DL1 (r=-0.645, P=0.013) expression on CD8 T cells and lower 
proportions KIR2DL3 (r=0.708, P=0.005) and NKp46 (r=0.625, 
P=0.017) expressing CD4 T cells.  
Conclusion: We have demonstrated a strong induction of iNKRs and 
aNKRs on T cells in LTNPs. Lower proportions and higher intensity of 
NKR expression on CD8 and CD4 T cells associate with higher CD4 
T cell counts and lower viral loads among LTNPs, highlighting the 
importance of their study in HIV-1. 
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P07.12
Therapeutic Vaccination Using HIV-1 gp120/
NefTat/AS02A Enhances Responsiveness of NK 
Cells Through the Induction of gp120-Specific 
CD4+ T Cell Help
S. Jost1, K. Rands1, M. Lichterfeld2, R.T. Gandhi2, and M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Massachusetts General Hospital, Boston, USA
Background: Recent studies in animal models suggested that antigen-
specific CD4+ T cells can provide immunological help not only to 
CD8+ T cells and B cells, but also to natural killer (NK) cells. As human 
NK cells can mediate anti-HIV-1 activity, novel approaches harnessing 
the function of both HIV-1-specific T cells and NK cells represent an 
attractive option to improve future vaccines. Using samples from a 
clinical trial employing a therapeutic subunit protein vaccine inducing 
strong HIV-1-specific IL2+ CD4+ T cell responses, we assessed whether 
enhancing HIV-1-specific CD4+ T cell function can restore NK cell 
activity in antiretroviral-treated HIV-1-infected individuals. 
Methods: Using flow cytometry, we examined the function of CD4+T 
cells and NK cells following HIV-1 peptides stimulation of PBMCs 
derived from subjects with untreated chronic HIV-1 infection and from 
treated HIV-1-infected volunteers participating in a double-blinded, 
randomized, placebo-controlled clinical trial of GlaxoSmithKline 
Vaccines’ HIV-1 gp120/NefTat subunit protein vaccine formulated with 
the AS02A   Adjuvant System.
Results: In a subset of chronically HIV-1-infected individuals, 
stimulation of PBMCs with Gag-derived peptides led to the production 
of IL-2 and IFN-gamma by antigen-specific CD4+ T cells and NK 
cells, respectively. Reconstitution of cytokine-producing CD4+ T cells 
by therapeutic immunization led to substantially enhanced NK cell 
function. In individuals receiving the therapeutic vaccine, CD4+ T 
cells produced significantly higher levels of IL-2 in response to gp120 
compared to controls at 6 weeks post-vaccination, and this enhanced 
antigen-specific CD4+ T cell response was associated with more than 
one log increase in IFN-gamma production by NK cells. 
Conclusion: Our data show that enhanced NK cell activity can be 
promoted by therapeutic immunization in HIV-1-infected individuals 
through reconstitution of HIV-1-specific CD4+ T cell function. Further 
investigations are warranted to examine whether vaccine-induced 
CD4+ T cells can improve cytotoxic NK cell responses against HIV-1.
P07.11
HIV Protective KIR/HLA Genotypes Influence 
NK Cell Mediated Inhibition of HIV Replication 
in Autologous CD4 T Cells via CC-chemokine 
Secretion
N.F. Bernard1, J. Bruneau2, and R. Song1
1McGill University Health Center, Montreal, Canada; 2Centre 
de Recherche du Centre Hospitalier de l’Université de 
Montréal, Montreal, Canada
Background: Carriage of the genetic combination encoding high 
expression Natural Killer (NK) cell inhibitory Killer Immunoglobulin-
like Receptors (KIR)3DL1 with their ligand HLA-B*57 (*h/*y+B*57) 
has the strongest effect on slowing time to AIDS and HIV viral load 
control compared to Bw6 homozygotes (Bw6hmz). NK cell education, 
which requires inhibitory NK receptor engagement and the integration 
of signals from NK receptors binding their ligands on target cells 
determines NK cell anti-viral functional potency. We questioned 
whether NK cells from *h/*y+B*57 carriers inhibited HIV replication 
more potently than those from Bw6hmz, as do those from carriers of 
another HIV protective genotype, i.e. 3DS1+*80I.
Methods: We studied 5 HIV seronegative *h/*y+B*57 carriers, 8 
3DS1+*80I, and 9 Bw6hmz. Purified NK cells were co-cultured with 
autologous HIV infected CD4 T cells for 10 days. Cultures were 
assessed for supernatant p24 levels and frequency of p24 positive 
CD4 T cells on days, 3, 7 and 10 and for CC-chemokine secretion on 
days 1, 2 and 3. 
Results: NK cells from carriers of *h/*y+B*57 and 3DS1+*80I inhibited 
HIV replication better than those from Bw6hmz (p<0.05 at days 7 and 
10). NK and CD4 T cell contact was required for NK cells activation but, 
once activated, NK cells inhibited viral replication in autologous CD4 
T cells in a non-contact dependent fashion through secretion of CC-
chemokines CCL3, CCL4 and CCL5. NK cells from carriers of protective 
genotypes produced higher levels of CC-chemokines than did those 
from Bw6hmz.
Conclusion: NK cells from individuals carrying protective KIR/HLA 
genotypes inhibit HIV replication in autologous CD4 T cells more 
effectively than those from a non-protective genotype. The inhibition 
of viral replication in autologous infected CD4 T cells is partially 
due to a block at the level of entry mediated by the secretion of CC-
chemokines. NK cell education likely influences the anti-HIV potency 
of NK cells from *h/*y+B*57. 
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P07.14
Sex Differences in IRF5 Levels and Implications 
for pDC IFNα Response to TLR7
M. Griesbeck1, P. Tomezsko1, G. Kourjian1, T. Diefenbach1,  
E. Doyle1, M. Sirignano1, S. LeGall1, M. Altfeld1, and J. Chang1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Background: Differential sex-dependent immune activation 
is a common feature in both HIV-1 and autoimmune diseases. 
Plasmacytoid dendritic cells (pDCs) derived from females have been 
shown to produce significantly more IFNα in response to HIV-1-
encoded TLR7/8 ligands than pDCs derived from males, resulting in 
stronger secondary T cell activation. We investigated the impact of 
the interferon regulatory factors 7 and 5 (IRF7/5) on the observed sex 
differences given their central role in TLR7 signaling.
Methods: Fresh PBMCs were isolated from healthy donors. IRF7 and 
IRF5 levels were measured by flow cytometry directly ex vivo and 
after TLR7 stimulation. Translocation of IRF5 to the nucleus of pDCs 
following TLR7 stimulation was visualized by confocal microscopy and 
quantified within cell populations among multiple individuals using 
the TissueFAXS slide scanner at high magnification. 
Results: Whereas no differences between males and females in baseline 
levels of IRF7 in pDCs were observed, baseline levels of IRF5 in pDCs 
were 1.8 times higher in females than in males (p<0.01). Importantly, 
after TLR7 stimulation, levels of IRF5 were significantly higher in 
pDCs secreting IFNα compared to the non-secreting pDCs (p<0.05). 
In addition, we observed a trend towards more IRF5 translocation 
into the nucleus in females than in males pDCs after 2hours of TLR7 
stimulation. Interestingly, significantly more IRF5 was localized in the 
nucleus than in the cytoplasm in pDCs already at baseline, in line with 
recent reports that IRF5 may constitutively bind the IFNA promoter in 
specific cell types.
Conclusion: These results indicate that sex differences in IRF5 levels 
might contribute to the described higher IFNα production upon TLR7 
stimulation in females, providing new insights into the mechanisms 
underlying higher inflammation observed in HIV-1-infected females 
and stronger responses to vaccines reported for females compared 
to males. These studies highlight potentially novel targets for the 
modulation of inflammation and immune responses.
P07.13
Inflammatory Biomarkers and Clinical 
Outcomes in Primary HIV-1 Infection
S.A. Vaidya1, C. Korner1, M.N. Sirignano1, M. Amero1, S. Bazner2, 
J. Rychert2, E.S. Rosenberg2, T.M. Allen1, R.J. Bosch3, and M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Massachusetts General Hospital, Boston, MA, USA; 
3Harvard School of Public Health, Boston, MA, USA
Background: Inflammatory biomarkers are associated with increased 
morbidity/mortality in chronic HIV-1 infection; however, their role in 
primary HIV-1 infection is poorly understood.  We sought to determine 
if previously described inflammatory biomarkers are associated with 
the viral load set point (VLSP) in primary HIV-1 infection and their 
utility in predicting clinical outcomes of disease progression.
Methods: A longitudinal retrospective analysis was conducted of 92 
patients with untreated primary HIV-1 who were clinically followed for 
a median of 591 days.  VLSP was determined for all study subjects 
during the first year post-infection and their plasma was tested for 
TNF-alpha, IL-6, CRP, D-dimer, IL-1-beta, and IFN-gamma.  Primary 
endpoints were VLSP and days to CD4+ T cell count <500 cells/µL, 
secondary endpoints were days to CD4+ T cell count <350 cells/
µL and days to antiretroviral therapy (ART) start.  The association of 
biomarkers with the endpoints was assessed by Spearman-rank, log 
rank, and Cox proportional hazard models.
Results: Only TNF-alpha was highly correlated with VLSP (R=0.39, 
p<0.0001). Log rank analysis separating the groups by mean TNF-alpha 
(≥8.9 pg/mL) showed a trend towards differences for predicting days to 
CD4+ T cell count <500 cells/µL (p=0.07), while days to ART start was 
significantly different (p=0.03) between groups.  In post-hoc analysis, 
the upper three quartiles for TNF-alpha were significantly associated 
with fewer days to CD4+ T cell count <500 cells/µL compared to the 
lowest quartile (p=0.005, log rank) with a Cox proportional hazard ratio 
of 5.0 in univariate analysis (CI 1.5-17, p=0.01), 3.1 when adjusted for 
concurrent viral load (CI 0.8-11.3, p=0.10) and 4.5 when adjusted for 
concurrent CD4+ T cell count (CI 1.3-16, p=0.02).
Conclusion: Plasma TNF-alpha correlates with the VLSP during primary 
HIV-1 infection and may be associated with early disease progression. 
The clinical impact of inflammation due to high TNF-alpha levels 
independent of viral replication deserves further study.
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P07.16
Frequency, Phenotype and Function of KIR+ 
and NKG2A+ NK Cell Subsets During Acute and 
Chronic HIV -1 Clade C Infection
C. Thobakgale1, K. Naidoo1, Z. Mncube1, M. Mokgoro1,  
P. Goulder2, T. Ndung’u1, and M. Altfeld3
1University of KwaZulu-Natal, Durban, South Africa; 
2University of Oxford, Oxford, UK; 3Ragon Institute of MGH, 
MIT and Harvard, Cambridge, MA, USA
Background: Mature NK cells are heterogeneous in the expression 
of activating and inhibitory receptors, and differ in proliferative and 
functional activity in response to a range of cytokines. Recent studies 
have suggested that NK cell maturation and function in response to 
infection is influenced by a stepwise decrease of NKG2A receptor 
expression and acquisition of KIRs by CD56dim NK cells over time. We 
investigated the frequency, phenotype and functional capacity of NK 
cells based on NKG2A and KIR expression during acute and chronic 
HIV-1 infection.
Methods: NK cell phenotypic changes were characterized on PBMCs 
from individuals with acute (n=12), progressive (n=12) and treated HIV-
1 clade C infection (n=12) versus healthy donors (n=12) using: NKG2A, 
KIR and CD57. The cytolytic potential of individual NK cell subsets 
was determined by CD107a, MIP1β, IFN-γ and TNF-α expression using 
multiparameter flow cytometry following stimulation with K562 and 
721.221 cells.
Results: The overall frequency of NKG2A and KIR-expressing NK cell 
subsets was similar in all studied groups; the KIR+NKG2Aneg were the 
most dominant subset while KIR+NKG2A+ was significantly less frequent 
(P<0.0001). Although alterations were noted in the KIRnegNKG2A+ 
and KIR+NKG2A+ NK cell subsets in individuals with progressive HIV-
1 infection, these differences were not statistically significant. The KIR+ 
NK cell subsets (KIR+NKG2A+ and KIR+NKG2Aneg) exhibited high 
CD57 expression across all studied groups compared to subsets lacking 
KIR. The absence of NKG2A in KIR+NKG2Aneg and KIRnegNKG2Aneg 
NK cell subsets was accompanied by a lower cytolytic activity of NK 
cells in all studied groups (P<0.0001). No significant differences were 
noted in differentiation phenotype and function between the individual 
groups of HIV-1-infected individuals.
Conclusion: In line with previous studies (Beziat et al, 2010), the 
KIR+NKG2Aneg NK cells were more terminally differentiated as shown 
by higher expression of CD57, however exhibited lower cytolytic 
activity compared to other NK cell subsets. 
P07.15
Erythrocytes’ Presence Enhance HIV Production 
on Monocyte Derived Macrophages (MDM) 
L. Fazzi1, R. Rabinovich1, and M. Avila1
1INBIRS (Instituto de Investigaciones Biomedicas en Retrovirus 
y Sida), Buenos Aires, Argentina
Background: Erythrocytes of HIV+ individuals present p24 Antigen, 
RNA-HIV and bounded-specific antibodies. HIV-erythrocyte association 
was described to be mediated by immune complexes or complement 
factors and DARC in the erythrocyte membrane. Given that macrophages 
are widely known reservoirs established at the first stages of infection 
and the close contact of erythrocyte and macrophages, this work 
focuses on the capacity of the HIV produced by macrophages to bind 
to erythrocytes membrane.
Methods: MDM (monocyte derived macrophages) were obtained from 
healthy donors’ buffy coats and infected with BaL Erythrocytes were 
obtained from healthy donors (one Afro-American woman DARC-), and 
purified with Dextran. After 7 and 10 days post inoculation (pi) MDM 
were incubated with erythrocytes DARC+, DARC– and RPMI. P24Ag 
was determined in erythrocytes supernatant.  The supernatant of the 
MDM incubated with RPMI was fractioned in 3, one to measure p24 
and other 2 incubated with purified erythrocytes DARC+ and DARC-. 
P24 was determined. 
Results: The total amount of virus produced by MDM incubated with 
erythrocytes was significantly higher than the amount produced when 
they were incubated with RPMI (p=0.005).  The binding capacity of 
the virus produced by MDM was analyzed with erythrocytes DARC+ 
and DARC- and no differences were observed between donors. The 
percentages observed were similar to those obtained when the 
erythrocytes were incubated with different viral stocks. Similar results 
were obtained in different pi days.
Conclusion: Due to the importance of macrophages and erythrocyte 
described, and as it was demonstrated here, the presence of erythrocytes 
may increase viral production of infected MDM, this fraction should be 
thoroughly considered in the pathogenesis of HIV infection, given that 
this close contact always occurs in the infected patient during the early 
stage of infection. So far, the presence or absence of DARC showed no 
relevance, therefore, other receptors involved in the binding process 
should be further studied.
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P07.18
Adjuvant Activity of Modified HIV that Induces 
Innate Sensing by Dendritic Cells in the 
Absence of Productive Infection
X. Lahaye3, T. Satoh3, S. Cerboni3, C. Conrad3, I. Hurbain1,  
A. El Marjou1, C. Lacabaratz2, J. Lelievre2, and N. Manel3
1Institut Curie UMR144, Paris, France; 2Hospital Henri Mondor 
INSERM U955 and Vaccine Research Institute, Creteil, France; 
3Institut Curie INSERM U932 and Vaccine Research Institute, 
Paris, France
Background: Although both HIV-1 and HIV-2 replicate in T cells of 
infected patients, HIV-2 typically causes a less severe disease and may 
even provide partial cross-protection from HIV-1-induced pathology. A 
key difference between these viruses is that HIV-2 infects dendritic cells 
(DCs) and activates them, but HIV-1 can do so only if complemented 
with the Vpx protein found in HIV-2/SIVmac particles. How HIV-2 
naturally activates dendritic cells was not known.
Methods: In addition to Vpx, HIV-1 and HIV-2 also differ by the affinity 
of their capsid for Cyclophilin A (CypA), a host factor known to be 
required for intracellular HIV-1 sensing in DCs. To study HIV-2 sensing, 
we designed mutations in capsid to increase its affinity for CypA (HIV-2 
affinity-enhanced capsid, HIVac-2).
Results: Strikingly, HIVac-2 induced more efficient DC activation and lost 
infectivity. This allowed us to dissect the determinants of HIV sensing. 
The ability of HIVac-2 to activate DCs in the absence of integration 
prompted us to apply the same principle to HIV-1 and to generate 
HIVac-1 using a similar approach. Indeed, HIVac-1 with Vpx behaved 
as a non-integrative agonist of sensing in DCs. Furthermore, HIVac-1 
stimulated proliferation of CD8+ T cells from HIV-1-infected patients.
Conclusion: Thus, we establish that innate sensing of HIV in DCs is 
genetically dissociable from productive infection. Our results constitute 
a unifying model of HIV sensing in human DCs that implicates SAMHD1 
and cooperation between the viral capsid and the viral cDNA. The 
adjuvant activity of HIVac in the absence of integration may be of 
interest for HIV vaccine development.
P07.17
HIV-1 Infection Induces IP-10 Production from 
Monocytes and Myeloid Dendritic Cells via 
TLR7/9 Dependent Pathways
E. Scully1, R. Simmons2, K. Benedict3, E.E. Groden4, J.J. Chang5,  
E. Rosenberg6, D. Lauffenburger3, and M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Boston University School of Medicine, Boston, MA, USA; 
3MIT, Cambridge, MA, USA; 4Northwestern University Feinberg 
School of Medicine, Chicago, IL, USA; 5Monash University, 
Melbourne, Australia; 6Massachusetts General Hospital, 
Boston, MA, USA
Background: HIV-1 infection induces both T cell activation and 
inflammatory cytokine production, and inflammation is an important 
driver of disease progression.  We sought to characterize the 
multivariate patterns of cytokine production associated with viral load 
and to identify cellular sources of the relevant cytokines.
Methods: Plasma samples from patients with early HIV-1 infection 
and patients enrolled in a single arm trial of structured treatment 
interruption (STI) were analyzed for levels of 19 cytokines.  To identify 
cellular sources of these cytokines and specific upstream stimuli, 
PBMCs from uninfected individuals were incubated with either live 
HIV-1, adriothiol inactivated HIV-1 (AT-2), the TLR7/8 agonist CL097, 
or the HIV-derived TLR7/8 agonist ssRNAGag1166 and analyzed by 
intracellular cytokine staining or by multiplex analysis of culture 
supernatants.  A TLR7/9 antagonist was added to cultures to assess the 
role of this pathway in production of relevant cytokines.
Results: Plasma concentrations of IP-10 were most strongly associated 
with HIV-1 viral load (p<0.0001 for STI group, Bonferroni correction 
threshold of significance p≤0.0026).  Partial least squares regression 
(PLSR) of all the plasma cytokine levels also identified IP-10. In vitro 
stimulation and intracellular cytokine staining identified monocytes 
and mDCs as the dominant source of HIV-1 induced IP-10.  Partial 
least squares discriminant analysis (PLSDA) identified distinct cytokine/
chemokine patterns in culture supernatants associated with whole 
virus versus TLR7/8 stimulation (IP-10, IL-2, IL-4, IL-13 and IL-5). TLR7/9 
blockade abrogated HIV-1 induced IP-10 in our in vitro culture system.
Conclusion: Among the inflammatory cytokines induced by HIV-1, the 
strongest individual predictor of viral load was IP-10, although a model 
integrating multiple cytokines via PLSR had superior performance.  In 
vitro stimulation with HIV-1 and TLR7/8 ligands induced production 
of IP-10 predominantly from monocytes and mDCs, and a TLR7/9 
antagonist significantly blocked IP-10 production.  These data suggest 
that HIV-1-mediated stimulation through TLR7/9 pathways may drive 
IP-10 production in viremic infection.
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P07.20
Alum and MF59, in Combination with ALVAC-
SIV and Gp120 Vaccines Recruit Functionally 
Different NK Cells to the Gut of Vaccinated 
Rhesus Macaque
N.P. Liyanage1, S.N. Gordon1, M. Vaccari1, P. Pegu1, M.N. Doster1, 
G.D. Tomaras2, D. Venzon1, D. Stablien3, J. Tartaglia4,  
S.W. Barnett5, J.H. Kim6, N.L. Michael6, and G. Franchini1
1National Cancer Institute, NIH, Bethesda, MD, USA; 2Duke 
Human Vaccine Institute, Durham, NC, USA; 3The EMMES 
Corporation, Rockville, MD, USA; 4Sanofi Pasteur, Swiftwater, 
PA, USA; 5Novartis Vaccines and Diagnostics Inc., Cambridge, 
MA, USA; 6U.S. MHRP, Silver Spring, MD, USA
Background: Increasing evidence suggest that HIV can be controlled by 
innate lymphoid cells (ILCs) such as NK cells, via multiple mechanisms 
including antibody dependent cellular cytotoxicity (ADCC). In the 
RV144 vaccine trial, that showed 31% protection from HIV acquisition, 
there was an inverse correlation between risk of infection and ADCC, 
suggesting the importance of NK cells. NKG2A can express CD16 and 
mediate ADCC. NKp44+ cells produce IL-17 and IL-22 are important 
for the homeostasis of mucosal compartments. Here we investigated 
whether the ALVAC/SIV gp120 vaccine regimen adjuvanted with ALUM 
or MF59 could affect vaccine efficacy and NK function.
Methods: Two macaque cohorts were vaccinated with ALVAC-SIV 
gp120 vaccines. One group was boosted with the gp120 protein, 
adjuvanted with ALUM (n=27) while the other group was given the 
gp120 formulated with MF59 (n=27). All the animals were challenged 
with low repeated dose of SIVmac251 intra-rectally. Rectal biopsies 
were analyzed at one week after the last immunization for the 
frequency and function of ILCs by flow cytometry.
Results: We observed a significant protection from SIVmac251 
acquisition versus the 47 control animals in the ALUM but not in the 
MF59 group. Both vaccines recruited NKG2A+ and NKp44 cells to 
the gut. However, the frequency of NKG2A+CD107a+ NK cells and 
NKG2A+TNFa+ cells were significantly higher in the MF59 group 
following stimulated with PMA/Ionomycin (p=0.015, P=0.0468) 
whereas the NKp44+IL17+ NK cells stimulated with SIV env peptides 
were significantly higher in the ALUM group (p=0.0098).
Conclusion: Our results indicate that vaccination with ALUM recruits 
regulatory NKp44+IL17+ cells whereas vaccination with MF59 recruits 
cytotoxic NKG2A+CD107+ cell subsets to the gut. Whether these 
results are related to the observed difference in vaccine efficacy is 
under investigation. 
P07.19
HLA-C2 Haplotype-Dependent Expansion of 
KIR2DL1+ NK Cells in Early HIV-1 Infection Is 
Accompanied by Increased Polyfunctionality of 
KIR2DL1+ NK Cells
C. Korner1, M. Granoff1, M. Amero1, S. Jost1, T. Allen1,  
E.S. Rosenberg2, and M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Massachusetts General Hospital, Boston, MA, USA
Background: Accumulating evidence suggest an HLA-dependent 
protective effect of certain Killer-cell immune-globulin like receptors 
(KIRs) in the course of HIV-1 infection. However, the mechanisms 
underlying these effects in individuals with protective KIR/HLA 
haplotypes still remain elusive. Licensing of KIR-expressing NK cells 
in the presence of their cognate HLA ligands might play a role in the 
control of viral replication through more rapid and efficient NK cell 
responses. To investigate this hypothesis, we analyzed the response 
of KIR2DL1/L3+ NK cell subsets in association with cognate HLA-C 
haplotypes in HIV-1 infected individuals and HIV-1 negative controls.
Methods: For this study 24 HLA-Bw4(-), KIR2DL1/L3(+) individuals 
with primary HIV-1-infection and 18 HIV-negative subjects were 
enrolled. NK cell responses and frequency of KIR expression were 
measured by flow cytometry. NK cell responses were defined by levels 
of degranulation and cytokine production (IFN-y, TNF-a) after co-
incubation with MHC-class I–deficient 721.221 target cells.
Results: While frequencies of KIR2DL1-expressing NK cells were 
increased in individuals carrying HLA-C group 2(+) haplotypes 
(C1C2, C2C2; p=0.02 as compared to C1C1 homozygous subjects), 
the proportion of KIR2DL2/L3(+) NK cells was not increased in 
the presence of HLA-C1(+) haplotypes (p=0.48). Of note, within 
HLA-C group 2(+) individuals levels of degranulation and IFN-y 
production of KIR2LD1(+) NK cells did not differ from KIR2DL1(-) NK 
cells. However, we observed a significantly increased frequency of 
polyfunctional KIR2DL1+ NK cells as determined by simultaneous 
degranulation and production of IFN-y and TNF-a (p=0.03 as 
compared to KIR2DL1(-) NK cells).
Conclusion: Our results indicate a HLA-C group 2 haplotype-dependent 
preferential expansion of NK cells expressing the inhibitory receptor 
KIR2DL1 during primary HIV-1 infection. This expansion seems to be 
accompanied by an increase frequency of polyfunctional KIR2DL1+ 
NK cells. Both observed effects might be explained by more efficient 
licensing of KIR2DL1+ NK cells in HLA-C2+ carriers.
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P07.21 LB
Elucidating NK Cell-Mediated Lysis of HIV-1 
Primary Infected Cells by Antibodies
M.E. Biedma1, T. Decoville1, B. Su1, M. Lambotin1, M. Peressin1,  
G. Laumond1, S. Schmidt1, and C. Moog1
1U1110, Universite de Strasbourg, Strasbourg, France
Background: Increasing evidence support a role of inhibitory activities 
beyond neutralization in the control of HIV-1 infection by antibodies 
(Abs). Antibody-dependent cellular cytotoxicity (ADCC) has been 
proposed as a possible mechanism of protection in several vaccination 
trials. ADCC Abs bridge infected target cells with FcγR bearing cells, 
such as Natural Killer (NK) cells. This binding results in cell lysis, 
besides direct lysis as part of innate NK cell-mediated mechanism. 
Currently, several in vitro assays are available to detect such activity. 
However, there is no protocol worldwide accepted. In this study, the 
antiviral contribution of ADCC was investigated using physiologically 
relevant conditions on primary HIV-1 infected CD4T cells and using 
autologous primary NK cells.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated by 
Ficoll-Hypaque centrifugation. NK cells and CD4 T-lymphocytes were 
purified from PBMC by magnetic positive selection. The contribution 
of NK cells in elimination of HIV-1 infected cells was detected by 
intracellular viral p24 staining. NK functional activity was evaluated by 
flow cytometry by detection of CD107a expression. 
Results: We found that effector NK cells display potent reduction 
of HIV-1 infected target cells in the absence and in the presence of 
Abs (monoclonal and polyclonal samples). Interestingly, cell lysis did 
not correlate with NK CD107a expression levels, a commonly used 
surrogate marker of ADCC activity in vitro. 
Conclusion: Detection of ADCC under physiologically relevant 
conditions with primary cells, support the potential in vivo role of 
this inhibitory mechanism and highlight the necessity to compare the 
outcome of currently used ADCC assays.
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P08.02
HIV-1 Specific Binding Antibody Titres in Blood 
Predict Detection in the Female Genital Tract in 
Women Who Became Infected in the CAPRISA 
004 Microbicide
D. Archary1, K. Seaton2, N.L. Yates2, L. Werner1, P.J. Bergin3,  
L.J. Liebenberg1, N. Samsunder1, N. Garrett1, Q. Abdool-Karim1, 
S.S. Abdool-Karim1, H. Liao2, J. Passmore4, L. Morris5, and  
G.D. Tomaras2
1CAPRISA, University of KwaZulu-Natal, Durban, South Africa; 
2Duke University Medical Center, Durham, NC, USA; 3Imperial 
College, London, UK; 4University of Cape Town, Cape Town, 
South Africa; 5National Institute for Communicable Diseases, 
Johannesburg, South Africa
Background: In the CAPRISA 004 trial, women who became HIV-
infected despite using 1% Tenofovir (TFV) gel had significantly higher 
systemic Gag-specific CD4 T cell responses than women infected in the 
placebo arm.  We hypothesized that preservation of CD4 T cells could 
augment B cell function resulting in higher levels of HIV-specific IgGs 
in the blood and genital tract of women in the TFV arm.   
Methods: HIV-specific IgGs in blood and cervicovaginal lavage (CVL) 
from women in the TFV (n=24) and placebo (n=24) arms to 10 HIV 
antigens (gp70_B.CaseAV1_V2, BioV3.C, gp41, gp41 immunodominant 
epitope, 1086 trimer, C.conEnv03 gp140, Con6 gp120/B, ConS gp140 
CFI, p24 & p66 RT) was measured by Luminex. IgG titres in the two 
compartments were analyzed using linear mixed effect models over 
2-39 months post infection and compared to viral load and CD4 T 
cell counts.
Results: There were no differences in binding IgG titres between 
TFV and placebo in either blood or CVL to any of the 10 antigens. 
Lower CD4 counts were associated with higher blood Env-specific IgG 
titres (all p<0.005). Higher viral loads were associated with higher 
gp41 and gp41 immunodominant epitope titres regardless of study 
arm (both p<0.05). Notably, blood titres for 9 of 10 HIV antibody 
specificities positively predicted the similar specificity in matching CVL 
for gp70_B.CaseAV1_V2 (β=0.21; R=0.27; p<0.05); p24 (β=0.5169; 
R=0.63), p66 (β=0.44; R=0.43), 1086 Trimer (β=0.3; R=0.45), gp41 
immunodominant epitope (β=0.37; R=0.41), ConSgp140 CFI (β=0.25; 
R=0.36), C.conEnv03gp140 (β=0.23; R=0.44), Con6 gp120/B (β=0.27; 
R=0.40) and BioV3.C (β=0.42; R=0.58)  (all p<0.001).  
Conclusion: Preserved CD4 T cell responses consequent to TFV use did 
not impact on binding IgG responses in women who became infected. 
In contrast, markers of disease progression were associated with 
higher systemic HIV-specific IgGs suggesting an immunopathogenic 
effect. The correlations between HIV-specific IgGs in blood and blood 
implied plasma IgG mucosal transudation.
P08.01
Env Binding to the ɑ4β7 Integrin Complex Is 
Not a General Property of Most HIV-1 Variants
L.G. Perez1 and D.C. Montefiori1
1Duke University, Durham, NC, USA
Background: HIV-1 gp120 has been reported to bind and signal 
through ɑ4β7 by means of a tripeptide motif in the V2 loop that 
mimics structures present in the natural ligands of ɑ4β7. These findings 
suggested that ɑ4β7 may facilitate selective infection of CD4+ T cells 
in the GALT, and could contribute to the massive depletion of T cells 
from this tissue in HIV-infected individuals.  Furthermore, the immune-
correlates in the RV144 vaccine trial have generated the hypothesis 
that V1V2 antibodies to an epitope near the putative ɑ4β7 binding 
motif may play a role in protection against HIV infection.  
Methods: We used retinoic acid (RA)-activated human PBMCs and 
transiently transfected 293T cells expressing the integrin complex, to 
study the ɑ4β7 binding properties of 12 HIV-1 glycoproteins by flow 
based methods.
Results:  The natural ɑ4β7 ligand, MAdCAM-1, bound efficiently to 
RA-activated PBMCs and transfected 293T cells and this binding could 
be blocked by anti-ɑ4 monoclonal antibodies HP2/1 and L25. Gp120 
and gp140 proteins from different HIV-1 subtypes bound to PBMCs 
from 3 different donors in a CD4-dependent manner but no binding 
was detected to ɑ4β7 as determined by MAdCAM-1, HP2/1 and L25 
inhibition.  Moreover, no gp120 binding was detected to CD4-negative 
293T cells transiently expressing ɑ4β7. Similar results were obtained 
when we assayed the same gp120 produced in 293T, CHO and 
293S/GnT-1-/- cells. The only exception to these findings was AN-1, 
a computer-designed gp120 produced in a glycosylation-deficient cell 
line (CHO/lec1.1-/-). AN-1 bound poorly to CD4 on RA-treated PBMCs. 
In addition, MAdCAM-1 and anti-ɑ4 mAbs partially blocked binding 
of this gp120 to RA-treated PBMCs and ɑ4β7-expressing 293T cells. 
Conclusion: We conclude that ɑ4β7 binding is not a general property 
of Envs from most strains of HIV-1, making it difficult to reconcile that 
this integrin complex plays a crucial role in GALT HIV-1 infectivity.
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P08.04
Adenovirus Vector-Based SIV Vaccines Induce 
Durable SIV-Specific CD4+ and CD8+ T Cells in 
the Foreskin in Rhesus Monkeys
E. Balandya1, A. Miller2, M. Beck2, J. Liu1, H. Li1, E. Borducchi1,  
K. Smith1, C. Cabral1, K. Stanley1, L. Maxfield1, and D.H. Barouch1
1Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA; 2New England Primate Research 
Center, Southborough, MA, USA
Background: Foreskin is the principal site of HIV infection in men. 
However, little is known about HIV-specific immune responses in the 
foreskin. Using the rhesus monkey model, we investigated whether 
SIV-specific T cells traffic to the foreskin following systemic vaccination 
and infection, and we compared the phenotype and activation status 
of foreskin and peripheral blood T cells.
Methods: 40 adult male Indian origin rhesus monkeys (Macaca 
mulatta) were used in the study. Animals were immunized with 
adenovirus (Ad) serotype 35 and 26 vectors expressing SIV-Gag, Pol 
and Env immunogens. Other animals were infected with SIVsmE660 
or SHIV-SF162P3 or served as non-immunized/non-infected controls. 
Paired peripheral blood and foreskin specimens were analyzed for 
SIV -specific CD4+ and CD8+ T cell responses, T cell phenotype, 
and activation status using intracellular cytokine staining and 
multiparameter flow cytometry.
Results: Immunization with Ad35/Ad26-based SIV vaccines elicited 
durable SIV-specific CD4+ and CD8+ T cells in the foreskin that 
were detectable beyond 1 year following vaccination. These SIV-
specific T cells in the foreskin were at higher magnitudes than those 
in peripheral blood (0.21% vs. 0.03% for foreskin vs. peripheral 
blood CD8+ T cells [n=14], p<0.001), were also detectable in the 
foreskin of SIV/SHIV infected animals (0.26% vs. 0.08% for foreskin 
vs. peripheral blood CD8+ T cells [n=22], p<0.01) and secreted 
both IFN-γ and TNF-α. CD4+ and CD8+ T cells in the foreskin were 
primarily transitional and effector memory phenotype, expressing 
high levels of the activation markers CD69, HLA-DR and CCR5. 
No increased activation of foreskin CD4+ T cells was observed in 
vaccinated monkeys compared with controls.
Conclusion: Ad35/Ad26-based SIV vaccines elicited durable SIV-
specific CD4+ and CD8+ T cell responses in the foreskin that were 
detected for more than 1 year following vaccination. These findings 
suggest that systemic SIV/HIV vaccination strategies can elicit 
potentially important SIV/HIV-specific immune responses in foreskin.
P08.03
Potent Neutralizing Antibodies Can Be 
Recovered from the Genital Tract Using the 
Non-invasive Softcup® Technique
N.N. Mkhize1, N. Garrett2, D. Archary2, T. Hermanus1, N. Majola2, 
N. Samsunder2, C. Williamson3, R. Shattock4, J. Passmore2,  
S. Abdool Karim2, and L. Morris1
1National Institute for Communicable Diseases, Johannesburg, 
South Africa; 2CAPRISA, University of KwaZulu-Natal, Durban, 
South Africa; 3University of Cape Town, Cape Town, South 
Africa; 4Imperial College, London, UK 
Background: The genital tract is an important site to test for HIV-
specific responses during natural infection and in vaccine trial settings, 
as it is the main point of entry during HIV infection. Mucosal sampling 
techniques continue to be investigated and optimised. Our previous 
results showed that IgG antibody yields obtained from cervicovaginal 
lavages (CVL) were very low due to the high dilution factor. Here 
we	 tested	 Softcup®	 specimens	 with	 undiluted	 genital	 secretions	 to	
determine	whether	the	Softcup®	technique	could	be	implemented	as	
a method for collecting antibodies to assess neutralization of HIV.
Methods: Softcup®	 samples	 were	 obtained	 from	 9	 women	 with	
known neutralization breadth in the CAPRISA 002 Acute Infection 
cohort during routine follow-up visits. The softcup was inserted at the 
beginning of the visit and was removed after two hours. IgG antibodies 
were isolated from the genital secretions by Protein G columns. Total 
and HIV-specific antibodies were quantified by ELISA. Neutralization 
assays were performed in TZM-bl cells using Env-pseudotyped wild 
type and mutated viruses for epitope mapping.
Results: The average collection time was 150 minutes (range; 95-
185	 minutes)	 and	 fluid	 phase	 secretions	 obtained	 per	 Softcup®	
ranged	 from	30ul	 to	135ul.	 The	 total	 IgG	 yields	 from	 the	 Softcup®	
collection method were about 3 fold higher than those from 1.8ml of 
CVL (p=0.0029) enabling us to perform neutralization assays against 
more viruses than possible with CVL. Purified IgG exhibited potent 
neutralization of SF162 (Tier 1) and at least three Tier 2 viruses for each 
participant. Epitope mapping suggested that mucosal IgG specificities 
mirrored matched plasma samples.
Conclusion: The	Softcup®	method	enabled	us	to	isolate	high	yields	of	
potent HIV-specific neutralizing IgG antibodies from genital secretions. 
Therefore,	the	Softcup®	technique	could	be	employed	as	an	efficient,	
non-invasive method for mucosal sampling and facilitate the mapping 
of neutralizing antibody specificities in vaccine trials.
Topic 08: Mucosal Immunity
Posters
P
O
ST
ER
S
215AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P08.06
Levels of HIV gp120-Specific Binding 
Antibodies in the Female Genital Tract Are 
Correlated with Genital Inflammation
S.L. Barnabas1, N.N.  Mkhize2, L. Masson1, L. Werner3,  
D. Archary3, K. Mlisana4, C. Williamson1, S.A. Karim3, L. Morris2, 
and J.S. Passmore1
1University of Cape Town, Cape Town, South Africa; 2National 
Institute for Communicable Diseases (NICD), Sandringham, 
Johannesburg, South Africa; 3CAPRISA, University of KwaZulu-
Natal, Durban, South Africa; 4Inkosi Albert Luthuli Central 
Hospital & UKZN, Durban, South Africa
Background: Genital inflammation has been implicated in 
recruitment of B and T cells to the genital mucosa and may play a 
role in the availability of total and HIV-specific antibodies present in 
genital secretions.
Methods: We investigated the longitudinal relationship between 
genital inflammation and HIV gp-120-specific antibodies present in 
genital secretions from women in the CAPRISA002 Acute Infection 
Study. A total of 40 consenting women, recently infected with HIV-
1, were included. Cervico-vaginal lavages (CVLs) were available from 
24/40 women 7 months post-infection, 26/40 at 12 months post-
infection, with 10/40 women having samples available at both time 
points. Twenty one cytokines were measured in CVLs using a high-
sensitivity and human cytokine Milliplex kits including IL-1β, IL-6, 
Eotaxin, MCP-1, MIPα, RANTES, IL-8, IL-2, IL-15, G-CSF, GM-CSF,TNF-α, 
sCD40L and  IFN-γ. The concentrations of total IgG, total IgA and IgG 
gp120 were determined by ELISA.
Results: In HIV-infected women, the concentration of total IgG in CVL 
was 80-3000 times higher than IgA. There was a significant positive 
correlation between the concentration of total IgG in CVL and the 
amount of HIV-specific gp120 which was seen at both months 7 and 
12. Women with the highest antibody titres at one time point tended 
to have the highest titres at the next time point. Total IgG in CVL was 
significantly positively correlated with 11/21 genital tract cytokines 
measured (IL-1β, IL-6, Eotaxin, MCP-1, MIPα, RANTES, IL-8, IL-2, IL-15, 
G-CSF and GM-CSF). Similarly, concentrations of HIV gp120 binding 
IgG were correlated with concentrations of 9/21 (IL-6, TNF-α, MCP-1, 
MIP-1α, RANTES, sCD40L, IFN-γ, IL-15, and GM-CSF.) 
Conclusion: This relationship between inflammatory cytokines and 
HIV-specific antibody detection in the genital tract needs attention 
since the production of mucosal antibodies in response to a vaccine is 
desirable; however these cytokines are also chemo-attractant for HIV 
target cells and could potentially increase the risk of infection.
P08.05
Inflammation in the Male Genital Tract: CMV 
and HIV Shedding
A.J. Olivier1, L. Masson1, G. Walzl2, D. Coetzee1, A. Williamson1, 
J.S. Passmore1, and W.A. Burgers1
1University of Cape Town, Cape Town, South Africa; 
2University of Stellenbosch, Tygerberg, South Africa
Background: In the male genital tract, reactivated replicating CMV 
increases HIV shedding in semen, target cell activation and seminal 
concentrations of pro-inflammatory mediators such as MCP-1, RANTES 
and IL-8.  The impact of HIV and CMV co-infections underscores the 
need for broadening HIV treatment strategies to include CMV treatment. 
We investigated the impact of seminal CMV infection in HIV-infected 
and uninfected men on inflammatory biomarkers present in semen.
Methods: CMV viral loads were measured in the semen of 38 
HIV-infected and 20 HIV-uninfected men. Concentrations of 20 
inflammatory and regulatory cytokines were measured in semenal 
plasma by Luminex. The relationship between CMV shedding in 
the seminal compartment and inflammation was investigated using 
multivariate regression analysis.
Results: We found that 13/25 (52%) of HIV-infected ARV naïve, and 
6/20 (30%) of HIV-uninfected men were shedding CMV in their semen. 
HIV plasma viral loads were significantly correlated with seminal CMV 
viral loads.  In semen, HIV viral loads were significantly higher in 
semen samples in which CMV was detectable compared to samples in 
which CMV was not detectable.  IL-15 and IL-7 was weakly associated 
with CMV viral loads in the semen of HIV-infected men, and the IL-7 
association was upheld after controlling for the effect of both seminal 
HIV and plasma viral load in a multivariate regression analysis.
Conclusion: Increases of seminal IL-15 and IL-7, both drivers of CD4 T 
cell homeostasis, may elevate levels of HIV target cells in the genital 
tract of men by contributing to T cell proliferation.  This may be due 
to HIV-induced depleted seminal target cell levels and/or CMV co-
infection.  Therefore, CMV shedding in the semen of HIV-infected men 
may increase the risk of secondary transmission and in uninfected 
men, may put men at risk for HIV acquisition.
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P08.08
HIV-1 Transfer from Mucosal Dendritic Cells 
and Macrophages to T Lymphocytes, and 
Inhibition by Antibodies
M. Peressin1, A. Lederlé1, A. Proust1, S. Schmidt1, B. Su1,  
M. Lambotin1, M. Biedma1, G. Laumond1, T. Decoville1, and  
C. Moog1
1UMR1110, INSERM, Université de Strasbourg, Strasbourg, France
Background: Following sexual transmission, Antigens Presenting Cells 
(APCs) in mucosal sites are considered as the first cells encountered by 
HIV. Their crosstalk with CD4 T lymphocytes favor efficient HIV cell-to-
cell transfer, leading to rapid viral dissemination. However, most HIV 
transfer studies involve monocyte derived dendritic cells displaying 
characteristic distinct from those of mucosa residing dendritic cells 
(DCs). The aim of this study was to define the respective role in HIV 
transfer of various DCs subsets and macrophages present at the 
mucosal site. The potential inhibition of HIV transfer by antibodies 
was determined.
Methods: Langerhans and Interstitial DCs (LCs/IDCs), purified 
plasmacytoid DCs (pDCs) or Monocyte Derived Macrophages (MDMs) 
were incubated with primary HIV-1 during 2 hours before addition 
of autologous activated CD4-T-lymphocytes. Different inhibitors were 
added in the cocultures: fusion inhibitor T20 to analyze the percentage 
of virus fused to APCs; Indinavir to define the percentage of trans-
infection; and neutralizing antibodies to determine their inhibitory 
potential. After 48 to 72 hours, the percentage of infected cells was 
quantified by intracellular p24 staining and flow cytometry analysis.
Results: We found that LCs/IDCs, pDC and MDMs efficiently transferred 
HIV particles to CD4-T-lymphocytes. Interestingly, the kinetic of HIV 
transfer was more rapid in MDMs compared to DCs subsets. Moreover, 
MDMs transferred HIV preferentially in trans whereas LCs/IDCs mainly 
in cis. Anti-gp120 neutralizing antibodies (2G12, VRC01, b12) were 
able to block viral transfer to T cells. Noteworthy, this inhibition was 
1000 fold more efficient in MDMs than in DCs cocultures. 
Conclusion: Altogether, these results highlight the important 
contribution of different HIV mucosal target cells and emphasize 
the role of macrophages in the rapid and efficient replication and 
transmission to T-lymphocytes. They demonstrate that the inhibition 
of cell-to-cell transfer by neutralizing antibodies involves different 
mechanisms of inhibition depending on the type of APCs targeted. 
P08.07
Prime Boost Mucosal HIV Vaccine Using 
Recombinant Influenza Virus Vector Stimulated 
Specific and Mucosal CD8+ T Cell Immune 
Response in BALB/C Mice
M. Shallal1 and J. Stambas2
1Deakin University, Geelong, St. Albans Park, VIC, Australia; 
2Deakin University, Melbourne, Australia
Background: Most HIV vaccine candidates to date have failed to elicit 
effective immune responses that are necessary to control HIV infection. 
The results of a promising phase III trial conducted in Thailand using 
a recombinant canary pox vector vaccine (ALVAC) expressing HIV 
Gag in combination with recombinant HIV-Env glycoprotein gp120 
(AIDSVAX), showed 31.2% efficacy in humans and raised the prospect 
of a protective vaccine. The most recommended HIV vaccines are 
focussing to induce specific CD8+ T as a critical to control progression 
of HIV virus.
Methods: This study project used influenza viruses as mucosal live 
vaccine vector to stimulate effective CD8+ T cell immunity. Recombinant 
influenza A viruses, H3N2 (HK-x31) and H1N1 (A/PR8/8/34) expressing 
defined mouse HIV-1 CD8+ T cell epitopes (H-2Kd Gag197-205 and 
H-2Kd Tat17-25) in the neuraminidase (NA) stalk were generated using 
reverse genetics and administered as a prime boost vaccine within 
different program of vaccination, intranasal-intranasal, intravaginal-
intravaginal, intranasal-intravaginal and intravaginal-intranasal 
vaccination in BALB/C mice. Following those prime-boost vaccinations, 
tetramer and intracellular cytokine staining assays used for detection 
of specific CD8+ T cell immune responseIn addition, mucosal HIV-
specific CD8+ T cells were detected using antibodies directed against 
specific integrins (LPAM-1, CD103 and CD44).  
Results: Our result showed comparable HIV and endogenous influenza 
specific CD8+ T cell responses following intranasally-intranasally prime 
boost vaccination in harvested lymphoid tissues.Also, intranasally-
intranasally prime boost expressed mucosal surface integrins of local 
and distal lymph nodes higher than the levels observed following 
intravaginal vaccination. 
Conclusion: The route of vaccination using mucosal viral vaccine 
vector in BALB/C mice has an important role in stimulation both 
specific and mucosal CD8+ T cells within a high level and These cells 
may be important for migration of mucosal specific CD8+ T cells given 
the mucosal acquisition of HIV infection and control of HIV infection.
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P08.10
Vaccine-Induced Intestinal and Salivary IgA 
Correlates with Reduced SIV Viremia in Orally-
Challenged Neonatal Macaques
K. Jensen5, R.L. Wilson1, M. Piatak2, J.D. Lifson2, U.D. Ranangathan3, 
W.R. Jacobs3, G. Fennelly3, M. Larsen3, K.K. Van Rompay4,  
P.A. Kozlowski1, and K. Abel5
1Louisiana State University Health Sciences Center, New 
Orleans, LA, USA; 2Frederick National Laboratory for Cancer 
Research, Frederick, MD, USA; 3Albert Einstein College of 
Medicine, New York, NY, USA; 4CNPRC at University of 
California-Davis, Davis, CA, USA; 5University of North Carolina 
at Chapel Hill, Chapel Hill, NC, USA
Background: Vertical transmission of HIV in breast milk remains a 
primary route of pediatric infections. While serum antibodies are critical 
for elimination of HIV within the host, the importance of mucosal IgA 
in preventing oral transmission is not known. Neonates produce less 
IgA than adults and are thus more susceptible to oral pathogens. Here 
we tested whether an oral pediatric SIV vaccine could induce SIV 
envelope (Env)-specific salivary and intestinal IgA, and protect against 
oral SIV acquisition. 
Methods: Rhesus macaques were immunized orally at birth with a live 
attenuated Mycobacterium tuberculosis strain engineered to express 
SIV Gag and SIV Env, and twice boosted with MVAgpe. Nine weeks 
after birth, the infants were orally challenged using a weekly regimen 
of low-dose SIVmac251 (5000 TCID50).  
Results: All vaccinated infants had developed SIV-specific T cell 
responses in blood and tissues at the time of challenge. In addition 
to the induction of SIV-specific plasma IgG and IgA antibodies in all 
animals, salivary and intestinal SIV-specific antibodies were detected 
in 8 of 8 and 3 of 8 vaccinated animals, respectively, prior to challenge. 
Although vaccination did not prevent infection, vaccinated infants 
(n=3) with intestinal and salivary IgA at the time of challenge had 
significantly lower peak and set-point viremia compared to the other 
vaccinated animals (P=0.0154 and P=0.0357, respectively). In fact, 
there was an inverse correlation between peak viremia and SIV Env-
specific IgA in fecal extracts (P=0.0019) and saliva (P=0.034).  Serum 
IgG and IgA antibodies to SIV Env were also induced by vaccination, 
but these were not associated with viremia.
Conclusion: Thus, mucosal, but not systemic, antibodies may have 
contributed to control of virus replication.  Vaccine strategies that 
promote the development of mucosal IgA antibodies may improve the 
efficacy of pediatric vaccines to prevent oral HIV acquisition.
Funding by: R01 DE019064, R01DE022287 (KA) and 
HHSN261200800001E (MP, JL).
P08.09
CCL19 and CCL28 Augment Immune 
Responses to HIV-1 gp140 by Mobilizing 
Responsive Immunocytes into Secondary 
Lymph Nodes and Mucosal Tissue
K. Hu3, S. Luo3, X. Huang3, W. Jin3, W. Huang3, T. Du3, L. Tong3, 
Y. Yan3, S. He3, G. Griffin1, R. Shattock2, and Q. Hu3
1St George’s University of London, London, UK; 2Imperial 
College, London, UK; 3Chinese Academy of Sciences, 
Wuhan, China
Background: Induction of broad and potent neutralizing antibodies at 
the mucosal portals of entry remains a primary goal for most vaccines 
against mucosally acquired viral infections. Selection of appropriate 
adjuvants capable of promoting both systemic and mucosal responses 
will be crucial for the development of effective immunization 
strategies. Given the central roles of APRIL, CCL19 and CCL28 in B 
cell maturation or T/DC/IgA-ASC migration; we asked whether plasmid 
co-delivery of CCL19, CCL28 or APRIL can enhance antigen-induced 
immune responses to HIV-1.
Methods: Using candidate HIV-1 plasmid DNA (p-gp140) and gp140 
recombinant protein (rec-gp140) as immunogens, we investigated the 
immunomodulatory roles of plasmid co-delivery of pAPRIL, pCCL19 
and pCCL28 in mice when administered by intramuscular and 
intranasal routes of administration. 
Results: We demonstrate that pCCL19 and pCCL28, but not pAPRIL, 
significantly enhance antigen specific systemic and mucosal antibody 
responses. gp140-specific antibodies in serum enhanced by pCCL19 
or pCCL28 were broadly distributed across all four IgG subclasses of 
which IgG1 was predominant. The enhanced systemic and mucosal 
antibodies showed increased neutralizing activity against both 
homologous and heterologous HIV-1, where potency correlated with 
gp140-specific serum IgG and vaginal IgA levels. Measurement of 
gp140-specific cytokines produced by splenocytes demonstrated 
that pCCL19 and pCCL28 augmented balanced Th1/Th2 responses. 
pCCL19 and pCCL28 also elevated IgA+ cells in colorectal mucosal 
tissue. pCCL19 co-delivery resulted in an increase of CCR7+ CD11c+ 
cells in mesenteric lymph nodes (MLNs) and both CCR7+ CD11c+ and 
CCR7+ CD3e+ cells in spleen, whereas pCCL28 co-delivery resulted in 
an augment of CCR10+ CD19+ cells in both spleen and MLNs. 
Conclusion: Our findings indicate that pCCL19 and pCCL28 
can enhance HIV-1 Env-specific systemic and mucosal antibody 
responses as well as T cell responses. Such enhancements appear 
to be associated with mobilization of responsive immunocytes into 
secondary lymphoid organs and mucosal tissues through interactions 
with corresponding receptors. 
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P08.12
Utilizing Data-Driven Modeling and Proteomic 
Approaches for Predicting Mucosal Immunity 
of the Female Genital Tract
A. Burgener1, K. Birse1, L. McKinnon2, R. Novak3, G. Westmacott4, 
T. Ball5, D. Lauffenburger6, and K. Benedict6
1Public Health Agency of Canada, Winnipeg, Canada; 
2University of Toronto, Toronto, Canada; 3University of 
Chicago, Chicago, IL, USA; 4National Microbiology Lab, 
Canada; 5Public Health Agency of Canada, Canada; 6MIT and 
Harvard University, Boston, MA, USA
Background: A major impediment to designing HIV vaccines/
microbicides to elicit protective mucosal immunity is a lack 
of understanding of what immunological patterns predict HIV 
susceptibility.  This is likely a function of the general complexity of the 
immune system.  Approaches to date have studied individual or few 
components in isolation, thus limiting the ability to make associations 
or predictions on disease outcome.  Therefore new approaches are 
critically needed.  Multivariate computational modeling, utilizing 
comprehensive high-throughput datasets, is fast emerging as an 
effective method to unravel complex immunological systems.  Partial 
least squares determinant analysis (PLSDA) is one such technique 
to determine patterns of features that best distinguish groups. Here 
we explore the utility of this approach using bacterial vaginosis as a 
surrogate mucosal condition.
Methods: Cervicovaginal lavage samples from BV+ women (n=9), BV- 
women (n=33), and trichomoniasis-infected (Trc) controls (n=6) were 
analyzed by LC-LC-MS/MS. Features (classifiers) were identified by 
PLSDA using Matlab software.
Results: Over 500 unique proteins were identified, and PLSDA 
analysis indicated distinct patterns of protein expression associated 
with BV+, BV-, and Trc+ samples.  Latent variable loadings of the 
model identified a pattern of ~30 specific proteins associated with 
BV+, and ~10 with Trc+ samples.  Multivariate analysis was required 
to discern these patterns.  PLSDA model performed with 92% 
accuracy in predicting BV+ samples from controls on calibration and 
78% accuracy on cross-validation. 
Conclusion: This demonstrates that mucosal proteomic datasets, 
parsed with multivariate analysis can distinguish a mucosal clinical 
condition with high accuracy. Our hypothesis is that this approach 
could identify protein expression profiles associated with increased 
risk of HIV acquisition to contribute to a predictive model.  This could 
be applied to vaccine/microbicide endpoints for efficacy and potential 
insight into mechanisms of protection.
P08.11
B-Cell Subset Phenotypes in Human Blood and 
Gut Mucosa in HIV-1 Infection
J. Ibarrondo1, W. Cao1, J. Elliot1, R.B. Effros1, B.D. Jamieson1,  
B.L. Shacklett2, and P.A. Anton1
1UCLA, Los Angeles, CA, USA; 2UC Davis School of Medicine, 
Davis, CA, USA
Background: The B cell population in the gut, the largest lymphoid 
organ in human body, has been largely overlooked in previous 
immunological studies. The objective of our study was to characterize 
the phenotypes of B cell subsets present in human gut and to compare 
their frequencies with those found in blood of healthy and HIV-1-
infected individuals.
Methods: Peripheral blood mononuclear cells (PBMC) and mucosal 
mononuclear cells (MMC) were isolated from blood and colon biopsy 
samples, respectively, from individuals recruited by the UCLA CFAR 
Mucosal Immunology Core Laboratory (MICL). B cell subsets were 
analyzed utilizing a 10-color flow cytometry panel. The reliability of 
the panel was established comparing the measurements obtained from 
five healthy low-risk individuals in two visits two weeks apart.
Results: B cells were defined as CD3-CD16-CD19+, and the B cells 
subsets as: naïve (CD27-IgD+, memory (CD27+), resting memory 
(CD27+CD21high), plasmablasts (CD27highCD38high), plasma 
cells (CD19+/-CD27highCD20-CD21-), and exhausted B cells 
(CD20+CD21lowCD27-). In healthy individuals, we found that mucosal 
gut samples had fewer naïve cells, more memory cells, fewer resting 
memory B cells, more plasmablasts and more plasma cells than 
blood samples. In HIV infected individuals, we found an increase 
in the percentages of plasmablasts and plasma cells in the gut as 
compared to healthy individuals. We also observed an increase in the 
proportion of exhausted B cells in the both the blood and gut of HIV 
positive individuals. Resting memory cell subsets in the gut of HIV-1 
seropositive subjects were almost nonexistent. HIV infection affected 
neither the circulating resting memory B cells nor the percentages of 
naïve B cells in blood and gut.
Conclusion: The observed B cell subset distribution was consistent 
with the high level of antigen exposure and the pro-inflammatory 
nature of the gut mucosa. In HIV-1-infected individuals, the gut 
mucosa was characterized by an increase in activated and terminally 
differentiated B cells.
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P08.14
Intestinal Commensal Bacteria Shape the Pre-
transmission Antibody Repertoire to HIV-1 
Infection
A.M. Trama1, H. Liao1, F.H. Jaeger1, S.M. Alam1, K. Wiehe1,  
T.L. Jeffries Jr.1, A. Foulger1, W.T. Williams1, D.J. Marshall1,  
C. Stolarchuk1, K.E. Lloyd1, R. Parks1, K. Soderberg1, T.B. Kepler2,  
N. Vandergrift1, K.J. Jackson3, A.Z. Fire3, S.D. Boyd3,  
J.F. Whitesides1, G.D. Tomaras1, M.A. Moody1, and B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2Boston 
University, Boston, MA, USA; 3Stanford University, Stanford, 
CA, USA
Background: The initial HIV-1 antibody response in plasma and 
mucosal sites is non-neutralizing and targeted to Env gp41. The blood 
plasma cell (PC) response to gp41 derives from a polyreactive memory 
B cell pool of gut flora- reactive B cells (Liao et al. J. Exp. Med. 208: 
2237 (2011)). These data gave rise to the hypothesis that a pre-
transmission commensal bacterial antibody response that cross-reacts 
with HIV-1 antigens may shape the B cell response to HIV-1. Here we 
study the repertoire of HIV-1 antibodies induced in terminal ileum and 
ask if HIV-1 antibodies are cross-reactive with commensal bacteria.
Methods: Terminal ileum antibodies from individuals early in HIV-
1 infection and chronically HIV-1-infected were isolated by reverse 
transcriptase/polymerase chain reaction from sorted single plasma and 
memory B cells, and evaluated for the reactivity to HIV-1 and gut flora 
whole cell lysates (WCL).
Results: Of 412 mAbs isolated from terminal ileum, 19 (5%) were 
HIV-1-reactive.  Of the 19 HIV-1+ Abs, 14 were gp41-reactive, and of 
these 11 (79%) were cross-reactive with gut flora WCL.  Analysis by 
454 pyrosequencing of blood B cells from 1 individual identified 3 
HIV-1+ reactive clonal lineages with antibody members in both the 
terminal ileum and blood. Two of these ileum/blood lineages were also 
reactive with gut flora WCL. Using western blot and mass spectrometry 
analyses, E.coli RNA polymerase was identified as one major antigen 
in gut flora WCL that was cross-reactive with Env gp41.
Conclusion: The isolation of clonal lineages shared by terminal ileum 
and blood that cross-react with commensal bacterial antigens and Env 
gp41 is evidence for the hypothesis that the initial non-neutralizing 
response to gp41 is a result of HIV-1 gp41 triggering of pre-existing 
gut flora-reactive B cells.  These data similarly suggest that pre-existing 
commensal bacterial-reactive B cells may also be involved in the 
response to HIV-1 gp41-containing vaccine candidates.
P08.13
Use of Tissue Explants to Evaluate Mucosal 
Immune Responses in Non-Human Primates 
(NHPs) Vaccinated with ALVAC/AIDSVAX B/E
C. Herrera1, N. Olejniczak1, N. Karasavva2, T.A. Rasmussen3,  
K. Rasmussen3, R.S. Veazey3, J.H. Kim4, and R.J. Shattock1
1Imperial College, London, UK; 2Armed Forces Research 
Institute of Medical Sciences (AFRIMS), Bangkok, Thailand; 
3National Tulane Primate Research Center, Covington, LA, 
USA; 4U.S. MHRP, Silver Spring, MD, USA
Background: The STEP and RV144 trials have revealed the need to 
further improve the NHP model in order to establish better correlation 
between NHPs and humans studies. This pilot study aimed to use NHP 
cervicovaginal and colorectal tissue explants to assess B cell responses 
elicited upon vaccination with the same regimen of ALVAC/AIDSVAX 
B/E used in RV144. 
Methods: Six Rhesus macaques were immunized at weeks 0 and 4 with 
ALVAC and at weeks 12 and 24 with ALVAC/AIDSVAX B/E. Colorectal 
and cervicovaginal biopsies were obtained four weeks pre-vaccination, 
and two weeks after each immunization. Serum was collected at the 
same time points and one week after each shot. Biopsies were cultured 
for up to 15 days. Supernatant cytokines were assessed by Luminex 
after 24 h. Total and specific anti-gp120 HIV-1CM244 IgG and IgA 
secreted in tissue explant culture supernatant were measured at days 
3, 7, 11 and 15 with quantitative ELISA. Serum total and specific IgG/
IgA were measured.
Results: Specific IgG/IgA were only detected in cervicovaginal and 
colorectal biopsies obtained after immunization with ALVAC/AIDSVAX 
and not after ALVAC alone. Specific IgG/IgA were detected in serum at 
the same time points after ALVAC/AIDSVAX boosts. IgG/IgA in culture 
supernatant of cervicovaginal and colorectal explants progressively 
decreased during the 15 days of explant culture. When comparing the 
cytokine profile following each immunization with pre-immunization 
baseline, a significant decrease in IL-2, GM-CSF, IL-12, IL-13, IL-15, 
IL-17, MIP-1α, MIP-1β and TGF-α was observed at both mucosal sites 
after introduction of the ALVAC/AIDSVAX combination.
Conclusion: Immunization with ALVAC/AIDSVAX B/E elicited specific 
anti-gp120 HIV-1CM244 IgG and IgA systemically and mucosally. 
Cytokine secretion was affected at both mucosal sites, which could 
represent a biosignature of the vaccine combination. Ex-vivo mucosal 
models allow assessment of mucosal B cell responses to vaccination, 
improving the NHP model and providing key information for 
subsequent clinical trials.
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P08.16
In Men at Risk of HIV Infection, Antibodies Can 
Reach the Human Foreskin Epidermis at Ratios 
Similar to Those in Blood 
M.P. Lemos1, J.R. Lama2, S.T. Karuna1, J. Vasylyeva1,  
M.E. Gamero3, S. Minaya2, R. Negrón2, Y. Fong1, J. Jurupe2,  
M. Nieto3, N. Gadea3, S.M. Montano3, C. Ganoza2, J. Sanchez2,  
J. McElrath1, and NIAID HIV Vaccine Trials Network1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Asociación Civil Impacta Salud y Educación, Lima, Peru; 3U.S. 
Naval Medical Research Unit 6 (NAMRU-6), Lima, Peru
Background: The characteristics of the humoral response in the 
human penis have been minimally explored, yet may be critical for 
protecting insertive men at the sites of sexual exposure to HIV. 
Methods: We characterized the humoral responses in foreskin samples 
collected by circumcision from 17 sexually active 21-29 year old men 
at risk of HIV infection in Lima, Peru. Dermal and epidermal explants 
were cultured for 48h and the antibody secretion was quantitated 
in the supernatants using multiple bead arrays. To compare foreskin 
to plasma antibody concentrations, we normalized the antibody 
concentrations to the levels of human serum albumin (HSA) that had 
transudated, and expressed them as a ratio. 
Results: Dermal foreskin IgM (median 0.2), IgG2 (median 0.71), IgA 
(median 0.42), and IgE (median 0.001), were present at increased 
concentrations compared to paired blood (median IgM/HSA 0.06, 
median IgG2/HSA 0.14, median IgA/HSA 0.07, median IgE/HSA 
0.00006), suggesting that there is local antibody secretion at the 
foreskin dermis (Dunn’s test p<0.05).  IgG4 and IgE minimally reached 
the foreskin epidermis (median IgG4/HSA 0.0008, median IgE/HSA 
0.000001), suggesting that these isotypes have limited ability to 
provide protection at this site of HIV exposure (Dunn’s test p<0.01). 
On the contrary, foreskin epidermis IgM (0.04), IgG1 (median 0.45), 
IgG2 (median 0.31), IgG3 (median 0.02) and IgA (median 0.11) had 
levels comparable to those of blood (median IgG1/HSA 0.36, median 
IgG3/HSA 0.02), indicating efficient access of the humoral responses 
to the area (Dunn’s test p>0.05).
Conclusion: The foreskin harbors antibody-secreting cells at the dermis 
with efficient antibody penetration to the foreskin epidermis. The 
results highlight how vaccine design could benefit from characterizing 
the antibody production at genital sites. 
P08.15
The Inner Foreskin of Healthy Men Resembles 
Inflamed Epithelium and Has Features of a 
Compromised Skin Barrier
M.P. Lemos1, S.T. Karuna1, J.R. Lama2, M.l. Perez1,  
T. Goodpaster1, J. Vasylyeva1, M.E. Gamero3, S. Minaya2,  
R. Negrón2, Y. Fong1, J. Jurupe2, M. Nieto3, S.M. Montano3,  
C. Ganoza2, R. Gotardo1, J. Sanchez2, J. McElrath1, and NIAID 
HIV Vaccine Trials Network1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Asociación Civil Impacta Salud y Educación, Lima, Peru; 3U.S. 
Naval Medical Research Unit 6 (NAMRU-6), Lima, Peru
Background: Circumcision provides partial protection against multiple 
viral sexually transmitted infections (STIs), but the mechanisms 
associated with risk are not fully understood. We hypothesized inner 
and outer foreskin might have distinctly modified epithelium.
Methods: To assess the barrier functions of the foreskin epithelium, 
we compared the inner and outer foreskin samples collected 
following elective circumcision using immunofluorescence 
microscopy, hematoxylin and eosin analysis, as well as quantitation 
of inflammatory mediators and structural skin proteins using multiple 
bead array technology.
Results: No evidence of microtrauma was identified in the foreskin 
of 21 healthy, sexually active men from Lima, Peru (ages 21-29 
years) as assessed by signs of keratinocyte activation, fibronectin 
deposition, or parakeratosis. However, multiple structural differences 
in the epithelium of the inner and outer foreskin suggested differential 
permeability and inflammation.  The inner foreskin stratum corneum 
was thinner (median 15.7µm, IQR 12.1-20.9) than the outer (19.2µm, 
IQR 15.9-23.8) (Wilcoxon, p=0.012), and it thickened as it approached 
the base of the penis. The prevalence of components of the cornified 
envelope (involucrin and keratin 1, 10) was reduced in inner vs outer 
foreskin suggesting differential barrier functions. Additionally, the 
distribution of tight junction components claudin 1, claudin 4 and 
occludin was suggestive of chronic inflammation at the inner foreskin 
of healthy, sexually active men. Epithelial explant cultures confirmed 
that the inner foreskin epithelium secreted higher levels of GM-CSF 
(inner median 2.9ng/ml IQR 0.8-10.4, outer median 0.9ng/ml IQR 
0.7-1.6), IP-10 (inner median 9.9ng/ml IQR 2.1-44.0; outer median 
2.2ng/ml IQR 1.9-9.7) and RANTES (inner median 16.6ng/ml IQR 6.6-
22.9; outer median 7.9ng/ml IQR 4.1-14.4) than the outer foreskin 
counterparts (p<0.003). 
Conclusion: Subclinical changes to the inner foreskin of healthy men 
might make this site inflamed and more permeable to STIs, potentially 
explaining the benefits of circumcision for STI prevention.
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P08.18
Delivery of Encapsulated Nod Ligands Enhance 
Their Ability to Induce Mucosal Immune 
Responses Against HIV-1 Gag After Systemic or 
Mucosal Immunization
V. Pavot1, N. Rochereau2, C. Genin2, E. Pérouzel3, T. Lioux3,  
F. Garcia4, S. Paul2, and B. Verrier1
1University of Lyon, Lyon, France; 2University of Saint-Etienne, 
Saint-Etienne, France; 3CAYLA InvivoGen, Toulouse, France; 
4IDIBAPS, Barcelona, Spain
Background: TLR ligands as mucosal adjuvants for vaccine 
administration are already largely described whereas the use of Nod-
like receptor ligands is still investigated. As activation of Nod receptors 
is able to induce pro-inflammatory cytokines, we have evaluated if 
co-delivery of those ligands into biodegradable nanocarriers carrying 
HIV-Gag antigen could amplify the mucosal immune responses in mice 
after mucosal or subcutaneous administration.
Methods: We used Poly (Lactic Acid) (PLA) nanoparticles for co-
delivery of p24 and Nod1/2 ligands. As Nod receptors are mainly 
expressed by antigen presenting cells, we first assessed the capacity of 
free or encapsulated ligands to induce dendritic cells (DCs) maturation 
and specific autologous lymphocyte proliferation from HIV+ patients. 
Then, as Nod receptors are mainly expressed at mucosal level we 
compared nasal, oral and subcutaneous immunizations of BALB/c mice 
with encapsulated ligands. To assess the adjuvant effect, p24-specific 
cellular and humoral responses were analyzed on splenocytes and in 
vaginal lavages, faeces and sera.
Results: Encapsulation of either Nod1 or Nod2 ligands increased 
significantly DC maturation, compared to free ligands, probably due 
to a better uptake of encapsulated ligands. Moreover, this maturation 
profile lead to high CD4+ and CD8+ lymphocyte proliferation in ex vivo 
assays using HIV+ samples. In vivo, we observed that co-delivery of 
p24 and Nod2 ligand by nasal and subcutaneous routes induced high 
specific IgG and IgA at vaginal and systemic levels. The immunization 
with p24 and Nod2 ligand in different nanoparticles by oral route 
induced significant IgA in intestine. By contrast, co-formulation of p24 
and Nod ligands in the same NP induced better CD8 IFNγ responses. 
Conclusion: Encapsulation of Nod ligands into PLA nanoparticles 
seems to favour their action on DCs maturation, their co-delivery with 
p24 inducing high adjuvant effect by mucosal and parenteral routes. 
Use of those ligands as mucosal adjuvant deserves further experiments, 
notably combining different immunization routes.
P08.17
Hormonal Contraception Use and HIV-1 Risk 
in the Context of Prevention Research: DMPA 
and NET-EN Dampen Immunity in the Female 
Genital Tract
S. Ngcapu1, L. Masson2, S. Sibeko1, M. Shey1, N. Samsunder1, 
S.S. Abdool Karim1, Q. Abdool Karim1, and J. Passmore2
1CAPRISA, University of KwaZulu-Natal, Durban, South Africa; 
2National Health Laboratory Services, Cape Town, South Africa
Background: The use of injectable hormone contraceptives (HCs) is 
common among women who wish to prevent unintended pregnancies, 
especially in regions with high HIV-1 prevalence such as Southern 
Africa. Recent observational studies suggest a relationship between 
the hormonal contraceptive use and increased risk for HIV acquisition. 
The biological intersection at the mucosa between risk associated with 
HC use and protection provided by microbicides or vaccines is not 
understood. Here we investigated the relationship between HC use, 
genital tract inflammation and tissue inhibitors of metalloproteinases 
(TIMPs) concentrations in genital fluid collected from HIV-uninfected 
women at high risk for HIV infection.
Methods: Concentrations of 25 inflammatory, regulatory and 
hematopoetic cytokines and TIMP-1, TIMP-2, TIMP-3, and TIMP-4 
were measured by luminex in cervicovaginal lavage samples (CVLs) 
from 156 high risk HIV-uninfected women. Information on HC use was 
collected by questionaire and confirmed by high performance liquid 
chromatography.
Results: Concentrations of 14/25 cytokines measured in CVL (including 
IL-1α, IL-9, IL-12p40, IL-15, IL-17, MIP-1α, IFNα, Eotaxin, Fractalkine, 
EGF, FGF2, PDGF-AA and TGF-α and MCP-1) were significantly lower 
in women using injectable contraceptives compared to those not 
using HC. While inflammatory cytokines and growth factors appeared 
to be suppressed in women using HCs, we observed no significant 
differences in TIMP levels from women using injectable contraceptives 
compared to non-users.
Conclusion: The data suggest that injectable HCs suppress innate 
immunity which could potentially result in decreased host resistance to 
invading pathogens.  The immunosuppressive properties of injectable 
HCs within the female genital tract could modulate the potential 
efficacy of vaccines and prevention strategies. 
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P08.20
Assessing Differences in HIV and Nanoparticle 
Transport in Mucus over the Course of the 
Female Menstrual Cycle
C.J. Gioia1, D. Stieh1, G. Cianci1, D.  Maric1, M. Anderson1,  
S. Allen1, O. De Leon1, and T.J. Hope1
1Northwestern University Feinberg School of Medicine, 
Chicago, IL, USA
Background: Mucus barriers offer the first line of defense against 
pathogen acquisition in the female reproductive tract (FRT). This study 
aims to determine how cervicovaginal mucus (CVM) changes over the 
course of the menstrual cycle in individual study participants.
Methods: CVM collected 3 times a week over a 6 week period 
from individual donors using an Instead Softcup worn for 3 hours. 
Parameters such as pH and blood hormone levels were recorded 
throughout the study period. The CVM was immediately isolated from 
the softcup by centrifugation.  Multiple strains of fluorescently labeled 
HIV (Clades B, C, & AE) were individually mixed with fluorescent 
pegylated polystyrene 119nm beads and introduced into the CVM 
sample with minimal dilution. Particle transport was determined using 
fluorescense at a 150ms frame rate for 1 minute collecting 400 total 
frames.  Particle transport was quantified using computer-assisted 
particle tracking algorithms. The rate of mean square displacement 
(MSD) and α, the exponent of the dependence of MSD on time-lag was 
determined for each particle observed. 
Results: We find that CVM pH remained relatively stable over the in 
individual donors, averaging around pH4. A pH increase was observed 
during the time of menstruation to a pH of 7. Particle mobility generally 
increased in the luteal phase of the menstrual cycle and during 
menstruation.  The differences in mobility between virus strains was 
not significant. 
Conclusion: This study reveals changes in the CVM mucosal barrier 
over the menstrual cycle.  These changes identify potential changes 
that normal hormonal fluctuations may have on the efficiency of HIV 
acquisition.  A better understanding of how the menstrual cycle may 
influence HIV acquisition by women serves to inform and facilitate the 
development of an HIV vaccine to decrease HIV acquisition in women.
P08.19
Intestinal Myeloid DCs Display an Activated 
Phenotype and Are Less Susceptible to HIV-1 
Infection Compared to Blood DCs 
M. Cavarelli2, B. Fusetti2, K. Tsilingiri1, M. Rescigno1, and  
G. Scarlatti2
1European Institute of Oncology, Milan, Italy; 2San Raffaele 
Scientific Institute, Milan, Italy
Background: We recently showed that human colonic lamina propria 
(LP) CD11c+ DC actively shuttle R5 HIV-1 across an intact epithelial 
barrier and transfer infection to CD4+ T cells. However the susceptibility 
of intestinal DC to HIV infection has been poorly investigated, due to 
difficulties in isolating mucosal DC. 
Methods: CD11c+ myeloid DC obtained from the colonic LP were 
further characterized as CD103+ and CX3CR1+ and the expression 
of HIV-1 receptors analyzed in comparison to blood DCs. Supernatant 
obtained from an ex vivo culture of healthy human colonic mucosa 
was used to condition monocyte-derived DC in an in vitro model as to 
mimic the exposure of DC to intestinal microenvironment. Conditioned–
DC (C-DC) were analyzed by flow cytometry for the expression of HIV-1 
receptors and activation markers, and incubated in vitro with either R5 
or X4 HIV-1 to study their susceptibility to infection. 
Results: C-DC displayed an activated phenotype, a significant down-
regulation of CCR5, CD4 and CX3CR1, an up-regulation of CXCR4 
and a moderate modulation of DC-SIGN expression compared to 
unconditioned DC. No change in the CD103 expression was observed. 
Interestingly, both R5 and X4 HIV-1 replicated less efficiently in C-DC 
compared to unconditioned DC. Colonic supernatants contained 
the CCR5-binding chemokines Mip1a and MCP-1 and the CX3CR1 
ligand fractalkine, whereas the CXCR4 ligand SDF-1a was absent. IL-
10 and IL-2, described to induce CXCR4 up-regulation on DC, were 
also detected. Thus, this specific intestinal milieu may determine the 
observed phenotype. Both CX3CR1+ and CD103+ CD11c+ DCs were 
detected in human colonic LP. Interestingly CD11c+ DC showed lower 
CCR5 and higher CXCR4 expression compared to blood DC, and a 
similar activation profile, which confirmed the results obtained after 
intestinal conditioning. 
Conclusion: Thus, the intestinal microenvironment module the 
expression of HIV receptors on DCs and their capability to replicate 
the virus.
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P08.22
Pharmacologic Expansion of Colonic Mucosal 
Th17 Cells in Rhesus Macaques
D. Hartigan-O’Connor1, K.K. Van Rompay2, D. Lin3, and  
J.M. McCune3
1University of California-Davis, Davis, CA, USA; 2California 
National Primate Research Center, Davis, CA, USA; 3University 
of California-San Francisco, San Francisco, CA, USA
Background: We previously found that circulating and gut-resident 
Th17 cells present at the time of SIV infection are associated with 
lower peak and set-point viral loads (Hartigan-O’Connor et al., Sci 
Trans Med 4:136ra69, 2012).  By screening for untreated macaques 
with extraordinarily large or small Th17 populations, we demonstrated 
that natural variability the size of the pre-existing Th17 population is 
sufficient to partly account for variability in control of SIV infection. 
We also showed that IL-2 treatment slows growth of Th17 cells in vitro, 
reduces the size of the Th17 population in vivo, and is associated with 
higher viral loads.
Methods: We assessed the potential of various pharmacologic 
treatments to expand Th17 cell populations in macaques and to 
thereby slow disease progression.  Drugs assessed include candidate 
aryl hydrocarbon receptor ligands (FICZ and tranilast), one antibody 
affecting IL-2 signaling (basiliximab), and immunoglobulin-linked IL-21 
cytokine (IL-21-Ig).
Results: Data from the drug treatment groups demonstrate considerable 
heterogeneity in effects on Th17 cells.  Most treatments produced either 
no effect or small, transient effects.  Tranilast, however, caused Th17 
compartment expansion that was sustained throughout the treatment 
period.  In three out of four cases, the expansion achieved was more 
than 3-fold over baseline.  Expansion of Th17 cells in blood was 
accompanied by similar expansion in colon tissue and lymph node.
Conclusion: These changes will allow testing of the link between Th17 
cells and SIV disease progression in future interventional studies.
P08.21
Qualification of the Particle Diffusion Assay for 
Single Particle Tracking 
W. Rutvisuttinunt1, S. Chantakulkij1, C.J. Gioia 2, M. McRaven2,  
S. Rittiroongrad1, C. Karnasuta1, G.C. Cianci2, N.L. Michael3,  
V. Ngauy1, M. de Souza4, J. Kim3, T.J. Hope2, and N. Karasavvas1
1Armed Forces Research Institute of Medical Sciences 
(AFRIMS), Bangkok, Thailand; 2Feinberg School of Medicine, 
Northwestern University, Chicago, IL, USA; 3U.S. MHRP, Silver 
Spring, MD, USA; 4SEARCH,Thai Red Cross AIDS Research 
Centre, Bangkok, Thailand
Background: Fluorescent microscopy allows the direct imaging of 
virus transport (diffusion) in vitro.  Shukair et al., 2012 tracked the 
movement of fluorescent HIV-1 virions in cervicovaginal mucus (CVM), 
calculated the mean squared displacement (MSD) of these particles, 
and found that HIV-1 diffusion was significantly hindered compared to 
controls.  Currently, the virion diffusion assay is being used to study 
the potential interaction of HIV-1 with antibodies in CVM induced 
by vaccination in a sub-set of volunteers previously enrolled in the 
RV144 Thai trial who received canarypox vCP1521 and bivalent gp120 
subtype B/CRF01_AE (AIDSVAX B/E), who received additional boosts 
with AIDSVAX B/E (RV305).  
Methods: To achieve Good Clinical Laboratory Practice (GCLP) for 
the laboratory assay, standard operating procedures (SOPs) were 
developed.  Assay qualification was conducted jointly at NWU and 
AFRIMS to ensure the consistency of assay performance and data 
validity.  Assay qualification included intra- variability, inter-assay 
variability and inter-operator variability.  Artificial mucus simulant 
and 200-nm PEGylated beads were utilized as controls and MSD was 
derived from tracking particles movement for 400 frames per minute. 
Statistical analysis of α, the exponent of the dependence of MSD on 
time-lag, was conducted to evaluate assay variability.
Results: The % Coefficient of variation (CV) of α values found in the 
intra-assay variability at NWU and AFRIMS were (3.2%-5.9%) and 
(1.8%-5.0%), respectively.  A slight increase of CV was observed in 
inter-assay variability at NWU (4.9%-6.0%) and AFRIMS (2.4%-4.1%) 
compared to intra-assay variability.  The inter-operator variability CV 
of all assays conducted by three performers each at NWU and AFRIMS 
was 7.3% and 2.4%, respectively.
Conclusion: The %CV from both NWU and AFRIMS was low and below 
25% that was used as acceptable value.  The assay was qualified for 
a clinical trials setting and can now be applied as a new tool to study 
mucosal immunology. 
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P08.24 LB
Combined Mucosal and Systemic C.1086 
Envelope Immunization of Lactating Monkeys 
Induces Potent IgA and Functional IgG Antibody 
Responses in Milk
E. Kunz3, G. Fouda3, C. Ho3, J. Amos3, L. Colvin3, D. Montefiori3,  
A. Martelli3, A. Allen3, L. Aramand3, D.J. Marshall3, N.L. Letvin1,  
H. Staats3, D. Pickup3, S.C. Barnett2, M.A. Moody3, B.F. Haynes3,  
H. Liao3, and S.R. Permar3
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA; 
3Duke University Medical Center, Raleigh, NC, USA
Background: Vaccination of lactating monkeys with a founder HIV 
Envelope (Env) in an MVA prime/intramuscular (IM) protein boost 
strategy induced functional IgG responses but poor Env-specific IgA 
responses in milk, whereas intranasal (IN) protein boost induced strong 
IgA but poorly functional IgG milk responses. Therefore, we sought to 
improve Env-specific antibody responses in milk using a combined IN/
IM protein boost strategy. 
Methods: Adjuvanted T/F clade C HIV Env C.1086 was administered 
simultaneously IN/IM to four hormone-induced lactating rhesus 
monkeys previously primed with MVA expressing C.1086 gp140 and 
boosted twice IN with C.1086 gp120. Plasma and milk samples were 
assessed for HIV Env-binding antibody and neutralization responses in 
TZM-bl and A3R5 cells. C.1086 Env-specific B cells were isolated from 
the blood and milk of one vaccinated animal, immunoglobulin genes 
were amplified by nested RT-PCR, and antibody reactivity was assessed 
with HIV Env proteins.
Results: Following IN/IM boost, plasma Env-specific IgG responses in 
plasma (median concentration 123 vs 616 mg/ml) and Env-specific IgA 
responses in milk (median concentration: 1.7 vs 7.6 mg/ml) increased 
compared to IN only boost. Importantly, whereas no autologous or 
tier 2 neutralization was detected in plasma or milk following IN only 
boost, autologous neutralization was detected in all plasma and two 
of four milk samples following IN/IM boost. Moreover, heterologous 
tier 2 neutralization in A3R5 cells was detected in the plasma of all 
vaccinated animals. Most isolated Env-reactive monoclonal antibodies 
reacted weakly against gp41 (19 in blood and 16 in milk), but three 
in blood and in milk reacted strongly against gp120. The majority of 
Env-reactive antibodies were IgG2 isotype, but one gp120-reactive 
antibody from blood and two from milk were IgA1 isotype.
Conclusion: IN/IM boost induces both functional Env-specific IgG 
responses and potent Env-specific IgA antibodies in breast milk, which 
may be advantageous for prevention of infant HIV-1 transmission. 
P08.23 LB D
The Nervous System Can Restrict ‘at a Distance’ 
Langerhans Cell-Mediated HIV-1 Transmission 
via the Neuropeptide Calcitonin Gene-Related 
Peptide 
M. Bomsel1, A. Drillet2, L. Lopalco3, G. Tambussi3, D. Tudor2,  
M. Zerbib4, N. Bary de Lonchanps4, and Y. Ganor2
1Institut Cochin, CNRS UMR 8104- INSERM U1016, Paris, 
Descartes University, Paris, France; 2Institut Cochin, Paris, 
France; 3San Raffaele Scientific Institute, Milan, Italy; 4GH 
Cochin-St Vincent de Paul, Paris, France
Background: Upon its mucosal entry, human immunodeficiency virus 
type 1 (HIV-1) is internalized by Langerhans cells (LCs) in stratified 
epithelia and transferred locally to T-cells. In such epithelia, LCs are 
in direct contact with peripheral neurons secreting calcitonin gene-
related peptide (CGRP). Although CGRP has immunomodulatory effects 
on LC functions, its potential influence on the interactions between LCs 
and HIV-1 is unknown. 
Methods: The impact of CGRP on LCs was evaluated in vitro in 
monocyte-derived-LCs and ex vivo, in mucosal explant tissues. 
Furthermore, correlation with infection in vivo was performed by 
measuring CGRP level in plasma of HIV-1-infected individuals, non- 
treated and ART-treated in comparison with normal individuals, as well 
as of rhesus monkeys acutely infected with SHIV.
Results: We show that CGRP acts via its receptor expressed by LCs 
and interferes with multiple steps of LC-mediated HIV-1 transmission. 
CGRP increases langerin expression, decreases selected integrins, 
and activates NFκB, resulting in decreased HIV-1 intracellular content, 
limited formation of LC-T-cell conjugates, and elevated secretion 
of the CCR5-binding-chemokine CCL3/MIP-1α. These mechanisms 
cooperate to efficiently inhibit HIV-1 transfer from LCs to T-cells and 
T-cell infection. In-vivo, HIV-1 infection decreases CGRP plasma levels 
in both vaginally SHIV-challenged macaques and HIV-1-infected 
individuals. CGRP plasma levels return to baseline following highly 
active anti-retroviral therapy.
Conclusion: Our results reveal a novel path by which a peripheral 
neuropeptide acts at the molecular and cellular levels to limit mucosal 
HIV-1 transmission, but also provide for the first time the evidence that 
the nervous system can restrict ‘at a distance’ the early events of HIV-
1 transmission at the mucosal level. More, CGRP receptors agonists 
might be used therapeutically against HIV-1. Novel CGRP receptor 
agonists, active especially at mucosal epithelia at targeting LCs, might 
represent a completely new class of anti-HIV-1 molecules. 
Ganor et al; J. Exp . Med, 2013 in press
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P08.26 LB 
Preliminary Evaluation of Mucosal Immune 
Responses with Mucosal Explants in Humans 
Vaccinated with ALVAC/AIDSVAX B/E During 
the Ongoing RV305 Trial
C. Herrera1, A. Schuetz2, N. Olejniczak1, V. Assawadarachai2,  
N. Karasavva2, S. Nitayaphan2, J. Kaewkungwal3, V. Ngauy2,  
P. Pitisuttithum3, S. Rerks-Ngarm4, N.L. Michael5, R.J. O’Connell5,  
J. Excler5, R.J. Shattock1, and J.H. Kim5
1Imperial College London, London, UK; 23Mahidol University, 
Bangkok, Thailand; 4Ministry of Public Health, Nonthaburi, 
Thailand; 5US MHRP, Silver Spring, MD, USA
Background: Analysis of antibodies elicited during RV144 showed 
absence of neutralizing antibodies despite partial protection. 
Furthermore, analysis of B-cell responses in clinical trial participants 
has been limited to biological fluids and not at the site of transmission 
in mucosal tissues; emphasizing the absence of models for B-cell 
responses in the field of anti-HIV vaccine. Ex vivo mucosal tissue 
explants models could provide a surrogate endpoint that might have 
been predictive of protection/susceptibility in the RV144 study. The 
ongoing randomized, double blinded, placebo-controlled RV305 
trial of late boost with ALVAC and AIDSVAX B/E used alone or in 
combination, provides a unique opportunity to test this hypothesis in 
human cervicovaginal and sigmoidal tissue explants.
Methods: Healthy study participants from RV144 were enrolled in 
RV305 and received at weeks 0 and 24 a vaccination with ALVAC/
AIDSVAX B/E (group I), AIDSVAX B/E (group II), ALVAC (group III) or 
placebo in each group. Sigmoidal and cervicovaginal biopsies were 
obtained at week 26. Total and specific anti-gp120 HIV-1CM244 IgG 
and IgA secreted in tissue explant culture supernatant were measured 
at days 3, 7, 11 and 15 with quantitative ELISA. Limited unblinding was 
performed only allowing correlation of samples to groups.
Results: Variable levels of total IgG and IgA were measured among 
participants in all explant cultures. Specific IgG was detected in certain 
cervicovaginal and sigmoidal tissue explants culture supernatants from 
groups I and II; and not in group III. No differences were detected 
in the levels of specific IgA between the three groups in both tissue 
explant models.
Conclusion: Specific anti-gp120 HIV-1CM244 IgG are elicited 
mucosally among some RV305 participants who received late 
boosting with ALVAC/AIDSVAX B/E or AIDSVAX B/E. Hence, ex-vivo 
mucosal tissue models could represent a new tool to assess mucosal 
B-cell responses to vaccination during clinical trials.
P08.25 LB 
No Increase in Activated T Cells and Limited 
Increase in Adenovirus-Specific T Cells in Colon 
and Rectal Mucosa Following HIV-1 DNA/rAd5 
Immunization
S.C. De Rosa1, N. Frahm1, G. Diaz1, P. Newling1, D. Morris1,  
C. Morgan1, B. Graham2, E. Swann3, J. Maenza1, A. Duerr1,  
and M.J. McElrath1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
3NIAID, NIH, Bethesda, MD, USA
Background: HVTN076 is an exploratory HIV vaccine trial designed 
to examine mucosal immune responses to the multiclade HIV-1 DNA/
rAd5 vaccine developed by the NIH Vaccine Research Center, also 
used in the HVTN505 test-of-concept study.
Methods: Seventeen healthy Ad5 seronegative HIV-1-uninfected 
adults were enrolled and 16 completed all vaccinations (3xDNA, rAd5, 
0, 4, 8, 24 weeks). Mucosal biopsies were obtained from sigmoid 
colon and rectum by flexible sigmoidoscopy at baseline and one 
month following rAd5. Rectal biopsies by anoscopy were obtained 2 
weeks following the final DNA and 1 week following rAd5. Single-cell 
suspensions following collagenase digestion were assayed directly for 
phenotyping and after overnight rest for intracellular cytokine staining. 
Results: Although HIV-specific CD4+ and CD8+ T-cells were detected 
in blood at one month post rAd5 (81% and 69% of participants, 
respectively), these were not detected in colon/rectum samples at any 
time point. Ad-specific CD4+ T-cells were detected at baseline in blood 
(77%) and colon (87%). Hexon-specific response rate and magnitude 
increased after vaccination in blood, but this increase was less common 
in colon/rectum. There was no change in the proportion of CD4+ 
T-cells expressing CCR5 or in activated CD4+ T-cells (Ki-67+BcL-2lo) in 
the rectum after rAd5 vaccination.
Conclusion: The HIV-1 DNA/rAd5 vaccine regimen did not induce 
detectable HIV-specific T-cells in colon/rectum, a site of HIV exposure 
where such cells could contribute to immune protection. These 
cells could be present, but in vitro expansion may be necessary for 
detection. Pre-existing mucosal Ad-specific T-cells were detected in the 
majority of these Ad5 seronegatives. Activation of these T-cells is a 
concern related to potential enhanced risk of HIV infection following 
rAd5 vaccination; however, post-vaccination increase in Ad-specific 
T-cells was detected in only a small proportion of vaccine recipients. 
Vaccine-induced activation of T-cells in bulk, at least as measured by 
Ki-67/BcL-2, was not detected.
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P08.27 LB 
Selection and Optimization of a Mucosal 
Sampling Method for Application in Phase 1 
Clinical Trials
P.J. Bergin1, R. Langat2, G. Omosa-Manyoni2, B. Farah2,  
J. Bizimana3, G. Umvirigihozo3, J. Nyombayire3, G. Ouattara2,  
R. Ingabire3, H. Park4, P. Chetty4, C. Verlinde4, D. Laufer4, J. Cox4, 
G. Stevens4, P. Fast4, J. Gilmour1, E. Karita3, O. Anzala2
1International AIDS Vaccine Initiative, Human Immunology 
Laboratory, Imperial College London, London, United 
Kingdom (Great Britain); 2Kenya AIDS Vaccine Initiative, 
University of Nairobi, Nairobi, Kenya; 3Project San Francisco, 
Kigali, Rwanda; 4International AIDS Vaccine Initiative, New 
York, NY, USA
Background: An efficacious preventive HIV vaccine will likely require 
induction of immune responses at mucosal surfaces. One approach 
is to deliver vaccines intra-nasally. A pilot study was performed in 
Rwanda and Kenya to determine if anti-HIV antibodies could be 
detected in nasal secretions collected from the nasal cavity (NC), 
naso-pharynx (NP) and oral secretions.
Methods: Nasal samples were collected using FloQ Swabs from 35 
HIV-seropositive and 35 HIV-seronegative volunteers. Saliva was 
collected from parotid glands using Salimetrics Oral Swabs, oral fluid 
(transudate) was collected into Falcon tubes. Eluted samples were 
tested for gp140 Env (Clade A UG37) and Gag p24 (Clade B LAI) IgG 
and IgA antibodies.
Results: Volunteers indicated that the NC collection was preferable 
to the deeper NP sample, suggesting that NC sampling may result in 
greater compliance with repeated sampling.  Anti-HIV antibodies were 
detected in nasal secretions of 100% of HIV-seropositive samples with 
IgG expressed at a higher level than IgA. Anti-gp140 IgG and anti-p24 
IgG were detected in 100% and 93.4% of nasal samples, respectively. 
IgA anti-gp140 and anti-p24 IgA were detected in 94% and 88.5% of 
nasal samples, respectively. No significant differences were detected 
between NC and NP samples in magnitude or quantity.  All nasal 
samples from HIV-seronegative volunteers were negative for IgG and 
IgA anti-gp140/p24 except for 4 Rwandan volunteers with low levels 
of IgA anti-p24.
Conclusion: NP sampling appeared to have little benefit over NC 
sampling, and HIV antibodies were detected in all HIV-seropositive 
individuals.  NC sampling may provide a unique and tolerable method to 
collect antibodies in an HIV vaccine trial following intranasal vaccination.
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P09.02 D
Neutralization of Diverse HIV Strains by V3 
Specific DARPins with Different Structural 
Preferences in Epitope Recognition
N. Friedrich1, A. Mann1, E. Stiegeler1, Y. Wu1, A. Batyuk1,  
P. Rusert1, J. Weber1, B. Dreier1, M. Robbiani2, J.A. Robinson1,  
A. Plückthun1, and A. Trkola1
1University of Zurich, Zurich, Switzerland; 2Population Council, 
New York, NY, USA 
Background: We previously utilized the DARPin technology, a novel 
binding protein scaffold, to derive gp120-reactive agents with inhibitory 
activity and succeeded in selecting a HIV gp120-V3-loop reactive 
clone, 5m3_D12, with neutralizing activity and a novel, structure-
dependent recognition mechanism which overcomes HIV envelope 
shielding (Mann A, J Virol 2013).  Expanding on our previous finding, 
we sought here to select DARPins specific for subtype B V3 loop 
utilizing a structurally arrested V3 loop mimetic peptide for selection.
Methods: Three selection strategies were explored using a V3 loop 
mimetic (MN sequence, IY register) and recombinant JR-FL gp120 
protein as panning targets and DARPin DNA libraries encoding either 
two or three internal ankyrin repeats. Obtained DARPin clones were 
sequenced, mapped for reactivity with diverse V3 mimetics, wt and 
mutant gp120 binding, antibody competition binding and probed for 
inhibitory activity using the TZM-bl pseudotype virus inhibition assay. 
The interaction of DARPins with V3 loop mimetics was analyzed by 
x-ray structure determination. 
Results: The mimetic based selection strategies proved successful, 
yielding V3-specific DARPins which differed substantially in their 
binding mode and preference for specific V3 structures. Several of 
the selected V3 specific DARPins displayed a considerable breadth in 
inhibiting subtype B isolates. Of note, neutralization profiles differed 
from DARPin 5m3_D12, highlighting the possibility that different 
structures of the V3 loop are sampled on different viruses.
Conclusion: The structure-dependent recognition of the V3 loop 
DARPins is of high interest, as it may allow generation of a new type of 
entry inhibitor, which specifically recognizes the native structure of the 
V3 loop on the trimer. V3 loop mimetics proved to be valuable panning 
targets, to focus the selection of DARPin clones to the V3 loop, which 
opens up multiple opportunities for future DARPin selections by using 
mimetics of diverse HIV envelope regions. 
P09.01 D
Anti-HIV Activity of 5-Hydroxytyrosol, a 
Microbicidal Candidate
L. Bedoya2, M. Beltrán2, D. Auñón1, E. Gómez-Acebo1, and  
J. Alcami2
1Seprox Biotech, Spain; 2Centro Nacional de Microbiología 
Instituto de Salud Carlos III, Madrid, Spain
Background: 5-Hydroxytyrosol (5-HT) is a natural compound that 
has previously shown biochemical activity against HIV integrase 
and gp41. In this work we show that 5-HT is able to diminish viral 
replication in vitro and prevent infection in vivo of humanized mice 
without toxic effects.
Methods: Recombinant viruses carrying luciferase-renilla reporters 
with different properties (Wild type and R5 and X4 tropic, VSV-
pseudotyped HIV or resistant HIV clones) were used to infect cell lines 
or primary lymphocytes. In vivo experiments were performed using 
BLT humanized mice challenged with HIV-1 JR-CSF 15 minutes after 
5-HT administration.
Results: 5-HT inhibited X4, R5 tropic HIV and NNRTI, NRTI and 
Integrase inhibitors resistant HIV infections with IC50 values between 
10 and 80 µM. 5-HT decreased VSV-pseudotyped HIV replication 
but did not inhibit replication driven by a full-length HIV-DNA clone 
transfected in lymphoid cells suggesting a pre-transcriptional target 
independent of viral entry. When antigen presenting cells (APCs) DC-
SIGN+ were present in cell culture, 5-HT potency was >10 fold higher, 
which would be essential for its microbicidal activity, since mucosae 
infection is highly enhanced by APCs. Lastly, humanized mice were 
pre-treated with 5-HT (0,03%) and 33% protection was reached.
Conclusion: Although 5-HT potency is not in the highest range, it is 
active against HIV in a wide range of situations including resistant 
viruses and is devoid of toxicity at doses 100 times higher than IC50. 
In vivo effect showed a level of protection of 33%, although 5-HT 
dose used was 30 times lower than that of Tenofovir 1% suggesting 
that higher doses would improve protection. Altogether these results 
and easy formulation made 5-HT a good microbicide candidate either 
alone or in combination with other antiretroviral drugs.
Topic 09: Non-Vaccine Prevention
228
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P09.04
Willingness to Use Rectal Microbicides for HIV 
Prevention Among HIV-Negative Argentinean 
MSM Differences According to Formulation 
M. Pando1, A. Carballo Dieguez2, I. Balan2, C. Dolezal2, R. Marone3, 
V. Barreda3, and M.M. Avila1
1Universidad de Buenos Aires, Buenos Aires, Argentina; 2New 
York State Psychiatric Institute and Columbia University, New 
York, NY, USA; 3Nexo Asociación Civil, Buenos Aires, Argentina
Background: The objective was to explore the willingness to use 
rectal microbicides for HIV prevention among MSM reporting HIV-
negative status. 
Methods: During 2006-2009 a sample of 500 MSM was recruited 
through Respondent Driven Sampling for an HIV prevalence/
incidence study. Microbicide acceptability was assessed using three 
10-point Likert-type questions inquiring whether the respondent 
would be willing to use a microbice 1)in general, 2)formulated as a 
suppository, and 3)formulated as a gel/lubricant. Possible responses 
ranged from 1(completely unwilling) to 10(completely willing). 
Participants underwent a consent process and responded to a survey 
that included demographic and behavior information. Data was 
weighted prior to analyses.
Results: Among 411 MSM reporting to be HIV negative, median score 
for microbicide acceptability was 8.0, with greater willingness to use a 
“gel” than a “suppository” (7.0 vs. 5.0).  Comparing men who only have 
sex with men vs. those who also have sex with women and/or trans 
partners, the former expressed higher acceptability in general (10 vs. 
5, p<0.001), for gel (10 vs. 5, p<0.001) and for suppository (8 vs. 2, 
p<0.001). Acceptability was significantly higher among men with high 
school level than among those with lower formal education level (in 
general: 10 vs. 5, p=0.002; gel: 10 vs. 5, p=0.003 and suppository: 7 
vs. 2, p=0.001). A trend toward lower acceptability was found among 
MSM who reported not using condoms during sexual intercourse 
(including receptive or insertive anal or vaginal sex with men, trans 
or women) during the past two months. Acceptability was significantly 
lower among those who do not consider probable the use of a rapid 
HIV self-test, in case it became available.
Conclusion: Results showed high acceptability of microbicides, 
especially for gel formulation. MSM not willing to use microbicides 
were also likely to not accept other prevention strategies, like condoms 
or using rapid self tests prior to intercourse. 
P09.03
Increasing HIV Testing for Prevention: 
Acceptability of Rapid HIV Test for Self Testing 
Among MSM from Buenos Aires, Argentina
M. Pando1, I. Balan2, C. Dolezal2, R. Marone3, V. Barreda3,  
A. Carballo Dieguez2, and M.M. Avila1
1Universidad de Buenos Aires, Buenos Aires, Argentina; 2New 
York State Psychiatric Institute and Columbia University, New 
York, NY, USA; 3Nexo Asociación Civil, Buenos Aires, Argentina
Background: Consistent with the incorporation of rapid HIV test in 
several clinics in Argentina, the objective of this study was to explore 
the acceptability of a rapid HIV test available over-the-counter for self 
testing (ST) among men who have sex with men (MSM). 
Methods: During 2006-2009, 500 MSM was recruited through 
Respondent Driven Sampling for an HIV prevalence/incidence study. 
Attitude toward HST was explored among HIV negative MSM (n=440). 
Data were weighted prior to analyses. 
Results: Participants reported they were likely to buy ST (73.1%), 
test themselves frequently (77.1%), and that it would simplify testing 
(70.8%). Furthermore, 70.4% reported they would probably use it alone, 
67.5% would use it with a stable partner, and 56.4% with a friend/
partner. Only a minority (21.3%) felt that they would be embarrassed 
to purchase it at a pharmacy. While a majority acknowledged that 
ST use would deprive them of receiving counseling (60.6%), 73.5% 
declared they would go for help if they tested positive; 16.6% said 
they would think about killing themselves if they tested positive (25% 
of which reported a previous suicide attempts). In terms of off-label 
use of ST, 66% would use it before having sex and 55.4% would do 
it in order to avoid the use of condoms. Those likely to buy a ST were 
older than those unlikely to buy it (median age, 29 vs. 24 years old, 
p=0.014). MSM who reported they would feel embarrassed to buy the 
test (25 vs. 29 years old, p=0.012) and those who think about killing 
themselves (22 vs. 30 years old, p<0.001) were younger. 
Conclusion: The high acceptability of an HIV ST found among MSM 
should be considered, as it can improve early diagnosis and prevention 
of future transmissions. Suicidal ideation expressed by some 
participants in case of positive results requires further exploration. 
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P09.06
ARV Use in HIV-Positive Pregnant Women 
Who Attend Couples’ Voluntary Counseling 
and Testing Services in the Copperbelt 
Province, Zambia
C. Kwok1, M. Inambao1, W. Kilembe1, E. Dissen1, N. Ahmed2,  
P. Chadd1, N. Munir1, K. Parris1, J. Abdallah2, W. Kuo2,  
A. Tichacek3, and S. Allen3
1Zambia-Emory HIV Research Project, Ndola, Zambia; 
2Rwanda-Zambia HIV Research Group, Kigali, Rwanda; 3Emory 
University, Atlanta, GA, USA
Background: One quarter to one third of couples presenting at 
Couples’ Voluntary HIV Counseling and Testing (CVCT) services in 
Zambian government clinics have at least one HIV+ partner. 96% of 
pregnant women in the Copperbelt accessed VCT services at antenatal 
clinics (ANC) and were offered PMTCT regimens if HIV+. Though 
16.4% of pregnant women tested at ANC were HIV+, only 69% 
received the PMTCT regimen. This abstract examines ARV use in HIV+ 
pregnant women identified at CVCT services in government clinics in 
the Copperbelt Province.
Methods: Zambia Emory HIV Research Project (ZEHRP) has expanded 
CVCT services between October 2010 – March 2013 in select clinics 
in Ndola, Kitwe, Chingola and Luanshya districts in the Copperbelt 
province. HIV results, pregnancy status, ages and previous HIV testing 
history are recorded anonymously. Couples attending CVCT are 
provided appropriate referrals within the government clinics, including 
PMTCT and ART when applicable. 
Results: During this period, 68,319 couples were tested: 25% of the 
couples tested were pregnant; 15% of whom included HIV+ women. 
30% of the HIV+ pregnant women were in discordant relationships 
and 75% were not on ARVs. Of all HIV+ pregnant women, 77% had 
been previously HIV tested but only 24% of them reported ARV use 
at the time of CVCT.
Conclusion: The proportion of pregnant women who test HIV+ is 
similar in ANC and CVCT services in the Copperbelt. ARV use is low 
among pregnant women tested at CVCT. Some may not yet have 
accessed ANC and PMTCT services due to early gestational age, but 
there are also gaps in comprehension about PMTCT, problems with 
ARV access, and concerns about stigma. CVCT can strengthen PMTCT 
programs in Zambian government clinics through male involvement 
and referral to PMTCT and ANC services.
P09.05
An Aptamer Neutralizing Diverse HIV-1 
subtype C Isolates, Bind to V1/V2 Region of 
gp120
G.M. London1, D. Sok2, B. Mayosi3, D. Burton2, and M. Khati4
1CSIR, Pretoria, South Africa; 2The Scripps Research Institute, 
La Jolla, CA, USA; 3University of Cape Town, Cape Town, 
South Africa; 4Emerging Health Technologies Platform, CSIR 
Biosciences, Pretoria, South Africa
Background: Aptamers, which are artificial nucleic acid ligands 
akin to antibodies in function, represent a new class of molecules 
that can prevent HIV-1 infection. We previously isolated a group of 
RNA aptamers against envelope trimer expressed on the surface of 
pseudotyped HIV-1CAP45, to inhibit virus entry. One of these aptamers, 
called CSIR1.1, significantly neutralized diverse HIV-1 subtype C isolates 
and bound to gp120 in a manner that competes with antibodies to the 
CD4 binding epitope.  In this study, we mapped the aptamer binding 
site (“aptatope”) of CSIR1.1 on gp120. 
Methods: Site directed mutagenesis was used to generate a panel 
of alanine mutations on gp120 from HIV-1CAP45to systematically map 
the CSIR1.1 aptatope. We used ELISA and luciferase reporter gene 
assay in TZM-bl to identify residues important for aptamer binding 
to monomeric gp120 and virus neutralization. Furthermore, we 
investigated the importance of N-glycans in forming CSIR1.1 aptatope 
on gp120 by ELISA.
Results: Alanine mutation of four residues (K121A, D167A, Y177A, 
V182A) located on the V1/V2 region of gp120 abrogated both binding 
and neutralization activity of CSIR1.1. We observed that CSIR1.1 
interacted with monomeric gp120 in a similar manner to CD4-IgG. 
Also, elimination of N-glycan 276 by site directed mutagenesis 
reduced neutralization activity of CSIR1.1 by 10-fold but did not affect 
binding to monomeric gp120 bearing the same mutation and to a 
deglycosylated protein. 
Conclusion: These results indicated that, CSIR1.1 interacts with 
residues on V1/V2 loops of gp120 and occlude access to the CD4 
binding site. The results also suggest that the 276 N-glycan is 
important for virus neutralization by CSIR1.1 but not binding to 
monomeric gp120. This study, gave an insight on the structural 
interaction between CSIR1.1 and gp120 thereby helping to elucidate 
the antiviral mechanism of CSIR1.1.
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P09.08
Aptamers that Inhibits Entry of Diverse HIV-1 
Subtype C Is Not Cytotoxic
H.T. Mufhandu1, W.R. Campos1, B. Mayosi2, L. Morris3, and  
M. Khati1
1Council for Scientific and Industrial Research (CSIR), Pretoria, 
South Africa; 2University of Cape Town, Groote Schuur 
Hospital, Cape Town, South Africa; 3National Institute for 
Communicable Diseases, Johannesburg, South Africa
Background: HIV-1 subtype C accounts for majority of the global AIDS 
epidemic yet most antiretroviral (ARV) drugs are developed against 
subtype B. The long-term cumulative cytotoxicity of ARVs is among 
the major causes of treatment failure in HIV infected patients. Thus, the 
objective of this study was to test the cytotoxicity and efficacy of RNA 
aptamer called B40 and its shortened derivative called UCLA1 against 
diverse HIV-1 subtype C isolates.
Methods: B40 aptamer that was previously shown to have efficacy 
against HIV-1 was tested for cytotoxicity in human cardiomyocytes 
and PBMCs by measuring cell viability, caspase 3/7 activity, levels 
of monoamine oxidases (MAO) A and B and cytochrome P450 3A4 
(CYP3A4) metabolic enzymes, and mitochondrial DNA (mtDNA) 
depletion. It was compared to a panel of non-nucleoside reverse 
transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, 
protease inhibitors, and the T20 entry inhibitor in all the assays. B40 
and UCLA1 were tested for cytotoxicity in TZM-bl cells and PBMCs. 
Activity of UCLA1 was tested against a large panel of subtype C viruses 
in different cell types and its therapeutic index (TI) estimated. 
Results: B40 and T20 did not affect the viability of cardiomyocytes 
and PBMCs at any concentration tested. They also did not interfere 
with the cellular activity of CYP3A4 or MAO A and B. Levels of the 
ratio of mtDNA: nuclear DNA remained unchanged in cells exposed 
to B40. UCLA1 neutralized Env-pseudotyped viruses and primary 
isolates in TZM-bls, PBMCs and monocyte-derived macrophages 
(MDMs), respectively, with low nanomolar 50% inhibition 
concentration (IC50) values. It was observed to be non-toxic and 
revealed a high TI. UCLA1 also showed synergism with both T20 and 
IgG1b12 monoclonal antibody. 
Conclusion: Overall, these data support the development of B40 
and UCLA-1 aptamers as new entry inhibitor molecules with no 
cytotoxicity at the estimated potential therapeutic dose, especially 
against HIV-1 subtype.
P09.07
Multilevel Analysis of HIV Predictors Among 
Female Sex Workers in Nigeria: Lessons for HIV 
Vaccine Trial
A.O. Adeyemi1, K. Issa2, A. Atobatele3, and O. Fakunle4
1MEASURE/NACA, Abuja, Nigeria; 2Federal Ministry of Health, 
Abuja, Nigeria; 3USAID/Nigeria, Abuja, Nigeria; 4Public Health 
Department, FCT, Abuja, Nigeria
Background: Female sex workers (FSW) are important high risk group. 
Their burden of HIV infection is of strategic importance to the national 
response since they have the highest HIV prevalence in Nigeria. Lessons 
learnt from HIV surveillance among them will play vital role in their 
involvement in HIV vaccine trial. This study examined the predictors of 
HIV infection and its effects at the state level.
Methods: This study involved further analysis of a national survey data 
targeted at high risk populations. This was 2010 Integrated Biological 
and Behavioral Surveillance Survey (IBBSS) that involved HIV testing 
among 4459 FSWs in brothels and non-brothels of 9 Nigerian states. 
Additionally, information was collected on demographic, and sexual 
and reproductive health variables. Random-effect logistic regression 
with a random slope was fitted to ascertain state level variation in 
predictors of HIV infection among FSW.
Results: The mean age was 26.5±5.8years; HIV prevalence was 
21.2% with brothel-based FSW having 25.6% and non-brothel based 
having 16.5%. The mean age at first sex was 17±2.7years; average 
clients/day was 4; 29.3% of married FSWs were HIV+, 21.7% of 
HIV+ FSW used condom with their last client while 21.9% of HIV+ 
FSW used condom consistently. Significant predictors of HIV infection 
were age 25-34years OR=1.5 95%CI (1.3-1.8); ever married OR=1.5 
95%CI (1.1-1.8), and protective factors include received education 
on HIV/AIDS/STIs OR=0.8 95%CI (0.6-0.9); secondary education 
OR=0.6 95%CI (0.4-0.9) and tertiary education OR=0.5 95%CI (0.3-
0.8). The estimated variance between state was 0.24 with a standard 
error of 0.13.
Conclusion: HIV infection among FSW is dependent on the state they 
practice their trade. This study provided better understanding of HIV 
infection among FSW; findings will be useful in designing state-level 
intervention and strategic document for FSW. As a result of their high 
HIV prevalence, FSWs are potential candidates of future HIV vaccine 
study in Nigeria. 
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P09.09 LB 
Seroconversion Incidence Cases Among 
Cohabiting Discordant Couples While the HIV 
Index Partner on ARVs in Kigali Rwanda
N. Ahmed1, E. Karita1, J. Nyombayire 1, R. Ingabire1, R. Sinabamenye1, 
J. Nduwamungu1, J. Bizimana1, G. Umvirigihozo1, H. Uwamahoro1, 
A. Tichacek2, E. Hunter1, and S. Allen1
1Rwanda Zambia HIV Research Group, Atlanta, GA, Rwanda; 
2Emory University, Atlanta, GA, USA
Background: Studies in Rwanda demonstrated that 90% of HIV 
infections acquired are in marriage and couples counseling reduces 
HIV incidence from 20% to 3% per year and could therefore prevent 
78.8% of all new heterosexual infections. In Africa, the introduction 
of antiretroviral medication (ARVs) resulted in substantial reduction 
in morbidity and mortality from HIV/AIDS, where ARVs reduced 
HIV transmission by up to 96% within discordant couple. Thus, it 
is important to supplement ARVs with Couples HIV Counseling and 
Testing (CHCT) to encourage adherence and reduce HIV transmission. 
Methods: The study enrolled 2,555 cohabiting discordant couples 
from January 2010-June 2013 in Kigali Rwanda. Couples were 
encouraged to come back for follow-up visits every three months. 
The overall seroconversion incidence cases were measured. Within 
the follow-up period, seroconversion incident cases among couples 
where one partner was on ARV were compared to seroconversion 
incident cases among couples where the positive partner was not on 
ARV. Sequencing is used to establish epidemiologic linkage between 
spouses in seroconverting couples.
Results: In this period, 2,555 discordant couples (M+F- 1,336 
and M-F+1,219) received CHCT and 1,356 (52%) were on ARVs at 
baseline and 362 (14%) discordant couples initiated ARVs during 
the follow up visits. 4,524 follow-up visits were recorded, with more 
than 50% of discordant couples having one or more follow-up visits. 
There were total of 33 seroconversion incident cases (23F, 10M). In 
the 11-seroconversion incident cases, the HIV index partners were 
on ARVs and in the 22-seroconversion incident cases the HIV index 
partners were not on ARVs. Sequencing results are pending to establish 
which of these seroconvertors acquired HIV from their HIV+ spouse, or 
from another partner.
Conclusion: Many studies demonstrated that antiretroviral therapy 
reduces the risk of HIV transmission among HIV discordant couples. 
Scaling up CHCT into the existing ARVs programs can reduce the HIV 
transmission rate.
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P10.02
Effectiveness of Maternal and Infant 
Prophlylaxes as PMTCT Strategies in Rift Valley 
Province, Kenya
J.M. King’oo1, J. Towett1, C. Mibey1, E. Okapesi1, F. Kirui1,  
M. Kirui1, S. Koech1, J.O. Oundo1, and B.A. Danboise1
1U.S. MHRP KEMRI/Walter Reed Project, Kericho Field Station, 
Kericho, Kenya
Background: Prevention of Mother to Child Transmission (PMTCT) of 
Human Immune Deficiency Virus (HIV) is a national program to prevent 
HIV-vertical transmission and comprises of exclusive breastfeeding, 
exclusive alternative feeding, infant and maternal PMTCT prophylaxes. 
In order to determine the effectiveness of these strategies we received 
and analyzed samples from HIV exposed infants under the Early Infant 
Diagnosis Program in the Rift Valley Province of Kenya.  
Methods: Samples received in the laboratory between January 
and December 2012 were analyzed using the Cobas Ampliprep/
Cobas Taqman and Abbott M200sp/rt test methods. Data on infant 
prophylaxis, maternal prophylaxis and infant HIV status were collected 
and frequencies, ratios and proportions calculated. The rates of infant 
HIV infection were compared with each PMTCT strategy.
Results: A total of 6466 samples were tested in of which 556 (8.6%) 
were HIV positive. One hundred ninety two (34.5%) of the 556 HIV 
positive infants had their mothers on prophylaxis while 228(41%) of 
the infants were on prophylaxis. Of the 5910 HIV negative infants, 
4442(75.2%) had their mothers on prophylaxis whereas 5137(86%) 
of the infants were on prophylaxis. 
Conclusion: Comparatively, the rate of HIV vertical transmission for 
infants whose mothers were on prophylaxis was lower than those 
without prophylaxis (OR= 5.7). Similarly, infants on prophylaxis 
were significantly less likely to be infected by HIV through vertical 
transmission OR=9.5). Adherence to prophylactic medication was self 
reported and which may lead to under or over estimation of the rates. 
Maternal and infant prophylaxes are important PMTCT strategies 
which if strictly rolled out can further help reduce vertical transmission 
of HIV. The provision of full HAART to HIV positive expectant and 
breastfeeding mothers is critical in reducing these high vertical 
transmission rates. A combination of these two modes of prophylaxes 
provides better protection to infants against vertical transmission.
P10.01
Factors Associated with In Vitro Immune 
Response to Mycobacterial and Tetanus 
Antigens Following BCG and Tetanus 
Immunisation in Infancy
S.A. Lule1, N. Gyavira1, L. Muhangi1, D. Kizito1, A. Elliott1, and  
E. Webb2
1MRC/UVRI Research Unit on AIDS, Entebbe, Uganda; 2London 
School of Hygiene and Tropical Medicine, London, UK
Background: BCG is a widely used vaccine but has a varied efficacy 
and reasons for this are still not clear. Several hypotheses have been 
advanced but none has been proven. In contrast tetanus toxoid (TT) 
usually confers good immunity. Understating factors that influence 
responses to cCFP of Mycobacterium tuberculosis and to TT might 
enable us to understand why BCG gives such a variable response and 
enable development of better vaccines.
Methods: Children aged five years from the Entebbe Mother and Baby 
Study (ISRCTN32849447) who received BCG or tetanus immunisations 
in infancy were assessed for in vitro cytokine responses to crude 
Culture Filtrate Protein of Mycobacterium tuberculosis (cCFP) and TT. 
Associations between cytokine responses and maternal and infant 
socio-demographic factors and infections were analysed in 
Results: 1191 and 1162 five year olds, respectively, were assessed 
for response to cCFP and TT. Among those who received BCG in 
infancy, 86.0%, 48.3%, 71.3% and 89.7% had detectable responses 
for IFN-γ, IL-5, IL-13 and IL-10 respectively. For those who received 
tetanus immunisatons in infancy 39.1%, 39.2%, 59.7% and 52.2% 
had detectable responses for IFN-_, IL-5, IL-13 and IL-10 respectively. 
The response to cCFP showed associations with BCG vaccine strain, 
child HIV status and stunting. The response to TT was associated with 
HIV and asymptomatic malaria.
Conclusion: BCG strain, nutrition and child’s HIV status may contribute 
to poor BCG efficacy in our setting. At age five years, we found no 
evidence of an effect of prenatal exposure to maternal helminth 
infections or malaria. Funding: Wellcome Trust 
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P10.03
Impact of In Utero HIV-1 Exposure on 
Chemokine Receptor Expression by Infant 
CD4+T Cells and Susceptibility to HIV-1
M.J. Bunders1, J.L. van Hamme1, M. Jansen1, N. Kootstra1, and 
T.W. Kuijpers1
1Academic Medical Centre, Amsterdam, Netherlands
Background: Uninfected infants born to HIV-1-infected women have 
lower CD4+ T cell counts in infancy than those born to uninfected 
mothers. In utero exposure to maternal HIV-1 infection could shape 
CD4+ T cell responses and chemokine receptor expression affecting T 
cell homing and numbers in the circulation.
Methods: Chemokine receptor expression on cord blood CD4+ T 
cells of uninfected HIV-1-exposed and healthy infants was assessed 
with flow cytometry directly and after culture. HIV-1 susceptibility of 
cord blood CD4+ T cells was assessed with an in vitro infection assay 
measuring p24. A multiparameter Luminex bead assay was used to 
assess levels of soluble factors.
Results:  A small yet significantly higher percentage of CD4+ T 
cells expressed chemokine receptors associated with inflammatory 
responses (i.e. CCR3, CCR8, CXCR6) in HIV-1-exposed infants compared 
to healthy controls. The cytokines IL-1_ and IL-8 were increased in 
plasma from HIV-1-exposed infants. In vitro culture of CD4+ T cells 
from HIV-1-exposed infants with i.e. IL1_ or IL-2 resulted in more CD4+ 
T cells bearing inflammatory-associated response chemokine receptors 
compared to controls, (CCR3 P<0.01, CCR8 P=0.03), whereas CCR7, 
largely expressed by naïve cells, was lower than in controls (P=0.01). 
Only after in vitro stimulation, CD4+ T cells could be infected with 
HIV-1. CD4+ T cells of HIV-1-exposed infants were more susceptible to 
HIV-1 after in vitro stimulation than from healthy controls.
Conclusion: In sum, CD4+ T cells of HIV-1-exposed infants have 
an enhanced state of activation, with an increased expression of 
inflammatory response-associated chemokine receptors. This likely 
affects the homing of CD4+ T cells and may be the underlying 
mechanism for reduced numbers in blood. Furthermore, the primed 
immune system alters susceptibility to HIV-1 and may enhance 
postnatal HIV-1 transmission in HIV-1-exposed children. 
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P11.02 D
A Survey of Community Opinions and 
Preferences on PrEP, Microbicides and Vaccines 
in 5 Regions and with Key Populations in 
Kenya
J.W. Mbogua1, B.P. Ngongo1, J. Ndegwa2, B. Bender1, and  
F. Manguyu1
1IAVI, Nairobi, Kenya; 2Kenya AIDS NGO Consortium, 
Nairobi, Kenya
Background: Recent results of PrEP, Microbicides and Vaccine trials 
have received mixed reactions at community level. We documented 
community, key populations (MSM, SW, Youth), and health 
providers’ preferences on New Prevention Technologies (NPT) in 5 
regions of Kenya.
Methods: A questionnaire was administered after workshops on 
NPTs and was followed by FGDs. Quantitative data was analyzed 
using MS Access 2007 and Stata version 11. FGD tapes and notes 
were transcribed and analyzed by two independent researchers who 
identified emerging themes.
Results: 42% of respondents (N=158) were involved in HIV/AIDS 
for more than 5 years and 20% were involved in NPT research and 
advocacy for more than 5 years. 62% reported having a fairly good 
knowledge of HIV vaccine research and discourse of the recent results 
against 51% for microbicides and 50% for PrEP. The average efficacy 
level that most respondents would be comfortable to advocate for 
introduction and use in their community was 74% for vaccines, 71% 
for microbicides and 76% for PreP. Vaccine was selected as preferred 
NPT across key populations but was equally ranked with microbicides 
for heterosexual women. Microbicides were ranked second. PrEP 
was ranked highest for discordant couples, MSM and MSW. Most 
respondents preferred microbicide gels (78%), injectable vaccines 
(69%) and injectable PrEP (67%). However, higher preference for 
microbicides ring was noted with SW and oral vaccine and oral PrEP 
with MSM.  The highest preference for product regimen was every 5 
years for a vaccine (64%), before and after sex for microbicides (61%), 
and twice a week for PrEP (59%) with varied preferences between 
key populations. Most preferred service delivery modes were health 
centers followed by family planning/HIV centers. Rationale for choices 
were guided by product characteristics, expected cost, accessibility, 
inclusivity, side-effect, efficacy and stigma.
Conclusion: Understanding evolving community preferences should 
be proactive, conducted in sync with trial and demonstration projects 
to inform R&D.
P11.01 D
Getting to Zero with an HIV Vaccine: Modeling 
the Impact of Introduction of the Current 
HIV Vaccine Pipeline Under the Investment 
Framework
J. Aylward2, E.D. Donaldson1, K. Fisher1, T. Harmon2,  
M. McGlynn2, A. Naeveke2, J. Stover3, and M. Warren1
1AVAC, New York, NY, USA; 2 IAVI, New York, NY, USA; 
3Futures Institute, Glastonbury, CT, USA
Background: The 2011 UNAIDS Investment Framework showed how 
scaling up key HIV interventions could dramatically reduce new HIV 
infections and deaths in low- and middle-income countries by 2015. 
Even with the reduction in HIV incidence modeled in the Framework 
there would still be approximately one million new infections per year. 
In order to further reduce incidence, introduction of new prevention 
options, including HIV vaccines, is necessary. With follow-on studies 
to RV144 well underway, DNA, MVA and adenovirus vaccine trials 
ongoing and promising work in candidates to elicit broadly neutralizing 
antibodies, it is a matter of time before an HIV vaccine will become 
part of the combination prevention paradigm. 
Methods: This study assesses the potential impact of an HIV vaccine 
in reducing new infections within combination HIV prevention 
programs and ultimately controlling the epidemic. Different potential 
candidates in the HIV vaccine pipeline are considered and their 
potential implementation modeled using assumptions including year 
of introduction, efficacy, cost and coverage. 
Results: While the timeframe for introduction of an HIV vaccine is 
longer than other options, the impact could be quite substantial. 
Potential vaccine efficacies of 30, 50 and 80 percent were modeled, 
with each scenario showing impact on incidence. At varying levels of 
efficacy, early and strategic introduction of a low- and moderate-cost 
HIV vaccine is shown to be cost-effective and beneficial. 
Conclusion: Remarkable progress is being made towards the 
development of a safe and effective HIV vaccine. Along with other new 
prevention options, including pre-exposure prophylaxis and treatment 
as prevention, HIV vaccines will have a major role to play in reducing 
new infections. Existing technologies and other new prevention options 
may lower new infections substantially, but an effective HIV vaccine 
could provide the push to achieve the final bend in the curve needed 
to bring new infections to near zero. 
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P11.04
Applying Market Research to Advance 
Implementation Science for New HIV 
Prevention Technologies: Two Case Studies 
with Most-at-Risk-Populations
P.A. Newman1, S. Roungprakhon2, S. Tepjan1, C.C. Williams1,  
J. Weaver1, and N. Massaquoi3
1University of Toronto, Toronto, Canada; 2Rajamangala 
University of Technology Phra Nakhon, Bangkok, Thailand; 
3Women’s Health in Women’s Hands, Toronto, Canada
Background: Widespread gaps between clinical trial efficacy and real-
world effectiveness of existing biomedical interventions highlight the 
importance of assessing end user preferences and concerns that may 
influence uptake of new HIV prevention technologies. We present 
methods and results from two studies to bridge research-to-practice 
gaps for HIV vaccines and rectal microbicides (RM).
Methods: We conducted community-based mixed-methods 
investigations using sequential triangulation designs among MSM 
and transwomen in Thailand and Black women in Canada. Focus 
groups were implemented using a semi-structured interview guide, 
analyzed thematically and applied to guide construction of discrete 
choice modeling (Thailand) and conjoint analysis (Canada). Thailand 
participants double-ranked 8 sets of 5 cards (best-worst) of hypothetical 
multi-attribute RMs. Full-rank data were analyzed using logit likelihood 
functions estimated with custom routines in Gauss matrix programming 
language. Canada participants rated the acceptability of 8 multi-
attribute HIV vaccine scenarios, with conjoint analysis to determine 
the relative impact of different attributes.
Results: Thailand: Informed by focus groups (n=37 participants; 
mean age=24.8 years), a pilot survey (n=24; mean age=24.5 years) 
indicated efficacy had the greatest marginal effect on choice, with 
participants more than twice as likely to choose a 99% vs. 50% 
efficacy RM. Pericoital (vs. daily) usage increased probability of choice 
by >70%; gel (vs. suppository) formulation increased choice by >40%. 
Canada: Informed by focus groups (n=26 participants; mean age=32.1 
years), the survey (n=206; mean age=35.1 years) indicated efficacy 
(99% vs. 50%) had the greatest impact (22.6/100) on acceptability, 
followed by side effects (none vs. minor; 8.6), cost ($10 vs. $250; 7.6) 
and duration (10 vs. 1 year; 6.5).
Conclusion: Methods traditionally used in marketing research can be 
applied in culturally appropriate ways to assess end user preferences 
and concerns about new HIV prevention technologies. Evidence 
from these analyses may inform product development and support 
implementation science to translate efficacious products into effective 
prevention tools. 
P11.03 D
The Role of Stakeholders Involvement Towards 
the Success of Vaccine/ Clinical Trials—The 
Partners PrEP Study 
C. Brown1
1Infectious Diseases Institute - PrEP Study, Kampala, Uganda
Background: Kampala clinical trial site was one of the 9 sites 
implementing the Partners PrEP Study, a double-blind randomized 
controlled trial of daily oral antiretroviral pre-exposure prophylaxis 
(PrEP) to prevent HIV acquisition. Like other clinical trials/vaccine 
trials, involvement of stakeholders greatly contributed to meeting 
recruitment targets
Methods: Before recruitment of participant into the partners PrEP 
study begun, stakeholders from target communities were sensitized 
about the study. Collaborating VCT sites, the Community Advisory 
Board (CAB), Community health workers, Local council and religious 
leaders were briefed about the objectives of the study to enhance 
acceptability to participate. Stakeholders engagement at planning 
and implementation regulated the activities of the study and ensured 
participants safety. 
Results: From 65 collaborating VCT sites, 245 counselors were trained 
in couple counseling and testing.  1758 couples were referred for 
screening and 582 couples were enrolled (screening to enrollment 
ratio 3:1). The VCT sites referred the highest number of couples to the 
study 1514 and 504 couples were enrolled (86%). The Community 
Advisory Board (CAB) referred 13 couples for screening, 2 couples 
were enrolled. From the 145 village health workers trained, 27 couples 
were referred for screening, 10 were enrolled (1.7 %). Out of the 42 
outreaches 121couples were screened 41 enrolled (7%). The media, 
religious leaders and local council leaders contributed 6%. 
Conclusion: Involvement of stakeholders in vaccine / clinical trials to 
mobilize participants and to explain the objectives of the study to the 
community / policy makers contributed to the success of the partners 
PrEP study. Stakeholders involvement in recruitment is an effective 
method of maintaining steady participant recruitment, adherence to 
study drug and retention.   
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P11.06
Will HIV Vaccination Reshape HIV Risk 
Behavior Networks? A Social Network Analysis 
of Drug Users’ Anticipated Risk Compensation
A.M. Young1, R.J. DiClemente1, D.S. Halgin2, H.L. Cooper1,  
C.E. Sterk1, and J.R. Havens2
1Emory University, Atlanta, GA, USA; 2University of Kentucky, 
Lexington, KY, USA
Background: A successful HIV vaccine could substantially impact the 
epidemic; however, risk compensation (increased risk behavior after 
vaccination) is a significant concern. While the impact of vaccine-related 
risk compensation on individual-level HIV risk has been explored, the 
potential impact on community-level risk network structure is largely 
unknown. The purpose of this study was to examine the impact of drug 
users’ anticipated HIV vaccine-related risk compensation on the overall 
structure of their risk network.
Methods: Data were collected from 405 rural drug users (75% 
with history of injection drug use) enrolled in a longitudinal, social 
network study in the US. HIV risk network ties were those in which 
partners had unprotected sex and/or shared injection equipment in 
the past 6 months.  Dyad-specific data were collected on self-reported 
likelihood of increasing/initiating risk behavior in response to HIV 
vaccination. Through cross-referencing names and demographic 
information about named network members, a sociometric HIV risk 
network was constructed.
Results: Anticipated increases in risk behavior and initiation of 
new risk relationships was reported for 8 dyads, resulting in a 4% 
increase in the number of ties in the overall HIV risk network (n=131 
to n=136) and the inclusion of four additional individuals in the 
network. The initiation of new relationships resulted in the connection 
of otherwise disconnected components of the HIV risk network; the 
largest component of the network doubled in size from five to ten. 
Interestingly, among all relationships in which increased risk behavior 
was anticipated, interviewees reported that they were likely to 
encourage their partners to receive the vaccine. 
Conclusion: These preliminary data suggest that HIV vaccine-related 
risk compensation could possibly impact risk network structure. The 
potential for network-level changes to mitigate the positive impact 
of HIV vaccination (particularly with low-efficacy vaccine) should be 
carefully examined, as should the dynamics and motives of peer-based 
vaccine promotion.
P11.05
“Sisters, Mothers, Daughters and Aunties”: HIV 
Vaccine Acceptability Among Black Women in 
Toronto
P.A. Newman1, C.C. Williams1, J. Weaver1, and N. Massaquoi2
1University of Toronto, Toronto, Canada; 2Women’s Health in 
Women’s Hands Community Health Centre, Toronto, Canada
Background: Black women in North America are at disproportionately 
high risk for HIV infection. In order to anticipate expectable research-
to-practice gaps between vaccine availability and uptake, we assessed 
the acceptability of future HIV vaccines among Black women in Toronto.
Methods: Women were recruited using venue-based sampling in 
Toronto. Data were collected on sociodemographic characteristics 
and acceptability of 8 hypothetical HIV vaccine scenarios, each 
defined by 7 variable attributes. Participants rated acceptability of 
each vaccine scenario, presented in a set of 8 laminated cards. We 
used conjoint analysis to quantify the relative impact of each vaccine 
attribute on acceptability.
Results: Among participants (n=206; mean age=35 years), 52% were 
of Caribbean and 48% African heritage, 81% born outside Canada. 
Mean monthly income was $1,683. Forty-percent had completed high 
school, 42% were single/never married, and 40% employed full-time. 
Acceptability of the 8 vaccine scenarios ranged from 82.1 (SD=24.6) 
to 37.1 (SD=25.3); mean vaccine acceptability = 58.8 (SD=17.2; 
100-point scale). Efficacy had the greatest impact on acceptability. 
Vaccine scenarios with 99% efficacy had an average acceptability 
score 22.56 (95% Confidence interval [CI]=19.30, 25.83) points higher 
than those with 50% efficacy, followed by side effects (none vs. minor; 
8.56, 95% CI=5.85, 11.27), cost ($10 vs. $250; 7.57, 95% CI=5.33, 
9.81), duration of protection (10 vs. 1 year; 6.53, 95% CI=4.38, 8.67), 
and doses (1 vs. 4; 1.75, 95% CI=0.32, 3.18). Women of African (vs. 
Caribbean) descent, single/never married (vs. married) and working 
part-time/unemployed (vs. full-time) had lower acceptability scores.
Conclusion: Black women in Toronto indicated a modest level of 
acceptability for future HIV vaccines. Educational interventions that 
promote the benefits of partially efficacious vaccines and include clear 
explanation of potential side effects, in conjunction with vaccine cost 
subsidies, may increase vaccine uptake. Differences in acceptability 
within Black communities suggest the need for tailored interventions 
to address barriers to uptake.
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P11.08
Enhancing Capacity of Ethics Review 
Committees in Developing Countries: The 
Kenyan Example 
W. Jaoko1, G.O. Manyonyi1, K. Bhatt1, S. Langat2, G. Mutua1,  
B. Farah1, J. Nyange1, J. Olenja1, S. Wakasiaka1, J. Oyugi1,  
M. Khaniri1, K. Fowke3, R. Kaul4, and O. Anzala1
1Kenya AIDS Vaccine Initiative (KAVI), University of Nairobi, 
Nairobi, Kenya; 2National Council for Science and Technology, 
Nairobi, Kenya; 3University of Manitoba, Canada; 4University 
of Toronto, Canada
Background: The high increase in HIV vaccine clinical trials taking 
place in developing countries and the complexity of the protocols 
for these trials requires that local ethics review committees (ERCs) 
reviewing them have the required capacity to ensure that they are 
conducted to the highest ethical standard.  
Methods: With a grant from Global Health Research Initiative (GHRI), 
Kenya AIDS Vaccine Initiative (KAVI) and the National Council for 
Science and Technology (NCST) embarked on an exercise to enhance 
the capacity of ERCs in Kenya to review such protocols. The process 
involved conducting an audit of all accredited and non-accredited ERCs 
in the country, conducting their training needs assessment to identify 
the gaps. The information obtained was then used to develop materials 
used to train the ERC members in several workshops conducted in 
different parts of the country. 
Results: Five accredited and 13 non-accredited ERCs in Kenya were 
identified. Four of the accredited ERCs were located in the capital city 
of Nairobi. The most common challenge/need cited by participants 
during the needs assessment was excess work load, and the lack of 
coordination/communication between the ERCs. To date, participants 
from 8 institutional ERCs have been trained as follows: 36 from 
institutions in the western part of the Kenya and 22 from institutions 
in the south eastern coastal region of the country. A total of 116 ERC 
members have attended the ethics training workshops to date. The 
training workshops are still on course.
Conclusion: KAVI and NCST have developed training modules for 
training ERC members in Kenya and are in the process of developing 
a manual for the trainings. The Kenyan experience may be used to 
enhance capacities of ERCs not only in the East African region, but in 
other developing countries.
P11.07
Engaging and Recruiting MSM in HIV Research: 
Experiences from the Early HIV Capture Cohort 
Study in Kampala, Uganda
N. Mutengu1, H. Kibuuka1, M. Millard 1, F. Kiweewa1,  
A. Sekiziyivu1, J. Nanyondo1, G. Kawooya1, N. Michael2, and  
M. Robb2
1Makerere University Walter Reed Project, Kampala, Uganda; 
2U.S. MHRP, Silver Spring, MD, USA
Background: HIV research among MSM in Uganda is uncommon with 
two documented studies since the onset of the epidemic.  Therefore, 
a knowledge gap exists on how best to engage and recruit MSM for 
HIV studies in general and during the debate surrounding the Anti-
Homosexuality Bill (AHB).  Makerere University Walter Reed Project is 
conducting the Early HIV Capture Cohort Study, which seeks to enrol 
HIV uninfected MSM in Kampala. We describe experiences engaging 
and recruiting this population during a challenging period.
Methods: Using leaders of identified organizations, five members 
of the MSM community were identified and selected to join a 
special advisory group to guide recruitment and link MUWRP to the 
community.  Brainstorming sessions with various community members 
and separate individual conversations with additional knowledgeable 
members were organized to discuss; most effective recruitment 
strategies, anticipated challenges and feasibility of certain study 
procedures including twice weekly clinic visits.    
Results: Recommended and adopted recruitment strategies included; 
Peer led approaches, extemporized approach and community 
Sundays.  There was consensus that twice weekly clinic visits would be 
acceptable.  Contention surrounded use of coupons as a recruitment 
tool and the impact the AHB would have on study participation. 
Within a month of recruitment initiation, 67 MSM were booked for 
screening, 47 were screened, 18/47 enrolled, 15/18 began bi-weekly 
clinic visits while 29/47 are awaiting results to determine eligibility. 
Only 8/67 did not turn up for screening for reasons not provided. 
For confidentiality, identification of participants at the site is by use 
of finger print scanning, which links to participant study number that 
appears on all study documents.  
Conclusion: Although replicating recruitment strategies used in 
previous studies is helpful, it is critical to undertake a real-time 
community assessment exercise however rudimental, to gain informed 
understanding of local or unique study populations as a matter of 
Good Participatory Practice.  
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P11.10
HIVACAT’s Community Advisory Board: An 
Experience on Community Engagement in an 
HIV Vaccine Research Project in Catalonia
L. Ruiz Mingote1, P. Coll1, P. García de Olalla1, J. Joseph1,  
J. Martínez Alonso1, M. Meroño1, S. Moreira1, F. Soler1, J. Palacio 
Vieira1, C. Brander1, R. Malagrida1, F. Pujol1, M. Meulbroek1,  
J. Roqueta1, J. Caylà1, and G. Boichat Sancho1
1HIVACAT’s Community Advisory Board, Barcelona, Spain 
Background: Aware of the importance of the community involvement, 
and to allow a fluent communication between researchers and 
community, the research project HIVACAT set up a Community 
Advisory Board (CAB). HIV activists, journalists, trials’ participants, 
researchers and public health professionals compose this CAB, created 
in July of 2010.
Methods: The HIVACAT launched an invitation to different members 
of the community. The identification took three months. The group 
meets on a quarterly basis. In each meeting, there are training; 
updates on the ongoing clinical trials; revision of protocols and 
material addressed to participants. The CAB uses a mailing list to 
share documentation, articles and proposals. All documents are sent 
at least 10 days before the meeting. A chair and a secretary were 
appointed to facilitate the group work.
Results: The CAB has fulfilled their objectives, assessing HIVACAT 
performance and providing important inputs for the improvement of 
protocols and communication strategies. These have incorporated 
the community needs in a more receptive way. At any stage, the CAB 
members have kept their independence, expressing all their opinions 
and proposals for the clinical trials design and implementation. During 
the three years the CAB has met in 10 occasions, has organised four 
trainings and has reviewed seven protocols, studies and/or materials.
Conclusion: Community engagement has shown to have a positive 
impact on science by facilitating the recruitment and retention of 
volunteers, through a better communication between researchers 
and community. That improves the research process and outcomes. 
However, it is important to evaluate the CAB performance and its 
impact on the overall goals of HIVACAT. We have identified the need 
to elaborate a work plan for the CAB, and to define qualitative and 
quantitative indicators that may help to have a better picture of the 
impact that community engagement has on the research project.
P11.09
Regulatory Capacity Building Under the 
Canadian HIV Vaccine Initiative: Addressing 
Challenges of Developing National Regulatory 
Authorities
B. Chauhan1, A. Ng1, and D. Smith1
1Biologics and Genetic Therapies Directorate, Health Products 
and Food Branch, Health Canada, Ottawa, Canada 
Background: The Canadian HIV Vaccine Initiative (CHVI) is a 
partnership between the Government of Canada and the Bill and 
Melinda Gates Foundation with the goal of developing a safe, 
affordable, effective and globally accessible HIV vaccine.  Health 
Canada, working in collaboration with the World Health Organization, 
is responsible for CHVI’s regulatory capacity building program which 
is aimed at strengthening the regulatory capacity of developing 
national regulatory authorities (NRAs) in order to help protect the 
ethical and scientific integrity of HIV vaccine clinical trials occurring 
in these countries.
Methods: The regulatory needs of developing NRAs were identified 
using surveys, face-to face meetings and teleconferences.  Health 
Canada vaccine and regulatory experts developed and administered 
training using case studies and interactive group discussions. Training 
sessions included clinical trial application review, clinical and quality 
review of vaccines and vaccine lot release.  
Results: Since 2010, Health Canada has trained of over 100 participants 
from more than 40 countries under the CHVI.  This includes the 
establishment and continued mentorship with regulatory agencies 
in Nigeria and Malawi and regional training in Southern and Eastern 
Africa.  Health Canada has prepared and delivered regulatory training 
sessions via vaccine and clinical trial forums, and sponsored NRAs to 
attend these forums to provide learning opportunities and encourage 
the exchange of best regulatory practices.  This also includes the 
development and implementation of guidance in the area of HIV 
vaccine clinical trials.
Conclusion: Health Canada has successfully implemented capacity 
building activities in countries with developing NRAs to help strengthen 
their capacity in the regulation of vaccines.  Moving forward, training 
efforts will utilize a regional approach in order to maximize training of 
regulatory staff in countries with similar training needs.
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P11.12
HIV Vaccine R&D Investment Amid a Changing 
Global Health and Development Landscape
K. Fisher1, E.  Donaldson1, R. Granich2, T. Harmon3, P. Harrison1, 
N. Saelens3, and M. Warren1
1AVAC, New York, NY, USA; 2UNAIDS, The Joint United 
Nations Programme on HIV/AIDS, Geneva, Switzerland; 3IAVI, 
New York, NY, USA
Background: Since 2004, the HIV Vaccines and Microbicides Resource 
Tracking Working Group has employed a comprehensive methodology 
to track trends in research and development (R&D) investments and 
expenditures for biomedical HIV prevention options, including HIV 
vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as 
prevention, voluntary medical male circumcision, female condoms, 
HSV-2 prevention and vertical transmission prevention.  Such 
monitoring is critical to identify investment trends and provide a fact 
base for policy advocacy on R&D spending 
Methods: To estimate annual investment in HIV vaccine R&D, data were 
collected from government agencies, nonprofit research organizations, 
foundations and pharmaceutical/biotechnology companies on annual 
disbursements for product development, clinical trials and trial 
preparation and policy advocacy. 
Results: Preliminary results suggest that funding was nearly flat in 
2012 as the global health and development landscape shifted  to 
accommodate budget and economic pressures in the US and Europe. 
The HIV vaccine field responded to increased focus by donors on 
country ownership, capacity sharing and a reduced priority for disease-
specific projects by formalizing relationships with research groups in 
HIV endemic countries and product development efforts outside the 
field. Public sector funding remained the main source of investment, 
with a slight increase in estimated industry spending and a slight 
decrease in philanthropic donations. 
Conclusion: 2012 was a year of sustained effort and steady progress. 
With promising discoveries in broadly neutralizing antibodies, follow-on 
trials to RV144 underway and new vaccine strategies entering clinical 
trials, development of a safe and effective HIV vaccine continues to 
advance. Pursuit of promising candidates and continued exploration 
of groundbreaking basic research to replenish the candidate pipeline 
will require sustained investment over the long timeline of HIV 
vaccine development. Tracking funding trends enables prioritization of 
promising research and the assessment of the impact of the economic 
environment, development trends and public policy decisions on HIV 
vaccine R&D investment. 
P11.11
An Integrated Approach to Clinical Trial 
Capacity Building
G.N. Mutua1, J. Nyange1, B. Farah1, J. Oyugi1, J. Olenja1,  
G. Omosa-Manyonyi1, M. Khaniri1, W. Jaoko1, and O. Anzala1
1University of Nairobi, Nairobi, Kenya
Background: Human resources required to ensure high standards 
of design and conduct of clinical trials are limited in resource poor 
settings such as Sub-Saharan Africa.  Using funding from the Global 
Health Research Initiative, we targeted ethicists, laboratory and clinical 
staff as well as local communities for training, as part of a multi-faceted 
approach to clinical trial capacity building in the East African region.
Methods: In 2010, we established a clinical research training unit whose 
mandate was to train clinical research staff in Good Clinical Practice in 
research organizations in Kenya Uganda and Tanzania. Laboratory staff 
in the three countries also received training in Good Clinical Laboratory 
Practice as well as in laboratory quality management systems. In order 
to build research literacy and acceptance among health care providers 
in Kenya, nationwide workshops were conducted among lecturers in 
the Kenya Medical Training Colleges (KMTC) which generate >80% of 
health care professionals in the country. We also partnered with the 
National Council for Science and Technology to conduct nationwide 
ethics training to members of ethics review committees in Kenya.  
Results: A total of 171 clinical staff, 248 laboratory staff, 177 KMTC 
lecturers and 58 ethicists have been trained to date. An inventory of 
all accredited and non-accredited IRBs has been compiled and the 
development of a standardized training manual for IRBs is underway. 
Conclusion: This program creates an opportunity to nurture South-to-
South collaborations and to develop and cascade training programs 
that are based on culturally relevant experiences. Sustainability of the 
program is a major challenge and in all cases, the demand for training 
has far outstripped the available resources. 
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P11.14
Is Omitting Couple’s Voluntary HIV Counseling 
and Testing (CVCT) in HIV Vaccine Trials 
Unethical?
S. Allen1, W. Kilembe1, B. Vwalika1, E. Karita1, and E. Hunter1
1Rwanda Zambia HIV Research Group, Emory University, 
Atlanta, GA, USA
Background: WHO has issued guidelines endorsing CVCT and assisted 
mutual disclosure for HIV prevention. Training materials are available 
on the CDC web site.
Methods: The Rwanda Zambia HIV Research Group (RZHRG) has 
pioneered CVCT since 1986: >90% of pregnant Rwandan women now 
test with spouses and >100,000 Zambian couples have been tested 
in RZHRG partner clinics. RZHRG has also provided CVCT technical 
assistance to 20 other African countries. In 2011, based on the results 
of HPTN 052, research sponsors instructed RZHRG to discharge large 
cohorts of discordant couples and refer them to government clinics 
for Treatment as Prevention (TAP). Follow-up confirms that few have 
initiated TAP.
Results: International guidelines endorse CVCT and functional models 
have been developed but neither Global Fund nor PEPFAR include 
required indicators or provide dedicated funding. More than 90% 
of African discordant couples have yet to be identified, and follow-
up services are not available in government clinics. In one southern 
African country that includes TAP for all discordant couples in the 
national guidelines, a prevention trial is underway that will identify 
but not counsel or treat discordant couples unless CD4 counts are 350 
cells/mm3. Paradoxically, because of this same guideline, vaccine trial 
sponsors no longer consider discordant couples eligible for trials in 
that country and have withdrawn funding for CVCT.
Conclusion: Clinical trial participants in Africa should be HIV-tested 
with their primary sexual partners whenever possible. Interpretation 
of TAP guidelines for prevention trials should be consistent and based 
not on aspirational goals but on what is actually the ‘locally achievable 
standard of care’. CVCT is cost-effective, feasible, and affordable. 
Studies and trials that ignore stable partners and do not provide CVCT 
have to be considered unethical, and vaccine trials should include 
discordant couples where choice or lack of TAP provide an ethical basis.
P11.13
The Role of Technical Assistance in Establishing 
Couples’ Testing as Standard of Care for HIV 
Vaccine Trial Participants
A. Appiagyei1, A. Mwaanga1, R. Sinabamenye1, E. Gudo1,  
H. Banda1, M. Mulenga1, B. Mutumwinka1, N. Ahmed1,  
B. Siangonya2, W. Kilembe1, M. Inambao1, E. Karita1, and  
S. Allen1
1Rwanda Zambia HIV Research Group, Lusaka, Zambia; 
2Emory University, Atlanta, GA, USA
Background: Most African adults are in a cohabiting sexual union and 
these couples represent the largest risk group for HIV transmission. 
Couples voluntary HIV counseling and testing (CVCT) is associated with 
a two-thirds reduction in HIV transmission among HIV serodiscordant 
couples. WHO guidelines recommend CVCT. Through CVCT, couples 
experience mutual disclosure of HIV results and receive targeted 
counseling which affects sexual risk behaviors and hence vaccine trial 
outcomes. CVCT must be provided as standard of care for vaccine 
trial participants across countries and sites. RZHRG provides technical 
assistance (TA) to countries and partners wishing to implement CVCT. 
TA is useful in ensuring that CVCT services are effectively adapted and 
implemented across the region.
Methods: International TA events from 2009-2012 are described. 
TA events were classified as high-level advocacy, training for service 
providers and promotional agents, as well as training of trainers. 
Monitoring and evaluation activities are also presented to illustrate 
country-adapted CVCT models, as well as changes in uptake of CVCT 
and subsequent identification of discordant couples.
Results: From 2009-2012, RZHRG provided TA to over 1,785 people 
from 146 partners in 18 countries. Available data from 2012 indicated 
significant increases in provision and uptake of CVCT in 12 of 18 
recipient countries either for research or programmatic purposes. 
Increased uptake of CVCT led to increased identification of discordant 
couples.  As yet, only two countries offer follow up for discordant 
couples in government facilities. Workshops held in Rwanda and 
Zambia in 2012 attracted participants from 23 countries, confirming 
growing interest in CVCT.
Conclusion: Through TA from an organization with experience in 
CVCT for vaccine trials and routine health services, recipient countries 
were able to acquire a multitude of skills which enabled them to 
more effectively implement CVCT. Countries with capacity to provide 
quality CVCT services should be considered in site selection for future 
vaccine trials.
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P11.15 LB
Vaccine-Induced Antibodies: Impact for HIV 
Diagnosis, Clinical Trial Participants and Public 
Health
H. Zinszner1, Y. Voronin1, M. Allen2, M. Busch3, U. Fruth4,  
H. Golding5, S. Khurana5, J. Mulenga6, S. Peel7, M. Schito7, and  
P. Fast8
1Global HIV Vaccine Enterprise, New York, NY, USA; 2NIAID, 
NIH, Bethesda, MD, USA; 3Blood Systems Research Institute, 
San Francisco, CA, USA; 4WHO, Geneva, Switzerland; 5FDA, 
Bethesda, MD, USA; 6National Blood Transfusion Services, 
Lusaka, Zambia; 7US MHRP, Bethesda, MD, USA; 8IAVI, New 
York, NY, USA
Background: The evaluation of vaccine candidates in volunteers is 
an essential component of HIV vaccine research and development. 
Vaccine trial participants may develop vaccine-induced antibodies 
to HIV without being actually infected by the virus. These antibodies 
are frequently detected by commonly used serological diagnostic 
tests and may be misinterpreted as a marker of HIV infection. This 
phenomenon is currently referred to as Vaccine-Induced Sero-Positivity 
(VISP) or Vaccine-Induced Sero-Reactivity (VISR). As vaccine candidates 
become more immunogenic and effective and trials more diverse, the 
number of post-study volunteers with durable VISP/R will rise with 
consequences for global healthcare systems.
Methods: The Global HIV Vaccine Enterprise recently hosted an 
international convening co-sponsored by NIAID and attended by 
representatives from academia, government, private institutions, and 
biotechnology companies to review the challenges presented by VISP/R 
and to articulate paths to resolution. A number of issues were considered. 
Results: Clinical vaccine trial participants with durable VISP/R may 
encounter a range of social harm and require long-term support in 
countries where vaccine trials are being conducted. Trial volunteers 
should be informed in advance of the possibility and implications of 
developing VISP/R. Differentiation of VISP/R from HIV infection poses 
technical challenges. Solutions must be advanced for vaccine trials 
and post-study, especially for participants at ongoing risk for HIV, and 
ultimately for the licensure and deployment of an effective vaccine. 
For trial sponsors, provision of specialized testing and other services 
to volunteers with durable VISP/R creates a logistical and financial 
burden. Review of current VISP/R management practices at a number 
of organizations indicated diverse approaches and technical solutions, 
some that could be adopted field-wide.
Conclusion: Addressing issues related to vaccine-induced antibodies in 
HIV vaccine recipients requires commitment and concerted action from 
the field as a whole in collaboration with local and global agencies.
Topic 11: Social/Ethical/Access/Regulatory Issues
242
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P12.02 D
HIV-1 Protease Inhibitor Alter Cellular Protease 
Activity, Epitope Processing and Presentation 
to CD8 T Cells
G. Kourjian1, Y. Xu1, J. Boucau1, M. Shimada1, P. Gourdain1, and 
S. Le Gall1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Background: Epitopes displayed by MHC-I are generated from 
the intracellular degradation of proteins by proteasome and 
aminopeptidases. We hypothesize that due to structural homologies 
HIV protease-inhibitors (PIs) used in antiretroviral-therapies may affect 
activities of cellular peptidases involved in epitope processing and alter 
epitope presentation to immune cells.
Methods: Using a fluorogenic assay the effect of 7 HIV-1 PIs (Ritonavir, 
Saquinavir, Nelfinavir, Indinavir, Atazanavir, Darunavir and Kaletra) 
on proteasome and aminopeptidase activities was tested in PBMCs 
from at least 6 healthy donors. Using PBMC cytosol as a source of 
peptidases the effect of HIV PIs on HIV epitope production kinetics 
and HIV epitope cytosolic half-life was assessed by HPLC and LC-MS-
MS analysis. Finally we assessed the impact of PIs on the endogenous 
processing and presentation of epitopes by HIV infected cells to CD8 T 
cells using a fluorescence-based cytotoxicity assay.
Results: HIV PIs variably altered proteasome and aminopeptidase 
activities. Depending on the PI, some activities were inhibited (up 
to 5-folds, p<0.001), enhanced (up to 9-folds, p<0.001), and others 
not changed. These PI-induced changes in protease activities were 
sequence dependent leading to enhanced or reduced cleavage of 
specific residues and resulting in alteration of HIV epitope production 
kinetics and intracellular half-life prior to MHC-I loading. For instance 
Ritonavir increased by 4.6-fold the intracellular B57-KF11 epitope 
production whereas Saquinavir reduced it by 3.3-fold. Depending on 
the PI and the epitope the half-life was increased 1.5-fold (p<0.01) or 
decreased 1.3-fold (p<0.05). Furthermore HIV PI altered (from 2.2-fold 
decrease to 1.3-fold increase, p<0.01) the presentation of HIV epitopes 
and recognition by epitope-specific CD8 T cells.
Conclusion: These findings suggest that in HIV-infected patients an 
antiretroviral therapy including PIs might -by altering host proteases 
function- modify the pattern of epitope presentation, leading to the 
elicitation of additional CTL responses against HIV and potentially 
against other pathogens co-infecting HIV+ persons.
P12.01 D
Host Immune Environment Impact the Level 
of CD4 Central Memory Reconstitution in HIV 
Subjects Receiving ZFN CCR5 Modified CD4 T 
Cells (SB-728-T)
J. Zeidan1, G. Lee2, J. Ahlers1, J. Lalezari3, R. Mitsuyasu4,  
S. Wang2, M. Giedlin2, W. Tang2, G. Nichol2, M. Cameron1,  
D. Ando2, and R. Sekaly1
1Vaccine and Gene Therapy Institute - Florida, Port St. Lucie, 
FL, USA; 2Sangamo Biosciences, Richmond, CA, USA; 3Quest 
Clinical Research, San Francisco, CA, USA; 4UCLA, Los 
Angeles, CA, USA
Background: Therapeutic vaccine modalities have yet to generate 
successful outcome; here we have used adoptive transfer of ZFN-
modified CD4 T cells to provide HIV-resistant cells to the host 
immune’s system. Long-term improvement in CD4 count was 
observed in all SB-728-T treated subjects. Here, we performed 
phenotypic and transcriptional analyses to elucidate the role 
of inflammation and persistent immune activation on CD4 
reconstitution and SB-728-T persistence.
Methods: Nine aviremic HIV+ subjects on ART with CD4 counts btw 
200-500 cells/uL received 10-30E9 SB-728-T. Analyses of survival and 
activation markers were performed on PBMCs collected pre-infusion 
and at late (M9-12) time points post-infusion.
Results: At 12 months post-infusion, 5 of 9 subjects showed greater 
improved CD4 count (high CD4 responders; median increase= 224 
cells/uL) than 4 other subjects (suboptimal responders; 44 cells/uL), 
which was primarily driven by the central memory T cell subset (TCM). 
Persistence of CCR5 modified cells does not fully explain the CD4 
increases observed in high CD4 responders. High CD4 responders 
showed decreased PD-L1 expression in monocytes post-infusion that 
correlated with lower PD-1 expression in TCM (r=.77,p=.02) and higher 
TCM counts (r=.83,p=.01) at M9. TCM isolated post-infusion from high 
CD4 responders showed down-regulation of genes involved in anergy 
and apoptosis (such as NFAT, Axin2, and Caspase-3). High levels of 
immune activation pre-infusion, as measured by expression of HLA-
DR, CD80 and CD40 in monocytes and LAG-3 in TCM, and expression 
of IFN type I stimulated genes in suboptimal responders at baseline 
inversely correlated with reconstitution of TCM 12 months post-infusion 
(r=-.73,p=.03).
Conclusion: Reduction of PD-1/PD-L1 mediated suppression in TCM in 
high CD4 responders suggests that decreased levels of inflammation 
may provide a survival advantage of TCM post-infusion. Identification of 
an inflammatory signature prior to treatment as an important predictor 
of reconstitution of TCM will help future study design of SB-728-T and 
other modalities aimed at immune reconstitution.
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P12.04 D
Local Cellular Immune Responses Precede 
Systemic Responses Following Intravaginal SIV 
Infection in Rhesus Monkeys
J. Liu1, H. Li1, K. Smith1, E. Borducchi1, K. Stanley1, W. Wagner2, 
M. Lewis2, and D. Barouch1
1Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA; 2Bioqual, Inc., Rockville, MD, USA
Background: Defining the earliest immunologic events following virus 
exposure will be critical for the design of an effective HIV-1 vaccine. 
In this study, we investigated the anatomic localization of mucosal and 
systemic SIV-specific cellular immune responses in rhesus monkeys 
following intravaginal infection with SIVmac251.
Methods: Ten juvenile and four adult naïve, unvaccinated rhesus 
monkeys were inoculated by the intravaginal route with a single high-
dose of SIVmac251 without depo pre-treatment. To evaluate local 
and systemic cellular immune responses early following infection, we 
sacrificed monkeys at day 7 and day 10, and we harvested multiple 
tissues to evaluate SIV gag specific T cell responses by multiparameter 
intracellular cytokine staining. 
Results: SIV gag-specific CD8 and CD4 T cell responses were 
detected first in the female genital mucosa (cervix, vagina, uterus) 
and bone marrow by day 7, and were detected in gastrointestinal 
mucosa (duodenum, jejunum, and colon) by day 10. At day 7 and 
10, systemic responses in PBMC, lymph nodes, and spleen were still 
negative. No clear differences in responses were detected between 
juveniles and adults.
Conclusion: These data show that the earliest cellular immune 
responses following intravaginal SIV infection in rhesus monkeys 
occur locally in the female genital tract and bone marrow.
P12.03 D
Targeting HIV-1 Where It Hurts
T. Ahmed1, P. Hayes2, N. Borthwick1, B. Ondondo1, E. Hayton1,  
S. Colloca3, A. Nicosia3, A. McMichael1, J. Gilmour2, L. Dorrell1, 
and T. Hanke1
1University of Oxford, Oxford, UK; 2IAVI Human Immunology 
Laboratory, Chelsea and Westminster Hospital and Imperial 
College, London, UK; 3Okairòs, Rome, Italy
Background: To address HIV-1 variability and escape, our group has 
assembled the vaccine immunogen HIVconsv from the most conserved 
functional regions (as opposed to epitopes) of the HIV-1 proteome with 
the underlying working hypothesis that early focus of vaccine-elicited 
immune responses on these regions will lead to a better control of 
both transmitting/founder and escaping viruses.
Methods: In the HIV-CORE002 trial, a gene coding for the HIVconsv 
immunogen was delivered by a combination of plasmid DNA 
(D), modified vaccinia virus Ankara (MVA; M) and non-replicating 
adenovirus of a chimpanzee origin ChAdV-63 (C) to healthy, HIV-1-
negative adults in Oxford.
Results: The two most immunogenic regimens, CM and DDDCM, 
induced total frequencies of HIV-1-specific; IFN-g-producing T cells that 
were up to 10- fold higher than the Merck STEP trial candidate.  We 
examined the ability of vaccine-elicited CD8 + T cells to inhibit HIV-1 
replication in-vitro using a panel of 8 viruses comprised of multiple viral 
clades.  The CM regimen induced the strongest magnitude and breadth 
of inhibition; with a group median of 2.8 log10 reductions in viral p24 
protein being detected in the IIIB virus isolate one week post MVA.
HIVconsv boost.  Breadth of inhibition following CM administration 
showed that all vaccinees inhibited 2/8 viruses from clades A and B, 
with one individual demonstrating superior control of all eight viruses. 
In addition, HIV-1 inhibitory responses to multiple viral clades were 
preserved in several vaccinees from the CM group for up to 20 weeks 
post vaccination.  Expanded CD8 + T cell IFN-g  ELISpot responses 
against Gag and Pol peptides present within the immunogen were 
also examined and correlation of the data showed that the strongest 
association was between the magnitude of viral inhibition and Pol-
specific expanded CD8+ T cell responses.
Conclusion: As a result of the promising IFN-g-ELISpot and viral inhibi-
tion results, further studies are planned with the HIVconsv immunogen.
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P12.06
Mechanism of a Novel PD1-Based DNA Vaccine 
in Amplifying HIV-1 GAG-Specific CD8+ T Cells 
in Mice
Z. Chen1, J. Zhou1, A.K. Cheung1, Z. Tan1, H. Wang1, W. Yu1,  
Y. Kang1, X. Lu1, L. Liu1, and K. Yuen1
1University of Hong Kong, Hong Kong, China
Background: An effective vaccine to elicit a high frequency of 
protective CD8+ T cell immunity against HIV-1 remains a continuous 
challenge.  Significant progress has been made to target vaccine 
antigen to dendritic cells (DCs) via DC surface proteins (e.g. anti-DEC205 
antibody) but only a low frequency of antigen-specific CD8+ T cell 
immunity was achieved. To date, it remains elusive which DC receptor 
targeting would intensify antigen specific CD8+ T cell immunity.
Methods: In this study, we report what we believed to be a novel 
antigen-targeting DNA vaccine method that exploits the binding 
of programmed death-1 (PD1) to its ligands expressed on DCs by 
fusing soluble PD1 with HIV-1 Gag p24 antigen. For mechanistic 
investigation, we further conducted a parallel study with an anti-
DEC205-based DNA vaccine.
Results: As compared with non-DC targeting vaccines, intramuscular 
immunization via electroporation (EP) of the fusion DNA vaccine in 
mice elicited consistently high frequencies of Gag-specific, broadly 
reactive, polyfunctional, long-lived and cytotoxic CD8+ T cells, besides 
robust anti-Gag antibody titers, which conferred significant protection 
against mucosal challenge with vaccinia-Gag viruses. Mechanistically, 
soluble PD1-based vaccination potentiated CD8+ T cell responses by 
enhancing DCs in antigen binding and uptake, and DC activation in 
draining lymph nodes. It also uniquely increased the frequency of 
IL-12 producing DCs in vivo and engaged the intracellular pathway 
of antigen cross-presentation when compared with the anti-DEC205-
based DNA vaccine. 
Conclusion: The high frequency of durable and protective Gag-specific 
CD8+ T cell immunity induced by soluble PD1-based vaccination has 
important implications for vaccine development and immunotherapy 
against HIV-1 infection.
P12.05 D
Immune-Correlates Analysis of the Step HIV 
Vaccine Efficacy Trial—A Post-Hoc Analysis of 
HIV-Specific and Non-specific Cellular Immune 
Responses
Y. Huang1, A. Duerr1, Z. Moodie1, N. Frahm1, S. DeRosa1,  
J. McElrath1, and P. Gilbert1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Background: As the first proof-of-concept efficacy trial of an HIV 
vaccine designed to elicit cell-mediated immunity, the Step study 
provides unique data on the role of cellular responses in predicting 
trial outcomes. 
Methods: We assessed IFN-γ-ELISpot responses at 4 weeks after the 
second Ad5 immunization in the male per-protocol (PP) cohort. We 
accommodated post-hoc sampling into Cox proportional hazards 
models to estimate hazard ratios (HRs) of HIV-1 infection per one-
log increase of ELISpot responses, as well as interactions between 
treatment and ELISpot responses in predicting HIV infection.
Results: We analyzed 112 PP infected cases (Vaccine: n=84, Placebo: 
n=28), and 962 PP uninfected non-cases (Vaccine: n=729, Placebo: 
n=233) with available ELISpot data. HIV non-specific background 
ELISpot responses (i.e.; IFN-γ secretion in the absence of antigen-specific 
stimulation) were directly correlated with risk of HIV infection among 
vaccine recipients (HR=1.61, 95% CI: (1.31, 1.97), p <0.001), but not 
among placebo recipients. This association among vaccine recipients 
persisted after controlling for ELISpot responses against Gag, Pol, Nef 
and baseline covariates. None of the HIV-antigen-stimulated responses 
were significantly associated with risk of HIV infection. Overall, there 
was no significant interaction between treatment assignment and 
background ELISpot in predicting risk of HIV infection, although 
such an interaction was more pronounced within both uncircumcised 
and Ad5 seropositive subgroups. Although the difference is small in 
magnitude, HIV non-specific ELISpot responses were higher in Ad5 
seropositive men (p < 0.001) and circumcised men (p=0.02), but lower 
in vaccine recipients (p<0.001) in multivariate regression models.
Conclusion: The proportion of cells producing IFN-γ without 
stimulation by exogenous antigen appears to carry information about 
a subject’s immune status beyond baseline covariates that predict risk 
of HIV infection among Step vaccine recipients. These results motivate 
additional research to understand the potential link between IFN-γ 
secretion and underlying causes of vaccine-associated enhanced 
infection risk in Step study.
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P12.08
ADA Reduces the HIV-1-Specific Tregs and 
Enhances HIV-1-Specific CD4+ and CD8+ 
Effector and Memory T Cell Responses
I. Naval-Macabuhay1, V. Casanova2, F. Garcia3, A. Leon3,  
C. Rovira3, L. Miralles3, C. Lluís2, C. Gil3, E.I. Canela3, J. Mallol3,  
J. Gatell3, T. Gallart3, P. McCormick3, and N. Climent3
1IDIBAPS, Barcelona, Spain; 2Department of Biochemistry 
and Molecular Biology, Faculty of Biology, Barcelona, Spain; 
3IDIBAPS-AIDS Research Group, HIVACAT, Barcelona, Spain
Background: The use of adjuvants to increase the immune response 
in therapeutic and prophylactic vaccines are gaining relevance today. 
In this regard, we previously reported that adenosine deaminase 
(ADA), a key enzyme in the adenosine pathway, acts as a costimulatory 
molecule, enhancing T cell activation and proliferation acting as a 
bridge between A2B adenosine receptors on dendritic cells (DCs) 
and CD26 on T cells. Here we investigated the costimulatory role of 
ADA by determining the ADA effect on HIV-specific memory and T 
regulatory cells. 
Methods: DCs from HIV+ patients pulsed with heat-inactivated HIV-1 
were cocultured with autologous lymphocytes and HIV-1 specific T cell 
responses were determined as: proliferation (CFSE), cytokine secretion, 
memory T cells (CD4+CD25-CD45RO+ and CD8+CD25-CD45RO+) 
and Tregs immunophenotype (CD4+CD25+FOXP3+) expression. 
Suppression assays were performed to assess the activity of Tregs in 
the presence of ADA in healthy individuals. 
Results: In cocultures, ADA significantly increased HIV-1-specific 
CD4+ and CD8+ T cell response, specifically induced HIV-1 memory 
T cells and enhanced secretion of Th-1 cytokines such IFN-γ, IL-1β, 
IL-6 (11-fold), IL-15 (5-fold), RANTES/CCL5, MIP-1α/CCL3 and MIP-1β/
CCL4. Interestingly, ADA significantly decreased the HIV-specific Tregs 
population and suppressive assays indicated that ADA has a dual role 
depending on the subpopulation of CD4 T cells: ADA decreases in a 
half the Tregs, but increases the T effector cells (p<0.001). Addition of 
5’-N-ethylcarboxamidoadenosine (NECA), an adenosine analog unable 
to be ADA-deaminated, increased Tregs 2-fold.  This NECA-effect was 
highly reduced (75%) when ADA was added (p<0.001), suggesting a 
potent role of ADA interfering with NECA signaling, by a mechanism 
independent of its enzymatic activity.
Conclusion: These findings demonstrate the role of ADA enhancing 
both the HIV-1-specific CD4+ and CD8+ memory T cell response against 
HIV-1 while reducing the suppression mediated by HIV-1 specific Tregs 
indicating that ADA could be an excellent immunomodulator for HIV 
prophylactic and therapeutic vaccines. 
P12.07
CD4+ Th17 and Treg Subsets During Acute/
Early HIV Infection Are Associated with Distinct 
Patterns of Disease Progression and Anti-HIV 
CD8+ Responses
J. Falivene3, Y. Ghiglione3, N. Laufer3, M.E. Socías1, J. Ruiz3,  
P. Cahn2, O. Sued2, H. Salomón3, G. Turk3, and M.M. Gherardi3
1Fundación Huésped, Buenos Aires, Argentina; 2Hospital 
Juan A. Fernández, Buenos Aires, Argentina; 3Instituto de 
Investigaciones Biomédicas en Retrovirus y Sida, Facultad de 
Medicina, UBA-CONICET, Buenos Aires, Argentina
Background: Th17 and Treg subsets have been related to HIV/SIV 
disease progression. Their role and direct relation with specific HIV-
adaptive T cell responses during primary HIV-infection (PHI) are largely 
unexplored topics. Aim: To analyze Th17 and Treg subsets, their 
balance and correlation with clinical parameters and specific anti-HIV 
responses during acute/early infection.
Methods: PBMCs were obtained from 6 healthy donors (HDs) and 22 
HIV infected-subjects: 6 elite controllers (ECs), 4 chronics, and 12 PHIs 
(within 6 months post-infection (mpi)). PHIs were classified as “PHI350” 
if CD4-counts dropped below 350 cells/ul within 12 mpi. Th17 and 
Treg cells (baseline and 12 mpi samples) were identified as CD3+CD4+ 
IL-17+ or CD25+FoxP3+ (respectively). Data was compared inter/intra-
groups and correlated to viral load (VL) and CD4-counts (baseline, 
set-point and 12 mpi), and specific anti-HIV CD8+ responses, using 
parametric and non-parametric statistics.
Results: Baseline CD4 (p=0.0669, r=0.3885) and set-point (p=0.0486, 
r=0.5) counts were directly correlated with baseline Th17 absolute 
counts, which were found to be higher in PHI350 vs. PHI350. Moreover, 
VL levels at 12 mpi inversely correlated with baseline (p=0.0406, 
r=-0.5965) and 12 mpi (p=0.0208, r=-0.6309) %Th17. Th17/Tregs 
ratio was higher for HDs compared to any HIV+ group (p<0.01), and 
within PHIs Th17/Tregs was directly associated with CD4-counts at 
12 mpi (p=0.0167, r=0.7928). Significantly, Th17 and quality of anti-
HIV T-CD8+ responses were directly associated, thus higher baseline 
%Th17 correlated with a higher CD8+-mediated viral inhibitory activity 
at 12 mpi (p=0.0036, r=0.8289). Moreover, Th17 counts at 12 mpi 
also related with anti-HIV CD8+ responses (% of HIV CD8+/CD107+/
IFN-gamma+ cells, p= 0.0238, r=0.8469).
Conclusion: Results suggest that higher counts and frequency of 
Th17 and Th17/Tregs ratio at early stages after HIV-infection are 
associated with slower disease progression in terms of clinical 
parameters. Importantly, preservation of Th17 compartment 
associates with the capacity to exert specific anti-HIV CD8+ 
responses at later times post-infection.
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P12.10
Development of Apoptosis Resistance During 
Acute HIV Infection
P. Fernandez-Larrosa1, M. Chertoff1, C. Espada1, M. Vacotto1, and 
L. Martinez Peralta1
1IMPaM, Buenos Aires, Argentina
Background: Reservoir cells protection is clue during HIV infection. 
However, in spite of the relevance of these reservoir cells in the control 
of viral persistence, how and when apoptosis resistance of persistently-
infected cells occurs is not well understood. Persistently infected 
cell lines showed to be apoptosis resistant under stress conditions, 
involving the intrinsic pathway (Fernandez Larrosa et al, Retrovirology, 
2008 6 19). The goal of this work was to evaluate the dynamics of the 
achievement of the resistant phenotype in HIV acute infected cells.
Methods: Jurkat cells were infected with HIV (HXB2 strain) at moi= 
1TICD/cell, treated with H2O2 as apoptosis-inducer, at different times 
postinfection (pi), and compared with uninfected (control) cells. Cell 
viability, p24+ production and apoptosis were evaluated by annexin/
IP staining, PMM, and caspase-3 activation by cytometry analysis. 
Caspase-9, bcl-2 and bax were analyzed by WB. 
Results: In Jurkat cells, infection didn´t induce an increase in apoptosis 
levels (∼10% AV+/IP- cells) during the first 5 days pi. H2O2 treatment 
was associated to 15%  apoptosis level in control cells, 12% in infected 
cells from day 3pi, with 9% from day 5pi (p<0.05). Mechanistic 
analysis in H2O2 treated cells revealed a significant decrease in 
caspase-3 activation (12% in control cells & 5% in day 5pi in infected 
cells, p<0.05) and a clear tendency in reduction in PMM (12% & 7%), 
caspase-9 activation ratio (2.5 % 1.5) and an increase in bcl-2/bax 
ratio (1.8 & 4).  The percentage of HIV infected cells (p24+ cells) was 
the same at day 3 or 5 pi. 
Conclusion: These results show that during a very early phase of 
acute infection, HIV infected cells show apoptosis protection to stress 
condition, and that this resistance involves modulation of the intrinsic 
pathway, similar to persistently infected cells.  This in vitro resistance 
could help to understand the dynamics of HIV reservoir. 
P12.09
Soluble CD40 Ligand Plays an 
Immunosuppressive Role in HIV Infection via 
IDO-Induced Tryptophan Catabolism, Treg 
Expansion and Microbial Translocation
M. Jenabian1, M. Patel1, I. Kema2, C. Kanagaratham3, D. Radzioch1, 
P. Thébault3, R. Lapointe3, C. Tremblay3, N. Gilmore1, P. Ancuta3, 
and J. Routy1
1McGill University Health Centre Research Institute, Montreal, 
Canada; 2University Medical Center, University of Groningen, 
Groningen, Netherlands; 3University of Montreal and CHUM 
Research Institute, Montreal, Canada
Background: CD40/CD40-ligand (CD40L) signaling is a key pathway 
which triggers the tryptophan (Trp) catabolizing enzyme IDO in 
dendritic cells and is immunosuppressive in cancer. We reported a 
higher IDO enzymatic activity and Trp catabolism in ART-Naïve patients 
resulting an imbalance of Th17/Treg and microbial translocation. Here 
we assessed the link between sCD40L, Tregs and IDO activity inHIV-
infected patients with different clinical outcomes.
Methods: Plasmatic levels of soluble CD40L (sCD40L) and 
inflammatory cytokines were measured by Beadlyte Multiplex in 
ART-naive, ART-successfully treated (ST), elite controllers (EC) and 
healthy controls (HS) (n=14 per group). Plasmatic levels of Trp and 
its metabolite Kynurenine (Kyn) were measured by isotope dilution 
tandem mass spectrometry and sCD14, a microbial translocation 
marker, was assessed by ELISA. IDO-mRNA expression was quantified 
by RT-PCR. The in vitro functional assay of sCD40L on Tregs induction 
and T cell activation (CD38/HLADR/PD-1) were assessed on PBMCs 
from HS (n=10). Wilcoxon matched pairs, Mann-Whittney and Pearson 
tests were used for Statistical analyses. 
Results: sCD40L levels in ART-Naïve subjects were significantly higher 
compared to ST and HS (1305±876 vs 503±626 and 442±270 pg/
mL; P=0.002) whereas EC showed a minor increase (969±944 pg/mL, 
P>0.05).In ART-Naïve, sCD40L was negatively correlated with CD4 T 
cell counts but not with viral load.sCD40L was positively correlated 
with IDO enzymatic activity (Kyn/Trp ratio) (P=0.004),Treg frequency 
(p=0.009), plasma sCD14 (P=0.04) and inflammatory cytokines IL-
1b, IL-6, IL-10 and IL-15 in all HIV-infected patients. Such correlation 
with IDO quantity (IDO-mRNA expression) was observed only in ART-
naïve (P=0.02). In vitro functional sCD40L stimulation induced Tregs 
expansion (P=0.04) and favoured Treg differentiation by reducing 
central memory (P=0.025) and increasing terminal effector Tregs 
(P=0.006) without impacting T cell activation defined by combination 
of CD38/HLADR/PD-1.
Conclusion: These results indicate that elevated sCD40L induce 
immuno-supression in HIV infection by mediating IDO-induced Trp 
catabolism, Treg expansion and microbial translocation.
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P12.12
Structure Prediction of Peptide-MHC 
Complexes for Identifying Immunogens 
Inducing Broad T Cell Reactivity
M. Park1, S. Park3, K. Miller2, E. Collins2, and H. Lee3
1Howard Hughes Medical Institute, Chevy Chase, MD, USA; 
2University of North Carolina at Chapel Hill, Chapel Hill, NC, 
USA; 3Kech School of Medicine, USC, Los Angeles, CA, USA
Background: Designing an optimal HIV-1 vaccine faces the challenge 
of identifying antigens that induce a broad immune capacity. The 
surface morphology of peptide-MHC complex is one of the key 
factors controlling the breath of reactive T cell population. Therefore, 
accurately determining the structure of pMHC can help to predict 
robust T cell reactivity.
Methods: Here, we present an in silico protocol for predicting peptide-
MHC structure. For the 17 test peptide-MHC complexes, a starting 
configuration of each complex was chosen by homology modeling. 
We then performed all-atom MD simulations on the ensemble 
of peptide-MHC conformations obtained by simulated annealing 
techniques. A robust signature of a conformational transition was 
identified during all-atom molecular dynamics, which results in a 
model with high accuracy. 
Results: Our protocol showed that the average all atom root mean 
square deviation for the 17 test peptides to each X-ray structure was 
1.58 Å. This protocol was used for a blind prediction test with a wild-
type peptide (KVAELVHFL) and its two highly immunogenic mutants 
(KVAEIVHFL and KVAELVWFL). The blind test predicted that the 
center residues at position five of the analogs were configured to be 
accessible to solvent, forming a prominent surface, while the residue 
of the wild-type peptide was to point laterally towards the side of the 
binding cleft. The high resolution X-ray crystallography data verified 
these substantial conformational changes in both mutants.
Conclusion: Our observation strongly supports a positive association 
of the surface morphology of a peptide-MHC complex to its 
immunogenicity, offering the prospect of enhancing immunogenicity 
of vaccines by characterizing the conformation of MHC binding 
peptides. Our protocol is applicable for screening antigens to optimize 
vaccines for not only HIV infection but also other pathogenic infections 
and cancer where the breadth of T cell responses is pivotal for the 
outcome of the diseases. 
P12.11
Defining Efficacious HIV-Specific Cytotoxic 
T Lymphocyte Responses Using Saporin-
Conjugated Peptide-MHC Tetramers
E.M. Leitman1, S. Sims1, R.P. Payne1, E. Adland1, H.N. Kløverpris1, 
A. Stryhn2, F. Chen3, L. Riddell4, S. Buus5, P.C. Matthews1, and  
P.J. Goulder1
1University of Oxford, Oxford, UK; 2University of Copenhagen, 
Copenhagen, Denmark; 3Royal Berkshire Hospital, Reading, 
UK; 4Northamptonshire Healthcare National Health Service 
Trust, Northampton General Hospital, Northampton, UK; 
5Laboratory of Experimental Immunology, Faculty of Health 
Sciences, University of Copenhagen, Copenhagen, Denmark
Background: In vitro killing of HIV-infected cells by CD8+ cytotoxic 
T lymphocytes (CTL) is a surrogate marker of CTL antiviral efficacy. 
Tetrameric peptide-MHC complexes (tetramers) enable identification 
of antigen-specific CD8+ T cells in a mixed population. Due to the 
rapid internalization of tetramers by cognate T cells, tetramers are an 
attractive delivery vehicle to target specific CTL. Conjugating tetramers 
to saporin, a potent cytotoxin that inactivates ribosomal activity, we 
have optimized an assay to selectively eliminate CTL of different 
specificities. This approach facilitates rapid comparison of the antiviral 
potency of several distinct CTL specificities and identification of the 
most efficacious anti-HIV responses.
Methods: Human peripheral blood mononuclear cells (PBMC) 
were incubated with HLA-matched or mismatched saporin-coupled 
tetramers (tet-SAP) or free saporin for 2h, washed and further cultured 
for up to 96h before cell loss was quantified by flow cytometry after 
labeling with corresponding phycoerythrin-coupled tetramers (tet-
PE). We then superinfected human CD4-enriched PBMC from long 
term non-progressors with NL4-3 and cultured alone, with whole 
autologous PBMC, or with ‘tetramer-zapped’ autologous PBMC. Viral 
inhibition was assessed by p24 intracellular staining and ELISA over 
a 10-day time course.
Results: Tet-SAP but not free saporin binds to the surface of antigen-
specific CD8+ T cells and is internalized by these cells. By 48h post-tet-
SAP treatment, up to 97% of tetramer-specific cells are eliminated from 
the diverse CTL population. Preliminary viral inhibition assays indicate 
that selective elimination of different CTL specificities has a significant 
impact on antiviral activity.
Conclusion: We have optimized a novel method to eliminate CTL of 
different specificities in vitro and thereby measure their individual 
contribution to viral suppression. This rapid and cost-efficient method 
will enable us to discriminate between the most efficacious and futile 
CTL responses in HIV infection – knowledge that may increase our 
chances of developing a therapeutic vaccine. 
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P12.14
Memory CD4 T Cells Provide Help Following 
Acute Viral Challenge, but Promote Lethal 
Immunopathology Following Chronic Viral 
Challenge
P. Penaloza-MacMaster1, E.J. Wherry2, D.L. Barber3, J.E. Teigler1, 
N.M. Provine1, and D.H. Barouch4
1Beth Israel Deaconess Medical Center, Harvard University, 
Boston, MA, USA; 2University of Pennsylvania, Philadelphia, 
PA, USA; 3NIAID, NIH, Bethesda, MD, USA; 4Ragon Institute of 
MGH, MIT and Harvard, Cambridge, MA, USA
Background: An understanding of the contribution of memory T 
cells following acute or chronic viral infections may be critical for 
the rational design of vaccines against HIV and other pathogens. We 
have analyzed the individual contribution of memory CD4 T cells 
following acute or chronic lymphocytic choriomeningitis virus (LCMV) 
infection in mice.
Methods: 6-8 week old C57BL6 mice (Jackson) were immunized 
intraperitoneally (i.p.) with 10^6 CFU of Listeria monocytogenes 
expressing the CD4 epitope GP61-80 (LMgp61), derived from LCMV. 
Around day 60, mice were challenged with acute (Armstrong) or 
chronic (Cl-13) LCMV, and immune responses were analyzed by flow 
cytometry, ELISA, luminex, and plaque assays.
Results: Immunization with a single CD4 T cell epitope (GP61) 
derived from LCMV resulted in contrasting outcomes depending if 
the viral challenge was acute or chronic. As expected, memory CD4 
T cells provided a helper function following an acute viral challenge, 
evidenced by enhanced Tem to Tcm conversion of virus-specific 
CD8 T cells, accelerated B cell responses, and slightly improved viral 
control. However, following a chronic viral challenge, memory CD4 T 
cells induced severe immune pathology characterized by progressive 
emaciation and death. Strikingly, this unexpected mortality was 
associated with bystander T cell activation, impaired maintenance of 
CD8 T cell and B cell responses, accelerated destruction of lymphoid 
tissues, lymphopenia, severe intestinal damage, and overall decline in 
CD4 T cell counts (despite the expansion of LCMV-specific CD4 T cells). 
Importantly, co-immunization with a vaccine that generated robust 
antiviral control by CD8 T cells responses, transfer of virus-specific 
CD8 T cells, or antibody-mediated depletion of CD4 cells prevented 
mortality following chronic viral challenge.
Conclusion: Following an acute viral challenge, memory CD4 T 
cells provided a helper function. However, following a chronic viral 
challenge, memory CD4 T cells became dysregulated and mediated 
a lethal immunopathology in the absence of protective CD8 T cells.
P12.13
Adaptation to HLA-I Is a Primary Correlate of 
HIV-1 Disease Progression
J.M. Carlson1, N. Pfeifer1, M. Schaefer2, C. Brumme3, A. Kreimer1, 
C. DeZiel1, V. Tan1, M. John4, S. Mallal4, T. Ndung’u5, J. Gilmour6, 
M. Price6, S. Lakhi7, R. Harrigan3, T. Miura8, P. Goulder9,  
Z. Brumme10, D. Heckerman1, and E. Hunter2
1Microsoft Research, Los Angeles, CA, USA; 2Emory 
University, Atlanta, GA, USA; 3BC Centre for Excellence in 
HIV/AIDS, Vancouver, Canada; 4Murdoch University, Perth, 
Australia; 5University of KwaZulu-Natal, Durban, South 
Africa; 6IAVI, London, UK; 7Zambia-Emory HIV Research 
Project, Lusaka, Zambia; 8University of Tokyo, Tokyo, Japan; 
9University of Oxford, Oxford, UK; 10Simon Fraser University, 
Burnaby, Canada
Background: The extent to which cellular immune escape mutations 
impact HIV disease is unknown. We developed an adaptation score 
based on a novel multistate, phylogenetically-corrected logistic 
regression model that estimates the probability of an HIV sequence 
given an HLA class I repertoire. 
Methods: An HLA allele-specific adaptation score was derived by 
comparing the probability of the sequence with and without the allele, 
conditioned on the other alleles expressed by the individual, and was 
averaged to produce a score for the individual’s class I repertoire. 
Models were trained on 1,888 full-proteome clade B and 2,083 Gag/
Pol/Nef clade C sequences. Associations with VL and CD4 were assessed 
out of sample using cross-validation and in independent cohorts of 
elite controllers and linked transmission pairs. All associations were 
conditioned on HLAs using stepwise regression.
Results: Adaptation was a more significant predictor of both VL 
(pCladeC=6E-12, NCladeC=1461; pCladeB=9E-6, NCladeB=1025) and CD4 
(pCladeC=4E-13, NCladeC=1260; pCladeB=1E-11, NCladeB=1025) than any HLA 
allele. Adaptation score correlated with VL and CD4 independently, 
and remained significant in the context of CTL responses to sets of 
overlapping peptides (pVL=0.002, pCD4=0.0001, N=435). Importantly, 
adaptation neutralizes the protective effects of all known protective 
alleles except A*74. Adaptation was significantly lower among 23 
elite controllers than 78 progressors (p=0.0006, B57+ p=0.02, B57-/
B27- p=0.008). Among transmission pairs, adaptation of the donor 
sequence to HLA alleles expressed by the recipient predicted higher 
VL 24 months post transmission (r=0.34, p=0.002, N=81) and shorter 
time to CD4<250 (HR=3.45, p=0.01); adaptation at 3, 6, 12 and 18 
months post transmission predicted subsequent changes in VL.
Conclusion: HLA-mediated adaptation is a primary correlate 
of disease progression in chronic HIV-1 infection and predicts 
subsequent VL increases and rate of CD4 decline in a longitudinal 
transmission pair cohort. Vaccine strategies that reduce the incidence 
of escape may be imperative.
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P12.16
Distribution of HIV-Specific and Total CD8+ 
T Cell Memory Phenotypes During Acute/
Early HIV Infection Is Associated with Disease 
Progression
Y. Ghiglione1, J. Falivene1, M.J. Ruiz1, N. Laufer2, M.E. Socias3,  
P. Cahn1, O. Sued1, H. Salomón1, M.M. Gherardi1, and G. Turk1
1Instituto de Investigaciones Biomedicas en Retrovirus y 
SIDA Universidad de Buenos Aires, Buenos Aires, Argentina; 
2Hospital Juan A. Fernández, Buenos Aires, Argentina; 
3Fundación Huesped, Buenos Aires, Argentina 
Background: Memory CD8 + T cells are important components 
of protective immunity. Understanding their development during 
primary HIV-infection (PHI) would contribute to optimal vaccine 
design. Aim: To analyze total and HIV-specific CD8 + T cell 
differentiation phenotypes, during acute/early infection, and their 
correlation with clinical parameters.
Methods: Twelve HIV + seroconverters (PHI group), 6 elite controllers 
(EC) and 4 Chronics were enrolled. Seroconverters were classified as 
“PHI<350” if CD4 count dropped below 350 cells/ul within 12 months 
post-infection. Phenotypic (CD45RO, CCR7) and functional markers 
(cytokines) were used to identify total and HIV-specific CD8 + memory 
populations. Data was compared inter-groups and correlated to viral 
load (VL), CD4 counts and both virological and immunological set-
points, using non-parametric statistics.
Results: The CD8 + T cell differentiation hierarchy was terminal 
effectors (T E)>naïve (T naive)>effector memory (TEM)>central memory 
(T CM) in all groups. However, EC showed higher proportion of T naive 
(38.3%) compared to Chronics (17.44%, p=0.0027) and PHI subjects 
(29.63%, p>0.05). EC had the lowest proportion of TE   cells (53.18%). 
TEM   was higher in Chronics (19.09%) compared to EC (4.71%, 
p=0.0046) and PHI (4.59%, p=0.0001). Regarding HIV-specific CD8 + 
T cell compartment, the same significant trends were observed among 
groups. Moreover, PHI>350 had two-fold higher proportion of T naive-
like   cells than PHI<350 (17.14% vs 9.2%). Spearman‘s correlation 
within PHI group showed that the proportion of total Tnaive   was 
directly associated with baseline CD4 count (p=0.007) and inversely 
with immune activation (p=0.0099). Conversely, percentage of TEM 
inversely correlated with baseline CD4 count (p=0.0035), immune set-
point (p=0.0006) and directly with immune activation (p=0.0022). The 
same significant associations were observed within the HIV-specific 
compartment. Additionally, HIV-specific TME   directly correlated with 
viral set-point (p=0.0269).
Conclusion: Results suggest that a less differentiated memory profile 
at early stages post-infection is associated with a slower disease 
progression, in terms of CD4 count and VL, indicating that not only 
CD8 + function but also phenotype is associated with disease control.
P12.15
PHPC T Cell Responses in Macaques 
Vaccinated with a Single Dose of a Novel Non-
integrative One Cycle Limited SHIV-Based DNA 
Vaccine
G. Arrode-Bruses1, M. Moussa1, A.  Malogolovkin1,  
M. Bacard-Longere2, and Y. Chebloune1
1Universite Joseph Fourier-CNRS, Saint Martin d’Heres, France; 
2Laboratoire de Virologie, CHU de Grenoble, Institut de 
Biologie, Grenoble, France
Background: Innovative strategies/vectors to induce immune responses 
that are capable of containing persistent infectious pathogens such as 
HIV-1 are hardly needed. Variety of vectors has been used in animal 
models of HIV vaccine but they fail to recapitulate the efficacy of Live-
attenuated vaccines. These latter are unsafe to be used in humans. 
In this work, we developed a novel lentiviral-based DNA vector non-
integrating and undergoing a single cycle of replication: CAL-SHIV-IN-.
Methods: Macaques were immunized with a single dose of CAL-SHIV-
IN- DNA by intramuscular and intradermal routes of injection plus 
electroporation. We assessed the vaccine induced T cells responses 
on PBMCs directly ex vivo or after culture of 12 days in vitro under 
antigenic and homeostatic driven proliferation conditions. We used 
conventional INF-γ ELISPOT assay to measure immediate cytokine 
secretion from antigen specific effector cells and from memory 
Precursor with High Proliferative Capacity (PHPC). We further identified 
vaccine-specific T cells and determined their memory phenotype and 
functions (proliferation, cytokines expression) with multiparametric 
FACS based assays.
Results: We found that all immunized macaques developed and 
maintained peripheral CD8+ and CD4+ T cells responses mainly 
against Gag and Nef antigens. After an extensive time following 
initial immunization (week 40 to 47), in absence of persistent antigen 
stimulation, all vaccinated macaques showed strong PHPC responses 
containing vaccine specific central memory and effector memory T 
cells that have expanded and acquired immediate effector functions. 
Conclusion: We demonstrated that a single dose delivery of a 
one cycle replication SHIV-based DNA lentivector allowed efficient 
generation and maintenance of PHPC T cell responses with both 
memory and effector cell characteristics. Importantly, PHPC 
responses have been detected in HIV Elite controllers and found to 
be associated with central memory responses. Thus, the evaluation 
of T cell responses by PHPC assay might be an attractive tool for the 
testing of prophylactic vaccines.
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P12.18
The Use of HLA Class II Associated HIV 
Polymorphisms in Predicting Novel CD4 T Cell 
Responses and Viral Escape
N. Erdmann1, V. Du1, J. Carlson2, E. Hunter3, and P. Goepfert1
1University of Alabama at Birmingham, Birmingham, AL, USA; 
2Microsoft Research, Seattle, WA, USA; 3Emory Vaccine Center, 
Atlanta, GA, USA
Background: CD4 T cells are the primary targets of HIV infection; 
however, their role in controlling viral replication remains unclear. 
We hypothesized that HIV adapts in response to CD4 T cell mediated 
immune pressure.
Methods: Using HIV sequence data and HLA-II alleles, we applied 
a novel computational approach to identify HIV-1 polymorphisms 
disproportionately associated with HLA-II alleles in a large African 
cohort of chronically HIV-infected individuals. Using this approach, 
we identified 17 HLA class-II associated adaptations. A panel of 34 
predicted adapted and nonadapted CD4 T cell epitopes (15-20mer) 
encompassing the identified polymorphisms were synthesized 
and evaluated for immunogenicity. Peripheral Blood Mononuclear 
Cells (PBMCs) from 10 uninfected controls, 20 chronically infected 
individuals on ART, 11 HIV-controllers (ART naive, viral load <2000) 
and 8 HIV non-controllers (ART naive, viral load >10,000) were 
depleted of CD8+ cells and CD4+ T cell responses were quantified 
using interferon-γ ELISpot assay.
Results: The median magnitude (SFC/10^6 cells) of HIV-specific CD4 
T cell responses seen in controllers (451; Range 70-2123) was higher 
compared to non-controllers (223; Range 60-997) p=0.004, and tended 
to be higher compared with ART treated individuals (343; Range 55-
1303).  Positive pool responses were mapped to the individual peptide. 
Some, but not all individuals encoded the HLA-II alleles associated 
with the predicted HIV polymorphism biologically confirming the CD4 
T cell epitope predictions.  The magnitude of responses for the adapted 
epitopes was lower compared to non-adapted epitopes (P=0.0003).
Conclusion: We have applied a novel computational approach 
to identify novel HLA class-II epitopes enabling us to correlate 
the magnitude and breadth of CD4 T cell responses with HIV 
progression. The finding that adapted peptides had significantly 
lower responses also lend credence to the use of HLA-II associated 
HIV polymorphism analysis in predicting CD4-mediated viral 
evolution. Our findings will help identify novel CD4 T cell targets 
relevant to future HIV vaccine design.
P12.17
Mapping and Characterization of HIV-1 Specific 
Immune Responses Present in Highly HIV 
Exposed Uninfected Individuals
A. Crespo Guardo3, M. Ruiz-Riol1, E. Fernández3, M. Maleno3,  
A. León3, M. Bargalló3, J. Gatell3, C. Brander2, and M. Plana3
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2IrsiCaixa Institute for AIDS Research, HIVACAT, 
ICREA, Barcelona, Spain; 3Hospital Clínic, IDIBAPS, HIVACAT, 
Barcelona, Spain
Background: To evaluate the specific T cell immune response in highly 
HIV exposed seronegative individuals (HESN). Previously reported 
data indicate that virus-specific responses are rarely detected by 
conventional approaches. We report here the reproducible detection of 
cellular immune responses in HESN by two novel and improved assays 
that could inform further development of a preventive HIV vaccine. 
Methods: HIV-specific T cell responses were analyzed by ELISPOT in 
PBMC from HESN after a 48h-co-culture with “accelerated” dendritic 
cells (acDC) in the presence of IL4 and GM-CSF and maturation cocktail. 
Additionally, a “boosted” flow cytometry approach was employed to 
more comprehensively capture the anti-viral T cell response to HIV by 
combining the detection of several effector functions into the same 
fluorescence channel. 
Results: Of 29 HESN individuals tested, 11 (38%) showed at 
least one response to peptide pools covering HIV Gag and Nef. 
Additionally, using VSV-pseudotyped HIV RT-defective vector 
as antigen source, positive responses were seen in almost 20% 
of the individuals tested. A positive correlation was observed 
between the intensity (p=0.0007) and magnitude (p=0.0137) of 
the response detected in the HESN and the viral load of the HIV+ 
partner. Moreover, the result from the boosted flow and cytomix 
analyses showed a dominant “Th1”- like response pattern against 
HIV antigens in both, CD8 and CD4 T cell populations.
Conclusion: The combined use of our improved acDC technique with a 
boosted flow cytometric approach allows to detect specific HIV positive 
responses in a higher percentage of individuals than generally seen 
with standard assays and to define specific effector function profiles in 
responses from HESN. The validity of the data is further validated by 
the positive correlation between the strength of the elicited response 
and the viral load of the sexual partners. 
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P12.20
HLA-Specific Intracellular Epitope Processing 
Mechanisms Shape an Immunodominance 
Pattern for HLA-B*57 that Is Distinct from 
HLA-B*58:01
H. Kløverpris1, A. Stryhn2, M. Harndahl2, A. Leslie3, B.D. Walker4, 
T. Ndung’u5, S. Buus2, and P. Goulder6
1K-RITH,  University of KwaZulu-Natal, Durban, South 
Africa; 2University of Copenhagen, Copenhagen, Denmark; 
3K-RITH, Nelson R. Mandela School of Medicine, University 
of KwaZulu-Natal, Durban, South Africa; 4Ragon Institute 
of MGH, MIT and Harvard, Boston, MA, USA; 5Doris Duke 
Medical Research Institute, University of KwaZulu-Natal, 
Durban, South Africa; 6University of Oxford, Oxford, UK
Background: HLA-B*57 is strongly associated with immune control 
of HIV and delayed AIDS progression. The closely-related, but less 
protective, HLA-B*58:01 presents similar epitopes, but HLA-B*58:01 
positive individuals do not generate CD8+ T cells targeting the KF11-
Gag epitope linked with low viraemia.
Methods: We tested KF11 peptide binding affinity, off-rate, tetramer 
staining and presentation from HLA-B*57:01, B*57:03 and B*58:01 
along with KF11 epitope processing from HIVNL4-3   infected CD4+ T 
cells to KF11 specific CD8+ T cells. 
Results: Here we show that HLA-B*58:01 binds and presents KF11 
peptide, but fails to process KF11 in HIV-infected cells. However, HIV 
infected individuals heterozygous for HLA-B*57:03/B*58:01 do make 
KF11 specific CD8+ T cells, suggesting that HLA-B*58:01 does not 
abrogate KF11 epitope processing in vivo.
Conclusion: This unexpected finding demonstrates that immuno-
dominance patterns can be influenced by intracellular events inde-
pendent of HLA binding motifs.
P12.19
Cross-Clade CD8+ T Cell Responses in 
Chronically HIV-1 Clade A/E-Infected 
Individuals
H. Murakoshi1, K. Watanabe2, Y. Tamura1, M. Koyanagi1,  
T. Chikata1, H. Gatanaga2, S. Oka2, and M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Tokyo, 
Japan; 2AIDS Clinical Center, National Center for Global 
Health and Medicine, Tokyo, Japan
Background: Cytotoxic T lymphocytes (CTLs) that can recognize 
HIV-1 variants are one of key factors for the development of a 
widely applicable AIDS vaccine. Although CTL responses to HIV-1 
clade B and C were well studied, there are only a limited number of 
studies about the cross-clade reactivity of CTLs. In the present study, 
we investigated cross-clade CD8 + T cell responses between clade 
B and A/E viruses in chronically HIV-1 clade A/E-infected Japanese 
individuals.
Methods: We analyzed cross-clade CTL responses by using 11-mer 
overlapping HIV-1 peptides derived from the clade B consensus 
sequence spanning Nef, Gag, and Pol regions, and identified cross-
clade epitopes. We analyzed cross-clade CTL recognitions for cells 
infected with clade B or A/E viruses by using an intracellular cytokine 
staining assay and finally confirmed cross-clade CD8 + T cells in 28 
clade A/E-infected individuals by using an ELISPOT assay.
Results: CD8 + T cell responses to 11-mer overlapping peptides derived 
from clade B were at a similar level to those to the same peptides found 
in 401 clade B-infected individuals. Fifteen cross-clade CTL epitopes 
were identified from 13 regions where the frequency of responders 
was high in the clade A/E infected-individuals. The sequences of 6 
epitopes were conserved between clade B and A/E viruses, whereas 9 
epitopes had different amino acid sequences between the 2 viruses. 
CD8 + T cells specific for 8 diverse epitopes recognized both the clade 
A/E virus-infected and clade B-infected cells. All of the cross-clade CD8 
+ T cells specific for conserved and diverse epitopes were detected in 
chronically HIV-1 clade A/E-infected individuals.
Conclusion: These results showed that cross-clade CD8 + T cells were 
frequently elicited in HIV-1-infected individuals and that in addition to 
conserved regions polymorphic ones across the clades can be targets 
for cross-clade CTLs. The present study highlights cross-clade epitopes 
for potential use in widely applicable CTL vaccines.
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P12.22
Cryptic Epitopes Restricted by Protective 
HLAs (B*57, B*5801 and B*27) Are Frequently 
Targeted in Chronic HIV Infection  
A. Bansal1, T. Mann1, S. Sterrett1, A. Bet1, J. Carlson2, and  
P. Goepfert1
1University of Alabama at Birmingham, Birmingham, AL, USA; 
2Microsoft Research, Los Angeles, CA, USA
Background: Cryptic Epitopes (CE) are peptides derived from the 
translation of one or more of the five alternative reading frames (ARFs; 
2 sense and 3 antisense) of existing genes and are commonly targeted 
during HIV/SIV infection.  In this study, we aimed to understand the 
role of HIV specific CE predicted to be restricted by protective alleles 
in HIV-1 pathogenesis.
Methods: Peptides (9-11mer) were formulated based on binding 
algorithms for HLA-B*27, B*57 or B*5801 (protective alleles or PA) and 
HLA-B*5301 (non-protective allele or NPA).  Peptides encompassing 
all five ARFs of each of the nine HIV-1 encoded proteins and with 
>50% probability of being an epitope were synthesized and tested for 
immunogenicity; B*27 (N=30), B*57 (N=39), B*5801 (N=90) and 72 
(B*5301).  Majority of these peptides were encoded by antisense ARFs 
(p=0.005 X10-49).  PBMC from HIV seronegative donors (N=42) and 
chronic HIV clade B infected patients (CHI, N=127 total) were used to 
evaluate T cell responses in an IFN-g ELISpot and ICS assay.
Results: Among the PA group (N=87), a majority of patients were B*57 
(57%) and were off ART (56%).  Overall, 22% and 2% of CHI patients 
had CE responses in the PA and NPA group respectively (p=0.006, 
Fischer’s exact).  Seronegative donors had a 2% response to CE.  In 
PA group, 21 novel CE specific responses were mapped (median 
magnitude of 95 SFC/106 PBMC).  These responses were detected in 
patients regardless of ART.  In an ICS assay, CE responses elicited IFN-g, 
TNF-a and Granzyme B production.  CE specific responses also showed 
proliferative capacity in a 5 day CFSE based assay.  The median VL 
off ART for responders and non-responders in the PA group was not 
statistically different.  
Conclusion: These data underscore the importance of CE targeting 
especially those that are presented by the so-called “protective alleles” 
in HIV-1 infection and hence have implications for vaccine design.  
P12.21
Increased Cytotoxic Capacity of 
Immunodominant HIV-Specific CD8+ T Cell 
Responses Is Associated with Immune Control 
Regardless of HLA Type
S.A. Migueles1, M.G. Zimmerman1, D. Mendoza1, S.A. Toulmin1, 
E.P. Kelly2, and M. Connors1
1NIAID, NIH, Bethesda, MD, USA
Background: HIV-specific CD8+ T cell cytotoxic responses have been 
implicated in the control of HIV replication in B*27/57+ long-term 
nonprogressors / elite controllers (LTNP/EC).  To determine whether 
most LTNP/EC regardless of HLA type control HIV replication by a 
similar mechanism, we measured the immunodominant HIV-specific 
CD8+ T cell responses and assessed their cytotoxic capacity in 
B*27/57-negative and B*27/57+ LTNP/EC.
Methods: Peripheral blood mononuclear cells from 23 B*27/57-
negative and 23 B*27/57+ LTNP/EC were stimulated with overlapping 
15-mer peptides spanning Nef, Gag, and Pol and analyzed for 
intracellular IFN-γ accumulation by flow cytometry. Determination 
of optimal epitopes targeted by dominant responses was performed 
with peptide truncations. HIV-specific CD8+ T cell-cytotoxic responses 
to autologous HIV-infected CD4+ T cell targets were measured by 
flow cytometric detection of granzyme (Gr) B delivery to live targets 
and infected CD4 elimination (ICE) in 17 B*27/57-negative and 18 
B*27/57+ LTNP/EC.  HLA restriction was assessed with heterologous 
targets matched at a single HLA allele. 
Results: Although the magnitude of the total HIV-specific CD8+ T 
cell response following 6-hour stimulation was equivalent between 
B*27/57-negative and B*27/57+ LTNP/EC (p>0.05), the optimal 
epitopes targeted by the immunodominant responses were variable. 
Following 6-day stimulation, bulk cytotoxic responses of B*27/57-
negative and B*27/57+ LTNP/EC were similar based on GrB target cell 
activity (p>0.5) and ICE (p>0.05).  The constituent dominant cytotoxic 
responses differed between B*27/57-negative and B*27/57+ LTNP/
EC and were largely mediated by the immunodominant specificities 
determined in the 6-hour assays.
Conclusion: Even though the epitopes targeted by immunodominant 
HIV-specific CD8+ T cell-responses differed between B*27/57-negative 
and B*27/57+ LTNP/EC, the increased cytotoxic capacity of these 
responses was comparable between the groups, suggesting a common 
mechanism of immune control. These results provide reason for 
optimism regarding the T cell component potentially stimulated by 
HIV vaccines by showing that robust HIV-specific CD8+ T cell cytotoxic 
responses can also be induced in individuals who are not B*27/57+.
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P12.24
Dual Recognition of Cells Infected with Wild-
Type and Escape Mutant Viruses by Cytotoxic 
T Cells Recognizing Overlapping 8-Mer and 10-
Mer Nef Peptides
X. Sun1, Y. Shi2, M. Fujiwara1, N. Kuse1, S. Oka3, F.G. Gao2, and 
M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan; 2Chinese Academy of Sciences, Beijing, China; 3National 
Center for Global Health and Medicine, Tokyo, Japan
Background: It is assumed that presentation of overlapping peptides 
induces different CTL responses to these peptides which may 
contribute to effective control of HIV-1 replication and selection of 
escape. However, the recognition of HIV-1-infected cells infected with 
wild-type and escape mutant viruses by these CTLs has not been well 
studied. We here investigated immunological and structural aspects 
of recognition of HIV-1-infected cells by HLA-A 24:02-restricted CTLs 
for 2 overlapping Nef epitopes (Nef138-8: RYPLTFGW and Nef138-10: 
RYPLTFGWCF).  
Methods: Abilities of CTLs to suppress HIV-1 replication and to select 
escape mutation were investigated by HIV-1 replication assay and 
competitive one, respectively. The frequency of specific T cells was 
measured by tetramer staining. Crystals of HLA-A *24:02 molecules 
with the peptides were grown using hanging drop method and the 
structures were determined by X-ray diffraction.  
Results: Tetramers binding analysis revealed no cross-recognition 
between RW8 and RF10 by the 8mer- and the 10mer-specific T cells. 
This was confirmed by crystallographic analyses of 2 HLA-A *24:02 
molecules with RW8 and with RF10 that demonstrated a structural 
difference in the center. Longitudinal analysis of HLA-A *24:02 + 
individuals infected with wild-type virus showed that not only CTLs 
specific for wild-type (WT) of 8-mer and/or those for 10-mer peptides 
but also those cross-recognizing WT and 2F 8-mer peptides were 
elicited at the early phase although 2F-specific CTLs became dominant 
at the chronic phase.  Competitive suppression assay showed that both 
cross-reactive 8-mer-specific and WT 10-mer-specific CTLs could select 
the 2F mutant virus.  Comparisons between two HLA-A *24:02 crystals 
with RW8 and RW8-2F or those with RF10 and RF10-2F demonstrated 
a structural similarity between the former structures but difference 
between the latter ones.   
Conclusion: The present study demonstrated that patients infected 
with WT virus can elicit cross-reactive 8-mer-specific and WT 10-mer 
specific CTLs and then they can effectively select the 2F mutant. 
P12.23
Vif-Derived Epitopes Can Be Efficiently 
Recognized by Cytotoxic T Lymphocytes
S. Seki1 and T. Matano1
1Japan Institute of Medical Science, University of Tokyo, 
Tokyo, Japan
Background: Determination of viral antigen targets for effective 
cytotoxic T lymphocytes (CTLs) could be important for development 
of a T cell based AIDS vaccine. Recent studies have suggested great 
contribution of CTL responses specific for some Vif epitopes to simian 
immunodeficiency virus (SIV) control in rhesus macaques (AIDS 
24:2777, 2010; Nature 491:129, 2012). Here, in order to evaluate the 
potency of Vif as a vaccine antigen, we examined whether epitopes in 
the context of Vif can be efficiently recognized by specific CTLs. 
Methods: We investigated efficiency of target killing by CTLs specific 
for Mamu-A1*065:01-restricted SW9 (Gag241-249) epitope. Mamu-
A1*065:01-positive B-lymphoblastoid cell lines (BLCLs) infected with 
Sendai virus vectors expressing EGFP (SeV-EGFP), SW9-EGFP fusion 
protein (SeV-SW9EGFP), and Vif-SW9 fusion protein plus EGFP (SeV-
VifSW9-EGFP), respectively, were used for the target cells. After 4-hr 
coculture of these target cells with SW9-specific CTLs, GFP-positive cell 
frequencies were measured to assess killing efficiency.
Results: Negative control target BLCLs infected with SeV-EGFP showed 
no killing. SeV-SW9EGFP-infected and SeV-VifSW9-EGFP-infected 
BLCLs both showed specific killing by SW9-specific CTLs, but the killing 
efficiency in the latter expressing SW9 in the context of Vif (58%) was 
significantly higher than the former (32%).
Conclusion: Our results suggest that Vif-derived epitopes can be 
efficiently recognized by specific CTLs, implying that Vif is a promising 
immunogen for T cell based AIDS vaccines. 
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P12.26
Expression of NKG2A on CD8+ T Cells 
Correlates with Markers of Disease Progression 
in Chronic HIV-1 Clade C Infection
P.N. Kamya1, Z.M. Ndhlovu1, F. Porichis1, G. Alter 1, T. Ndung’u2, 
and B.D. Walker 3
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Nelson R. Mandela School of Medicine, University 
of Kwa-Zulu-Natal, Durban, South Africa; 3Howard Hughes 
Medical Institute, Chevy Chase, MD, USA
Background: HIV-1 specific CD8+ T cells have been strongly 
implicated in the control of viral replication. However, during chronic 
HIV-1 infection, HIV-1-specific CD8+ T cells progressively lose critical 
effector functions. Inhibitory Natural Killer Receptors (NKRs) such as 
NKG2A/CD94 are up regulated and on antiviral CD8+ T cells during 
acute polyoma infection in mice and    are responsible for down-
regulating antigen-specific cytotoxicity during both viral infection and 
virus-induced oncogenesis.  The up regulation of inhibitory NKRs may 
serve to restrain antiviral CD8+ T cells following antigen clearance as 
a mechanism to limit immunopathology. The effect of inhibitory NKR 
receptor expression on HIV-specific CD8+T cell function and HIV-1 
clinical progression has not been characterized.
Methods: We used multi-parametric flow cytometry to compare the 
frequencies of NKG2A CD8+ T cells from 24 chronically infected HIV-1 
patients and 12 HIV-negative controls from Durban, South Africa. 
Results: Our data show elevated frequencies of CD8+NKG2A+ T cells 
(p=0.01) and as well as increased expression of NKG2A receptors 
(p=0.03) on CD8+ T cells from HIV-1 positive patients in comparison 
to HIV-negative controls. There was significant inverse correlation 
between frequencies of CD8+NKG2A+ T cells and absolute (abs) CD4 
count (p=0.03 Spearman r=-0.44) and significant positive correlation 
between frequencies of CD8+NKG2A+ and HIV-1 log viral load 
(VL) (p=0.03; Spearman r=0.45). Interestingly, the frequencies of 
CD8+NKG2A+ T cells also positively correlated with frequencies of 
the T cell exhaustion marker PD-1 on CD8+ T cells (p<0.05; Spearman 
r= 0.44) and the senescence marker CD57 on CD8+ T cells (p<0.001; 
Spearman correlation 0.64). 
Conclusion: Our data suggest that NKG2A expression may contribute 
to the functional impairment of HIV-specific CD8+T cells during chronic 
HIV-1 infection and NKG2A+CD8+ T cells may represent an important 
population of exhausted T cells. Understanding how NK2GA and other 
NKRs regulate of antiviral CD8+ T cell responses may provide novel 
insights into potential therapeutic targets aimed at harnessing T cell 
immunity for prophylactic HIV vaccine strategies. 
P12.25
Selection of Pol283-8V Mutant by Pol283-8-
Specific CTLs in HLA-B*51:01+Long-Term Non 
Progressors
N. Kuse1, T. Akahoshi1, H. Gatanaga2, S. Oka2, and M. Takiguchi1
1Kumamoto University, Kumamoto, Japan; 2National Center 
for Global Health and Medicine, Tokyo, Japan
Background: We previously showed that 8V mutation at an Pol283-
8(TI8) epitope, which was found in only long-term non progressors 
(LTNPs) of HLA-B*51:01 + Japanese hemophiliacs, weakly reduced TI8-
specific CTL recognition, suggesting that selection of the 8V mutant 
was a critical factor for　the long-term control of HIV-1. However, the 
mechanism underlying selection of the 8V remains unclear. We here 
investigated how the 8V was selected by TI8-specific CTLs. To clarify 
the mechanism of　the long-term control of HIV-1 in HLA-B*51:01 + 
LTNPs having the 8V, we further analyzed the function of the CTLs 
elicited after selection of the 8V.
Methods: We measured the ability of TI8-specific CTL clones to suppress 
the replication of the 8V mutant virus and to select this mutation in 
CD4 + T cells infected with the 8V and WT viruses. Furthermore, we 
investigated the affinity of TCR on the CTL clones by using tetramers of 
HLA-B*51:01-Pol283 or -Pol283-8V peptide complex.
Results: TI8-specific CTL clones, which were established from PBMCs 
collected at the time that WT virus was found, had a little weaker 
ability to suppress the replication of the 8V mutant compared to that of 
WT virus. They could select the 8V in vitro. In contrast, the CTL clones, 
which were established from PBMCs after selection of the 8V, had 
similar ability to suppress the replication of the 8V as that of WT virus 
and failed to select the 8V in vitro. The former CTLs carried TCR with 
stronger affinity to the WT tetramer than that to the 8V one, whereas 
the latter ones carried TCR with similar affinity to both tetramers.
Conclusion: These results suggest that Pol283-8V is an escape mutant 
selected by TI8-specific CTLs carrying TCR with weak affinity to the 
8V. This mutant can elicit the CTLs evenly recognizing WT and 8V 
mutant so that they can control HIV-1 after the emergence of the 8V 
in　HLA-B*51:01 + LTNPs.
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P12.28
Extensive Yet Ineffective Gag Epitope Variant 
Recognition Observed in HIV-Progressors
J. Sunshine1, M. Kim1, J. Carlson2, D. Heckerman2, S. Migueles3, 
J. McElrath4, J.I. Mullins1, and N. Frahm4
1University of Washington, Seattle, WA, USA; 2Microsoft 
Research, Los Angeles, CA, USA; 3NIH, Bethesda, MD, USA; 
4Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Background: Efficacy of future HIV vaccines will likely depend 
on the capacity of the induced immune responses to cope with the 
extensive sequence diversity found in circulating strains. Vaccination 
strategies shown to induce T cell responses with improved epitope 
variant recognition in NHP models are moving into human phase I 
clinical trials. In order to fully evaluate the protection potential of these 
vaccines, a better understanding of variant recognition and its role in 
HIV control is imperative. 
Methods: We comprehensively evaluated Gag epitope variant 
recognition in an untreated cohort of 15 HIV-controllers (viral load 
[VL] <2,000 RNA copies/ml) and 15 HIV-progressors (VL>10,000 
RNA copies/ml). A Gag peptide set of 11-mers overlapping by 10 
amino acids (AA) was generated to reflect all variants found in ≥5% 
of clade B sequences in the LANL HIV Sequence Database. This set 
includes 1300 peptides and covers all AA in Gag. All subjects were 
screened for responses by IFN-γ/IL-2 FluoroSpot. For each epitope, 
variant recognition was calculated as the proportion of variants 
eliciting a response among all variants tested. Gag was sequenced 
by single genome amplification of ~20 clones for five controllers and 
five progressors.
Results: Progressors trended towards recognizing a greater proportion 
of naturally occurring variants per epitope than controllers (median 
56% per epitope vs. 49%, p=0.06). Variant recognition was significantly 
correlated with VL in individuals with detectable VL (r=0.61, p=0.001). 
Gag sequencing showed that viral diversity within epitopic regions was 
higher in progressors than controllers (p=0.0005). Interestingly, viral 
populations in progressors more often matched the recognized epitope 
variants than observed in controllers (p=0.13)
Conclusion: These data suggest that diverse viral populations drive 
epitope variant recognition in progressive infection, but that responses 
to variants were largely ineffective in either controlling or applying 
pressure on HIV. Future investigations are necessary to identify 
immune correlates of effective variant recognition
P12.27
HIV-1 Infection Impairs Regulatory T Cell 
Function
M. Angin1, M. King1, M.K. Bhasin2, S. Sharma1, T.T. Murooka3, 
T.R. Mempel3, B.D. Walker1, and M.M. Addo1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 
USA; 2Dana Farber/Harvard Cancer Center, Boston, MA, USA; 
3Massachusetts General Hospital, Harvard Medical School, 
Boston, MA, USA
Background: Understanding disease progression and the nature of 
the immune response needed for protection are essential to continue 
the pursuit of an effective HIV-1 vaccine. The impact of Tregs on HIV-1 
immune pathogenesis, including potential benefits through suppression 
of HIV-1-associated generalized immune activation and control of HIV 
replication, versus possible deleterious effects via suppression of HIV-
1-specific immunity, remains incompletely understood. While it has 
been shown that Tregs can be infected by HIV-1 in vivo and in vitro, 
the consequences of HIV-1 infection on a per cell basis have not been 
investigated to date.
Methods: CD4+CD25+CD127- Tregs were isolated from healthy donors 
and infected with a VSV-pseudotyped HIV-1-GFP virus. GFP-positive 
(infected) and GFP-negative (non-infected) Tregs were isolated using 
flow-based cell sorting and their capacity to suppress the proliferation 
of T cells was tested in vitro. RNA from infected- and non-infected 
Tregs was isolated and expression of 511 genes was compared using 
the NanoString technology.
Results: Expanded Tregs were readily infectable by HIV-1-GFP in vitro. 
We found that HIV-1-infected Tregs were significantly less suppressive 
than non-infected Tregs, suggesting that HIV-1 infection impairs Treg 
function on a per-cell basis. Gene expression analysis showed 23 genes 
differentially expressed after HIV-1 infection. Several genes involved 
in the Treg lineage and function were down regulated after infection 
(including ETS1, LEF1, CD27, TRAF5, STAT5), possibly contributing to 
their impaired suppressive function.
Conclusion: Our data suggest that HIV-1 infection alters suppressive 
function at a single cell level. HIV-1 Infection of Tregs may thereby 
impair their capacity to limit detrimental generalized immune 
activation and promote disease progression by providing additional 
targets. We believe this study provides important insights on the role 
of regulatory T cells in the context of HIV-1 infectionand may lead to 
new approaches for developing an effective HIV-1 vaccine.
Topic 12: T Cell Immunity
256
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P12.30
Limited HIV Infection of Central Memory CD4+ 
T Cells Is Associated with Lack of Progression in 
Viremic Individuals
N. Klatt1, S. Bosinger2, A. Heigele3, M. Lederman4, B. Juelg5,  
D. Camerini6, C. Torti7, J. Martin8, S. Deeks8, E. Sinclari8,  
J. Brenchley9, M. Paiardini2, F. Hecht8, F. Kirchhoff3, P. Hunt8, and 
G. Silvestri2
1University of Washington, Seattle, WA, USA; 2Emory 
University, Atlanta, GA, USA; 3Ulm University Medical Center, 
Ulm, Germany; 4Case Western Reserve University, Cleveland, 
OH, USA; 5Ragon Institute of MGH, MIT and Harvard, 
Cambridge, MA, USA; 6University of California-Irvine, Irvine, 
CA, USA; 7University of Brescia, Brescia, Italy; 8UCSF Positive 
Health Program, San Francisco, CA, USA; 9NIH, NIAID, LMM, 
Bethesda, MD, USA
Background: A rare subset of HIV-infected individuals, viremic non-
progressors (VNP), remain asymptomatic and maintain preserved 
CD4+ T cells despite persistently high viremia. While these individuals 
have been characterized, mechanisms underlying protection from 
AIDS progression are unclear.
Methods: To identify mechanisms potentially responsible for delayed 
disease progression in VNPs, we compared VNPs (average >9 years 
of HIV infection) to HIV-infected individuals with similar CD4+ T cell 
counts and viral load, but analyzed within 2 years from infection 
(“putative progressors”, PP), thus avoiding the confounding effect of 
immunological defects present in chronically HIV-infected subjects. 
Results: We found that VNP, compared to PP, expressed similar levels 
of T cell activation and a comparable profile of gene expression, but 
higher levels of the cell cycling marker Ki67 on CD4+ T cells, a finding 
suggestive of preserved CD4+ T cell homeostasis. Importantly, VNPs 
showed lower levels of HIV infection of central memory CD4+ T cells 
(P=0.0272), but not effector memory, compared to PP. 
Conclusion: Our results suggest that decreased levels of central 
memory CD4+ T cell infection in HIV-infected VNP may be a key 
contributor to preservation of CD4+ T cell homeostasis and lack of 
disease progression despite high viremia. These data suggest that 
targeting prophylactic vaccines to prevent HIV infection of central 
memory CD4+ T cells, or therapeutic vaccines to decrease levels of 
HIV infection in central memory CD4+ T cells, may be essential in the 
development of novel vaccination strategies. 
P12.29
Ad5 but Not Ad26 Induces an IFN-
Γ+IL-10+ CD4+ T Cell Population Following 
Immunization
R.A. Larocca1, N.M. Provine1, E.N. Borducchi1, and D.H. Barouch1
1Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA
Background: Adenovirus-based vaccines have arisen as an attractive 
method to elicit robust cellular and humoral immune responses. 
Multiple vector serotypes have been developed, but the CD4 T cell 
responses generated by these vectors have not previously been 
compared. We therefore, compared the functionality of antigen-specific 
CD4 T cells induced following Ad5 or Ad26 immunization.
Methods: C57BL/6 mice were immunized intramuscularly with 
1010vp of Ad5-SIVgag or Ad26-SIVgag. In another set of experiments, 
mice were immunized with increasing concentrations of Ad5-SIVgag 
(107vp to 1010vp). For both experiments, spleen cells were harvest at 
day 10, and SIVgag-specific CD4 + T cell responses were evaluated 
by flow cytometry.
Results: Immunization with 10 10vp of Ad5-SIVgag induced a 
population of IL-10 + producing cells that comprised 30% of gag-
specific IFN-γ + CD4 + T cells. In contrast, the number of CD4 + T 
cells that co-produced IFN-γ and IL-10 was 8 times lower following 
Ad26 immunization (p<0.0001). These cells were T-bet + and FoxP3 -. 
In addition, Ad5 immunization induced a substantially larger fraction 
of IL-10 + cells that co-express PD-1 than Ad26 immunization (85% 
versus 23%). Moreover, a larger fraction of IFN-γ + CD4 + T cells were 
Tim-3 + following Ad5 versus Ad26 immunization (23.7% versus 6%). 
We also observed increasing frequency of IFN-γ +IL-10 + CD4 + T cells 
with increasing doses of Ad5.
Conclusion: Ad5 vectors, but not Ad26 vectors, induce a large 
population of CD4 + T cells that produce IFN-γ and IL-10, an 
immunosuppressive cytokine that may potentially limit vaccine 
efficacy. Both the dose and the serotype of the vaccine vector impacted 
the generation of this population of regulatory CD4 + T cells.
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P12.32
Synergistic Effect of Multiple Ctls on Control 
of HIV-1 in Japanese Individuals Carrying 
HLA-B*35:01 Allele Associated with Rapid 
Disease Progression
M. Koyanagi1, H. Murakoshi1, H. Gatanaga2, S. Oka2, and  
M. Takiguchi1
1Kumamoto University, Kumamoto, Japan; 2National Center 
for Global Health and Medicine, Tokyo, Japan
Background: Our recent study have demonstrated that HLA-B*35:01 
is associated with high viral load (VL) in chronically HIV-1 clade 
B-infected Japanese individuals (Naruto T. et al. J. Virol. 2012). 
However, some HIV-1 clade B-infected HLA-B*35:01-positive Japanese 
individuals showed low VL. But it still remains unclear how HIV-1 can 
be controlled in these individuals.
Methods: To investigate the effect of HIV-1 specific CTL responses 
on the control of HIV-1 infection in HLA-B*35:01-positive Japanese 
individuals, IFN-gamma Elispot assay was performed using 15 HLA-
B*35:01-restricted epitopes in 64 HLA-B*35:01-positive Japanese 
individuals chronically infected with HIV-1 clade B. 
Results: We found significant associations between the individual 
response to Nef YY9 or p17 NY9 epitope and lower VL (p=0.0039, 
or p=0.0233, respectively). To investigate synergistic effect of CD8+ 
T cell responses on the control of HIV-1 infection in HLA-B*35:01-
positive clade B infected individuals, we first performed statistical 
analysis of the correlation between the total responses to the 15 
epitopes and VL. Breadth of them was significantly associated with 
VL (p=0.0125).　To identify the more effective combination of CD8+ T 
cell responses to the epitopes to control of HIV-1 infection in the clade 
B-infected HLA-B*35:01 individuals, we selected the responses which 
were observed relative correlation with lower VL (RT VY10, p17 NY9, 
Nef RY11, and Nef YY9; p < 0.1). Breadth of them was significantly 
associated with VL (p = 0.0075).  Furthermore, in the comparison of 
each group, the VL of responders to 3 or 4 epitopes (median 14,000 
copies/ml) was significantly lower than that of non-responders (median 
375,000 copies/ml, p < 0.001).
Conclusion: These results suggest that the multiple CD8+ T cell 
responses to RT VY10, p17 NY9, Nef RY11, and Nef YY9 epitopes were 
critical in the control of viraemia even in HIV-1 clade B-infected HLA-
B*35:01-positive individuals.
P12.31
Polyfunctional T Cell Responses to Gag p24 
Is Sustained During Effective Anti-retroviral 
Therapy
L. Brandt3, T. Benfield1, G. Kronborg1, J. Gerstoft2, A. Fomsgaard3, 
and I. Karlsson3
1Hvidovre University Hospital, Hvidovre, Denmark; 2University 
Hospital Copenhagen, Copenhagen, Denmark; 3Statens Serum 
Institut, Copenhagen, Denmark
Background: The goal of many therapeutic HIV-1 vaccines is to 
induce effective CD8 T cell responses in order to control HIV-1 
disease progression, often in combination with anti-retroviral therapy. 
Three qualities of the HIV-specific CD8 T cells could be involved in 
this control: frequency, breath of epitope recognition and functional 
quality. Knowledge about the residual immune response during 
effective treatment and suppressed viral load is therefore important for 
the development of an HIV-1 vaccine. 
Methods: We determined the magnitude, breadth and quality of the 
HIV-1 specific T cell response in HIV-1 infected viremic individuals 
(n=19) and individuals on highly active anti-retroviral treatment 
(HAART) (n=14) following stimulation with peptide pools covering the 
entire HIV-1 genome (clade B). Cytokine response (IFN-gamma, TNF-
alpha, IL-2, MIP-1b and CD107a) was measured by flow cytometry.
Results: We found that magnitude and breadth of the CD8 T 
cell response was significantly higher in viremic individuals than 
individuals on HAART (p<0.0001 and p<0.0001, respectively) and that 
the functionality of the overall HIV-1 specific response was significantly 
different in individuals on HAART and viremic individuals (p=0.0020). 
In individuals on HAART, the remaining responses were primarily 
detected upon stimulation with overlapping peptides from Gag p24, 
integrase and Nef. The Gag p24 response was more polyfunctional 
than corresponding responses observed in viremic individuals. 
Conclusion: Identification of highly immunogenic regions also 
recognized by individuals on HAART may be important for HIV-
1 vaccine development. Irrespective of HLA haplotype, we have 
identified specific regions within the HIV-1 genome that is targeted 
more frequently in individuals on HAART. These particular regions 
could be interesting for a future vaccine that might limit the time and 
opportunity for escape mutations.
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P12.34
Analysis of the Relationship Between Founder 
Virus Fitness, Primary T Cell Response Breadth 
and Viral Control in Acute HIV-1 Infection
K. Pfafferott1, L. Yue2, J. Baalwa3, J. Salazar-Gonzalez 3,  
K. Conrod1, E. Cormier4, J. Gilmour4, E. Karita5, E. Sanders6,  
G. Shaw7, E. Hunter2, and P. Borrow1
1University of Oxford, Oxford, UK; 2Emory University, Atlanta, 
GA, USA; 3University of Alabama at Birmingham, Birmingham, 
AL, USA; 4Chelsea and Westminster Hospital, London, UK; 
5Projet San Francisco, Kigali, Rwanda; 6KEMRI-Wellcome Trust 
Collaborative Programme, Kilifi, Kenya; 7Perelman School of 
Medicine, University of Pennsylvania, Philadelphia, PA, USA
Background: Understanding determinants of the efficiency of HIV 
control by CD8 T cell responses during acute infection is important to 
inform T cell-based vaccine design. In a pilot study of two HIV clade 
A-infected subjects with different infection outcomes we found that 
good viral control was associated with establishment of infection by 
a less fit founder virus and expansion of a broad primary HIV-specific 
CD8 T cell response, some components of which were nonetheless 
rapidly escaped. The current study extends similar analyses to 
additional subjects to determine the generality of these observations.
Methods: 10 HIV clade A-infected subjects sampled at serial timepoints 
from acute infection, 5 establishing low and 5 high persisting viral 
loads, were studied. Longitudinal single genome amplification and 
sequencing of viral RNA was performed, the founder virus sequence 
deduced, and longitudinal mutations identified. The T cell epitopes 
recognised in the autologous founder virus were mapped; the kinetics 
of epitope-specific responses determined and effects of putative 
escape mutations verified using ELISPOT assays. 
Results: The HIV-specific CD8 T cell response expanded during acute 
infection in subjects with good viral control was of greater epitope 
breadth than that in subjects with poor viral control; nonetheless, 
viral escape from initially immunodominant CD8 T cell responses 
was observed in both subject groups. The fitness of the virus initiating 
infection in these subjects and its reduction by escape mutations is 
currently under investigation.
Conclusion: The results obtained to date suggest that contrasting 
infection outcomes may be shaped by interplay between viral fitness 
and the host T cell response, with establishment of infection by a 
less fit virus enabling expansion of a broader primary HIV-specific T 
cell response, escape from which may drive further reduction of viral 
fitness. Vaccines should therefore be designed to induce responses that 
constrain acute viral replication and drive costly escape mutations. 
P12.33
HIV- Toggle Peptides Identify Super-agonistic 
Minor Sequence Variants in HIV Gag and Broad 
T Cell Reactivity to Nef Variants 
A. LLano1, B. Spreng2, B. Mothe1, and C. Brander4
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, 
Spain; 2University of Konstanz, Konstanz, Germany; 3IrsiCaixa 
Institute for AIDS Research, HIVACAT, ICREA, Barcelona, Spain
Background: Minor sequence variants have been suggested to be of 
potentially increased immunogenicity and thus being selected against 
in natural HIV infection. Toggle peptides (TP), representing an approach 
where sequence variability is directly incorporated into the peptide 
synthesis, has the potential to identify such superagonistic minor 
variants with relative ease. Their inclusion in future T cell immunogen 
sequences could help broaden and functionally improve vaccine 
induced responses. 
Methods: 50 HIV-1 clade B infected subjects (28 HIV controllers, 22 
no-controllers) were assessed for HIV-specific T cell responses against 
14 Toggle peptides and their corresponding consensus overlapping 
peptide (OLP) sequence and individual variants. Nine TP were located 
in Gag, the remaining 5 in Nef. Ex-vivo responses were detected by 
IFNg ELISpot.
Results: In agreement with earlier reports, HIV controllers recognized 
overall more variant peptides and mounted stronger responses than 
non-controllers (3790 SFC [259-11752] vs 1166 SFC [98-2451] 
for magnitude (p=0.002) and 6.7 [2.1-13.6] vs 3.06 [0.62-5.1] for 
number of targeted variants (<0.0001), respectively. In two of the Gag 
TP, two minor variant sequences were identified, each augmented 
the frequency of reactivity 2.5-fold and increased the magnitude of 
the response up to 20-fold compared to the consensus-sequence 
based OLP. Surprisingly, the frequency of variant recognition and 
the magnitude of variant-specific responses was higher for Nef TP 
compared to TP covering Gag (p= 0.007 and p=0.059, respectively). 
Conclusion: Our results establish the differential screening with Toggle 
and consensus OLP as a rapid approach to identify minor epitope 
variants with potentially superior immunogenicity than consensus 
sequences. Further analyses are needed to discriminate between 
broad Nef variant recognition and the presence of T cell populations 
targeting individual variant Nef peptides and to determine whether the 
identified superagonistic variants in Gag can induce responses with 
stronger anti-viral activity. 
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P12.36
Specificity of T Cell Response, Not Protective 
HLA Restrictions, Determines Control of HIV 
Replication in Thai Viraemic Controllers
Y. Tansiri1, J. Ananworanich1, S. Rowland-Jones2, and P. Hansasuta1
1Chulalongkorn University, Bangkok, Thailand; 2University of 
Oxford, Oxford, UK
Background: Previous studies have demonstrated that protective HLA 
alleles such as HLA-B*27 and HLA-B*57/58 alleles are related to HIV 
control. However, development of T cell vaccine based on this finding 
may be problematic due to diversity of HLA alleles in different ethnic 
backgrounds. We hypothesized that T cell targets were more essential 
than HLA-restrictions.  
Methods: Sixty-eight HIV-infected volunteers were classified into 
viraemic controllers (VC) and non-viraemic controllers (NC) according 
to their HIV-RNA loads (those with HIV-RNA < 2,000 copies/ml were 
categorized into VC group). CBC, CD4 count and HIV loads (VL) were 
determined in ISO-15189-accredited laboratories. T cell responses 
were analyzed by ELISpot, polychromatic ICS and, in selected cases, 
by HIV suppression assays.
Results: The VC had a median VL of 682 and NC had 17,313 copies/
ml, whilst the CD4 counts were similar. Duration of Infection and other 
clinical parameters were not different. All volunteers were CCR5 wt/wt 
genotype. Volunteers with HLA-B*27 and HLA-58 supertype did not 
have lower VL. VC and NC had similar p24-specific T cell response by 
ELISpot assay. VL in HLA-B27-KK10 responders were not statistically 
different from those in the non-responders. All HLA-B57/58 epitope 
responses, except LW9, were not associated with low VL or controller 
status. Our observation that only LW9-specific T cells had full functional 
response by ICS and the CTL line suppressed in vitro HIV replication 
to under detection limit might help explain efficacy of this epitope 
response. By plasma HIV-RNA sequencing, escape of T cell response 
did not explain absence of low VL associations in other epitopes. 
Surprisingly, immunodominant response to AK11 epitope was related 
to low HIV-RNA load, though this epitope was restricted through non-
protective HLA-A*11.
Conclusion: In conclusion, targets of T cell response are important 
for HIV control, and may not be relevant to the epitope restrictions. 
The observation helps alleviate concerns over HLA restriction in T cell-
based HIV vaccine.
P12.35
SIV Infection of the Macaque Testis—An 
Immune Privileged Site?
W.R. Winnall1, R. De Rose1, C.S. Fernandez1, S.B. Lloyd1,  
S. Gooneratne1, T. Amarsena1, S. Jegaskanda1, M. Kramski1,  
M.P. Hedger2, and S.J. Kent1
1The University of Melbourne, Melbourne, Australia; 2Monash 
University, Melbourne, Australia
Background: The rodent testis is a site of immune privilege where 
adaptive and innate immune responses are suppressed. Evidence 
for immune privilege in the primate testis, however, is inconclusive. 
The testes of humans and macaques become infected with HIV and 
SIV, respectively, so a successful vaccine must prevent testicular 
infection. We have used the pigtail macaque model to characterize 
the leukocytes present in the testis, SIV infection of the testis and the 
strength of immune responses in this region.
Methods: Testes from 14 pigtail macaques were studied. Two 
macaques were infected with SIVmac239. “Tru-cut” core biopsy (2 
weeks) and unilateral orchidectomy (10 weeks) were used to sample 
testes. Interstitial cells were isolated from uninfected (n=12) and 
infected testes by collagenase digestion and phenotyped using flow 
cytometry. Nested RT-PCR reactions were used to amplify the SIV env 
gene from testis samples. T cell responses to mitogen stimulation were 
measured by intracellular cytokine staining.
Results: The leukocyte population of the uninfected macaque testis 
consisted of >45% monocytes and macrophages, 15% CD4+ and 16% 
CD8+ T cells (central and effector memory, but few naïve) and smaller 
populations (<10%) of dendritic, NK and NKT cells. T cell responses 
to mitogens and super-antigens were highly suppressed in the testis 
compared to blood (p=0.028). SIV was detected by PCR at 2 and 10 
weeks after infection. SIV Infection led to a decrease in the proportion 
of CD4+ T cells, increase in CD8+ T cells and a shift away from central 
memory and towards effector memory T cells.
Conclusion: Cells within the macaque testis becomes infected with 
SIV within 2 weeks, resulting in CD4 T cell depletion and CD8 T cell 
expansion. However, T cell responses are dramatically suppressed in 
the primate testis. This raises important questions about whether “non-
sterilizing” immunity-inducing HIV vaccines will seed HIV into this 
immune-privileged site and lead to eventual breakthrough infections. 
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P12.38
The Antiviral Efficacy of CD8+ T Cells in Early 
HIV-1 Infection Is Dependent on Targeting of 
Low Entropy Regions of the Viral Proteome 
G. Hancock1, H. Yang2, N. Frahm3, L. Dorrell2, and  
A.A. McMichael2
1University of Oxford, Oxford, UK; 2Oxford NIHR Biomedical 
Research Centre, Oxford, UK; 3HIV Vaccine Trials Network, 
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Background: Reliable correlates of immunological control are critical 
for HIV vaccine development. We and others have shown the capacity 
of CD8+ T cells to inhibit HIV-1 replication in vitro is highly predictive 
of their antiviral efficacy in vivo. The design of immunogens that could 
elicit effective CD8+ T cell responses is a major challenge.
Methods: Ex vivo CD8+ T cell mediated antiviral inhibitory activity 
was measured in 22 HIV-1-infected Step and Phambili trial participants 
using PBMC sampled within one year of diagnosis. Investigators were 
blind to vaccine/placebo receipt. Several CD8+/CD4+ T cell ratios were 
tested with a panel of ≤ 5 viruses representing clades A, B and C. In 
parallel, ex vivo IFN-γ Elispot assays were used to quantify responses to 
overlapping Gag, Pol, Nef, and Vif peptides (OLPs) that were previously 
defined as targets of protective T cell responses by association with 
low viral load in chronically infected responders. 
Results: Three individuals showed potent inhibition (>90%) of a clade-
matched viral isolate at an optimal CD8+/CD4+ T cell ratio (1:1). This 
remained detectable at a 1:10 CD8+/CD4+ T cell ratio and cross-clade 
inhibition was also observed. In contrast, the majority of subjects 
showed weaker antiviral activity at a 1:1 CD8+/CD4+ T cell ratio 
(median - 42%). Consistent with this, only 4 had beneficial HLA class I 
alleles. Frequencies of IFN-γ-producing T cells targeting the ‘protective’ 
OLPs were modest overall (median 120 SFU/million PBMC, range 
0-1880 SFU/million PBMC). Critically, there was a strong correlation 
between IFN-γ responses to these protective regions and CD8+ T cell 
mediated virus inhibitory activity (r2 = 0.47, p = 0.003). 
Conclusion: Potent CD8+ T cell antiviral inhibitory responses were 
rare in this cohort but were strongly associated with targeting of 
low entropy regions in HIV-1 Gag and Pol, supporting their inclusion 
in HIV-1 immunogens. Analysis of unblinded data to ascertain any 
vaccine impact on CD8+ T cell responses is planned.  
P12.37
IL-10 Receptor Blockade Enhances CD4 and 
CD8 T Cell Responses to a Simian Adenovirus-
Vectored HIV-1 Vaccine, ChAdV63.HIVconsv
G.T. Clutton1, A. Bridgeman1, A. Mbewe-Mvula1, G. Hancock1,  
T. Hanke1, and L. Dorrell1
1University of Oxford, Oxford, UK 
Background: HIV-specific CD8 T cells limit viral replication in both 
acute and chronic infection, but T cell-inducing vaccines tested to 
date have failed to reduce viral load in clinical trials.  Adenoviral 
vectors stimulate potent T cell responses, but also induce the immuno-
regulatory cytokine interleukin-10 (IL-10), which may limit their 
efficacy.  We investigated whether blockade of IL-10 signalling could 
enhance priming of T cell responses to the candidate HIV-1 vaccine 
ChAdV63.HIVconsv. 
Methods: Female BALB/c mice were injected intraperitoneally with 
200µg anti-IL-10 receptor (IL-10R) antibody or isotype control antibody 
24 hours prior to a single intramuscular immunisation with 5 x 108 
infectious units ChAdV63.HIVconsv (day 0).  Cytokine production 
and costimulatory molecule upregulation in splenic dendritic cells 
was examined 24 hours post immunisation and HIV-specific cytokine 
production by CD4 and CD8 T cells was analysed on days 14 and 21.  
Results: Blockade of IL-10 signalling resulted in a significant 
upregulation of CD86 on CD8α - CD11c + dendritic cells 24 hours post 
immunisation.    Blockade did not enhance peak HIV-specific CD4 or 
CD8 T cell responses (IL-2, IL-4 and IFN-γ production) at day 14 but by 
day 21 there was a significant increase in the frequency of HIV-specific 
IL-2-producing CD4 T cells and IFN-γ-producing CD8 T cells from mice 
treated with the IL-10R blocking antibody.  The breadth of HIV-specific 
CD4 T cell responses (in terms of IL-2 production) was also increased at 
day 21 in mice treated with the IL-10R blocking antibody.
Conclusion: IL-10R blockade resulted in improved maintenance 
of CD4 T helper and CD8 effector T cell responses to the HIVconsv 
immunogen at day 21.  This may be due to enhanced priming by 
dendritic cells.  Blockade of IL-10 signalling is a potential strategy to 
increase the immunogenicity of viral vector vaccines for HIV-1 that 
warrants further investigation. 
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P12.40
Longitudinal Analysis of the Human 
Immunodeficiency Virus-1 Specific T Cell 
Response During Primary HIV-1 Infection and 
Association with Viral Control
M. Radebe1, K. Gounder1, Z. Ndhlovu2, M. Mokgoro1,  
M. van der Stok1, L. Maphumulo1, M. Jaggernath1,  
B.D. Walker2, and T. Ndung’u1
1University of KwaZulu-Natal, Durban, South Africa; 2Ragon 
Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Background: HIV-1-specific CD8+ T cells play a significant role in 
the control of HIV-1 infection but there is great heterogeneity and 
progressive diminution in their antiviral effectiveness. Longitudinal 
analysis of CD8+ T cell responses following acute HIV-1 infection may 
help distinguish effective versus ineffective CD8+ T cell responses and 
elucidate mechanisms that lead to CD8+ T cell dysfunction.  
Methods: We performed longitudinal characterization of CD8+ T cell 
responses to consensus peptides spanning the full viral proteome in 20 
HIV-1C acutely infected, antiretroviral naïve subjects using both the ex 
vivo and the cultured IFN-γ ELISPOT assay from 28 days post infection 
and up to one year. Viruses from plasma were also sequenced within 
defined CD8+ T cell epitopes. 
Results: There was an inverse correlation between the breadth of Gag 
responses and viral set point recorded from 25 weeks post infection 
(P= 0.0003; r= -0.70). A number of responses which were no longer 
detectable by the ex vivo ELISPOT at one year, were detected when the 
cultured ELISPOT assay was used. At the earliest time point evaluated, 
T cell responses were only mounted against 14% of the wild type 
epitopes and 7% of epitopes with variant sequences.  However, 
analysis at 52 weeks showed that a significantly higher number of 
both wild type (P=0.006) and variant epitopes (P=0.01) were targeted 
at 32% and 23%, respectively.
Conclusion: These data suggest an important role of Gag-specific T 
cell responses in the control of viremia during early HIV-1 infection. 
Some effector T cell responses, which disappear and are considered 
lost, may still be present in circulation, albeit below the limit of 
detection by ex vivo ELISPOT. Our data also implies that there is both 
a defect in the ability of T cells to expand to a cognate stimulus and 
weak immune selection pressure mediated through some responses 
during primary infection. 
P12.39
A Synthetic Multi-Env DNA Vaccine Induces 
Functional In Vivo T Cell Immunity Against 
Diverse HIV Env Immunogens by Novel In Vivo 
Assay
M. Wise1, J. Mendoza2, N. Hutnick1, K. Muthumani1, J. Yan2,  
K. Broderick2, N. Sardesai2, and D. Weiner1
1University of Pennsylvania, Philadelphia, PA, USA; 2Inovio 
Pharmaceuticals, Blue Bell, PA, USA
Background: In designing new immunogens for the induction 
of T cells against HIV, testing the effectiveness of the resulting T 
cell responses against a diverse set of viral antigens is challenging. 
Primary tools include ex vivo assays and highly animal specific 
in vivo assays usually limited to single epitope analysis. Recent 
improvements in DNA technology allowed for the development of 
minimally invasive local intradermal gene delivery array. We have 
adapted this technology for visual in vivo determination of viral gene 
clearance induced by host immunity. 
Methods: Following immunization, guinea pigs (GP) are injected and 
electroporated in specific dermal sites with plasmids expressing a HIV 
gene and GFP. Two days later, sites are assessed for GFP signal. If 
cells express epitopes specific for the induced CD8+T cells, they are 
targeted for killing, leading to reduced GFP signal. Naïve animals do 
not drive this in vivo clearance.
Results: When assessing killing responses against the vaccinated 
gene, we show a decrease in GFP signal, supporting a strong CD8+T 
cell response directed against that specific gene. By expressing 
alternate genes from those used during vaccination, the breadth of 
the killing response is determined. GP vaccinated with consensus C 
vs consensus A envelope develop comparable breadth and robustness 
of killing against genetically similar envelopes. GP vaccinated with 
both plasmids have increased ability to kill more diverse unrelated 
primary envelopes, previously unaffected by either plasmid alone. 
Immunization with a combination of consensus A, C, D envelope 
plasmids further broadens clearance against highly diverse primary 
envelopes, supporting better induction of cross clade CD8+T cells 
without negative competition by these immunogens. 
Conclusion: This novel technology allows for increased in vivo 
assessment of vaccine induced viral gene clearance with no ex vivo 
manipulations required. It allows for both linear and conformational 
epitopes to be tested in a simple model system.
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P12.42
Assessing the Role of Antigen-Specific CD8+ T 
Cells in Delayed Progression to AIDS
M.M. Herman1, L.R. McKinnon2, S. Kiazyk1, J. Kimani3,  
F.A. Plummer4, and T. Ball4
1University of Manitoba, Winnipeg, Canada; 2CAPRISA, 
Durban, South Africa; 3University of Nairobi Institute for 
Tropical and Infectious Disease, Nairobi, Kenya; 4Public Health 
Agency of Canada, Winnipeg, Canada
Background: One major challenge in the development of an HIV-1 
vaccine is the extreme genetic diversity of the virus.  A more cross-
reactive T cell response would be beneficial in circumventing this 
issue, but many aspects of the variant-epitope CD8+ T cell response 
remain poorly defined.  Here, we characterize CD8+ T cells specific 
to 4 immunodominant HIV-1 epitopes, and their common variants, to 
better understand their cross-reactivity and how this changes over time 
with progression to AIDS.
Methods: Blood samples were collected from HIV+ female commercial 
sex workers from Nairobi, Kenya. Samples were stimulated for 6 hours 
with HIV-1 Gag and Envelope peptides, and IL2, IFNy, TNF, and MIP1B 
were measured via intracellular flow cytometry. Each sample was 
stained with tetramers specific to each peptide to assess which cells 
were actively secreting cytokines.  Multiple samples were collected 
from the same patients over 1-6 years when available.
Results: This study revealed that the majority of cytokine production 
was by CD8+ T cells specific to the stimulating peptide.  Cross-
reactivity existed between epitopes and their variants, particularly with 
Gag IW9/LW9 epitopes, indicating that those regions may be better 
targets for future therapeutic agents. Cytokine production in response 
to Gag KF11 and KGF peptides were positively correlated to CD4 count. 
Production of IL2 was low or absent in all patients, and more likely 
produced by CD8lo cells in response to PMA stimulation.
Conclusion: Considering the ease with which HIV-1 mutates, it is 
important to consider how effective CD8+ T cell responses are to 
these common HIV variants, and how they may change as disease 
progresses. This study provides unique insight into not only how 
responses to these variants differ, but how but how they change 
throughout long-term HIV infection.  A better understanding of the 
dynamics of these important responses will be essential in guiding 
future vaccine or therapeutic candidates. 
P12.41
Viral Evasion of Immune Control Mediated by 
Coexpression of HLA-B*27:05 and HLA-B*57:01
J. Brener1, F. Chen2, L. Riddell3, F. Pereyra4, L. Mori1, E. Adland1, 
N. Robinson1, A. Harrison1, B. Walker4, J. Frater1, P. Klenerman1, 
P. Matthews1, and P. Goulder1
1University of Oxford, Oxford, UK; 2Royal Berkshire Hospital, 
Reading, UK; 3Northampton General Hospital, Northampton, 
UK; 4Ragon Institute of MGH, MIT and Harvard, Cambridge, 
MA, USA
Background: Human leukocyte antigen (HLA) class I variation 
has been consistently linked to differential disease outcome in HIV 
infection. HLA-B*27:05 and HLA-B*57:01 are the two HLA alleles most 
strongly associated with viral control and slow disease progression in 
Caucasian subjects. Establishing the mechanisms responsible for loss 
of viral control in individuals that express both these favourable alleles 
provides a unique opportunity to define the key immune responses 
mediating immune control. 
Methods: We studied a total of 12 HIV-infected HLA-B*27:05/B*57:01-
positive adult subjects including: (i) a B Clade infected transmission 
pair and a CRF1_AE Clade infected transmission pair, where the 
recipient carried HLA-B*27:05/B*57:01 in each case; (ii) 10 B clade 
infected subjects comprising 2 progressors, 3 elite controllers and 5 
viraemic controllers. 
Results: Loss of immune control in a B*27:05/B*57:01 B clade infected 
subject was associated with acute HCV infection and acquisition of 
an HIV virus that differed substantially in Pol and Gag (by 13.1% in 
the amino acid sequence), but not in Nef (by 3.4%), suggesting that 
progression resulted from HIV superinfection and recombination. 
Escape mutations in critical HLA-B*27:05 and HLA-B*57:01-restricted 
epitopes within the superinfecting viral sequence may account for 
disease progression in this subject. The alternative hypothesis, that viral 
escape in subjects expressing HLA-B*27:05/B*57:01 arises through 
selection of multiple escape mutations that are acquired sequentially, 
despite considerable fitness cost to the virus, is currently being tested 
in the additional case studies. Disease progression in the CRF1_AE 
Clade infected B*27:05/B*57:01-positive subject was associated with 
escape mutations in key HLA-B*57:01-restricted Gag epitopes, but not 
with superinfection.
Conclusion: Studying loss of immune control of HIV that occurs in 
individuals despite expression of HLA alleles strongly associated with 
immune control may provide important evidence to define factors 
contributing to disease regulation. These features of efficient immune 
control may be important targets for T cell vaccine design. 
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P12.44
Recombinant Pox-, Adeno- and Herpesviral 
Vectors Differ in Their Capacities to Induce 
Antigen Presentation on Dendritic Cells
P. Rosenstock1, J. Köstler1, B. Asbach1, J.P. Meier1, J. Wild1, and  
R. Wagner1
1University of Regensburg, Regensburg, Germany
Background: Cytotoxic T cell (CTL) responses were found to efficiently 
control disease progression in some HIV-positive elite controllers 
and long term non-progressors. Thus, HIV-1 vaccines eliciting broad 
CTL responses may provide control of HIV replication. Nevertheless, 
previous vaccination approaches failed to induce protection. Not 
only improved immunogens but also effective delivery systems for 
elicitation of strong immunogen expression and protective immune 
responses are required for the development of vaccines. For the 
induction of CTL responses, the vectors have to activate dendritic cells 
(DCs) and induce antigen presentation.
Methods: Here, we compare the recombinant viral vectors NYVAC 
(poxvirus), Ad5 (adenovirus) and EHV-1 (herpesvirus), all coding for the 
same artificial polyprotein GPN, for their immunogenicity in a human 
ex vivo system. 
Results: We could show that only NYVAC and EHV-1 induced efficient 
GPN-expression in DCs, while Ad5 demanded high multiplicity 
of infection (MOI) and long incubation periods. Due to the low 
immunogen expression in DCs induced by the Ad5 vector, only 
remote direct-presentation by infected cells was observed. In contrast 
NYVAC and EHV-1 induced strong direct-presentation with EHV-1-
induced presentation being stronger and longer lasting. In a cross-
presentation assay, vaccine-infected HeLa cells were cocultivated with 
DCs. Only Ad5- and NYVAC-infected cells were able to induce cross-
presentation on DCs whereas EHV-1 infection could not elicit cross-
presentation. These results are surprising, as EHV-1 induces extensive 
GPN expression in HeLa cells.
Conclusion: Thus, we could show that the vector choice dramatically 
influences antigen presentation, and therefore the delivery system for 
vaccination purposes has to be chosen carefully.
P12.43
HIV Specific T Cell Responses in HIV-1/S.
Mansoni Coinfection
A. Obuku1, K. Musinguzi2, B. Gombe2, J. Serwanga2, G. Asiki2,  
A. Setala3, J. Mpendo3, G. Pantaleo4, A. Elliott2, P. Kaleebu2, and 
P. Pala2
1Medical Research Council Entebbe/Makerere University, 
Entebbe, Uganda; 2Medical Research Council/Uganda Virus 
Research Institute, Entebbe, Uganda; 3UVRI/IAVI, Entebbe, 
Uganda; 4Centre Hospitalier Universitaire Vaudois, University 
of Lausanne, Lausanne, Switzerland 
Background: HIV and Schistosomiasis coinfection are a common 
occurrence in Sub-Saharan Africa. It is unclear how schistosomiasis 
might influence the course of HIV infection. We hypothesized that 
coinfection with S. mansoni and HIV might downmodulate the T 
cell response to HIV, regulatory T cell proportions and negative and 
positive regulatory markers.
Methods: Fifty HIV infected cases, 26 of which were co-infected with 
S. mansoni were recuited. PBMC were stimulated with pools of HIV PTE 
peptides, SEB or unstimulated. PBMC stained for viability, CD3, CD4, 
CD8, IFN-γ, IL-2, TNF-α, CD25, CD45RO, CD127, Foxp3, GARP, CD150, 
CD244, CD160 and CD279, CD38 and HLADR in three staining panels 
were acquired on a BD LSRΙΙ analyzer.  Background subtracted cytokine 
responses and FMO gated marker expression were analysed in FlowJo, 
Stata 10 and Qlucore.
Results: The mean frequency of T cells secreting IFN-γ, IL-2 and TNF-α 
in response to HIV peptides was not significantly different between 
HIV only infected and coinfected individuals, with mean response 
differences ranging between  -0.19 and 0.3% and p values between 
0.052 and 0.9 for any cytokine combinations using two tailed student 
t test. There was a trend towards higher mean frequency of HIV 
specific cells producing IFN-γ or IFN-γ & TNF α and higher frequencies 
of regulatory T cells in the coinfected participants, who also had 
lower frequencies of CD8+CD38-CD150+CD160CD244+CD279-
HLADR+ and CD8+CD38-CD150+CD160+CD244+CD279+ HLADR- 
cells compared to those infected with HIV alone (p=0.046; q=0.145). 
Other patterns of regulator markers were also found to be different 
in these contrasts. 
Conclusion: HIV specific cytokine secretion did not appear 
downregulated in co-infection compared with HIV alone, although 
different patterns of expression of regulatory markers were observed 
in the two groups, suggesting that complex regulatory interactions 
might occur without a major effect on the chosen functional outcome 
measure.The trend suggests enhanced anti HIV specific responses in 
HIV S.mansoni coinfection.
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P12.46
Pre-infection MHC Class I Allele Expression 
Correlates with SIV Control
J. Greene1, B. Cain1, N. Pham1, M. Budde1, and D. O’Connor1
1University of Wisconsin-Madison, Madison, WI, USA
Background: CD8 T cells contribute to controlling human 
immunodeficiency virus and simian immunodeficiency virus 
replication. These responses are restricted by MHC class I proteins 
which present endogenously derived peptides on the cell surface. 
MHC class I protein expression is regulated at multiple levels and can 
change depending on an individuals MHC class I repertoire. 
Methods: We explored whether Mafa-A1*063 expression on the 
surface of CD4+ T cells is associated with control of SIV replication 
in a cohort of MHC-defined Mauritian cynomolgus macaques.  The 
expression of Mafa-A1*063 on the surface of cells was determined by 
incubating cells with a saturating amount of FITC-conjugated peptides 
known to bind Mafa-A1*063 and measuring the geometric mean 
fluorescent intensity of the bound peptides by flow cytometry. 
Results: We found that higher levels of pre-infection Mafa-A1*063 
expression on the surface of CD4+ T cells correlated with reduced viral 
loads while total pre-infection MHC class I expression did not. 
Conclusion: These results suggest that differences in expression of 
MHC class I alleles can impact viral loads. Ultimately, this may help 
explain why some individuals that have MHC class I alleles associated 
with control of viral replication are unable to maintain low viral loads.
P12.45
Epitope Mapping of the Response to 
Vaccination with Dendritic Cells Loaded with 
HIV Lipopeptides
M. Surenaud3, M. Raimbault1, M. Montes2, C. Lacabaratz3,  
L. Richert1, S. Zurawsky2, K. Palucka2, S. Hue3, J. Banchereau3,  
R. Thiébaut1, and Y. Levy3
1INSERM U897, Bordeaux, France; 2Baylor Institute for 
Immunology Research, Dallas, TX, USA; 3ANRS/VRI, Creteil, France
Background: We have reported that vaccination with ex vivo generated 
Dendritic-Cell (DC) loaded with HIV-lipopeptides (Gag17-35, Gag253-
284, Nef66-97, Nef116-145 and Pol325-355) in patients (n=19) under 
ART was well tolerated and immunogenic (CROI 2012 PB440). Here we 
have performed an epitope mapping of HIV responses using multiplex 
cytokine secretion assay.
Methods: Aphereses were performed at w16 (4 weeks after the last 
vaccination). PBMCs were stimulated for 48 hours with pools (n=36) of 
15-mer overlapping peptides spanning vaccine epitopes. Measurements 
of cytokine secretion (IL-2, IL-10, IL-13, IL-17, IL-21, IFN-γ and IP10) was 
performed	using	Luminex®	multiplex.	Fluorescence	 intensity	 (FI)	has	
been analysed on continuous scale and as binary response defined by 
> Q90 background and > 3 fold median FI among negative controls. 
Predictions of binding of peptides to HLA class II molecules according 
to patient’s HLA alleles were performed using netMHCII-2.2 and 
netMHCIIpan-2.0. Wilcoxon rank-sum tests were used for statistical 
analyses with estimation of False Discovery Rates (FDR) for controlling 
test multiplicity.
Results: Patients’ HLA class II alleles (19 HLA-DRB1 and 12 HLA-
DQB1 molecules represented) predicted a high frequency of responses 
against Gag253 and Pol325 and to a lesser frequency against Nef116 
epitopes. At w16, vaccinations elicited a significant increase of HIV 
responses as assessed by production of IL-2, IFN-γ, IL-21, IL-13 
(dFDR<0.05). Among the 587 responses against vaccine peptides, 415 
concerned weak (n=201) and strong (n=214) binders to HLA class II 
molecules. 37% and 23% responses were directed against Gag253 
and Pol325 epitopes, respectively. Profile of cytokine responses was: 
IFN-g (28%), IL-2 (18%), IP-10 (15%) and less than 32% for Th2 
cytokines (IL-10 and IL-13).
Conclusion: DC Vaccination elicited broad T cell responses to 15-
mers that matched with HLA class II allele predictions of responses to 
vaccine epitopes. The majority of them were directed against Gag and 
Pol epitopes and exhibit a Th1/Th2 profile.
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P12.48
PD-1hi CD4 T Cells Accumulate in Lymphoid 
Tissue and Support Viral Replication During 
Chronic SIV Infection
G.H. Mylvaganam1, V. Velu1, and R.R. Amara1
1Emory University, Atlanta, GA, USA
Background: The inhibitory receptor PD-1 has been shown to regulate 
both CD8 T cell and B cell function during chronic SIV infection, but 
the effects of PD-1 on CD4 T cell function are less well understood. 
Here, we investigated the role of PD-1 on CD4 T cells in regulating 
their function and its contribution to viral persistence during chronic 
SIV infection. 
Methods: Lymphocytes isolated from the blood, lymph node (LN), 
and rectum of SIV naïve and SIV infected rhesus macaques (RM) were 
separated into PD-1 neg, PD-1 lo, and PD-1 hi memory CD4 T cell 
subsets and characterized by flow cytometry. Sorted cells were used 
for measuring cell associated viral DNA and RNA by qPCR.
Results: IIn SIV naïve RM, PD-1 lo and PD-1 neg subsets were found in 
all three compartments, whereas PD-1 hi cells were restricted mainly 
to the LN and rectum. Following TCR independent (PMA/ionomycin) 
stimulation, PD-1 hi cells predominantly produced high levels of IL-2 
and IL-21. However, they failed to produce any cytokines following 
stimulation through the TCR. Following SIV infection, despite a global 
depletion of CD4 T cells, there was a significant increase in PD-1 hi 
CD4 T cells in both the rectum and LN, with frequencies of PD-1+ 
memory CD4 T cells correlating directly with viral load. Furthermore, 
PD-1 hi cells retained cytokine production following PMA/ionomycin 
stimulation. Interestingly, the PD-1 hi CD4 T cells were found to contain 
the highest concentration of cell associated viral RNA and DNA. The 
majority of these cells co-expressed CXCR5 suggesting that these may 
be localized to germinal centers (GC) where the anti-viral CD8 T cell 
response is limited. 
Conclusion: These data suggest that PD-1 hi cells may localize to GC 
to escape anti-viral CD8 T cell killing, serving as an important source of 
virus production and promoting viral persistence, at sites of preferential 
SIV replication.
P12.47
Direct Identification of Vaccine-Induced HIV-
1-Specific MHC Class I Associated Epitopes by 
Mass Spectrometry
N. Ternette1, N.L. Dudek2, A.W. Purcell2, B.M. Kessler1, and T. Hanke1
1University of Oxford, Oxford, UK; 2Monash University, 
Melbourne, Australia
Background: The challenge of vaccine development for HIV-1 is the 
high mutation rate and resulting diversity of the virus that allows for 
the escape from an established adaptive immune response in infected 
or vaccinated individuals. The immunogen HIVconsv was designed 
as fusion protein of the 14 most conserved regions across the HIV-1 
genome in order to limit viral escape (Letourneau et al., 2007). This 
vaccine is currently evaluated in clinical trials, inter alia, using Modified 
Vaccinia Ankara as delivery vector (MVA.HIVconsv).
Methods: In order to investigate the potential of this vaccine to induce 
HIV-1 specific epitope presentation, we have purified the MHC class 
I associated peptidome of MVA.HIVconsv infected cells followed 
by identification of the obtained epitope sequences by LC-MS/MS. 
Furthermore, we monitored changes in epitope presentation during 
the first hours following MVA.HIVconsv infection by MS based relative 
quantitation of peptide abundances.
Results: In addition to identification of several thousand self-
epitopes and over 100 MVA-derived sequences, we also identified 
4 HIVconsv-derived epitopes. In the analysed time range, individual 
vaccine-derived epitope presentation increased with time of infection 
and correlated with the increase of HIVconsv protein expression in 
the cytoplasm. 
Conclusion: This experimental workflow is a powerful new tool 
for direct identification of epitope sequences and will contribute 
extensively to the understanding of immunological processes and 
future vaccine design. 
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P12.50
Cytotoxic Capacity During a Recall Response 
Parallels Increases in Lytic Granule Contents of 
Virus-Specific CD8+ T Cells 
M. Connors1, D.C. Rogan1, E.P. Kelly1, S.A. Toulmin1,  
M.G. Zimmerman1, and S.A. Migueles1
1NIAID, NIH, Bethesda, MD, USA
Background: Although HIV-specific CD8+ T cell cytotoxicity is a 
clear correlate of immune control in LTNP/EC, the kinetics of lytic 
granule loading and cytotoxicity remain incompletely understood. 
A better understanding of the pathways and timing of expression of 
lytic granule contents is critical for the study of these responses and 
ultimately their induction.
Methods: Perforin (delta G9 and B-D48 clones) and GrB expression 
were measured by flow cytometry in HLA B57-KF11 tetramer+ cells 
at times 0, 6 hours and daily for 6 days following stimulation with 
HIV-infected CD4+ T cell targets. In parallel, HIV-specific CD8+ T 
cell proliferative and cytotoxic responses to the same targets were 
measured by flow cytometric detection of CFSE dilution, GrB delivery 
to live targets and infected CD4 elimination (ICE). 
Results: Perforin and GrB expression were lowest in un-stimulated 
tetramer+ cells, increased significantly by day 2 and peaked between 
days 4-6. Perforin and GrB expression correlated with proliferation 
(r=0.95, p<0.01 and r=0.9, p=0.02, respectively). Perforin expression 
over time based on staining with the delta G9 or B-D48 clones was 
highly correlated (r=0.95, p<0.001).  These increases in perforin and GrB 
expression were strongly associated with cytotoxic capacity measured 
by GrB activity (r=0.93, p<0.01 and r=0.86, p=0.02, respectively) and 
ICE (r=0.96, p<0.01 and r=0.93, p=<0.01, respectively). 
Conclusion: Increases in perforin and GrB expression in HIV-specific 
CD8+ T cells that occurred over several days with proliferation and 
were highly correlated with the magnitude of HIV-specific CD8+ 
T cell cytotoxic responses.  Cells stimulated for only 48 hours 
that contained only granzyme B were poorly cytotoxic. Maximal 
cytotoxicity requires coordinate expression of perforin in addition 
to granzymes. Measurement of cytotoxic functions under conditions 
of low levels of antigen, such as in LTNP/EC or vaccinees, requires 
prolonged stimulation.
P12.49
The N-Terminal Domain of HIV-1 Nef 
Regulates Its Ability to Inhibit or Stimulate T 
Cell Receptor-Mediated Signaling Events
T. Markle1, E. Martin2, P. Mwimanzi1, and M. Brockman2
1Simon Fraser University, Burnaby, Canada; 2BC Centre for 
Excellence in HIV/AIDS, Vancouver, Canada
Background: Productive HIV-1 replication depends on host CD4+ T 
cell activation state. The Nef protein modulates T cell activation through 
interactions with various signaling proteins; however, literature on 
this topic is equivocal. Some reports suggest that Nef enhances TCR 
signaling, while others describe an inhibitory effect. To examine this 
question, we measured transcription factor activation following TCR 
stimulation in the presence of wild-type (SF2) or mutant Nef.
Methods: We constructed a panel of SF2-Nef mutants in motifs known 
to affect myristoylation (G2A), CD4 (LLAA) or HLA class I (M20A) down-
regulation, SH3 (AxxA) or PACS-1 (AAAA) binding, as well as truncated 
versions of the protein expressing N-terminal (1-57aa) or C-terminal 
‘core’ (58-206aa) domains. Jurkat cells were co-transfected with Nef 
and NFAT- or AP-1-driven luciferase plasmids. At 20h, cells were 
stimulated with anti-CD3 antibody for 6-8 hours, and TCR-mediated 
transcription factor activity was measured by luminescence.
Results: WT SF2-Nef inhibited TCR-mediated NFAT and AP-1 activity 
up to 5- and 10-fold, respectively.  CD4 and HLA down-regulation and 
PACS-1 binding functions of Nef were not required for inhibition, since 
LLAA, M20A, and AAAA mutants inhibited NFAT to similar levels as 
WT. Myristoylation and SH3 binding mutants, as well as the N-terminal 
domain alone, failed to inhibit NFAT activity. In contrast, NFAT activity 
was enhanced 2-fold relative to negative control in the presence of the 
C-terminal domain alone.
Conclusion: Results indicate that full-length Nef inhibits TCR signaling 
through a process that requires myristoylation and the proline-rich 
motif.  Notably, the core domain, which mimics the Nef product 
generated by protease cleavage, enhanced TCR signaling.  The capacity 
of Nef to carry out opposing functions might reconcile contradictory 
reports in the literature.  Our data suggest that Nef may stimulate T 
cell activation at early stages following viral entry and suppress similar 
events at later stages of viral replication. 
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P12.52 LB 
Impact of HLA-Selection Pressure on HIV 
Replication Capacity at a Population Level
C. Juarez-Molina1, R. Payne1, M. Soto-Nava2, S. Avila-Rios2,  
H. Valenzuela-Ponce2, G. Reyes-Teran2, S. Branch3, C. Landis3,  
and P. Goulder1
1University of Oxford, Oxford, UK; 2Center for Research in 
Infectious Diseases (CIENI), Mexico City, Mexico; 3University of 
West Indies, Bridgetown, Barbados
Background: Previous studies have suggested that effective CTL 
responses drive selection of escape mutations that reduce viral 
replication capacity (RC). There is also evidence that certain escape 
mutations can be transmitted from one host to another, allowing for its 
accumulation in a population. Here, we hypothesize that high frequency 
of protective alleles in a population can drive the accumulation of 
escape mutants with a significant fitness cost at the population level.
Methods: The study compared two ART-naïve HIV B-clade infected 
cohorts, in Mexico (n=976) and Barbados (n=190), in which protective 
HLA alleles (HLA-B*27/57/5801/8101) were expressed at 10% and 35%, 
respectively. Gag genes were amplified from plasma virus and gag-pro 
chimeric viruses for RC analysis were created as previously described. 
Results: Viral loads (VL) were significantly higher in Mexico compared 
to Barbados (median x versus y; p=<0.0001), and absolute CD4+T-
cell counts significantly lower (median x vs. y, p=0.007). RC was 
analysed in a subset of subjects in each cohort matched by CD4+T-cell 
counts between 300-500 cells/µl that did not differ between the two 
cohorts (p=0.8). The VL was significantly higher in the Mexican subset 
(p=0.03). A significantly higher median RC (1.11 versus 1.01, p=0.01) 
was observed in the Mexican cohort. This RC difference was associated 
with accumulations in Barbados of four previously described Gag 
escape mutation where fitness cost has previously been implicated: 
B*57-A163X (p=0.0021), B*57/B*58-T242X (p= <0.0001), B*57-I147X 
(p= <0.0001) and B*58-T310X (p=0.0006).
Conclusion: RC measured by chimeric virus constructed from CD4-
matched cohorts was significantly higher in Mexico compared to 
Barbados. Our data suggest that this may be related to the higher 
frequency of protective alleles in Barbados and a higher frequency 
of Gag escape mutants that reduce viral fitness. Thus viral loads and 
disease progression rates may differ between distinct populations as a 
result of distinct frequency of protective alleles.
P12.51
Sensitive Detection of Vaccine-Induced T Cell 
Responses by Intracellular Cytokine Staining 
Using Automated Gating and Comparison to 
Baseline
S. DeRosa1, M.J. McElrath2, G. Finak2, and R. Gottardo2
1University of Washington, Seattle, WA, USA; 2Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA
Background: Intracellular cytokine staining (ICS) using ex vivo 
stimulation of cells with antigens included in vaccines is a common 
method to determine T cell immunogenicity.  Positivity is determined 
by comparison between the antigen-stimulated and unstimulated 
conditions or by comparison between pre- and post-vaccination. 
Methods: To assess the feasibility of automated gating to accurately 
distinguish pre- and post-vaccination samples, HVTN trial 065 with a 
range of responses to vaccine-encoded proteins (to 80%) was selected. 
To test for sensitivity in detecting low-level responses, a peptide pool 
that demonstrated few positive responses by the standard HVTN 
positivity criteria based on the Fisher’s exact test for IFNγ and/or IL2 
was chosen, PTE-G Pol-3 (1 responder).  Data were from 74 vaccinees 
(37 training set and 37 test set) at day 0 and 2 weeks after the last 
vaccination. OpenCyto was used to gate the data following the gating 
hierarchy from manual gating, including all Boolean combinations 
of cytokine-producing subsets of CD4+ and CD8+ T cells. Penalized 
logisitic regression was used for classification.  
Results: Four features predictive of vaccination status were selected 
by the model.  All were cytokine-producing CD4+ T cell subsets: 
IL2+IFNγ+TNFα+, IL2+IFNγ-TNFα+, IL2-IFNγ-TNFα+, and IL2-
IFNγ+TNFα-.  Overall, 33 of the 37 test samples (90%) were correctly 
classified as pre- or post-vaccination. Prediction accuracy in placebo 
recipients (not part of the training set) was 52%, no better than 
randomly guessing pre- or post-vaccination status.
Conclusion: This study demonstrates that automated 2-dimensional 
gating applied in the hierarchy determined manually accurately 
identifies cytokine-producing T cells post-vaccination.  The sensitivity 
of detecting vaccine responses was far greater than that determined 
by standard methods, suggesting previous underestimation of 
immunogenicity.  Major factors resulting in increased sensitivity may 
include the use of baseline samples (a feature not included in the 
standard method), automated gating, or statistical methods taking into 
account single cytokines or co-expression of cytokines.
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P12.54 LB
Adenovirus 5 Hexon-Specific CD4 T Cells Are 
More Susceptible to HIV and Preferentially 
Depleted During Infection Compared to CMV-
Specific CD4 T Cells
H. Hu1, M. Eller1, S. Zafar1, J. Currier1, M. Marovich2, M. Robb1,  
J. Kim1, N. Michael1, and S. Ratto-Kim1
1US MHRP, Silver Spring, MD, USA; 2NIAID, NIH, Bethesda, 
MD, USA
Background: Different antigen-specific CD4 T cells manifest different 
susceptibilities to HIV with CMV-specific CD4 T cells being particularly 
resistant. It remains unclear whether such HIV resistance is unique to 
CMV or can also be found for CD4 T cells specific to other viruses. Like 
CMV, adenovirus 5 (Ad5) is an important human viral pathogen and 
has been commonly used as vector for HIV/SIV vaccine delivery. We 
investigate the susceptibilities of Ad5- and CMV-specific CD4 T cells 
to HIV. 
Methods: ELISPOT was used to monitor antigen-specific T cell 
responses in HIV-infected patients and un-infected volunteers. An in 
vitro assay was established to assess HIV infection of antigen-specific 
CD4 T cells. PBMC from HIV-negative individuals were CFSE-labeled, 
stimulated with Ad5 hexon and CMV antigens, and exposed to HIV. 
HIV infection of Ad5- and CMV-specific CD4 T cells was determined by 
intracellular p24 in CFSE-low, CD4 T cells.
Results: We observed that Ad5-specific T cell response is preferentially 
lost compared to CMV-specific response in a chronic HIV infection 
cohort. Alternatively, the responses specific to both viruses are present 
at high magnitudes in the HIV-negative volunteers. In vitro studies 
show that compared to CMV, Ad5-specific CD4 T cells are more 
susceptible to both R5 and X4 HIV infection. Ad5-specific CD4 T cells 
demonstrate a mucosal homing phenotype (expression of α4β7 and 
CCR9), and produced IL-17 in addition to IL-2 and IFN-γ, whereas IL-17 
was not detected in CMV-specific CD4 T cells. Analyses of cytokine and 
intracellular p24 co-expression show that HIV preferentially infects IL-
17 and IL-2-producing antigen-specific CD4 T cells. 
Conclusion: Our in vitro and in vivo data demonstrate that human 
Ad5-specific CD4 T cells are more susceptible to HIV and preferentially 
depleted during infection compared to CMV-specific CD4 T cells. 
The results may have important implications for HIV vaccine design 
regarding selection of viral vectors.
P12.53 LB
Evaluating CTL-Based “Flush and Kill” HIV 
Eradication Strategies Against Primary Cell 
Models of Latency and Natural Viral Reservoirs
B. Jones1, R. O’Connor1, S. Mueller1, D. Karel1, M.J. Buzon1,  
M. Lichterfeld1, M. Ostrowski2, D.J. Irvine1, and B.D. Walker1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; 
2University of Toronto, Toronto, Canada
Background: Purging of HIV-infected resting CD4+ T-cells will likely 
require the coordinated action of latency-reversing agents (LRAs) and 
cytotoxic T-lymphocytes (CTL). We have developed an assay that 
incorporates HIV-specific CTL as sensors of latency reversal, and used 
this to assess LRAs in primary cell models. Based on our findings, we 
prioritized “flush and kill” strategies and tested these for eradication of 
HIV from natural reservoirs in vitro. 
Methods: CD4+ T-cells were depleted of activated cells and infected 
with HIV. Autologous HIV-specific CTL clones were co-cultured with 
these targets in the presence or absence of LRAs. IFN-γ was quantified 
as a measure of CTL recognition. Optimal combinations of CTL and 
LRAs were co-cultured with autologous CD4 (natural HIV reservoirs) 
for 96-117 hours. CTL and dead cells were depleted and the residual 
reservoir was measured by qPCR and viral outgrowth assays.
Results: While HDAC inhibitors (HDACi) and common gamma-chain 
cytokines both reversed HIV latency, HDAC is suppressed CTL function 
and thus performed poorly in integrated “flush and kill” assays. In 
contrast, IL-15 superagonist (IL-15SA) both reversed HIV latency and 
enhanced CTL function. Treating patient CD4+ T-cells with a romidepsin 
pulse/wash followed by co-culture with HIV-specific CTL and IL-15SA 
resulted in a 5-fold reduction in proviral DNA and in the elimination of 
infectious virus as measured by viral outgrowth assays.
Conclusion: There are advantages to incorporating CTL into early 
screening of LRAs for use in eradication strategies. First, CTL can 
be used as sensors to detect latency reversal above an expression 
threshold that is intrinsically relevant to CTL-mediated clearance. 
Second, this allows consideration of the effects of LRAs on CTL 
function. We show that an optimal LRA/CTL combination approach is 
capable of depleting the reservoir in vitro. Further study will determine 
the minimal elements required for this depletion, and the nature of 
residual proviral DNA.
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P12.56 LB
Evaluation of Peripheral and Mucosal Cellular 
Immune Responses Induced by Late Boost 
Strategies in HIV-Negative Participants Prior 
Enrolled in RV144 
A. Schuetz1, Y. Phuangngern1, M.S. de Souza2, S. Sukhumvittaya1, 
S. Jongrakthaitae1, R. Rerknimitr3, P. Saengtawan4,  
J. Ananworanich5, S. Vasan1, S. Ratto-Kim6, P. Pitisuttithum7,  
N. Michael6, R.J. O’Connell1, V. Ngauy1, S. Rerks-Ngarm8, and  
J.H. Kim6
1USAMC-AFRIMS, Bangkok, Thailand; 2Thai Red Cross 
AIDS Research Center, Bangkok, Thailand; 3Chulalongkorn 
University, Bangkok, Thailand; 4SEARCH, Bangkok, Thailand; 
5Thai Red Cross AIDS Research Center, Chulalongkorn 
University, SEARCH, Bangkok, Thailand; 6US MHRP, Silver 
Spring, MD, USA; 7Mahidol University, Bangkok, Thailand; 
8Ministry of Public Health, Bangkok, Thailand
Background: To determine cellular immune responses in periphery 
and sigmoid mucosa in participants enrolled in a randomized, double-
blind evaluation of late boost strategies to define relative contribution 
of	AIDSVAX®B/E,	ALVAC-HIV	or	ALVAC-HIV/AIDSVAX®B/E	6-8	years	
after receiving the original RV144 prime/boost 
Methods: Sixteen participants receiving 2 injections of ALVAC-HIV/
AIDSVAX®B/E	 (5),	 AIDSVAX®B/E	 (3),	 ALVAC-HIV	 (5)	 or	 placebo	
(3) at baseline and week24, underwent sigmoid biopsies at peak-
immunogenicity (week26). Mucosal mononuclear cells and paired 
PBMC were isolated and HIV-specific responses were measured using 
IFNγ/IL-2 Intracellular Cytokine Staining. Assays were conducted to the 
following HIV-1 peptide pools: Env, EnvΔV2 (V2 loop depleted) and V2 
loop only. Positive responses were defined as >0.05% corrected and at 
least 3 times background. In PBMC activation of CD4 and CD8 T cells 
was determined by the expression of HLA-DR, CD38, Ki67 and CD69. 
Results: Peripheral responses were largely CD4-mediated and Env-
specific. No positive CD4-responses were observed at baseline in 
the active vaccination arms and in placebo recipients at any time 
point.	 4/5	 participants	 receiving	 ALVAC-HIV/AIDSVAX®B/E	 showed	
Env-specific CD4-responses at week26, while none were seen with 
AIDSVAX®B/E	or	ALVAC-HIV	alone.	 In	the	ALVAC-HIV/AIDSVAX®B/E	
arm V2-specific and non-V2 responses were seen in 2/5 and 3/5 
participants, respectively. Peripheral Env-specific CD8-responses were 
only observed with ALVAC-HIV (2/5). HIV-nonspecific activation of 
CD4 T cells indicated by HLA-DR and CD69 expression increased 
significantly	 after	 administration	 of	 ALVAC-HIV/AIDSVAX®B/E	
(p=0.005 and p=0.01, respectively), with no significant changes in 
CD8 T cell activation regardless of the vaccination arm. In the sigmoid 
mucosa no Env-specific CD4-responses were observed, whereas 
modest CD8-responses were seen in participants receiving ALVAC-HIV/
AIDSVAX®B/E	(2/5)	and	AIDSVAX®B/E	(1/3).
Conclusion: A	 late	 boost	 with	 ALVAC-HIV/AIDSVAX®B/E	 induced	 a	
strong Env-specific recall CD4-response in the periphery accompanied 
by CD4 activation. In the sigmoid mucosa only Env-specific CD8-
responses were observed, possibly suggesting differences in HIV-
specific lymphocyte trafficking between these compartments.
P12.55 LB
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P12.57 LB 
The Essential Role of Epigenetic Regulation for 
CD4+ T Cell Dysfunction During Chronic HIV-1 
Infection
K. Nakayama-Hosoya2, T. Ishida1, H. Nakamura2, M. Koga2,  
N. Hosoya2, T. Koibuchi2, A. Iwamoto2, and A. Kawana-Tachikawa2
1University of Tokyo, Beijing, China; 2University of Tokyo, 
Tokyo, Japan
Background: The molecular mechanisms of CD4+ T cell dysfunction 
during chronic HIV-1 infection remains still unknown.
Methods: Expression of IL2, IFNγ, and TNFα after T cell stimulation 
was measured in mRNA and protein levels in HIV-1 infected subjects 
with different clinical status. DNA methylation status of individual CpG 
site in the promoter region of these 3 genes was analyzed in CD4+ 
and CD8+ T cells. Differentiation status and CD57 expression in CD4+ 
T cells were also assessed. 
Results: Expression level of IL-2 after brief T cell stimulation was 
significantly lower in non-controllers (NC, HIV-VL >25,000 copies/ml) 
than viremic controllers (VC, HIV-VL <1,000 copies/ml), and there was 
no significant difference in the expression levels of IFN-γ and TNF-α 
between the groups. Although DNA methylation status in IFNG and 
TNF genes were indistinguishable between the groups, frequency 
of methylated CpG sites in the IL2 promoter region in CD4+ T cells, 
not in CD8+ T cells, was significantly higher in NC compared to VC. 
Especially, difference in the methylation status at CpG site 1 located 
between the NFAT- and Oct-1-binding sites was remarkable between 
the groups, and the methylation status was inversely correlated to the 
IL-2 expression level. Although there was no significant difference in 
differentiation status between the groups, CD57 expression in memory 
(CD45RA-) CD4+ T cells, a marker as senescence of T cells, was higher 
in NC than VC. CD57+ memory CD4+ T cells hardly expressed IL-2 
even after PMA/ionomycin stimulation, and the CpG site 1 in IL2 gene 
was hyper-methylated compared to CD57- memory CD4+ T cells. 
Conclusion: Our data indicate that DNA hyper-methylation in IL2 
gene, which is associated with immunological senescence, contributes 
to the dysfunction in CD4+ T cells during chronic HIV-1 infection. 
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P13.02 D
Synthetic Enhanced EP Delivered Ig DNA 
Vector Drives Biologically Relevant Anti-HIV-1 
Envelope Responses In Vivo
K. Muthumani1, S. Fligai1, M.  Wise1, C. Tingey1, J. Yan2,  
K.E. Ugen3, and D.B. Weiner1
1University of Pennsylvania School of Medicine, Philadelphia, 
PA, USA; 2Inovio Pharmaceuticals, Blue Bell, PA, USA; 
3University of South Florida, Morsani College of Medicine, 
Tampa, FL, USA
Background: Monoclonal Ab’s have demonstrated therapeutic utility 
against several malignancies and infectious diseases. A drawback 
of this strategy is the time-consuming and expensive process 
requiring purification and scale up production of the Ab’s for clinical 
use. A method to produce antibodies in vivo would be significant 
improvement for this platform. It would be important if these Ab’s 
could be administered with out induction of vector serology allowing 
repeated administrations. Furthermore, delivery in a non-permanent 
fashion would also have advantages. 
Methods: Here we report development of new synthetic optimized 
plasmid vector/improved EP encoding Abs genes for delivery in vivo. 
This strategy allows for in vivo synthesis and serum expression of 
such ex vivo developed antibodies.  The antibodies were found to be 
expressed in the blood as well as in other compartments and were 
functional and at protective levels for model systems.    
Results: An “enhanced and optimized” DNA plasmid generates 
immunoglobulin heavy and light chains (Fab) of an established 
neutralizing anti-HIV monoclonal antibody (VRC01). We demonstrate 
that the serum of transfected animals exhibited the ability to bind to 
HIV envelopes in ELISA and FACS analysis against diverse isolates and 
this serum possessed HIV neutralizing activity equivalent to the “native” 
VRC01 antibody in vivo. In vivo delivery seroconverted the animals 
with in a few hours and neutralizing activity lasted for weeks.  This 
technology has important advantages for in vivo antibody production 
which could compliment or circumvent the need for standard antigen 
based vaccination, particularly in situations where there is difficulty in 
generation of protective antibody responses by immunization.  
Conclusion: This is the first study we are aware of using synthetic 
DNA EP delivery to produce circulating bioactive antibody responses 
in a living animal. The study has implications for prophylactic and 
therapeutic strategies for HIV and other important diseases.    
P13.01 D
Cross-Neutralizing Antibodies Are Elicited in 
Macaques Immunized with DNA and Protein 
Env Vaccines Derived from Subjects During 
Development of Breadth
A.J. Hessell1, D.C. Malherbe1, F. Pissani1, N. Sather2, H. Robins3, 
W.F. Sutton1, S. Pandey1, B. Park1, L. Stamatatos2, and  
N.L. Haigwood1
1VGTI, Oregon Health & Science University, Beaverton, OR, 
USA; 2Seattle Biomed, Seattle, WA, USA; 3Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA
Background: During infection, the dynamic interaction between HIV-
1 and the host immune responses drives the selection of Envelope 
(Env) to evade antibody pressure. Over time the changing virus 
influences the evolving responses, including the maturing neutralizing 
antibodies (NAbs). We have SGA cloned and studied the phylogeny of 
Env sequences that evolved during infection in two broad neutralizer 
human subjects and characterized the epitope targets of the NAbs. In 
preceding studies, we developed immunization strategies in rabbits 
using rationally selected Envs from these two individuals. Here, we 
vaccinate macaques with the most successful vaccine designs from the 
rabbit studies.
Methods: Twelve macaques were divided into two groups of six 
animals and co-immunized with motif-optimized gp160 Env DNA and 
gp140 trimeric protein at week 0, 4, 12 and 20. Serological samples 
were collected including blood, bone marrow, and lymph nodes 
for serum antibody and neutralization monitoring and for avidity 
measurements and B and T cell-associated analysis.
Results: After one immunization, all macaques rapidly developed 
>10 4 binding antibody titers to autologous Envs. Autologous NAbs 
developed after two immunizations that were boosted with subsequent 
immunizations. Heterologous SF162 NAbs developed after a single 
immunization and increased following the second vaccination 
(P=0.022 and P=0.0087 for each group), with titers eventually 
reaching 104. Neutralization breadth was detected at week 5 after 
two immunizations against Tier 1 and Tier 2 viruses and increased 
with further immunizations. Fine mapping of macaque NAb responses 
provided evidence of recapitulation of epitope specificities in the 
human subjects.
Conclusion: The non-human primate vaccine model has great value 
for defining the correlates of protection for humans during exposure 
events. In this study we show that it is possible to recapitulate in 
macaques NAb immune responses that developed in human subjects by 
presenting Envs in a programmed manner, based on specific molecular 
characteristics uncovered by probing the human quasispecies.
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P13.04 D
Association of CD8+ T Cell Responses to 
Conserved HIV Epitopes with Viral Control: 
Implications for HIV Vaccine Design
P. Kunwar1, N. Hawkins2, W.L. Dinges3, Y. Liu4, E.E. Gabriel2,  
D.A. Swan2, C. Stevens4, J. Maenza4, A.C. Collier4, J.I. Mullins4,  
T. Hertz2, X. Yu2, and H. Horton4
1Seattle Biomedical Research Institute, Seattle, WA, USA; 
2Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
3Polyclinic Infectious Disease, Seattle, WA, USA; 4University of 
Washington, Seattle, WA, USA 
Background: The enormous diversity of HIV-1 has hampered the 
development of a safe and effective prophylactic HIV-1 vaccine. To 
tackle the HIV-1 diversity problem, a global T cell based HIV-1 vaccine 
will potentially need to elicit vaccine-induced responses against 
multiple conserved regions of the virus. This project was designed to 
determine if epitope-conservation of induced HIV-specific CD8+ T cell 
responses is important for early viral control following HIV-1 infection. 
Methods: Using IFN-γ ELISpot, we comprehensively mapped HIV-1 
CD8+ T cell epitope-specificities in 23 ART-naïve individuals during 
early infection. We computed conservation score (CS) of targeted 
CD8+ T cell epitopes by three different methods (prevalence, entropy 
and conseq) using clade-B and group-M sequence alignments. We 
assessed the association between CS of targeted CD8+ T cell epitopes 
and each individual’s set-point viremia. Comparisons were performed 
by Spearman-rank-correlation and Wilcoxon-rank-sum tests. 
Results: The majority of CD8+ T cell responses were directed against 
variable epitopes (p<0.01). Interestingly, increasing breadth of CD8+ 
T cell responses specifically recognizing conserved epitopes was 
associated with lower set-point viremia (r=-0.65,p=0.009). Moreover, 
subjects possessing CD8+ T cells recognizing at least one conserved 
epitope had 1.4log10 lower set-point viremia compared to those 
recognizing only variable epitopes (p=0.021). The association between 
viral control and the breadth of conserved CD8+ T cell responses may 
be influenced by the method of CS definition and sequences used 
to determine CS. Surprisingly, targeting variable versus conserved 
epitopes was independent of HLA type (p=0.215). The associations 
with viral control were independent of functional avidity of CD8+ T cell 
responses elicited during early infection. 
Conclusion: These data suggest that the next-generation of T cell 
based vaccines should focus on strategies to induce greater breadth 
of CD8+ T cell responses particularly recognizing only conserved 
epitopes of HIV-1.Taken together; our results provide information that 
may guide the selection of immunogens for development of effective 
HIV-1 vaccines. This project is funded by NIH-grant#R01AI090783. 
P13.03 D
Increased Neutralizing Antibody Responses 
Elicited by a Bivalent HIV-1 Env Protein Vaccine 
Comprising Stable Mosaic and Clade C HIV-1 
gp140 Trimers
J.P. Nkolola1, C.A. Bricault1, A. Cheung1, J. Perry1, M. Seaman1, 
and D. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: The generation of globally relevant HIV-1 immunogens 
mimicking the native, trimeric Envelope (Env) spike, remains a major 
challenge for HIV-1 vaccine development. We identified a mosaic 
Env sequence which was capable of forming biochemically stable 
trimers. We assessed the mosaic Env gp140 trimer in guinea pig 
immunogenicity studies either alone or with the clade C C97 trimer.
Methods: Mosaic and clade C gp140 trimers were stabilized with a T4-
fibritin C-terminal trimerization tag and produced in 293T cells. Guinea 
pigs were immunized three times at 4–week intervals with 100 µg of 
mosaic (M), 100 µg of clade C (C) or 100 µg total of an equal mixture 
of C+M gp140 protein trimers in CpG/Emulsigen adjuvant. Antibody 
responses were determined by ELISA and TZM.bl neutralizing antibody 
(NAb) assays.
Results: M, C and C+M gp140 trimer vaccination regimens elicited 
high-titer, cross reactive binding antibodies in guinea pigs by ELISA. 
In TZM.bl NAb assays, the C gp140 elicited significantly higher NAb 
titers than the M gp140 against clade A virus DJ263.8 (P<0.05; NAb 
titer range 200-950 versus 35-125) and clade C virus MW965.26 
(P<0.05; NAb titer range 11,900-35,200 versus 330-630). In contrast, 
the M gp140 elicited higher NAb titers than the C gp140 against clade 
B viruses SF162.LS (P<0.05; NAb titer range 800-2300 versus 125-
925) and Bal.26 (P<0.05; NAb titer range 730-1800 versus 25-65). 
NAb responses elicited by the C+M gp140 combination (MW965.26 
= 9270-43,750, DJ263.8 = 240-1185, Clade B SF162 = 240-1570 
and clade B Bal.26 = 400-1380) proved additive and were superior to 
either M or C gp140 alone.
Conclusion: The combination of C+M gp140 trimers elicited NAbs with 
increased breadth compared with either trimer alone in guinea pigs. 
These data suggest that relatively small numbers of immunologically 
complementing Env trimers may be a feasible strategy to improve the 
immunogenicity of antibody-based HIV vaccines.
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P13.06
HIV p24 as Scaffold for Presenting 
Conformational HIV Env Antigens
M. Tagliamonte5, D. Marasco1, A. Ruggiero2, A. De Stradis3,  
M. Tornesello5, M. Totrov4, F.M. Buonaguro5, and L. Buonaguro5
1University of Naples Federico II and National Resource 
Council, Naples, Italy; 2National Resource Council, Naples, 
Italy; 3National Resource Council, Bari, Italy; 4Molsoft LLC, La 
Jolla, CA, USA; 5Istituto Nazionale Tumori “Fond. Pascale” - 
Napoli, Italy
Background: Heterologous protein scaffolds engrafted with structurally 
defined HIV Env epitopes recognized by broadly neutralizing 
monoclonal antibodies (MAbs) represent a promising strategy to elicit 
broad neutralizing antibodies. 
In such regards, a protein scaffold based on the HIV p24 CA protein is 
a highly attractive approach, providing also Gag epitopes for eliciting 
HIV non-neutralizing protective antibodies and specific CD4+ and 
CD8+ T cell responses. 
Methods: In the present study, computational techniques were 
employed to verify the presence of acceptor sites for conformational 
HIV Env epitopes and, as proof of concept, the analysis of HIV p24 
CA-based scaffolds using a complete V3 loop in a MAb-bound 
conformation is presented.Evaluation of binding of p24:V3 proteins to 
anti-V3 MAbs was performed by ELISA and SPR analysis.
Results: The V3-p24 epitope-scaffold proteins show the formation of 
capsomers made of hexamers similarly to the p24 wild type protein. 
Moreover, the conformational V3 loop presented on p24 scaffold 
is recognized by a panel of anti-V3 MAbs. The results suggest that 
HIV p24 CA protein has suitable acceptor sites for engrafting foreign 
epitopes, without disrupting the formation of capsomer hexamer 
structures, and that the V3 epitope does retain its antibody-bound 
conformation. ELISA results show that the V3 loop inserted on the 
p24 scaffold is sufficiently exposed and retained the ability to bind to 
anti-V3 mAbs. Moreover, SPR analsysis indicates that chimeric proteins 
bound anti V3 mAb in a quite similar fashion providing a KD values 
ranging from 10 to 13 µM.
Conclusion: This strongly support the feasibility of developing 
a scaffolding strategy based on p24 CA proteins displaying 
conformational minimal structural, antigenic HIV Env epitopes. 
Immunization analysis in animal model is currently ongoing and 
results will possibly presented. (Tagliamonte et al., PLoS One. 2012; 
7(8):e43318)
P13.05
An Inactivated Viral Vaccine that Displays 
Conformationally Intact HIV-1 Clade B 
Envelope Trimers Induces Neutralizing 
Antibodies in Rabbits
R. Lindsay1, R.L. Powell1, K. Wright1, A. Wilson1, M. Yuan1,  
M. Kemelman1, H.E. Arendt1, J. DeStefano1, A. Carpov1, A. Domi1, 
C.R. King1, and C.  Parks1
1IAVI, Brooklyn, NY, USA
Background: An ideal HIV vaccine should induce broadly neutralizing 
antibodies (bNAbs); however, the generation of native, trimeric Env 
has proven to be a difficult task. To meet this need, we have developed 
recombinant vesicular stomatitis virus (VSV) vectors that display 
functional, trimeric HIV-1 clade B (JRFL) Envelope (Env). 
Methods: JRFL Env was cloned onto the VSV Glycoprotein (G) 
transmembrane/cytoplasmic tail domain to generate a hybrid EnvG 
surface protein in the context of a ∆G VSV (VSV-EnvG-∆G). EnvG 
antigenicity was analyzed by flow cytometry. Female New Zealand 
rabbits were immunized IM with 3x106 , 3x107 or 3x108 PFU formalin 
inactivated VSV (iVSV-EnvG-∆G) in a dose optimization study. An 
immunization of 10ug  JRFL gp140 foldon trimer (FT) served as control. 
Immunizations were given at weeks 0, 4 and 18 and all vaccines were 
adsorbed	to	100ug	Adju-Phos®	(Brenntag,	Denmark)	and	mixed	with	
75 ISCO TM units of ISCOMATRIX TM adjuvant (CSL, Australia). Serum 
was assessed by anti-Env IgG ELISA, competition-binding and TZM-bl 
neutralization assays.
Results: Analysis of alum-bound iVSV-EnvG-∆G confirmed binding 
to various bNAbs including PGV04 (CD4 binding site), PGT126 
(glycan/V3-loop), PG9 (V1/V2 quaternary epitope), and 2F5 (gp41-
MPER), and importantly, the trimer-specific PGT151. At peak, 3x10 7 
, 3x10 8 PFU and gp140 FT control groups exhibited similar  anti-Env 
titers, while the 3x10 6 group titers were ~1 log lower. In addition, 
3x10 7 and 3x10 8 PFU-immunized animals exhibited significantly 
enhanced serum competition for PGV04 and PGT126 binding and 
neutralization capacity.
Conclusion: Animals immunized with iVSV displaying conformationally 
intact trimer demonstrated an improved quality of Ab response as 
compared to those immunized with gp140 FT control.
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P13.08
Immunogenicity Potential of MVA Vectors 
After Removal of the Immunomodulatory 
A44L and A46R Viral Genes
M.P. Holgado1, J. Falivene1, M.P. del Medico Zajac2, C. Maeto1, 
A.M. Rodriguez1, M.F. Pascutti1, G. Calamante2, and  
M.M. Gherardi1
1Instituto de Investigaciones Biomedicas en Retrovirus y SIDA - 
Universidad de Buenos Aires, Buenos Aires, Argentina; 2Instituto 
de Biotecnología, CICVyA-INTA Castelar, Castelar, Argentina
Background: Modified Vaccinia Ankara (MVA) still retains genes 
involved in host immune response evasion.  We have previously 
reported the optimization of MVA vaccine potential after the deletion 
of the C12L gene encoding an IL-18 binding protein. Here we analyze 
the immunogenicity of MVA vectors harboring the simultaneous 
deletion of two viral genes: A44L, implicated in synthesis of steroid 
hormones and A46R, which inhibit transduction signals from TLR 
receptors (MVAΔA44L-A46R); or with an additional gene deletion: 
C12L (MVAΔC12L/ΔA44L-A46R).
Methods: C57Bl/6 mice were intramuscularly immunized with wild 
type (MVAwt), or deleted MVAs (dMVAs). T cell responses to VACV 
(Vaccinia Virus) epitopes were evaluated at acute and memory phases 
(7 and 45 days post-immunization (dpi) respectively). The proportion of 
IFN-γ and IL-2 producing cells was measured by ELISPOT. Percentage 
of cytotoxic CD8-T cells was analyzed by flow citometry through 
CD107a/b surface-marker, and memory T cell responses by expression 
of CD44 and CD62L among proliferating (CFSElow) T cell populations.
Results: Compared with MVAwt at 7dpi both dMVAs induced significant 
increases in the IFN-γ anti-VACV CD8 and CD4-T cells (1,5 to two-fold, 
p<0,01; 2,5 to five-fold, p<0.01 respectively); and IL-2 anti-VACV CD8-
Tcells (up to five-fold higher; p<0,01). Importantly, increments at 45 
dpi in IFN-γ CD8 and CD4-T cell responses were maintained (p<0,05); 
regarding anti-VACV IL-2 secreting cells, improvements were of two 
or four-fold against CD4 and CD8 peptides (p<0,05). Proliferating 
anti-VACV CD8-T cells were incremented from 1% (MVAwt) to 2,8% 
(MVAΔC12L/ΔA44L-A46R) and significantly this vector elicited a higher 
proportion of specific TCM (45,2%) than TEM (43,5%) compared to 
MVAwt (TCM:19,5%, TEM:63%). Percentage of specific cytotoxic 
CD8-T cells that secrete IFN-γ (CD107/IFN-γ), were also incremented by 
MVAΔC12L/ΔA44L-A46R.
Conclusion: Simultaneous deletion of specific viral genes from the 
MVA genome with inter-related functions as A46R and C12L is an 
adequate strategy to improve the vaccine potential of this vector.
P13.07
Development of Novel Simian Adenovirus 
Based Vaccine Vectors
P. Abbink1, L. Maxfield1, D. Ng’ang’a1, Z. Cama1, F. Ball1,  
C.  Bleckwehl1, E. Borducchi1, and D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: Human adenovirus serotype 5 is a potent vaccine vector, 
but its use has been hampered by high seroprevalence amongst 
people in sub-Sahara Africa. Novel adenoviral vaccine vectors from 
strains with lower seroprevalence worldwide are being developed that 
can evade pre-existing immunity. Here we describe the development 
of a panel of novel old world monkey adenovirus vaccine vectors.
Methods: Wild type adenoviruses were isolated from rhesus monkey 
stool samples tested positive for adenovirus by metagenomic 
sequencing. Novelty was determined by whole genome sequencing. 
sAd4287, sAd4310A and sAd4312 were cloned from these new 
isolates and subjected to immunology and seroprevalence assays. 
Neutralizing antibodies against sAd287, sAd4310A and sA4312 were 
determined using a panel of 106 rhesus macaque sera and 128 
human sera from Rwanda and South Africa using a luciferase-based 
adenovirus neutralization assay. The immunogenicity of a single dose 
of 10E7, 10E8 or 10E9 virus particles of each sAd-SIV Gag based vector 
was determined in C57BL/6 mice. SIV-Gag-specific immune responses 
were assessed by Db/AL11 tetramer binding assays, IFN-γ ELISPOT 
assays and ICS assays. 
Results: 85-95% of human sera from sub-Saharan Africa had 
undetectable neutralizing antibody titers to these novel sAd vectors 
with 90% of positive tested sera showing titers <200. In comparison, 
seroprevalence of Ad5 in sub-Saharan Africa is 86.4-89.5% with 
61.1-78.7% of this population showing titers >200 and 25.1-46.8% 
showing titers >1000. Neutralizing antibodies in monkey sera were 
detected in 5-45% of the population, 90% of which showing titers 
<200. Gag specific CD8+ T-lymphocyte responses were readily 
detected with Db/AL11 tetramer as well as IFN-γ ELISPOT assays. SIV 
Gag specific immune responses elicited by these sAds are comparable 
to those seen with the human Ad26 and Ad28 vectors currently in 
development at all doses.
Conclusion: These data suggest that these novel simian Ad vectors are 
promising for further studies as candidate vaccine vectors.
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P13.10
Longitudinal Assessment of Immunogenicity 
and Pathology of Dual HIV/TB Vaccines 
Constructed Using Modified Strains of BCG
S. Chetty1, E. Shephard1, D. Bowers1, R. Chapman1, and  
A. Williamson1
1University of Cape Town, Cape Town, South Africa
Background: An efficacious vaccine is required to combat the dual 
pandemic of HIV and TB. Our group has recently shown BCGΔpanCD 
Pasteur to be safer and more immunogenic as an HIV vaccine than 
wildtype BCG when used in conjunction with a Modified Vaccinia 
Ankara boost (MVA). Furthermore, TB vaccine studies have shown 
BCG expressing perfringolysin (pfo) promotes antigen translocation 
and induces stronger CD8+ T cell responses. In this study, wild type, 
ΔpanCD, pfo and a combination ΔpanCDpfo strain of BCG from 
Aeras were constructed to express HIV-1 subtype C Gag.  We aimed 
to longitudinally assess pathology and cellular events leading to the 
development of HIV-specific immunogenicity.
Methods: rBCG vaccines were given intraperitoneally to BALB/c mice, 
sacrificed 2, 3,7,12 and 28 days post-vaccination. Using flow cytometry 
and immuno-histochemistry we assessed the roles of dendritic cells, T 
cells, B cells and macrophages in the development of pathology and 
immunogenicity. Additional groups of rBCG vaccinated mice were 
boosted MVA boost (day 28) and sacrificed (day 40). Using ELISPOT 
and flow cytometry, we assessed HIV specific immunogenicity at the 
day 40 time point.
Results: HIV-specific polyfunctional CD4+ and CD8+ T cell responses 
induced by the modified strains of BCG were of higher magnitude as 
compared to the wildtype strain following an MVA boost. Increased 
infiltration of antigen presenting dendritic cells and macrophages 
were observed in ΔpanCD and pfo containing strains at days 2 and 
3. However, at peak rBCG infection (day 21) and later time points 
(day 28 and 40), the modified BCG strains induced significantly less 
pathology than the wildtype strain as measured by BCG granuloma 
count (p<0.05). 
Conclusion: We have shown modified rBCG containing gag to be more 
immunogenic and less pathogenic than wildtype BCG when used in 
conjunction with an MVA-boost. These characteristics suggest that 
optimised BCG is attractive dual HIV/TB vaccine vector. 
P13.09
Sequence Evolution in SIVNef Refocuses the 
CD8 T Cell Response on More Conserved 
Epitopes
S. Adnan1, A.D. Colantonio1, Y. Yu1, J. Gillis1, F.E. Wong1,  
E.A. Becker2, S.L. O’Connor2, and R.P. Johnson1
1Harvard Medical School, Southborough, MA, USA; 2University 
of Wisconsin-Madison, WI, USA
Background: Vaccination with live attenuated simian immunodeficiency 
virus (LASIV) induces robust protection against wild-type SIV challenge, 
including sterile protection, which is rarely observed using other 
vaccine modalities. Protection induced by LASIV matures with time, 
significantly increasing at 15-20 weeks after vaccination. Neither the 
breadth nor the magnitude of the T cell response correlate with this 
increased protection, here we demonstrate that sequence evolution of 
LASIV and a concomitant shift in CD8 T cell specificity do.
Methods: Plasma or lymph node CD4 T cell-associated viral RNA from 
8 SIVΔnef-vaccinated animals was obtained at time points ranging 
between 2 and 34 weeks after vaccination. Viral RNA was reverse 
transcribed, quantitated by qPCR, and sequenced using an Illumina 
MiSeq next generation sequencing platform. The CD8 T cell response 
was mapped to the epitope level for 6 animals at weeks 5 and 20 post-
vaccination using ELISPOT assays. CD8 T cell responses at the protein 
level were mapped for 18 animals. 
Results: SIVΔnef sequence evolution occurred as early as 3 weeks 
post-infection and continued into the chronic phase of infection, even 
in animals with undetectable plasma viral load. Viral mutations were 
concentrated in mapped and known CD8 T cell epitopes. Epitope 
escape was followed by a decreased frequency of epitope-specific CD8 
T cells relative to the total SIV-specific CD8 T cell response. Epitopes 
with the lowest Shannon Entropy score did not escape, and their 
response frequencies were maintained. The Response Conservation 
Index (RCI), a measure of the extent to which the CD8 T cell response 
is focused on conserved regions of the virus, increased in all animals 
between weeks 5 and 20. 
Conclusion: Extensive SIVΔnef sequence evolution occurs in 
vaccinated animals, even at low plasma viral load levels, and drives 
a concomitant shift in the specificity of the CD8 T cell response, 
refocusing it on more conserved epitopes.
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P13.12
Immunofocusing to HIV’s V2 Loop C ß-Strand
S. Shmelkov1, M. Rao2, S. Wang3, X. Kong1, S. Lu3, and T. Cardozo1
1New York University School of Medicine, New York, NY, USA; 
2Henry M. Jackson Foundation, Bethesda, MD, USA; 3University 
of Massachusetts Medical School, Worcester, MA, USA
Background: The RV144 trial is the only HIV vaccine clinical trial to 
show evidence that a vaccine can prevent HIV infection. We aligned 
the V2 reagents with odds ratios (OR) lower than 0.5 reported in the 
RV144 immune correlates study, and we determined that at least 
some protective antibodies (Abs) from the RV144 trial target the 
peptide segment from positions 165-181 of the V2 loop (V2 165-181 
), which is centered on the V1V2 domain’s C ß–strand. Thus, vaccine 
immunogens that exclusively present V2 165-181 may preferentially 
elicit Abs that protect against HIV infection.
Methods: We fused a V2 165-181 peptide to a non-HIV scaffold in 
a manner that recapitulates the conformation of this segment in the 
native folded V1V2 domain. We tested this designed immunogen by 
immunization in rabbits using a DNA prime-protein boost approach.
Results: We found that IgG from the immunized rabbits’ sera bound a 
cyclic V2 peptide with high endpoint titers and neutralized Tier 1 HIV 
viruses from subtypes B, C and AG.
Conclusion: Our data demonstrate that Abs elicited from a synthetic 
peptide consisting of only the key C ß-strand-centered segment 
of the V1V2 domain can bind to V2 165-181 in its native context 
within the HIV virus, and in some cases can neutralize the virus. Our 
results provide proof of concept that a V2 165-181 immunofocused 
immunogen, which can be further designed to preferentially present 
the epitopes associated with protection in the RV144 trial, can elicit 
neutralizing antibodies.
P13.11
Elaboration of Imiquimod-Loaded 
Biodegradable Micelles as HIV-1 Vaccine 
Adjuvant  
T. Trimaille1, G. Jimenez-Sanchez2, D. Gigmes1, and B.  Verrier2
1Aix-Marseille Université, France; 2Université Lyon 1, Lyon, France
Background: The development of antigen-based vaccines requires the 
use of particulate adjuvants (emulsions, polymers,) to improve antigen 
immunogenicity. An important challenge to improve efficiency of such 
vaccines relies on their ability to target and activate dendritic cells 
(DCs), which play a crucial role in the immune response. This can be 
achieved by incorporating, in addition to the antigen, DC ligands to 
the particulate adjuvant. In this context, we have developed polymeric 
micelles functionalized with HIV-1 p24 at their surface and imiquimod, 
a TLR7 ligand, in their inner core.  
Methods: Micelles of amphiphilic block copolymer poly (D, L-lactide)-
b-poly (N-vinylpyrrolidone-co-N-acryloxysuccinimide) (PLA-b-P 
(NVP-co-NAS), 19000-22000 g.mol -1, PDI=1.5) were prepared 
by nanoprecipitation and characterized in terms of size (DLS) and 
critical micellar concentration (cmc). Imiquimod was incubated with 
the aqueous micellar solution for 1 hour and imiquimod loading in 
the micelles was quantified by fluorimetry. The micelles were further 
surface functionalized p24 antigen, through amine reaction with the 
N-succinimidyl esters of the NAS units at micelle surface in PBS pH 
7.4 for 20 hours. Protein coupling on the micelles were investigated 
by SDS-PAGE. The expression of DC maturation/activation markers 
CD80, CD83, CD86 induced by the micelles was assessed in vitro by 
flow cytometry. 
Results: The micelles initially prepared from the PLA-b-P(NVP-co-
NAS) copolymer exhibited a mean diameter of 58 nm and a CMC 
of 20 mg/mL -1 . Hydrophobic imiquimod was encapsulated at a 
loading of 1.5% (w/w). The imiquimod-loaded micelles were further 
highly surface-functionalized with p24 antigen, at a level of 0.12 
mg p24 per mg of micelle, with a final size of 110 nm. Imiquimod 
encapsulated in the micelles was shown to induce up-regulation of 
the DC maturation markers.   
Conclusion: Such novel micelle-based systems could thus be promising 
for vaccine delivery, particularly considering their ability to potentially 
reach DCs in the lymph nodes, due to their small size (<120 nm).
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P13.14
Thwarting HIV Evasion of Antibody Avidity 
with Novel Antibody Architectures
R.P. Galimidi1, A.P. West1, and P.J. Bjorkman2
1California Institute of Technology, Pasadena, CA, USA; 
2Howard Hughes Medical Institute and California Institute of 
Technology, Pasadena, CA, USA
Background: Despite decades of effort, no current vaccine elicits 
neutralizing antibodies at concentrations blocking HIV infection. In 
addition to structural features of HIV’s envelope spike that facilitate 
antibody evasion, a hypothesis for the ineffective immune response lies 
in the low density and limited mobility of HIV envelope spikes, which 
impedes bivalent binding by antibodies, reducing avidity, minimizing 
the potential for high affinity binding and virus neutralization. 
Methods: We intend to engineer anti-HIV reagents that bind with 
high avidity to single spikes, overcoming potential problems with 
the low density of HIV spikes. Here, we demonstrate a strategy to 
use dsDNA as a rigid molecular ruler to map epitopes on the HIV 
envelope protein to gain insight into the relatively unknown spatial 
environment of the spike trimer. Upon determining the optimal 
separation distance between epitopes, the dsDNA linker will be 
replaced with a structured protein linker. This technique should 
allow for the development of a novel multivalent antibody reagent 
improving binding and increasing avidity. 
Results: Optimal HIV binding proteins will be trimerized by attaching 
a trimerization motif, reducing the concentration required for sterilizing 
immunity. To date, we have several bispecific DNA reagents that have 
the ability to neutralize various strains of HIV with greater potency 
than its individual components. 
Conclusion: These results demonstrate the promise for discovery of 
optimal anti-HIV reagents using this technology.
P13.13
Replicating Vesicular Stomatitis Virus Vectors 
(VSV) Expressing Membrane-Anchored MPER 
Immunogens
M. Yuan1, M. Kemelman1, M. Lopez1, A. Wilson1, H.H. Arendt1, 
J. Martinez1, A. Domi1, J. DeStefano1, C.R. King1, R.W. Lindsay1, 
and C.L. Parks1
1IAVI, Brooklyn, NY, USA
Background: The membrane-proximal external region (MPER) is an 
important vaccine target because it is a well-conserved element of 
Env that is recognized by several broadly neutralizing monoclonal 
antibodies. Moreover, MPER-specific neutralizing antibodies are 
generated in some HIV-infected patients emphasizing that the human 
immune system does recognize MPER structures presented on HIV 
particles and infected cells.  Because the native MPER structure is 
dependent on its association with the lipid bilayer, we have developed 
plasmid DNA and live VSV vectors that express the MPER as a 
membrane-anchored immunogen.
Methods: The transmembrane domain and cytoplasmic tail of VSV G 
were used as a platform (G-stem) for surface expression of an ectodomain 
composed primarily of MPER sequence.  Live VSV and plasmid DNA 
vectors were constructed encoding G-stemMPER immunogens.
Results: Plasmid DNA and VSV vectors were designed to express 
G-StemMPER immunogens as integral membrane proteins.  The VSV 
vectors coexpress G-stemMPER and native G, thus they are replication-
competent.  Western blot analysis conducted with transfected or 
infected cells confirmed expression of G-stemMPER proteins by both 
vectors, and flow cytometry showed that the MPER epitopes also were 
present on the cell surface and bound to neutralizing monoclonal 
antibodies.  Consistent with G-stemMPER incorporation into the cell 
plasma membrane, analysis of purified VSV vectors revealed that 
the immunogen also was present in virus particles along with native 
VSV G. A murine study is underway to evaluate the immunogenicity 
of electroporated DNA prime followed by an intranasal boost with 
replicating VSV-G-StemMPER vectors and we are currently analyzing 
immune responses.
Conclusion: Plasmid DNA and replicating VSV vectors expressed 
membrane-anchored G-stem-MPER which were antigenic and 
have been used to safely vaccinate mice. Data from the ongoing 
murine immunogenicity study will determine if the G-stemMPER 
immunogen strategy is an effective approach for inducing 
antibodies with MPER specificity. 
Topic 13: Vaccine Concepts and Design
278
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P13.16
Construction, Stability and Immunogenicity of 
Recombinant BCG Expressing HIV-1 Subtype C 
Gag Under Control of Different Promoters and 
Signal Peptides
M. Lebeko1, R. Chapman1, and A. Williamson 1
1University of Cape Town, Cape Town, South Africa
Background: The HIV epidemic continues to spread globally, thus 
highlighting the need for the development of an effective HIV 
vaccine, most especially for developing countries. Mycobacterium 
bovis bacilli-Calmette-Guerin (BCG) has been widely used as an HIV 
vaccine vector due to its proven safety record. However, high level 
expression of viral antigens can often increase the metabolic burden 
resulting in genetic instability and hence poor immune responses. 
This study aimed to compare recombinant mycobacteria expressing 
HIV-1 gag under the control of different promoters and leader 
sequences. This was done to determine whether the genetic stability 
of the recombinant mycobacteria could be improved by modification 
of these vector features. 
Methods: The optimal vector backbone was selected by stability 
assays. A series of shuttle vectors with different promoters (hsp60, 
psmcyc or mtrA) and leader sequences (α-antigen or 19kDa signal 
peptide) were constructed and their stability was determined by 
means of relative colony size scoring and growth curves. Lastly the 
immunogenicity of recombinant BCG expressing HIV-1 Gag alone or 
Gag fused to either of the leader sequences was evaluated in mice.
Results: It was shown that the addition of various vector features such 
as 19kDa/-α leader sequences and codon optimisation of HIV-1 gag 
did not have an effect on vector stability as indicated by the similar 
colony size score. Furthermore, the use of leader peptides resulted in 
differential expression levels of Gag as shown by p24 assays cultures 
with pEMαGag2(V3SV5) seamed to express more Gag as compared 
to pEM19Gag2(V3SV5) and pEMGag2(V3SV5) recombinants (64pg/
ml as compared to 39 and 17 respectively).
Conclusion: Despite the low immune responses elicited by the rBCG 
vaccines, the panBCG[pEMαGag2V3SV5] maybe a promising vaccine 
as seen by increased immune responses to the V3 CTL epitope as well 
as Gag p24 levels from M. smegmatis with the same vector.
P13.15
Membrane Biophysical and Structural 
Investigations of HIV-1 Envelope Glycoproteins 
Epitopes in the Aim of Eliciting Liposomal 
Vaccine
O. Rifi1, E. Glattard1, and B. Bechinger1
1Chemistry Institute of Strasbourg UMR7177, Strasbourg, France
Background: A few stable regions have been discovered on the 
envelope glycoproteins of HIV-1 against which some patients produce 
neutralizing antibodies. The most promising epitopes are located in 
the membrane proximal external region and are probably exposed 
transiently during the fusion of cellular and viral membranes. Whereas 
the peptides isolated from this region failed to induce neutralizing 
immunogenic response. Previous studies suggest that the lipid 
membrane plays a role in antigens structure and in the immunogenic 
response developed by these patients.
Methods: We investigate these epitopes (one from gp120 and two 
from gp41) and their insertion into liposomal carriers by structural 
approaches (Nuclear Magnetic Resonance, Circular Dichroism: CD). 
This requires the production of the polypeptides by bacterial over-
expression and their purification by using biochemical methods, 
and their reconstitution into liposomal carriers. In addition, the 
immunogenicity of these epitopes will be investigated by mice 
immunization and the immune response will be quantified by ELISA.
Results: The conditions for expression and purification of these 
polypeptides are established. The purified polypeptides solubilised 
in detergent are reconstituted overnight into liposomal carriers by a 
dialysis approach. Their secondary structure is investigated by CD. 
gp120 and gp41a adopt mainly an alpha-helical structure in the 
detergent. In contact with the lipids, gp41a maintains this helical 
structure and it is reinforced in liposomes having a similar composition 
of the viral membrane. In contrast the gp120 construct adopts a 
predominantly beta-sheet structure.   
Conclusion: The comparative analysis of the potential for 
immunogenicity and structural results obtained will be confronted 
in order to better understand the fusion of the cellular and viral 
membranes and thereafter to help in the design of vaccines directed 
against HIV-1.
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P13.18
Acceptability and Tolerability of Novel Mucosal 
Secretion Collection Methods in an HIV Vaccine 
Trial in East Africa
P. Mann1, J. Kosgei2, A. Sekiziyivu3, F. Sawe2, L. Maboko1,  
H. Kibuuka3, T. Tong4, N. Karasavva5, M. Robb4, L. Eller4, J. Ake4, 
M. Marovich6, and V. Ngauy5
1National Institute of Medical Research - Mbeya Medical 
Research Center (NIMR-MMRC), Mbeya, United Republic of 
Tanzania; 2Kenya Medical Research Institute/Walter Reed 
Project, Kericho, Kenya 3Makerere University, Walter Reed 
Project, Kampala, Uganda; 4U.S. MHRP, Silver Spring, MD, 
USA; 5Armed Forces Research Institute of Medical Sciences, 
Bangkok, Thailand; 6Division of AIDS, NIAID, NIH, Bethesda, 
MD, USA
Background: Mucosal surfaces are important portals of HIV-1 entry 
and considerable scientific effort has been dedicated to understanding 
virus-host interactions at these sites. The evaluation of mucosal 
immune responses presents a significant challenge due to the 
variability in specimen yields and introduction of unknown dilution 
factors in certain methods. We evaluated the acceptability of the 
Instead SoftCup device for collecting genital secretions from women 
and for collecting semen through masturbation from men in an HIV 
vaccine trial conducted in East Africa.
Methods: Healthy, low-risk, HIV uninfected, men and women enrolled 
in a Phase I HIV vaccine study (RV 262) conducted in Kenya, Uganda 
and Tanzania were asked to donate mucosal secretions. Volunteers 
refusing mucosal collections could still participate in the main trial. 
Cervico-vaginal (CV) secretions were collected through self-insertion 
of the SoftCup and semen through masturbation in clinic. Volunteer 
demographics and reasons for participation or refusal were noted in 
source documents.
Results: In total, 46 of 63 (73%) male participants agreed to semen 
collection. Among female participants, 12 of 22 (55%) agreed to 
provide specimens using the SoftCup. Average yield for semen was 
2.12 mL and for CV secretions was 4.7g, respectively. More men 
participated in the study than women at all three sites. No social harm 
or adverse events associated with the mucosal collection was reported. 
Participants who refused to take part in mucosal collections did so for 
cultural and religious reasons.
Conclusion: Despite initial concerns regarding the acceptance of 
the SoftCup device and masturbation, overall acceptability for both 
methods was high. The clinic staff was able to overcome concerns 
raised by other clinical staff, volunteers, and regulatory bodies through 
education and counseling. Our experience shows that SoftCup and 
masturbation are acceptable and well-tolerated methods for collecting 
cervico-vaginal secretions and semen to evaluate mucosal responses 
in low-risk, East African vaccine trial participants.
P13.17
Development of Broadly Neutralizing Antibody 
Responses in a Large Sub-Sahara African HIV 
Primary Infection Cohort
E. Landais1, M. Simek2, M.A. Price3, E. Cormier4, J. Gilmour4,  
P. Fast2, S. Allen5, W. Kilembe6, E. Karita6, S. Lakhi6,  
M. Inambao6, A. Kamali7, E.J. Sanders8, O. Anzala9, T. Wrin10, 
and P. Poignard1
1IAVI, La Jolla, CA, USA; 2IAVI, New York, NY, USA; 3IAVI, 
University of San Francisco, San Francisco, CA, USA; 4IAVI, 
London, UK; 5Rwanda Zambia HIV Research Group (RZHRG), 
Emory University, Atlanta, GA, USA, Kigali, Rwanda; 6Rwanda 
Zambia HIV Research Group (RZHRG), Lusaka, Zambia; 7MRC/
UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 
8Kenya Medical Research Institute (CGRMC/KEMRI), IAVI, 
University of Oxford, Kilifi, Kenya; 9Kenyan AIDS Vaccine 
Initiative (KAVI), Nairobi, Kenya; 10Monogram Biosciences Inc., 
San Francisco, CA, USA 
Background: About 10 to 20% of HIV-1-infected individuals are 
capable of generating broadly neutralizing antibodies (bNAbs), 
usually after a few years of infection. Understanding how these 
broad responses develop over time is crucial for the design of a 
protective vaccine.
Methods: The IAVI Protocol C investigates a large longitudinal cohort 
of primary HIV-1 infection in Eastern and Southern Africa. Plasma 
neutralizing activity was assessed at Monogram Biosciences on 
longitudinal samples from 360 donors using a 6 cross-clade pseudo-
virus panel predictive of neutralization breadth on larger panels. The 
specificity of the Env-specific broadly neutralizing antibody response 
was characterized in 29 Top neutralizers.
Results: At a median time post-infection of 3.7 years, broad neutralizing 
responses have so far developed in about 15% of individuals, essentially 
between year 3 and 4. Cross-clade neutralization appears to correlate 
with low CD4 T cell count and high viral load. Overall, neutralization 
potency is relatively low as compared to the cross-sectional IAVI 
Protocol G cohort (median time post-infection > 5 years) (Simek et 
al. J.Virol, 2009). The N332 glycan-dependent epitope appears to be 
the most commonly targeted (20%) in Top neutralizers. We also found 
2 volunteers (7%) with a PG9-like activity and one volunteer with a 
10E8-like activity. However, no broad CD4bs neutralizing activity 
was detected. In contrast, broad CD4bs activity was found in about a 
quarter of Protocol G Elite neutralizers.
Conclusion: In conclusion, our data suggest that highly potent broadly 
neutralizing antibody responses, and more particularly responses 
targeting the CD4bs, may in general require more than 4-5 years of 
infection to develop. Concurrent longitudinal monoclonal antibody 
isolation and viral Env sequencing are currently ongoing for Top 
neutralizers with different broad specificities (PG9-like, N332-Glyc, 
MPER). Retracing the interplay between B cell and HIV leading to broad 
neutralizing antibody responses will be crucial for the design of an 
efficient AIDS vaccine.
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P13.20
Engineering New E.coli-Mycobacterial Shuttle 
Vector for a Dual HIV-TB Pediatric Vaccine 
Vectored by Lysine Auxotroph of BCG
N. Saubi1, E. Gea-Mallorquí1, C. Hurtado1, T. Hanke2, P. Ferrer3,  
J. Gatell1, and J. Joseph1
1AIDS Research Unit, Hospital Clínic, IDIBAPS, HIVACAT, 
Barcelona, Spain; 2The Jenner Institute, University of Oxford, 
Oxford, UK; 3Group of Bioprocess Engineering and Applied 
Biocatalysis Chemical Engineering, University of Barcelona, 
Barcelona, Spain
Background: We previously proposed the use of recombinant 
BCG prime-recombinant modified vaccinia virus Ankara (MVA) 
boost pediatric vaccine platform against HIV-1 and Mycobacterium 
tuberculosis (Mtb). Most of the selection methods for recombinant 
bacterial strains are based on antibiotic resistances. In this study, we 
have engineered a new mycobacterial vaccine design by using an 
antibiotic-free plasmid selection system. 
Methods: We assembled a novel E.coli-mycobacterial shuttle 
plasmid p2auxo.HIVA, expressing the HIVA immunogen. This 
shuttle vector employs an antibiotic resistance-free mechanism for 
plasmid selection based on glycine complementation in E.coli and 
lysine complementation in mycobacteria. This shuttle plasmid was 
transformed first into glycine auxotroph of E.coli M15Δgly strain and 
further transformed into lysine auxotroph of BCG strain to generate 
vaccine BCG.HIVA 2auxo. Genetic and phenotypic characterization of 
BCG.HIVA 2auxo strain was performed. The HIV-1 and Mtb-specific 
cell mediated immunogenicity was assessed in adult BALB/c mice, in 
a heterologous prime-boost regimen using MVA.HIVA as a booster. 
Body mass loss of mice was monitored to assess the biosafety profile.
Results: Genetic and phenotypic features of antibiotic marker-less 
BCG.HIVA 2auxo strain were determined, and we demonstrated that 
the episomal plasmid p2auxo.HIVA was stable in vivo over a 7 weeks 
period. The presence of HIVA gene sequence and protein expression 
was confirmed. The BCG.HIVA 2auxo vaccine in combination with 
MVA.HIVA induced HIV-1 and Mtb-specific interferon γ-producing T 
cell responses in adult BALB/c mice. Polyfunctional HIV-1-specific CD8 
+ T cells producing IFN-γ, TNF-α and degranulating were induced.  No 
significant difference in body mass was observed between the groups 
of animals.
Conclusion: We demonstrated T cell immunogenicity of a novel 
and safe BCG-vectored vaccine. In addition, this plasmid selection 
system based on double auxotrophic complementation might be a 
new mycobacterial vaccine platform to speed-up the development of 
recombinant BCG based HIV vaccines for clinical trials, but also for 
other major pediatric pathogens, to prime protective response soon 
after birth. 
P13.19
The HIV-1 gp120 C5 Region Shows HLA-like 
Properties for Immune Activation that May Be 
Masked by Antibodies
B. Sørensen1, M.A. Sommerfelt1, G. Stjernholm1, P.L. Smith2,  
M. Ökvist1, B.O. Brandsdal3, A. Hovden1, J. Zeldis4, G. Hoddevik5, 
R. Redfield6, and A. Dalgleish2
1Bionor Pharma ASA, Oslo, Norway; 2St Georges, University of 
London, London, UK; 3University of Tromsø, Tromsø, Norway; 
4Celgene Corporation, Summit, NJ, USA; 5Norwegian Institute 
of Public Health, Norway; 6University of Maryland School of 
Medicine, College Park, MD, USA
Background: The 5th constant domain (C5) of HIV-1 gp120 has 
previously been postulated to contribute to immune hyperactivation 
and shows serological and sequence similarity to human leukocyte 
antigens (HLA). Cross clade sequence and structural analysis was used 
to investigate the similarity of C5 to HLA as well as the potential for C5 
epitope presentation on HLA classes I and II.
Methods: Sequence and statistical analysis was carried out based on 
curated alignments of HIV env gene sequences (M group) downloaded 
from the HIV sequence database (www.hiv.lanl.gov/). Sequence, 
structural and serological analysis allowed for the design of a peptide 
incorporating both C5 and regions identified on gp41. This was used 
to determine the prevalence of anti-C5 antibodies in a treatment naive 
historical longitudinal cohort (n=32) and a cohort of natural viral 
suppressors (n=58). Overlapping peptides were used to determine the 
HLA class I and II binding profiles of C5 epitopes using ProImmune 
REVEAL MHC-binding assay.
Results: The C5 region was conserved with limited, largely clade-
specific, variation at predominantly two positions reminiscent of the 
anchor points for epitope binding/presentation on HLA. The C5 region 
showed partial homology to the third hypervariable domain of HLA-
DRβ alleles. A region on gp41 with potential to interact with C5 was 
identified. A peptide antigen combining C5 and this region on gp41 
improved serological reactivity to C5, presumably by preserving C5 
conformation. Antibody responses to this C5/gp41 antigen correlated 
with low-moderate viral load and slow disease progression. C5 
overlapping peptides did not bind HLA class I alleles, nor HLA class II 
(HLA-DR or HLA-DP). C5 epitopes did bind to certain HLA-DQ alleles.
Conclusion: C5 is hypothesized to cause immune activation either 
by presentation as allo HLA-DR epitopes on HLA-DQ molecules or 
by representing a ‘pseudo HLA’ with immune activating properties. 
Anti-C5 antibodies may mask the C5 domain and prevent pan-
immune activation.
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P13.22
HVTN-Tested Candidate HIV Vaccines Induce 
Early, Antigen-Specific Plasmablast- and Tfh-
like Responses in Peripheral Blood
A. Heit1, F. Schmitz2, M. Moore1, S. Gerdts1, P. Spearman3,  
S. Barnett4, B. Graham5, H. Robinson6, R. Astronomo1,  
E. Andersen-Nissen1, N. Frahm1, S. De Rosa1, and M. McElrath1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Seattle Biomedical Research Institute, Seattle, WA, USA; 
3Emory University School of Medicine, Atlanta, GA, USA; 
4Novartis Vaccines and Diagnostics, Cambridge, MA, USA; 
5Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; 
6GeoVax Inc., Atlanta, GA, USA
Background: Long-term humoral immunity is the primary goal 
of protective vaccines. To generate this, a vaccine needs to prompt 
B cell differentiation into plasma cells and into long-lived memory 
populations. The induction of a functional B cell compartment requires 
the presence of pathogen-specific T follicular helper cells (Tfh), 
supporting formation of germinal centers in lymphoid tissue. The 
kinetics of early B cell responses to vaccination, including plasmablasts 
as well as peripheral blood CD4+ T cells with Tfh-like characteristics, 
are not well studied in humans. 
Methods: We used PBMC samples from healthy, HIV-negative 
volunteers vaccinated with either Ad5- (n=10, HVTN 068) or MVA-
vectored (n=5, HVTN 205/908) HIV vaccines or an HIV Env protein/
MF59 regimen (n=10, HVTN 088), to assess the kinetics of B cell and 
Tfh-like responses following vaccination.
Results: Irrespective of regimen, early B cell responses (CD19+CD27-
CD20-CD38+ plasmablasts) consistently peaked one week after 
vaccination. Interestingly, no major changes in bulk memory B cell 
frequencies (CD19+CD27+CD20+IgD-) or naïve B cells (CD19+CD27-
CD20+IgD+) were observed for any regimen. Additionally, we 
identified a peripheral blood T cell subset with Tfh characteristics 
(CD4+CXCR5+PD1+ICOS+) that also peaked one week following 
vaccination, suggesting that B cell and Tfh-like responses are 
synchronized. When we analyzed samples from the Ad5-vectored 
vaccine regimes, we further found that both, Tfh-like cells and 
plasmablasts, were antigen-specific.
Conclusion: Our data demonstrate that candidate HIV vaccines 
induce plasmablast- and Tfh-cell responses in peripheral blood. These 
cell types could be useful early surrogates for monitoring long-term 
vaccine-induced functional responses.This work is supported by NIAID 
UM1 AI068618 and UM1 AI068614.
P13.21
Changes in Codon-Pair Bias of Human 
Immunodeficiency Virus Type 1 Have Profound 
Effects on Virus Replication in Cell Culture 
G. Martrus1, M. Nevot1, C. Andrés1, B. Clotet1, and M. Martínez1
1IrsiCaixa Institute for AIDS Research, HIVACAT, Barcelona, Spain
Background: Human immunodeficiency virus type 1 (HIV-1) has 
biased nucleotide compositions different from human genes This 
raises the question of how evolution has chosen the nucleotide 
sequence HIV-1 observed today, or to what extent the actual encoding 
contributes to virus replication capacity, evolvability and pathogenesis. 
Here, we applied the previously described synthetic attenuated virus 
engineering (SAVE) approach to HIV-1.
Methods: Using synonymous codon pairs, we rationally recoded and 
codon pair–reoptimized and deoptimized different moieties of the 
HIV-1 gag and protease genes. Then redesigned gag and protease 
fragments were recombined with HIV-1 infectious clones that lacked 
gag or protease. Replication capacity of the resulting viruses was tested 
in MT-4 cells and peripheral blood mononuclear cells (PBMCs).
Results: Deoptimized viruses had significantly lower viral replication 
capacity in MT-4 and PBMCs. Varying degrees of ex vivo attenuation 
were obtained, depending upon both the specific deoptimized region 
and the number of deoptimized codons. A protease reoptimized virus 
carrying 38 synonymous mutations was not attenuated and displayed 
a replication capacity similar to that of the wild-type virus in MT-4 
cells and PBMCs. Although attenuation is based on several tens of 
nucleotide changes, deoptimized HIV-1 reverted to wild-type virulence 
after serial passages in MT-4 cells. Remarkably, no reversion was 
observed in the reoptimized virus.
Conclusion: These data demonstrate that SAVE is a useful strategy 
to phenotypically affect the replicative properties of HIV-1. HIV-1 with 
different degrees of attenuation can be useful tools for the development 
of a safe and effective vaccine as well as the development of safer 
gene-therapy lentiviral vectors. 
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P13.24
The Viral Vector Vaccine VSV-GP Boosts 
Immune Response upon Repeated Applications
R. Tober2, Z. Banki2, L. Egerer2, A. Muik1, D. von Laer2, and  
J. Kimpel2
1Georg-Speyer-Haus, Frankfurt/Main, Germany; 2Innsbruck 
Medical University, Innsbruck, Austria
Background: Vesicular stomatitis virus (VSV) is a potent candidate 
vaccine vector for various diseases. However, VSV’s inherent 
neurotoxicity has limited its clinical application. Additionally, VSV 
induces neutralizing antibodies rapidly and is thus ineffective 
upon repeated applications. Our group has recently shown that 
VSV pseudotyped with the glycoprotein (GP) of the lymphocytic 
choriomeningitis virus, VSV-GP, is not neurotoxic. Here, we evaluated 
the potential of VSV-GP as a vaccine vector.
Methods: We used Ovalbumin (OVA) as a model antigen and analyzed 
immunogenicity of GP-pseudotyped and wild-type VSV expressing 
OVA (VSV-GP-OVA and VSV-OVA) in vitro and in vivo in mouse models.
Results: Both vectors infected murine bone marrow-derived dendritic 
cells (bmDCs) in vitro. These bmDCs were able to activate OVA specific 
CD8+ and CD4+ T cells. Mouse experiments revealed that both VSV-
OVA and VSV-GP-OVA induced functional OVA-specific CTLs and 
anti-OVA antibodies upon single immunization. However, boosting 
with the same vector was only possible for the GP-pseudotype but 
not for wild-type VSV. The efficacy of repeated immunization with 
VSV-OVA was most likely limited by the high levels of neutralizing 
antibodies, which we detected after the first immunization. In contrast, 
no neutralizing antibodies against VSV-GP were induced even after 
boosting. CTL responses induced by VSV-GP-OVA were as potent 
as those induced by an adenoviral state-of-the-art vaccine vector. 
Additionally, immunization with both vectors completely protected 
mice from infection with Listeria monocytogenes expressing OVA.
Conclusion: Taken together, VSV-GP is non-neurotoxic, induces potent 
immune responses, enables boosting and thus is a promising novel 
vaccine vector.
P13.23
Sequential Immunization Approach for the V3 
Epitope Using Constrained Peptides   
A. Moseri1, S. Tantry2, B.  Arshava2, F. Naider2, and J. Anglister1
1Weizmann Institute of Science, Rehovot, Israel; 2College of 
Staten Island of the City University of New York, Staten Island, 
NY, USA
Background: The V3 is a well-known target for neutralizing antibodies. 
However, masking of the V3 loop remains a problem limiting the 
breadth of V3 directed antibodies. Nevertheless, V3 antibodies with 
impressive breadth and potency such as KD-247 and F425-B4e8 have 
been identified. These antibodies can neutralize some resistant primary 
isolates such as JR-CSF. Interestingly, these antibodies recognize a 
shorter epitope centered on the GPGR tip. Therefore, our current efforts 
are aimed at eliciting antibodies with high affinity to a short segment 
of the V3 tip by active immunization using constrained V3 peptides.  
Methods: We have applied a structure based approach for designing 
constrained V3 peptides. Our most effective immunogen, C4-
V3T303C-E322C, was able to neutralize tier1B strains such as ss1196 
and 6535. Our present studies combine the application of such C4-V3 
peptides used for priming followed by additional boosts with peptides 
representing shorter constrained V3 segment to focus the immune 
response to a shorter which may be exposed.
Results: We have examined several immunization strategies using 
long and short constrained V3 peptides.  The neutralization data 
reveals that sequential immunization using long constrains peptides 
followed by shorter constrained peptide immunogens is superior to 
repeated boosting with long V3 peptides only. Furthermore, boosting 
with short constrained peptide is more effective than using short linear 
peptides. Binding data indicated that boosting with short V3 peptide 
increase the level of antibodies to the V3 tip. Studies to further support 
and improve our immunization strategy are ongoing.
Conclusion: High level of V3 directed neutralizing antibodies would 
contribute to any vaccine formulation. We believe that a sequential 
immunization approach which mimics to some extent natural infection 
can maximize the effectiveness of the V3 directed antibody response. 
If proven effective such an approach can be applied to other HIV-1 
neutralizing epitopes.   
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P13.26
Deletion of the VACV A46R Gene, Encoding 
for a TLR Signalling Inhibitor, Enhances the 
Immunogenicity of the HIV/AIDS Vaccine 
Candidate NYVAC-C
B. Perdiguero1, C.E. Gómez1, C.O. S. Sorzano1, J. Delaloye2,  
T. Roger2, T. Calandra2, G. Pantaleo2, and M. Esteban1
1Centro Nacional de Biotecnología, Madrid, Spain; 2Centre 
Hospitalier Universitaire Vaudois and University of Lausanne, 
Lausanne, Switzerland
Background: Viruses have developed strategies to counteract 
signalling through Toll-like receptors (TLRs) that are involved in the 
detection of viruses and induction of proinflammatory cytokines and 
IFNs. Vaccinia virus (VACV) encodes A46 protein which disrupts TLR 
signalling by interfering with TLR: adaptor interactions. Since the innate 
immune response to viruses is critical to induce protective immunity, 
we studied whether deletion of A46 in a NYVAC vector expressing 
HIV-1 Env, Gag, Pol and Nef antigens (NYVAC-C) improves immune 
responses against HIV-1 antigens.
Methods: NYVAC-C was used to generate the A46R deletion 
mutant NYVAC-C-deltaA46R. Cytokines produced by human primary 
macrophages infected with NYVAC-C or NYVAC-C-deltaA46R were 
quantified by ELISA. BALB/c mice were subjected to a DNA prime/
NYVAC boost immunization protocol. The magnitude, quality and 
phenotype of the cellular immune response were assayed by 
polyfunctional flow cytometry (IL-2/IFN-gamma/TNF-alpha/CD107a) 
on splenocytes from immunized animals collected at days 10 and 53. 
Results: NYVAC-C and NYVAC-C-deltaA46R replicated similarly in 
primary chicken embryo fibroblast (CEF) cells. Compared to NYVAC-C, 
NYVAC-C-deltaA46R markedly increased TNF, IL-6 and IL-8 secretion 
by primary human macrophages. Analysis of the immune responses 
elicited in BALB/c mice after DNA prime/NYVAC boost immunization 
showed that deletion of A46R improved the magnitude of the HIV-1-
specific CD4 and CD8 T cell immune responses during adaptive and 
memory phases and maintained the functional profile observed with 
the parental NYVAC-C.
Conclusion: These findings establish the immunological role of A46 
on innate immune responses of macrophages in vitro and antigen-
specific T cell responses in vivo and suggest that deletion of viral 
inhibitors of TLR signalling is a useful approach for the improvement of 
poxvirus-based vaccine candidates.
P13.25
HIV-1 Env-Specific Antibody Responses and 
Generation of Broadly Neutralizing Antibodies 
Using Multimeric BAFF and IL-12
S. Gupta1, J. Termini1, S. Kanagavelu1, C. Labranche2,  
D. Montefiori2, R. Kornbluth3, and G. Stone1
1University of Miami, Miami, FL, USA; 2Duke University, 
Durham, NC, USA; 3Multimeric Biotherapeutics Inc., San 
Diego, CA, USA
Background: High titers of broadly neutralizing antibodies (bNtAbs) 
are essential for protection against HIV-1 infection. The hypothesis of 
this study is that the B cell autonomous function of BAFF increases 
HIV neutralizing Abs by enhancing the generation of gp120-specific 
Bmem cells. Env-specific antibody responses are further enhanced by 
the cytokine IL-12.
Methods: BAFF soluble multi-trimers were evaluated for anti-Env 
antibody responses in DNA and DNA/protein prime/boost mice 
vaccinations.  Antigen plasmid p96ZM651gp140-CD5-opt encoding 
membrane-bound HIV-1 gp140 protein (AIDS Research Reagent 
Program) and plasmid encoding soluble 4-trimer pBAFF were tested 
for immune responses in combination with plasmid expressing 
murine IL-12p70.  
Results: Combinations of p96ZM651gp140-CD5-opt with pSPD-BAFF 
and pIL-12 enhanced humoral immune responses, as determined by 
significantly higher IgG2a titers when compared to gp140 plasmid 
plus pIL-12 alone (p<0.05).  BAFF + IL-12 also increased the number 
of gp120-specific B cells in the spleen, suggesting enhanced Bmem 
recall. Soluble multi-trimeric BAFF in combination with IL-12 increased 
Tier 2 neutralization compared to IL-12 alone. BAFF + IL-12 adjuvants 
generated neutralizing titers in 13/18 mice relative to only 2/8 in an 
IL-12 alone control.
Conclusion: Vaccination with BAFF soluble multi-trimers together 
with IL-12 enhanced the induction of humoral immunity against HIV-
1 ENV. We propose that the B cell autonomous function of BAFF 
increases HIV neutralizing Abs by enhancing the generation of ENV-
specific Bmem cells and these responses are further enhanced by 
cytokines such as IL-12.
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ABSTRACT WITHDRAWN
P13.27
Broad and Cross-clade CD4+ T Cell Responses 
Elicited by a DNA Vaccine Encoding Highly 
Conserved and Promiscuous HIV-1 M-Group 
Consensus Peptides
R.R. Almeida1, D.S. Rosa2, S.P. Ribeiro1, V.C. Santana1,  
E.G. Kallás1, J. Sidney3, A. Sette3, J. Kalil4, and E. Cunha-Neto1
1University of São Paulo, São Paulo, Brazil; 2Federal University 
of São Paulo, São Paulo, Brazil; 3La Jolla Institute for Allergy 
and Immunology, La Jolla, CA, USA; 4Heart Institute, São 
Paulo, Brazil
Background: Broad, polyfunctional and cytotoxic CD4+ T cell 
responses have been associated with control of HIV-1 replication and 
may represent a beneficial component of an efficacious HIV vaccine. 
Also, strategies to cope with virus and host genetic diversity are 
urgently needed. 
Methods: We used the TEPITOPE algorithm in order to identify 
conserved, multiple HLA-DR-binding peptides in the HIV-1 M-group 
consensus sequence. In vitro MHC-peptide binding assay was 
performed to determine the ability of the selected peptides to bind to 
different MHC class II molecules. The frequency of peptide recognition 
was evaluated using PBMC from HIV-1-infected patients. A DNA 
vaccine encoding the selected peptides was designed and evaluated 
in BALB/c mice.
Results: We identified 27 peptides in the HIV-1 Gag, Pol, Nef, Vif, Vpr, 
Rev and Vpu sequences. The peptides bound in vitro to an average of 
12 out of the 17 tested HLA-DR molecules and also to HLA-DP, -DQ 
and murine IAb and IAd molecules. Sixteen out of the 27 peptides 
were recognized by PBMC from HIV-1-infected patients and 72% 
of such patients recognized at least 1 peptide. Immunization with a 
DNA vaccine (HIVBr27) encoding the identified peptides elicited IFN-γ 
secretion against 11 out of the 27 peptides in BALB/c mice; CD4+ 
and CD8+ T cell proliferation was observed against 8 and 6 peptides, 
respectively. HIVBr27 immunization elicited cross-clade T cell responses 
against several HIV-1 peptide variants and polyfunctional CD4+ 
and CD8+ T cells against the pool of HIVBr27 peptides. In addition, 
HIVBr27 immunization led to lower viral load in mice challenge with 
recombinant Vaccinia virus encoding HIV-1 Gag and Pol.
Conclusion: We believe that our concept may cope with HIV-1 genetic 
diversity, provide increased population coverage and elicit protective T 
cell immunity against HIV-1/AIDS.
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P13.30
Vaccination Directed Against the Human 
Endogenous Retrovirus-K Envelope Protein 
Shows Efficiency in a Murine Tumor Model 
System
B. Kraus1, K. Fischer1, S. Büchner1, K. Sliva1, and B.S. Schnierle1
1Paul-Ehrlich-Institut, Langen, Germany
Background: Human endogenous retrovirus (HERV) genomes are 
chromosomally integrated in all cells of an individual. They are 
normally transcriptionally silenced and transmitted only vertically. 
Enhanced expression of HERV-K accompanied by the emergence 
of anti-HERV-K-directed immune responses has been observed in 
tumor patients and HIV-infected individuals. As HERV-K is usually not 
expressed and immunological tolerance development is unlikely, it is 
an appropriate target for the development of immunotherapies of the 
HIV infection. 
Methods: We generated a recombinant vaccinia virus (MVA-HKenv) 
expressing the HERV-K envelope glycoprotein (Env), based on the 
modified vaccinia virus Ankara (MVA), and established an animal model 
to test its vaccination efficacy. Murine renal carcinoma cells (Renca) 
were genetically altered to express E. coli beta-galactosidase (RLZ cells) 
or the HERV-K Env gene (RLZ-HKenv cells). Intravenous injection of 
RLZ-HKenv cells into syngenic BALB/c mice led to the formation of 
pulmonary metastases, which were detectable by X-gal staining. 
Results: A single vaccination of tumor-bearing mice with MVA-HKenv 
drastically reduced the number of pulmonary RLZ-HKenv tumor 
nodules compared to vaccination with wild-type MVA. Prophylactic 
vaccination of mice with MVA-HKenv precluded the formation of RLZ-
HKenv tumor nodules, whereas wild-type MVA-vaccinated animals 
succumbed to metastasis. Protection from tumor formation correlated 
with enhanced HERV-K Env-specific killing activity of splenocytes. 
Conclusion: These data demonstrate for the first time that HERV-K 
Env is a useful target for vaccine development and might offer new 
opportunities as an HIV vaccine. 
P13.29
Attenuation of Replication-Competent Ad26 
Infectivity by Vectorization
L.F. Maxfield1, P. Abbink1, D. Ng’ang’a1, Z. Cama1, F. Ball1,  
C. Bleckwehl1, and D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: Replication-competent Adenovirus (Ad) vectors may 
offer important immunological advantages compared with replication-
incompetent Ad vectors, but also raise important safety and regulatory 
issues. In this study, we assessed the effect of vectorization on the 
infectivity of replication-competent Ad26 (rcAd26). Specifically, we 
evaluated whether deletion of E3/E4 and insertion of an HIV Env 
transgene would attenuate replication-competent Ad26 vectors.
Methods: Replication-competent Ad26 (rcAd) vectors were produced 
by adding the E1 region back into replication-incompetent rAd26. We 
have produced rcAd26 vectors that have either the E3 or E3/E4 regions 
deleted. The growth of various rcAd26 vectors, with and without the 
Env transgene, were compared to wild-type Ad26 in Per55K (E1-
complementing) and A549 (non-complementing) cells at a range of 
MOI and were scored daily for the presence of CPE. 
Results: In the non-complementing A549 cell line, all rcAd26 vectors 
were attenuated as compared to wild-type Ad26. The vectors with 
both E3 and E4 deleted were attenuated more than those with only E3 
deleted. The addition of the HIV Env transgene attenuated the growth 
of the vector further. The rcAd26 vector with E3 and E4 deleted and 
containing the Env transgene, which is a candidate for clinical studies, 
exhibited 2 logs less growth than did wild-type Ad26 at 100 MOI. All 
vectors grew equally well in the E1-complementing cell line Per55K, 
as expected.
Conclusion: All of the rcAd26 vectors were significantly attenuated as 
compared to wild-type Ad26. The attenuation was most pronounced 
when both E3 and E4 were deleted and when containing the HIV Env 
transgene, which reflects the design of our clinical candidate vector. 
Attenuation as a result of vectorization suggests that replication 
competent vectors may have the potential to be safely used in humans.
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P13.32
Optimized Poly-CTL-Epitope HIV-1 
Immunogens for Inducing CD8+ HIV-Specific 
Immune Responses
A.Y. Reguzova1, D.V. Antonets1, R.A. Maksyutov1, S.I. Bazhan1, 
and L.I. Karpenko1
1State Research Center of Virology and Biotechnology 
VECTOR, Koltsovo, Novosibirsk Region, Russian Federation
Background: CD8+ T cell mediated immunity is crucial to the 
development of HIV vaccine. Three artificial optimized HIV-1 
polyepitope immunogens have been designed on the basic knowledge 
about antigen processing and presentation to T cells and realize a 
promising approach for inducing CD8+ HIV-specific immune responses.
Methods: Using original software TEpredict and PolyCTLDesigner 50 
CD8+ and 5 CD4+T cell epitopes in the structure of HIV-1 antigens 
have been predicted with the conservatism of 80% among A, B and 
C HIV-1 isolates. Designed immunogens contain optimized core 
polyepitope sequence polyE and three flanking “signal” sequences 
in different combinations, including N-terminal ubiquitin, N-terminal 
signal peptide and C-terminal tyrosine motif of LAMP-1 protein 
to improve efficacy of different strategies of polyE processing and 
presentation on the pathways of MHC-I and MHC-II restriction. For 
enhancement of CD8+ and CD4+ T cells responses highly conservative 
HLA-DR binding T-helper peptides and “PADRE” peptide were included 
in the structure of target immunogens. Genes encoding designed 
immunogens were cloned in vector plasmid pcDNA3.1 and three 
DNA vaccine constructs have been obtained: pcDNA3.1_Kozak_polyE 
(TCI-N), pcDNA3.1_Kozak_ER-signal_polyE_LAMP-1 (TCI-N2) and 
pcDNA3.1_Kozak_Ub-V76_polyE (TCI-N3). Target genes expression in 
vitro after transfection of 293-T cells with obtained plasmids have been 
evaluated with mRNA detecting, Western blot analysis and with flow 
cytometry using antibodies to p24 marker epitope. Immunogenicity 
of engineered vaccines has been studied on mice model after DNA 
immunization with created plasmids. Intracellular cytokine staining 
assay was applied to evaluate HIV-specific CD4+ and CD8+ responses 
in this study.
Results: All plasmid constructs provide intracellular processing and 
gene expression of engineered artificial immunogens. Following 
immunization all investigated DNA vaccines elicited HIV-specific cellular 
immune responses. Immunogens contained ubiquitin and LAMP-1+ER-
signal show tendency for increasing CD8+ HIV-specific responses.
Conclusion: Experiments on animal models demonstrate that 
optimization of polyepitope HIV-1 immunogen structure influences on 
quantity and magnitude of CD8+ HIV-specific responses. 
P13.31
A Multivalent Mixture of Clade C HIV-1 
Env Trimers Elicits a Greater Magnitude of 
Neutralizing Antibodies than Individual Trimer 
Components
C.A. Bricault1, J.P. Nkolola1, J.M. Kovacs2, J.L. Shields1, J. Perry1, 
A. Cheung1, M.S. Seaman1, B. Chen2, and D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Harvard Medical School and Children’s Hospital Boston, 
Boston, MA, USA
Background: Increasing the magnitude and breadth of neutralizing 
antibody responses to the HIV-1 envelope (Env) protein by vaccination 
remains an important challenge for HIV-1 vaccine development. We 
assessed a panel of novel, stable, acute clade C trimeric gp140 Env 
protein immunogens in vaccination strategies, including a multivalent 
mixture of trimers.
Methods: Three acute clade C HIV-1 Env sequences from HVTN503 
(405c, 459c, and 939c) were cloned, stabilized with the T4-
fibritin C-terminal trimerization tag, and produced in 293T cells. 
Characterization of trimers was performed by SDS-PAGE, size-
exclusion chromatography (SEC), and surface plasmon resonance 
(SPR). Guinea pigs were immunized three times with a total of 100 
ug of trimer formulated in CpG/Emulsigen adjuvants. Vaccination 
regimens included all single trimers as well as a mixture of these three 
trimers. Antibody responses were determined by ELISA and TZM.bl 
neutralizing antibody assays, and comparisons were determined by 
Mann-Whitney U tests.
Results: Three novel, acute clade C gp140 trimers were confirmed 
to represent stable and homogeneous populations as assessed by 
SDS-PAGE and SEC, and contained the epitopes for CD4 and a panel 
broadly neutralizing antibodies as measured by SPR. A mixture of 
these trimers combined with our C97ZA012.1 trimer elicited a greater 
magnitude of neutralizing antibodies against cross-clade viruses, 
including clade A DJ263.8 (4.6-fold higher titer; p<0.05), and clade B 
SF162.LS and SS1196.1 (2.8- and 18.0-fold higher titer, respectively; 
p<0.05), as compared to any individual trimer administered alone. 
Against clade C viruses (MW965.26, TV1.21, and ZM109F.PB4), the 
mixture elicited neutralizing antibodies that were comparable to the 
most immunogenic single trimer component.
Conclusion: These data demonstrate that a mixture of acute clade 
C trimers elicited a greater magnitude of neutralizing antibodies 
than any individual trimer component against cross-clade viruses. 
These findings have important implications for the development of 
multivalent Env immunogen cocktails.
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P13.34
Safety in a Phase 1 Randomized, Double-
Blinded, Placebo-Controlled Trial Evaluating 
Two Adenovirus HIV Vaccines in Three 
Different Geographic Regions
E. Karita1, G. Mutua2, L. Bekker3, G. Gray4, L. Page-Shipp5,  
L. Baden6, R. Bayingana1, J. Nyombayire1, O. Anzala2, D. Nyasani2, 
S. Roux3, N. Mangenya7, F. Laher4, M. Mambe4, C. Innes5,  
K. Mngadi5, S. Walsh6, J. Johnson6, R. Dolin6, G. Stevens8,  
N. Grunenberg9, D. Barouch10, P. Fast8, and D. Laufer8
1Projet San Francisco, Kigali, Rwanda; 2Kenya AIDS Vaccine 
Initiative, Nairobi, Kenya; 3University of Cape Town, 
Cape Town, South Africa; 4Perinatal HIV Research Unit, 
Johannesburg, South Africa; 5The Aurum Institute, South 
Africa; 6Brigham and Women’s Hospital, Boston, MA, USA; 
7The Desmond Tutu HIV Centre and University of Cape Town, 
Cape Town, South Africa; 8IAVI, South Africa; 9HIV Vaccine 
Trials Network, Seattle, WA, USA; 10Beth Israel Deaconess 
Medical Center, Boston, MA, USA
Background: Homologous and heterologous prime-boost regimens 
were compared using two adenovirus vectors (Ad26.EnvA.01 [Ad26] 
and Ad35-EnvA [Ad35]) in the USA, East Africa and South Africa. This is 
the first trial using either vector for an HIV preventive vaccine in Africa. 
Safety data between these regions were compared.
Methods: The B003/IPCAVD-004/HVTN 091 trial vaccinated 217 
healthy HIV-1 negative adults in a randomized, double-blinded, 
placebo-controlled study in three regions – USA, (Boston, n=51), 
East Africa (Rwanda, n=45; Kenya, n=40) and South Africa (n=81). 
Volunteers received Ad26 and/or Ad35 vaccines (5 x 10e10 
viral particles) intramuscularly at 0, 3- or 0, 6-month (USA only) 
intervals. Reactogenicity was collected for 7 days (Days 0 through 7) 
postvaccination, adverse events (AEs) through one month following 
second vaccination, serious adverse events (SAEs) throughout the trial 
and viral cultures for adenovirus post first vaccination (USA only). Local 
reactogenicity included pain, tenderness, erythema and induration. 
Systemic reactogenicity included fever, chills, malaise, myalgia, 
arthralgia, headache, nausea and vomiting.
Results: Safety data are still blinded. Median age was 25.0 (range: 
18-50); 49% were female and 78% were black. Reactogenicity was 
self-limited and did not vary by vaccine regimen or increase with 
second vaccination. Local reactogenicity was similar across regions 
and mostly mild (65% overall) in severity. Systemic reactogenicity 
was also similar across regions with comparable moderate (29.5% 
overall; range: 28.2%-31.4%) and severe (3.7% overall; range: 1.2%-
7.8%) events. Related nonserious AEs (33/452, 7.3%) were mild or 
moderate and similar (e.g., pruritis, dizziness) between regions. No 
vaccine-related SAEs were reported. No pregnancies occurred within 
the disallowed 4-month period post last vaccination. Two volunteers 
acquired intercurrent HIV infections. No viral shedding was reported.
Conclusion: All regimens were well tolerated.  Similar safety profiles 
were noted in all three regions despite potential differences in Ad26 
and Ad35 exposure.
P13.33
A gp41 Vaccine with Dual Effect to Both 
Neutralize HIV and Inhibit CD4 Depletion
V. Vieillard1, C. Petitdemange1, A. Achour1, R. Ho Tsong Fang2,  
J. Crouzet2, V. Calvez3, G. Scarlatti4, and P. Debre1
1INSERM UMR945, Paris, France; 2InnaVirVax, Evry, France; 
3Hôpital La Pitié-Salpêtrière, Paris, France; 4San Raffaele 
Scientific Institute, Milan, Italy 
Background: We previously demonstrated that a specific HIV gp41 
motif (3S) induces expression of NKp44L, a ligand of the NK activating 
receptor (NKp44L), on CD4 cells. This 3S motif is highly conserved in all 
HIV-1 clades, and appears critical during HIV infection in inducing both 
a sharp increase in NK lysis and the CD4 cells decrease. Experiments 
in macaques showed that both preventive and therapeutic vaccine 
against the wild-type (WT) 3S motif blocks CD4 depletion, and inhibits 
cells apoptosis, activation and inflammation, without significant effect 
on the viral load
Methods: Mutants were prepared from plasmid pNL4.3 with the 
QuickChange II XL Site-directed mutagenesis kit, transfected into 
293T cells and then tested in purified CD4 cells. Virus production was 
monitored by p24 antigenemy. Neutralization assays were performed 
after immuno-purification of antibodies (Abs) on purified CD4 cells and 
TZB-bl cells. Expression of NKp44L on CD4 cells and degranulation 
assay on NKp44+ NK cells were both performed by flow cytometry. 
Cross reactivity of 3S Abs was also tested by Elisa.
Results: We show here that a specific substitution in the 3S motif, 
called W614A, reduces viral infection without affecting gp41 
production. Generation of murine Abs against this mutated elicited a 
capacity to neutralize cross-clade tier 1 and tier2 viruses, impressive 
in its magnitude, breadth and durability. Importantly, anti-W614A-3S 
neutralizing Abs (NAbs) were naturally found in sera from some HIV-1 
infected patients. Remarkably, these NAbs do not react against the WT 
3S peptide, but preserve their capacities to inhibit NKp44L expression 
and therefore to protect against CD4 depletion.
Conclusion: These findings suggest that a specific substitution in 
the 3S-based immunogen might allow the generation of NAbs while 
protecting CD4 depletion and thus provide a foundation for a rational 
vaccine design that can neutralize HIV-1 and protect CD4 cells
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P13.36
Characterization of Anti-SIV Antibody 
Responses Elicited by a DNA Prime/Trimeric 
Envelope Protein Boost Vaccine in Rabbits and 
Non-human Primates
V. Menon1, S. Priya Rangasamy2, I. Kalisz2, S. Whitney1, J. Francis1, 
N. Petrovsky3, and V. Kalyanaraman1
1Advanced Bioscience Laboratories, Inc., USA; 2Indian Institute 
of Technology Madras, Chennai, India; 3Flinders Medical 
Center, Bedford Park, Australia
Background: Recent preclinical studies have demonstrated the use of 
properly folded trimeric HIV-1 envelope proteins in eliciting broadly 
neutralizing antibodies.  Understanding the type of antibody responses 
generated by such envelope may be important for the development of 
an effective HIV-1 vaccine.  As a proof of concept, trimeric envelope 
proteins from SIV may be used in non-human primates to test the 
efficacy of such vaccine for protection against a pathogenic viral 
challenge via mucosal route.
Methods: Trimeric gp145 proteins from SIVmac251 and SIVsmE660 
isolates expressed in 293H cells were purified and characterized for 
their oligomeric conformation and high affinity binding to CD4.  Rabbits 
and macaques were electroporated with DNA encoding Env from both 
isolates and subsequently boosted with homologous proteins either 
in adjuplex or inulin adjuvant.  Sera collected at different times post 
immunization were examined for antibody affinity and linear epitope 
specific reactivity.  Neutralization assays were performed in TZM-bl 
cells with SIVmac251 and SIVsmE660 isolates.
Results: Trimeric gp145 immunogen was shown to bind both rhesus 
and human CD4 with strong affinity comparable to monomeric gp120. 
Anti-envelope responses to SIVmac251 and SIVsmE660 gp145 were 
detected in rabbit and macaque sera following DNA immunizations 
and such responses were markedly enhanced following gp145 protein 
boost. Reactivity to both variable and constant domains of envelope 
was noted after protein boost accompanied with significant increase 
in binding affinity to gp145.  At peak response, low to moderate 
level of neutralizing activity was observed against SIVmac251/M766, 
SIVsmE660-BR/CG7V and SIVmac251.30 isolates while significantly 
higher titers were induced against neutralization sensitive isolates 
SIVmac251.6 and SIVsmE660CG7G. 
Conclusion: Trimeric envelope proteins from SIVmac251 and 
SIVsmE660 isolates elicited broadly reactivity anti-Env antibodies 
capable of neutralizing both sensitive and partially neutralization 
resistant SIV isolates.  These envelopes together with other 
antigens that elicit cellular responses may be tested for efficacy 
against SIV challenge. 
P13.35
Dual Deletion of Type I and Type II Interferon-
Binding Proteins in NYVAC-HIV1 Env-Gag-
Pol-Nef Poxvirus Vectors Markedly Improves 
Vector Immunogenicity
J. Delaloye1, A. Filali-Mouhim2, M. Cameron2, E. Haddad2,  
A. Harari1, J. Goulet2, C. E. Gomez3, B. Perdiguero3, M. Esteban3, 
G. Pantaleo1, T. Roger1, R. Sékaly2, and T. Calandra1
1Centre Hospitalier Universitaire Vaudois and University 
of Lausanne, Lausanne, Switzerland; 2Vaccine and Gene 
Therapy Institute, Port St. Lucie, FL, USA; 3Centro Nacional de 
Biotecnología, CSIC, Madrid, Spain 
Background: NYVAC, a replication deficient derivative of the 
Copenhagen vaccinia virus used, is a safe and immunogenic HIV 
vaccine vector. Deletion of immune evasion genes is an attractive 
strategy for improving NYVAC immunogenicity. Our aim was to 
characterize the innate immunological profile of NYVAC expressing 
the HIV-1 clade C env-gag-pol-nef genes (NYVAC-C) with single or 
double deletion of genes encoding type I (B19R) or type II (B8R) IFN-
binding proteins.
Methods: Human monocytes were infected with NYVAC-C, B19R or 
ΔB8RB19R. Gene arrays and biological pathways were analyzed using 
the Illumina BeadChips and Ingenuity Pathway Analysis. Cytokines 
were quantified by RT-PCR, Western blot and ELISA. Proliferation of 
allogenic CD4-T cells was measured by H3-incorporation.
Results: Transcriptomic analyses of monocytes infected with 
NYVAC-C, B19R and B8RB19R revealed a concerted up-regulation of 
innate immune pathways (IFN-stimulated genes-ISGs) of increasing 
magnitude with B19R and B8RB19R relative to NYVAC-C. Deletion 
of B8R or B19R enhanced activation of IRF3, IRF7 and STAT-1 and 
production of IFNs whose expressions were inhibited by anti-type I IFN 
antibodies. B8RB19R induced the production of much higher levels 
of pro-inflammatory cytokines than NYVAC-C or B19R and a strong 
inflammasome response. Consistent with these findings, B8RB19R-
infected monocytes induced stronger type I IFN-dependent and IL-1b-
dependent allogenic CD4-T cell responses than NYVAC-C or B19R.
Conclusion: Deletion of type I and II IFN evasion genes in NYVAC 
markedly enhanced its immunogenic properties via an increased 
expression of type I IFNs and IL-1b and make it an attractive candidate 
HIV vaccine vector.
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P13.38
Development of Germline-Specific HIV-
1 Envelope Immunogens Using Directed 
Molecular Evolution
S. Hoot1, S. Gudavalli1, J. Muranaka1, A. Kutach1, K.M. Narayan1, 
Y. Lie2, T. Wrin2, and R.G. Whalen1
1Altravax, Inc., Sunnyvale, CA, USA; 2Monogram Biosciences, 
San Francisco, CA, USA
Background: Elicitation of broadly neutralizing antibodies against 
HIV-1 remains a major challenge for vaccine design.  VRC01 belongs 
to a class of potent and broadly neutralizing antibodies targeting 
the CD4 binding site on gp120 and it has been suggested that the 
inability to engage germline precursors to these antibodies may be 
one reason for the failure of current immunogens to elicit VRC01-like 
responses. A recent study demonstrated that a viral envelope lacking 
specific N-linked glycosylation sites could activate B cells expressing 
germline VRC01, indicating that development germline-specific HIV-1 
immunogens is possible. 
Methods: We used in vitro homologous recombination of genes 
encoding wild-type Env sequences to generate libraries of gp120 
stabilized core variants. We expressed 1,000 individual library clones 
in HEK-293 cells and screened culture supernatants for binding to 
VRC01 as well as human and macaque partial germline versions of 
VRC01. Selected variants from this initial screen were used to create 
recursive libraries which were screened for further improvements in 
antibody binding. 
Results: Variants with increased affinity to VRC01 and partial 
germline versions of VRC01 were identified in the recombined 
libraries. Additionally, some variants showed increased affinity to b12, 
demonstrating that diverse phenotypic properties can be identified by 
this approach. Recursive libraries prepared using variants identified 
in the initial screen contained clones with further improved affinity 
to partial germline revertants. Importantly, we identified variants that 
bind to partial germline revertants of the macaque homologue of 
VRC01, indicating that immunogenicity studies in the macaque model 
are feasible. 
Conclusion: The in vitro recombination method of generating variant 
proteins is capable of producing libraries of potential immunogens 
with diverse properties including increased affinity for partial 
germline antibodies. This directed molecular evolution approach 
is a valuable tool in the generation of immunogens with desired 
properties, including the ability to bind to germline precursors to 
broadly neutralizing antibodies.  
P13.37
Multimeric Scaffolds Displaying the HIV-
1 Envelope MPER Induce MPER-Specific 
Neutralizing Antibodies When Co-immunized 
with gp160 DNA Vaccines
S.P. McBurney1, S.J. Krebs1, C. Smith1, M. Trovato2,  
P. De Berardinis2, and N.L. Haigwood1
1VGTI, Oregon Health & Science University, Beaverton, OR, 
USA; 2Institute of Protein Biochemistry, C.R.N., Naples, Italy
Background: Broadly neutralizing antibodies (bNAbs) have been 
shown to block infection in HIV-1 infection models. These bNAbs 
target conserved regions of HIV-1 envelope (Env), which allow for 
their breadth of reactivity.  The elicitation of antibodies targeting these 
conserved regions through vaccination has proven to be difficult. One 
epitope of particular interest is the membrane proximal external region 
(MPER) of gp41.
Methods: We developed an MPER-directed vaccine by fusing the 
MPER epitope to the E2 protein of Geobacillus stearothermophilus. The 
MPER-E2 fusion protein self-assembles into a particle with icosahedral 
symmetry, displaying 30 copies of MPER on the surface, refolded with 
30 copies of nonrecombinant E2 for stability. These particles were 
used in conjunction with an HIV-1 SF162 envelope DNA plasmid 
encoding either full-length gp160 or gp160 lacking hypervariable 
regions V2, V3, or V1, V2 and V3 to vaccinate rabbits. DNA plus 
protein vaccinations were given with the MPER-E2 particles delivered 
by intramuscular injection and the DNA plasmid delivered by Gene 
Gun inoculation.
Results: All groups developed anti-MPER binding antibodies following 
the second vaccination, with the gp160 lacking V3 group having 
significantly higher anti-MPER antibody titers (p<0.0001). Autologous 
NAbs (ANAbs) were also observed in all groups following the 
second vaccination with the V3-deleted group again demonstrating 
significantly higher titers (p<0.01). Low levels of MPER-specific NAbs 
were observed in all groups following the second vaccination, and 
increased with the third inoculation.  NAbs to Tier 1 and 2 viruses were 
also observed for all groups with the breadth of the response trending 
with the MPER-specific NAb titers.
Conclusion: This study provides evidence that an MPER-E2 multimeric 
particle plus gp160 DNA vaccine can elicit moderate NAbs targeting 
the highly conserved MPER region, and that MPER-specific responses 
can be further enhanced by removing the immunodominant variable 
regions.  These findings represent a significant advance in HIV 
vaccine design.
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P13.40
Modulation of Vaccine Induced Humoral 
Immune Responses by Heterologous T Cell 
Help
M. Storcksdieck genannt Bonsmann1, T. Niezold1, D. Hannaman2, 
M. Tenbusch1, and K. Überla1
1Ruhr-University Bochum, Bochum, Germany; 2Ichor Medical 
Systems, Inc., San Diego, CA, USA
Background: The recent RV144 trial has not only renewed the hope 
in antibody mediated protection, but also the interest in secondary 
antibody functions. In our mouse studies we have observed a strong 
bias of HIV-1 Env protein and DNA vaccine regimens towards the less 
protective mIgG1. Thus, we tried to modulate the humoral immune 
response towards mIgG2a via heterologous T cell help.
Methods: To determine if BCR-dependent uptake of lentiviral particles 
enables Env-specific B cells to receive help from Gag-specific CD4 + 
T cells, we primed animals with Gag and/or Env expressing plasmids 
by intramuscular electroporation. Successful DNA immunization was 
verified by intracellular cytokine staining (ICS) and ELISA for cytokine 
and antibody production. Five and eight weeks after priming animals 
were boosted with Env and Gag containing virus like particles and 
antibody responses were followed by ELISA.
Results: DNA priming induced polyfunctional HIV-1 Env- and Gag-
specific CD4 + T cells. Compared to Gag, Env-specific restimulation 
of splenocytes resulted in higher secretion of the prototypic TH 2 
cytokines IL-4, 5 and 13. In line with these findings the Env-specific 
humoral immune response was dominated by mIgG1, while the Gag 
response was balanced. In the presence on Env-specific T cells the 
subsequent VLP immunization led to an increase in the humoral 
immune response against Env with mIgG1 still being the predominant 
subtype. In contrast, mice primed only with the Gag expression plasmid 
displayed a balanced mIgG1/mIgG2a ratio for Env-specific antibodies.
Conclusion: Following boost with Env and Gag containing VLPs BCR-
dependent uptake enabled Env-specific B cells to receive help from 
previously induced Gag-specific CD4 + T cells. Thus, by employing 
heterologous CD4 + T cells we overcame the mIgG1 predominance of 
Env immunogens leading to a balanced humoral immune response. 
This strategy might prove useful considering the higher protective 
capacity of mIgG2a due to their increased ability to mediate secondary 
antibody functions.
P13.39
Modulation of Immune Responses to HIV-1 
Env and Gag-Pol-Nef Antigens by Selective 
Deletion of a Poxvirus Gene
J. García-Arriaza1 and M. Esteban1
1Centro Nacional de Biotecnología CSIC Madrid, Madrid, Spain
Background: The poxvirus vector Modified Vaccinia Virus Ankara 
(MVA) expressing HIV-1 Env, Gag, Pol and Nef antigens from clade B 
(MVA-B) is currently used as a HIV/AIDS vaccine candidate. A general 
strategy to try to improve the immunogenicity of poxvirus HIV-1 vaccine 
candidates is the deletion of known or suggested immunomodulatory 
vaccinia virus (VACV) genes. 
Methods: We have generated and characterized the immunogenicity 
profile of a new HIV-1 vaccine candidate, which contains a deletion in 
a VACV gene. 
Results: Deletion of this VACV gene from the MVA-B had no effect 
on virus growth kinetics; therefore this VACV protein is not essential 
for virus replication. The innate immune signals elicited by the 
MVA-B deletion mutant in human macrophages and monocyte-
derived dendritic cells were characterized. In a DNA prime/MVA boost 
immunization protocol in mice, flow cytometry analysis revealed 
that the MVA-B deletion mutant enhanced the magnitude and 
polyfunctionality of the HIV-1-specific CD4+ and CD8+ T cell adaptive 
and memory immune responses, with most of the HIV-1 responses 
mediated by the CD8+ T cell compartment with an effector phenotype. 
CD4+ T cell immune responses were preferentially directed against 
Env in both immunization groups. However, contrary to other MVA-B 
deletion mutants previously described, where a pattern of GPN-specific 
CD8+ T cell immune responses were induced, this new MVA-B deletion 
mutant triggered CD8+ T cell immune responses preferentially directed 
against Env. Furthermore, MVA-B and the MVA-B deletion mutant are 
able to induce antibodies against Env. 
Conclusion: These findings revealed that this new VACV protein can 
be considered as an immunomodulator and that deleting this gene 
in MVA-B confers an immunological benefit by inducing innate 
immune responses and modulating the magnitude and quality of the 
T cell adaptive and memory immune responses to HIV-1 antigens. 
Our observations are relevant for the selective improvement of MVA 
vectors as HIV-1 vaccines.
Topic 13: Vaccine Concepts and Design
Posters
P
O
ST
ER
S
291AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P13.42
Immunogenicity of Novel DosR Candidate 
Vaccine Antigens of Mtb in ARV-Naïve HIV+ 
Patients with a Range of CD4 Counts from a 
High-Burden Country
A.G. Loxton1, K. Stanley1, N. Chegou1, T. Ottenhoff2, G. Walzl1, 
and G. Biomarkers for TB Consortium1
1Stellenbosch University, Cape Town, South Africa; 2Leiden 
University Medical School, Leiden, Netherlands
Background: Characterizing host immune responses to molecular 
targets of Mycobacterium tuberculosis (M.tb) is essential to develop 
effective immunodiagnostics and better vaccines. M.tb DosR regulon-
encoded antigens are highly immunogenic in M. tuberculosis-infected 
humans and are associated with latent tuberculosis infection. 
Methods: We tested several DosR, resuscitation promoting factors (rpf) 
and reactivation antigens in HIV positive (CD4 range: 79-641) and 
negative patients to assess the level of interferon gamma produced 
in response to stimulation. A 7-day diluted whole-blood assay and 
IFN-gamma ELISA was used to measure the level of cytokine induced 
to:  Rv0569, Rv0081, Rv1733, Rv1735, Rv1737, Rv2028, Rv2029, 
Rv3131 (DosR), Rv1131 and Rv1471 (reactivation), Rv0867, Rv1009 
and Rv2450 (RPFs) and M.tb classical antigens. 
Results: The responses to the antigens were classified as: 55% no 
responses (<32pg/ml), 15% low responses (32-125pg/ml), 10% 
intermediate (126-1000pg/ml) and 10% high responses (>1000pg/
ml). In the HIV positive patients, TB10.4 was the most immunogenic 
producing interferon-gamma levels above 32pg/ml in more than 40% 
of individuals tested. Of the DosR regulon candidates, Rv1737 and 
Rv2029 produced IFN-gamma in more than 60% of the HIV positive 
participants. In our study, the latency antigens Rv0569, Rv0867 and 
Rv1131, but not Rv2031, induced significantly different responses 
between HIV negative, non-TB diseased and TB diseased participants.
Conclusion: The results indicate that HIV infection affects anti-
mycobacterial immune responses, as measured by 7-day whole blood 
IFN-γ responses, to growth phase specific mycobacterial antigens. 
These are important findings as the antigens could prove useful as 
future vaccine constructs or components of diagnostic tests.
P13.41
Immunodominance of HIV-1 Consensus M Gag 
and Nef Peptides in a Mono- and Multiclade 
Epidemic: Implications for Vaccine Design and 
Testing
M. Tongo1, L. Zembe1, E. Ebong2, E. Mpoudi Ngole2, C. Williamson1, 
and W.A. Burgers1
1University of Cape Town, Cape Town, South Africa; 
2Institute of Medical Research and Study of Medicinal 
Plants, Yaounde, Cameroon
Background: Measuring the impact of HIV diversity on immunological 
responses to new candidate immunogens is an important issue for 
HIV vaccine design/testing. This study investigated the reactivity and 
immunodominance patterns of  HIV-1 consensusM Gag and Nef in (i)
Cameroon, where individuals infected with the predominant CRF02_
AG clade were compared with those infected with diverse non-CRF02_
AG clades; and (ii)in a multi-clade epidemic, Cameroon, compared with 
a mono-clade C epidemic, South Africa.
Methods: We analysed CRF02_AG (n=24) and non-CRF02_AG-infected 
individuals (n=22) from Cameroon and 44 HIV-infected individuals 
from South Africa for differences in detecting HIV-1 consensusM Gag 
and Nef Tcell responses using the IFN-γ ELISpotassay. 
Results: There was no difference in the magnitude and breadth of 
responses for CRF02_AG and non-CRF02_AG-infected individuals in 
Gag and Nef. The specificity of peptides targeted, however revealed 
marked differences. For Gag, CRF02_AG and non-CRF02_AG-
infected individuals showed a similar number of targeted peptides 
(27 and 22 respectively). Less than a third of these (11/38), however, 
were commonly recognised by both groups, with only one peptide 
commonly recognised by at least three individuals from both AG and 
non-AG groups, indicating poor immunodominance. In Nef, this pattern 
differed, with three times more peptides exclusively targeted in the 
diverse non-CRF02_AG group compared to the CRF02_AG group (10 vs 
3), and more than half of all targeted Nef peptides (14/27) recognised 
by both groups. In contrast to Gag, four peptides were commonly 
targeted by at least three individuals in each group. Interestingly, 
very similar results to the within-Cameroon clade comparison were 
observed when South Africa, a mono-clade epidemic, and Cameroon, 
a multi-clade epidemic, were compared.
Conclusion: The central nature of consensusM sequences resulted in 
their broad recognition, but failed to identify highly immunodominant 
peptides between homogeneous and diverse epidemics. Further 
refinement of these immunogens may contribute to the development 
of a globally relevant vaccine. 
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P13.44
HIV-Recombinant Murine Leukemia Virus-like 
Particle Based Vaccines Induce Mucosal and 
Systemic Immune Responses in Mice
T. Vazquez1, L. Torrieri-Dramard1, F. Pitoiset1, J. Vigneron1,  
D. Klatzmann1, and B. Bellier1
1UPMC Paris 6 CNRS UMR7211 INSERM U959, Paris, France
Background: We developed DNA-vaccines expressing recombinant 
retrovirus-based VLPs (plasmoVLPs) pseudotyped with envelope 
glycoproteins expressed in their wild-type conformation. This strategy 
combines the efficiency of VLP-based vaccines with the simplicity 
and versatility of DNA-based vaccines. We previously demonstrated 
that plasmoVLPs induce significantly better epitope-specific CTL and 
envelope-specific neutralizing responses than standard plasmids 
expressing non-particulate antigens.
Methods: We designed HIV-specific retrovirus-derived VLP-based 
vaccines and investigated their immunogenicity after mucosal 
administration. BALB/c mice were immunized intranasally with PEI-
formulated plasmoVLPs and boosted (or not) with VLPs or proteins by 
intravaginal or intrarectal routes. Immune responses were evaluated 
by ELISA in sera and lavages, and by T-, B cell ELISpot and ICS in 
spleen, lung, vagina and gut mucosal tissue.
Results: Our results show that the delivery vehicle and route of 
immunization are critical factors governing the vaccine efficacy. 
Remarkably, we demonstrated that potent HIV-specific mucosal and 
systemic immune responses are induced after intranasal immunization 
with plasmoVLPs in contrast to standard DNA vaccines. Using a prime-
boost strategy, our results show strengthening T and B responses 
in both systemic and mucosal compartments. Remarkably, high 
numbers of HIV-specific IgA-secreting cells were observed in mucosa 
after intravaginal or intrarectal VLP administration, demonstrating 
the importance of local antigen administration to improve mucosal 
immunity. Importance of antigen form delivery was investigated by 
comparing VLP to protein boost. We observed that VLPs lead to similar 
systemic responses than protein boost but only VLPs induce high 
level of T cell multifunctionnality at both systemic and mucosal level.
Finally, we demonstrated that addition of genetic adjuvants encoding 
CCL28 or TSLP to our VLP-based vaccines have no effect on antibody 
responses but enhance significantly systemic T cell response.
Conclusion: Taken together, our VLP-based vaccines (plasmoVLPs and 
VLPs) represent efficient vaccine candidates that can be used to induce 
HIV-specific systemic and local immunity. Supported by CUT’HIVAC 
(EU FP7 #241904) and ANRS.
P13.43
Characterization of Antigenicity and 
Immunogenicity of a Trimeric Envelope Protein 
from an Indian Clade C HIV-1 Isolate 
S. Rangasamy1, V. Menon2, S. Whitney2, I. Kalisz2, S. Mahalingam1, 
R. Pal2, and V. Kalyanaraman2
1Indian Institute of Technology, Madras, Chennai, India; 
2Advanced Bioscience Laboratories, Rockville, MD, USA
Background: An effective HIV-1 vaccine may include properly 
folded envelope capable of inducing broad neutralizing antibodies. 
Recent studies have shown that trimeric HIV-1 gp140 fits this profile. 
However, selection of envelope proteins that can elicit such antibodies 
is challenging. Many Indian clade C HIV-1 envelopes have open 
conformation being fairly resistant to neutralization by sCD4 and CD4 
binding site antibodies, while being more sensitive to CD4i antibody 
17b.  Therefore it is of interest to study the immunogenicity of trimeric 
Env derived from these isolates.
Methods: Trimeric gp145 protein from an Indian isolate 93IN101 
was expressed in 293H cells and purified. Antigenicity of trimer 
was probed by binding of well characterized anti-Env antibodies. 
Immunogenicity was tested in rabbits as well as macaques. Rabbits 
were primed with codon optimized DNA vaccine expressing gp145 
followed by trimeric gp145 protein boost.  Macaques received gp145 
protein alone. Immune sera binding affinity to gp145 and reactivity 
to linear overlapping envelope peptides were measured by ELISA. 
Neutralization of HIV-1 clade B and C pseudoviruses by immune sera 
was performed in TZM-bl cells.
Results: Trimeric gp145 showed strong binding to antibodies B6, B12, 
VRC01, NIH45-46, 4E10 and PG9.  Significant binding was noted with 
17b, which was markedly enhanced in the presence of sCD4.  In rabbits 
and rhesus macaques, gp145 elicited strong antibody responses to 
both variable and conserved domains of gp120.  Neutralization of Tier 
1 isolates was noted with rabbit sera, and this was enhanced by a 
subsequent boost with clade B Env.  Neutralization by macaque sera 
extended to some Tier 2 isolates.
Conclusion: Env protein from an Indian isolate with unique antigenic 
properties is highly immunogenic in rabbits and macaques eliciting 
broadly reactive antibodies against multiple HIV-1 isolates.  This 
protein, along with other antigens that elicit cellular responses, will be 
tested against appropriate SHIV challenge in future efficacy studies.
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P13.46
Immunogenicity of Oligomeric gp41 
Immunogens Exposing the MPER of HIV-1 
Envelope Glycoprotein
C. Weiss1, R. Vassell1, A. Dey2, Y. He1, Y. Sun2, I. Srivastava2, and 
S. Barnett2
1U.S. Food and Drug Administration, Center for Biologics 
Evaluation and Research, Bethesda, MD, USA; 2Novartis 
Vaccines and Diagnostics, Cambridge, MA, USA
Background: To overcome HIV diversity, vaccines for HIV/AIDS 
may need to elicit neutralizing antibodies to several conserved sites 
on the envelope glycoprotein (Env). Here we describe our efforts 
to focus antibody responses to the poorly immunogenic MPER by 
designing stable, oligomeric gp41 immunogens that have features 
of the fusion-intermediate conformation of Env. Our prior studies of 
conformational changes in Env suggested that immunogens based 
on fusion intermediate-type conformations may expose the MPER 
better than the native pre-fusion conformation or the final post-fusion 
conformation of Env in which gp41 forms a stable six-helix bundle 
(6HB) structure. 
Methods: We created a panel of gp41 immunogens that lack gp120 
to eliminate its contribution to epitope masking, but retain trimeric 
structure in part due to the inclusion of a partial six-helix bundle 
structure upstream of the MPER. Several iterations of this basic 
gp41 scaffold were analyzed in single antigen and prime-boost 
protocols involving gp41 and gp160 DNA primes and gp41 and 
gp140 protein boosts. 
Results: We found that our gp41 protein immunogens elicited 
moderately strong MPER binding antibodies in a variety of assays, 
though significant neutralization to this determinant was not seen. We 
further describe how the various modifications of our immunogen or 
immunization protocol, such as inclusion of a V3 immunodominant 
epitope in the protein antigen or use of gp160 or gp41 DNA priming 
affected MPER-directed responses. 
Conclusion: These findings inform the design of next-generation 
MPER immunogens and immunization protocols.   
P13.45
Somatic Hypermutation in a Broad and Potent 
Neutralizing Antibody Response to HIV as 
Probed by Deep Sequencing
D. Sok1, U. Laserson2, J. Laserson3, Y. Liu3, F. Vigneault4,  
J. Julien1, B. Briney1, A. Ramos5, K.F. Saye1, K. Le1, D. Koller3,  
I.A. Wilson1, G.M. Church6, D.R. Burton1, and P. Poignard5
1The Scripps Research Institute, La Jolla, CA, USA; 
2Massachusetts Institute of Technology, Boston, MA, USA; 
3Stanford University, Stanford, CA, USA; 4AbVitro Inc., Boston, 
MA, USA; 5IAVI, New York, NY, USA; 6Harvard Medical School, 
Boston, MA, USA
Background: Broadly neutralizing HIV antibodies (bNAbs) can 
protect against mucosal challenge in macaque models suggesting 
that elicitation of bNAbs should be a high priority for candidate 
HIV vaccines. To date, however, no immunogen has reliably elicited 
significant levels of HIV bNAbs. Part of this failure might be due to the 
unusually high levels of somatic hypermutation (SHM) levels described 
for bNAbs and the inability of immunization approaches to elicit such 
levels. The level of SHM that is absolutely required for broad and 
potent neutralization remains to be determined.
Methods: We used 454 sequencing and designed a novel phylogenetic 
method to construct lineage evolution of the bNAbs PGT121-123. 
We characterized lineage intermediates for the development of 
neutralization breadth and potency and evaluated changes in how 
lineage variants recognize HIV Env.
Results: We found a positive correlation between the level of SHM 
and the development of neutralization breadth and potency. We also 
identified putative antibody intermediates that are only 6-10% mutated 
from germline in VH, which is approximately half the mutation level 
of PGT121-123, but are still capable of neutralizing 40-80% of viruses 
in a large panel with a potent median IC50 that is only 14 to 1.5-fold 
higher than the affinity-matured antibodies. 
Conclusion: These lower mutation levels are close to the SHM levels 
that are commonly elicited through human vaccination and the 
antibody potency and breadth of neutralization at the levels of SHM 
described in this work have not been discovered previously. The results 
imply that elicitation of a combination of antibody specificities of lower 
SHM than the most mutated mature bNAbs might represent a viable 
approach to HIV vaccine design. Patterns of neutralization of putative 
bNAb intermediates further suggest hypotheses as to how SHM may 
lead to potent and broad HIV neutralization and provide important 
clues for immunogen design.
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P13.48
HIV Envelope Immunogens Derived from 
Critical Timepoints in the Development 
of Breadth Rapidly Elicit Heterologous 
Neutralizing Antibodies in Rabbits
D.C. Malherbe1, F. Pissani1, A.J. Hessell1, B. Guo1, S. Pandey1,  
D.N. Sather2, H. Robins3, J.T. Schuman4, C.K. Wibmer5, B. Park1, 
S. Kalams6, L. Stamatatos2, P.L. Moore5, and N.L. Haigwood1
1VGTI, Oregon Health & Science University, Beaverton, OR, 
USA; 2Seattle BioMed, Seattle, WA, USA; 3Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA; 4GE Healthcare, 
Piscataway, NJ, USA; 5National Institute for Communicable 
Diseases, Johannesburg, South Africa; 6Vanderbilt University, 
Nashville, TN, USA
Background: A major goal of vaccine efforts is the design of Envelope 
(Env)-based immunogens effective at eliciting broadly neutralizing 
antibodies (NAbs). During infection, HIV-1 evolves rapidly within the 
host, resulting in the development of a viral quasispecies population. 
We hypothesize that B cells become programmed to develop broad 
NAbs by exposure to Envs presented by viral quasispecies variants. 
We propose that similar programming could be achieved by a vaccine 
concept exposing the host to selected Env quasispecies variants 
isolated from individuals who rapidly developed broad NAbs. 
Methods: Full-length functional env genes were cloned longitudinally 
from VC10014, VC20013 and CAP257, three clade B and C subjects, 
who developed neutralization breadth within two years of infection. 
Vaccine candidates from each subject were rationally selected using a 
combination of in silico phylogeny analyses and in vitro neutralization 
criteria. Rabbits were co-immunized with gp160-DNA and gp140-
trimeric Envelopes from each subject to assess whether broad NAbs 
could be induced by Env immunogens derived from specific timepoints. 
Results: NAbs were detected after only two DNA-protein co-
immunizations and increased after subsequent co-immunizations. 
Antibody avidity also significantly increased after additional co-
immunizations. Importantly, Env immunogens derived from timepoints 
preceding or contemporaneous with the development of neutralization 
breadth elicited significantly higher NAbs than a single early 
immunogen or a longitudinal collection of Envelopes. Depending upon 
the Env source, neutralization breadth was elicited against clade A and 
B viruses and the epitope targeting observed in the broad neutralizer 
was replicated.
Conclusion: Taken together, these vaccine experiments show 
that HIV-1 Envelopes derived from timepoints preceding and 
contemporaneous with the appearance of neutralization breadth 
are a promising source of immunogens to elicit heterologous 
neutralizing antibodies via DNA-protein co-immunizations. This study 
exploring the use of multiple native and related Envs as immunogens 
emphasizes the value of understanding the development of breadth 
in subjects with broad NAbs.
P13.47
Early Life Immunity and Ability to Respond 
to Vaccines Hindered by Myeloid Derived 
Suppressor Cells: Implications for Infant HIV 
Vaccinology
A. Gervassi1, N. Lejarcegui1, S. Dross1, A. Jacobson1, S. Gantt2,  
H. Jaspan3, and H. Horton4
1Seattle Biomedical Research Institute, Seattle, WA, USA; 
2Seattle Children’s Hospital and University of Washington, 
Seattle, WA, USA; 3University of Cape Town, Cape Town, South 
Africa; 4Seattle Biomedical Research Institute and University of 
Washington, Seattle, WA, USA
Background: Despite great progress in reducing HIV mother-to-child 
transmission (MTCT), there are still serious challenges due to ART 
adherence.  Elimination of new childhood HIV infections will likely 
require an effective infant HIV vaccine.  However, development of such 
a vaccine may necessitate different approaches from the development 
of an adult HIV vaccine.  Young infants respond poorly to infections and 
vaccines but the basis of reduced immunity is ill defined.  Historically 
the infant’s immune system has been regarded as immature. Here, we 
describe, for the first time, myeloid-derived suppressor cells (MDSC) in 
healthy infants, a heterogeneous population of immature, activated 
myeloid cells with immune suppressive function.
Methods: The prevalence of MDSC during early life was analyzed by 
flow cytometry in blood mononuclear cells isolated from healthy cord 
blood (CB), infants and adults. Phenotypically, MDSC were identified 
as HLA-DRneg, CD14neg, CD33pos, CD11bpos, and CD15 pos.  To 
determine the effect of MDSC on T cell proliferation, T cells and MDSC 
were depleted/purified from CBMC using CD3 or CD15 magnetic beads 
respectively. CFSE-labeled CBMC or CB-derived CD3pos T cells were 
stimulated with anti-CD3/anti-CD28 beads with or without MDSC.
Results: We identified a prominent population of MDSC in CB that 
decreased with age and were generally absent in healthy adults 
(Median frequencies: 5.8% in CB; 4% at 6-weeks of age; 1.2% between 
6-24 months and 0.8% in adults). The amount of suppression imposed 
by MDSC after CD3 stimulation of CBMC directly correlated with the 
frequency of MDSC (r=0.73, p=0.002, Spearman-rank-correlation-
test).   Addition of MDSC resulted in significantly reduced proliferative 
capacity of neonatal T cells (p<0.001, Wilcoxon-Matched-Pair-Signed-
Rank-test).
Conclusion: In order to achieve effective infant immune responses 
to HIV vaccination or to control of HIV infection, MDSC populations 
will need to be manipulated in vivo.  This project is funded by NIH 
(R01AI100018, K08HD069201) and UW CFAR (P30 AI027757). 
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P13.50
Env-Specific Immunogenicity of Asian Mosaic 
HIV-1 Subtype AE/B gag/pol/env Combination 
and HIV-1 env Alone DNA Vaccine in BALB/c 
Mice
S. Sirivichayakul1, S. Buranapraditkun1, P. Thantiworasit1,  
M. Rosati2, B. Felber2, P. Pitakpolrat1, B. Korber3, and  
K. Ruxrungtham1
1Chulalongkorn University, Bangkok, Thailand; 2NIH, 
Bethesda, MD, USA; 3LANL, Los Alamos, NM, USA
Background: To overcome the genetic diversity of HIV-1 among Asian 
countries, mosaic design of HIV-1 DNA vaccines encompassing gag, 
pol and env regions derived from HIV-1 CRF01_AE and Asian subtype 
B were constructed.
Methods: Full-length gag, pol and env sequences derived from 
156, 101 and 113 CRF01_AE and 72, 30 and 59 Asian subtype B, 
respectively, were computerized to generate 3 representative each of 
Asian mosaic HIV-1 gag/pol/env DNA. The mosaic were humanized 
and cloned into pCMV expression vector. The immunogenicity of the 
combination of gag/pol/env and env alone was tested in BALB/c  mice 
by electroporation with 100 µg total DNA at the 1st dose and 20µg 
DNA at the 2nd and 3rd doses and an additional group of 12 and 5 
million (4 million each of gag,pol,env in gag/pol/env and in env alone 
groups) pfu AE-vaccinia boosted. Thus, total env dose was 3-fold less 
when compared env alone to the env/gag/pol combination. Cellular 
immune responses were measured from splenocytes by IFN-gamma 
ELISpot  assay by both HIV-1 AE and B pooled truncated peptides.
Results: The median ELISpot responses to env AE and B peptides of 
the Asian mosaic HIV-1 env alone group were 1088 and 680, while 
the responses of the gag/pol/env combination were 81 and 18 SFU/
million splenocytes, respectively. Boosting with recombinant env-
vaccinia alone (5x106 pfu) or recombinant gag/pol/env (12x106 pfu) 
to the above respective groups significantly enhanced (p = 0.002) 
the responses to 2012 and 1550 and 1833 and 1285 SFU/million 
splenocytes against AE and B pooled peptides, respectively.
Conclusion: Our results suggest that the Asian mosaic env HIV-1 
DNA vaccine was more immunogenic when immunized alone at high 
dose, but it was much less immunogenic when 3-fold lower dose 
was used in the gag/pol/env combination. The DNA priming effect 
of both groups was however similarly effective when boosted with 
recombinant AE-vaccinia.
P13.49
Deletion of C7L and K1L Genes Leads 
to Significantly Decreased Virulence of 
Recombinant Vaccinia Virus TianTan
Z. Liu1
1National Center for AIDS/STD Control and Prevention/
Chinese Center for Disease Control and Prevention, Beijing, 
China
Background: The vaccinia virus TianTan (VTT) has been modified as 
an HIV vaccine vector in China and has shown excellent performance 
in immunogenicity and safety. However, its adverse effects in 
immunosuppressed individuals warrant the search for a safer vector in 
the following clinic trails.
Methods: In this study, we deleted the C7L and K1L genes of VTT 
and constructed six recombinant vaccinia strains VTT△C7L, VTT△K1L, 
VTT△C7LK1L, VTKgpe△C7L, VTKgpe△K1L and VTT△C7LK1L-gag. 
The pathogenicity and immunogenicity of these recombinants were 
evaluated in mouse and rabbit models.
Results: Comparing to parental VTT, VTT△C7L and VTT△K1L 
showed significantly decreased replication capability in CEF, Vero, 
BHK-21 and HeLa cell lines. In particular, replication of VTT△C7LK1L 
decreased more than 10-fold in all four cell lines. The virulence of all 
these mutants were decreased in BALB/c mouse and rabbit models; 
VTT△C7LK1L once again showed the greatest attenuation, having 
resulted in no evident damage in mice and erythema of only 0.4 
cm diameter in rabbits, compared to 1.48 cm for VTT. VTKgpe△C7L, 
VTKgpe△K1L and VTT△C7LK1L-gag were immunized twice, and 
elicited as strong cellular and humoral responses against HIV genes 
as did VTKgpe, while humoral immune response against the vaccinia 
itself was reduced by 4-8-fold. 
Conclusion: These data show that deletion of C7L and K1L genes leads 
to significantly decreased virulence without compromising animal host 
immunogenicity, and may thus be key to creating a more safe and 
effective HIV vaccine vector.
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P13.52
Immunogenicity and Safety of Vaccinia Virus 
LC16m8∆ Expressing SIV Gag Under a Strong 
or Moderate Promoter in BCG Prime-Vaccinia 
Virus Boost Protocol
H. Shida1, H. Sato1, C. Jing1, M. Isshiki1, K. Matsuo2, M. Kidokoro3, 
S. Takamura4, X. Zhang1, and T. Ohashi1
1Hokkaido University, Sapporo, Japan; 2Japan BCG Laboratory, 
Japan; 3National Institute of Infectious Diseases, Japan; 4Kinki 
University School of Medicine, Japan
Background: Previously, we developed the very strong vaccinia virus 
(VV) pSFJ1-10 promoter that consists of ten repeats of the mutated 
early region of the p7.5 promoter and the ATI late promoter. But, 
too much expression of foreign protein decreased the propagation 
of VV.  Balance between expression of the foreign antigen and viral 
propagation in vivo might be crucial for optimal immunogenicity. Thus, 
we compared the effect of the pSFJ1-10 and moderately strong p7.5 
promoters on the immunogenicity and pathogenicity of the replication-
competent VV LC16m8 (m8) harboring the SIV gag gene. We adopted 
vaccination regimen consisting of a recombinant BCG-SIVGag prime 
followed by a recombinant VV boost. This regimen may be expected 
to maintain effector memory T cells for long time because of persistent 
infection of BCG-SIVGag, and to elicit potent immunities because of 
replication competency of m8 recombinants.
Methods: C57BL/6 mice were injected with rBCG-SIVGag followed 
with rVVs. Mice splenocytes were analyzed by intracellular staining 
assay. For safety evaluation, suckling CD1 mice were intracerebrally 
inoculated with various amounts of rVVs.
Results: m8/pSFJ/SIVGag synthesized more Gag protein than m8/
p7.5/SIVGag but replicated less efficiently in vitro. In addition, m8/
pSFJ/SIVGag was less pathogenic and elicited Gag-specific IFN-γ+, 
CD107a+, CD8+ cells more efficiently than m8/p7.5/SIVGag. 
Vaccination by this regimen elicited long-lasting Gag-specific CD8+ 
T cells, the majority of which showed a CCR7- phenotype. Tetramer 
staining analyses revealed maintenance of Gag specific tetramer+, 
CD62L-, CD8+ T cells, phenotype characteristic of effector memory T 
cells. Although both recombinants were less pathogenic than parental 
m8 that harbors intact HA gene, an insertion site for the gag gene, Gag 
expression increased the neurotoxicity of the empty HA- m8VNC110, 
indicating the necessity of safety testing for each recombinant VV. 
Conclusion: We propose that this recombinant BCG prime-m8∆/pSFJ/
HIVGag boost regimen would be a promising vaccination procedure 
for preventing HIV infection.
P13.51
Expression of HIV Envelope Glycoprotein at the 
Yeast Cell Surface for Vaccine Development
S.M. Connelly1, E. Mathew1, and M.E. Dumont1
1University of Rochester Medical Center, Rochester, NY, USA
Background:  We are developing a system in which random 
mutagenesis and screening approaches are being used to identify 
forms of the HIV envelope glycoprotein (Env) that can act as effective 
immunogens for the elicitation of broadly neutralizing antibodies. 
In particular, we are trying to identify variants of Env with enhanced 
affinity for germline precursors to neutralizing antibodies, since poor 
affinity of most forms of Env for such precursors appears to be a major 
limitation on the ability to develop protective immune responses.
Methods: A synthetic gene encoding the sequence of YU2 Env using 
optimal codons for yeast expression has been used for cloning of 
constructs encoding gp120, gp140, and additional truncated forms of 
gp140 fused to sequences from the yeast Aga2p and Sag1p proteins 
in order to anchor the expressed proteins to the outer surface of 
the yeast cell wall. Expression of constructs containing a variety of 
signal sequences, flexible linker sequences, trimerization sequences, 
introduced protease cleavage sites, and normal or mutated furin 
cleavage sites has been evaluated by immunoblotting and flow 
cytometry using anti-Env and anti-epitope tag antibodies.   
Results: We detect expression and cell surface display of gp120 and 
some longer Env fragments. The expressed proteins are glycosylated 
and undergo at least partial cleavage at the furin site apparently 
catalyzed by the endogenous yeast Kex2p protease. Reactivity of 
different forms of expressed Env with a battery of anti-HIV antibodies 
is currently being evaluated. 
Conclusion: Exression of variants of Env displayed at the yeast cell 
surface system appears to be a useful system for identifying improved 
immunogens for HIV vaccine development. Libraries of variant forms 
of Env created by large-scale targeted random mutagenesis are being 
screened to identify variants exhibiting enhanced stability, preservation 
of oligomeric state, and affinity for germline precursors to broadly 
neutralizing antibodies. 
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P13.54
A Pure Native Env Trimer Vaccine Elicits Potent 
Tier 2 Neutralization to a Quaternary, Glycan-
Sensitive Epitope
J.M. Binley1, E.T. Crooks1, K.M. Narayan2, B. Chakrabarti3,  
K. Osawa1, J. Muranaka2, S.X. Du2, T. Tong1, R. Whalen2, and  
R. Wyatt3
1Torrey Pines Institute, San Diego, CA, USA; 2Altravax, Inc., 
Sunnyvale, CA, USA; 3IAVI Antibody Research Center at 
Scripps, La Jolla, CA, USA 
Background: As the exclusive target of nAbs, the native Env trimer is 
a logical basis for a nAb vaccine. Given its immunorecessive nature, 
purity may be essential for its success as a nAb immunogen.  In other 
words, it must be free of contamination by more immunogenic forms 
of Env.
Methods: Four groups of rabbits were immunized with: 1) “trimer 
VLPs”, expressing pure native JR-FL Env trimer, cleared of non-
functional Env by a protease digest,  2) undigested control VLPs, 
3) a JR-FL gp140F trimer DNA prime-protein boost, and 4) JR-FL 
gp120 prime-boost. Immune sera were characterized for binding, 
neutralization and specificity. 
Results: All four immunogens were effective in eliciting anti-Env 
antibodies, as judged by gp120 ELISA, although “trimer VLP”-immune 
sera bound only weakly. One serum each from groups 1 and 3 
exhibited remarkable IC50s >1:1,000 against the JR-FL index virus 
in the TZM-bl assay. Two group 4 sera exhibited titers of ~1:100. 
Mapping revealed that both potent sera targeted sites unusually 
lacking glycans. Specifically, the group 1 serum neutralization was 
regulated by a glycan at residue 197 in the V1V2 loop stem and 
the group 3 serum was regulated by a glycan at residue 230 in the 
C2 of gp120. Interestingly, the N197-regulated activity recognized a 
quaternary epitope. The two neutralizing sera of group 4 mapped to 
the C3-V4 region. 
Conclusion: It is perhaps no coincidence that the two most potent sera 
targeted sites that unusually lack a glycan. Similar glycan-deprived 
sites have also accounted for autologous neutralization in natural 
infection. We are now working on strategies to elicit this activity more 
consistently, and to broaden its neutralization coverage. 
P13.53
Dissection of Antibody-Induced Structural 
Changes in a Soluble HIV-1 Trimer by 
Hydrogen/Deuterium-Exchange Mass 
Spectrometry
M. Guttman1, J. Julien2, A. Cupo3, R.W. Sanders3, I.A. Wilson2, 
J.P. Moore3, and K.K. Lee1
1University of Washington, Seattle, WA, USA; 2The Scripps 
Research Institute, La Jolla, CA, USA; 3Weill Cornell Medical 
College, New York, NY, USA
Background: The HIV Envelope glycoprotein (Env) is the sole target 
for neutralizing antibodies on the virus surface. Recent efforts have 
led to the discovery of several broadly neutralizing antibodies (bNAb), 
capable in some cases of neutralizing >90% of circulating isolates. 
High-resolution structures exist for many antibody Fabs complexed 
to fragments of Env, and electron microscopy has imaged large-scale 
changes in the trimer. The underlying, detailed structural changes 
resulting from bNAb binding to the native trimer, however, have yet 
to be determined.
Methods: Hydrogen/deuterium-exchange mass spectrometry (HDX-
MS) reports on the protection of backbone amides resulting primarily 
from their involvement in secondary structure hydrogen-bonding. This 
analysis provides a detailed map of local structural dynamics as well 
as changes in structural order resulting from ligand binding. Here, we 
investigate the extent of structural reorganization in trimeric SOSIP 
gp140s when complexed with 17b, b12, VRC01, and PGT123 Fabs.
Results: 91% sequence coverage of Clade A KNH1144.664 SOSIP 
trimer enabled changes throughout most of the glycoprotein to be 
monitored. Antibody 17b, which binds a CD4-induced epitope, stabilizes 
portions of gp120 while loosening trimeric interactions involving the 
loops V1/V2 and V3. CD4 binding site-targeted antibody b12 stabilizes 
the binding site, but also produces a moderate disruption of trimeric 
interactions involving the variable loops. In contrast, another CD4 
binding site-directed antibody, VRC01, stabilizes the CD4 binding loop 
without altering V1/V2 structure relative to the unliganded trimer. 
Variable loop and glycan-targeted PGT123 appears to stabilize both 
the loops and the CD4 binding site.
Conclusion: HDX-MS provides a robust method for dissecting 
conformational changes induced by antibody binding, including 
detection of distal allosteric effects. This study indicates that multiple 
mechanisms of neutralization may exist. Some bNAbs lock the trimers 
in the “closed” conformation, while others disrupt trimer interactions 
inducing it to adopt an “open” form.
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P13.56
A Common Transitional Structure Revealed 
by a New Broadly Neutralizing Antibody as a 
Novel HIV-1 Vaccine Candidate
Y. Guan1, T. Liu1, M. Sajadi1, L. Yu1, W. Huang1, M. Seaman2,  
Z. Zhang3, M. Pazgier1, R. Lewis1, R. Gallo1, A. DeVico1, and  
G. Lewis1
1University of Maryland School of Medicine, Baltimore, MD, 
USA; 2Harvard University, Boston, MA, USA; 3University of 
Nebraska Medical Center, Omaha, NE, USA
Background: Large numbers of broadly neutralizing antibodies 
(bnAbs) have been cloned in recent years. However, they typically show 
unusually high levels of somatic hypermutation and autoreactivity that 
might be major roadblocks to using them as templates for rational 
HIV-1 vaccine design. Novel bnAbs with less somatic hypermutation 
and no autoreactivity, therefore, should be explored as templates for 
rational HIV-1 vaccine design.
Methods: By functional screening, we have identified a novel bnAb, 
N60-B1.1 that is encoded by VH4-39 with 13.3% mutation at the 
nucleotide level. It uses a germline-like VK3-15*01 light chain.  Further, 
it is not autoreactive. N60-B1.1 recognizes a transitional co-receptor 
associated region of Env involving epitopes in V1/V2 and V3 region. 
The neutralization pattern of N60-B1.1 is complementary to other 
bnAbs in that it potently neutralizes viruses that are often resistant 
to other bnAbs. N60-B1.1 also shows moderate ADCC function in a 
bound-virion assay. 
Results: The binding of N60-B1.1 to gp120 was competed by V1V2 
mAbs, V3 mAbs, traditional CD4i mAbs and non-broadly neutralizing 
CD4bs mAbs. In contrast, broadly neutralizing CD4bs mAbs, b12 
and VRC01, as well as non-neutralizing ADCC Abs against conserved 
N terminal region of Env substantially enhance N60-B1.1 binding 
to gp120. Importantly, fusion proteins of gp120 with single-chain 
fragment variable regions (ScFV) of these enhancing mAbs substantially 
expose epitopes of N60-B1.1 and other bnAbs, like PG9 and PGT128. 
Conclusion: Therefore, N60-B1.1 stands as a new, unique bnAb against 
HIV-1. Our results suggest that N60-B1.1 locks gp120 in an inactive 
conformation similar to those reported for the broadly neutralizing 
mAbs b12 and VRC01.  The ScFV-gp120 fusions with improved and 
stabilized exposure of the N60-B1.1 epitope as well as other epitopes 
recognized by the bnAbs, PG9, PGT128 and VRC01, represent a 
common transitional structure that is a new candidate for evaluation in 
preclinical studies as a HIV-1 vaccine.  
P13.55
HIV-1 VLP Production Platform Based on 
Transient Transfection of HEK 293 Suspension 
Cultures in Bioreactors
L. Cervera1, S. Gutiérrez-Granados1, M. Segura1, and F. Gòdia1
1Universitat Autònoma de Barcelona, Barcelona, Spain
Background: Robust and scalable Gag VLP production processes are 
required to generate VLPs for preclinical and eventually clinical testing. 
Transient gene expression offers a convenient route to accelerate the 
identification of candidate VLP vaccines as it allows for the production 
of a large number of product variants with relative ease. Considerable 
progress has been made in the past several years towards establishing 
large-scale transient transfection protocols. The human embryonic 
kidney 293 (HEK 293) is the preferred host system due to the many 
industrially relevant features this cell line offers including high 
transfectability, ability to grow in suspension, ability to grow to high 
cellular densities and adaptation to serum-free culture conditions.
Methods: HEK 293 mammalian cell cultures were grown in suspension 
and serum-free conditions in disposable shake flasks and WAVE 
bioreactors. VLPs were generated by transient transfection using a Gag-
GFP plasmid construct and polyethilenimine as transfection reagent. 
The GFP tagged VLPs were quantified using a spetrofluorometer.
Results: An optimized platform for the generation of Gag VLPs in 
mammalian suspension cultures is described in this work. To facilitate 
process optimization, a fast and reliable quantitation technique based 
on fluorescence was developed and validated. An in house culture 
medium supplemented with non-animal derived components was 
defined and the different transient transfection parameters were fine-
tuned to allow maximum cell growth and VLP production. The great 
majority of Gag-GFP recovered from cell culture supernatants was 
shown to be correctly assembled into VLPs of the expected size and 
morphology. The scalability of this strategy was demonstrated using a 
1L WAVE bioreactor.
Conclusion: The quantity and quality of Gag VLPs generated using 
the described platform is suitable for pre-clinical studies in mice. By 
using a GMP-compliant suspension cell line, disposable bioreactors 
and a culture medium devoid of animal-derived components, a fast 
translation into clinical trials is envisioned. 
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P13.58
Advances in DNA Delivery and Formulation 
Enhanced by Low-Current Electroporation 
Improves Antigen Expression and Immune 
Responses In Vivo
K.E. Broderick1, N. Hutnick2, D. Myles2, B. Ferraro2, M. Wise2,  
C. Lucke2, J. Yan1, A. Khan1, N. Sardesai1, and D.B. Weiner2
1Inovio Pharmaceuticals, Blue Bell, PA, USA; 2University of 
Pennsylvania, Philadelphia, PA, USA
Background: DNA has conceptual advantages as a vaccine platform 
for HIV and many infectious diseases because of its safety, lack of 
negative anti-vector serology, stability, and ease of manufacture. 
However, the immunogenicity of DNA vaccines has traditionally been 
low compared with viral vectors and recombinant protein.  Recent 
work has established that the immunogenicity of DNA vaccines has 
been significantly enhanced by delivery with in vivo electroporation. 
Further improvements in delivery design allow electroporation to be 
performed in the dermis, which likely will impact tolerability and with 
improved delivery, further enhancing immunogenicity. 
Methods: Guinea Pigs and non-human primates received intradermal 
DNA vaccination followed by in vivo electroporation at 0.2 or 0.1A. 
Results: Here we report that the current of intradermal vaccination 
impacts antigen expression, inflammation, and the induction of both 
humoral and cellular immunity to HIV antigens as well as reporter 
genes delivered into both guinea pigs and non-human primates. In 
contrast to prior studies with a variety of diverse delivery devices, we 
observed that by using a new focused EP array and much lower (0.1 
A) current we saw a reduction in inflammation which significantly 
improved antigen expression resulting in a much longer immune 
priming in vivo.  In contrast, using higher current expression, in vivo 
priming was reduced. The improved antigen expression resulted 
in higher cellular immune responses with strong breadth and more 
consistent antibody responses.  
Conclusion: This study supports the further development of 
electroporation technology in order to balance enhanced plasmid 
transfection with a loss of expression due to tissue inflammation 
and necrosis. We have also studied multiple delivery arrays and 
conditions for improving DNA transfer into the dermis.  These all 
produce significant antibody responses in multiple animal species. 
These results have major importance for next generation DNA/EP 
approaches with improved delivery, improved immune potency and 
also improved immunogenicity. 
P13.57
VAC-3S, an Immunoprotective HIV Vaccine 
Directed to the 3S Motif of gp41, in Patients 
Receiving ART: Safety, Dose and Immunization 
Schedule Assessment
S. Gharakhanian1, C.  Katlama2, O. Launey3, H. Bodilis3,  
R. Calin4, R. Ho Tsong Fang1, M. Marcu1, B. Autran5, V. Vieillard6, 
J. Crouzet1, and P. Debre5
1InnaVirVax, Cambridge, MA, USA; 2INSERM U943, AP-HP 
Pitié Salpêtrière, Paris, France; 3AP-HP Cochin and INSERM 
CIC BT505, Paris, France; 4AP-HP Pitié Salpêtrière, Paris, 
France; 5INSERM UMR-S945 and University of Paris, Paris, 
France; 6INSERM UMR-S945, Paris, France
Background: We have developed a novel immunotherapeutic 
vaccine (VAC-3S), comprised of 3S peptide, a highly conserved 
HIV gp41motif coupled to commercially used carrier and adjuvant. 
The 3S motif leads, by NKp44L expression on CD4, to apoptosis of 
uninfected CD4. In vitro, anti-3S antibodies (Ab) protect CD4 from 
apoptosis. In cohort studies, anti-3S Ab correlate with lack of CD4 
decrease and/or disease progression. VAC-3S primate proof-of-
concept showed effect on immune and inflammatory biomarkers. 
Dose ranging studies, GLP toxicity, local tolerance studies were 
performed in rats and rat/mice, respectively
Methods: First-Time-In-Human randomized, double-blind, placebo-
controlled study conducted in multiple sections. (A) Dose escalation of 
0.1, 1, 10 µmicrog given IM, q4weeks in virologically ART controlled 
patients (pts) to assess safety. (B) a booster injected in 1 & 10 µmicrog 
groups, 6 month post-initial vaccination
Results: First 2 study sections reported: 25 HIV pts (23 m) completed 
vaccination in 3 groups of 8. Median (range) age 47 yrs (32-54), CD4 
710 c/mm3 (311-1187), CD4 nadir 336 c/mm3 (127-739), ART initiated 
3.0 yrs (1.1-7.1), none had detectable HIV RNA. Section A) No SAE or 
viral rebound reported. Gr1-2 AEs: fever, local reactions, myalgia (1), 
LFT increases (3). One pt in 1 microg, 2 pts in 10 µmicrog groups 
increased anti-3S Ab above 50 arbitrary units (A.U.) with dose-effect 
signal. No change in immune endpoints noted at month 3. Section 
B) Ab titers dropped to pre-vaccination levels, but, fter boost, 1 pt in 
1 µmicrog and same 2 pts in 10 _microg groups increased anti-3S Ab 
titers, including one to >200 A.U. with higher dose.
Conclusion: VAC-3S, an immunoprotective HIV vaccine directed to the 
3S motif of gp41, is safe at doses studied and immunogenic. Boosting 
seems of interest. Further dose escalation to 20 microg is ongoing. 
Subsequent dose high & comprehensive biomarker studies are also 
in planning.
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P13.60
Screening of HIV Envelope Spike Variants for 
Binding to Broadly Neutralizing Antibodies by 
Yeast and Mammalian Cell-Surface Display
S.K. Grimm1, M. Gilman1, and M.E. Ackerman1
1Dartmouth College, Hanover, NH, USA
Background: HIV-1 broadly neutralizing antibodies (bnAbs) are 
challenging to elicit in a vaccine setting. Reasons could be the very 
low to absent affinity of bnAb germline precursors to HIV-1 spike-
derived immunogens or a non-adequate structural representation of 
the native spike. Protein display technologies are powerful tools to 
evolve proteins towards desired properties. We here investigated yeast 
and mammalian cell surface display to evolve an HIV-1 spike protein 
towards improved binding to bnAbs.
Methods: JR-FL gp140 was displayed on the surface of S. cerevisiae or 
HEK293F cells. Displayed spike proteins were characterized for biding 
to bnAbs using flow cytometry. HEK293F cell-displayed test libraries 
were subjected to multiple rounds of fluorescence-activated cell sorting 
(FACS) for binding to quaternary structure-specific bnAb pg16. Between 
sort cycles, episomal vector DNA encoding for gp140 was recovered, 
amplified in E. coli and transfected. Sorted spike populations were 
analyzed for enrichment of variants with improved binding to PG16.
Results: Yeast-displayed gp140 showed a restricted binding profile 
to CD4bs-, V1/2/3 loop- and quaternary structure-specific bnAbs and 
bound well to MPER-specific bnAbs, while HEK293F cell-displayed 
spike bound well to bnAbs against all of these epitope classes. GPI-
anchored gp140 but not monomeric gp120 showed binding to 
quaternary structure-specific bnAb pg16, indicating the display of 
properly folded, trimeric spike. Episomal vector DNA of two different 
kinds could be isolated and reliably amplified between FACS cycles. 
After multiple rounds of FACS of test libraries for binding to bnAb pg16, 
enrichment of the affinity-enhancing JR-FL gp140 E168K mutant over 
JR-FL gp140 wild-type could be shown.
Conclusion: (1) As a platform for vaccine discovery, S. cerevisiae-
displayed HIV-1 gp140 requires further protein engineering towards 
a better bnAb binding profile. (2) Mammalian cell surface display 
is a viable option for the selection of novel HIV-1 spike-derived 
immunogens with improved properties such as quaternary structure 
or bnAb binding.
P13.59
Prime-Boost Vaccine Strategies Using Different 
Subtype Antigens Can Induce Broader 
Neutralized Antibodies
W. Kong1 and X. Yu1
1Jilin University, Changchun, China
Background: Vaccine development to induce broadly neutralizing 
antibodies against HIV-1 is a global health priority. We proposed using 
different vaccine immunogens in series to trigger the appropriate 
maturation pathway of nentralized antibodies.
Methods: Guinea pigs were divided into 3 groups; Guinea pigs in 
group 1 and 2 were primed with DNA vaccines expressing HIV-1 clade 
A/E gag and env three times at two weeks intervals. Then they were 
boosted with rMVA carrying clade B/C gag and env twice at weeks 8 
and 12. Additionally, at week 16, guinea pigs in group 2 were boosted 
once with rAd5 vaccine containing clade B gag and gp160. As negative 
control, guinea pigs in group 3 were inoculated PBS.
Results: Binding antibody responses from immunized groups were 
significantly higher than the PBS-injected group. By using TZM-bl 
cell neutralizing antibody assay, we measured post-immunization 
sera from each guinea pigs of three groups using HIV-1 clade B/C 
pseudovirus-pool containing 2 sensitive strains (tier 1 viruses, SC19-15 
and BJ22-5) and 4 epidemic strains (tier 2 viruses, SC17-32, SC21-28, 
CX78-8, and XJ16-6). The endpoint titers were determined by ID50 
value 2-fold higher than that from pre-immunization sera. Guinea pigs 
of both group 1 and 2 could induce moderate neutralizing antibodies 
compared with negative controls group. And sera form guinea pigs 
boosted with rAd5 showed better neutralization ability, in both 
intensity and width than those only boosted with rMVA.
Conclusion: By using this heterologous prime-boost immunization 
strategy, immunization with our DNA, rMVA and rAd5 vaccines 
could elicit high-titer biding antibodies, as well as broad neutralizing 
antibodies. Although the strength of induced neutralizing antibodies 
were moderate, these neutralizing antibodies could neutralize both 
tier 1 and 2 viruses which is important for vaccine design. Further 
exploration and refinement of this strategy may contribute to the 
development of an effective vaccine in China.
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P13.62
Attempt at HIV Elimination by Enfuvirtide-IgG 
B. Wahren1, C. Chang2, J. Hinkula3, M. Loo4, T. Falkeborn3, R. Li2, 
T. Cardillo2, E. Rossi4, and D. Goldenberg5
1Karolinska Institutet, Stockholm, Sweden; 2Immunomedics, 
Inc., Morris Plains, NJ, USA; 3Linkoping University, Linkoping, 
Sweden; 4IBC Pharmaceuticals,Inc., Morris Plains, NJ, USA; 
5Immunomedics, Inc., IBC Pharmaceuticals, Inc., Morris 
Plains, NJ, USA
Background: There is a need for new anti-HIV agents or approaches, 
with the ultimate challenge of eradicating latent HIV-1 reservoirs in 
infected patients.
Methods: The proprietory Dock-and-Lock (DNL) platform technology 
was used to label human monoclonal antibody of anti-HIV or other 
specificities with four copies of enfuvirtide (T20), a peptide that 
inhibits HIV fusion to cell membranes. Labelling provides target 
specificity, prolonged serum half-life, higher binding avidity, and 
enhanced potency of anti-HIV activity. This was determined by virus 
neutralization, cell-to-cell virus inhibition assays and inhibition of virus-
infected cells in an experimental in vivo murine HIV-1 model using 
HIV-1/MuLV. The potential of IgG-(T20-4) to purge latently infected 
cells was investigated by measuring the efficacy of compounds to 
inhibit the spread of HIV-1 following activation with suberoylanilide 
hydroxamic acid (SAHA). 
Results: The variant of hIg-(T20-4), inhibited and neutralized in vitro 
HIV subtype B strains of primary and cell-adapted origins to 20-100 
fold that of either antibody or T-20 alone.
The potential of IgG-(T20)4 to purge latently infected cells was 
investigated in a cell-to-cell viral inhibition assay by which the efficacy 
of hIg-(T20-4) to inhibit the spread of HIV-1 following activation with 
100 nM SAHA was measured. The substantially activated HIV replication 
was suppressed by each of the T20 labelled agents to 0-3%. Enhanced 
potency was observed for a doxorubicin DNL conjugated anti-HIV IgG 
to neutralize free virus, inhibit intercellular spread of viral infection, as 
well as to eliminate HIV-1/MuLV infection in vivo.
Conclusion: The combination of HIV targeting molecules by the 
DNL method resulted in compounds with highly enhanced anti-HIV 
potency. HIV virions, HIV infected cells and infected non-producing 
cells adjacent to HIV-infected cells could be targeted, leading to new 
possibilities to decrease cells in the viral reservoir.  
P13.61
Developing an Anti-HIV Vaccine Using 
Nucleoside-Modified mRNA Encoding Envelope
N. Pardi1, K. Kariko1, A. Conde1, H. Muramatsu1, J.A. Hoxie1, and 
D. Weissman1
1University of Pennsylvania, School of Medicine, 
Philadelphia, PA, USA 
Background: Despite enormous progress in understanding the 
molecular mechanisms of HIV-1 infection, effective vaccine 
development has been protracted. Recent advancements in mRNA-
based vaccination, however, provides a promising new modality 
to generate potent vaccines, which is further enhanced by using 
nucleoside-modified mRNA. 
Methods: To create a vaccine with maximal potency, in vitro transcribed 
mRNAs were optimized for higher levels and extended translation 
with optimized UTRs, modified nucleosides, 5’ cap, 3’ poly(A)-tail and 
were HPLC-purified. In the present approach, sequences of HIV-1 ENV 
derived from different viral isolates (iR3A and 89.6) were used. The 
mice were immunized with naked mRNAs administered intradermally. 
Flow cytometry was used to evaluate T cell responses after a single or 
multiple administrations. To increase the robustness of the immune 
response, we co-injected mRNAs encoding adjuvant molecules, 
including CD40 ligand and constitutively active TLR3 and TLR4. 
Results: Significant antigen-specific CD4+ and CD8+ T cell responses 
could be measured following one or more rounds of mRNA injections. 
Conclusion: The promising preliminary results show that the use of 
mRNA might open up new possibilities in the field of HIV-1 vaccination. 
It is important to identify the most immunogenic HIV-1 ENV isolate 
and determine the optimal parameters and conditions, in order to elicit 
robust anti-HIV-1 B and T cell immune responses. 
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P13.64
Study 2: Engineering DNA Vaccines Expressing 
the Membrane Proximal External Region 
of HIV-1 gp41 to Optimize Exposure of 
Neutralizing Epitopes
N. Gulzar1, M. Parfyonov1, K. Klaric1, B. Hannigan2, M. McCully2, 
G. Ulas2, W.F. DeGrado2, and J.K. Scott1
1Simon Fraser University, Burnaby, Canada; 2University of 
California-San Francisco, San Francisco, CA, USA
Background: We hypothesize that to elicit HIV-neutralizing antibodies 
(Abs), vaccines targeting the membrane proximal external region of 
HIV-1 gp41 (MPER) must mimic its neutralization-competent structure 
(NCS), defined as being bound tightly by broadly neutralizing Abs 
2F5 and 4E10, and weakly by their non-Nt mutant counterparts.  Our 
first-generation vaccine, MPER-TM1, fully exposed the 2F5 and 4E10 
epitopes, but failed to elicit neutralizing Abs against them, due to 
immunodominance of elements within the gp41 cytoplasmic domain. 
Here, we engineered ecto- and transmembrane domains (TMDs) 
surrounding the MPER to enhance exposure of its neutralizing epitopes.
Methods: Our first-generation DNA vaccine tethered the MPER via 
the gp41-TMD.  Hypothesizing that alternative TMDs can optimize 
exposure of neutralizing epitopes of the MPER, we fused the MPER to 
the membrane soluble region of GCN4 (MS1), a trimeric TMD.  DNA 
vaccines, MS1.1-MS1.7, were constructed with each encoding the 
MPER followed by MS1 shifted C-terminally by a single residue.  These 
constructs and the MPER-TM1 were “capped” with a trimeric coil-VaLd 
(CC) domain inserted N-terminal to the MPER.  DNA vaccines were 
expressed in cells and analyzed for exposure of the 2F5 and 4E10 
epitopes using a cell-lysate ELISA.
Results: Capped and uncapped MPER-MS1.1-1.7 were expressed in the 
context of the plasma membrane and were bound by MAbs 2F5 and 
4E10, though 4E10 binding was not to levels observed for the MPER-
TM1 vaccine.  Optimal MPER reactivity was observed for the MS1-
TM shifted C-terminally by a single residue (MPER-MS1.1) or by four 
residues (MPER-MS1.4).  Capping increased 2F5 and 4E10 binding for 
the MS1.1 construct (CC-MPER-MS1.1) and decreased it for CC-MPER-
TM1; capping had no effect for other MS1 constructs (MS1.2 – MS1.7). 
Conclusion: Our results suggest the MS1 TMD, and possibly capping, 
can support optimal 2F5 and 4E10 epitope exposure.  Immunogenicity 
studies of these MPER-MS1 DNA vaccines are planned.
P13.63
Study 1: Optimizing DNA Vaccines that Target 
the 2F5 Epitope of the Membrane Proximal 
External Region of HIV-1 gp41
N. Gulzar1, K. Klaric1, M. Parfyonov1, M. Montero1, S. Wang2,  
N. Huarte3, B. Appellaniz3, J. Nieva3, S. Lu2, and J. Scott1
1Simon Fraser University, Burnaby, Canada; 2University 
of Massachusetts Medical School, Worcester, MA, USA; 
3University of the Basque Country, Bilbao, Spain
Background: HIV vaccines targeting the membrane proximal external 
region of HIV-1 gp41 (MPER), the site of three broadly neutralizing 
(bNt) monoclonal antibodies (Abs), we hypothesize must mimic the 
neutralization-competent structure (NCS) of the MPER, as defined by 
tight binding by broadly Nt Abs and weak binding by their non-Nt 
mutant counterparts.  We developed two DNA vaccines that express 
the NCS of the MPER in the context of the cell membrane, and a 
liposome-based vaccine bearing peptides covering the MPER and 
portions of the gp41-TMD.
Methods: Immunization 1: Rabbits were immunized via gene gun 
delivery with DNA vaccines encoding the MPER fused to the 
transmembrane domain (TMD) of the platelet-derived growth factor 
receptor (PGDFR-TMD), or to the gp41-TMD + 27 residues of the 
cytoplasmic tail (TM1).  Immunization 2: Rabbits were immunized with 
DNA vaccines encoding PGDFR-TMD and boosted intra-muscularly with 
liposomes bearing peptides expressing the 2F5 epitope (POPG: Npre-
TM).  Immune sera were analysed by ELISA and neutralization assays.
Results: Serum Abs elicited by the MPER-PDGFR vaccine mapped to 
the 2F5 epitope and had equivocal neutralizing activity.  While the 
MPER-TM1 vaccine exposes both the 2F5 and 4E10 epitopes well, 
it elicited Abs that mostly cross-react with the TM1 cytoplasmic tail. 
N-terminal addition of flagellin to DNA vaccines did not alter 2F5 and 
4E10 antigenicity, and MPER reactivity was boosted by MPER-TM1 
DNA vaccines encoding it. POPG:N-pre-TM liposomal vaccines were 
found to elicit 2F5-like Abs. As such, MPER-PGDFR and POPG:N-pre-
TM vaccines are currently being tested for its ability to elicit high-titer 
2F5-like Nt Abs in a DNA-prime liposome-boost immunization study. 
Conclusion: We identified DNA- and protein-based vaccines that 
expose the 2F5 epitope in the context of lipids, and will report on the 
results of this novel immunization strategy.  Our studies suggest DNA 
vaccines must be re-engineered to fully expose the 4E10 epitope via 
alternative TMDs.
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P13.66
HIV CD4 Based Vaccine Increases CD8 T Cell 
Responses and Confers Protection 
Against Challenge with Recombinant Vaccinia 
Encoding HIV Gag-Pol Proteins
S.P. Ribeiro1, D.S. Rosa2, J. Kalil3, and E. Cunha-Neto4
1University of São Paulo School of Medicine, São Paulo, Brazil; 
2Federal University of São Paulo, Brazil; 3Butantan Institute 
Heart Institute, São Paulo, Brazil; 4Heart Institute iii-INCT, São 
Paulo, Brazil
Background: Generation of competent and long-lived memory CD8+ T 
cells is highly dependent on CD4+ T cell help. A vaccine able to provide 
cognate help may efficiently prime CD8+ T cell responses establishing an 
appropriate immune control of HIV. Furthermore CD4 T cells responses 
also have been correlated with HIV infection control. Our group has 
identified a set of 27 conserved and promiscuous CD4 epitopes from 8 
HIV-1 proteins. HIVBr27 encoding such epitopes was highly immunogenic 
in BALB/c mice inducing strong and broad CD4+ responses.
Methods: Here we tested whether pre-immunization with HIVBr27 
could provide cognate help and improve CD4 and CD8 T cell responses 
against other HIV proteins (Gag, Pol and Vif) correlated with HIV 
protection/disease control. To answer that we used ELISPOT assays 
as well as CFSE based proliferation assays against 15 mer overlapping 
peptides from Gag, Pol and Vif.
Results: The pre-immunization with the CD4 based vaccine increased 
and broadened the CD8 T cell response against Gag, Pol and Vif. 
Higher proliferation and cytokine secretion were observed in pre-
immunized animals. In relation to the CD8 T cells, we observed an 
overall increase in 57% and 40% of the breadth and magnitude of 
the responses, respectively, when comparing the CD4 based vaccine 
pre-immunized group to the control. Into the CD4 T cell compartment 
we noticed an increase of 3 and 2 times in the breadth and magnitude 
of the responses, respectively, comparing CD4 versus control primed 
group. We also observed 1 log reduction on the PFUs after recombinant 
Gag-Pol vaccinia virus challenge as well as a 32 fold increase in the 
anti-p24 antibody levels in the HIVBr27 pre-immunized group when 
compared to the control one.
Conclusion: These results highlight importance of a CD4 inducer 
based component as primer for global responses, impacting in both 
cellular and humoral immune response.
P13.65
Lentiviral-Based Anti-HIV Therapeutic Vaccine: 
Design, Preclinical Studies and PhaseI/II 
Clinical Trial Preliminary Results 
M. Rodriguez1, A. Bejanariu1, E. Sarry1, E. Sabbah-Petrover1, and 
C. Bauche1
1Theravectys, Villejuif, France
Background: Theravectys, a spin-off the Pasteur Institute, develops 
a new generation of prophylactic and therapeutic vaccines using 
optimized lentiviral vectors. It’s most advanced product, a therapeutic 
anti-HIV vaccine treatment, has entered clinical Phase I/II end of 
2012. This vaccination should allow seropositive patients to gain an 
immunological status identical to the so-called “Functional Cured” 
patients who develop an efficient immunological response capable of 
controlling the infection without therapy.
Methods: Vaccine candidates are integrative and self-inactivated live-
recombinant lentiviral vectors. They encode an HIV antigen, under 
the regulation of a patented promoter that is preferentially induced in 
APC (generating the specific immune reponse), and showing a basal 
level expression in all cells (allowing their elimination by the settled 
immune response). Furthermore, Theravectys developed a vaccination 
regimen based on iterative immunizations with lentivectors encoding 
the same HIV transgene, relying on different VSV-G serotypes for 
pseudotyping without generating cross-neutralizing antibodies. These 
vaccine candidates are classified as “Live recombinant vectored 
vaccines” (EMA, 2011). 
Results: Preclinical studies demonstrated i)the generation of a 
strong, specific and very long lasting T cell immune response (up to 
2 years in murine animal models), ii) the restricted diffusion of the 
vaccine candidates after injection and iii)their fast disappearance 
within few weeks, correlated with an absence of macroscopic and 
microscopic toxicity.
Conclusion: These data allowed the settlement of an anti-HIV 
therapeutic Phase I/II clinical trial that has received the authorizations 
of the French and Belgium regulatory agencies in 2012. This trial is 
held in France and Belgium and is actually enrolling 36 HIV-1 infected 
patients. Theravectys’ anti-HIV vaccine treatment is assessed at three 
doses and safety, tolerability and immunogenicity compared to a 
placebo group. Furthermore, vaccine efficiency will be evaluated by 
the interruption of the HAART treatment in all patients, including 
placebo. Results are expected by 2014 with intermediary analysis in 
September 2013. 
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P13.68 LB D
Novel R5 Tropic Founder Env SHIV for 
Nonhuman Primate Immunoprophylactic 
Studies 
J.D. Lifson1, G.Q. Del Prete1, B. Moldt2, B.F. Keele1, J.D. Estes1,  
K. Oswald1, R. Fast1, C.M. Trubey1, J. Smedley1, D.R. Burton2,  
V. KewalRamani3, M. Piatak, Jr.1, P. Bieniasz4, and  
T. Hatziioannou4
1SAIC Frederick, Inc., Frederick National Laboratory, Frederick, 
MD, USA; 2The Scripps Research Institute, La Jolla, CA, USA; 
3National Cancer Institute, NIH, Frederick, MD, USA; 4The 
Rockefeller University, New York, NY, USA
Background: Optimal use of nonhuman primate (NHP) models to 
evaluate in vivo antibody-mediated protection from HIV infection 
requires appropriate challenge viruses. Challenges with chimeric 
simian-human immunodeficiency viruses (SHIV) bearing HIV-1 Envs 
are particularly attractive because they allow for direct testing of HIV-1 
Env-directed approaches, obviating the need for multi-step evaluations. 
New CCR5-tropic SHIVs that authentically represent transmitted HIV-1 
Envs are needed to enhance the relevance of NHP studies of antibody-
based vaccine modalities.
Methods: A novel, mucosally transmissible CCR5-tropic SHIV bearing 
an unadapted founder HIV-1 envelope (Clade B) capable of high level 
replication in rhesus macaques was identified via in vivo competition after 
infecting naïve rhesus macaques with pools containing multiple unique 
SHIVs (16-21 SHIVs per pool) bearing distinct CCR5-tropic founder HIV-1 
Envs. To assess the utility of this SHIV for studies designed to evaluate 
neutralizing antibody-based prevention strategies, six rhesus macaques 
were passively immunized with the broadly neutralizing anti-HIV-1 
gp120 antibody PGT-121, 24 h prior to intrarectal SHIV challenge; six 
control animals received an antibody of irrelevant specificity (DEN03). 
Results: All six PGT-121-infused animals were protected from 
infection. In contrast, all six control animals became infected, with 
peak plasma viral loads between 106-107 viral RNA copies/ml . At the 
time of challenge, all six PGT-121 infused animals had serum PGT-121 
concentrations >5,000-fold higher than the in vitro IC50 of PGT-121 for 
the challenge virus and serum IC50 neutralization titers >3,000. 
Conclusion: Through in vivo selection, we have identified a novel 
CCR5-tropic SHIV bearing a transmitted/founder HIV-1 envelope 
that is mucosally transmissible and replicates to high titers in rhesus 
macaques and is suitable for in vivo NHP studies to evaluate antibody-
based protection strategies.
P13.67 LB D
High Affinity Recognition of Synthetic 
Glycopeptides by HIV-1 gp120 V1V2 Loop 
Broadly Neutralizing Antibodies and Their 
Unmutated Common Ancestors
M. Alam1, M.S. Dennison1, B. Aussedat2, Y. Vohra2, P.K. Park2,  
A. Fernández-Tejada2, S. Stewart1, F.H. Jaeger1, K. Anasti1,  
J.H. Blinn1, T.B. Kepler3, H. Liao1, J.G. Sodrosk4, S.J. Danishefsky2, 
and B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2Sloan-
Kettering Institute for Cancer Research, New York, NY, USA; 
3Boston University School of Medicine, Boston, MA, USA; 
4Dana-Farber Cancer Institute, Boston, MA, USA
Background: Current HIV-1 vaccines elicit dominant strain-specific 
neutralizing antibodies. Broadly neutralizing antibodies (BnAbs) are 
not dominant and arise in ~20% of HIV-1-infected individuals after 
several years of infection. One strategy for induction of subdominant 
antibody responses is to produce homogeneous immunogens that 
selectively express BnAb epitopes but do not express dominant strain-
specific epitopes. An HIV-1 vaccine should target the unmutated 
common ancestor (UCA) B cell receptors of naïve B cells, but to date, 
no HIV-1 envelope constructs have been found that bind to the UCA 
of V1V2 BnAb PG9.
Methods: We have designed and chemically synthesized homogeneously 
glycosylated peptides reflective of the HIV-1 envelope V1V2 region with 
Man3GlcNAc2 or Man5GlcNAc2 glycans at N156 and N160 (JACS, in 
press, 2013). We tested the reactivity of these synthetic glycopeptides with 
mature antibodies and their unmutated common ancestors (UCAs) of both 
broadly neutralizing antibodies (BnAbs) PG9 and CH01 and strain-specific 
V2 neutralizing antibody CH58.
Results: The Man5GlcNAc2 V1V2 glycopeptide bound avidly to V1V2 
BnAbs PG9 and CH01 with Kds of 29 nM and 46 nM respectively, and 
bound as well to their UCAs at 98 nM and 118 nM, respectively. Whereas 
PG9 and CH01 BnAbs bound similarly well to the Man3GlcNAc2 V1V2 
glycopeptide, their UCAs bound with an order of magnitude weaker 
affinity to Man3GlcNAc2 V1V2 glycopeptide, indicating a requirement 
for Man5GlcNAc2 glycans for naïve B cell UCA binding. In contrast, the 
V2 strain-specific neutralizing antibody CH58 bound minimally with 
unmeasurable affinity to either V1V2 glycopeptide.
Conclusion: The selective high-affinity binding of these homogeneous 
V1V2 glycopeptides to BnAbs and their UCAs, but not to strain-specific 
neutralizing antibody CH58, makes these synthetic glycopeptide 
constructs promising immunogens for targeting subdominant HIV-1 
envelope V1V2 neutralizing antibody producing B cells. 
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P13.70 LB
Validation of the Predicted Fitness Landscape 
in HIV-1 Gag: A Rational Approach to HIV 
Immunogen Design 
J.K. Mann1, J.P. Barton2, A.L. Ferguson3, S. Omarjee1, B.D. Walker4, 
A. Chakraborty2, and T. Ndung’u1
1University of KwaZulu-Natal, Durban, South Africa; 
2Massachusetts Institute of Technology, MA, USA; 3University of 
Illinois at Urbana-Champaign, IL, USA; 4Ragon Institute of MGH, 
MIT and Harvard, Cambridge, MA, USA
Background: HIV-1 immune evasion by sequence variation is a major 
hindrance to vaccine design. To address this challenge, our group has 
developed a computational model, rooted in physics, that predicts 
HIV-1 fitness landscapes and may thereby inform design of vaccine 
immunogens that maximise targeting of sites harmful to HIV-1 when 
mutated simultaneously, to block viable HIV-1 escape. Here, we aimed 
to address previous computational model limitations and also directly 
tested model predictions by in vitro fitness measurements of HIV-1 
strains containing multiple Gag mutations. We further assessed whether 
refined models improved predictive power for fitness measurements.
Methods: To address under-sampling, a regularisation term was 
introduced into our published model. Further, an extended model 
was developed to introduce residue-specific resolution (while our 
previous models used a binary approximation – consensus versus 
non-consensus). Gag mutation combinations (17 pairs, 1 triple and 25 
single mutations within these) predicted to be either harmful to HIV-1 
viability or fitness-neutral were introduced into HIV-1 NL4-3 by site-
directed mutagenesis. Replication capacities of mutants were assayed 
in an HIV-1-inducible green fluorescent protein reporter cell line. 
Results: A strong correlation was observed between the predicted 
and measured fitness of the corresponding mutants for the original 
model (R=-0.74, p=3.6 x 10-6), and this was further strengthened in 
the two new models (R=-0.83, p=3.7 x 10-12 and R=-0.73, p=9.7 x 
10-9, respectively). 
Conclusion: Our results support the ability of computational models to 
robustly predict the relative fitness of mutant HIV-1 Gag viral strains 
that are phylogenetically not too distant, and the potential value of 
these to address the problem of HIV-1 immune evasion.  
P13.69 LB
Multiple Pathways of HIV-1 Autologous 
Neutralizing Antibodies Cooperate to Drive CD4 
Binding Site Broadly Neutralizing Antibody 
Responses
F. Gao1, M. Bonsignori1, H. Liao1, A. Kumar1, S. Xia1, F. Cai1,  
X. Lu1, D.M. Kozink1, P. Kwong2, T. Zhou2, R. Lynch2, S.M. Alam1, 
G. Ferrari1, G. Kelsoe1, G. Sandrasegaram3, G.M. Shaw4,  
B.H. Hahn4, D.C. Montefiori1, G. Kamanga5, M. Cohen5, P. Braber3, 
B.T. Korber3, J.R. Mascola2, T.B. Kepler6, and B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2Vaccine 
Research Center, NIAID, NIH, Bethesda, MD, USA; 3Los Alamos 
National Laboratory, Los Alamos, NM, USA; 4University of 
Pennsylvania, PA, USA; 5University of North Carolina at Chapel 
Hill, Chapel Hill, NC, USA; 6Boston University, Boston, MA, USA
Background: Defining the virus pathways that drive HIV-1 broadly 
neutralizing antibodies (BnAbs) is critical for HIV-1 vaccine design. 
Methods: We have previously reported the evolution and structure of a 
CD4 binding site (CD4bs) broadly neutralizing antibody (BnAb) CH103 
clonal lineage from an African donor followed from time of infection. 
In this report we probed the initial events driving the CD4bs bnAb 
CH103 lineage in which contact residues of the BnAb included the 
CD4bs, the V5 loop and loop D in envelope glycoprotein gp120. 
Results: As the CH103 BnAbs matured, they potently neutralized the 
transmitted/founder (T/F) virus. Whereas a mutation in the CD4bs 
and insertions in the V5 loop 30 weeks after transmission led to 
virus escape from the CH103 lineage, mutations in the loop D did 
not lead to virus escape; rather loop D mutant viruses were 8-fold 
more sensitive than the T/F virus to neutralization by the CH103 BnAb, 
implying the existence of non-CH103 lineage Nabs targeting the 
gp120 loop D.  Demonstration of such a lineage required the isolation 
of antibodies that neutralized early autologous viruses but not loop 
D mutant viruses. Clonal cultures of memory B cells from 41 weeks 
after transmission indeed found such antibodies, and demonstrated a 
frequency of 0.48% of non-CH103 autologous NAb B cells that did not 
neutralize loop D mutant viruses, while the frequency of the CH103 
BnAb lineage B cells was 0.01%. 
Conclusion: The dominant initial antibody response was an autologous 
NAb response different from the CH103 lineage that targeted the 
gp120 loop D, and in turn, induced escape mutants with greater 
affinity for the CH103 CD4bs neutralizing antibody lineage. Including 
both the T/F Env and loop D mutant Envs in HIV-1 immunogen design 
will be a critical component of experimental immunogens designed to 
recapitulate this sequence of antibody maturation events. 
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P13.72 LB
Single Glycan Binding by a Broadly Neutralizing 
Antibody to HIV-1 Env
F. Garces1, D. Sok1, H.J. Kim1, R. McBride1, L. Kong1, Y. Hua1,  
J.C. Paulson1, A.B. Ward1, D.R. Burton1, and I.A. Wilson1
1The Scripps Research Institute, La Jolla, CA, USA
Background: The HIV-1 envelope glycoprotein is a primary target of the 
neutralizing antibody response. However, sequence variable loops on 
gp120 mediate antibody escape, and extensive N-linked glycosylation 
shields much of the gp120 protein surface from immune recognition. 
Recently, a number of highly potent broadly neutralizing antibodies 
(bnAbs) have been discovered that bind to a glycosylated region around 
the base of the V3 loop. Although these bnAbs penetrate the glycan 
shield to make interaction with the underlying protein, most of their 
interactions are with the conserved N-linked glycans. While antibody-
protein interactions are well characterized, antibody-glycan interactions 
are relatively poorly understood. Therefore, further structural studies of 
glycan-dependent bnAbs in complex with their glycosylated antigens 
are needed, especially if glycosylated immunogens are to be designed 
to elicit glycan-dependent broadly neutralizing responses. 
Methods: Towards this end, we have combined various biophysical 
techniques including x-ray crystallography, electron microscopy, 
glycan arrays, isothermal titration calorimetry, neutralization assays, 
and deep sequencing, to characterize how a novel glycan-dependent 
bnAb, PGT 124, interacts with gp120.
Results: The crystal structure shows that PGT124 primarily interacts 
with a high mannose glycan linked to Asn332 of gp120, accounting for 
over 50% of the contacts in the antibody-antigen interaction. Indeed, 
removal of the N332 glycan by alanine mutagenesis completely 
abrogated neutralization on a cross-clade 6 virus panel, while removal 
of other glycan sites in the high-mannose patch demonstrated no 
effect. Although protein-glycan interactions typically achieve mM to 
uM Kd in the absence of multimerization, surprisingly, the PGT 124-
gp120 interaction, apparently mediated primarily by the glycan at 332 
with limited protein involvement, achieves a Kd of 20 nM.
Conclusion: Thus, these findings provide a framework for engineering 
high affinity monovalent antibody-glycan interactions, and thereby 
contribute to HIV-1 vaccine design.
P13.71 LB
Human HIV-1 Vaccine Induced Antibody 
Durability and Env IgG3 Responses 
K. Seaton1, N. Yates1, W. Williams1, L. Liao1, A. deCamp2,  
Y. Fong2, D. Montefiori3, P. Spearman4, M. Elizaga5, S. Barnett6, 
M. Koutsoukos7, P. Bourguignon7, G. Protocol Team7, H. Protocol 
Team8, R. Protocol Team9, V. Protocol Team10, J. McElrath5,  
L. Corey5, N. Michael9, P. Pitisuttithum11, S. Rerks-Ngarm12,  
J. Kim9, G. Voss7, P. Gilbert2, B. Haynes1, and G. Tomaras1
1Duke Human Vaccine Institute, Durham, NC, USA; 2SCHARP, 
Seattle, WA, USA; 3Duke University, Durham, NC, USA; 4Emory 
University, Atlanta, GA, USA; 5Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA; 6Novartis, USA; 7GlaxoSmithKline, 
UK; 8HVTN, USA; 9US MHRP, Silver Spring, MD, USA; 10GSID, 
USA; 11Mahidol University, Bangkok, Thailand; 12Ministry of 
Public Health, Bangkok, Thailand
Background: Effective HIV-1 vaccine design requires induction of 
long-lived protective antibody responses. Substantial differences in the 
IgG subclass profile among vaccine strategies have been previously 
demonstrated and in RV144, Env IgG3 was correlated with decreased 
risk of infection. Notably, several bNAbs are of IgG3 origin, suggesting 
that induction of this antibody subclass may be an important goal for 
HIV-1 vaccine design.
Methods: Vaccine-induced Env IgG subclass responses were evaluated 
from 4 human HIV-1 vaccine clinical trials with distinct immunogen 
and adjuvant strategies. Antibody kinetics and/or durability of Env 
IgG3 were measured in 40 RV144 (ALVAC prime, Clade B/E gp120/
alum) vaccinees at 3.5 yrs post vaccination, in 120 VAX003 (Clade 
B/E gp120/alum) vaccinees between protein boosts, in 30 GSK PRO 
HIV-002 (Clade B gp120, AS01B) vaccinees out to 18 months post 
vaccination, and in 34 HVTN 088 (Clade C gp140/M59) vaccinees 
boosted 6-17 yrs after prior vaccination.
Results: GSK PRO HIV002 (Clade B gp120/AS01B) elicited more 
durable vaccine induced IgG responses compared to RV144 (Clade B/E 
gp120/ alum) with a significantly slower decline. Additionally, HVTN 
088 (Clade C gp140/MF59) IgG antibody levels were detectable 6-17 
years after prior vaccination in 64-79% of vaccinees tested. However, 
in each study we found that Env IgG3 responses declined more 
rapidly compared to overall IgG responses (29% Env IgG and 0% IgG3 
response rates 3.5 yrs post-vaccination in RV144).
Conclusion: The more rapid decline in vaccine induced IgG3 responses 
compared to overall IgG responses indicates that the character of the 
vaccine induced antibody responses is time-dependent. The changing 
levels among antibody subclasses after vaccination can potentially 
influence the functional properties of the vaccine induced humoral 
responses.  Evaluating differences in vaccine induced antibody 
durability is important for immunogen and adjuvant designs that 
aim to strategically target the durability of HIV-1 Env antibodies with 
optimal antiviral properties.
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P13.74 LB
Using an Autologous HIV Vaccine/activator 
(Based on the Full Length Genome and 
Intrapatient Virus Population) to Induce Latent 
HIV and Boost Immunity
E.J. Arts1, T. Biru1, D. Canaday1, M. Quinones-Mateu1, and  
G. Nickel1
1Case Western Reserve University, Cleveland, OH, USA
Background: HIV persists in cellular reservoirs as latent proviral 
integrants even with fully supressive HAART. Prior to treatment, HIV-
1 primarily infects HIV-specific CD4+ T cells that then transitions 
to the latently infected memory T cells. Thus, we propose that the 
most effective and specific activator of latently infected T cells is the 
patient´s HIV-1 quasipecies prior to treatment. This same autologous 
activator can act as an immunogen.
Methods: The entire HIV-1 genome and population was amplified from 
multiple plasma samples prior to HAART. The HIV-1 genome was RT-
PCR amplified in overlapping halves or thirds, which is then recombined 
into a yeast-based vector via homologous recombination/gap repair. 
The vector lacks the 5’LTR and through PCR, we destroyed the RNA 
packaging sites, integrase active site, and PPT. Defective proviral 
plasmids are transfected into 293T cells to produce a replication-
incompetent vector based on the intrapatient HIV-1 population prior 
to treatment.
Results: Autologous HIV-1 vector, a NL4-3-based vector, and a cocktail 
of flu/tetanus/CMV antigens were loaded onto the patient DCs and then 
co-cultured with T cells, both obtained and isolate from samples: 3 yrs 
on stable HAART. In five different patients, the autologous HIV vector, 
presented by DCs, induced at least 30-fold higher HIV-1 production 
from the T cells than did the NL4-3 vector and 100-fold higher than the 
Flu/TT/CMV cocktail. In contrast, gamma interferon ELISPOTS on the 
DC-antigen-T cell cocultivations revealed >10-times more sfu’s with the 
Flu/TT/CMV antigen cocktail than with the autologous vector.
Conclusion: These findings suggest that the intrapatient HIV-1 population 
in a safe, dead vector may be the most effective, specific stimulus to 
drive HIV-1 out of the latent T cells. Activation of the HIV-specific T cells 
(lacking latent HIV-1) may also provide help for both the humoral and CTL 
responses, boosted by this autologous HIV-1 immunogen.
P13.73 LB
HIV-1 Envelope Glycoprotein Signatures that 
Correlate with the Development of Cross-
Reactive Neutralizing Activity
T. van den Kerkhof2, A. Feenstra1, Z. Euler2, M. van Gils2,  
L. Rijsdijk1, B. Boeser-Nunnink2, J. Herringa1, H. Schuitemaker2,  
and R. Sanders2
1VU University, Amsterdam, Netherlands; 2University of 
Amsterdam, Amsterdam, Netherlands
Background: Current HIV-1 envelope glycoprotein vaccines are 
unable to induce cross-reactive neutralizing antibodies. However, such 
antibodies are elicited in 10-30% of HIV-1 infected individuals, but 
it is unknown why these antibodies are induced in some individuals 
and not in others. We hypothesized that the envelope glycoproteins 
(Env) of early HIV-1 variants in individuals who develop cross-reactive 
neutralizing activity (CrNA) may have unique characteristics that 
support the induction of CrNA.
Methods: We retrospectively generated and analyzed env sequences 
of early HIV-1 clonal variants from 31 individuals with diverse levels 
of CrNA 2-4 years post-seroconversion. The Sequence Harmony (SH) 
algorithm was used to analyze amino acid differences between the env 
sequences of the individuals who developed CrNA and the individuals 
who did not develop CrNA. SH is an entropy-based method that 
measures the overlap in distribution of amino acid types between two 
groups of sequences.
Results: Our analyses revealed a number of Env signatures that 
coincided with CrNA development. These included a statistically shorter 
V1 and a lower probability of glycosylation as implied by a high ratio 
of NXS versus NXT glycosylation motifs. Furthermore, lower probability 
of glycosylation at position 332, which is involved in the epitopes of 
many broadly reactive neutralizing antibodies, was associated with the 
induction of CrNA. Finally, Sequence Harmony identified a number of 
amino acid changes associated with the development of CrNA. These 
residues mapped to various Env subdomains, but in particular to the 
V1 and V4 as well as the underlying α2 helix of the C3. 
Conclusion: These findings imply that the development of CrNA might 
depend on specific characteristics of early Env. Env signatures that 
correlate with the induction of CrNA might be relevant for the design 
of effective HIV-1 vaccines.
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P13.76 LB
Antigen Design to Maximize Anti-HIV CD4+ 
T Cell Responses: Provision of Cognate Help, 
Increased Coverage and Coping with HIV 
Genetic Variability
E. Cunha-Neto1, D.S. Rosa2, S. Ribeiro1, R.R. Almeida1,  
V.C. Santana1, and J. Kalil1
1University of São Paulo, São Paulo, Brazil; 2Federal University 
of São Paulo, São Paulo, Brazil
Background: Purposely eliciting CD4+ T cell responses has been 
essentially unexplored in the HIV vaccine field, despite increasing 
evidence for the importance of the CD4+ T cell response in protection 
against HIV. In the RV144 trial, Env-specific CD4+ but not CD8+ T cell 
responses were demonstrated in a fraction of vaccinees. Direct effector 
CD4+ T cells have been associated with better outcomes in SIV 
and HIV infection, and Rhesus macaques protected by SIV vaccines 
displayed robust CD4+ T cell responses. 
Methods: We used rational vaccine design to develop a DNA vaccine 
encoding 18 HIV-1 B subtype (HIVBr18) or M-type (HIVBr27) conserved, 
multiple HLA-DR-binding CD4 epitopes, known to be recognized by 
multiple HIV-1-infected patients. 
Results: Both vaccines elicited broad, polyfunctional, and long-lived 
CD4+ T cell responses in BALB/c and several HLA class II transgenic 
mice. In addition, HIVBr27 elicited extensive cross-clade immunity. 
Immunization with HIVBr27 increased CD8 T cell responses against 
subsequent whole HIV protein immunization, and reduced viral titers 
after challenge with a recombinant vaccinia virus encoding HIV Gag-
Pol proteins. Immunization with HIVBr18 prior to recombinant gp140 
HIV envelope protein drastically increased the IgG2a/IgG1 ratio of 
elicited anti-gp140 antibodies under multiple adjuvants. 
Conclusion: By virtue of inducing broad responses against multiple 
conserved CD4+ T cell epitopes that can be recognized across widely 
diverse, common HLA class II alleles, this vaccine concept may induce 
T cell responses against multiple peptides in large proportion of the 
genetically heterogeneous population. By increasing the chance of 
matching the responses with multiple epitopes in the infecting HIV 
isolate, the vaccine concept may also cope with HIV genetic variability. 
The vaccine concept may be a candidate for standalone use or in 
association with conventional immunogens, to increase the amplitude, 
coverage and effectiveness of the induced response. 
P13.75 LB
Filling in the Immunological Space: Low 
Seroprevalent Ad HIV Vaccines +/- Adjuvanted 
Protein or Electroporated DNA Elicit Different 
Immune Profiles
J. Gilmour1, J.H. Cox2, M.C. Keefer 3, E. Ruzagirwa4, J. Mpendo5,  
W. Kilembi6, G. Omosa-Manyonyi7, L.R. Baden8, E. Karita9, G. Mutua10,  
G. Gray11, L. Bekker12, G. Churchyard13, N. Kiwanuka5, F. Roman14,  
M.G. Pau15, J. Eldridge16, D. Hannaman17, M. McElrath18, D.H. Barouch19,  
P. Bourguignon14, O. Anzala7, J. Excler20, F. Priddy2, D. Laufer2, and P. Fast2
1IAVI Human Immunology Laboratory, London, UK; 2IAVI, New York, NY, 
USA; 3University of Rochester School of Medicine and Dentistry, Rochester, 
NY, USA; 4Medical Research Council, Entebbe, Uganda; 5Uganda Virus 
Research Institute, Entebbe, Uganda; 6Zambia Emory HIV Research 
Program, Lusaka, Zambia; 7Kenya AIDS Vaccine Initiative and University 
of Nairobi, Nairobi, Kenya; 8Brigham and Women’s Hospital and Harvard 
Medical School, Boston, MA, USA; 9Projet San Francisco, Kigali, Rwanda; 
10Kenya AIDS Vaccine Initiative, Nairobi, Kenya; 11Perinatal HIV Research 
Unit and University of Witwatersrand, Johannesburg, South Africa; 
12University of Cape Town, Cape Town, South Africa; 13Aurum Institute for 
Health Research, Johannesburg, South Africa; 14GlaxoSmithKline Vaccines, 
Rixensart, Belgium; 15Crucell Holland BV, Leiden, Netherlands; 16Profectus 
BioSciences, Tarrytown, NY, USA; 17Ichor Medical Systems, Inc., San Diego, 
CA, USA; 18Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
19Beth Israel Deaconess Hospital and Harvard Medical School, Boston, MA, 
USA; 20US MHRP, Bethesda, MD, USA
Background: Since correlates of immune protection for HIV are still poorly 
defined, it is difficult to prioritize vaccines for further development. Assigning 
distinct immunological profiles to HIV vaccine candidates may be helpful. IAVI 
and partners have assessed the clinical safety and immunogenicity profiles of 
Ad35 vectored HIV vaccines alone or combined with HIV vaccines based on 
Ad26, adjuvanted protein or electroporated DNA. 
Methods: Four randomized, placebo-controlled, phase I trials of 4-5 arms each 
enrolled 498 healthy HIV-uninfected participants at low risk for HIV in the US and 
Africa. Trial 1: dose escalation of a replication-defective Ad35 vector containing 
HIV-1 subtype A genes encoding gag, RT, integrase, nef (GRIN) and envelope 
(Env). Trial 2: adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein (F4/AS01) co-
administered or sequentially administered with Ad35-GRIN. Trial 3: heterologous 
and homologous sequences of Ad35-HIVEnv and Ad26-HIVEnvA.01. Trial 4: 
multi-antigenic HIV plasmid DNA (HIVMAG) vaccine encoding clade B gag-pol, 
env, nef-tat-vif, alone or co-administered with pDNA IL12 given IM/EP using 
TriGrid™ Delivery System, and Ad35GRIN-ENV. Central laboratories with qualified 
assays assessed immunogenicity across the trials.
Results: The IFN-gamma ELISPOT response rates, magnitude and breadth in 
the best arms from the trials were similar 2-4 weeks post-boost (for Env and 
for Gag-RT-Nef). However, the immune profiles differed. CD8 T-cell responses 
predominated after Ad35 and Ad35-Ad26; co-administration of F4/AS01 + Ad35-
GRIN induced balanced, persistent CD4 and CD8 T-cell responses; and DNA EP 
+/- IL-12 + Ad35GRIN-ENV elicited CD4 and CD8 T-cell responses after prime 
and boost respectively. Polyfunctional T cell responses were detected across 
all arms, to different degrees. Antibody responses to adjuvanted protein were 
strongest and durable compared with other regimens. Adenovirus neutralization 
titers remained low in all groups. 
Conclusion: Distinct immunological profiles were revealed in the 4 trials. Further 
characterization of the responses will enhance understanding of the profiles.
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P13.78 LB
Novel Epitopes of Nef, Suitable for an HIV 
Vaccine in Africa
B. Wahren1, A. Kilpelainen1, R. Axelsson Robertson1, E. Sandstrom1, 
M. Maeurer1, and T. Leitner2
1Karolinska Institutet, Stockholm, Sweden; 2Los Alamos 
National Laboratory, Los Alamos, NM, USA
Background: Understanding of host responses to HIV antigens is of
importance for continued rational development of HIV vaccines. 
Immunogenic epitopes of HIV proteins have predominantly been 
identified for HLA alleles commonly expressed in Caucasian 
populations, but the need for HIV vaccines is particularly urgent in 
many African countries. 
Methods: By combining analysis tools of the Immune Epitope Database 
Analysis Resource (IEDB), the HIV/AIDS database of Los Alamos and 
proteasomal cleavage evaluation, we predicted high affinity novel 
peptides for five alleles common in African populations. The de novo 
predicted HLA epitopes were validated by biologically identified HLA 
epitopes for A*02:01. 
Results: We identified previously not described epitopes for the 
common African HLA alleles HLA-A*02:01, A*30:01, A*30:02, B*58:01 
and C*07:01. Among the ten best for these alleles, all had low percentile 
ranks below 10, indicating high affinities related to induction of cellular 
immunity. Locations for mutations to preserve immunogenicity of the 
Nef protein, modified not to confer HLA- or CD4+ down-regulating 
activities were identified.
Conclusion: Our study of the HIV-1 Nef aa sequence has brought to 
light several candidate epitopes, which indicates that incorporation of 
the Nef protein or gene in an HIV vaccine should contribute effectively 
to stronger and broader cellular immunogenicity of an HIV-1 vaccine. 
This appears to be true particularly for African populations.
P13.77 LB
Evaluation of Dendritic Cell Targeted Consensus 
B and MOSAIC HIV Gag Protein Vaccines In Vitro 
in PBMC of Treatment Naive HIV-1 Infected 
People 
G.W. Nchinda1, N. Nji1, J. Tchadji1, G. Ambada1, N.C. Sake1,  
S. Sosso1, R. Kamgaing1, S. Bertrand1, D. Takou1, E. Temgoua1, 
A.M. Salasar2, T. Keler3, C. Trumpheller4, M. Caskey4, C. Park1,  
S. Schlessinger1, M. Tenbusch1, K. Ueberla5, J. Torimiro1, V. Colizzi1, 
P.J. Fouda1, V. Mve Koh1, M. Nkam1, M. Nussenzweig1,  
and R.M. Steinman1
1Chantal Biya International Reference Center for Research on the 
Prevention and Management of HIV/AIDS, Yaounde, Cameroon; 
2Oncovir, USA; 3Celldex, USA; 4The Rockefeller University, New 
York, NY, USA; 5Ruhr University, Bochum, Germany
Background: Our consortium has developed a first generation 
dendritic cell (DC) targeted consensus B HIV gag protein vaccine 
for proof of concept studies that selected delivery of proteins to DC 
will allow proteins to be more immunogenic . This should provide a 
cheaper and effective way to immunize people repeatedly with no 
negative impact of pre-existing immunity. This vaccine is already in 
an ongoing phase 1 clinical trial in New York however it is not known 
whether this consensus B based vaccine would work in sub Saharan 
African where unrelated strians of HIV-1 are predominant. 
Methods: To assess the consequense of targeting a consensus B and 
MOSAIC gag protein vaccines to DC from people infected with unrelated 
strains of HIV-1 in Africa we added the protein vaccines to their blood 
cells in vitro and measured proliferation and IFNy production by bulk 
PBMCs as well as a coculture between monocyte derived DC and T 
cells of treatment naive HIV-1 infected people. 
Results: Dendritic cell targeted Consensus B and MOSAIC  HIV gag 
Protein vaccines recalled pre-existing T cell responses in blood cells 
of treatment naïve people infected with unrelated strains of HIV-1. DC 
targeted MOSAIC gag vaccine was more efficient than the consensus 
B vaccine and stimulated significant proliferation of HIV gag specific 
cells (P<0.001).
Conclusion: Thus dendritic cell targeted consensus B and MOSAIC HIV 
gag protein vaccines could recall pre-exhisting CD4 and CD8 T cell 
responses in vitro in PBMC of treatment naïve people infected with 
unrelated strains of HIV-1 in Africa. DC targeted MOSAIC gag protein 
vaccine should be further evaluated for possible incorporation in future 
vaccines especially for therapeutic vaccination in Sub Saharan Africa
Topic 13: Vaccine Concepts and Design
310
Posters
P
O
ST
ER
S
AIDS Vaccine 2013
Odd-numbered posters will be presented in Poster Session 01 on Tuesday, 8 October from 17:30 – 19:00 in L2, Room 211 – 212.
Even-numbered posters will be presented in Poster Session 02 on Wednesday, 9 October from 17:30 – 19:00 in L2, Room 211 – 212.
P13.80 LB
Redesign of Replicating LucR HIV-1 Reporter 
Viruses with Innovative IRES Elements for 
Expanded Immune Monitoring Applications 
M.O. Alberti1, J.J. Jones1, H. Ding1, T.G. Edmonds1, J.C. Kappes1,  
and C. Ochsenbauer1
1University of Alabama at Birmingham, Birmingham, AL, USA
Background: We previously reported on replication competent 
HIV-1 reporter viruses expressing Renilla luciferase (Env-IMC-LucR; 
Edmonds, 2010) which have enabled a novel T-cell based assay with 
heightened sensitivity for neutralizing antibody in vaccinee sera for 
testing of samples from RV144 and Vax003 trials (Montefiori, 2012). 
Furthermore, these reporter viruses are enabling novel CD8 T cell virus 
inhibition assays (LucR-IMC-VIA; Naarding, in press), ADCC and other 
approaches. Env-IMC-LucR technology (in which a self-cleaving T2A 
peptide enables Nef expression in frame with, and release from, LucR) 
has found wide application. However, the molecular approach may not 
be optimal for certain approaches to Correlates of Protection discovery 
which aim at utilizing “whole-genome” Transmitted/Founder reporter 
IMC, or those which require unaltered Nef.
Methods: In Env-IMC-LucR viruses, LucR is stable over multiple 
replication cycles, and read-out is highly sensitive and robust. The 
small T2A peptide is advantageous in that regard and allows nef 
expression at normal levels, but it adds an N-terminal residue to Nef 
which may affect some Nef function. Thus, we have explored if novel 
IRES elements of small size or with attenuating features can outperform 
“classic”, and potentially destabilizing, EMCV IRES in HIV-1 proviruses. 
We designed 8 novel IRES containing HIV-1 reporter viruses with IRES 
elements from insect viruses, HCV, and modified EMCV IRES. 
Results: Compared to Env-IMC-LucR, all IRES containing proviruses 
were similarly infectious and expressed LucR. Nef was not detected 
from insect IRES elements. Expression of Nef from HCV and some 
“attenuated” EMCV IRES elements was similar to that of parental 
virus. Constructs with physiologic Nef levels were tested for replication 
kinetics and genetic stability of LucR, and behaved encouragingly 
similar to Env-IMC-LucR.
Conclusion: Redesigned reporter viruses with modified IRES elements 
promise to be useful virologic tools for augmenting HIV vaccine 
immune monitoring efforts, including neutralization, ADCC, and CD8 
VIA approaches, and novel assays.
P13.79 LB
Env-Specific Tfh Responses and Neutralizing 
Antibodies Develop Concomitantly Following 
Co-Immunization of Rhesus Macaques with HIV 
Env DNA and Protein
A.J. Hessell1, B.J. Burwitz1, D.C. Malherbe1, F. Pissani1, N. Sather2, 
H. Robins3, W.F. Sutton1, S. Pandey1, L. Stamatatos2, J.B. Sacha1, 
and N.L. Haigwood1
1Oregon Health & Science University, Beaverton, OR, USA; 
2Seattle BioMed, Seattle, WA, USA; 3Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA
Background: RV144 vaccinees harbored Env-specific IgG and HIV-1 
specific CD4+ T cells. Thus, the modest success of RV144 may be 
due to induction of both HIV-1 specific B cell and Tfh responses. We 
designed DNA and protein immunogens, using Env sequences from two 
HIV-infected subjects who developed broadly neutralizing antibodies 
(bNAb) and co-immunized macaques (DNA+protein) to explore the 
ontogeny of bNAb development. This strategy rapidly elicits strong 
NAb responses, and our goal here was to measure Tfh responses in 
lymph nodes from these immunized macaques. 
Methods: Twelve macaques, divided evenly into two groups, were 
co-immunized with gp160 Env DNA and gp140 protein at weeks 0, 
4, 12 and 20. Serum antibodies were monitored for Env binding, 
neutralization, and avidity. Lymphocytes collected from inguinal 
lymph nodes at weeks 21 and 22 were incubated with soluble gp140 
Env antigens, anti-CD28, anti-CD49d, and Brefeldin A. Tfh cells were 
defined as CD3+ CD4+ CD95+ PD-1mid/hi and Env-specific responses 
were measured by IL-21 and IFNγ intracellular staining.
Results: DNA+protein-immunized macaques developed neutralization 
breadth against HIV-1 Tier 1 and Tier 2 viruses. Using previously 
described rhesus macaque CD4 Tfh cell phenotypes, we examined 
Tfh responses in inguinal lymph nodes two weeks after the fourth 
immunization. All animals developed measurable Env-specific Tfh 
responses specific for HIV Env-SF162 and for cognate Envs derived 
from broad neutralizers. 
Conclusion: This is the first reported identification of Env-specific Tfh 
responses in vaccinated rhesus macaques. The significance of memory 
T cell and protective B cell responses induced by vaccination is central 
to HIV vaccine success. Non-human primates are valuable models to 
monitor vaccine induction of cellular immunity by measuring HIV Env-
specific Tfh responses in lymph nodes to investigate their kinetics and 
frequency in response to vaccination and to correlate their appearance 
and strength with the emergence of binding and neutralizing antibodies. 
NIH/NIAID P01AI078064 N.L.H.
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P13.81 LB
Exogenous Expression of HIV-1 Envelope 
Glycoprotein Trimer in Suspension Culture-
Adapted HEK293 and CHO-K1 Cells
A. Mulky1, H. Ding1, Y. Mao2, J.K. Wakefield1, C. Ochsenbauer1,  
M. Ray1, A. Herschhorn2, C. Gu2, L. Castillo-Menendez2,  
J.E. Robinson3, H. Liao4, L.J. DeLucas1, B.F. Haynes4, J.G. Sodroski2, 
and J.C. Kappes1
1University of Alabama at Birmingham, Birmingham, AL, USA; 
2Harvard Medical School, Boston, MA, USA; 3Tulane University 
Medical Center, New Orleans, LA, USA; 4Duke University 
Medical Center, Durham, NC, USA 
Background: HIV-1 Env is the only virus-specific protein presented 
on the virion surface and thus, it’s the principal target of neutralizing 
antibody. Until recently, gp120 and gp41 structures did not include 
several functionally important regions. This knowledge gap limits 
immunogen design vaccine research. Using Env trimer purified from 
293F cells, Mao et al, 2012. recently described an ~11-Å cryo-EM 
structure of an unliganded, fully glycosylated Env trimer in its pre-
fusion state, elucidating new structural information on gp120/gp41 
subunit interactions in context of the Env trimer. These findings 
demonstrated utility of single-particle cryo-EM for structural analysis 
of the trimeric HIV-1 Env glycoprotein complex.
Methods: To augment structure studies of the Env trimer, TRE-env-
ires-puromycin-T2A-EGFP expression cassettes were stably integrated 
into DNA of CHO and HEK293 cells via lentiviral vectors. Env 
expression and conformation were assessed by analyzing binding of 
monoclonal antibodies. Env was purified from the plasma membrane 
using detergents, density-gradient ultracentrifugation and affinity 
chromatography.
Results: Stable high-producer clonal cell lines were obtained that over-
expressed variants of the JRFL env, including cleavage deficient and 
cleavage competent full-length and truncated variants. Exogenous 
Env exhibited native conformation based on recognition by MAbs that 
bind diverse epitopes in gp120 and gp41, including conformation-
dependent neutralizing antibodies. Microgel filtration chromatography 
of Env solubilized and purified from the cell plasma membrane 
suggested the presence of intact trimeric glycoprotein. The suspension 
cells were readily scalable to 10 liter batch cultures, comprising 50-
70 billion cells with peak Env expression observed 15-24 hrs after 
doxycycline induction. Analysis of microsomal membranes indicated 
0.1-0.5 pg of Env production per cell.
Conclusion: Our findings suggest that the robust nature of the expression 
system offers new opportunities for characterizing biophysical and 
biochemical properties of native HIV-1 Env.
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Zhan, Wei  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P01 .19 LB
Zhang, Baoshan  .  .  .  . P01 .10, P03 .02 D, 
P03 .13, P03 .22, P03 .40, 
P03 .53
Zhang, Jinsong   .  .  .  .  .  .  .  .  . OA02 .06 LB
Zhang, Jason  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P02 .04
Zhang, Kui  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P06 .12
Zhang, Lily  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . PL04 .06
Zhang, Linqi  .  .  .  .  .  .  .  .  . P02 .18, P03 .15
Zhang, Mei-Yun  .  .  .  .  .  .P03 .11, P03 .34, 
P03 .61 LB
Zhang, Ruijun   .  .  .  .  .P02 .01, P03 .65 LB
Zhang, Xinrui  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .57
Zhang, Xianfeng   .  .  .  .  .  .  .  .  .  .  .  . P13 .52
Zhang, Yu  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .61 LB
Zhang, Zhenhai  .  .  .  . OA05 .02, P03 .13, 
P03 .20, P03 .38, P03 .49
Zhang, Zhixin  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P13 .56
Zhanhai, Zhenhai  .  .  .  .  .  .  .  .  . P03 .69 LB
Zhao, Hong  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P05 .05
Zhou, Jingying  .  .  .  .  .  .  . P01 .01, P12 .06
Zhou, Tongqing  .  .  .  . P01 .10, P03 .02 D, 
P03 .22, P03 .53, P13 .69 LB
Zhu, Jiang  .  .  .  .  .  .  .  .  .  .P01 .10, P03 .20, 
P03 .22, P03 .53, P03 .77 LB
Zhu, Zhongyu   .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .32
Zimmerman, Matthew G  .  .  .  .  . P12 .21, 
P12 .50
Zinszner, Hélène  .  .  .  .  .  .  .  .  . P11 .15 LB
Zirkle, Brett  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .32
Zolla-Pazner, Susan  .  .  . P01 .17, P03 .31, 
 P03 .44, P03 .56, P03 .73 LB, 
P06 .19 LB, P06 .20 LB 
Zorrilla, Carmen   .  .  .  .  .  .  .  .  .  . P04 .04 D
Zoya, Gin’ko   .  .  .  .  .  .  .  .  .  .  .  .  .  .OA03 .02
Zuo, Teng  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .15
Zuo, Yanan  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .15
Zurawski, Gérard  .  .  . OA02 .04, P01 .06, 
P04 .46 LB
Zurawski, Sandra   .  . OA02 .04, P01 .06, 
P04 .46 LB, P12 .45
Zurla, Chiara  .  .  .  .  .  .  .  .  .  .  .  .  .  .OA04 .01
Zwick, Michael  .  .  .  .  .  .  .  .  .  .  . P03 .64 LB
Wittrup, K . Dane  .  .  .  .  .  .  .  .  .  .  .  . P01 .04
Wolf, Hans  .  .  .  .  .  .  .  .  .  .  .  .  .  . P04 .44 LB
Wong, Fay E  .  .  .  .  .  . P02 .33 LB, P13 .09
Wong, Gary  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P02 .19 
Wong, Patrick   .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .59
Woo, Sangsoon  .  .  .  .  .  .  .  .  .  . P03 .74 LB
Wrammert, Jens .  .  .  .  .  .  .  .  .  .  .  .  . P01 .09
Wren, Leia  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .51
Wright, Kevin  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P13 .05
Wrin, Terri  .  .  .  .  .  .  .  .  . OA07 .05, P13 .17, 
P13 .38
Wu, Fan  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .46
Wu, Xueling  .  .  .  .  .  .  . P03 .02 D, P03 .13, 
P03 .22, P03 .53, P03 .59
Wu, Yufan   .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P09 .02 D
Wyatt, Richard  .  .  .  .  .OA02 .05, P03 .03 D, 
P03 .48, P03 .49, P03 .62 LB D, 
P03 .77 LB, P13 .54, S02 .04, S06 .01
X
Xia, Shi-Mao  .  .  .  .OA02 .06 LB, P13 .69 LB
Xiao, Lijun  .  .  .  .  .  .  .  .  .  . P01 .12, P02 .18 
Xiao, Peng  .  .  .  .  .  .  . P01 .09, P05 .36 LB
Xiao, Yongli  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .77 LB
Xie, Jiuyong  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P06 .15
Xu, Jianqing  .  .  .  .  .  .  .P01 .14, P03 .61 LB
Xu, Ling  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P01 .11
Xu, Rong  .  .  .  .  .  .  .  .  .  .  . P02 .28, P02 .29 
Xu, Tong .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . PL04 .04
Xu, Yang   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P12 .02 D
Y
Yager, Eric J  .  .  .  .  .  .  .  .  .  .  .  . OA08 .06 LB
Yahia, Chebloune  .  .  .  .  .  .  .  .  .  .  .  . P02 .24 
Yamamoto, Hiroyuki  .  .  .  .  .  .  .  .  . P03 .26
Yamkram, Thippawan  .  .  .  .  .  .  .  . P04 .14
Yamoon, Doungporn  .  .  .  .  .  .  .  .  . P04 .09
Yan, Celine  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .OA03 .05
Yan, Jian   .  .  .  .  .  .  .  .  . OA04 .02, P01 .15, 
P03 .04, P04 .26, P12 .39, 
P13 .02 D, P13 .58
Yan, Yan  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P08 .09
Yang, Guang   .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .14 
Yang, Hongbing  .  .  .  .  .  .  .  .  .OA01 .06 LB, 
P12 .38
Yang, Jing   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .15
Yang, Yongping  .  .  .  . OA05 .02, P01 .10, 
P03 .02 D, P03 .08, P03 .20, 
P03 .22, P03 .32, P03 .38, 
P03 .53
Yang, Yi  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P02 .01 
Yang, Zhi-yong .  .  .  .  .  .  .P02 .21, P03 .22, 
P03 .63 LB, PL04 .04
Yao, Chen  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .15
Yao, Jiqiang  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .57
Yasmeen, Anila   .  .  .  .  .  .  .  .  . OA06 .06 LB
Yates, Nicole   .  .  .  .  .  . OA05 .06, P08 .02, 
P13 .71 LB
Yin, Li  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .57
Ying, Huazhong  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .11
Yipp, Bryan  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P04 .07
Yokoyama, Masaru  .  .  .  .  .  .  .  .  .  . P03 .46
Yola, Ntando  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .OS .01
Yong, Ouyang   .  .  .  .  .  .  .  .  .  .  . P02 .30 LB
Yoshimura, Kazuhisa  .  .  . P03 .10, P03 .19, 
 P03 .29, P03 .46
Young, April M .  .  .  .  .  .  .  .  .  .  .  .  .  . P11 .06
Weber, Jacqueline  .  .  .  .  .  .  .  .  .P05 .04 D, 
P09 .02 D
Wegmann, Frank  .  .  .  .  .  .  .  .  .  .  .OA02 .02
Wei, Danlan  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . OA07 .01
Wei, Qing  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .60
Weiner, David  .  .  .  .  . OA04 .02, P01 .15, 
P02 .22, P12 .39, P03 .04, 
P04 .26, P13 .02 D, P13 .58
Weiser, Keren   .  .  .  .  .  .  .  .  .  .  .  .  .  . P06 .07
Weiss, Carol  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P13 .46
Weissman, Drew  .  .  .  .  .P01 .05, P01 .08, 
P13 .61
Welles, Hugh  .  .  .  .  .  .  .  . P02 .21, S08 .04
Welsh, Sabrina   .  .  .  .  .  .  .  .  .  . P04 .45 LB
Wendel, Sarah K  .  .  .  .  .  .  .  .  .  .  .  . P05 .06
Werner, Lise  .  .  .  .  .  .  .  .  .P06 .13, P08 .02, 
P08 .06
Wesberry, Maggie  .  .  .  .  .  .  .  .  .  .  . P01 .17
West, Anthony P  .  .  .  . OA02 .01, OA05 .01, 
P03 .78 LB, P13 .14
Westmacott, Garrett  .  .  . OA08 .03, P08 .12
Whalen, Robert  .  .  .  .  .  .P13 .38, P13 .54, 
S06 .01
Wheatley, Adam   .  .  .  .  .  .  .  .  .  .  .OA03 .03
Wherry, E J   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P12 .14
Whitesides, John F  .  .  .  .  .  .  .  .  .  . P02 .01, 
P03 .01 D, P03 .76 LB, P08 .14
Whitney, James  .  .  .  .  .  .  .  .  . OA04 .06 LB
Whitney, Stephen   .  .  .  . P01 .16, P01 .17, 
P13 .28, P13 .36
Wibmer, Constantinos K  .  .  .  .  . P03 .52, 
P13 .48
Wieczorek, Lindsay  .  .  .  .  .  .  .  .  .  . P01 .17
Wiedemann, Aurélie  .  .  .  .  .  . P04 .44 LB
Wiehe, Kevin  .  .  .  .  .  . OA03 .04, P03 .14, 
P03 .71 LB, P03 .72 LB, P08 .14
Wietgrefe, Stephen W  .  .  .  .  .  . OA08 .04
Wilck, Marissa  .  .  .  .  .  .  .  .  .  .  . P04 .39 LB
Wild, Jens   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . P12 .44
Wilkinson, Peter   .  .  .  .  .  .  .  .  . P04 .42 LB
Willer, David O  .  .  .  .  .OA04 .05, P02 .15 
Williams, Constance   .  . P01 .17, P03 .31, 
P03 .44, P03 .56
Williams, Corey  .  .  .  .  .  .  .  .  .  .  .  .  . P05 .05
Williams, Charmaine C   .  .  .  .  .  . P11 .04, 
P11 .05
Williams, Walton  .  .  .  .  .  .  .  .  . P03 .72 LB
Williams, William  .  .  .  .P08 .14, P13 .71 LB
Williams, Wilton B  .  .  .  .  .  .  .  .  .  .OA03 .04
Williamson, Anna-Lise  .  .  .  .  .  .  . P02 .25, 
P04 .36 LB, P08 .05, P13 .10, 
P13 .16, P13 .43
Williamson, Carolyn   .  .  .  .  .  .  .  . P02 .25, 
P04 .36 LB, P05 .19, P08 .03, 
P08 .06, P13 .41
Willsey, Jeremy  .  .  .  .  .  .  .  .  .  .  .  .  . P03 .50
Wilson, Aaron  .  .  .  .  .  .  .P02 .06, P13 .05, 
P13 .13
Wilson, Ian   .  .  .  .  .  .  .  .  .  .  . OA06 .06 LB, 
P03 .62 LB D, P03 .66 LB, 
P13 .45, P13 .53, P13 .72 LB
Wilson, Richard  .  .  .  .  .  .  .  .  .  .  .P03 .03 D, 
P03 .62 LB D, P03 .77 LB, P08 .10
Winkler, Cheryl  .  .  .  .  .  .  .  .  .  .  .  .  . P06 .13
Winnall, Wendy R  .  .  .  .  .  .  .  .  .  .  . P12 .35
Wise, Megan  .  .  .  .  .  . OA04 .02, P01 .15, 
P02 .22, P03 .04, P12 .39, 
P13 .02 D, P13 .58
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